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Abstract
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Background: Critical examination of the quality and validity of available allergic rhinitis (AR)
literature is necessary to improve understanding and to appropriately translate this knowledge to
clinical care of the AR patient. To evaluate the existing AR literature, international
multidisciplinary experts with an interest in AR have produced the International Consensus
statement on Allergy and Rhinology: Allergic Rhinitis (ICAR:AR).
Methods: Using previously described methodology, specific topics were developed relating to
AR. Each topic was assigned a literature review, evidence-based review (EBR), or evidence-based
review with recommendations (EBRR) format as dictated by available evidence and purpose
within the ICAR:AR document. Following iterative reviews of each topic, the ICAR:AR document
was synthesized and reviewed by all authors for consensus.

Author Manuscript

Results: The ICAR:AR document addresses over 100 individual topics related to AR, including
diagnosis, pathophysiology, epidemiology, disease burden, risk factors for the development of AR,
allergy testing modalities, treatment, and other conditions/comorbidities associated with AR.
Conclusion: This critical review of the AR literature has identified several strengths; providers
can be confident that treatment decisions are supported by rigorous studies. However, there are
also substantial gaps in the AR literature. These knowledge gaps should be viewed as
opportunities for improvement, as often the things that we teach and the medicine that we practice
are not based on the best quality evidence. This document aims to highlight the strengths and
weaknesses of the AR literature to identify areas for future AR research and improved
understanding.
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I.

Introduction

Author Manuscript

The available literature on allergic rhinitis (AR) grows more quickly with each passing
decade. A search of “allergic rhinitis” in the PubMed database yielded 4135 articles
published between 1945 and 1979. The next 20 years (1980-2000) saw 7064 AR articles
published. Each subsequent decade has surpassed this number with 8143 AR articles
published between 2000 and 2010, and 8212 published from 2010 to the present day. Like
many other areas of medicine, a close look at the available literature demonstrates a wide
variation in the type and quality of AR publications, ranging from case reports to metaanalyses, review articles to randomized controlled trials (RCTs), and large prospective
studies to small retrospective case series. As a medical professional reads the literature or
hears literature quoted by others, it is important that he/she understand the quality of the
evidence in order to appropriately translate the findings and recommendations into daily
clinical care of the AR patient. With such vast AR literature available, developing an
appropriate understanding of the relevant evidence can be daunting.

Author Manuscript

This International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
(ICAR:AR) was developed to summarize the best external evidence relating to AR, with the
goal of gathering and critically reviewing the available literature on AR epidemiology, risk
factors, diagnosis, management, and associated conditions/comorbidities. More than 100
international authors from various specialties utilized a structured review process to evaluate
the evidence related to AR. Initial topic development and writing by a primary author or
team of authors, followed by a stepwise anonymous iterative review process for over 100 AR
topics held this process to extremely high standards. The resulting document provides a
strong review of the existing AR literature. The recommendations for AR diagnostic
modalities and treatment contained herein rely directly on this evidence, with a clear
delineation of the benefit, harm, and cost considerations that supported each
recommendation level.

Author Manuscript

Like the 2016 International Consensus Statement on Allergy and Rhinology: Rhinosinusitis
(ICAR:RS) by Orlandi et al.,1 this ICAR:AR document places high value on the strength of
the evidence in making recommendations. Therefore, for example, expert opinion receives
lower value (Table II.A-1). There are limitations, however. Like ICAR:RS, this document is
not a clinical practice guideline (CPG) or a meta-analysis. This document summarizes the
findings of meta-analyses and other systematic reviews when those are identified in the
literature for a specific AR topic area. However, a meta-analysis was not performed on the
data included in this document. In addition, much of the available AR literature is not
appropriate for meta-analysis due to its heterogeneous nature and inconsistent
methodologies. ICAR:AR is also not a CPG, as the typical steps of a CPG (ie, medical
specialty society and patient advocate review) were not employed here.
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Throughout this document, certain topic areas have very strong evidence whereas other
topics demonstrate relatively weak evidence. Many of our common practices in the
diagnosis and care of the AR patient are based upon weak external evidence. As
practitioners, academicians, and scientists, we must examine this evidence and strive to
increase the strength of the evidence in areas where gaps exist.

Author Manuscript

Within the ICAR:AR document, recommendations are given based on the evidence in a
specific topic area. However, this document is a compilation of the best AR evidence, not a
manual for the care of the AR patient. Evidence-based medicine requires that the clinician
has the best evidence available, but also uses his/her expertise and takes the patient’s values
and expectations into account.2 Therefore, with a background of evidence-based knowledge,
the practitioner must approach each patient as an individual to determine the most
appropriate diagnostic and treatment modalities for that particular patient. Given the
numerous potential conditions in the AR differential diagnosis, various diagnostic and
treatment options available, and diverse comorbidities and associated conditions that may
accompany AR, treatment of the AR patient with an evidence-based approach requires
careful consideration.
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As previously stated by Orlandi et al.,1 the recommendations provided in an ICAR
document must be interpreted based on the strength of the evidence that forms their
foundation. The recommendations in this document are evidence-based. They do not define
the standard of care or medical necessity. Recommendations written in this document, or any
similar document, do not dictate the specific care of an individual patient. There are
numerous other factors that enter into the treatment decisions for each individual patient.
Finally, it is expected that these recommendations will change with time and with new
evidence. We encourage new research, especially rigorous studies that aim to fill the
identified knowledge gaps. With new evidence, recommendations will undergo necessary
revisions and better patient outcomes should result.

II.
II.A.

Methods
Topic development
In a similar fashion to the 2016 ICAR:RS document by Orlandi et al.,1 this ICAR:AR
document is formulated with the utmost reliance on published evidence. With the 2011
Rudmik and Smith3 evidence-based review with recommendations (EBRR) method as its
foundation, ICAR:AR strives to analyze the existing literature on each AR topic, grading the
evidence and providing literature-based recommendations where appropriate.
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The subject of AR was initially divided into 103 topics or content areas. A senior author
who is a recognized expert in allergy, rhinology, or the assigned topic was appointed to each
topic. Authors were initially selected via online literature searches for each ICAR:AR topic.
Authors of high-quality publications in each topic area were invited as ICAR:AR
contributors. Other invited authors included experts in the EBRR process, experts in
teaching/lecturing on specific AR topic areas, and those with knowledge of the systematic
review process.
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Some of the topics, such as those providing background or definitions, were assigned as
literature reviews without evidence grades. Certain topics that were not appropriate for
clinical recommendations were assigned as evidence-based reviews without
recommendations (EBRs). Topics that had evidence to inform clinical recommendations
were assigned as EBRRs.

Author Manuscript

Each topic author received specific instructions to perform a systematic review for the topic
literature using the Preferred Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) standardized guidelines.4 Ovid MEDLINE® (1947-September 2016), EMBASE
(1974-September 2016), and Cochrane Review databases were included. The search began
by identifying any previously published systematic reviews or guidelines pertaining to the
assigned topic. Since clinical recommendations are best supported by high-quality evidence,
the search focused on identifying RCTs and meta-analyses of RCTs to provide the highest
level of evidence (LOE). Reference lists of all identified studies were examined to ensure all
relevant studies were captured. If the authors felt as though a non-English study should be
included in the review, it was instructed that the paper be appropriately translated to
minimize the risk of missing important data during the development of recommendations.4
To optimize transparency of the evidence, all included studies in EBR and EBRR topic
sections are presented in a standardized table format and the quality of each study was
evaluated to receive a level based on the Oxford LOE (level 1a to 5).5 At the completion of
the systematic review and research quality evaluation for each clinical topic, an aggregate
grade of evidence was produced for the topic based on the guidelines from the American
Academy of Pediatrics Steering Committee on Quality Improvement and Management
(AAP SCQIM)6 (Table II.A-1).

Author Manuscript

After providing an aggregate grade of evidence for each EBRR topic (A to D), a
recommendation using the AAP SCQIM guidelines was produced (Table II.A-2). It is
important to note that each evidence-based recommendation took into account the aggregate
grade of evidence along with the balance of benefit, harm, and costs. A summary of the
EBRR development process is provided in Figure II.A-1.
II.B.

Iterative review

Author Manuscript

Following the development of the initial topic text and any associated evidence tables,
evidence grades, and recommendations, each section underwent a 2-stage online iterative
review process using 2 independent reviewers (Fig. II.A-2). The purpose of the topic
iterative review process was to evaluate the completeness of the identified literature and
ensure that any EBRR recommendations were appropriate. The content of the first draft
from each topic section was reviewed by a first reviewer, and all changes were agreed upon
by the initial author and this first reviewer. The revised topic section was then subsequently
reviewed by a second reviewer. Initial authors of the topic and both assigned reviewers
agreed upon all changes before each section was considered appropriate to proceed into the
final ICAR statement stage.
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After the content of each of topic was reviewed and consensus reached among the initial
author and 2 iterative reviewers, the principal editor (S.K.W.) compiled all topics into a
single ICAR:AR statement. The first draft of each large ICAR:AR portion (ie, Evaluation
and Diagnosis, Pharmacotherapy, Immunotherapy, etc.) then underwent additional reviews
for consistency and understanding using a group of 6 to 8 authors. Finally, the draft
ICAR:AR was circulated to all authors. The final ICAR:AR manuscript was produced when
all authors agreed upon the literature and final recommendations. External peer review, with
20 reviewers, was also undertaken for the final ICAR:AR document (Fig. II.A-3).
II.D.

Limitations of methods and data presentation

Author Manuscript

It should be noted that because each topic author individually performed the literature search
for his/her assigned topic, search results may demonstrate some inherent variability despite
specific and detailed search instructions. Furthermore, while aiming to be as comprehensive
as possible, this document may not present every study published on every topic. For certain
topics, the literature is extensive and only high-quality studies or systematic reviews are
listed. If the aggregate evidence on a topic reached a high evidence grade with only highlevel studies, an exhaustive list of lower level studies (or all studies ever performed) is not
provided.

III.
III.A.

Definition and differential diagnosis
Allergic rhinitis definition

Author Manuscript

AR is an immunoglobulin E (IgE)-mediated inflammatory nasal condition resulting from
allergen introduction in a sensitized individual.7 AR was defined in 1929 as a process which
included 3 cardinal symptoms: sneezing, nasal obstruction, and mucus discharge.8
Symptoms occur with allergen exposure in the allergic patient. AR is a widely prevalent
condition that can result in significant physical sequelae and recurrent or persistent
morbidities.7

Author Manuscript

The prevalence of AR is approximately 10% to 40%, depending on geographic location,9
with the highest incidence occurring in children.10 However, AR is nearly absent in infants,
typically not manifesting until the second year of life at the earliest. When AR presents in
children, this is likely secondary to the rapidly evolving immune system. AR often results
from an overactive response of T helper (Th) 2 lymphocytes that can initiate a systemic, IgEdriven reaction which may dominate child’s immune system until it is completely mature.
During this time, a skin-prick test (SPT) or in vitro antigen-specific IgE (sIgE) test can be
used to confirm the diagnosis of AR.
In the atopic individual, exposure to indoor and outdoor allergens may prompt antigenspecific IgE production. Reintroduction of the allergen triggers early-stage and late-stage
reactions, leading to the clinical manifestations of AR. The early-stage reaction occurs
within minutes after reintroduction of the sensitized allergen, producing nasal itching, nasal
congestion, and rhinorrhea.11 The late-stage reaction occurs during the 4-hour to 8-hour
period after allergen introduction and results in nasal blockage, hyposmia, increased mucus
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secretion, and nasal hyperresponsiveness to the same or different allergens. Additionally,
even in the absence of overt symptoms, IgE has an increased presence in the lymphoid tissue
of the atopic patient, which can result in persistent mucosal inflammation.12
III.B.

Allergic rhinitis classification
Seasonal vs perennial allergic rhinitis—The Allergic Rhinitis and its Impact on
Asthma (ARIA) proposals have categorized AR by presumed cause and seasonal vs
perennial presentation. Classically, this has included seasonal AR (SAR; hay fever) and
perennial allergic rhinitis (PAR).7 SAR is triggered by a wide assortment of outdoor
allergens, especially pollens.7 PAR is commonly brought about by indoor allergens that are
present through-out the year, such as dust mites, molds, insects (cock-roaches), and animal
dander.7

Author Manuscript

Intermittent vs persistent allergic rhinitis—The classification of “seasonal” and
“perennial” AR can often be in conflict, as manifestations of perennial allergy may not occur
throughout the entire year. This is particularly the case for patients allergic to house dust
mites (HDM), who may demonstrate mild or moderate/severe intermittent allergic rhinitis
(IAR).9,13-15 In addition, because of the priming effect on the nasal mucosa initiated by low
levels of pollen allergens16-21 and minimal persistent nasal inflammation in patients with
“symptom-free rhinitis,”14,22,23 symptoms may not occur entirely in conjunction with the
allergen season, therefore resulting in nonspecific exacerbations. Air pollution may also
contribute to alterations in allergen sensitivity, resulting in varying degrees of symptoms
depending on location and air quality.24 Furthermore, individuals sensitized to multiple
pollens may have symptoms across several seasons while individuals with PAR may
encounter symptoms for short periods of time with frequent, repetitive relapses.

Author Manuscript

Because of the issues outlined above, ARIA proposed a new method of classification based
on the length and recurrence of the symptom manifestations.25 IAR is characterized by
symptoms for less than 4 days per week or less than 4 consecutive weeks. Persistent AR
(PER) is characterized by symptoms occurring more than 4 days per week for at least 4
consecutive weeks; therefore, PER patients are symptomatic most of the time.26 It has been
recommended that the previous categories of seasonal and perennial AR (ie, SAR and PAR)
not be used along with the new classification of IAR and PER, as they do not represent the
same stratification of the disease state. As such, IAR and PER are not synonymous with
seasonal and perennial.25,27-30 In describing AR, one should determine which classification
scheme best conveys the message that he/she wishes to relay: seasonal/perennial or
intermittent/persistent.

Author Manuscript

Severity of allergic rhinitis—AR can result in significant disturbances in quality of life
(QOL), sleep, exercise tolerance, productivity, and social functioning. The ARIA guidelines
have likewise proposed the stratification of severity (mild and moderate-severe) in view of
these disabilities.13 (See section VII. Disease Burden for additional information on this
topic.)
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Sensitization vs clinical allergy—Monosensitization is sensitization (as indicated by
positive reactions on standardized SPTs or serum sIgE levels) to only 1 allergen, such as
grass pollen, tree pollen, HDM, or cat dander (even though extracts of these concentrates
contain numerous diverse polypeptides).31 Monoallergy is defined as a single sensitizing
allergen causing clinical allergy symptoms. Polysensitization is sensitization to 2 or more
allergens. Polyallergy is affirmed clinical symptoms to 2 or more sensitizing allergens.
Findings of allergy testing, either skin testing or sIgE must be correlated with clinical
symptoms to identify the allergen(s) likely responsible for the symptoms.32 Allergen
challenges (ie, nasal provocation testing, conjunctival challenge, or allergen challenge
chambers (ACCs)) can reproducibly confirm the clinical significance of a sensitized
allergen, but these tests may be difficult to perform, subjective, and limited by irritant
effects.33

Author Manuscript

Allergy skin testing and sIgE titer must be carefully interpreted at the patient level, and can
also be valuable at the population level when evaluating sensitization for epidemiological
studies.34 With increasing availability of component-resolved diagnosis (CRD), physicians
will have a more objective means of identifying clinically relevant allergens and
distinguishing true co-sensitization from polysensitization due to cross-reactivity. (See
section VIII.F.6. Evaluation and diagnosis - In vitro testing - Component resolved diagnosis
(CRD) for additional information on this topic.)
III.C.

Allergic rhinitis differential diagnosis

Author Manuscript

The symptoms of AR may be similar to symptoms of other types of sinonasal disease, and at
times multiple types of rhinitis may coexist. It is important to correctly determine the
etiology of rhinitis to appropriately treat the patient and have the best chance of resolving his
or her symptoms. In the following sections, a discussion of the differential diagnosis of AR
is presented, along with a description of how each rhinitis entity differs from AR. Of note,
this section on AR differential diagnosis is specific to various etiologies of rhinitis. Other
entities that may enter into the differential diagnosis of AR, such as structural sinonasal
conditions (ie, deviated septum), tumors, and cerebrospinal fluid leak are not discussed here
(Table III.C).

Author Manuscript

III.C.1. Drug-induced rhinitis—Rhinitis secondary to systemic medications can be
classified into local inflammatory, neurogenic, and idiopathic types35,36 (Table III.C.1). The
local inflammatory type occurs when consumption of a drug causes a direct change in
inflammatory mediators within the nasal mucosa. The neurogenic type occurs after use of a
drug that systemically modulates neural stimulation, leading to downstream changes in the
nasal mucosa. Idiopathic drug-induced rhinitis is used to classify drugs without a welldefined mechanism contributing to symptoms. Topical nasal decongestants can cause druginduced rhinitis, known as rhinitis medicamentosa (RM). (See Section III.C.2. Definitions,

classifications, and differential diagnosis - Allergic rhinitis differential diagnosis - Rhinitis
medicamentosa (RM) for additional information on this topic.)
Local inflammatory type.: Systemic ingestion of non-steroidal anti-inflammatory drugs
(NSAIDs) in patients with a disorder of eicosanoid synthesis can result in rhinitis and nasal
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congestion, which may also be associated with chronic rhinosinusitis (CRS) and asthma.37
In brief, NSAIDs inhibit cyclooxygenase (COX)-1 and COX-2 enzymes, shifting
arachidonic acid metabolism toward the lipoxygenase pathway, with decreased production of
prostaglandins and thromboxane in exchange for inflammatory leukotrienes (LT). Reduction
in nasal mucosal prostaglandin E2, as well as increased LTC4, LTD4, and LTE4 causes
mucus production and nasal mucosal edema, hallmarks of rhinitis.35,38

Author Manuscript

Neurogenic and neuromuscular type.: Neurogenic type non-allergic rhinitis (NAR) is
caused by drug-induced modulation of the autonomic nervous system. Antihypertensives
and vasodilators are among the many classes of drugs that cause drug-induced NAR. Other
nonspecific drugs, such as psychotropics and immunosuppressants, have unknown
mechanisms and are categorized as idiopathic, but can cause neuromodulatory effects as
well. Modulation of the autonomic nervous system leads to downstream changes in nasal
mucosa, blood vessels, and secretory glands.39 For example, α- and β-adrenergic
antagonists, and presynaptic α-agonists, cause decreased sympathetic tone and unopposed
parasympathetic stimulation producing mucosal engorgement, nasal congestion, and
rhinorrhea.40-42

Author Manuscript

Phosphodiesterase (PDE)-5 specific inhibitors promote penile vasodilation and erection.
PDE-3 and nonselective PDE inhibitors result in vasodilation and increased extremity blood
flow, relieving symptoms of peripheral artery disease. Nitric oxide (NO)/cyclic nucleotidemediated vasodilation occurs in the nasal mucosa as well, causing nasal mucosal
engorgement and edema.43-46 Finally, angiotensin converting enzyme inhibitors (ACE-Is)
inhibit the conversion of angiotensin I to angiotensin II in the lungs, resulting in a decrease
in sympathetic activity. Bradykinin is also formed. Bradykinin B1 and B2 receptors have
been demonstrated in nasal mucosa47; bradykinin application to the nasal mucosa has been
shown to increase sneezing,44,48 suggesting a role of ACE-Is in NAR.

Author Manuscript

Illicit drug use.: The nose provides a unique portal for illicit drug use, as nasal mucosa is
well vascularized and easily accessible. The illicit drug user can avoid invasive intravascular
or intramuscular administration of a desired product by applying a crushed solid, liquid, or
aerosolized form of the product directly to the nasal cavity. For some drugs, nasal
administration increases bioavailability and shortens time to onset when compared to oral
ingestion.49,50 Cocaine is most commonly associated with nasal illicit drug use and exerts its
effect by modulating dopamine transporters to inhibit reuptake at the synapse, increasing
dopamine available for postsynaptic stimulation.51 Cocaine-induced rhinitis is a result of
vasoconstrictive events, which can be followed by rebound nasal mucosal edema and
mucous production, similar to those seen in RM.52-55 In the repeat user, vasoconstriction,
direct trauma compounded by anesthetic effects, and/or injury secondary to contaminants
may result in nasal septal perforation.56-59 Similarly, prescription narcotics,59
antidepressants,47 anti-cholinergics, and psychostimulants can be abused by intranasal
administration.47,60 Intranasal hydrocodone has been shown to induce nasal tissue necrosis
and loss in a similar manner to cocaine.59 Antidepressants such as bupropion have been used
to achieve a euphoria similar to that of cocaine and may induce seizures.47
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In summary, systemic medications and intranasal illicit drugs affect the nasal mucosa.
Increased mucosal edema, vasodilation, and inflammatory mediators are a consequence of
systemic medications. Vasoconstriction and direct mucosal injury often accompanies illicit
drug use. The physiologic response in drug-induced rhinitis differs from AR as it is not
allergen-induced nor dependent on IgE mechanisms, although symptomatology may be
similar.
III.C.2. Rhinitis medicamentosa (RM)—RM, or rebound rhinitis, is a condition
induced by prolonged use of topical intranasal decongestant (IND)26,61 (Table III.C.2).
Although no consensus diagnostic criteria exist, RM is classically associated with the triad
of prolonged IND use, constant nasal obstruction, and poor shrinkage of the nasal mucosa61
in the setting of nasal congestion, rhinorrhea, and decreased efficacy of further INDs.55,62,63
Physical exam findings consist of mucosal edema, erythema, and hyperemia.

Author Manuscript

The exact physiologic mechanism causing RM is unclear. Continuous IND use may decrease
endogenous norepinephrine production and cause upregulation of the parasympathetic
system, leading to rebound congestion once the decongestant is discontinued.54,55 This may
be further exacerbated by recurrent nasal tissue hypoxia and negative neural feedback with
chronic decreased α-2 receptor responsiveness.64 Mucosal changes include ciliary damage
and loss, epithelial metaplasia and hyperplasia, dilated intercellular spaces, goblet cell
hyperplasia, and edema.65-67 Benzalkonium chloride (BKC), an antimicrobial preservative
used in many nasal decongestants, has been implicated in the mechanism of RM. Studies
have suggested that BKC is toxic to nasal epithelium and may propagate RM, although the
data are inconclusive.68-71

Author Manuscript

Neither duration, nor cumulative dose of IND needed to initiate RM is known. Rebound
congestion has developed after 3 to 10 days of medication use,55,66 but may not occur until
after 30 days.72,73 Other studies have demonstrated a lack of rebound after 8 weeks of
continuous use.72-75 Furthermore, doubling the dose of intranasal imidazoline did not
increase the extent of rebound edema.72 Although inconclusive, studies suggest that IND use
should be discontinued after 3 days to avoid rebound congestion.62,76,77

Author Manuscript

Treatment of RM involves discontinuation of INDs. Various medications have been used to
improve nasal decongestion including nasal cromolyn, sedatives, nasal saline spray, oral
antihistamines, oral decongestants, and intranasal corticosteroids (INCSs; sometimes used in
conjunction with brief courses of systemic corticosteroids).50,62,78-82 Only the use of INCSs
has been demonstrated to mitigate rebound congestion after discontinuation of topical INDs.
67,81-83 Often there is an underlying rhinitis and/or anatomic issue that initiated the
decongestant use. This underlying issue should be addressed to diminish the drive to
continue to use INDs.
Importantly, RM is typically associated with repeated exposure to INDs, with increasing
symptoms at times when the medication is withheld. In contrast, AR is classically associated
with an allergic trigger with similar symptoms increasing upon allergen exposure, and is
dependent upon IgE-mediated inflammation.
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III.C.3. Occupational rhinitis—Occupational rhinitis is an inflammatory condition of
the nasal mucosa, characterized by intermittent or persistent nasal congestion, sneezing,
rhinorrhea, itching, and/or hypersecretion due to causes and conditions attributable to a
particular work environment, and not to stimuli encountered outside the workplace.84
Occupational rhinitis is considered a form of “work-related rhinitis,” which also
encompasses work-exacerbated rhinitis, which is preexisting or concurrent rhinitis that is
worsened by workplace exposures84,85 (Fig. III.C.3).

Author Manuscript

Occupational rhinitis may be allergic, consequent to exposure to a sensitizing highmolecular (HMW) or low-molecular weight (LMW) compound acting through an
immunological mechanism, and characterized by the presence of a latency period between
beginning of exposure and symptom onset. Alternatively, occupational rhinitis may be nonallergic, mediated by and irritant or non-immunological mechanism. Symptoms occur after
single or multiple exposures to irritant compounds, and usually present without a latency
period. Non-allergic occupational rhinitis resulting from a single exposure to a very high
concentration of irritants is also referred as reactive upper airways dysfunction syndrome
(RUDS). The most severe form of irritant-induced occupational rhinitis is corrosive rhinitis,
which is characterized by permanent inflammation of the nasal mucosa sometimes
associated with ulcerations and perforation of the nasal septum.84,85
The results of cross-sectional studies in working groups show a wide range of prevalence of
occupational rhinitis (3-87%),86 lower prevalence for LMW-agent exposure, and higher
prevalence for HMW-agent exposure. Examples of occupations at increased risk are reported
in Table III.C.3.87-98 Occupational rhinitis due to HMW-agents tend to be 3 times more
prevalent than occupational asthma,86 with which it is often associated (up to 92% of cases).
99

Author Manuscript

Occupational rhinitis and occupational asthma share etiologic agents and pathogenic
mechanisms,100 and can be considered in the broader context of the Unified Airway Disease
model.85,93,101,102 The severity of occupational rhinitis may also affect the severity of
occupational asthma.103 In a high proportion (20-78%) of workers exposed to sensitizers,
work-related nasal symptoms tend to develop 5 to 6 months before the onset of bronchial
symptoms.84,86 Consequently, occupational rhinitis may be considered a marker of the
likelihood of developing occupational asthma.

Author Manuscript

The clinical presentation of occupational rhinitis is nonspecific. Nasal symptoms do not
differ from those of non-occupational rhinitis. An occupational origin should be sought for
all rhinitis of new onset in adults, especially in subjects employed in high-risk occupations
(Table III.C.3). The diagnostic assessment first includes a thorough clinical and occupational
history, aimed to investigate type of symptoms and work-relatedness, and to collect
information on occupational exposure. Typical nasal symptoms are often accompanied by
crust formation, sporadic epistaxis, olfaction impairment, or conjunctivitis, or are associated
with pharyngeal, laryngeal, or bronchial symptoms (which should always be evaluated). The
presence of a latency period between an occupational exposure and symptom onset suggests
an allergic mechanism. Documentation of noxious compounds (sensitizers and irritants) in
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the work-place to which the worker is more directly exposed are typically posted by the
employer (ie, Material Safety Data Sheets).84,85

Author Manuscript

Nasal examinations by anterior rhinoscopy and nasal endoscopy, assessing nasal
patency85,104 and inflammation in nasal secretions,105 are often performed as part of the
clinical evaluation. Sensitization to a suspected HMW-agent can be evaluated through SPT
and/or in vitro sIgE assessment, when standardized and validated extracts are available. A
suggestive history associated with a positive immunological test for an occupational agent
could be considered as probable allergic occupational rhinitis. A definitive diagnosis is
obtained by objective demonstration of the causal relationship between rhinitis and the work
environment through a nasal provocation test (NPT) with the suspected agent(s) in the
laboratory, which is considered the gold standard for diagnosis.84,85 If NPT is negative,
further evaluation of work-related changes in nasal parameters at the workplace is
recommended, especially in the presence of a highly suggestive clinical history. In subjects
exposed to HMW-agents with a suggestive history and negative immunological tests, the
type of inflammatory response to NPT might demonstrate the presence of an occupational
local allergic rhinitis (LAR).106,107 Due to the relationship between the upper and lower
airways, spirometry, measurement of nonspecific airway responsiveness, and measurement
of bronchial inflammation by means of exhaled NO may also be performed.84,85
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Primary treatment of allergic occupational rhinitis is avoidance or reduction of culprit
exposures.108 Pharmacologic treatment does not differ from that of non-occupational
rhinitis.101 In allergic occupational rhinitis due to HMW-sensitizers, specific immunotherapy
may be proposed when validated extracts are available.109 The prevention and early
identification of occupational rhinitis during medical surveillance of exposed workers and of
young apprentices may provide an excellent opportunity to prevent the development of
occupational asthma.110,111
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III.C.4. Chemical rhinitis—Chemical rhinitis largely falls under the category of
occupational rhinitis; however, there are chemical exposures that are not necessarily
occupational (and vice versa). Some chemicals may cause sensory irritation, which can
include congestion, rhinorrhea, nasal discomfort, postnasal drainage, headache, and even
epistaxis.112 Exposures, or exposure risk, are important elements to elicit in the history.
There are many chemicals with which specific occupations are closely associated, though
household chemicals and sport/leisure exposures (ie, chlorine-induced rhinitis in
swimmers113) may play a role as well. Larger chemical particles are typically the culprit in
this form of rhinitis as smaller particles usually pass through to the lower airways. Water
soluble agents such as ammonia, formaldehyde, or sulfur dioxide may readily dissolve into
the mucous membrane layer.114 These responses are non-IgE-mediated by a reflex response
which is often termed neurogenic inflammation.115 A subset of these individuals involved in
high-level single-exposure incidents may develop persistent symptoms. This phenomenon
has been described as RUDS when only rhinitis symptoms are present, and Reactive
Airways Dysfunction Syndrome when asthma-like symptoms are present.116,117
Although chemicals are not always thought of as sensitizers, some of these compounds can
induce immunologic disease. Chemicals known to cause sensitization of the respiratory tract
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include diisocyanates, acid anhydrides, some platinum salts, reactive dyes, glutaraldehyde,
plicatic acid, and chroamine.118-120 There is still much debate as to the exact mechanism
behind sensitization to these chemicals. However, smaller chemical compounds must
associate with larger protein molecules to induce an immune response. While specific IgE
production toward chemicals causing respiratory allergy is seen, evidence to show symptoms
related to chemical exposure without concomitant rise in IgE has also been documented.121
It is possible that these findings may be due to the inability to synthesize appropriate in vitro
conjugates for diagnostic assays to detect serum IgE that binds these chemicals.122,123
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Typically, the differential should include causes of both AR and NAR, as well as mixed
rhinitis, recurrent acute rhinosinusitis (RARS), and potentially CRS. Some symptoms of
chemical rhinitis may be similar to AR with nasal discharge, congestion, sneezing, and
itching all being reported. Nasal discharge may be anterior or posterior with chemical
rhinitis or AR but is typically not unilateral with either of these diagnoses. Chemicalinduced rhinitis may be associated with olfactory dysfunction, both temporary and
longlasting. These disturbances include hyposmia or anosmia, as well as dysosmia or
agnosmia (inability to identify smells).112 Nasal discomfort, discharge, congestion,
headaches, and sometimes epistaxis may also be present.112
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III.C.5. Smoke-induced rhinitis—Environmental tobacco smoke exposure is
associated with chronic rhinitis and in some cases, AR.124,125 In several studies, selfreported symptoms tend to be elicited by exposure to smoke and can correlate with serum
cotinine levels.126-128 Symptoms common to both AR and smoke-induced rhinitis include
rhinorrhea and congestion, but smoke-induced rhinitis does not appear to be driven by IgEmediated hypersensitivity (which tends to exhibit a constellation of congestion, rhinorrhea,
and sneezing on exposure to a specific allergen). As AR symptoms are immunologically
mediated, there must be a sensitization period prior to the exposure that elicits symptoms. In
contrast, smoke induced-rhinitis typically does not require sensitization, although there has
been report of potential allergenic compounds in smoke.129 Interestingly, although active
smokers are likely to have an elevated serum IgE, they exhibit a lower skin test reactivity to
allergens than allergic nonsmokers.130
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In contrast to AR, smoke-induced rhinitis is likely multi-factorial, and other mechanisms
such as neurogenic or irritant etiologies play a more predominant role.131,132 Neurogenic
nasal inflammation is mediated by neuropeptides such as substance P, neurokinin A, and
calcitonin gene-related peptide. These mediators are released by sensory nerve fibers in the
nose and result in vasodilation, edema, and inflammation.133 Patients who are reactive to
tobacco exposure are identified by both subjective (congestion, rhinorrhea, sneezing) and
objective response (increased nasal resistance) to controlled challenge with tobacco smoke.
In a prospective study, patients were defined as demonstrating reactivity if nasal resistance
on acoustic rhinometry increased by over 35% in response to tobacco smoke. Patients with
less than 5% increase in nasal resistance were defined as nonreactive.131 In addition, altered
mucociliary clearance (MCC) resulting from tobacco smoke exposure has been
demonstrated. Congestive responses have been demonstrated on challenge with both brief
and prolonged exposure to tobacco smoke. In individuals who report a history of smokeinduced rhinitis, brief smoke exposure (45 parts per million [ppm] for 15 minutes) led to
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increased nasal resistance as measured by posterior rhinometry. In individuals with and
without a history of smoke-induced rhinitis, prolonged exposure to moderate levels of smoke
(15 ppm for 2 hours) also induced a congestive response lasting for an hour or longer.134
Even though the objective response was short lived, patients reported symptoms lasting
hours to days following exposure. Significant symptom overlap may exist, but a thorough
history and allergy testing can help further differentiate smoke-induced rhinitis from AR.
(See section VI.E. Risk factors for allergic rhinitis - Tobacco smoke for additional
information on this topic.)
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III.C.6. Infectious rhinitis—Infectious rhinitis may be classified into acute and chronic
forms, with both bacterial and viral etiologies. Physical findings and chronicity of symptoms
play an important role in differentiating between different forms of rhinitis, including
infectious, allergic, and the inflammation associated with CRS. Symptoms suggestive of a
noninfectious etiology include nasal itching and sneezing, while findings of mucosal
inflammation and rhinorrhea may be present in either infectious or noninfectious rhinitis.26
Taken in isolation, dark or purulent rhinorrhea is not pathognomonic for bacterial rhinitis/
rhinosinusitis. Additional findings suggestive of infectious etiologies include associated
pharyngeal inflammation or cervical lymphadenopathy.135
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Viral rhinitis typically manifests in an acute form, and accounts for up to 98% of infectious
rhinitis in the young child. The incidence of viral rhinitis in young children is 6 episodes per
patient-year.136 In adult viral rhinitis, the incidence is 2 to 3 episodes per year. Symptoms
associated with viral rhinitis include clear rhinorrhea, nasal obstruction, and often, fever. The
responsible organisms of viral rhinitis can be rhinovirus, adenovirus, influenza virus, and
parainfluenza virus.81 Most viral rhinitis is self-limiting within 4 to 5 days, with prolonged
symptoms lasting longer than 2 weeks suggestive of a noninfectious etiology or conversion
to bacterial infection. There are instances when continued rhinitis beyond 10 days is felt to
be due to worsening infection (ie, possible superimposed bacterial rhinosinusitis) and these
patients should be treated more aggressively.137 Approximately 2% of viral rhinitis episodes
are secondarily infected by bacterial organisms such as Streptococcus pneumoniae,
Haemophilus influenzae, and Moraxella catarrhalis, with subsequent presentation of acute
bacterial infection.138
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III.C.7. Rhinitis of pregnancy and hormonally-induced rhinitis—The
development of a type of rhinitis unique to the pregnant patient has been referred to as
rhinitis of pregnancy or pregnancy rhinitis. It occurs in about 22% of pregnancies139 and,
although symptoms may occur at any time, it typically starts after the second month of
pregnancy and is most severe in the second trimester.26,140 Rhinitis of pregnancy has been
defined as nasal congestion in the last 6 or more weeks of pregnancy, without other signs of
respiratory tract infection or allergic cause, followed by complete, spontaneous resolution of
symptoms within 2 weeks after delivery.141
The symptoms of rhinitis of pregnancy, like those of AR, include rhinorrhea and nasal
congestion, which can be prominent and prolonged. Clinical history frequently elicits a prior
history of chronic rhinitis, obscuring the extent to which pregnancy is a causal or
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aggravating factor.139 In addition, preexisting AR can worsen in approximately one-third of
pregnant women.142
There are several etiologic factors potentially associated with the nasal symptoms in rhinitis
of pregnancy. Hormonal changes, such as increased progesterone, estrogen, prolactin,
vasoactive intestinal peptide, and/or placental growth hormone have been implicated,143,144
but there is little evidence to support this theory.145 Other physiologic phenomena occurring
during pregnancy that may contribute to increased nasal congestion or obstruction include
vasodilation, progesterone-induced smooth muscle relaxation, and a massive expansion of
the circulating blood volume, which may contribute to increased nasal vascular pooling.146
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Rhinitis of pregnancy does not usually require therapy, nor does it respond well to standard
allergy medications. Its management is made more difficult by the lack of high-quality
studies on the efficacy of treatment and fetal out-comes. In those who seek treatment,
conservative non-pharmacologic measures are suggested. These can include elevation of the
head of the bed,147 nasal dilator strips,148 and exercise.149,150 Saline lavage using hypertonic
saline has been demonstrated to be effective without obvious deleterious effects on the fetus.
151 Several medications, including INCS, have been studied in rhinitis of pregnancy but have
failed to demonstrate clear efficacy.152 More recently, a systematic review by Kumar et al.
153 identified only 1 RCT that failed to demonstrate any additional benefit of fluticasone
compared to placebo for symptom control in this patient population. Although an extensive
discussion of rhinitis of pregnancy management is beyond the scope of this document, the
use of various other medications (ie, topical and oral decongestants) is controversial and
should be addressed at the individual patient level, with close involvement of the
obstetrician.
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Direct stimulation of the nasal mucosa by estrogen may induce mucosal gland hyperactivity
resulting in increased nasal secretions/rhinorrhea.154 As such, nasal symptoms can be
associated with conditions other than pregnancy that affect hormone balance, such as
hypothyroidism and acromegaly.155 Rhinitis may also arise as a result of changing blood
hormone concentrations during puberty, menstruation, and the perimenopausal years.145
Although oral contraceptives have also been implicated as causes of nasal symptoms, a study
by Wolstenholme et al.156 found no nasal physiologic effects in patients receiving oral
contraceptive treatment.
In summary, there are numerous metabolic conditions with symptoms like those of AR.
Accurate diagnosis can be made on history and presentation, but additional testing may be
required for symptoms that are persistent or severe.
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III.C.8.

Food- and alcohol-induced rhinitis

Food-induced rhinitis.: Certain food ingestions may result in rhinitis based on a
nonimmunologic reaction, and therefore are not characterized as an allergy. For instance, in
subjects with gustatory rhinitis, shortly after ingestion of hot or spicy foods, unilateral or
bilateral watery rhinorrhea develops in the absence of nasal congestion, pruritus, or facial
pain. This is considered a reflex response due to an adrenergic and cholinergic neural
reaction of the nose.157
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The prevalence of “food-induced rhinitis” seems to be under 1%.157 While rhinitis may
frequently be observed as part of systemic IgE-mediated food allergy reaction, it is rarely the
only presenting symptom. In a double-blind, placebo-controlled food challenge study of 480
children, 185 children (39%) experienced ocular and upper respiratory symptoms, but only
5% had symptoms confined to the upper respiratory tract alone.158
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Patients with pollen-food allergy syndrome (PFAS), also referred to as oral allergy syndrome
(OAS), often experience oropharyngeal itching, tingling, and/or mild swelling of the lips,
tongue, palate, and throat, and less commonly AR symptoms, after ingestion of certain raw
fruits and vegetables. The assessed prevalence of this disorder ranges from 5% to 17%, and
it affects up to one-half of pollen-allergic patients.159-161 It occurs in individuals who are
sensitized to pollen aeroallergens through the respiratory tract, which then predisposes them
to clinical symptoms of PFAS after ingestion of cross-reactive, heatlabile food proteins of
plant origin. Because the antigens are heatlabile, patients are usually able to tolerate cooked
forms of the causative fruits and vegetables.162 (See section X.E. Associated conditions Food allergy and pollen-food allergy syndrome (PFAS) for additional information on this
topic.)
Alcohol-induced rhinitis.: Nasal symptoms can also occur after alcohol consumption.
However, very little is known about the prevalence and presentation of alcoholinduced nasal symptoms. Additionally, there is a paucity of information about the
relationship between alcohol-induced nasal symptoms and other diseases, such as AR, nasal
polyposis, asthma, and other chronic lower airway diseases.165
163,164
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Airway symptoms are predominantly initiated by inhaled components that contact the
airway mucosal membrane. However, several forms of rhinitis and asthma may not operate
through this mechanism. One such example is known as alcohol-induced asthma. In these
patients, alcoholic beverages, particularly red and white wines, have been shown to trigger
bronchial symptoms.163,166,167
Alcohol-induced nasal symptoms are about twice as common in females as in males,165 but
the basis for this predilection is not well understood.168-170 Nasal congestion is the
predominant symptom, and red wine is the most common alcoholic beverage to elicit
symptoms. Additionally, wine, particularly red, is also the most widely recognized trigger of
alcohol-induced bronchial symptoms.163 Finally, direct alcohol utilization has also been
associated with a trend toward developing SPT positivity,171 and with increased serum total
IgE (tIgE) levels.172
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III.C.9. Non-allergic rhinitis with eosinophilia syndrome (NARES)—Nonallergic rhinitis with eosinophilia syndrome (NARES) is a clinical disorder comprising
symptoms consistent with PAR in which an absence of atopy has been demonstrated, and
eosinophilia is found on nasal cytology.173 The pathophysiology of NARES is not well
understood, but a key component involves an eosinophilic, self-perpetuating inflammation,
with nonspecific histamine release. It is the most common type of inflammatory NAR, and
was first described in 1981 by Jacobs et al.174
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NARES patients report symptoms that are typical, although often more pronounced, than
those of PAR. These include, nasal congestion, profuse aqueous rhinorrhea, sneezing, and
nasal and ocular pruritis. A prominent feature not shared with AR is anosmia, a frequent
finding in NARES patients.175 NARES is diagnosed by careful history, findings on physical
exam (pale, boggy turbinates, like those found in PAR patients), and negative skin or in vitro
allergy testing. Cytologic examination in NARES reveals the presence of prominent
eosinophilia, usually 10% to 20%173 on nasal smear, with a diagnostic criterion (described
by some) of more than 25% eosinophilia.176 In addition, nasal biopsies from these patients
commonly show increased numbers of mast cells and prominent mast cell degranulation.
177,178
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Research has supported the role of chronic inflammation in the development of NARES.
Though there is still a lack of understanding as to the exact pathophysiology, studies have
shown an increased transendothelial migration of eosinophils, attracted and activated by
chemokines and cytokines.179,180 Specifically, NARES is characterized by elevated nasal
fluid levels of tryptase (also seen in PAR patients) and eosinophilic cationic protein (ECP)
(markedly increased solely in NARES).181 In addition, increased Th2 cytokines (interleukin
[IL]-6 and IL-17) appear to be a factor in the remodeling process seen in NARES.182 Other
proinflammatory chemokines that have been implicated for their role in eosinophil
chemotaxis and infiltration include macrophage/monocyte chemoattractant protein (MCP)-1
and regulated on activation, normal T-cell expressed and secreted (RANTES). Elevated
RANTES concentrations have been found in the nasal fluid of patients with PAR and
NARES.183 Recently, Peric et al.184 demonstrated a correlation between the concentration of
RANTES with nasal symptoms and eosinophil counts in PAR patients. However, levels of
MCP-1 and RANTES were significantly higher in the nasal fluid of NARES compared to
PAR subjects, which again, correlated with nasal symptom scores and density of
eosinophilia in these patients. Nasal neural dysfunction has also been described as a
contributing factor to the symptomatology in NARES.185
NARES usually occurs in isolation but may be associated with aspirin-exacerbated
respiratory disease (AERD), characterized by asthma, nasal polyps, and NSAID intolerance.
173 NARES has also been identified as a risk factor for the induction or augmentation of
obstructive sleep apnea (OSA).186
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The treatment of NAR centers on its underlying cause. Given the inflammatory changes
demonstrated on nasal cytology and physical exam, NARES is primarily treated with INCS
sprays.154 This method of treatment is known to decrease neutrophil and eosinophil
chemotaxis, reduce mast cell and basophil mediator release, and result in decreased mucosal
edema and local inflammation.187 The intranasal antihistamine azelastine is U.S. Food and
Drug Administration (FDA)-approved for both AR and NAR. In clinical trials, azelastine has
been shown to reduce symptoms of rhinitis, including postnasal drainage, sneezing,
rhinorrhea, and congestion.188 However, these multicentered, placebo-controlled trials
studied azelastine for the treatment of vasomotor rhinitis (non-allergic rhinopathy) rather
than NARES specifically.
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III.C.10. Vasomotor rhinitis (nonallergic rhinopathy)—Vasomotor rhinitis is the
most common cause of NAR, and is found in 71% of cases.189-191 The absence of an IgEmediated immune response differentiates vasomotor from allergic forms of rhinitis.101
Therefore, the term “non-allergic rhinopathy” is recommended to replace vasomotor rhinitis,
as inflammation is not regarded as a crucial part in the pathogenesis of non-allergic
rhinopathy. In Europe, “idiopathic rhinitis” has also been used to describe this condition.
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Non-allergic rhinopathy is a diagnosis of exclusion, and other etiologic factors for
rhinopathy must be evaluated. These include CRS, NARES, AERD, infectious rhinitis,
anatomical abnormalities, RM, drug side effects, cerebrospinal fluid (CSF) rhinorrhea, and
rhinitis of pregnancy. Clinical characteristics of non-allergic rhinopathy have been
summarized in a consensus paper by Kaliner et al.40 Non-allergic rhinopathy represents a
chronic disease with primary symptoms of rhinorrhea. Associated symptoms of nasal
congestion, postnasal drip in the absence of acid reflux, throat clearing, cough, Eustachian
tube dysfunction, sneezing, hyposmia, and facial pressure/headache may also be present
with non-allergic rhinopathy. These symptoms may be perennial, persistent, or seasonal, and
are typically elicited by defined triggers, such as cold air, climate changes (ie, temperature,
humidity, barometric pressure), strong smells, tobacco smoke, changes in sexual hormone
levels, environmental pollutants, physical exercise, and alcohol. While often associated with
non-allergic rhinopathy, the lack of a defined trigger does not preclude this diagnosis. In
addition, nasal hyperreactivity to nonspecific stimuli may occur in both allergic and nonallergic rhinitis.192
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Non-allergic rhinopathy is primarily found in adults, with a female-to-male ratio of 2:1 to
3:1. On physical exam, the nasal mucosa usually appears normal, but may show signs of
erythema and clear rhinorrhea. While systemic allergy testing (skin or in vitro testing) is
typically sufficient to differentiate between AR and non-allergic rhinopathy, a diagnosis of
LAR may be considered in the setting of negative systemic testing. Individuals with LAR
suffer from typical allergic symptoms upon allergen exposure, but display a lack of systemic
IgE sensitization. Local provocation is necessary to definitively exclude this diagnosis.
193,194
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While the exact pathophysiology of non-allergic rhinopathy remains incompletely described,
neurosensory abnormalities are thought to play a crucial role.40 In a prior study of central
responses to olfactory stimuli, subjects with non-allergic rhinopathy underwent functional
magnetic resonance imaging following exposure to different odors (vanilla and hickory
smoke). Findings included increased blood flow to the olfactory cortex, leading to the
hypothesis of an altered neurologic response in non-allergic rhinopathy.195,196 Patients with
non-allergic rhinopathy with a predominant symptom of rhinorrhea will often respond to
treatment with intranasal anticholinergics such as ipratropium bromide (IPB).
III.C.11. Age-related rhinitis (ie, elderly)—Age-related changes occur in every organ
system, including the respiratory system. Specific to the nasal cavity, the physiological
process of aging results in neural, hormonal, mucosal, olfactory, and histologic alterations
that cause morphological and functional changes in the aging nose.197,198 This makes the
elderly population more vulnerable to symptoms such as rhinorrhea, nasal congestion,
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postnasal drip, dry nose, intranasal crusting, and decreased olfaction.199,200 A recent
publication by DelGaudio and Panella201 reviewed the literature pertaining to intranasal
findings of the aging nose, which they have termed “presbynasalis.”
Age-related rhinorrhea.: Rhinitis of the older adult (ie, “drippy nose” or “senile
rhinorrhea”) is a well-recognized entity. Rodriguez et al.202 used a questionnaire to
demonstrate that clear rhinorrhea increases with age. Results showed that only 33% of the
younger age group respondents (n = 76, mean age 19 years) regularly reported clear anterior
drainage as compared to 74% of the older age group respondents (n = 82, mean age 86
years).
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The physiologic reason for increased rhinorrhea with age is not entirely known. However, it
is known that α and β receptors become less sensitive and autonomic function declines with
age, which leads to an imbalance of sympathetic and parasympathetic tone.202-204 It is
possible that decreased sympathetic tone with unopposed parasympathetic stimulation
results in a rise in glandular activity in the nasal cavity, leading to increased nasal drainage.
202,205 This mechanism is similar to vasomotor rhinitis/non-allergic rhinopathy, where the
autonomic response to certain stimulants causes the nasal mucosal blood vessels to
vasodilate and the mucus glands to become over-active, resulting in hypersecretion and
drainage.206 Vasomotor rhinitis/non-allergic rhinopathy is the most common type of NAR,
205 and the highest prevalence of NAR is seen in the elderly.144,189,200,207 This would
suggest an autonomic dysregulation as the reason for increased rhinorrhea in the aging
population.
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Age-related nasal obstruction and congestion.: Factors that contribute to an increase in
nasal obstruction/congestion in the aging nose include thicker mucus secondary to a
decrease in body water content,208-210 nasal airflow obstruction secondary to structural
changes caused by the loss of nasal cartilage elasticity and tip support,198,200,210 and mucus
stasis secondary to less effective MCC.200,209 Ho et al.211 demonstrated a decline in MCC
effectiveness with age in 90 healthy subjects aged 11 to 90 years. Subjects over 40 years of
age had a slower ciliary beat frequency, increased microtubule disarrangement, and longer
MCC times on saccharin testing. Thickened mucus and a less effective MCC system may
also lead to postnasal drip, which is a common nasal complaint in the elderly population.200
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Another factor contributing to nasal obstruction/congestion in the elderly is age-related
central nervous system changes that affect the physiologic nasal cycle.208,212 Mirza et al.212
measured the relative airflow of the 6 nasal chambers at 15-minute intervals for 6 hours
across 4 different age groups (n = 60) using liquid crystal thermography. They found that the
proportion of subjects exhibiting the classic nasal cycle decreased with age, being lowest in
the 70-year-old to 85-year-old group.
Age-related nasal dryness and intranasal crusting.: Nasal dryness and intranasal crusting
are more common in the elderly population. This is likely due to age-related changes of the
nasal mucosa,199 such as a decrease in mucosal blood flow and an increase in epithelial
atrophy.213 Schrodter et al.214 evaluated nasal mucosa samples from the middle turbinate of
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40 healthy subjects between the ages of 5 and 75 years, and found an age-related increase in
atrophic epithelium and thickened basement membranes in patients over 40 years old.
Nasal dryness in the elderly population may also be caused by a decrease in intranasal
temperature and humidity.200 Lindemann et al.199 measured these values in 80 healthy
patients and found them to be significantly lower in older patients (age 61 to 84 years) than
in younger patients (age 20 to 40 years). The authors attributed the difference to an increase
in intranasal volume (INV) from age-related atrophy of the nasal mucosa, with INV
measured by minimal cross-sectional areas and volumes of each nasal cavity. An increase in
INV with age has also been demonstrated by Loftus et al.215 using 3D-volumetric analysis
of computed tomography (CT) scans from subjects without sinonasal pathology. Mean INV
was 15.73 mL in the 20 to 30 year age group (n = 22), 17.30 mL in the 40 to 50 year age
group (n = 20), and 18.38 mL in the over 70 year age group (n = 20).
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Allergic rhinitis in the elderly.: Although there is overlap between age-related rhinitis and
AR in the elderly in terms of symptoms and recommended treatment with INCS,210,216 the
underlying physiologic process of each is quite different. AR is a type I IgE-mediated
hypersensitivity reaction,217,218 whereas allergy and allergens do not play a role in the
symptoms and physiologic changes of age-related rhinitis. However, it has been shown that
aging does not reduce the prevalence of AR and that AR in the elderly is likely
underdiagnosed, so AR should be considered when diagnosing new-onset nasal symptoms in
the elderly population.210
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III.C.12. Empty nose syndrome and atrophic rhinitis—The descriptive term
“empty nose syndrome” (ENS) was originally coined in 1994 by Kern and Stenkvist to
describe empty space in the region of the inferior and middle turbinates on coronal CT
images of patients who had partial or total inferior and middle turbinectomies.219 Today,
ENS is defined as an upper airway disorder characterized by impaired nasal airflow
sensation and often involves tissue loss from nasal surgery. ENS is divided into at least 3
subtypes: ENS-inferior turbinate, ENS-middle turbinate, and ENS-both, which are classified
based on the site of tissue loss.219 ENS-inferior turbinate is the most common type.220 A
fourth subtype is ENS-type, wherein a patient has sufficient appearing turbinate tissue but
suffers ENS symptoms after surgery affecting the mucosal surface of the turbinates.
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ENS typically occurs following surgery in the turbinates. Most turbinate surgery has
successful outcomes, with ENS occurring after a very small percentage of sinonasal
procedures.221,222 ENS occurs most frequently after total turbinate excision, but also with
lesser procedures such as submucosal cautery or resection, laser therapy, and cryosurgery.223
Patients often complain of dryness and crusting, although the hallmark complaint of ENS
patients is paradoxical nasal congestion that may be so severe that they feel as if they are
suffocating.223 Recent research has validated that the primary physiological mechanism that
produces the sensation of ample nasal airflow is activation of trigeminal cool
thermoreceptors, specifically TRPM8, by nasal mucosal cooling.224-228 Beyond alterations
in airflow and a reduction in surface area, aberrations in neurosensory systems likely play a
major role in the abnormal sensations ENS patients experience. Not only does turbinate
resection remove nasal mucosa and consequently airflow sensing thermoreceptors, such
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surgery causes nerve damage that if improperly healed, results in failure to return to a
normal physiologic state.221 Differences in nerve recovery after surgery may explain why
only some patients develop ENS despite identical turbinate surgeries. Indeed, certain
surgeons have identified patients with unilateral ENS symptoms while their normal sensing
side looks like a mirror image in terms of absent inferior turbinate tissue. Diagnosis is made
based on history, physical exam, and the cotton test, where a piece of slightly moist cotton is
placed in the nasal cavity for 10 to 30 minutes with alleviation of symptoms, validating the
diagnosis.223 Other conditions that present with nasal dryness and crusting should be ruled
out (ie, atrophic rhinitis, sarcoidosis, etc.). The Empty Nose Syndrome 6-Item Questionnaire
has documented validity in identifying ENS patients.229 Surgery for submucosal expansion
of the internal nasal mucosa can often bring relief for patients.223 It has also been reported
that depression and anxiety are prevalent among ENS patients.230
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Atrophic rhinitis is a chronic, degenerative condition characterized by inflammation and
atrophy of the nasal and paranasal mucosa.231 Primary atrophic rhinitis runs a protracted
course. It can occur spontaneously with unknown etiology, but it is also associated with a
bacterial infection, almost exclusively Klebsiella ozaenae. In a study examining 45 patients
diagnosed with primary atrophic rhinitis, all nasal cultures were positive for Klebsiella
ozaenae.231 Mucosal injury is hypothesized to result from prolonged microvascular or
ischemic injury.231-233 Secondary atrophic rhinitis is far more common and usually develops
following direct injury from trauma, irradiation, reductive nasal or sinus surgery, or in
certain rare granulomatous diseases.231,234 Secondary atrophic rhinitis is also associated
with a bacterial infection, but Staphylococcus aureus, Proteus mirabilis, and Escherichia coli
are the more common pathogens, with Klebsiella ozaenae rarely isolated.231
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Atrophic rhinitis presents as thick, adherent nasal crusting, nasal congestion, foul odor, and
atrophy of mucosal and turbinate surfaces, with severe cases having complete absence of
recognizable anatomic landmarks, septal perforations, or saddle nose deformity.231-233
Hyposmia, epistaxis, and facial pain or pressure may also occur. Histological examination of
intranasal tissue demonstrates squamous metaplasia, glandular atrophy, and diffuse
endarteritis obliterans in both types of atrophic rhinitis.231 Diagnosis is established from
clinical examination, nasal biopsy, and nasal cultures for associated bacteria.

Author Manuscript

Both atrophic rhinitis and ENS patients complain of nasal congestion. For atrophic rhinitis
patients, this is often a result of significant nasal crusting, although as the disease progresses
and mucosa and turbinate tissue is lost, the widened nasal cavity can very closely resemble
that of an ENS patient. The pathophysiology of the paradoxical sensation of nasal
congestion at this point is the same in both disease states, although the origin of the inciting
event differs.
In the literature, ENS has repeatedly been described erroneously as a form or subset of
atrophic rhinitis. ENS results from iatrogenic removal of turbinate tissue and is not
associated with a bacterial infection whereas atrophic rhinitis results from a chronic, often
idiopathic inflammatory process associated with bacterial infection that progresses to
resorption of turbinate tissue. Atrophic rhinitis patients suffer from heavy crusting whereas
ENS patients exhibit only minor crusting or no crusting.
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To differentiate AR [allergic rhinitis] from atrophic rhinitis, it should be noted that AR is an
immunological response to a benign substance, the allergen, that manifests primarily as
nasal inflammation. AR is IgE-dependent235 and characterized by sneezing, clear
rhinorrhea, watery eyes, and nasal and ocular pruritus.1 This condition has a clear distinction
from ENS and atrophic rhinitis in its clinical presentation and pathophysiology.
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III.C.13. Autoimmune, granulomatous, and vasculitic rhinitis—Both the upper
and lower airways can be affected by systemic disorders including vasculitic,
granulomatous, and autoimmune diseases. Commonly, affected patients may present with
nonspecific sinonasal symptoms (nasal obstruction, rhinorrhea, facial pain, and loss of
smell) mimicking AR. Allergy testing will, however, be negative or not clinically relevant.
Clinicians should consider broadening the differential to consider systemic etiologies if
either crusting or recurrent epistaxis is seen.236 Oral steroids are the mainstay of treatment
for the entities discussed in this section, although the recent introduction of monoclonal
antibodies targeting specific biomarkers represents an important hallmark for future therapy.
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Granulomatosis with polyangiitis.: Previously referred to as Wegener’s disease,
granulomatosis with polyangiitis (GPA) is an idiopathic disease characterized by necrotizing
and granulomatous inflammation of the upper and lower airways (85%), glomerulonephritis
(75%) and systemic vasculitis.237-239 Limited forms of GPA involving only the head and
neck may also be seen. GPA predominantly affects small to medium sized arteries and vein
walls.240 GPA affects both men and women in a similar proportion, being frequently
diagnosed in the fourth to sixth decades of life.240 In the US, estimated prevalence is 13 to
30 cases permillion people per 5-year period. Nasal symptoms include obstruction,
rhinorrhea, recurrent epistaxis, crusting, and pain over the nasal dorsum.237,241 Nasal
mucosa disruption may lead to anosmia while tissue necrosis with secondary infection may
lead to cacosmia.236 Nasal endoscopy can reveal an erythematous, friable mucosa with
crusting and granulation that is seen in the septum and inferior turbinate.240 Patients with
severe forms can present with nonvascular necrosis causing perforation or bony destruction
of the nasal septum and/or other nasal structures.242 Diagnosis is based on clinical
symptoms, physical findings, radiological examinations, laboratory tests (positive c-ANCA
[anti-nuclear cytoplasmic antibody] in 60–90%), and biopsy of affected tissue for
pathological examination.237,238,240 Profiling the nasal transcriptome in GPA reveals unique
gene expression signatures related to innate immunity, inflammatory cell chemotaxis,
extracellular matrix composition, and epithelial barrier integrity that may eventually be used
clinically.243,244 Treatment includes prednisone, cyclophosphamide, or methotrexate.
237,238,245 Rituximab, anti-CD20 monoclonal antibody, may be an effective therapy in
refractory or relapsing c-ANCA vasculitis,246 although additional study is needed.
Eosinophilic granulomatosis with polyangiitis.: Previously known as Churg-Strauss
Syndrome, eosinophilic granulomatosis with polyangiitis (EGPA) is a rare small-sized vessel
vasculitis with a prevalence of 1.3 cases per 100,000,247 typically diagnosed in patients age
30 to 50 years.236 Rhinitis (75% of patients) is one of the initial manifestations of EGPA,248
in addition to CRS with nasal polyps (CRSwNP), and partial/total smell loss.249 Diagnosis
should be suspected in patients with asthma, with increased peripheral blood eosinophil
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count (>10%) and pulmonary manifestations.238,248 EGPA is often associated with the
presence of p-ANCA.247 CRSwNP is present in approximately 50% of patients.238 Nasal
pain with purulent or bloody nasal discharge, nasal crusting, or nasal septal perforation can
be present but are less common than in GPA patients.238,250 Treatment usually includes high
doses of corticosteroids and immunosuppressants.248,251 Anti-IL-5 therapy (mepolizumab)
is a potential biological treatment offering clinical benefit and stability and reducing
corticosteroid needs.252
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Sarcoidosis.: Sarcoidosis is a chronic multisystem disorder characterized by bilateral hilar
adenopathy, pulmonary infiltration, ocular, and skin lesions.238,253 More commonly seen in
young and middle-aged adults,254 females more frequently than males, and AfricanAmericans,255 a prevalence of 50 per 100,000 individuals has been reported.236 The
involvement of the upper respiratory tract epithelium is infrequent236 and nasal symptoms
are nonspecific: obstruction, epistaxis, nasal pain, epiphora, and anosmia.237 The most
consistent findings are erythematous, edematous, friable, and hypertrophied mucosa in the
septum and inferior turbinate. Submucosal yellow nodules representative of intramucosal
granulomas may be identified in mucosal biopsies, while nasal polyps, rhinophyma, and
septal perforations have also been reported.238,256 Aggressive non-caseating granulomas can
cause hard or soft palate erosions as well as septal perforations leading to saddle-nose
deformity.257,258 The diagnosis of sinonasal sarcoidosis is based on the clinical findings
with either polypoid changes or characteristic yellowish submucosal nodularity.238 Tissue
for diagnosis is usually obtained by transbronchial-lung biopsy254 or nasal biopsy, as well as
from skin lesions, minor salivary glands, and lymph nodes.238 The primary treatment for
sarcoidosis is systemic steroids, chloroquine, immunosuppressants, and lung-transplantation.
237,238,256,257 The emergence of biological therapies has increased the therapeutic options to
treat refractory organ-threatening sarcoidosis, with monoclonal anti-TNF (tumor necrosis
factor) agents (infliximab) being the most promising.259
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Systemic lupus erythematosus.: Systemic lupus erythematosus (SLE) is an autoimmune
disease that can affect any body system. SLE predominantly affects women (10:1) with an
incidence of 5.6 per 100,000 people.260 The skin of the nose and nasal vestibule can also be
involved in the skin rashes.237 Mucosal lesions are seen in 9% to 18% of cases, with oral,
nasal, and pharyngeal mucosa being commonly affected.260 The diagnosis requires a
detailed medical history, a physical examination, and laboratory tests (anti-nuclear antibody
[ANA] or anti-double-stranded DNA), including a complete blood count, chemistry panel,
and urinalysis.236,261 Therapy with corticosteroids, immunomodulators (prasterone, vitamin
D, hydroxychloroquine), or immunosuppressants (azathioprine, cyclophosphamide, or
mycophenolate) is prescribed for symptom control,238,262 while belimumab is a recent
biological (anti-BAFF [B-cell activating factor] monoclonal antibody) to potentially treat
SLE.263
III.C.14. Rhinosinusitis—The symptoms of AR may overlap with other forms of nasal
inflammation, including rhinosinusitis. It is important to differentiate between AR and
rhinosinusitis to ensure the correct diagnosis and subsequent treatment can be pursued. AR
may be associated with comorbid rhinosinusitis, although whether AR increases the risk of

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Wise et al.

Page 23

Author Manuscript

rhinosinusitis is debatable.1 Identifying comorbid rhinosinusitis is essential to ensure the
appropriate management of both conditions. Of note, these conditions are not mutually
exclusive and there may be an association between rhinosinusitis and AR. It is possible to
have concurrent AR and rhinosinusitis, and this possibility should be considered when
patients meet diagnostic criteria for both independently and when patient symptomatology
or response to treatment does not fit with a single diagnosis.1 A high degree of clinical
suspicion is required; however, careful consideration of these factors may help guide
clinicians to the correct diagnosis or diagnoses.
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Rhinosinusitis is a broad term that includes the diagnoses of acute rhinosinusitis (ARS),
RARS, and CRS, demarcated as CRSwNP or CRS without nasal polyposis (CRSsNP).
Symptomatically, these conditions are characterized by nasal obstruction, nasal congestion,
facial pressure or pain, anterior or posterior nasal discharge, and anosmia/hyposmia for
varying durations of time.1,138 AR shares several overlapping symptoms, namely rhinorrhea
and nasal congestion, which may be confused with the subtypes of rhinosinusitis.264,265
Conversely, rhinosinusitis may be mistaken for AR due to the similar symptomatology.1
Understanding the diagnostic criteria for the subtypes of rhinosinusitis will aid clinicians in
solidifying the correct diagnosis, as well as identifying comorbid conditions.
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ARS is defined as the sudden onset of sinonasal symptoms with associated sinonasal
inflammation that lasts less than 4 weeks.1,137,138,266,267 Symptoms include nasal
congestion, nasal obstruction or nasal discharge, and facial pressure or pain, or anosmia/
hyposmia. Nasal discharge is often purulent and may be discolored, with a tendency to be
unilateral although may be bilateral.1,138 Facial pressure and pain is described as moderate
to severe.137 ARS may be viral or bacterial. In general, viral ARS is present for less than 10
days. A longer duration of illness suggests bacterial ARS.137,138 Progressive worsening over
a short period of time (ie, 5 days) is also suggestive of bacterial ARS.137,138 In the European
Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) statement, fever and elevated
serum markers of inflammation (C-reactive protein or erythrocyte sedimentation rate) are
also included as diagnostic criteria.138 Fever is not included in other guidelines, due to its
low specificity and sensitivity.137 RARS is defined as at least 4 episodes of ARS per year,
with disease-free intervals between episodes.1,137,138,266,268
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CRS is an inflammatory condition of the sinonasal cavity persisting for more than 12 weeks
with at least 2 symptoms of nasal obstruction and congestion, mucopurulent nasal drainage
(anterior or posterior), facial pressure or pain, and anosmia/hyposmia.1,137,138,266,267 In
addition, patients must have objective evidence of sinonasal inflammation on either nasal
endoscopy (polyps, edema, mucopurulent rhinorrhea) or on CT scans of the sinuses.
137,138,266,267 CRS is divided into 2 main phenotypic groups: CRSwNP and CRSsNP.
Comparatively, AR is characterized by nasal obstruction, nasal congestion, clear watery
rhinorrhea (anterior or posterior), and allergic symptoms.264,265 The presence of these
symptoms should raise suspicions of AR as either a primary or comorbid diagnosis.
Conversely, AR is typically not associated with purulent or unilateral nasal discharge.
Moderate to severe facial pain and/or fever would also be atypical for isolated AR and may
indicate the presence of an episode of ARS or an acute exacerbation of CRS, differentiated
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by duration and chronicity of symptoms.1,137,138 The timing of symptoms may also help
delineate between rhinosinusitis and AR as ARS symptoms typically last days to weeks (but
no more than 4 weeks), CRS symptoms persist daily for greater than 12 weeks. In
comparison, while AR symptoms are variable in duration, they tend to have seasonal or
exposure-related fluctuations.1,137,138 AR symptoms are present for at least 1 hour on most
symptomatic days; however, patients may have symptom-free intervals.264,265 AR symptoms
are also exacerbated by exposure to allergens in a time dependent fashion.264 The early
reaction occurs immediately after exposure and is characterized by sneezing, nasal and
ocular itching and rhinorrhea, which typically resolves within 30 minutes.264 The late
reaction takes place up to 6 hours after exposure and is characterized by nasal obstruction
and congestion.264 Superimposed late reactions may blunt the manifestation of acute phase
symptoms and make the diagnosis of AR less obvious.
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When attempting to determine whether a patient has AR, ARS, RARS, or CRS, it is
important to elicit a history of specific symptoms from the patient that includes onset and
duration of symptoms. A history of allergic symptoms or allergen exposure-related
symptoms support a possible diagnosis of AR, as these are not associated with rhinosinusitis
and AR may or may not be seasonal in nature, which can also be elicited by history.264,265
The development of acute, moderate to severe symptoms, and nasal purulence may be
consistent with ARS or RARS rather than AR.1,137,138 A prolonged duration of symptoms
(greater than 12 weeks) should raise suspicions for CRS and prompt further investigation.
1,137,138 (See section X.B. Associated conditions - Rhinosinusitis for additional information
on this topic.)

IV.

Pathophysiology and mechanisms of allergic rhinitis
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A background understanding of the pathophysiology and underlying mechanisms of AR is
necessary as we examine the clinical presentations, physical manifestations, goals of allergy
testing, and response to treatment. This section addresses the cellular inflammation, soluble
mediators, local allergic manifestations, and systemic effects associated with AR. While this
document is not intended to provide an extensive review of the pathophysiology of AR, the
following short section provides a foundation for understanding the clinical expression of
AR and its treatment.
IV.A.

IgE-mediated allergic rhinitis

Author Manuscript

IV.A.1. Systemic mechanisms and manifestations—The immune response leading
to IgE production in AR is often a systemic phenomenon, and patients with AR demonstrate
evidence of systemic atopy.269,270 One manifestation of systemic atopy in AR is the
cutaneous reaction elicited during traditional allergy skin testing.271 Further evidence for the
systemic nature of the IgE response in AR includes the temporal relationship of AR to a
number of other allergic diseases, including atopic dermatitis (AD), food allergy, and
allergic asthma, a phenomenon known as the “atopic march.”272 This pattern of atopic
disease progression is well-known and supported by prospective studies.273
The immunologic processes underlying IgE-mediated AR are similar to those of other atopic
conditions and involve activation of the adaptive immune system. The adaptive immune
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response can be broadly classified into 2 categories based upon the predominant Th
lymphocyte subtype.274 The Th1 profile is responsible for defense against intra-cellular
pathogens, while Th2 responses are implicated in the defense against parasitic infections as
well as the IgE-mediated eosinophilic inflammation of allergy.272 Whether AR will develop
as a result of inhalant allergen exposure therefore depends largely upon the balance between
Th1 and Th2 effector cells.274
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A number of steps in the sensitization process are responsible for eliciting the Th2predominant response. The process begins with exposure of the nasal mucosa to inhalant
allergens.275 While mucosal epithelial cells were once thought to function simply as a
mechanical barrier to allergen penetration, recent research suggests that epithelial cells play
a much more sophisticated role in allergy development, through the secretion of numerous
inflammatory mediators including cytokines, chemokines, eicosanoids, and endopeptidases,
as well as through upregulation of cellular adhesion molecules and release of matrix
metalloproteinases.276 They also provide an important early stimulus toward a Th2-weighted
immune response, through the secretion of thymic stromal lymphopoietin (TSLP).272,275,276
TSLP causes maturation of dendritic cells into Th2-promoting subtypes,277 which secrete
chemokines that attract Th2-destined T lymphocytes, foster clonal amplification of Th2
cells, and enhance survival of memory B-cells.272 TSLP also promotes recruitment of
eosinophils and enhanced activity of basophils and mast cells.272
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Allergens are then engulfed by dendritic cells, which migrate to lymphoid organs where the
antigen is presented to naive helper T (Th0) cells on MHC class II molecules.274 Th2
differentiation also requires co-stimulation via the interaction of CD28 on T cells with CD80
and CD86 on antigen-presenting cells (APCs).278 Additionally, the presence of the cytokine
IL-4 is required.279 IL-4 binds STAT-6 on the Th0 cell, activating the master switch
GATA-3.272 This stimulates IL-4, IL-5, and IL-13 production,274 which is characteristic of
the Th2 response. These cytokines, produced by the newly differentiated Th2 cell, have
several effects that further promote IgE-mediated eosinophilic inflammation and allergy.
IgE is produced by B-cells under the influence of Th2 effector cells and the cytokines they
secrete.275 Development of an IgE-secreting B cell requires the presence of IL-4 or IL-13,
which induce class switching via upregulation of ε-germline gene transcription and clonal
expansion, as well as interaction between CD40 ligand on the T-cell surface and CD40 on
the B-cell surface, which promotes B-cell activation and the production of IgE.279 Allergenspecific IgE (sIgE) is then released into the circulation by plasma cells.
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IgE antibodies subsequently bind high-affinity receptors (FcεRI) on the surface of mast cells
and basophils, rendering them sensitized.280 Future allergen exposure results in crosslinking
of IgE on the surface of mast cells and basophils causing degranulation, release of
inflammatory mediators such as histamine, and the classic symptoms of AR.
IV.A.2. IgE-IgE receptor cascade—IgE plays a central and defining role in the
pathophysiology of acute allergic reactions as well as chronic atopic disease.281 In
individuals with AR, exposure to specific allergens results in the production of allergenspecific IgE, which then binds to effector cells such as mast cells and basophils via the high-
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affinity receptor FcεRI. Although IgE in plasma is short-lived, IgE that is receptor-bound
remains attached to these cells for weeks or months. Moreover, when IgE bound to FcεRI
cross-links with a specific allergen, it induces the release of preformed inflammatory
mediators from mast cells and basophils, resulting in clinical manifestations of allergic
diseases.
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Cytokines including IL-4 and IL-13 released from T cells and mast cells drive the
differentiation of B cells into IgE-secreting plasma cells. Several studies, both in vivo and in
vitro have confirmed the production of local IgE in the nasal mucosa of patients with AR.
282-284 The locally produced IgE plays a key role in ongoing inflammation by up-regulating
FcεRI expression in mast cells.283-285 The augmented expression of FcεRI allows them to
bind greater numbers of IgE-antigen complexes, which in turn enhances the sensitivity of
mast cells to allergen. This results in an increased production of immunomodulatory
cytokines and chemical mediators, forming an important positive-feedback amplification
loop involving the IgE-IgE receptor cascade, thus perpetuating ongoing inflammation.285,286
Interestingly, the density of IgE receptors and IgE molecules in mast cells within the nasal
mucosa of patients with AR have been shown to correlate with levels of serum IgE.285 The
presence of elevated levels of IgE in nasal secretions has been demonstrated in non-allergic
rhinopathy as well, which potentially further highlights a significance of the IgE-IgE
receptor cascade in driving the disease process of rhinitis.287
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IV.A.3. Local IgE production and local allergic rhinitis (LAR)—LAR is a regional
inflammatory condition defined by local symptoms and sIgE-mediated inflammation
without evidence of systemic hypersensitivity.107,194,284,288 It is important to remember that
conventional allergy testing, such as SPT and the radioallergosorbent test (RAST), only
indicates sensitization (atopy), but not symptomatic allergy. While it is possible for a
positive allergy skin or in vitro test result to lack clinical relevance, the opposite is also true,
as a negative allergy skin or in vitro test result does not exclude regional IgE-mediated
sensitivity, as in the case of LAR.194,288-290 LAR may affect more than 47% of children and
adults previously classified as NAR,290-295 and persists throughout the years with a low rate
of conversion to clinical AR.296-298 However, LAR may evolve to the development of
asthma.296,297 Diagnosis of LAR is based on demonstration of a positive response to NPT
and/or the detection of nasal sIgE and/or a positive basophil activation test (BAT) in the
absence of systemic atopy. The pathophysiology of LAR is complex and not completely
understood. Immunologic studies have revealed the existence of a Th2 inflammatory
response in the nasal mucosa of LAR patients,177,299-301 with positive response to NPT,
291,300-302 and local production of sIgE177,290,299-301,303-305 and inflammatory mediators.
304,306,307
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Nasal Th2 inflammatory response.: Flow cytometry studies in nasal secretions have
confirmed that aeroallergen exposure induces a Th2 inflammatory response in the nasal
mucosa of LAR patients with increased eosinophils, basophils, mast cells, CD3+, and CD4+
T cells.300,301 NPT studies have demonstrated the existence of characteristic immediate/
early and late-phases of the allergic response in LAR patients with local production of sIgE,
mast cell, and eosinophil activation, with mucosal secretion of tryptase and ECP.306,307 A
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recent study showed that 83% of LAR subjects sensitized to Olea europaea pollen responded
to NPT with nOle e 1 (the most significant allergen of Olea europea), demonstrating that
purified allergens can also induce an allergic response with secretion of ECP.308
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Local sIgE production.: The respiratory airway mucosa is a site of IgE production during
allergic inflammation, as has been demonstrated in patients with AR309-312 and LAR,
299-301,303-307 with both somatic hypermutation and class switching occurring in the nasal
mucosa.309,312-315 Cellular studies have confirmed the expression of ε-germline gene
transcripts and messenger RNA (mRNA) for the ε heavy-chain of IgE in nasal mucosal Bcells.310 The rate of local IgE production316 is sufficient to saturate IgE receptors on local
mast cells, and potentially spill over into the circulation.316,317 In LAR, the presence of sIgE
in nasal secretions has been confirmed after natural allergen exposure,300,301 NPT,
300,301,303-305 and periods of non-exposure.300,301 Furthermore, local sIgE in LAR has the
capability of activating basophils via the high-affinity receptor FcεRI, leading to the release
of inflammatory mediators characteristic of AR.308,318
IV.B.

Non–IgE-mediated inflammation in allergic rhinitis
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It is commonly accepted that AR is primarily an IgE-driven response.319 However, in recent
years our understanding and appreciation of the important contributions of the nasal innate
immune response to the pathogenesis of AR has grown substantially.320 The
pathophysiologic mechanisms of inflammatory airway disease are related to large
physiologic networks that influence host-environment interactions. The nasal epithelium is
the first structure to encounter inhaled aeroallergens. Intrinsic proteolytic activity of
allergens may disrupt the nasal epithelial barrier, facilitating allergen penetration and chronic
inflammation.321 Recent data provide additional evidence that epithelial barrier dysfunction
contributes to the development of inflammatory diseases such as AR, but it remains to be
elucidated to what extent primary (genetic) vs secondary (inflammatory) mechanisms drive
this breakdown.322 Epithelial cells not only act as a physical barrier toward inhaled
allergens, but also actively contribute to airway inflammation by detecting and responding to
environmental factors. The nasal epithelium expresses pattern recognition receptors in the
form of toll-like receptors (TLRs) that, after activation by allergens or pathogens, lead to the
production of different mediators.323,324 These mediators affect recruitment of inflammatory
cells to local tissues and create a microenvironment that affects the function of immune
cells, thereby propagating local inflammatory processes.325 In allergic disease, the nasal
epithelium seems to be in a permanently activated state,326 potentially as a consequence of
the inability to switch off the activation response.327
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An interesting recent development was the discovery of innate lymphoid cells (ILCs) as
potential key players in the pathogenesis of Th2-type diseases such as AR, CRSwNP, and
asthma.328-330 ILCs are a family of effector cells that are important for protection against
infiltrating pathogens and restoration of tissue integrity. ILCs do not express antigen-specific
T-cell receptors, but can react promptly to “danger signals” and produce an array of
cytokines that direct ensuing immune responses. Three major subsets have been defined
based on their phenotype and functional similarities to Th1 (ILC1), Th2 (ILC2), and Th17
(ILC3) cells. Upon exposure to environmental antigens, including viruses and allergens,
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airway epithelial cells rapidly release the cytokines IL-25, IL-33, and TSLP which directly
activate ILC2s that then produce the prototypical type 2 cytokines IL-5 and IL-13.331
Allergen challenge in AR subjects induces an increased number of peripheral serum
ILC2s332,333; however, a similar increase in the nasal mucosa is yet to be demonstrated. In
addition to treatments aimed at modulating IgE-mediated inflammation, novel therapies
directed toward the innate immune system are in development for treatment of AR.334,335
IV.C.

Unified airway concept
The upper and lower airways are linked from anatomical, histological, and immunological
perspectives with inflammation in one part of the airways influencing the other part, thus
forming a united airway system.336 New systemic treatment options make understanding of
the relationship between upper and lower airways even more important.337
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The mucosa of the upper and lower airways is similar, containing pseudostratified
epithelium with ciliated columnar cells lining. Basal epithelial cells are also present,
attached to the basement membrane (lamina reticularis), and have an epithelial stem cell
function. In the submucosa there are vessels, mucus glands, fibroblasts, and some
inflammatory cells. The main difference in mucosal components is the absence of smooth
muscles in the upper airways as compared to the lower airways, and the lack of extensive
subepithelial capillaries, arterial systems, and venous cavernous sinusoids in the lower
airways as compared to the upper airways.
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The characterization of phenotypes of rhinitis and asthma are very similar, with emphasis on
allergy and eosinophilia, non-allergic phenotypes in both upper and lower airways, and the
link between CRS, especially with nasal polyps, and late onset asthma.319,338,339 Both AR
and asthma may also be characterized by hyperreactivity that is not correlated to the atopic
state.192,340 Also in endotyping, similarities can be pointed out with emphasis on type 2 vs
non-type 2 immune responses. In allergic diseases, the prominent endotype is type 2 (eg,
Th2 cells, type 2 B-cells, IL-4-producing natural killer [NK]/T cells, basophils, eosinophils,
mast cells, ILC2, IL-4, IL-5, IL-13, IL-25, IL-31, IL-33).319,341 In general, the type 2 profile
in AR and asthma is associated with a good response to corticosteroid treatment. New
targeted treatments that focus on (subgroup) type 2 elements, such as anti-IgE antibodies,
anti-IL-5 (mepolizumab), and anti-IL-4/IL-13 (dupilumab) are currently used in asthma, but
are not currently approved for use in the upper airways.342 Similarities are not only found in
the acquired immune response, but also in the role of innate immunity like epithelial barrier
function334 and innate lymphoid cells.332 Epithelial barrier leakiness, particularly tight
junctions that seal the upper and lower respiratory mucosal epithelial surface, has been
shown in asthma, AR and CRS.343,344
Several mechanisms may explain the influence of sinonasal inflammation on the lower
airways; ie, altered breathing pattern, pulmonary aspiration of nasal contents, the
nasobronchial reflex, and the uptake of inflammatory mediators in the systemic circulation.
345 The nose acts as a filter and air conditioner, protecting the lower airways. Reduced filter
and air-conditioning functions of the nose may lead to increased exposure of the lower
airways to allergens. Mouth breathing is independently associated with asthma morbidity,
indicating that air conditioning can be of major importance. The efficacy of the nasal filter
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depends on the size of the inhaled particles. Small molecules, such as molds and cat dander,
are more associated with an increased risk for asthma, whereas larger molecules, such as tree
and grass pollen, are primarily associated with upper airway symptoms. The role of
preferential mouth breathing in the development of asthma is unclear.346
Although there is a relationship between postnasal drip and coughing, no direct association
has been proven between overproduction of nasal secretions and bronchial hyperreactivity.
Moreover, after nasal application, deposits of radioactive-labeled allergen can be found in
the digestive tract but not in the respiratory tract.347 Stimulation of pharyngolaryngeal
receptors is more likely to be responsible for a postnasal drip-related cough.348 Interestingly,
cough is not induced in patients with rhinitis or healthy controls in simulated models of
postnasal drip.349
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There is not much evidence supporting the nasobronchial reflex as an important contributor
to the unified airway. Nasal allergen challenge can be blocked with a vasoconstrictor but not
with lidocaine. Moreover, lower airway responses after allergen challenge are in general
more delayed than would be expected following a nasal-bronchial reflex.350
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Allergen provocation studies represent a good model to study nasal-bronchial crosstalk in
allergic airway disease. In patients with AR, segmental bronchial or nasal provocation can
induce allergic inflammation in both the nasal and bronchial mucosa.347-349 Presumably,
absorption of inflammatory mediators (eg, IL-5 and eotaxin) from sites of inflammation into
the systemic circulation results in the release of eosinophils, basophils, and their progenitor
cells from the bone marrow.351 The systemic allergic response is further characterized by
increased expression of adhesion molecules, such as vascular cell adhesion molecule 1 and
E-selectin on nasal and bronchial endothelium, which facilitates the migration of
inflammatory cells into the tissue.352
Increases in CD34+ cells capable of eosinophil differentiation, as well as other circulatory
mediators (IL-5, eotaxin, and cysteinyl leukotrienes), are associated with impaired lung
function parameters and enhanced mucosal inflammation in asthmatic patients,353 and react
to local corticosteroids in AR.354 Treatment with anti-IL-5 and other interleukins relevant in
the eosinophilic pathway has been shown to be effective in asthma, with some beneficial
results in eosinophilic upper airway disease.342
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In conclusion, these studies demonstrate that the same mechanisms behind AR may be
important in airway inflammation throughout the respiratory tract, even in the absence of
clinical asthma. Systemic factors, such as the number of circulatory eosinophils and atopic
severity are indicative of more extensive airway disease.
IV.D.

Cellular inflammatory infiltrates
A variety of cells are involved in the pathophysiology of AR. Due to the nature of the
disease, with different mechanisms and endotypes, it is practically impossible to
comprehensively describe each of these inflammatory cells in detail. This suggests a need
for an extensive endotyping and characterization of the cellular infiltrate for each endotype.
355 In addition, many studies focusing on cell types in allergic diseases, including recently
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identified cells such as type 2 ILCs, Th17 cells, and Th22 cells, have been mostly restricted
to investigations of peripheral blood cells, not tissue biopsies. There is evidence from a
limited number of studies that different cells are involved at different stages of
inflammation, such as exacerbation, remission, and extensive remodeling. Furthermore,
different tissue sites such as sinus mucosa, polyp tissue, or inferior turbinates show a variety
of different infiltrating immune and inflammatory cells.
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Nasal epithelial cells are at the interface of the human body and the environment, and often
act as the first line of defense against external pathogens. Epithelial cells interfere with nonself allergens and regulate infiltrating cells in AR through the production of various costimulatory molecules, chemokines, cytokines, and lipid mediators. These cytokines start to
orchestrate a type 2 immune response characteristic of AR.356 However, when allergens
have additional protease activity and/or they are accompanied by microbial components such
as endotoxins or inorganic particles, epithelial secretory responses can lead to mixed type 2
and type 17 immunity, or even type 1 responses.357,358 In response to respiratory viruses,
epithelial cells produce a wide range of mediators such as type I interferons, granulocyte
macrophage colony-stimulating factor (GM-CSF), RANTES/C-C Motif Chemokine 5
(CCL5), and interferon gamma-induced protein 10/C-X-C Motif Chemokine 10 (IP-10/
CXCL10).359 These mediators orchestrate further downstream innate and adaptive antiviral
cellular immune responses.
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To activate allergen-specific CD4 T-cells, adequate co-stimulation is required. Dendritic
cells are professional APCs that are directly related to AR, with increased numbers and
concentrations of IgE in atopic disease.360 They are in close contact with epithelial cells and
ILCs and control T-cell and B-cell activation and differentiation.356 Also, elimination of
dendritic cells has been shown to suppress the development of AR.360
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Both innate and effector mechanisms play essential roles during the development of allergic
disease.361 T-helper subset imbalance and production of typical Th2 cytokines,362 along
with increased expression of GATA-3,363 is generally seen in AR nasal mucosa.
Furthermore, CD4+ memory T-cells and gamma/delta-T-cells are increased in PAR patients’
mucosa.364 Effector Th2 cells produce IL-4, IL-5, IL-9, and IL-13.356,365 In addition, TSLP,
IL-25, IL-31, and IL-33 contribute to the development and intensity of Th2 responses and
inflammation. These cytokines have roles in production of sIgE, eosinophilia, mucus, tissue
migration of Th2 cells and eosinophils, regulation of tight junctions, and epithelial barrier
integrity.343,356,366,367 T-regulatory (Treg) cell subsets have distinct phenotypes and include
constitutive and inducible subsets of CD4+CD25+ Forkhead box P3 (FOXP3)+ Treg cells,
and type 1 Treg cells.368-370 Treg cells play a major role in allergen tolerance and allergen
immunotherapy (AIT).371-373 The production of IL-10 and transforming growth factor
(TGF)-β from other cells is decisive for their immune regulatory functions. The ratio
between effector and regulatory cell types determines whether an allergic response is
triggered by an allergen or not.
Populations of lymphoid cells that lack rearranged antigen receptors and markers for
myeloid and lymphoid lineages, such as T-cells, B-cells, and NK-cells have been defined as
ILCs. Type 1 ILCs (ILC1) mainly produce interferon (IFN)-γ, ILC2s produce IL-5 and
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IL-13,374 and ILC3s produce IL-17 and IL-22.361 Type 2 ILCs are found in AR, where they
closely interact with epithelial and other cells controlling the mucosal environment. Through
the production of cytokines and induction of chemokines, a type 2 immune response is
favored, supporting further development of an allergic tissue inflammation.375
Although it was believed that IgE-producing B-cells reside in lymphoid follicles of the
Waldeyer ring376 and antibodies were then transferred to the mucosa, newer evidence has
identified B-cells and plasma cells capable of producing IgE in nasal tissue of AR patients.
377 The local production of allergen-specific antibodies is further supported by the detection
of secondary lymphoid tissue and IgE formation to Staphylococcus aureus in CRSwNP.378
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Within the nasal epithelium of allergic individuals increased numbers of major basic proteinpositive and EG2+ (activated) eosinophils can be encountered during the pollen season.
Similarly, mast cells are found within the epithelium and the submucosal layer; however, no
increases are observed in cell counts of T-lymphocytes or their subsets, nor of neutrophils or
macrophages during seasonal allergen exposure.379 Basophil numbers in the lamina propria
of the nasal mucosa increase within 1 hour of allergen provocation.380 Degranulation of both
mast cells381 and basophils occurs during the early and late phases of a type I reaction after
allergen encounter and crosslinking of IgE molecules as well as upon stimulation by
IL-33.382
In the late phase of the allergic reaction, the influx of inflammatory cells is facilitated by
chemoattractants and upregulation of adhesion molecules.383 This leads to further
infiltration of the tissue by eosinophils, basophils, and T-cells. Last, those inflammatory cells
driving remodeling of the mucosa in AR, and upregulating factors such as matrix
metalloproteinases and angiogenic factors, remain to be identified.384
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IV.E.

Cytokine network and soluble mediators
Cytokines are immunomodulatory proteins important in cellular signaling. Complex
interactions of innate and adaptive immune cells, as well as structural cells and their
cytokines, play crucial roles in regulating allergic airway inflammation. The inflammatory
process underlying AR is coordinated by a network of cytokines.
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Type 2 cytokines such as IL-4, IL-5, IL-6, and IL-13 are crucial in regulating the allergic
inflammatory cascade characterized by an increased presence of eosinophils and mast cells
and an upregulation of IgE production. Besides their role in the induction of IgE synthesis,
type 2 cytokines up-regulate the production of other cytokines and chemokines from
epithelial cells and fibroblasts,283 which then leads to the influx of inflammatory cells
including eosinophils and mast cells.385,386 Scadding et al.387 demonstrated the
immunological aspects of rhinitis with nasal allergen challenge. After nasal challenge with
grass pollen in sensitive individuals, the levels of IL-4, IL-5, and IL-13 were elevated 2 to 3
hours postchallenge and increased for up to 5 or 6 hours.387 Similarly, levels of chemokines
such as thymus-regulated and activation-regulated chemokine (TARC, CCL17), macrophage
derived chemokine (MDC, CCL22), eotaxin, RANTES, MCP-1, and macrophage
inflammatory protein (MIP)-1α were elevated.388-391 Increases in these type 2 cytokines and
associated chemokines were strongly correlated to allergic clinical responses.
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Although type 2 cytokines were originally referred to as Th 2 cytokines after their suspected
cellular source, several other cells have been identified as significant sources including mast
cells, epithelial cells, type 2 ILCs, and eosinophils. Airway mast cells are an important
source of type 2 cytokines, proinflammatory cytokines, chemokines, and the IL-7–like
cytokine TSLP.283,392-394 IL-13 from mast cells plays a crucial role in mast cell–induced
local IgE synthesis by B cells,286,395 which in turn upregulate FcεRI expression on mast
cells.286 Further, several mast cell products heavily influence epithelial cells. TNF-α, a
proinflammatory cytokine produced by mast cells, in concert with IL-4 and IL-13, enhances
the production of TARC, TSLP, and eotaxin from epithelial cells.385 And chemokines such
as tryptase and chymase can upregulate RANTES and GM-CSF production from epithelial
cells.385 Thus, there appears to be a crucial interplay between mast cells and epithelial cells
in promoting and regulating the allergic inflammatory cascade.
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In addition to the cytokines and chemokines listed in the previous paragraphs, nasal
epithelial cells are an important source for IL-1, IL-6, IL-8, and TNF-α. Through these
signals, epithelial cells play a crucial role in the migration and activation of eosinophils,
basophils, and Th2 cells.396 In addition, epithelial cells release the cytokines IL-25, IL-33,
and TSLP that orchestrate both the innate and adaptive Type 2 immune response. These
same cytokines are also released by tissue damage, pathogen recognition, and allergen
exposure. They can regulate Th2 cell function either directly or via innate lymphoid cells,
which in turn produce IL-5, IL-9, IL-13, TSLP, IL-25, and IL-33, which are all increased in
the nasal mucosa of AR patients, indicating a role of these cytokines in the pathophysiology
of AR.397-400 In fact, levels of IL-33 in nasal secretions have been shown to correlate with
total nasal symptom scores.400 Further, TSLP has been shown to activate dendritic cells,
promote Th2 responses, and activate mast cells.401
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Eosinophils are another cell type that appears to play a significant role in the
pathophysiology of AR. They are a major source of the inflammatory cytokines macrophage
migration inhibitory factor (MIF)402 and nerve growth factor (NGF).403 Eosinophils express
5-lipoxygenase, LTC4S, and CysLT1 and CysLT2 receptors, which play a role in the
arachidonic acid pathway.404 IL-5 has a key role modulating eosinophil maturation,
differentiation, and survival.405 Eosinophilic chemoattractants include eotaxin, MCP4,
RANTES, and cysteinyl leukotrienes, among others.406-408 As discussed in earlier
paragraphs within this section, mast cells and epithelial cells either directly produce or
upregulate many of these same chemoattractants.
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Finally, Th17 cells are a unique subpopulation of CD4+ T cells. They produce IL-17A,
IL-17F, IL-22, TNF-α, and IL-21.409 They have been demonstrated to be in the nasal
mucosa of AR patients and are therefore thought to play a role in allergic inflammation.
409,410 Further, IL-17A has been shown to be upregulated in SAR patients 5 hours after nasal
allergen challenge.411 Finally, increased numbers of IL-17A+ cells and IL-17A mRNA were
demonstrated in the nasal mucosa of patients with dust mite allergy, indicating a possible
role in AR.412
In summary, AR is a type 2–mediated disease, characterized by important regulatory
cytokines such as IL-4, IL-5, and IL-13. Newer type 2 cytokines have been identified in AR,
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including IL-17 family cytokines. Finally, Type 2 ILCs and epithelial cell-derived cytokines
such as TSLP, IL-25, and IL-33 play a crucial role in the regulation of the allergic
inflammatory cascade.
IV.F.

Histologic and epithelial changes
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Normal nasal mucosa comprises pseudostratified columnar ciliated epithelium with goblet
cells over a basement membrane. The nasal submucosa contains stromal elements including
fibroblasts, blood vessels, seromucinous glands, sensory nerves, and leukocytes. Leukocytes
present in the nasal mucosa include CD4+ and CD8+ T lymphocytes, B lymphocytes,
eosinophils, neutrophils, basophils, mast cells, and macrophages. The combined functions of
ciliated and secretory cells allow for nasociliary clearance, removing pathogens and
allergens as a host defense mechanism. In addition to the physical barrier, nasal epithelium
plays an important role in the innate and acquired immunologic defense against
pathogens359,413,414 by: (1) expressing pattern recognition receptors that recognize
pathogen-associated molecular patterns; (2) secreting a vast arsenal of host defense
molecules, such as antimicrobial enzymes, opsonins, permeabilizing proteins, collectins, and
binding proteins; and (3) producing inflammatory cytokines in response to antigenic stimuli.
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Allergy mediates epithelial change in the nasal mucosa. Nasal epithelium is thicker in
patients with AR after allergen challenge,415,416 but studies on epithelial thickness in AR
without allergen challenge are conflicting.415-417 While epithelial remodeling is a key
feature of CRS (epithelial hyperplasia, goblet cell hyperplasia, and squamous
metaplasia)418-420 and asthma (epithelial desquamation, subepithelial fibrosis, and smooth
muscle hypertrophy), remodeling in AR is less marked. In general, limited studies have
found no significant increase in basement membrane thickness, subepithelial fibrosis, goblet
cell hyperplasia, or blood vessel volume and surface density,415,421,422 though increased
vascular permeability was noted.423 In contrast to epithelial remodeling, epithelial
inflammatory response to allergens is a key feature of AR. Upon allergen exposure, there is
significantly higher infiltration of inflammatory cells, and increased levels of cytokines
(such as IL-4, IL-5, and IL-13) in the nasal epithelium of allergic compared to non-allergic
patients.182 This inflammatory response translates into mucosal edema, autonomic neural
stimulation, and increased mucosal secretions, which manifest as the hallmark symptoms of
nasal obstruction, pruritus, sneezing, rhinorrhea, and smell loss in severe cases.
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The epithelial barrier is noted to have specific functions in allergy. Penetration of allergens
through this barrier may lead to allergen sensitization and local and/or systemic
inflammatory response. In the nasal mucosa, this barrier is comprised of mucus and
epithelial cells, which are linked by apical junctional complexes (tight junctions and
adherens junctions).367 Mechanical or infective insults to the epithelium or defective
epithelium leads to barrier breach and allergen penetration.367,424-426 Loss-of-function
mutations and polymorphisms in genes coding for epithelial barrier markers such as
filaggrin are associated with AR and eczema.427,428 Some allergens can induce junctional
dysfunction, leading to penetration of the epithelial barrier by allergens.322,429 Proteolytic
allergens directly disrupt the apical junctional complex via proteolysis, leading to barrier
dysfunction.430 Detection of allergens by APCs, and the ensuing Th2 responses and
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cytokine release (such as IL 4, IL-13, and IFN-γ) induces further “leakiness” of the apical
junctional complex via various mechanisms, allowing increased levels of allergen
penetration.367 Evidence suggests that this barrier impairment may be reversed with
corticosteroids. Fluticasone propionate has been found to increase expression of tight
junction proteins zonula occludens 1 and occludin and a more intact nasal epithelial barrier.
322 Corticosteroids have not, however, been shown to cause thinning of nasal epithelium.
322,431

Author Manuscript

Allergy is now considered both a systemic and local epithelial condition.337 Evidence points
to the epithelium being an active participant in the development and progress of allergy,
rather than as a passive barrier.432 Birch pollen has been found to rapidly bind to Bet v 1–
binding proteins in sensitized nasal epithelium, and is transported through a lipid raft and
caveolar-dependent process before binding to mast cells in the lamina propria.433-435
Epithelial response to allergens differs from healthy individuals in that allergic patients do
not mount as robust an epithelial defense response to allergens, leading to increased
penetration of allergens.432
IV.G.

Microbiome
The human microbiome comprises the complex community of microorganisms that resides
in and interacts with the human body. The adult intestine is a haven to approximately 100
trillion microbes and it is thought that the microbiome accounts for roughly 90% of all the
cells in the human body.436,437 The microbiomes of individuals vary, likely due to the fact
that the growth, development, and composition of the microbiome are affected by intricate
interactions between the environment, diet, and host-related factors.437
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With the advent of culture-independent high-throughput bacterial DNA sequencing
techniques, a detailed description of the composition and variety of the microbiome can be
described among organs and individuals.438 The Human Microbiome Project began in 2007,
and as a result, extensive data have emerged examining the associations of the microbiota of
the respiratory tract, oral cavity, gut, skin, and genitourinary tract to the development of
disease processes including allergy and asthma.437
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Increasing literature in animals and humans has implicated changes in the microbiome with
the development of allergic disease.439,440 Mechanistically, a disruption in gastrointestinal
bacteria is thought to alter mucosal immunological tolerance.441 Several authors have found
associations of reduced gut microbial diversity with development of allergic disease in
school-aged children.442,443 For example, the development of allergic symptoms in children
has been associated with overall lower microbial diversity, increased prevalence of
Bacteroides and Bifidobacterium adolescentis, and lower counts of Akkermansia
muciniphilia, Faecalibacterium prausnitzii, and Clostridium.444 In addition, Fujimura et al.
445 recently noted that a lower abundance of Bifidobacterium, Akkermansia, and
Faecalibacterium were associated with a higher risk of development of polysensitization by
age 2 years and physician-diagnosed asthma by age 4 years. The authors concluded that
neonatal intestinal microbial dysbiosis may foster CD4+ T-cell dysfunction associated with
childhood allergic disease.445,446
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The most comprehensive collection of evidence evaluating a potential association between
the microbiome and the development of allergic disease is from a recent systematic review
by Melli et al.444 Studies included in this systematic review compared intestinal microbiota
of allergic patients with healthy controls. A total of 21 studies were noted to report an
association between the intestinal microbiota and allergic disease when stool collection was
performed prior to the outcome assessments. Only 4 of the analyzed studies had specific
outcomes related to AR or sensitization. Penders et al.447 found that the presence of
Clostridium difficile at 1 month of age was associated with an increased risk for allergic
sensitization (odds ratio [OR] 1.54; 95% confidence interval [CI], 1.09 to 2.31) until the age
of 2 years. Adlerberth et al.448 noted an increased ratio of gram-negative to gram-positive
bacteria at 1 year of age to be associated with IgE levels greater than 100 kU/L at 1.5 years
of age. Bisgaard et al.449 found lower bacterial diversity was associated to higher risk of
allergic sensitization (p = 0.003) and AR (p = 0.007). Johansson et al.450 reported lower
frequency of colonization with Lactobacilli and Bifidobacterium bifidum in allergic
children.15 Ultimately, Melli et al.444 found that most of the studies linking the microbiome
to the development of atopic disease were varied and difficult to interpret due to differing
methodologies, samples sizes, and culture techniques.
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There are some thoughts that the composition and/or dysbiosis of the microbiota (viruses,
fungi, and/or bacteria) of other sites such as the nasopharynx, lungs, and sinonasal cavities
may also play a role in the development of allergic disorders. However, these studies are in
their infancy and little can be concluded at this time.451
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A thorough understanding of the role of the microbiome and how it influences allergic
disease has not been fully elucidated. Although some data suggest associations between
allergic disease and the microbiota, based on the current evidence it is difficult to distinguish
between protective microorganisms and those that increase risk for allergic disease.446
Future research should provide an enriched and diverse understanding of the human
microbiome and the way it impacts AR.

V.
V.A.

Epidemiology of allergic rhinitis
Prevalence of allergic rhinitis in adults
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A variety of population-based surveys have been used to estimate the prevalence of AR
within the adult population. Prevalence estimates largely rely on self-reports of “hay fever”
or “nasal allergies,” or of nasal symptoms “when you did not have a cold or the flu.”
Questions on seasonality (to separate seasonal from perennial rhinitis) are sometimes asked,
but there are few large-scale well-conducted population-based studies that have evaluated
persistent (lasting more than 4 days/week for more than 4 consecutive weeks) vs intermittent
symptoms. Because many surveys differ in terms of disease definitions, geography, and
seasonality prevalence estimates drawn from surveys vary widely.
One of the earliest studies, conducted in Tecumseh, Michigan, in 1959–1960 included a
physician assessment and suggested that the prevalence of hay fever (diagnosed as “upper
respiratory symptoms believed to be allergic in origin and occurring predominantly in either
spring, summer or autumn”) was about 11% in those aged over 20 years.452 About 20 years
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later, the National Health and Nutrition Examination Survey (NHANES) 1976–1980 was
conducted among a geographically representative sample of the U.S. population. This survey
gave broadly similar estimates for prevalence of AR, defined as “physician diagnosis of hay
fever or frequent nasal and/or eye symptoms that varied by both season and pollen during
the last 12 months, not counting colds or the flu.”453 A more recent report based on
NHANES (2005-2006), presented population prevalence figures in which two-thirds were
over the age of 20 years, and showed the lifetime prevalence of physician-diagnosed hay
fever was 11.3%, with 6.6% having symptoms in the last 12 months. However, reliance on
physician diagnosis of AR is likely to considerably under-estimate the actual prevalence of
AR, since many patients self-diagnose and self-treat. Surveys involving patient selfreporting AR have shown that one-third of the population reported “sneezing and/or nasal
symptoms in the absence of cold or a flu,” with about 24% reporting that this was seasonal
in nature, and a further 10% reporting these symptoms occurred year-round (ie, perennial).
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454
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In the early 1990s, the European Community Respiratory Health Survey (ECRHS), a
multicenter population-based study of adults age 20 to 44 years in 23 countries (mainly
Western Europe, but also Australia and New Zealand), used a self-completed questionnaire
to estimate the prevalence of “hay fever or nasal allergies.” Prevalence varied between 10%
and 40% across participating centers,455 with even more participants (12-65%) reporting
that they experienced a runny or stuffy nose or started to sneeze on exposure to sources of
allergen.456 If a positive SPT was included in the disease definition, the prevalence of AR
fell by a variable amount (absolute fall in prevalence between 4% and 16% across all
centers). In the Swiss Study of Air Pollution and Lung Disease in Adults (SAPALDIA),
conducted around the same time as the ECRHS, the prevalence of self-reported “nasal
allergies including hay fever” in adults aged 18 to 60 years was 17.9%, and the prevalence of
current symptoms (“hay fever this year or last year”) was 14.2%.457 Prevalence estimates
were lower if a positive SPT was included (11.2% for current hay fever with at least 1
positive SPT and 9.1% for current hay fever with positive SPT to 1 of grass, birch, or
Parietaria). More recently, the Global Allergy and Asthma Network of Excellence
(GA2LEN) study suggested the prevalence of “nasal allergies and hay fever” varied between
22% and 41% in adults age 18 to 75 years living in the 12 participating European nations.458
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Population-based studies have shown increases in AR prevalence in the adult population in
recent decades. For example, in Renfrew Paisley, UK, the prevalence of hay fever was higher
in adults and children in 1996 than in their mothers and fathers at an equivalent age in
1972.459 Hay fever prevalence doubled between 1981 and 1990 in Busselton, Australia,460
increased in Italy from 1991 to 2010,461 and increased in 8 of 11 cities in China surveyed in
2005 and again in 2011.462 In Uppsala, Umea, and Goteborg, in Sweden, “hay fever and
nasal allergies” increased from 21% to 31% between 1990 and 2008,463 although recent
reports from Stockholm suggest there may be a leveling off in the increase in nasal allergies
over more recent years.464
From these data, the lifetime prevalence of AR in the United States can be estimated
between 11% (physician-diagnosed) and approximately 33% (self-reported). In Europe,
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prevalence of AR in adults likely ranges between 10% and 41%, depending on the specific
country.
V.B.

Incidence and prevalence of allergic rhinitis in children

Author Manuscript

There are relatively few studies on the incidence of AR in children. There is evidence that
AR may start as early as during the first year of life. In the Cincinnati Childhood Allergen
and Air Pollution Study (CCAAPS), 9% of the 12-month-old children with a parental
history of respiratory allergy fulfilled the criteria of AR.465 In the Pollution and Asthma
Risk: an Infant Study (PARIS) birth cohort, 9.1% of the 18-month-old children had AR-like
symptoms with a strong association with atopy and sensitization to inhalant allergens. Of
these, 23.7% had rhinoconjunctivitis.466 In a study of 29,662 children from the United States
that used health care records to follow participants, the incidence of physician-diagnosed AR
during the first year of life was 1%. From 1 to 5 years of age, the annual incidence was
between 3.6% and 4.5%, with the highest incidence between 2 and 3 years of age.467 This is
broadly in line with estimates of a SAR incidence of 3% to 4% per year from 3 to 7 years of
age reported in a birth cohort of 1314 German children.468
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In longitudinal studies, AR often occurs for the first time in childhood and increases in
prevalence with increasing age.467-471 Most children with symptoms of AR early in life have
persistent symptoms for several years.469-471 The International Study of Asthma and
Allergies in Childhood (ISAAC) estimated the prevalence of allergic diseases in 2 different
age groups, 6 to 7 years and 13 to 14 years, through a multicenter global survey. Two crosssectional surveys were performed approximately 7 years apart (range, 5 to 10 years).
Overall, an increase in rhinoconjunctivitis prevalence was observed between the 2 surveys.10
However, there were geographical differences in both baseline prevalence and in the
increases observed; therefore, it is difficult to determine whether the observed differences
represented a true increase in prevalence over time. The proportion of children with
symptoms of rhinoconjunctivitis was higher in the older age group. Data from the second
survey (ISAAC Phase Three 1999–2004) state that the worldwide prevalence of current
rhinoconjunctivitis in the 6-year to 7-year-old age group was 8.3% (range between countries,
1.8% to 24.2%) and in the 13-year to 14-year age group was 15.1% (range, 4.5% to 45.1%).
472 In a more recent meta-analysis of all studies performed according to the ISAAC-protocol
(1,430,329 children aged 0 to 18 years), the overall prevalence of AR was 12.66%.473
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Rhinoconjunctivitis has been reported to be slightly more common among boys than girls in
the 6-year to 7-year-old age group, with the opposite tendency seen in the 13-year to 14year-old age group.474 However, gender differences were not seen in all countries in the
survey. Other studies show a greater prevalence of AR among boys of all ages. For example,
in the Isle of Wight (UK) birth cohort of 1456 children, the prevalence of rhinitis among
boys as compared to girls was higher across all age groups (4 years 4.7% vs 2.1%, 10 years
14.9% vs 11.7%, 18 years 31.0% vs 24.0%).469
V.C.

Geographic variation of allergic rhinitis
The prevalence of AR shows marked geographic variation. Many factors likely contribute to
this disparity and not all are completely understood. The central difficulty in meaningfully
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comparing AR prevalence rates between locations is the difference in methods used to
recruit participants to studies and differences in assessing the presence of disease. For
example, Bauchau and Durham9 diagnosed Belgian patients via serological IgE testing after
a positive telephone screen and reported that Belgium had an AR prevalence of 28.5% (the
highest of the European countries evaluated). In contrast, Bousquet et al.456 skin-tested a
random sample of Belgian subjects and reported a positive rate in Belgium of 16.4% (one of
the lowest of 15 countries examined).
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There have been major international efforts to compare variations in the national prevalence
of AR using standardized methods (ie, ECRHS and ISAAC). These studies show marked
geographic variation of “hay fever or nasal allergies” (adults) or “a problem with sneezing,
or a runny, or a blocked nose when you DID NOT have a cold or the flu that was
accompanied by itchy-watery eyes?” (children). A higher prevalence of these responses is
seen in people living in “English-speaking” countries (eg, UK, Australia, New Zealand), a
lower prevalence in Eastern Europe than in Western Europe, and a diagnosis of AR is more
frequently seen in countries with higher asthma rates and sensitization to seasonal allergens.
455,475 Because these studies have evaluated national rates based on only one or a few
centers within each country, substantial intracountry variation may have been overlooked.
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In understanding the effects of geographic location, differentiating between seasonal and
perennial AR is an important consideration not examined in the ECRHS or ISAAC studies.
Smaller studies over more limited geographic regions that examined PAR suggest increased
sensitivity rates in urban settings and colder climates.476-479 Several hypotheses have been
put forward for these observed differences. Li et al.477 theorized that urban dwellers
participate in more indoor activities compared to their rural counterparts, amplifying their
exposure to HDM, and possibly leading to increased sensitization to these perennial
allergens. Additionally, some reports suggest that exposure to urban pollutants may be
associated with increased risk for developing AR in children.476 Latitude may also play a
role with regard to PAR. For example, the prevalence of persistent AR was found to be
higher in both Northern Europe and Northern China compared to their southern
counterparts.9,477
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Latitude may also be an important determinant of SAR. Allergenic plant species may have a
propensity for growing in certain geographic locations, and pollen concentrations of various
species depend on the climate conditions of the area. Colder climates present at northern
latitudes tend toward shorter growing seasons, and many allergenic species do not thrive in
extreme northern climates. For instance, grass pollen, which is found across Europe, causes
wide variations in atopic sensitizations across regions with different climates.480
Additionally, this increased environmental exposure has been shown to affect development
of AR and patient symptoms of atopic nasal diseases.481,482
Overall, improved knowledge of the prevalence and seasonal variations in AR based on
geographic location is important in that it allows patients to anticipate and better manage
their symptoms through avoidance techniques and preemptive use of pharmacologic
therapies.480,482 Currently, prevalence data do not fully address the different phenotypes of
AR and further study is needed to expand epidemiologic understanding of this disease.
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Risk factors for allergic rhinitis
Genetics
AR is well-known to run in families, and 1 of the strongest risk factors is the presence of
disease in first-degree family members.483 Studies of twins support the genetic
underpinnings of AR with a higher concordance rates for AR in monozygotic twins
compared to dizygotic twins.484,485 The estimated heritability of AR has been suggested to
be as high as 70% to 80%. Like many complex diseases, no single gene or polymorphism
accounts for the hereditary effect on AR. Instead, many genes and several variants, each with
small effects, are believed to contribute to disease initiation, persistence, and severity. In this
section, the current literature on the genetics of AR is reviewed, including candidate gene
studies and recent large-scale genome-wide association studies (GWASs). In addition, geneenvironment interaction effects and epigenetics studies are briefly covered.

Author Manuscript

Single-nucleotide polymorphisms associated with AR

Author Manuscript

GWASs.: GWASs with an unbiased approach that include hundreds of thousands of
common gene variants, or single-nucleotide polymorphisms (SNPs), have successfully
identified important variants for complex diseases over the past decade. Five GWASs on AR
(or hay fever) have been published as of September 2016, as summarized in Table VI.A.
SNPs in leucine-rich repeat-containing protein 32 (LRRC32) have been strongly associated
with AR in 3 of the GWASs,486-488 and with asthma,487,489 eczema,488,490 and other
allergy-related comorbidities.486,489,491 At the protein level, LRRC32 is known to regulate
T-cell proliferation, cytokine secretion, and TGF-β activation.492 These associations suggest
shared genetic mechanisms for AR and other allergy-related diseases, evidence further
supported by the large-scale GWAS on self-reported cat, HDM, and pollen allergies (as well
as AR), which revealed 16 shared susceptibility loci with strong association (p < 5 × 10−8;
TLR-locus top hit).487 In an accompanying GWAS on allergic sensitization, there was strong
overlap between top hits for sensitization and self-reported allergies.487,493 In the GWAS by
Ferreira et al.,489 11 variants were associated with the combined asthma phenotype and hay
fever below the genome-wide significance level (HLA-DQB1 top hit). TLRs play a crucial
role in immune regulation and SNPs in different TLRs have been associated with AR in both
GWASs (TLR1, TLR6, TLR10)486,487 and candidate gene studies (TLR8), as discussed in
the next paragraph.494 In addition to shared genetic effects between different allergy-related
diseases, a significant overlap between susceptibility loci for allergy and autoimmune
diseases has been observed.495

Author Manuscript

Candidate gene studies.—The candidate gene approach for selecting disease-relevant
genes is based on previous associations reported from GWAS or biological features which
could be relevant for disease risk. Studies on AR using this approach have found several
well-replicated genes as summarized previously.496-498 Notably, SNPs in genes involved in
antigen presentation (for example HLA-DQA1), pathogen recognition (TLR2, TLR7,
TLR8), IL signaling and proinflammation (IL13, IL18, and TSLP) are considered important
susceptibility variants for AR.496-502 Recently, functional evidence in blood immune cells
for genetic variants in brain-derived neurotrophic factor (BDNF), a secretory
proinflammatory protein implicated in AR pathogenesis, was reported.503 However, many of
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the candidate genes reported in the literature have not been well-replicated across studies
and populations.427,504 This could be due to inadequate statistical power related to small
sample sizes, inconsistent phenotype definition, or lack of true disease association.
Additionally, rare variant studies focusing on candidate genes have not been particularly
successful.494 The candidate gene approach is particularly necessary for hypothesis-driven
analyses and functional genetic analyses, for example in populations with specific
environmental exposures or with mixed ethnic backgrounds.

Author Manuscript

Gene-environment interactions and epigenetic effects—Epigenetic mechanisms,
defined as changes in phenotype or gene expression caused by mechanisms (eg,
methylation) other than changes in the underlying DNA sequence, have been proposed to
constitute a link between genetic and environmental factors. Recent studies show that DNA
methylation in children is very strongly influenced by well-known risk factors for allergic
diseases such as maternal smoking during pregnancy505 and air pollution exposure.506
Currently, however, it is not known if these methylation changes are causally related to the
development of AR and asthma, or if these “biomarkers” are solely markers of exposure.
Several studies have convincingly linked methylation profiles to AR507-509 and IgE-related
outcomes,510,511 but large-scale studies have yet to be completed.

Author Manuscript

In summary, a family history of AR remains a risk factor for disease development, and
strong associations have been identified with genes involved in T-cell activation (eg,
LRRC32) and innate immunity (eg, TLRs). Shared genetic mechanisms for AR and other
allergy-related diseases have been very clearly identified in recent large-scale studies. There
is, however, a need to functionally characterize variants in these candidate genes to
understand mechanisms underlying the pathogenesis of AR. With increasing evidence for
the role of epigenetics in AR, future research should also focus on investigating epigenetic
mechanisms, thereby providing a functional explanation for the link between environmental
exposures, genetic variants, and disease development.
•

VI.B.

Aggregate Grade of Evidence: C (Level 2a: 5 GWASs. Candidate gene studies
not assessed regarding grade of evidence).

Inhalant allergens (in utero and early childhood exposure)

Author Manuscript

AR is characterized by a loss of immunological and clinical tolerance toward a specific
allergen. This involves production of sIgE which initiates allergic inflammation following
allergen exposure. Therefore, sIgE is a hallmark of allergy and its production defines
sensitization. Sensitization is a complex phenomenon, regulated by genetic and
environmental factors, requiring a primitive exposure to a specific allergen. If a subject is
never exposed to an allergen, sensitization to that allergen cannot occur. On the other hand, it
is fundamental to distinguish between sensitization and allergy. Allergy, which involves the
development of symptoms after the sensitizing exposure, is different from mere
sensitization. Without sensitization allergy cannot exist, but not vice versa. In this section,
the in utero and early childhood exposure to inhalant allergens, including mites, pollens,
animal dander, and fungal allergens, will be evaluated as risk factor the development of AR.
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Mites—There are 6 studies on the topic of early mite exposure and the development of AR
(Table VI.B-1). Most of the studies failed to demonstrate an association between early
exposure to mites and the development of AR.468,516-519 Marinho et al.520 reported that
early exposure to HDM is not a protective factor for current AR, and Kim et al.521 proposed
exposure to spider mites as a risk factor for AR. Interestingly, pets may be a relevant source
of mites, as their fur is often settled by mites; this association may confound AR evaluation
and treatment. Ultimately, the studies on early mite exposure and the development of AR are
conflicting and additional research is needed.
•

Aggregate Grade of Evidence: C (Level 2b: 5 studies; Level 3b: 1 study; Table
VI.B-1).

Author Manuscript

Pollens—There are only 2 studies that addressed the impact of early pollen exposure on
AR (Table VI.B-2). Kihlström et al.519 reported no association to allergic rhinoconjunctivitis
whereas Erbas et al.481 showed that pollen exposure during infancy is a risk factor for hay
fever.
•

Aggregate Grade of Evidence: C (Level 2b: 1 study; Level 3b: 1 study; Table
VI.B-2).

Author Manuscript

Animal dander—Numerous studies have evaluated the association between early exposure
to animal dander and subsequent development of AR, with conflicting results (Table
VI.B-3). Studies are divided according to the findings: positive studies (reporting a
protective effect on AR development522-535), negative studies, (showing that early exposure
to pets represents a risk factor for AR523,536-542), and neutral studies (reporting that early
exposure to animal dander is not associated with
AR468,517,518,520,524,528,530,532,536,538,539,543-554). Additional factors should be considered:
pet age, gender, and species; number of household pets; home characteristics; atopic
predisposition of the pet owners; and others. Considering these complex variables, debate
regarding the influence of early pet exposure on developing allergic disease remains
unresolved. Thus, evidence-based guidelines regarding having pets at home cannot be
established. (See section VI.G.2. Risk factors for allergic rhinitis – Protective factors against
allergic rhinitis – Childhood exposure to pets for additional information on this topic.)
•

Aggregate Grade of Evidence: C (Level 2b: 15 studies; Level 3b: 24 studies;
Table VI.B-3).

Author Manuscript

Fungal allergens—Several studies have explored the role of early exposure to fungal
allergens as a predisposing factor for AR (Table VI.B-4). Most studies demonstrated
evidence that early exposure to fungal allergens represents a risk factor for AR development.
527,538,551,553,555-560 However, 3 studies demonstrated that early exposure to fungal
allergens is not associated with AR.465,542,557 Home moisture level, which is closely and
positively associated with the presence of fungal allergens in the home, may be a
confounding factor in interpreting the evidence on fungal exposure and AR. Ambient
humidity may an intrinsic risk factor, but high moisture is also associated with increased
level of mites, as mites grow in presence of elevated moisture. Moisture can be easily
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assessed both by direct measurement with a hygrometer and indirectly by observing the
presence of mold spots on the walls.
•

Aggregate Grade of Evidence: C (Level 2b: 3 studies; Level 3b: 10 studies; Table
VI.B-4).

In summary, the clinical relevance of early inhalant allergen exposure to AR development is
still debated. Despite several indepth reviews and a growing body of literature,561-563 no
definitive and consensus may be drawn regarding risk-benefit of early inhalant allergen
exposure, and further research is welcomed to address the unmet needs on this issue.
VI.C.

Food allergens (in utero and early childhood exposure)

Author Manuscript

In some studies, early sensitization to food allergens has been linked to the development of
AR in childhood.468,564,565 A meta-analyses by Alduraywish et al.564 demonstrated that
food sensitization in the first 2 years of life was associated with an increased risk of AR
during childhood (OR = 3.0; 95% CI, 2.1 to 4.2) (Table VI.C). The relationship between
sensitization to food allergens and the subsequent development of AR during childhood has
been investigated in both population-based and high-risk cohorts.468,565-568 While there is a
statistically significant correlation in the high-risk cohort,567 there are mixed results in the
population-based studies.566,568,569 These findings prompted prospective investigation of the
effects of allergen avoidance in utero and during early childhood.

Author Manuscript

In an RCT evaluating the effects of in utero exposure to food antigens and the development
of AR, 162 high-risk pregnant women (history of respiratory allergy to animal danders
and/or pollens) were randomized 1 of 2 diets during the last 3 months of pregnancy: either
very low ingestion of hen’s egg and cow’s milk, or a daily ingestion of 1 hen’s egg and 1
[liter] of cow’s milk. A total of 163 infants were followed prospectively up to 18 months of
age, at which time the incidence of atopic disease, including AR, was evaluated in a blinded
fashion. There was no significant difference in the incidence of AR between the 2 groups.570
In another RCT, restricted diet during pregnancy (cow’s milk-free and egg-free diet from
week 28 to delivery) was associated with a small but statistically significant lower mean
gestational weight gain and did not protect the offspring from atopy.571 The pooled results of
2 trials suggest that maternal food antigen avoidance may be associated with a higher risk of
preterm birth and a possible adverse effect on mean birth weight without beneficial effects
on AR development in the children.570,571

Author Manuscript

Studies have also evaluated the early introduction of foods compared to food avoidance with
respect to the effects on development of allergic disease. In a prospective birth cohort study
of 2073 children, delayed introduction of solids (past 4 or 6 months of age) was not
associated with decreased odds for AR, asthma, or sensitization against food or inhalant
allergens at 6 years of age. In fact, food sensitization occurred more frequently in children
who were introduced to solids later.572 In a prospective RCT of food allergen avoidance in
infancy, the incidence of subsequent allergic disease, including AR, was assessed. The
intervention arm of the trial required mothers to avoid cow’s milk, egg, and peanut during
the last trimester of pregnancy and subsequent lactation, and required infants to avoid cow’s
milk until age 1 year (casein hydrolysate supplementation before age 1), egg until age 2
years, and peanut and fish until age 3 years. Compared to maternal-infant control pairs who
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followed standard feeding practices, infants in the food-avoidance arm showed a significant
reduction in rates food allergy and milk sensitization before age 2 years. However, by the
age of 7 years, the prevalence of food allergy was no longer different between the 2 groups.
Furthermore, there was no difference in rates of AR, AD, asthma, and other atopic disease at
age 7 years.573
Based on the presented meta-analysis, prospective randomized studies, and a large
prospective birth cohort study, there is no data to support maternal diet as a contributing
factor for the development of food allergy and AR; however, there is some evidence that the
presence of food allergy during childhood (greater than 2 years old) is a risk factor for AR.
•

Author Manuscript

VI.D.

Aggregate Grade of Evidence: A (Level 1b: 3 studies; Level 2a: 1 study; Level
2b: 1 study; Table VI.C).

Pollution

Author Manuscript

The relationship between pollution and AR has received increasing attention over the past
decade. Environmental air pollutants contain several compounds; however, most studies
have primarily focused on particulate matter <10 μm (PM10), particulate matter <2.5 μm
(PM2.5), nitrogen dioxide (NO2), sulfur dioxide (SO2), carbon monoxide (CO), and ozone
(O3). These particles may potentiate atopy through multiple mechanisms, including injuring
the nasal epithelium, altering the immune response, and increasing the allergenicity of
certain antigens.574,575 For example, pollution may damage the nasal mucosa and impair
MCC, thereby facilitating the access of inhaled allergens to cells of the immune system.576
Additionally, airborne particles, including diesel fuel exhaust, are also able to carry
allergens, thus potentially increasing the spread of allergens or the duration of their
exposure.574 In nasal provocation studies of HDM-sensitive individuals, a combined nasal
challenge with HDM allergens and diesel exhaust particles led to enhanced mast cell
degranulation and increased severity of rhinitis symptoms compared to a challenge with
HDM alone.577

Author Manuscript

Numerous studies have examined the effects of air pollutants on the development of AR in
both pediatric and adult patients (Table VI.D). However, 3 prospective cohort studies (the
highest level of evidence identified for this topic) found no significant correlation.578-580
Codispoti et al.578 specifically looked at the relationship between exposure to diesel exhaust
particles (DEP) at 1 year of age and the subsequent development of AR at 2, 3, and 4 years
of age. While they found that DEP had a marginally positive association with aeroallergen
sensitization at 2 and 3 years, and increased aeroallergen sensitization increased the risk of
AR, they failed to identify a significant direct correlation between DEP and AR
development. Additionally, Kim et al.579 evaluated exposure to NO2, SO2, CO, and PM10 in
children and found no significant association with a new diagnosis of AR after 2 years.
However, they did note a positive association between increased levels of O3 and an AR
diagnosis in industrial areas only; O3 was also significantly associated with the development
of new sensitizations to outdoor allergens, which may explain the mechanism for the related
increase in AR prevalence. Finally, Gehring et al.580 pooled 4 prospective pediatric birth
cohort studies with 14 to 16 year follow-up and found no indication that NO2, PM2.5, or
PM10 levels influenced the development of rhinoconjunctivitis.
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Several international case-control and cross-sectional studies have also evaluated the
relationship between pollution and AR with varied results. Anderson et al.581 performed the
largest cross-sectional study evaluating the effect of PM10 levels on the development of
rhinoconjunctivitis in 322,529 children from 51 countries. There was no between-country
association of rhinitis with modeled pollution levels, and within countries (24 countries had
more than 1 study center) there were weakly positive associations between PM10 levels and
rhinoconjunctivitis symptoms in 6-year-olds to 7-year-olds and diagnosed hay fever in 13year-olds to 14-year-olds. Interestingly, they did show a positive association between high
PM10 levels and the development of atopy.581 Some pediatric studies have identified a
positive correlation between increased exposure to various pollutants and an increased
diagnosis of AR during childhood.476,557,582-589 Liu et al.586 and Deng et al.557 even found
that prenatal/gestational exposure to high concentrations of NO2 were associated with a
higher prevalence of AR diagnosis during childhood. However, almost all of these studies
utilize nearby traffic density or home address geocodes to estimate local pollution exposure.
In many countries, people living in more polluted areas with high levels of traffic may also
be more likely to have other confounding features that influence their development of AR
(ie, socioeconomic status [SES], exposure to different aeroallergens) and not all studies fully
adjust for these potential confounders. Additionally, several of these studies were restricted
to specific cities in Asia, in turn, limiting generalizability.

Author Manuscript

Overall, the relationship between pollution exposure and the development AR is currently
unclear. More prospective pediatric and adult studies in diverse geographic locations are
needed to better understand this complex relationship.
•

Author Manuscript

VI.E.

Aggregate Grade of Evidence: C (Level 2b: 3 studies; Level 3b: 2 studies; Level
4: 9 studies; Table VI.D).

Tobacco smoke
AR has frequently been associated with both active and passive (secondhand) exposure to
tobacco smoke. However, the pathophysiology behind this relationship is complex and, at
times, contradictory. Studies have shown that tobacco smoke exposure can propagate the
development of atopic diseases via several mechanisms including direct surface damage to
nasal mucosa, altered epigenetic mechanisms through histone acetylation, expression of
microRNA, and DNA methylation.590,591 Alternatively, it has also been shown that nicotine
may exert an immunosuppressive effect on allergic disease by suppressing eosinophil
trafficking and Th2 cytokine/chemokine responses.592

Author Manuscript

Recently, 2 large meta-analyses were published which sought to better define the
relationship between tobacco and AR (Table VI.E). Saulyte et al.593 identified a significant
correlation between passive smoke exposure and the development of AR, but no significant
relationship between active smoking or maternal prenatal passive smoke exposure and AR.
However, they did find a significant correlation between active smoking and non-allergic/
chronic rhinitis. Hur et al.594 also systematically evaluated the relationship between
secondhand smoke and AR and that meta-analysis of studies in adults showed an association
between passive smoke and AR, while a similar analysis of pediatric studies did not. This
raises the possibility that the atopic effects of secondhand smoke in the nasal mucosa may
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take several years to manifest. In fact, Lin et al.595 found that allergic adults were more
likely to have been exposed to secondhand smoke 20 years prior when compared to nonallergic adults.

Author Manuscript

Five prospective cohort studies examined the effect of tobacco on the development of AR,
all of which failed to find a correlation between active or passive tobacco smoke and the
development of AR.596-600 Keil et al.596 found that while passive smoke was not
significantly related to AR, it was strongly associated with allergic sensitization and asthma
symptoms in children with a genetic predisposition (at least 1 or more atopic parents).
Additionally, Wright et al.597 found that while there was no significant association between
secondhand smoke exposure and AR, 63% of asthmatics born to heavy smokers developed
rhinitis in the first 6 months, vs 43% of asthmatics whose mothers did not smoke. Finally,
Bendtsen et al.598 found that actively smoking more than 15 cigarettes per day actually
decreased a patient’s risk of developing AR.
This inverse correlation has been identified in several other studies.124,601-603 Eriksson et al.
124 found that while smoking was associated with a high prevalence of chronic rhinitis in
both men and women, it was correlated with a low prevalence of AR in men. Additionally,
they found a significantly lower prevalence of sensitization to common airborne allergens in
current and exsmokers compared to nonsmokers. In contrast, the significant positive
association between tobacco and the development of non-allergic/chronic rhinitis has been
repeatedly identified.124,128,604 Therefore, when discussing the effects of tobacco on rhinitis,
differentiating between allergic and non-allergic/chronic is paramount.

Author Manuscript

Finally, tobacco does not appear to influence the efficacy of AR treatment. Katotomichelakis
et al.605 evaluated 163 patients (both smokers and nonsmokers) receiving sublingual
immunotherapy (SLIT) for AR and found that, regardless of tobacco status, total symptom
scores and QOL questionnaires equally improved. Overall, while most studies evaluating
AR and tobacco are case-control or cross-sectional in nature, multiple prospective cohort
studies and 2 systematic reviews predominantly found no correlation between active or
passive tobacco smoke and AR. Additionally, some studies suggest that tobacco may have a
protective effect against the development of AR. Further investigation is needed to identify if
specific patient populations (eg, asthmatics or those with atopic parents) or temporal
variations (eg, exposure for 20+ years) may alter our understanding of this relationship.
•

VI.F.

Aggregate Grade of Evidence: C (Level 2a: 1 study; Level 2b: 5 studies; Level
3a: 1 study; Table VI.E).

Socioeconomic factors

Author Manuscript

In 1829, John Bostock described 29 cases in the UK, including himself, of individuals who
suffered from catarrhus aestivus or “summer cold,” which he noted occurred in patients of
middle to high SES.606 During the 1870s, Blackley found no hay fever among farmers and
people living in deprived areas of cities.606 The positive association between hay fever and
high social class was later reported in the British 1958 and 1970 cohorts,607,608 as well as a
Swedish survey of conscripts born from 1952 to 1977.609 However, during the study period,
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this association seemed to weaken with an OR estimate for AR among subjects with low
SES changing from 0.79 to 0.92.

Author Manuscript

In 2000, an article was published from the German Multicentre Allergy Study (MAS) birth
cohort including 1314 children born in 1990.610 In this study, it was found that the lifetime
prevalence of hay fever was elevated in parents of high SES compared to low. However, in
their children, the occurrence of hay fever was not elevated in families with high SES.
Alternatively, in the Swedish birth cohort BAMSE (Swedish abbreviation for Children
Allergy, Milieu, Stockholm, Epidemiology) with 4089 children born between 1994 and
1996, it was noted that high SES actually resulted in a decreased risk of AR, along with
decreases in asthma and food sensitization rates.611 In a recent study from Denmark of 9720
children born between 1994 and 2006, AR was associated with low educational level of the
parents.612 Interestingly, in the follow-up of the German MAS birth cohort study, SES was
not associated with AR at all by the age of 20 years.613 Thus, among children born in the
Western world before 1970 high SES was a risk factor, but among children born in the same
regions after 1990 low SES, particularly early in life, seemed to be a risk factor614 (Table
VI.F).

Author Manuscript

More recently, 2 studies from Korea have reconfirmed the previously noted association
between high SES and the development of AR. Ahn et al.478 found a positive association
between higher family income and symptom-based AR diagnosis (but not allergy test-based
AR diagnosis). Lee et al.615 also found family affluence, or high SES, to be a significant risk
factor for AR in Korean adolescents. However, additional recent studies from South America
and Europe have shown varying results. In 2016, Penaranda et al.616 found high SES to be
associated with AR in children/adolescents but not in adults, while Wronka et al.617
identified a significantly higher incidence of AR in adult female university students (19 to 25
years old) from families with high SES.
Overall, SES is likely a proxy for various exposures like number of siblings, viral infections,
exposure to tobacco smoke, housing conditions and location, allergen exposures, dietary
factors, and nutrition including breastfeeding and general diet. Some of those exposures are
associated with the hygiene hypothesis, introduced by Strachan618 in the late 1980s.
However, it is worth noting that exposures relevant to the hygiene hypothesis were important
predictors for the development of AR at an early age.614

Author Manuscript

Currently, there is conflicting evidence regarding the association between SES and AR.
While most studies show an association between high SES and the diagnosis of AR, this is
not a consistent outcome. This disparity may be explained by the additional factors evaluated
in several of these studies which may confound the exact relationship between SES and AR.
Additionally, there may be a temporal relationship between SES and AR considering
different outcomes in children compared to adults. Additional investigation is needed to
determine the true relationship between AR and SES.
•

Aggregate Grade of Evidence: C (Level 2b: 4 studies; Level 4: 6 studies; Table
VI.F).
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Protective factors against allergic rhinitis VI.G.1. Breastfeeding
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Breastfeeding is associated with several beneficial effects on mother and child health and
therefore has been recommended for all infants.619 One potential benefit is the prevention of
allergic disease.620 Breast milk is an immunologically complex solution, containing multiple
compounds that support infant growth and facilitate development of the infant immune
response.621,622 The association between breastfeeding and the prevention of allergic disease
has been frequently studied and often debated.

Author Manuscript

Mimouni Bloch et al.623 performed a meta-analysis of prospective studies evaluating the
effects of exclusive breastfeeding for the first 3 months of life on the development of AR
(Table VI.G.1). Six prospective studies met the inclusion criteria. In their pooled analysis,
they found a protective effect of exclusive breastfeeding for the first 3 months of life that
approached statistical significance in the general population (OR 0.74; 95% CI, 0.54 to
1.01). Interestingly, the protective effect was not seen in children with a family history of
atopic disease (OR 0.87; 95% CI, 0.48 to 1.58).

Author Manuscript

More recently, Lodge et al.624 performed a systematic review and meta-analysis in 2015.
Their analysis evaluated the association between breastfeeding and AR and included 5
cohort studies550,599,607,625,626 and 11 cross-sectional studies.627-637 The number of
participants varied between 361 and 13,889 for the cohorts, and 1402 to 206,453 for the
cross-sectional studies. Pooling of estimates from the various studies found a nonsignificant
protective effect of breastfeeding on the development of AR (OR 0.92; 95% CI, 0.84 to
1.01). The results were then stratified by incidence of AR in different age groups. After
stratification by age, a reduced risk of AR in patients under 5 years of age was associated
with breastfeeding (OR 0.79; 95% CI, 0.63 to 0.98). However, there was no association after
5 years of age (OR 1.05; 95% CI, 0.99 to 1.12). While the authors of this meta-analysis
argued for the benefit of breastfeeding in the prevention of AR, they do acknowledge that
the protective effect of breastfeeding seen in patients less than 5 years of age may have been
confounded by known protective effects of breast milk against viral respiratory infections.
The authors hypothesized that, given the difficulty of differentiating between AR and viral
rhinitis in young children, a reduction in viral respiratory infections have been possibly
interpreted as a reduction in rhinitis symptoms.624

Author Manuscript

•

Aggregate Grade of Evidence: C (Level 3a: 2 studies; Table VI.G.1).

•

Benefit: Possible benefit from breastfeeding with reduction in AR, especially
seen in young children.

•

Harm: None. No studies have shown harm with breast-feeding for 6 months.

•

Cost: Low.

•

Benefits-Harm Assessment: Possible benefit with no harm.

•

Value Judgments: There is evidence that breastfeeding may reduce the risk of AR
with no perceived harm. Given the general benefits to the mother and child,
breast-feeding for 4 months and possibly 6 months has been advocated.
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•

Policy Level: Option for breastfeeding for the specific purpose of AR prevention,
based upon current evidence. In general, breastfeeding has been strongly
recommended due to its multiple benefits.

•

Intervention: Breastfeeding is generally encouraged for at least 4 months due to
its multiple benefits. When specifically related to the prevention of AR,
breastfeeding is an option.

VI.G.2. Childhood exposure to pets—Among subjects sensitized to pet allergens,
exposure tends to exacerbate symptoms. However, the association of pet-keeping in
childhood with the subsequent development of AR is more controversial, and difficult to
establish. (See section VI.B. Risk factors for allergic rhinitis – Inhalant allergens (in utero
and early childhood exposure) – Animal dander for additional information on this topic.)

Author Manuscript

Prevalence of household pet ownership is used to estimate pet allergen exposure. However,
pet owners are frequently contaminated with pet allergens, leading to generalized exposures
via social contact. Therefore, a non-exposed reference population does not exist, limiting our
ability to clearly understand the relationship between exposure to pet allergens and
development of AR.

Author Manuscript

The timing of pet allergen exposure early in life may be an important factor for the maturing
immune system. Therefore, self-reported perinatal and newborn exposures are frequently
analyzed. Few studies have measured the concentration of the major cat (Felis catus)
allergen (Fel d 1) or the major dog (Canis familiaris) allergen (Can f 1) in home dust. Rather,
most studies merely report exposure to cats and/or dogs, or furred pets, and some to rodents
and birds. In a systemic review of epidemiologic studies of allergy and asthma, only 10 of
96 included studies reported avoidance of pets.638 Additionally, studies may often fail to
account for confounding variables such as a family history of pet allergy which, in turn, may
predispose likely atopic children to pet avoidance.

Author Manuscript

There is significant inconsistency with regard to pet ownership in childhood and the
subsequent development of allergy. Demographic features related to pet-keeping, including
race, urban vs rural environment, family size, and SES may help account for some of the
conflicting results. A meta-analysis of 32 studies reported a lower prevalence of AR among
subjects with furred pets in cross-sectional studies, and less asthma among cat-exposed
subjects.639 An extensive systematic review of 62 studies found different associations
depending on study design.640 In most of the birth cohort studies, dog exposure in early
childhood was protective for sensitization against aeroallergens.640,641 On the contrary,
cross-sectional studies reported inconsistent associations between cat or dog exposure and
sensitization as well as the subsequent development of atopic diseases later in life562,640
(Table VI.G.2).
The impact of pet avoidance on AR development is best evaluated via longitudinal birth
cohort studies. A systematic review of 9 studies conducted solely in urban environments
evaluated perinatal pet exposure.642 Six studies found that exposure to dogs, or cats/dogs
protected against allergic disease. Two studies found increased risk of allergy only in highly
atopic families. Furthermore, in a cohort of 620 children with family history of allergic
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diseases, exposure to cats or dogs was protective only in children with non-allergic fathers.
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534

In a pooled analysis of 11 European birth cohorts, any furred pet ownership during the first 2
years was associated with lower risk of sensitization to aeroallergens, but not with a
decreased prevalence of AR later in childhood.552 In a recent study which investigated urban
vs rural differences, the risk of AR in adulthood was 20% lower in subjects exposed to pets
at birth or during childhood. However, pet keeping did not explain the protective effect of
living on farm with livestock compared to urban dwelling.643

Author Manuscript

Overall, pet allergens are ubiquitous. There is no evidence that pet avoidance in childhood
prevents the development of AR or sensitization to aeroallergens later in life. Alternatively,
early pet exposure may induce immune tolerance and thus reduce the chance of development
of allergic disease. This protective effect seems to be strongest in non-allergic families with
dog exposure in early childhood.
•

Aggregate Grade of Evidence: C (Level 2a: 6 studies; Level 2b: 2 studies; Table
VI.G.2).

Author Manuscript

VI.G.3. Hygiene (aka biodiversity or microflora) hypothesis—The inverse
association of the number of siblings and the prevalence of hay fever was reported nearly 3
decades ago in British cohorts.618 Strachan618 proposed the term “hygiene hypothesis” and
speculated that exposure to frequent infections in large families could be the protective
factor. The hygiene hypothesis has evolved toward a more contemporary “biodiversity
hypothesis” that looks beyond the effect of infections and single protective microbes to the
potential protective effect of the colonization of mucous membranes and the skin with
diverse environmental microflora.644 Recently, the term “microbiota hypothesis” has been
proposed. In addition, the term “microflora” should be substituted for the term “microbiota.”
Various related potential cofactors and their relationship to the development of AR are
discussed in this section.
Number of siblings.: The association between number of siblings and presence of allergic
diseases has been studied extensively. In a meta-analysis of 53 studies, 48 studies
demonstrated that higher number of siblings was associated with decreased atopy, an effect
that was more evident for AR than for sensitization and asthma645 (Table VI.G.3). A large
study based on questionnaire data for children aged 6 to 7 years from 31 countries and 13 to
14 years from 52 countries confirmed that the inverse association between the number of
older siblings and prevalence of hay fever was strongest in more affluent countries.646

Author Manuscript

Farming.: Since the first publications in 1999–2000, there is a growing interest in the “farm
effect” on allergy. In a meta-analysis of 8 studies, the risk of sensitization, measured by sIgE
or SPT in childhood or adulthood, was 40% lower (OR 0.60; 95% CI, 0.52 to 0.70) among
subjects who had lived on a farm during the first year of life.647 In a recent U.S. case-control
study, farm exposure in utero and in early childhood protected against allergen sensitization
but not asthma in adulthood.648 The protective farm effect seems to be stronger when
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exposed to farm animals and stables.522,649-655 The protective effect is greatest with highest
exposure occurring early in life.650
Bacterial endotoxin.: Exposure to bacterial endotoxin has been studied as a possible
protective factor. Inverse association between exposure to endotoxin in infancy and
childhood and the development of allergic sensitization has been shown in rural and urban
environments, but the results have not been uniform between the studies.656,657
Probiotics.: A meta-analysis of 29 randomized controlled studies showed no significant
association of probiotics supplementation of pregnant or breastfeeding mothers or infants
with sensitization or allergic rhinitis at age 12 to 36 months.658 (See section IX.B.9.
Management – Pharmacotherapy – Probiotics for additional information on this topic.)

Author Manuscript

Microbial diversity.: Changes in lifestyle, urbanization, diet, and the use of antibiotics have
changed the microbiota of the environment, human skin and mucosal membranes.
Differences in the microbiota may explain the difference in atopic diseases between rural
and urban areas, as well as Finland and the Russian Karelia (a part of Russia geographically
adjacent to Finland).659-661 Households with dogs have rich, diverse house dust microbiota
with abundance of Firmicutes and Bacteroides species.662
In the GABRIEL study the mattress dust of farm children and their controls was analyzed by
quantitative DNA analysis. Especially high mattress levels of Mycobacterium sp.,
Bifidobacteriaceae sp., and Clostridium sp. were found among farm children, and that high
level was inversely associated with atopy.661

Author Manuscript

Low diversity of gut microbiota in early infancy has been related to greater risk of asthma
and sensitization in some longitudinal studies with different designs in childhood.
442,445,449,663 The dysbiosis of the microbiome driven by higher Bacteroides and reduced
Clostridia taxa in adulthood was associated with greater prevalence of seasonal and nut
allergies in adulthood in the American Gut Project.664
Skin microbiota may also be associated with protection from atopy. Compared with healthy
individuals, atopic individuals have shown to have lower environmental bio-diversity at
home and significantly lower generic diversity of gammaproteobacteria on their skin.665
Skin Acinetobacter (gammaproteobacteria) species were associated with anti-inflammatory
immune responses only in healthy subjects.666

Author Manuscript

In summary, hygiene is important to prevent infections worldwide. Urbanization first in
affluent and later in developing countries has led to reduced microbial diversity in the
environment. Large microbial diversity of the skin, airways, and gut in childhood is
important for the prevention of sensitization and of allergic disease in populations. More
longitudinal studies are needed to show the association.
•

Aggregate Grade of Evidence: B (Level 2a: 2 studies; Level 2b: 10 studies; Level
3a: 2 studies; Level 3b: 1 study; Table VI.G.3).

•

Studies included in the Aggregate Grade of Evidence are systematic reviews and
meta-analyses for the various aspects of the hygiene hypothesis discussed above.
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Also included are recent studies, published after the noted systematic reviews
and meta-analyses. If systematic reviews and meta-analyses are not available,
individual studies are listed.

VII.
VII A.

Disease burden
Individual burden

Author Manuscript

VII.A.1. Effect on quality of life—Two systematic reviews have evaluated the effect of
AR on QOL, with both concluding that AR patients suffer from significantly decreased
general and disease-specific QOL due to the impact of physical and mental health.
Furthermore, both studies demonstrated that treatment of AR leads to improvement in
QOL667,668 (Table VII.A.1). While the impact of AR on QOL has been suggested in the
literature for decades, only recently has the effect of AR on QOL been rigorously studied.
This is in part due to the development of validated general and disease-specific QOL
instruments, and their use in clinical investigations and trials. The most commonly used
general QOL instruments in the AR literature appear to be the Short Form 12 and 36
(SF-12/36),669,670 which measure generic physical and mental health-related QOL. The
most commonly used AR disease-specific QOL tool is the Rhinoconjunctivitis Quality of
Life Questionnaire (RQLQ), or 1 of its variations (ie, mini-RQLQ, nocturnal RQLQ).671
However, despite the availability of these instruments, many studies in the published
literature rely upon nonvalidated methods to assess QOL, leading to difficulty comparing
outcomes between some studies.

Author Manuscript

Several high-quality studies have evaluated the impact of AR on overall and disease-specific
QOL (Table VII.A.1). Most level 1b evidence includes RCTs evaluating the effect of topical
nasal corticosteroids,671-673 antihistamines,672,674-677 or AIT.678,679 The general consensus
of these studies is that AR has a significant negative impact on general and disease-specific
QOL, and that the successful treatment of AR by any of the aforementioned therapies leads
to the improvement of symptoms and QOL. One RCT that examined monotherapy vs polytherapy showed that the combination of mometasone with either levocetirizine or
montelukast led to greater symptom and QOL improvement than mometasone alone, but
there was no difference between the levocetirizine and montelukast groups.672 Additionally,
a RCT of acupuncture vs medical therapy showed that the improvement in QOL occurred in
both groups, but the degree of improvement was larger in the acupuncture group.680

Author Manuscript

While the remaining evidence is of lower quality, it includes important and interesting
findings in addition to the conclusions reached by the RCTs and systematic reviews. For
example, extranasal symptoms, particularly ocular symptoms, have a significant impact on
QOL and should not be ignored in the evaluation and management of AR.681-684
Furthermore, the productivity, practical/activity, emotional, social, and memory function of
patients appear to be significantly impacted by AR.685-689
No high-quality studies have explicitly attempted to establish variations of QOL in AR
patients over time, and most have short follow-up periods or only a single follow-up.
However, some observations regarding the natural variation in QOL in AR can be extracted
from the placebo arms of level 1 studies. Two RCTs have studied the effect of levocetirizine
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over 6 months.675,677 These RCTs show that over a 6-month period, both the placebo and
treatment group experience clinically and statistically significantly improvements in generic
and disease-specific QOL; however, the improvement is greater in the treatment arm. The
AIT RCTs have longer follow-up periods (12 to 18 months) and show similar results, with
placebo patients either staying at their baseline QOL impairment, or improving to a lesser
degree than the treatment arms.678,679 As expected in patients with SAR, QOL is better
outside of peak season and worsens during allergen exposure.690,691

Author Manuscript
Author Manuscript

•

Aggregate Grade of Evidence: B (Level 1b: 11 studies; Level 2a: 2 studies; Level
2b: 16 studies; Level 2c: 1 study; Level 3b: 3 studies; Table VII.A.1).

•

Benefit: Successful management of AR leads to improved overall and diseasespecific QOL.

•

Harm: Management strategies for AR are associated with variable levels of harm
and are further specified in Section IX. Management.

•

Cost: Management strategies for AR are associated with variable levels of cost
and are further specified in Section IX. Management.

•

Benefits-Harm Assessment: The benefits of treating patients with AR to improve
QOL may outweigh risks of treatment.

•

Value Judgments: Successful control of AR symptoms leads to important
improvements in generic and disease specific QOL.

•

Policy Level: Recommend treatment of AR to improve QOL.

•

Intervention: AR patients may be offered various management strategies to
improve general and disease-specific QOL.

Author Manuscript

VII.A.2. Effect on sleep—Like generic and disease-specific QOL, validated tools exist
for the assessment of sleep-related QOL in AR, but they are not always utilized in studies
reported in the AR literature. Some studies evaluating generic and disease-specific QOL
suggest that AR negatively impacts patients’ sleep673,685,687 (Table VII.A.1). Several studies
have specifically investigated the relationship between AR and sleep in adults and children
(Table VII.A.2-1 and Table VII.A.2-2). The general conclusion from the aggregate data is
that, like overall and rhinitis-specific QOL, AR negatively impacts sleep QOL and the
successful treatment of AR reduces sleep disturbance. The overall quality of the data is
higher for adults than for children. For the adult population, there is level 1b evidence
supporting the conclusion that AR negatively impacts sleep.705-709 These data deal with
subjective reporting of daytime sleepiness, sleep quality, and symptoms usually through
validated tools, in the setting of testing the effect of nasal corticosteroids and/or montelukast.
Results demonstrate that AR patients have improvements in sleep quality and daytime
sleepiness, in addition to sinonasal symptoms and QOL after treatment with nasal
corticosteroids705,706,709,710 or a combination of corticosteroids and montelukast.709
Additionally AR has been associated with worse sleep fragmentation711,712 and snoring.
713,714 Treatment of AR has been also suggested to also improve continuous positive airway
pressure (CPAP) compliance in patients with OSA.715 The data on the effects of AR on
polysomnogram (PSG) parameters in adults is mixed. Most studies that included PSG
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analysis found that AR is associated with worsened PSG parameters712,714,716-719; however,
2 level 3b studies found either no difference or a modest change.720,721
Two studies looked at variations in sleep symptoms with changes in nasal inflammation over
time. It seems that changes in nasal cytokine levels are associated with changes in PSG719
and that AR patients have worse PSG parameters and sleep disturbance when their
symptoms are present or during their peak allergen season.718 In children, level 2 and 3
studies suggest that AR is associated with sleep disturbance in the form of increased risk of
snoring, sleep disordered breathing, and OSA. Furthermore, AR has been suggested to be a
risk factor for deterioration of OSA QOL after adenotonsillectomy.722 (See section X.K.
Associated conditions – Sleep disturbance and obstructive sleep apnea for additional
information on this topic.)

Author Manuscript
Author Manuscript

VII.B.

•

Aggregate Grade of Evidence: B (Level 1b: 5 studies; Level 2b: 10 studies; Level
2c: 3 studies; Level 3a: 1 study; Level 3b: 21 studies; Level 4: 6 studies; Tables
VII.A.2-1 and VII.A.2-2).

•

Benefit: Successful management of AR leads to decreased sleep disturbance.

•

Harm: Management strategies for AR are associated with variable levels of harm
and are further specified in Section IX. Management.

•

Cost: Management strategies for AR are associated with variable levels of cost
and are further specified in Section IX. Management.

•

Benefits-Harm Assessment: The benefits of treating patients with AR for
symptoms of sleep disturbance may outweigh risks of treatment.

•

Value Judgments: Successful control of AR symptoms leads to improvements in
sleep.

•

Policy Level: Recommend treatment of AR to decrease sleep disturbance.

•

Intervention: AR patients may be offered various management strategies to
improve sleep.

Societal burden

Author Manuscript

As described in Section VII.A.1, AR may have significant negative effects on QOL with
considerable consequences if left untreated. For many years, AR has been trivialized despite
its prevalence, chronicity, and the burden it imposes on individuals and society.101,681,753
The total burden for AR lies not only in the impairment of physical and social functioning,
but also in the financial burden, which is greater when its role in comorbid conditions such
as asthma and rhinosinusitis are taken into account.754-756 In Europe, the total societal cost
of AR and its comorbidities in 2002 was estimated at 355.06 Euros per patient per month.755
The burden of AR is now being recognized by the European Academy of Allergy & Clinical
Immunology (EAACI) and also at the European Union (EU) parliament level in order to
feature the dramatic impact this condition has on the QOL of patients with AR.757,758
In terms of the overall economic burden of illness, AR ranks fifth among chronic conditions
in the United States.759 Estimates of the annual direct cost of AR range from $2 billion to $5
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billion, with more than one-half of the AR direct costs coming from prescription
medications.760-762 The direct costs attributed to AR include physician office visits,
laboratory tests, medications, and AIT.763 Compared with matched controls, patients with
AR have an almost 2-fold increase in medication costs and a 1.8-fold increase in visits to a
healthcare provider.756,764,765 Hidden direct costs include treatment of comorbid conditions
that occur at an increased incidence in patients with AR.

Author Manuscript

Recently, the TOTALL (TOTal costs of ALLergic rhinitis in Sweden) study estimated the
total cost of AR using a sample representing the entire Swedish working-age population.
Data from this study suggested that patients with mild AR have less impact on the health
economy, with costs averaging about 25% of the costs for those with moderate to severe
disease.667,766 Patients with moderate to severe AR reported visiting their primary care
provider for their AR more frequently than those with mild AR (1.61 vs 1.19 times per
year).753
The indirect costs of AR, such as absenteeism and presenteeism, are also significant and
actually make up the majority of the cost burden of AR.767,768 Impaired productivity and/or
missed work occurred as a result of AR in 52% of patients.753 In a survey of over 8000 U.S.
employees at 47 employer locations, 55% reported AR symptoms for an average of 52.5
days per year. They reported missing 3.6 days of work per year because of AR and reported
being unproductive 2.3 hours per workday when symptomatic. The mean total productivity
losses (absenteeism and presenteeism) for AR were calculated at $593 per employee per
year.769 In another UK study, patients with moderate to severe AR reported 37.7 days a year
when their productivity was affected by their AR symptoms; this is almost double that
reported by patients in the same study with mild AR symptoms (21.0 days).753

Author Manuscript

Health impairments associated with AR are often not severe enough to cause absenteeism,
but they do interfere with cognitive functioning, resulting in fatigue and an impaired ability
to learn, concentrate, and make decisions.770 In a study by Blanc et al.,771 more than onethird of AR patients reported reduced workplace performance.
In the United States, AR results in 3.5 million lost workdays and 2 million lost school days
annually.772 On any given school day in the United States, approximately 10,000 children
are absent from school because of AR.773 This absence from school may also affect parents’
productivity or cause them to be absent from work themselves.

Author Manuscript

In a study by Hellgren et al.,774 the average productivity loss for all Swedish workers
because of absenteeism, presenteeism, and caregiver absenteeism during a year was 5.1
days, of which 2.3 days were accounted for by absenteeism and 2.0 days by presenteeism. If
only those with children aged 0 to 7 years in their household were included in the analyses,
the average number of days for caregiver absenteeism was 3.6 days. The cost of caregiver
absenteeism comprised 19% of the mean total costs per year in this study. The cost related to
caregiver absenteeism was highest for women aged 30 to 44 years.
AR is the most common chronic disorder in the pediatric population. AR can affect sleep,
result in daytime sleepiness, and impair cognition and memory, which may significantly
affect the learning process and impact school performance. Even when present during school
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hours, children with AR exhibit decreased productivity. Comorbidities associated with AR,
such as like rhinosinusitis, Eustachian tube dysfunction, and associated conductive hearing
loss may further contribute to learning dysfunction.775,776
AR poses a substantial burden to individuals and society. It can reduce productivity and
QOL in affected patients, and contribute to comorbid conditions. This results in a significant
impact to the overall health system.773

VIII.

Evaluation and diagnosis
In an individual patient, the clinical suspicion for a diagnosis of AR is highlighted by the
clinical history and often supported by the physical examination. The diagnosis is confirmed
by objective testing, which may be performed by various means. This section reviews the
existing evidence behind various aspects of evaluation and diagnosis of the AR patient.

Author Manuscript

VIII.A.

Clinical examination History
Clinical history is an essential part of the evaluation of patients with a suspected diagnosis of
AR.7,26,218,761,777 History taking includes the type of symptoms experienced, timing and
duration of symptoms, frequency of symptoms, any environmental exposures eliciting
symptoms at home/work/school, and medications or other measures that relieve or
exacerbate symptoms.7,26,218,761,777,778 In addition, past medical history including comorbid
conditions such as asthma or obstructive sleep apnea, family history of atopic disorders,
social history (ie, pets, work exposures, home environment), and current medications should
be obtained.7,26,218,761,777,778 Information regarding patient response to self-treatment with
over-the-counter medications for AR is also helpful.

Author Manuscript

Nasal congestion or obstruction, nasal pruritis, clear rhinorrhea, and sneezing are classic
symptoms of AR.7,26,218,761,777,778 Patients may complain of associated symptoms of ocular
pruritis, erythema, and/or tearing, oral cavity or pharyngeal pruritis, and wheezing or cough
(reactive airway disease and/or asthma).7,26,778 Additional associated symptoms may
include hyposmia or anosmia, snoring or sleep-disordered breathing, aural congestion or
pruritis, and sore throat.778,779 Commonly, patients with suspected AR will present with
multiple complaints, with 96% presenting with 2 or more symptoms.778 Patients with PAR
tend to report more congestive symptoms (sinus pressure, nasal block-age/congestion, and
snoring) than patients with SAR. Patients with persistent AR are more likely to report the
presence of sore throat, cough, sneezing, rhinorrhea, and postnasal drip.778 Rhinorrhea,
sneezing, sniffing, hyposmia/anosmia, nasal obstruction, and itchy nose rank highest for
diagnostic utility among symptoms of AR.779

Author Manuscript

Several guidelines suggest the diagnosis of AR be made when patients present with a history
consistent with an allergic cause and 1 or more of the symptoms listed in the previous
paragraph, despite the lack of high-level evidence to support such a
recommendation7,26,218,761,777,780 (Table VIII.A). However, the lack of higher level
evidence is not surprising as a clinical history and physical examination is essential to any
medical diagnosis and randomized studies would require participants to receive an
intervention without a clinical history. Using a physical examination alone to diagnose AR
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has been shown to have poor predictive value.781 The reliability and predictive value of the
patient history alone for AR exceeds that of the physical exam alone.781 In clinical practice,
the diagnosis of AR is often made by history alone.780
Physical examination—Physical examination is part of the evaluation of patients with
suspected AR.7,26,218,761,777 This includes an assessment of the multiple organ systems of
the head and neck, such as the integumentary system; external auditory canal, tympanic
membrane, and middle ear; nasal cavities; orbits and periorbital tissues; oral cavity and
pharynx; larynx via indirect laryngoscopy; and cervical tissues.26,218,761,777 It may include
auscultation of the lungs, given comorbid conditions of asthma, or complaints of wheezing
or coughing with exposure.7

Author Manuscript

It is not uncommon for physical examination of patients with AR complaints to be
completely normal, particularly in patients with intermittent exposure.779 However, physical
signs suggestive of AR may include mouth-breathing, nasal itching, or a transverse supratip
nasal crease, throat clearing, periorbital edema, or “allergic shiners” (dark discoloration of
the lower lids and periorbital area).26,777 Examination of the ear may reveal retraction of the
tympanic membrane or transudative fluid.26,218,777 Examination of the nose may reveal
inferior turbinate hypertrophy, congested/edematous nasal mucosa, purplish or bluish nasal
mucosa, and clear rhinorrhea.26,218,761,777 Examination of the eyes may reveal conjunctival
erythema and/or chemosis.26,777
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Physical examination alone is poorly predictive and more variable when compared to history
taking in the diagnosis of AR, with the average sensitivity, specificity, positive predictive
value, and negative predictive values of the patient history higher than those of the physical
examination.781 Most guidelines recommend a physical examination as part of the diagnosis
of AR, despite a lack of high-level evidence. Without a physical examination, other potential
causes of symptoms such as CRS, could not be fully evaluated or eliminated. A patient
history combined with a physical examination improves diagnostic accuracy.781

Author Manuscript

•

Aggregate Grade of Evidence: D (Level 3b: 1 study; Level 4: 3 studies; Level 5:
4 guidelines; Table VIII.A).

•

Benefit: Improve accuracy of diagnosis, avoid unnecessary referrals, testing, or
treatment. Possible improved diagnosis of AR with physical examination
findings, evaluation/exclusion of alternative diagnoses.

•

Harm: Possible patient discomfort from routine examination, not inclusive of
endoscopy. Potential misdiagnosis, inappropriate treatment.

•

Cost: Minimal.

•

Benefits-Harm Assessment: Preponderance of benefit over harm, potential
misdiagnosis and inappropriate treatment if physical exam used in isolation.

•

Value Judgments: Making a presumptive diagnosis of AR on history (ideally
combined with physical examination) is reasonable and would not delay
treatment initiation. Confirmation with diagnostic testing is required for
progression to AIT, or desirable with inadequate response to initial treatment.
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•

Policy Level: Recommendation.

•

Intervention: History taking is essential in the diagnosis of AR. Physical
examination is recommended in the diagnosis of AR, and when combined with
patient history, it increases diagnostic accuracy and excludes alternative causes.

Nasal endoscopy

Author Manuscript

Diagnostic nasal endoscopy is an option for the evaluation of patients with suspected AR.
Several uncontrolled observational studies evaluated the association of endoscopic findings
with symptomatic rhinitis, with inconsistent results (Table VIII.B). Ameli et al.782 evaluated
children with suspected AR, reporting that endoscopic findings of inferior or middle
turbinate septal contact was predictive for AR, while pale turbinates were not. Conversely,
Eren et al.783 evaluated a population of adult patients with rhinitis, concluding that findings
of nasal endoscopy do not provide a reliable diagnosis of AR. Among adults and children
with AR that is confirmed by allergy testing, no significant correlation was found between
nasal endoscopy and specific nasal symptoms.784
Central compartment atopic disease (CCAD) represents the recently described association
between atopic states and centrally-located inflammation involving the middle/superior
turbinates or superior nasal septum.785-787 In a recently published parallel case series (LOE
= 4), Brunner et al.788 evaluated patients with CRSwNP vs isolated polypoid change of the
middle turbinate. Significant findings include a higher prevalence of AR in patients with
middle turbinate polypoid change (83% vs 34%, p < 0.001), further supporting CCAD as a
unique atopic condition.

Author Manuscript

Although the association of endoscopic findings with AR has been shown to be inconsistent,
nasal endoscopy may aid in the identification or exclusion of other possible causes of
symptoms, such as nasal polyposis or CRS.
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•

Aggregate Grade of Evidence: D (Level 3b: 2 studies; Level 4: 3 studies; Table
VIII.B).*

•

Benefit: Possible improved diagnosis with visualization of turbinate contact or
isolated central compartment edema.

•

Harm: Possible patient discomfort.

•

Cost: Moderate equipment and processing costs, as well as procedural charges.

•

Benefits-Harm Assessment: Equal.

•

Value Judgments: None.

•

Policy Level: Option.

•

Intervention: Nasal endoscopy may increase diagnostic sensitivity among
children and adults with AR and may aid in ruling out other causes for nasal
symptoms.

*Due to recent publication and in accordance with ICAR methodology, DelGaudio et al.787
and Brunner et al.788 are excluded from the Aggregate Grade of Evidence.
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Routine radiographic imaging is not recommended for the diagnosis of AR, although may be
considered to rule in/out other conditions (ie, rhinosinusitis). Some recent studies have
established the association between central compartment mucosal disease and aeroallergen
sensitivity.787,788 However, concerns regarding unnecessary exposure to ionizing radiation,
with the risk for future cancer development, preclude recommendations for routine use.
789,790
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•

Aggregate Grade of Evidence: Not applicable.*

•

Benefit: None appreciated.

•

Harm: Unnecessary radiation exposure with concern for tumor development.

•

Cost: High equipment and processing costs.

•

Benefits-Harm Assessment: Preponderance of harm over benefit.

•

Value Judgments: Long-term risks of unnecessary ionizing radiation exposure
outweigh potential benefit.

•

Policy Level: Recommend against.

•

Intervention: Routine imaging is not recommended in the evaluation of suspected
AR, but may be considered to rule in/out other sinonasal conditions.

*Due to recent publication and in accordance with ICAR methodology, DelGaudio et al.787
and Brunner et al.788 are excluded from the Aggregate Grade of Evidence.
VIII.D.

Use of validated survey instruments

Author Manuscript

Validated clinical outcome surveys and questionnaires may be used as precise clinical
assessment instruments to evaluate patients with suspected AR. Clinicians often use SPT,
sIgE serology, and other laboratory tests to confirm or refute the diagnosis, but these tests
are only useful in the context of an effective clinical history.791 Validated clinical assessment
tools offer a more structured way to expose important historical elements. Furthermore, in
regions where resources are scarce, SPT and laboratory testing may not be as readily
available. Advancing technologies such as multiplex allergen screening, component
serology, and automated SPT imaging devices may be expensive and unattainable by some
clinicians.792-795 In these settings, validated surveys offer a rapid and simple point-of-care
tool to formally evaluate allergic disease.

Author Manuscript

Patient reported outcome measures (PROMs) can assess a number of different aspects of
how AR affects patients.796 These include symptom severity surveys, such as the Total Nasal
Symptom Score (TNSS) and health-related QOL questionnaires, such as the RQLQ.
Additional surveys measure aspects such as medication usage (Daily Medication Score),
disease prediction (Respiratory Allergy Prediction) and disease control (Rhinitis Control
Test). Each of these surveys examines slightly different, although related aspects of clinical
outcomes. Several of these instruments have been used extensively in many large clinical
trials to determine the effectiveness of drugs and biologics for treating AR.797-802 SPT and
nasal challenge may be used to cross-validate these clinical survey tools but ultimately, how
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a patient reports their own symptoms could very well be the best predictor of disease
control.
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Validated clinical surveys for AR often include questions about congestion, rhinorrhea
and/or sneezing and may either be instantaneous or reflective over a period of days or weeks.
The TNSS is typically administered as an instantaneous daily survey comprised of only 4
questions about runny nose, nasal itching, sneezing, and congestion. Some studies have used
the TNSS as a reflective score calculated as the average of both the 12-hour nighttime and
12-hour daytime average (rTNSS). The TNSS score can be combined with questions about
rescue medication use to yield the Daily Combined Score (DCS) and the Total Combined
Rhinitis Score (TCRS). Both have been used in many therapeutic intervention studies.803
The RQLQ is a more comprehensive survey that asks the patient to reflect upon the past
week and includes global QOL questions. While this test can suffer somewhat from potential
recall bias, it can be administered on site and avoids the possibility that self-administered
daily scores could be missed periodically when the patient is home. The Control of Allergic
Rhinitis and Asthma Test (CARAT10) evaluates rhinoconjunctivitis and asthma symptoms
over the past 4 weeks giving a broader evaluation of seasonal symptom control.804 The
Respiratory Allergy Prediction (RAP) test is a 9-question survey incorporating upper and
lower respiratory queries as well as a question about medication use. If conjunctivitis is to be
assessed simultaneously with rhinitis symptoms, then the Rhinitis Total Symptom Score
(RTSS) can be combined with Rescue Medication Score (RMS) to yield the combined score
(CS).805 Table VIII.D-1 lists several validated clinical survey tools.696,804,806-813
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The choice of which validated survey to use depends on which aspect of clinical outcomes is
being studied. For example, if the goal is for a primary care physician to determine the need
for referral and further testing, then the RAP test may be used because it has been
scrutinized in this setting.814 The mini-RQLQ and DCS have been used extensively in
clinical trials to evaluate the effectiveness of drugs and immunotherapies,797-801 and
therefore may be helpful in selecting the right medication for a given population. It is
important to note that some tools use a higher score to indicate severe disease whereas other
tools use a higher score to indicate better control of symptoms. For example, a high score on
the RCAT, ARCT, and CARAT10 indicate good control of allergic symptoms.
Unfortunately, not all studies use consistent terminology and interpretation of the scoring
systems.801 Inconsistent use of questionnaires can weaken the conclusions drawn in certain
therapeutic intervention studies. However, a well-executed and validated survey can be
essential in research settings and help clinicians screen patients for AR and further render
specific diagnostic decisions.

Author Manuscript

Overall, validated clinical survey instruments may be used as a tool to assist with the
diagnosis of AR and determine the success of various therapies. This conclusion is based on
review of more than 30 studies of which 9 of these reports range from level 1a to 2b (overall
Grade A evidence) (Table VIII.D-2). An example approach using specific validated survey
instruments is as follows. The TNSS may be used for daily symptom monitoring to
determine the effectiveness of therapies and control of AR. The TNSS should be combined
with a daily medication score to account for the effects of pharmaceuticals on
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symptomatology. Assessment of both conjunctivitis and rhinitis symptoms as well as
medication use can be performed with the Combined Score (RTSS + RMS) or the
Rhinoconjunctivitis Allergy Control Score (RC-ACS). The RQLQ or mini-RQLQ can be
used as an additional measure to incorporate disease impact on QOL and can be
administered in person by the clinician. For quick assessments or to follow a patient’s
therapeutic success, a simple visual analogue scale (VAS) or global assessment is
acceptable. The RAP test can be used as quick and easy tool for primary care physicians to
determine the need to refer to an allergist for further testing. Many validated options are
available for AR and should be tailored to the patient and clinical setting.

Author Manuscript
Author Manuscript

•

Aggregate Grade of Evidence: A (Level 1a: 2 studies; Level 1b: 4 studies; Level
2b: 4 studies; Table VIII.D-2). Note: multiple additional studies were reviewed,
but Grade A evidence was reached with these 10 studies, so an extensive listing
of all studies employing validated survey instruments is not provided here.

•

Benefit: Validated surveys offer a simple point-of-care option for screening and
tracking symptoms, QOL, and control of allergic disease.

•

Harm: Minimal to none.

•

Costs: No financial burden to patients. Some fees associated with validated tests
used for clinical research.

•

Benefits-Harm Assessment: Preponderance of benefit over harm. Low risk of
misdiagnoses leading to unnecessary additional testing. Likewise, there is a low
risk that false negative responses may lead to delay in testing and further
management.

•

Value Judgments: Level 1 evidence to use validated surveys as a screening tool
and primary or secondary outcome measure.

•

Policy Level: Strong recommendation.

•

Intervention: Validated surveys may be used to screen for AR, follow treatment
outcomes and as a primary outcome measure for clinical trials. Specific tests are
optimized for various clinicopathological scenarios and should be tailored to the
patient and clinical setting.

Author Manuscript

VIII.E.1. Skin-prick testing (SPT)—SPT can be used, along with the history and
physical examination, to confirm the diagnosis of AR and differentiate from non-allergic
types of rhinitis. The confirmation of an IgE-mediated process guides avoidance measures
and appropriate pharmacologic therapy. Skin testing is crucial to directing AIT, and
therefore, should be utilized in eligible patients when AIT is being considered. According to
the ARIA guidelines, patients should be considered for AIT when they have failed a 2-week
to 4-week trial of moderatedose INCS combined with antihistamines.101
When an antigen is applied to the skin of a sensitized patient, the antigen cross-links IgE
antibodies on the surface of cutaneous mast cells resulting in degranulation and release of
mediators (including histamine), which leads to the formation of a wheal and flare reaction
within 15 to 20 minutes.816,817 Given the limited depth of penetration, SPT is safe with very
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rare reports of anaphylaxis and no reported fatalities.818 SPT can be performed in any age
group and is of particular value in pediatric populations given the speed at which multiple
antigens can be applied and the limited discomfort experienced during testing.
Skin testing is not appropriate in all patients. Absolute or relative contraindications to SPT
include uncontrolled or severe asthma, severe or unstable cardiovascular disease, concurrent
beta-blocker therapy, and pregnancy. Certain medications and skin conditions may interfere
with skin testing. These are covered in detail in section VIII.E.4. Issues that affect the
performance or interpretation of skin tests: VIII.E.4.a. Medications; and VIII.E.4.b. Skin
conditions, respectively.

Author Manuscript

Aside from an excellent safety profile, SPT has a reported sensitivity and specificity around
80%.818-820 It is reported to be more sensitive than serum testing with the added benefit of
lower cost.818,821,822 Despite studies aimed at comparing SPT, intradermal testing, and
serum testing, conclusive evidence that one type of testing is superior to the others is
lacking.761
The number and choice of antigens used in testing varies considerably between clinical
practices. A panel of antigens representing an appropriate geographical profile of allergens
that a patient would routinely be exposed to is recommended. Positive (histamine) and
negative (glycerin or saline) controls should always be included. Variability in quality and
potency between commercially available allergen extracts has been demonstrated.823,824
Therefore, whenever possible, standardized allergens should be used.820
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SPT is performed with lancets, which come in a variety of forms. Generally, lancets are
designed to limit skin penetration depth to 1 mm. However, varying amounts of pressure
applied to the delivery device can alter the depth of skin penetration, which ultimately
influences the skin reaction to an antigen.825 Prick testing devices can come as single-lancet
devices or multiple-lancet devices. Multiple-lancet devices have the advantage of being able
to rapidly apply multiple antigens to the skin at 1 time with a more consistent amount of
pressure.826,827 Wheal size, sensitivity, and reproducibility all differ from 1 device to
another826-828; therefore, any healthcare provider performing SPT must thoroughly
familiarize themselves with his/her testing device. Typically, the lancet is dipped into a well
containing an antigen and then applied to the skin.
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The volar surfaces of the forearms and the back are the most common testing sites for SPT.
Choice of site is directed by the age/size of the patient. Tests should be applied 2 cm or
greater apart as placing them closer to one another can cause cross-contamination.829 After
15 to 20 minutes, the results are read by measuring the size of the wheal by its greatest
diameter. A wheal 3 mm or larger than the negative control is considered positive.
There is a large body of evidence detailing the use of SPT in clinical practice (Table
VIII.E.1). Based upon several prospective studies and systematic reviews, SPT has been
demonstrated to be a safe method of allergy testing. It is not inferior to serum or intradermal
testing and is less expensive than serum testing. It does carry a risk of systemic reaction, so
caution should always be exercised. It is also associated with some discomfort during
testing; however, the discomfort is generally less than that experienced during intradermal
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testing. Reviewing the available literature, a preponderance of benefit over harm for SPT
exists. Therefore, the use of SPT is recommended in situations where the diagnosis of AR
needs to be supported or a patient with presumed AR has failed appropriate empiric medical
therapy.
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•

Aggregate Grade of Evidence: B (Level 1a: 1 study; Level 3b: 7 studies; Table
VIII.E.1).

•

Benefit: Supports diagnosis and directs pharmacological therapy while possibly
avoiding unnecessary/ineffective treatment; guides avoidance; directs AIT.

•

Harm: Adverse events from testing including discomfort, pruritus, erythema,
worsening of asthma symptoms, and anaphylaxis, inaccurate test results, and
misinterpreted test results.

•

Cost: Low.

•

Benefits-Harm Assessment: Preponderance of benefit over harm.

•

Value Judgments: Patients can benefit from identification of their specific
sensitivities. SPT is a quick and relatively comfortable way to test several
antigens with accuracy similar to other available methods of testing.

•

Policy Level: Recommendation.

•

Intervention: SPT is recommended for evaluation of allergen sensitivities in
appropriately selected patients. Regular use of the same SPT device will allow
clinicians to familiarize themselves with it and interpretation of results may
therefore be more consistent. The use of standardized allergen extracts can
further improve consistency of interpretation.

VIII.E.2. Skin intradermal testing—The placement of allergenic proteins in the
intradermal space is often used for diagnosing AR. Intradermal testing has also been
described in the evaluation of sensitivities to other substances, including local anesthetic
agents, neuromuscular blocking agents, antibiotics, and contrast media.837-840 While
previous protocols have described the use of intradermal testing for suspected food or
chemical allergies, this type of diagnostic testing is currently not recommended in routine
practice.841,842 Intradermal testing may be used as a primary testing modality, or as a
secondary test following SPT. Intradermal testing has also been used, primarily by
otolaryngic allergists, as a method to help determine the starting point for specific AIT and
as a vial safety test prior to an injection from a new treatment vial, though the level of
evidence supporting these uses is low.843,844
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Intradermal testing may be performed as a single injection. A short bevel needle is used to
inject a diluted allergenic extract solution into the superficial dermis. Approximately 0.02
mL is used, or enough to produce a well-defined wheal, which is 4 mm in diameter.845 The
wheal will expand to 5 mm by hydrostatic forces, and the reaction is observed for 10
minutes. The positive control for intradermal testing is histamine and the negative controls
are typically phenolated saline and a glycerin solution that equals the concentration of
glycerin in the test solution. If the diameter of the resulting wheal is at least 7 mm, and at
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least 2 mm wider than the glycerin control, this is considered a positive test.846 While this is
a very reproducible test, it is more technically demanding than SPT, is difficult to perform in
young children, and carries a higher risk of adverse reactions.847 Severe adverse events
related to intradermal testing are rare. Over a 42-year period, from 1945 to 1987, only 5
fatalities were attributed to intradermal testing without prior prick/puncture testing.848
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Intradermal testing may also be performed using multiple dilutions of the same allergen to
more precisely quantify the level of sensitivity to that allergen and suggest a starting point
for immunotherapy.849 A series of dilutions of concentrated allergenic extract (typically
supplied as a 1:20 wt/vol solution) can be prepared in either a 1:5 or 1:10 ratio. Intradermal
dilutional testing (IDT, previously referred to as skin endpoint titration, or SET) begins with
the intradermal placement of a dilute allergen, along with appropriate controls, followed by
the placement of progressively more concentrated dilutions of that allergen. The dilution
producing the first positive test (defined earlier in this section as a wheal is at least 7 mm and
at least 2 mm wider than the glycerin control) followed by progressively larger wheals is
called the “endpoint.” To establish progression, a confirmatory wheal, produced by the next
higher concentration, must be at least 2 mm wider than the suspected endpoint. IDT
endpoint correlates with SPT wheal.844,850,851 While IDT endpoints have been shown to
correlate with biologically relevant measures, such as basophil histamine release, a clear
correlation with other measures, such as in vitro sIgE levels, has not yet been established.
852,853 Currently, no studies have demonstrated a clear benefit of quantitative intradermal
testing over single intradermal testing with regard to the diagnosis of clinical allergy or the
outcome of specific immunotherapy (Table VIII.E.2).
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As a stand-alone diagnostic test for AR, estimates for sensitivity for intradermal testing
range between 60% (95% CI, 31% to 83%) and 79% (95% CI, 63% to 90%), while
estimates for specificity range between 68% (95% CI, 49% to 82%) and 69% (95% CI, 52%
to 86%).793,833 This is lower than the pooled estimates of sensitivity (85-88%) and
specificity (77%) for SPT, calculated from recent meta-analyses.830,854 Factors affecting the
predictive value of intradermal testing include the comparator used and the concentration of
allergen used with the intradermal test.855
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It has been suggested that intradermal testing could potentially increase the sensitivity of
SPT by injecting allergenic proteins into deeper tissue layers beneath the keratinized
epidermis.847 However, the literature has not supported a clear benefit of intradermal testing
for this purpose. Using intradermal testing in addition to SPT to predict a positive response
from nasal challenge with Timothy grass only increased the sensitivity from 87% to 93%.832
In a similar study, Krouse et al.831 determined that adding intradermal testing to SPT as a
method to predict positive nasal challenge to Alternaria increased the sensitivity from 42%
to 58%. These studies suggest marginal increase in sensitivity that may vary based upon the
allergen being tested.
Nelson et al.856 studied 28 individuals with a history of SAR. One group had negative SPT
to Timothy and Bermuda grass, but positive intradermal testing for Timothy grass, while the
other group had negative SPT and negative intradermal testing for Timothy and Bermuda
grass. In both groups, 11% of individuals had a positive nasal challenge with Timothy grass.
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Likewise, when 39 individuals with clinical cat allergy and negative SPT underwent a cat
challenge, there was no difference in the development of upper respiratory symptoms
between those who had positive or negative intradermal testing (24% vs 31%, p = 0.35).793
Reddy et al.857 evaluated allergy test results in 34 patients with perennial rhinitis. Patients
with only intradermal positive skin tests (SPT negative) did not have a positive RAST nor a
positive leukocyte histamine release. In contrast, SPT positivity was associated with positive
RAST test and leukocyte histamine release assay.857 Schwindt et al.858 studied 97 subjects
with allergic rhinoconjunctivitis symptoms. Prick testing was followed by intradermal
testing if prick was negative. If patients were prick-negative and intradermal-positive, a nasal
challenge was performed against 5 different allergens. If SPT with the multi-test II device
was negative, only 17% of subjects had a positive intradermal test that corresponded with
clinical history. None of these positive ID tests corresponded with a positive nasal challenge.
858 Taken together, these studies suggest that intradermal testing does not improve the
diagnosis of allergy in subjects with negative SPT.
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Nevis et al.830 conducted a systematic review of 4 studies to determine the sensitivity and
specificity of intradermal testing when used as a confirmatory test following negative SPT.
Sensitivity ranged from 27% (95% CI, 10% to 57%) to 50% (sample sizes were too small to
calculate CI), while specificity ranged from 69% (95% CI, 51% to 83%) to 100% (95% CI,
83% to 100%). From a retrospective study by Larrabee and Reisacher,859 when the clinician
was guided by high clinical suspicion, the incidence of positive intradermal testing following
negative SPT was 36.9% for indoor allergens (D. pteronyssinus, D. farinae, cat, dog, and
cockroach), 12.7% for outdoor allergens (ragweed, red birch, Timothy grass, white oak, and
red maple) and 9.2% for molds (Aspergillus, Candida, Penicillium, Alternaria, and
Cladosporium). However, no correlation between positive intradermal testing and nasal
challenge testing was performed in this study. Escudero et al.860 found that in rhinitis
patients, SPT, intradermal and conjunctival challenge were more sensitive than serum sIgE.
All testing methods had the same specificity.
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In summary, current evidence supports the use of intradermal testing for the diagnosis of AR
due to airborne allergens as a stand-alone test, although this form of testing demonstrates no
clear superiority over SPT when comparing sensitivity and specificity. There were no studies
identified that directly compared single-dilution intradermal testing with IDT in terms of
sensitivity, specificity, or patient outcomes. There appears to be a small gain in sensitivity
when intradermal testing is used as a confirmatory test following negative SPT; however,
positive intradermal test results in this setting could represent false-positive test results. It is
also more likely that an intradermal test following a negative SPT will be positive when
indoor allergens are being tested and least likely to be positive when testing for mold
sensitivity. It is unknown whether the type of allergen has an impact on the sensitivity and
specificity, as most studies examined used only 1 allergen, but intradermal testing seemed to
be least sensitive and specific when mold was being tested. Other limitations of the studies
identified for this review include low sample population sizes (the largest included 120
participants), variable study design, and the lack of randomized, controlled trials.
•

Aggregate Grade of Evidence: B (Level 1a: 1 study; Level 2b: 11 studies; Level
3b: 4 studies; Level 4: 1 study; Table VIII.E.2).
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•

Benefit: Generally well tolerated, easy to perform, and a favorable level of
sensitivity and specificity when used as a stand-alone diagnostic test.

•

Harm: Very low risk of severe adverse reactions.

•

Cost: Low.

•

Benefits-Harm Assessment: Benefit over harm when used as a stand-alone
diagnostic test. Balance of benefit and harm when used to confirm the results of
SPT, as a quantitative diagnostic test or as a vial safety test.

•

Value Judgments: It is important to determine the presence of IgE-mediated
sensitivity for individuals with suspected AR. If SPT is negative, there is limited
clinical benefit to performing intradermal testing for confirmation.

•

Policy Level: Option for using intradermal testing as a stand-alone diagnostic test
for individuals with suspected AR. Option for using intradermal testing as a
confirmatory test following negative SPT for nonstandardized allergens. The
evidence for quantitative IDT is sparse and prevents a recommendation for this
specific testing technique.

•

Intervention: Intradermal testing may be used to determine specific airborne
allergen sensitization for individuals suspected of having AR.
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VIII.E.3. Blended skin testing techniques—Blended allergy skin testing involves the
combined use of SPT and intradermal testing to establish an “endpoint” for a specific
antigen.844,847,850 The protocol, initially described by Krouse and Krouse,861 and referred to
as “modified quantitative testing” (MQT), serves as an example of a blended technique.
MQT involves an algorithm where a SPT is used initially to apply an antigen. Depending
upon the SPT result, an intradermal test may or may not be applied.844,847,850,861 With these
results, the algorithm is used to determine an endpoint for each antigen tested.844,847,850,861
The endpoint signifies the skin reactivity to the applied antigen on a graded scale and is
considered to be a safe starting dose for the application of AIT.861 There is a small amount
of literature on blended techniques, but AIT based upon the MQT results has been shown to
be successful, with immune system alterations in line with other skin testing techniques861
(Table VIII.E.3).

Author Manuscript

The advantages of blended techniques, such as MQT, are that they provide the practitioner
with both qualitative data (the patient demonstrates sensitivity) and quantitative data
(endpoint; safe starting dose for AIT) for specific antigen sensitivities in less time than IDT.
844,847,850 Disadvantages include the additional risk and time involved in placing
intradermal tests. In comparison to IDT and in vitro testing methods, MQT has been shown
to be more cost-effective when the prevalence of AR in a population is 20% or higher.862
While blended skin testing techniques may be considered in the evaluation of AR, especially
to determine the starting point for AIT, the evidence to support this technique is not strong.
•

Aggregate Grade of Evidence: D (Level 3b: 1 study; Level 4: 4 studies; Table
VIII.E.3).

•

Benefit: Ability to establish an endpoint in less time than IDT.
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•

Harm: The additional risks, including systemic or anaphylactic reactions, of
intradermal tests; additional time and discomfort.

•

Cost: Similar to intradermal testing.

•

Benefits-Harm Assessment: Benefit outweighs harm.

•

Value Judgments: AIT can be initiated from SPT results alone; however,
endpoint-based AIT may decrease time to reaching therapeutic dose.

•

Policy Level: Option.

•

Intervention: MQT is a skin testing technique that may be used to determine a
starting point for AIT.

VIII.E.4.

Issues that affect the performance or interpretation of skin tests
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VIII.E.4.a. Medications.: The wheal and flare reaction seen in allergy skin testing
depends upon the physiologic actions of histamine released from mast cells upon
degranulation. Thus, any medications that inhibit mast cell degranulation or that function as
histamine H1 receptor antagonists have the potential to suppress appropriate skin test
responses. The suppressive effects of H1 antihistamines on allergen and histamine induced
wheal and flare responses vary greatly,863,864 and the duration of this suppression depends
upon the skin tissue concentration and half-life of these agents.865,866 In fact, skin test
suppression can be used as a biological assay for the onset and duration of action of
antihistamines.865 Agents such as astemizole (now removed from the market due to QT
prolongation) have the potential to suppress skin test reactions for a period of weeks after
cessation.867 However, most antihistamines only suppress skin test responses for a period of
2 to 7 days after cessation.867,868 Topically administered antihistamines have the potential to
suppress skin wheal and flare responses. One randomized placebo-controlled study showed
that 14 days of azelastine nasal spray treatment reduced the histamine induced wheal and
flare response, and this suppression disappeared by 48 hours after cessation869 (Table
VIII.E.4.a-1).
Randomized, placebo-controlled trials have demonstrated that H2 receptor antagonists such
as ranitidine can reduce skin whealing responses,870,871 and 1 study showed an additive
effect of H1 and H2 antihistamines on skin wheal suppression.872 Some antidepressants have
the potential to suppress skin wheal and flare responses, in particular the tricyclic
antidepressants that have antihistaminic properties (such as doxepin).873 However, newer
classes of antidepressants such as selective serotonin reuptake inhibitors (SSRI) do not
appear to affect allergy skin test responses.874

Author Manuscript

Recombinant humanized anti-IgE monoclonal antibody (mAb), omalizumab, interferes with
IgE-mediated mast cell degranulation reactions in the allergy skin test response. A
randomized placebo-controlled trial demonstrated a significant reduction in allergen-induced
skin whealing after 4 months of treatment.874 Omalizumab appears to suppress skin test
reactivity in tandem with dramatic reductions in serum free IgE, and allergy skin test
responses return to normal within 8 weeks of discontinuation.875
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Leukotriene receptor antagonists (LTRAs) do not appear to interfere with allergy skin test
results. Hill and Krouse876 as well as Simons et al.866 found no effect of montelukast on
intradermal skin test results in allergic subjects. Cuhadaroglu et al.877 found no change in
SPT results in allergic subjects before and treatment with zafirlukast.
In general, the highest level evidence shows that systemic steroid treatment has no effect on
SPT and intradermal test results,878,879 though some less rigorous retrospective studies
suggest that systemic steroid treatment could affect skin whealing responses.880,881 Topical
steroid treatment has been demonstrated to suppress the wheal and flare reaction in treated
skin areas, creating the possibility of false-negative test results.882-885 No studies were
identified that examined the effect of intranasal or inhaled steroids on skin test results.
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The effects of many classes of medications on allergy skin test responses remain
inadequately studied. Benzodiazepines have been implicated as possibly suppressing skin
test responses.886,887 The calcineurin inhibitor tacrolimus was shown to inhibit SPT
whealing,885 whereas a study of a similar drug, pimecrolimus, did not show any effect on
skin whealing responses.888 The pharmacologic effects of herbal preparations are generally
unstudied, and it is unclear which of these agents could interfere with allergy skin test
responses. More et al.889 performed a double-blind, placebo-controlled, single-dose
crossover study in 15 healthy volunteers, examining the histamine-induced skin test
response. None of the 23 herbal supplements tested caused suppression of the histamineinduced wheal response.
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There are many classes of medications for which the actual impact on allergy skin testing
are unknown. To mitigate against the risk of false-negative skin test results induced by
medications, all allergy testing should be performed after application of appropriate positive
controls (usually histamine) to ensure that the histamine-induced skin test reaction is intact
at the time of testing. See Table VIII.E.4.a-1 for a comprehensive review, with Aggregate
Grades of Evidence in Table VIII.E.4.a-2.
VIII.E.4.b. Skin conditions.: The usefulness of allergy skin testing depends upon the
ability to detect a Type I hypersensitivity reaction after allergen introduction into the skin.
Abnormal skin (eg, dermatitis) may not respond appropriately to histamine, glycerin, or
allergen. Additionally, the physical trauma of prick/puncture or intradermal testing may
induce a local inflammatory response. The wheal and flare reaction also may be difficult to
detect due to preexisting skin changes. Further, skin color may inhibit the ability to visualize
the flare reaction, especially in darker skinned individuals.
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Common sense dictates that allergy skin testing should not be performed at sites of active
dermatitis, but clinical studies to investigate this phenomenon are lacking. Individuals with
dermatographism may have exaggerated responses to allergy skin testing, requiring close
attention to the results of negative control tests. In some cases, it may be preferable to
perform in vitro specific IgE testing in patient with skin disease or dermatographism, but
this is not based on data or outcomes from controlled studies.
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Due to the lack of published studies on this topic, an Aggregate Grade of Evidence and
evidence based recommendation cannot be provided.
VIII.F.

In vitro testing
VIII.F.1. Serum total IgE (tIgE)—The literature addressing the role of serum tIgE in the
evaluation and diagnosis of allergic disease offers conflicting outcomes and divergent
opinions. Positive studies, demonstrating a relevant role of measuring tIgE in the evaluation
and diagnosis of AR, are listed in Table VIII.F.1-1. Negative studies that report a limited role
of measuring tIgE are listed in Table VIII.F.1-2. When taken together, however, this body of
literature provides some information that can inform decisions related to the utility of tIgE in
directing patient care decisions.
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Perhaps the strongest statement that can be made on behalf of tIgE is its ability to generally
identify patients or populations with atopic or allergic disease. For example, Ando and
Shima892 reported that tIgE is higher in children with AR than in peers with NAR. Marinho
et al.893 found a borderline association between tIgE and current rhinitis. In a retrospective
study, Kalpaklioglu and Kavut894 reported that tIgE is higher in AR than in NAR. Jung et al.
895 conducted a prospective study that showed a tIgE cutoff of 98.7 IU/mL as a strong
predictor of AR. Salo et al.454 performed a cross-sectional study reporting significant
associations between tIgE levels and current hay fever in different age classes. Demirjian et
al.896 demonstrated that a tIgE level over 140 IU/mL is suggestive of an atopic cause for
patients with clinical symptoms of AR. Hatcher et al.897 showed that an elevated tIgE in the
presence of a negative inhalant-specific IgE screen may suggest the presence of unidentified
inhalant allergen sensitization or chronic respiratory inflammatory disease other than AR.
Karli et al.898 reported that tIgE is helpful in confirming the diagnosis but it cannot be
recommended for routine use due to its high cost and the time to perform the test. Chung et
al.899 reported that tIgE (cutoff value 150 IU/mL) is a reliable biomarker for AR diagnosis.
Jacobs et al.900 reported a favorable role of measuring tIgE in diagnosing AR, mainly if
levels are higher than 100 IU/mL. Li et al.901 observed that tIgE is higher in AR than in
NAR in a retrospective study. Finally, in a 2-year follow-up study, Park et al.902 showed that
in subjects without allergic sensitization at the initial examination, tIgE greater than 17.7
IU/mL was associated with the risk for allergic sensitization, whereas in patients with
allergic symptoms but negative SPT results at the initial examination, tIgE greater than 17.4
IU/mL was associated with newly developed allergic sensitization.
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In contrast, there are 4 studies with negative results in the setting of tIgE and AR/allergy.
Satwani et al.903 reported no association between tIgE level and AR diagnosis. Tu et al.904
demonstrated an insufficient diagnostic accuracy of tIgE levels to detect allergic diseases
regardless of which cutoff value is being used; tIgE was linked more to atopy than directly to
symptoms. In the same follow-up study noted above, Park et al.902 reported that in subjects
without allergic sensitization at the initial examination, tIgE less than 17.7 IU/mL was not
associated with newly developed allergic nasal symptoms. Finally, Tay et al.905 conducted a
retrospective analysis in patients with high tIgE levels (> 1000 IU/mL) and concluded that
the elevated IgE level in AR is of limited clinical/diagnostic value.
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Another opportunity offered by tIgE assessment is the ratio between allergen-specific and
tIgE. It has been reported that this ratio might be useful in the prediction of AIT
effectiveness,906-908 as recently outlined by the EAACI Position Paper.909
In summary, tIgE is frequently increased in AR, but the clinical utility is modest in common
practice. In fact, the literature is a divergent set of studies that fails to find a consistent role
or value for tIgE in the management of AR patients.
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•

Aggregate Grade of Evidence: C (Level 2b: 5 studies; Level 3b: 10 studies;
Tables VIII.F.1-1 and VIII.F.1-2).

•

Benefit: Possibility to suspect allergy in a wide screening.

•

Harm: Low level does not exclude allergy.

•

Cost: Modest cost of test.

•

Benefits-Harm Assessment: Slight preponderance of benefit over harm. In
addition, the ratio tIgE/sIgE may be useful.

•

Value Judgments: The evidence does not support a routine use.

•

Policy Level: Option.

•

Intervention: Total IgE assessment is an option to assess atopic status.
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VIII.F.2. Serum antigen-specific IgE (sIgE)—sIgE testing became commercially
available in 1967 with an assay reliant on radioactive anti-IgE for labeling IgE in serum.
910,911 This radioactive technique, known as RAST, has largely been replaced with other
technologies using enzymatically-driven reactions to produce a chemiluminescent,
colorimetric, or fluorimetric reaction quantified or “read” by an autoanalyzer.910,912 The
process is as follows: allergens are bound to a substrate (typically in the form of a solid or
liquid phase) to which a patient’s serum is added. sIgE in the patient’s serum then binds to
the allergen on the substrate. Excess serum is washed off and with it, any unbound IgE. Nonhuman anti-IgE antibodies tagged by a marker are subsequently added and bind any
corresponding sIgE that is immobilized. Excess anti-IgE antibodies are then washed off and
the autoanalyzer reads the intensity of the radioactive, chemiluminescent, colorimetric, or
fluorimetric reaction. The intensity of the reaction is proportional to the amount of sIgE in
the serum and a report is generated. All tests approved by the FDA are calibrated against a
World Health Organization (WHO) tIgE standard serum.913 Different units are reported
depending on the assay system used, but many vendors offer conversion factors.

Author Manuscript

Serum sIgE testing offers several benefits. The safety profile of serum sIgE testing is the
best of all available allergy tests as the risk for anaphylaxis is nonexistent. Furthermore, the
use of skin testing is limited by the presence of certain medical conditions. In patients where
skin testing is contraindicated or potentially impacted by medications or skin conditions,
sIgE testing offers a safe and effective option for determining the presence of sensitization as
a biomarker of IgE-mediated hypersensitivities and confirming specific allergen triggers.
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There are some important similarities and differences between skin testing and sIgE testing
that warrant discussion. First, studies have indicated that while patients are accepting of both
in vitro and in vivo allergy testing, skin testing may be preferred because it allows for
immediate feedback and visible results.914 Second, neither skin or sIgE testing can
definitively predict the severity of a patient’s sensitivity to an aeroallergen. Third, crossreacting allergens and poly-sensitizations can confound both skin and in vitro testing,
leading to false-positive results.915 In contrast to skin testing, sIgE tests use more
extensively quality-controlled allergens and defined human serum controls. Whereas skin
testing depends upon the clinician administering and interpreting the test, sIgE tests have
coefficients of variation less than 15% in the College of American Pathologists diagnostic
allergy proficiency survey, which is performed 3 times per year by all Clinical Immunology
Laboratories licensed by the Clinical Laboratory Improvement Act of 1988. However,
several reports have demonstrated poor agreement in results from testing the same sera by
different commercially available assay systems.916,917 As with skin testing, sIgE results
should be interpreted within the context of the patient’s clinical history.
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One application of sIgE technology is multiallergen screens consisting of 10 to 15 allergens.
In scenarios where a clinician wishes to either rule in or out allergy as a driving factor
behind symptoms without subjecting patients to the time and cost of a full testing battery,
sIgE screens are an option. Generally, either a negative or positive result is given. Screens
testing for 10 to 12 allergens (ie, molds, regional pollens, cat, and mite) are positive in up to
95% of patients who would have tested positive on a larger battery.912,918 Therefore, they
are effective in identifying allergic patients. Conversely, if the test is negative, there is
evidence that this reliably supports an absence of allergy.910 A second application lies in the
fact that levels of sIgE may correlate with severity of AR symptoms.919-923 Given that
patients with more severe symptoms have been shown to respond better to AIT than those
with milder symptoms, sIgE may help in the selection of candidates for AIT and possibly
predict the response.919,924 Third, in polysensitized patients, it can be difficult to determine
the most relevant allergen on SPT. In these situations, sIgE levels can help discriminate the
most relevant allergen and guide AIT.920

Author Manuscript

Studies have shown that sIgE testing has a sensitivity between 67% and 96% and specificity
of between 80% and 100%.793,822,835,925,926 Further, it has been demonstrated that sIgE
shows excellent correlations with both NPT and SPT in the diagnosis of AR.
793,822,835,857,911 There is good evidence to show that sIgE is, in many ways, equivalent to
SPT.218,818,925 The decision to perform sIgE must be based upon a thorough history and
physical examination to confirm the presence of allergy and guide therapy when necessary.
It is important to note that while sIgE levels are a biomarker of allergic sensitization, this test
alone cannot provide a definitive diagnosis of allergy due to the high rate of clinically
irrelevant (false-positive) tests without an indicative clinical history. Based on the reviewed
literature, sIgE testing is an acceptable alternative to skin testing and is safe to use in
patients who are not candidates for skin testing (Table VIII.F.2).
•

Aggregate Grade of Evidence: B (Level 3b: 7 studies; Table VIII.F.2).
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•

Benefit: Confirms sensitization in support of an AR diagnosis and directs
appropriate therapy while possibly avoiding unnecessary/ineffective treatment;
guides avoidance measures; and directs AIT.

•

Harm: Adverse events from testing including discomfort from blood draw,
inaccurate test results, false-positive test results, misinterpreted test results.

•

Cost: Moderate cost of testing.

•

Benefits-Harm Assessment: Preponderance of benefit over harm.

•

Value Judgments: Patients can benefit from identification of their specific
sensitivities. Further, in some patients who cannot undergo skin testing, sIgE
testing is a safe and effective alternative.

•

Policy Level: Recommendation.

•

Intervention: Serum sIgE testing may be used in the evaluation of AR. Using
standardized allergens and rigorous proficiency testing on the part of laboratories
may improve accuracy.

VIII.F.3. Correlation between skin and in vitro testing—Allergen skin testing has
been used to diagnose allergic disease since first introduced by Blackley 140 years ago.
791,928 The discovery of IgE in 1969 allowed for the development of in vitro serological tests
which have become increasingly utilized.929 However, skin testing and sIgE serology
portend unique biological functions. Therefore, the 2 tests are not fully interchangeable.
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Modern SPT of aeroallergens can be up to 25% more sensitive than sIgE serology depending
on the patient population and the methodologies employed.793,930-934 In the United States,
SPT also generally costs about one-half as much as sIgE serology ($6.82 vs $12.50 per
allergen tested).935 Other factors to consider include access to laboratory technology,
comorbid disease, and the age of the patient. In vitro testing avoids the need to withhold
medications that affect skin testing and allows for testing in subjects with dermatographism
or other widespread skin disorders. SPT measurements are directly observable within 20
minutes, which is typically much faster than laboratory reports are obtained. Both sIgE
serology and SPT are considered very safe techniques; however, SPT does carry a very small
risk of anaphylaxis.
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The sensitivity and specificity of SPT depends on the allergen tested, quality of reagents, the
specific methodologies employed, technician expertise, and patient demographics.928,937-942
For example, SPT wheal size and sensitivity depend on the specific device selection and the
choice of control reagents used for testing.928,938 Nonetheless, a recent meta-analysis
indicates that SPT remains an accurate test, which when combined with a detailed clinical
history, helps confirm the diagnosis of AR830 (Table VIII.F.3-1).
The performance and reliability of serum sIgE testing likewise depends on several factors
including the choice of reagents, modernization of equipment, and patient demographics.932
The cutoff value for a positive test affects both the sensitivity and specificity.943 In a Korean
population, SPT was found to be superior to ImmunoCAP for measuring dust mite
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sensitivity if the patient was less than 30 years of age.792 For the group older than age 50
years, ImmunoCAP was more sensitive.792 Intradermal or epicutaneous testing demonstrates
higher sensitivity but lower specificity than SPT for several allergens.793,856,931,932,944
Based on this, intradermal tests should be selected judiciously. There is evidence to suggest
that a positive intradermal reaction to grass pollen in the setting of negative prick testing
may not be clinically relevant.793,856
In recent years, microarray allergy testing systems such as ImmunoCAP ISAC (Thermo
Fisher Scientific/Phadia AB, Uppsala, Sweden) have been introduced in an effort to offer a
comprehensive in vitro allergen test panel.794 The precision and utility of microarray testing
needs more rigorous scrutiny so that consensus guidelines can be more firmly established.
794,945 The cost of a single Immuno-CAP ISAC test, which includes 112 components from
51 allergens, is approximately $500 to $600 in the United States.794,945
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Various studies have compared sIgE serology to allergen SPT.793,943,946,947 Both techniques
are sensitive and are generally well correlated; however, interpretation of the results depends
upon the gold standard reference used to define allergic status. Environmental chambers,
nasal challenge, and validated questionnaires are typically used to determine the diagnostic
accuracy of allergen testing. Table VIII.F.3-2 summarizes several comparative studies
between skin testing for aeroallergens, specific IgE serology, and other in vitro tests.
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It is important to understand that selection and interpretation of allergen testing is not based
on sensitivity and specificity alone. The intended physiological mechanism to be
interrogated also needs to be considered. SPT and intradermal testing both measure endorgan pathological mechanisms associated with sIgE bound to the surface of mast cells. In
contrast, serum sIgE testing and microarray approaches measure circulating IgE that may or
may not represent downstream allergic inflammatory responses. Both intradermal testing
and SPT rely heavily on technician skill for interpretation of the wheal and flare reaction.
856,928,937 In the case of subjects with dermatographism (or other inflammatory skin
conditions in the testing area), hairy arms, or darkly pigmented skin color, the interpretation
of the SPT can prove to be difficult.942 Specialized imaging systems have been developed to
measure the wheal reaction in an automated fashion in both light and dark skinned
individuals, but additional validation is required. Until these automated systems become
more widespread, in vitro testing affords the benefits of temporal and multicenter
reproducibility.
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The average pooled sensitivity of SPT is 85% which is often slightly higher than that of
serum sIgE testing830; however, this is not universally true depending on the allergen tested
and the characteristics of the patient. Based on accuracy, convenience, cost, and promptness
of results, SPT is often chosen as the first line diagnostic instrument to detect sensitivity to
aeroallergens. Intradermal testing can be used as a second line test to exclude reactivity if
the clinical suspicion is very high. In cases where dermatographism is present and/or
patients are unable to wean off medications that affect skin testing, sIgE testing may be a
better choice. More studies are required to determine the role of small volume blood testing
through emerging microarray technology such as the ImmunoCAP ISAC.
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Aggregate Grade of Evidence: B (Level 1a: 1 study; Level 1b: 7 studies; Level
1c: 1 study; Level 2a: 1 study; Level 2b: 6 studies; Level 3a: 2 studies; Level 5: 1
study; Table VIII.F.3-1).
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VIII.F.4. Nasal specific IgE—AR is classically diagnosed by clinical history and with
objective testing for confirmation, usually SPT or in vitro testing with serum sIgE.301 In
addition to positive systemic sIgE, AR patients have been shown to have sIgE in the nasal
mucosa with evidence that class switching and antibody production occurs locally.
309-312,377,950,951 However, some patients have negative SPT or serum sIgE despite a clinical
history suggestive of AR and meeting ARIA clinical criteria.101,300 These patients are
usually given the diagnoses of idiopathic rhinitis, vasomotor rhinitis, or NAR.300 However, it
has been demonstrated that many of these patients may have local allergic phenomena or
LAR, a type of rhinitis characterized by the presence of a localized allergic response in the
nasal tissues, with local production of sIgE and positive response to NPT without evidence
of positive SPT or serum sIgE elevation.107 LAR may affect more than 45% of patients
otherwise categorized as NAR,296,302,952 and up to 25% of patients referred to allergy
clinics with suspected AR.291 Like traditional AR patients, LAR can be classified as
perennial or seasonal, and similar findings in the nasal mucosa have been reported in both of
these populations.300,301,953 It has even been suggested that some patients with occupational
rhinitis may suffer from LAR.107 Recent studies suggested a low rate of conversion of LAR
to systemic AR.296,302 The first 5 years of a long-term followup study performed in a cohort
of 194 patients with LAR and 130 healthy controls found that patients with LAR of recent
onset (less than 18 months from the diagnosis) had a similar conversion to systemic AR
when compared to controls.296 A small retrospective study performed in 19 patients with a
long clinical history of LAR (greater than 7 years from the diagnosis) and negative SPT to a
wide panel of allergens had a similar rate of development of systemic AR302 compared with
epidemiologic data of prevalence of atopy in a healthy population from that geographic area.
954 Upcoming data from the 10-year follow-up study should help to clarify the rate of a
long-term conversion to systemic AR in patients with LAR. In fact, LAR can present later in
life, and in elderly patients with rhinitis the incidence of LAR has been reportedly been as
high as 21%.304
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The diagnosis of LAR is confirmed by positive response to NPT, and evidence of sIgE in the
nasal secretions. A variety of allergens have been tested in this fashion including dust mites,
grasses, pollens, and molds.300,301,306,307,955 The production of nasal mast cells,
eosinophils, and sIgE rapidly increases after allergen-specific stimulation in the nasal
mucosa.288,294,307 Different methods have been reported regarding how to best identify
nasal sIgE including nasal lavage, cellulose disks, mucosal biopsy, and brushing (Table
VIII.F.4). While there is no gold standard, most of these techniques appear to yield similar
results in identifying nasal sIgE in LAR patients. Additionally, normative data for nasal sIgE
levels and their clinical correlations have yet to be established and agreed upon, but work
has begun in this area.956
When evaluating a rhinitis patient, in the setting of negative systemic testing, the
differentiation of LAR from NAR can provide important information for management.
While both typically respond to pharmacologic treatment, identification of offending
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allergens in LAR may permit allergen avoidance and immunotherapy.107 AIT is the
treatment of choice for patients with AR who have failed allergen avoidance and medical
therapy. Patients who are classified as NAR, would not typically be candidates for AIT.
However, as previously noted, roughly 50% of patients with negative systemic testing have
been shown to have LAR. In this LAR population, early studies suggest that AIT can
decrease symptoms and medication usage, and improve QOL.288,957
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•

Aggregate Grade of Evidence: C (Level 2b: 13 studies; Level 3b: 3 studies; Level
4: 8 studies; Table VIII.F.4).

•

Benefit: Identifying patients with LAR allows for the opportunity to treat a
subset of patients who may respond to avoidance or AIT. Identification of nasal
sIgE allows for diagnosis and AIT.

•

Harm: Measurement of nasal sIgE is minimally invasive, and no adverse effects
have been reported.

•

Cost: Associated costs consist of the direct costs of testing, and indirect cost of
increased time and effort for performing nasal sIgE diagnostic test.

•

Benefits-Harm Assessment: The benefits of identifying patients with an allergic
component to their rhinitis may outweigh any associated risks.

•

Value Judgments: In patients with rhinitic symptoms and negative systemic
testing, identifying nasal sIgE may assist with appropriate treatment. Standards
for abnormal levels of nasal sIgE have not been established nor correlated with
clinical outcomes.

•

Policy Level: Option.

•

Intervention: Nasal sIgE levels is an option in patients with suspected or known
LAR to aid in diagnosis or guide allergen-specific therapy.

VIII.F.5. Basophil activation test (BAT)—The basophil activation test (BAT) is an ex
vivo peripheral blood test that has been shown to be useful in the diagnosis of allergy to food
and drugs, along with other hypersensitivity syndromes, when first-line tests (SPT and
serum sIgE) are discordant with clinical history or do not exist, and for monitoring of AIT.
966 Within the field of AR, there are small-scale trials evaluating the utility and reliability of
BAT in testing for the diagnosis of specific allergens related to AR symptoms and
monitoring therapy (Table VIII.F.5).
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BAT methodology was found to be heterogeneous between trials. Most data pertaining to its
accuracy used the tetraspanin CD63 (lysosome-associated membrane glycoprotein 3 [LAMP
3]) as an activation marker.967-971 CD203c (ecto-nucleotide pyrophosphatase/
phosphodiesterase 3) is less frequently used.968,972 In 1 trial, it held potential as a sensitive
and specific method of testing for AR as compared to CD63.968
The diagnosis of AR is a clinical decision guided by skin or serological tests; ex vivo
basophil testing is rarely required. However, BAT has been shown to be comparable with
traditional allergen testing methods.967,970,973,974 BAT has been shown to be useful in
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defining the allergen responsible for LAR in patients who have had false-negative results
with first-line tests and a high suspicion for clinically-relevant allergy.308,318
Basophil reactivity (% CD63+ cells determined at 1 allergen concentration) does not reflect
the effect of allergen immunotherapy. There is good evidence to suggest that basophil
sensitivity (EC50, or eliciting concentration at which 50% of basophils respond; also named
CD-sens if it is inverted and multiplied by 100) is a marker for treatment effect of
AIT969-971,975-977 and anti-IgE treatment.975
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In summary, BAT may be a useful ex vivo test when diagnosis of AR is in doubt or the
allergen responsible for clinical symptoms is unknown. Basophil sensitivity is also useful for
measuring response to AIT. When the methodology of BAT is more clearly standardized, it
may become a more useful second line test in AR diagnosis, as using an ex vivo test is
beneficial in terms of time taken to undergo testing and symptoms evoked during testing.
Most studies included small samples sizes with less than 100 patients. There is an
opportunity for a meta-analysis of these studies or a larger scale trial to confirm the findings
of the works included in this review.
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•

Aggregate Grade of Evidence: B (Level 1b: 2 studies; Level 2b: 2 studies; Level
3b: 8 studies; Level 4: 3 studies; Table VIII.F.5).

•

Benefit: Ex vivo test, patient discomfort minimal, less time consuming than nasal
provocation and SPT for patient, reliable correlation between clinical symptoms
and basophil sensitivity when measuring response to therapy, no risk of
anaphylaxis compared to provocation testing.

•

Harm: None known.

•

Cost: Requires proximity of laboratory trained in basophil testing. Cost of
testing.

•

Benefits-Harm Assessment: Balance of benefit over harm.

•

Value Judgments: Basophil sensitivity may be a useful marker for following
response to immunotherapy. Differences in BAT methodology for diagnosis of
AR and rare need for laboratory tests to diagnose AR make it likely to be
implemented for diagnosis in tertiary care centers only.

•

Policy Level: Option.

•

Intervention: BAT is an option for AR diagnosis when first-line tests are
inconclusive or for measuring response to AIT. Many small-scale studies have
been completed. There is scope for meta-analysis and for larger trials to be
completed.

VIII.F.6. Component resolved diagnosis (CRD)—Molecular diagnosis (MD) or
component resolved diagnosis (CRD) is used in allergy to define the allergen sensitization of
a patient at the individual protein level by measuring sIgE to purified natural or recombinant
allergens, allowing identification of the potential disease-eliciting molecules. Overall, MD
can potentially improve diagnostic accuracy (specificity), distinguish cross-reactivity
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phenomena from true co-sensitization, resolve low-risk markers from high-risk markers of
disease activity, and may improve the indication and selection of suitable allergens for AIT
when compared to diagnosis based on SPT and/or sIgE determination with raw commercial
extracts.980-984 Indeed, changes in immunotherapy prescription aided by MD have been
demonstrated to be cost-effective in some scenarios.985 Certain patterns of sensitization to
grass or olive pollen allergens may also identify patients with higher risk of adverse reaction
during immunotherapy.986,987 Nevertheless, all in vitro test results should be evaluated
alongside the clinical history, since allergen sensitization does not necessarily imply clinical
responsiveness.
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IgE to purified or recombinant allergens is usually measured by using a fluorescence
enzyme immunoassay in singleplex platforms. However, a multiplex platform with 112
allergens is also available (ISAC, Thermo Fisher Scientific, Uppsala, Sweden). Results of
singleplex and multiplex platforms are not interchangeable. When comparing the singleplex
and multiplex assays, concordance of results vary between allergens tested, and the
sensitivity of multiplex platform is lower than that of singleplex, particularly when sIgE
levels are low.983 Otherwise singleplex platforms are quantitative assays and multiplex are
semiquantitative.
Specific antigens.: In the case of mite sensitivity, markers of specific sensitization include
Der p 1 and Der p 2 for Dermatophagoides pteronyssinus and Dermatophagoides farinae,988
Lep d 2 for Lepidoglyphus destructor (storage mite, with limited cross-reactivity with other
HDMs),989 and Blo t 5 for Blomia tropicalis (non-Pyroglyphidae mite).990 Der p 10, a
tropomyosin from D. pteronyssinus, has been shown to be a good maker of clinical
sensitivity to crustaceans but not a marker of sensitization to mites.991,992
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Can f 1, Can f 2, and Can f 5 are specific allergen components indicating specific
sensitization to dog.993 Interestingly, Can f 5, a prostatic kallikrein produced only by male
dogs is responsible for monosensitivity in up to 25% to 38% of dog-allergic patients.994,995
In these cases, patients can tolerate exposure to female dogs. Fel d 1 is the major allergen
component in cat allergy, indicating specific sensitization.996 Other cat allergens have some
cross-reactivity with allergens from other sources; eg, Fel d 2 is likely to cross-react with
other mammal albumins, such as dog Can f 3, horse Ecu c 3, pig Sus s PSA, and cow Bos d
6,997 and Fel d 4 is shown to cross-react with major allergens from horse Equ c 1, dog, or
cow.998 Therefore, CRD for cat allergy provides more information about cross-reactivity and
specificity of the diagnosis. Equ c 1, is the major allergen of horse dander and has some
cross-reactivity with mouse Mus m 1 and cat Fel d 4.999 Equ c 3 is a serum albumin showing
cross-reactivity with other mammals’ serum albumins mentioned above (i.e. Fel d 2). In
summary, CRD in patients with allergy to dog, cat, and horse are not only predictive markers
of allergy, but may also help clinicians to predict clinical symptoms and their severity, since
some patterns of sensitization are related to more severe rhinitis and asthma.994,995
Allergens related to sensitization to cockroaches are Bla g 1, Bla g 2, Bla g 4, and Bla g 5,
although in certain populations tropomyosins (Bla g 7 and/or Per a 7) can be important.1000
Alt a 1 is a major allergen that is recognized in approximately 80% to 100% of Alternariaallergic patients.1001 Markers of sensitization to several pollen are summarized in Table
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VIII.F.6. Sensitization to profilin has been associated with more severe respiratory
symptoms in grass-allergic patients, as well as sensitization to the minor olive allergens Ole
e 7 and Ole e 9.987,1002 IgE antibodies to Phl p 1 and/or Phl p 5 can be used as specific
markers of sensitization to grass pollen and Phl p 4 as a marker of sensitization to nonPooideae grasses. However, Phl p 6 is contained only in Pooideae grasses. Allergens from
groups 1, 2, 5 and 6 are only expressed in grasses but not in other plants, so they detect a
genuine sensitization to grasses.981
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In summary, CRD in patients with AR can help to better define the sensitization to inhalant
allergens, especially in those who are polysensitized, have unclear symptoms and/or
sensitization patterns, or who do not respond to treatment. On the contrary, monosensitized
patients with a clear case history and symptom profile may not benefit from CRD compared
to traditional diagnostic tests. Nevertheless, CRD remains a third-level approach, not to be
used as a screening method in current practice. One of the most useful aspects of CRD is
that it can help clinicians to better select patients and allergens for prescribing AIT,1003 and
in some cases, predict the risk of adverse reactions. The pattern of sensitization to allergens
may predict the severity of the disease and could potentially predict the efficacy of AIT,
provided these immunotherapy products contain a sufficient amount of allergen. As there are
multiple individual allergens available for CRD and several different uses for CRD,
extensive evidence grading is not undertaken in this document.
VIII.G.

Sensitization vs clinical allergy
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Sensitization vs allergy—Although IgE-mediated sensitization has been consistently
shown to be an important risk factor for rhinitis,520,1004 the strength of this association is not
consistent.1005,1006 In epidemiology and clinical practice, patients are typically diagnosed as
being “sensitized” based on a positive SPT (usually ≥3 mm wheal diameter), or a positive
specific serum IgE (usually ≥0.35 kU/L [specific IgEs are reported in arbitrary units, thus
the unit kU]).1007,1008 However, both of these tests can be positive in the absence of any
symptoms, and neither positive SPT nor IgE can confirm the expression of rhinitis
symptoms upon allergen exposure.1009,1010 Thus, a clear distinction has to be made between
“sensitization” (which usually refers to positive allergy tests, irrespective of any symptoms),
and clinical allergic disease such as AR, which denotes the presence of sensitization and
related clinical symptoms.
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“Positive” allergy test vs sIgE titer or SPT wheal size—Quantification of atopic
sensitization by using the level of sIgE antibodies or the size of SPT wheals increases the
specificity of allergy tests in relation to the presence and severity of rhinitis.893,1004 This has
changed the way we interpret the results of allergy tests, with a move from dichotomization
(labeling patients as being sensitized based on a “positive” test using arbitrary criteria), to
quantification of blood or skin tests using sIgE titer and SPT wheal size.893,1010-1012
Whole-allergen extract vs individual allergenic molecules—Homologous proteins
present in the whole-allergen extracts from different allergen sources may be cross-reactive
(eg, profilins and PR-10 proteins in various plants, or tropomyosin present in mites, various
insects, and shrimp). Thus, a positive test to the whole-allergen extract may reflect
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sensitization to a cross-reactive component.1013 Measuring sensitization to individual
allergen molecules in a CRD may more be informative than standard tests using wholeallergen extracts.470,1014-1016 Current multiplex CRD platforms allow the testing for
component-specific IgE to more than 100 allergenic molecules in a single assay, and in a
small volume of serum.1013,1015 The patterns of component-specific IgE responses to
multiple allergenic proteins have a reasonable discrimination ability for rhinoconjuinctivitis,
1017 and distinct patterns of IgE responses to different protein families are associated with
different clinical symptoms. For example, sensitization to proteins of plant origin strongly
predicts AR, and sensitization to animal lipocalins is predictive of asthma.1018,1019 The risk
of allergic disease increases with the increasing number of sensitizations to individual
allergenic proteins, and IgE polysensitization to several HDM molecules strongly predicts
rhinitis.1019,1020 It is important to emphasize that the age of onset of sensitization is
crucially important, and that development of AR may be predicted by the unique molecular
nature of IgE responses to individual allergen components.1019
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Disaggregating atopic sensitization—It is becoming increasingly clear that “atopic
sensitization” is not a single phenotype, but an umbrella term for several different atopic
vulnerabilities which differ in their association with rhinitis and asthma.1021,1022 Different
subtypes of atopy are characterized by a unique pattern of the responses to different
allergens and the timing of onset of allergen-specific sensitization.1023 Translation of these
findings into clinical practice requires the development of biomarkers which can
differentiate between different subtypes of sensitization, and can be measured at the time of
clinical evaluation.
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Beyond IgE—Recent data suggest that among individuals sensitized to grass pollen, the
decreasing ratio of grass allergen-specific IgG/IgE antibodies is associated with increasing
risk of symptomatic SAR,1024 suggesting that the IgG/IgE ratio may help distinguish
between “benign” sensitization (sensitization with no symptoms) and “pathologic”
sensitization.1024 However, the measurement of allergen-specific IgG cannot as yet be
recommended in a routine clinical practice.1009,1010
VIII.H.

Allergen challenge testing
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VIII.H.1. Allergen challenge chambers (ACCs)—Environmental exposure chambers
(EECs) have been used for decades for controlled exposure of subjects to a well-defined
atmosphere of a variety of substances such as allergens, particulate and gaseous air
pollutants, chemicals, or climate conditions. The generation of valid exposure conditions
with high temporal and spatial stability is technically demanding, and there are a limited
number of EECs world-wide. Besides the opportunity to use EECs for well-designed
mechanistic studies on the effect of environmental pollutants on human health, allergen
challenge in the chamber setting with induction of symptoms in patients with allergic
disease is an intriguing way for efficacy testing of new drugs. Therefore, several chamber
facilities were installed in recent years with the focus on allergen exposure resulting in
currently 15 allergen challenge chamber (ACC) facilities around the globe.1025
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ACC studies have contributed to our understanding of the pathophysiology of allergic
diseases. For example, it has been demonstrated that controlled allergen exposure
exacerbates atopic dermatitis.1026 Also, the impact of exposure with pollen allergen
fragments on AR symptoms has been shown.1027 Furthermore, the importance of the
integrity of the epithelial barrier for induction of local and systemic inflammatory responses
has been investigated in patients with allergic rhinoconjunctivitis using the ACC setting.1028

Author Manuscript

The use of ACCs in clinical trials for efficacy testing of investigational new drugs, and their
acceptance by regulatory authorities is peremptorily dependent on the technical and clinical
validation of ACCs. Many ACCs have been intensively validated regarding specificity and
dose-dependency of symptom induction as well as technical aspects such as temporal
stability and spatial homogeneity of the allergen exposure.1029-1037 Also, repeatability of
outcome measures in the ACC has been systematically investigated and found to have
excellent repeatability as measured by TNSS.1038 With the given level of technical and
clinical validation, ACCs have been intensively used in clinical drug development to study
pharmacological properties of new drugs during phase II trials, such as dose-finding,
1039-1041 onset of action,1042-1046 and duration of action.1047-1049 In this respect, numerous
randomized, placebo-controlled clinical trials have been conducted using parallel-group or
crossover designs in order to test the efficacy of drugs with immediate therapeutic activity,
such as antihistamines,1050-1053 or with prophylactic therapeutic potential, such as topical
steroids,1054-1056 novel anti-inflammatory compounds,1057-1060 or probiotics.1061 Major
advantages in the ACC setting compared to field studies are better signal-to-noise ratios, a
safeguarded minimum level of symptomatology in the ACC, and repeatability of symptoms
allowing intraindividual comparisons.
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With availability of a variety of validated allergen atmospheres in challenge chambers,
efficacy testing for dose-finding of AIT has also been performed in RCTs.
1062-1066 While regulatory authorities accept the use of ACC in phase II of drug
development,1067,1068 they have been reluctant to approve them in pivotal phase III studies
because the clinical validation is still imperfect. Differences between natural exposure in
field studies and ACC studies exist, for example with regard to exposure time (continuous vs
intermittent), exposure atmosphere complexity (natural mix vs artificial purity), or selection
of study population (all-comers vs allergen-challenge responders). Therefore, evaluation of
efficacy during natural exposure in phase III field studies is still mandatory. However, recent
joint activities of the EAACI with experts from academia, chamber owners, and regulators
have defined the most relevant unmet needs and prerequisites for clinical validation to
further develop the use and regulatory acceptance of ACC in pivotal phase III studies.
1029,1030,1034,1035
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In summary, numerous well-designed RCTs using technically validated ACCs for efficacy
testing of investigational new drugs with detailed analysis of dose-response, onset of action,
and duration of action provide evidence for the use of ACCs in phase II of clinical drug
development.
VIII.H.2. Local allergen challenge tests—Challenging the target organs of
respiratory allergy (ie, nose, bronchi, eye) with a suspected allergen is aimed at
demonstrating the actual clinical reactivity when the results of the initial allergy tests (skin
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tests, in vitro measurement of sIgE) are inconclusive. The NPT is designed for AR, while
conjunctival provocation test (CPT) may be used in patients with rhinoconjunctivitis or AR
alone.1069,1070
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Nasal challenge.: The aim of nasal challenge is to reproduce the response of the upper
airway upon nasal exposure to allergens.1071,1072 However, currently the only technique
fulfilling this aim is the EEC (as described in the previous section), while the allergen
amounts administered during an NPT usually exceed natural exposure levels, sometimes to a
large extent. The allergen for NPT can be administered by various devices, including
syringes, nose droppers, micropipettes, nasal sprays, or impregnated disks, none of them
being free from limitations or pitfalls.1071 The result of a NPT can be assessed by several
measures, including symptom scores (especially the TNSS), rhinomanometry, acoustic
rhinometry, optical rhinometry, peak nasal inspiratory flow, inflammatory markers in nasal
lavage fluid, and nasal NO concentration.1072 Contraindications to NPT are acute bacterial
or viral rhinosinusitis, exacerbation of AR, history of anaphylaxis to allergens, severe
general diseases, and pregnancy.1073 Recent studies evaluating the sensitivity and specificity
of the different techniques using specific allergens are available (Table VIII.H.2). It is
apparent from the contrasting findings that a standardized technique for NPT is not yet
available. In fact, in the coming years, the use of NPT in the diagnosis of AR is likely to
decrease, due to the diagnostic ability of emerging tools such as CRD1074 and the BAT,1075
which are able to identify the causative allergen in patients with dubious results from initial
analysis.
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Despite its limitations, a pivotal role for NPT is currently acknowledged in diagnosis of
occupational rhinitis and LAR. According to the position paper of the EAACI, occupational
rhinitis “can only be established by objective demonstration of the causal relationship
between rhinitis and the work environment through NPT with the suspected agent(s) in the
laboratory, which is considered the gold standard for diagnosis.”84 The best time to perform
a NPT is in the morning to limit the effects of common daily-life stimuli. Baseline
evaluation of symptoms and nasal function should be done after adaptation to room
temperature. A control test must be performed to ensure that the nasal response is specific to
the tested agent.1076 A positive control test suggests rhinitis induced by irritants or
nonspecific hyperresponsiveness.
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In regard to LAR, the absence of sIgE in serum and in the skin requires that IgE are found
locally or that they are revealed by a positive NPT.1077 Despite the introduction of
techniques to detect IgE in the nose in the 1970s,1078 the ability to measure locally-present
IgE in the clinic setting is not currently available. This makes NPT of critical importance,
though contrasting observations have been reported. NPT with mites, pollens and Alternaria
was positive in 100% of 22 adults with previously diagnosed LAR,1079 but in a casecontrolled, prospective study on 28 children with a diagnosis of NAR, tested with mites and
grass pollen, NPT was positive in only 25% of subjects.293
Conjunctival challenge.: While several different techniques exist for NPT, CPT is generally
performed by instilling 20 to 30 μL of an allergen solution into the inferior external quadrant
of the ocular conjunctiva, using diluent in the contralateral eye as a control.1069 Also, the
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positive response to CPT is simple to evaluate, because it consists of an immediate reaction
(from 5 to 20 minutes from the instillation) with ocular itching, tearing, redness, and
possibly conjunctival edema. In 1984, a study of 20 children with seasonal
rhinoconjunctivitis tested 3 times with CPT reported good reproducibility.1080 In 2001, a
diagnostic sensitivity and specificity of 90% and 100%, respectively, was reported in miteallergic patients.1081 A very recent systematic review was performed and the results were
published in the EAACI guidelines for daily practice of CPT, with grade B evidence for the
capacity to individuate the allergen trigger.1082 The conclusion highlighted that allergists
should be more familiar with CPT due to its simplicity. However, the scales to assess the
symptoms need to be validated, the standardization of allergen extracts must be improved
and the indication to perform CPT in patients with forms of conjunctivitis other than allergic
remains uncertain.
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•

VIII.I.

Aggregate Grade of Evidence for Nasal Provocation Testing: C (Level 2b: 4
studies). Of note, this evidence grade is based on the studies listed in Table
VIII.H.2. However, due to the variation in NPT technique and outcome
measures, a reliable evidence grade for NPT is difficult to determine.

Nasal cytology and histology

Author Manuscript
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Nasal cytology (NC) is a simple diagnostic procedure that evaluates the health of the nasal
mucosa by recognizing and counting cell types and their morphology.1087 NC requires 3
steps. The first is sampling the surface cells in the nasal mucosa with an appropriate device
via anterior rhinoscopy. The most commonly used collection device is the Rhino-probe
(Arlington Scientific, Springville, UT, USA).1088 The second step is staining by the MayGrunwald-Giemsa method, which allows for identification of all inflammatory cells present
in the nasal mucosa (ie, neutrophils, eosinophils, lymphocytes, and mast cells) as well as
normal mucosal cells (ciliated and mucinous), and even bacteria or fungi. The third step is
examination through an optical microscope able to magnify up to 1000×. For the analysis, at
least 50 microscopic fields must be read to be sure to detect all the cells in the sample.1087
NC may detect viruses, fungi, and bacteria (including biofilms) in the nose, allowing for the
diagnosis of infectious rhinitis.1089 Specific cytological patterns on NC can help in
discriminating among various forms of rhinitis, including AR, NAR, idiopathic rhinitis, and
overlapping forms. AR is commonly diagnosed by the combination of clinical history and
results of in vivo and/or in vitro tests for sIgE antibodies.1090 When assessed by NC, the
predominant cell type is the eosinophil, followed by mast cells and basophils.1091-1094 In a
logistic regression model, elevated nasal eosinophil counts on NC has an OR of 1.14 (95%
CI, 1.10 to 1.18) to identify AR.1092 It has been described that NC in polyallergic patients
shows a more intense inflammatory infiltrate than in monoallergic patients.1093 NC has also
demonstrated seasonal changes of inflammatory cells in the nose, probably mirroring the
variations in allergen exposure, in patients with mite-induced rhinitis.1095
Negative allergy testing in patients with persistent rhinitis usually suggest a diagnosis of
NAR.1096 The first variant of NAR, known as NARES, was described after the identification
of a subset of patients with perennial rhinitis, negative skin tests, and marked eosinophilia in
nasal secretions.174 In more recent years, other variants have been defined, including NAR
with mast cells (NARMA), with neutrophils (NARNE), and with eosinophils and mast cells
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(NARESMA).1097 Idiopathic rhinitis is also characterized by high levels of eosinophils and
mast cells in some patients.1098 Overlapping forms may occur.1099
NC is 1 method of diagnosing NAR and has been used to differentiate between variants in
experiments.1100 However, few studies investigating the diagnostic performance of NC in
diagnosing AR or NAR are available (Table VIII.I-1).
•

Aggregate Grade of Evidence: C (Level 3b: 3 studies; Level 4: 1 study; Table
VIII.I-1).
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Nasal histology as assessed by biopsies of the nasal cavity was the only technique to study
tissues and cells in patients with AR for many decades. In the 1990s, biopsy-based
investigations allowed researchers to define the role of the different inflammatory cells in
AR.379 The original technique begins by spraying a local anesthetic and topical
vasoconstrictor into the nasal passages. After anesthesia has taken effect, a piece of tissue is
removed from the middle turbinate using small punch biopsy forceps. After immediately
placing the tissue in buffered formalin, each specimen can then be stained with various
reagents to detect different tissue components and cells.1101 Reagents used include Giemsa,
hematoxylin/eosin, periodic acid-Schiff, Masson trichrome, azure A, and chloroacetate
esterase.299,415,1101 After staining, the slides are examined by an optical double-headed light
microscope, using a grid reticule divided into 100 squares to quantitate cells and tissue per
square millimeter.
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The introduction of NC made it possible to obtain the similar information as histology, but
without the associated discomfort and potential risk for bleeding. Further, NC allows for
sequential sampling where histology does not. In addition, when Lim et al.415 compared
nasal histology with cytology in patients with perennial and seasonal rhinitis compared to
controls, the results suggested that nasal secretions and the nasal mucosa represent 2 distinct
cellular compartments. Specifically, following allergen challenge an influx of inflammatory
cells was detected by cytology, while the epithelial layer assessed by histology was
unchanged from baseline.415 In 2005, Howarth et al.1102 stated that, compared to simple
techniques such as NC or nasal lavage, nasal biopsy requires expertise both in tissue
sampling and in biopsy processing, thus being applicable only in specialist centers. This
issue, as well as the previously reported drawbacks, makes nasal histology a technique of
interest in the research on pathophysiology of AR but hardly feasible for routine clinical
practice. Table VIII.I-2 shows the available studies on AR pathophysiology as evaluated by
nasal histology.
•
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IX.
IX.A.

Aggregate Grade of Evidence : B (Level 1b: 8 studies; Level 3b: 3 studies; Table
VIII.I-2).

Management
Allergen avoidance
Allergen avoidance and environmental controls (ECs) are frequently discussed as part of the
treatment strategy for AR, along with pharmacologic management and AIT. AR patients are
keen to learn about avoidance measures and ECs, especially those who wish to avoid
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medications or cannot commit to an AIT regimen. Considering this, it is important to
examine the evidence supporting allergen avoidance and EC measures for the allergic
patient.

Author Manuscript

IX.A.1. House dust mite—Techniques to reduce environmental HDM exposure have
been investigated for the treatment of AR. HDMs represent 1 of the most common triggers
of AR,1114 and EC measures have been advocated as a management strategy, with evaluation
of both physical barriers and chemical treatments.1114-1118 Various physical techniques (eg,
heating, ventilation, freezing, barrier methods, air filtration, vacuuming, and ionizers) have
been evaluated for the treatment of AR, with variable findings. While several studies have
demonstrated decreased concentrations of environmental HDM antigens,1119-1124 an
associated reduction in clinical symptoms has not been reliably demonstrated (Table
IX.A.1). Despite reductions in HDM antigen concentration, Ghazala et al.1120 and
Terreehorst et al.1124 both found no clinical benefits of HDM-impermeable bedding as an
isolated intervention. Similar findings were reported by Antonicelli et al.1125 following a
trial of high efficiency particulate air (HEPA) filtration.

Author Manuscript

Chemical techniques include the use of acaricides in household cleaners to reduce HDM
concentration. Geller-Bernstein et al.1119 evaluated an acaricide spray in the bedrooms of
patients with HDM sensitization, demonstrating improved mean symptom scores vs control
patients without acaricide. Similar findings were reported by Kniest et al.1121 No serious
adverse effects were reported from any of the evaluated interventions, and no study
evaluated cost-effectiveness as an outcome measure. A 2010 Cochrane review examined the
effectiveness of environmental measures for HDM including impermeable covers, HEPA
filters, acaricides, or combination treatments.1126 This systematic review found acaricides to
be the most effective as a single measure or in combination with other measures to decrease
HDM levels and improve AR symptoms.
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•

Aggregate Grade of Evidence: B (Level 1a; 1 study; Level 1b: 3 studies; Level
2a: 1 study; Level 2b 7 studies; Table IX.A.1).

•

Benefit: Reduced concentration of environmental HDM antigens with potential
improvement in symptom scores and QOL.

•

Harm: None.

•

Cost: Low to moderate; however, cost-effectiveness was not evaluated.

•

Benefits-Harm Assessment: Benefit outweighs harm.

•

Value Judgments: The use of acaricides and/or bedroom-based control programs
in reducing HDM concentration is promising, but further, high-quality studies
are needed to evaluate clinical outcomes.

•

Policy Level: Option.

•

Intervention: Concomitant use of acaricides and EC measures, such as
personalized air filtration techniques, are options for the treatment of AR.
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IX.A.2. Cockroach—Cockroach infestation and allergen concentrations are often high in
multi-occupant dwellings in densely populated inner city areas; although elevated levels of
cockroach allergen are also found in homes in warmer, rural regions.1129-1131 Interventions
are targeted at eliminating infestations and abating cockroach allergen in homes. A
systematic review by Le Cann et al.,1132 identified 3 key strategies for home environmental
interventions: (1) education-based methods that included instruction on house cleaning
measures and sealing cracks and crevices in areas where infestation occurs (ie, kitchens); (2)
physical methods using insecticides or bait traps; and (3) combination therapy containing
both educational-based interventions and physical methods (Table IX.A.2).

Author Manuscript

Most studies included 1 or more interventions aimed at reducing cockroach counts and
allergen (Bla g 1 and Bla g 2) levels1133-1140; however, a few focused on eliminating
multiple allergens (eg, HDM, cockroach, rodent, cat, dog).1141,1142 The most effective
treatment for eliminating infestation and reducing allergen load was professional pest
control.1135 Sever et al.1133 found placement of insecticide bait traps to be more effective in
reducing cockroach populations with a concomitant reduction in cockroach allergen
compared to homes that received applications of insecticide formulations to baseboards,
cracks, and crevices monitored over a 12-month period.

Author Manuscript

When cost was considered, the price of bait traps along with labor and monitoring costs
were found to be less expensive than multiple commercial applications of insecticide sprays
to baseboards and cracks.1133 As the expense of integrated home management consisting of
professional cleaning, education, and pest control is not economically sustainable,
investigations are focused on assessing the efficacy of single interventions, such as
extermination alone, to assess possible cost benefits.1135,1143 In addition, family adherence
to home-based interventions was generally poor, resulting in elevated cockroach
concentrations over time.1138
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Although there are a substantial number of RCTs that evaluated the efficacy of specific
environmental control measures to eliminate the number of cockroaches and reduce
cockroach allergen level, respiratory health outcomes were rarely measured. Even though
cockroach count and Bla g1 and Bla g2 allergen levels were reduced in many studies with
home interventions, the level of cockroach allergen following treatment remained higher
than acceptable median levels associated with clinical benefits in sensitized individuals.
1134,1137-1140 Although cockroach count could be significantly reduced in single-family
homes using bait traps, re-infestation and high allergen levels remained an ongoing problem
in multifamily buildings.1140 Thus it is difficult to dramatically reduce cockroach allergen
levels in the home unless a significant reduction in cockroach counts is maintained over
time.1133 Most studies did not include clinical endpoints; however, those that did evaluate
clinical outcomes focused on asthma symptoms, hospitalizations or emergency room visits,
and medication usage.1141,1142 No studies included any assessment of symptoms associated
with AR or its treatment.
•

Aggregate Grade of Evidence: B (Level 1a: 1 study; Level 1b: 8 studies; Level
2b: 1 study; Level 3b: 1 study; Table IX.A.2).
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•

Benefit: Reduction in cockroach count, but allergen levels (Bla g 1 and Bla g 2)
often above acceptable levels for clinical benefits. No studies included clinical
endpoints related to AR.

•

Harm: None reported.

•

Cost: Moderate. Multiple treatments applications required as well as a multiinterventional approach.

•

Benefits-Harm Assessment: Balance of benefit and harm, given lack of clear
clinical benefit.

•

Value Judgments: Control of cockroach populations especially in densely
populated, multifamily dwellings is important to controlling allergen levels.

•

Policy Level: Option.

•

Intervention: Combination of physical measures (such as insecticide bait traps,
house cleaning) and educational-based methods are options in the management
of AR related to cockroach exposure.
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IX.A.3. Pets—Pet avoidance and EC represent options for the treatment of AR. Pet
removal is a commonly cited strategy without high-quality outcomes evaluation.
1118,1144,1145 Sánchez et al.1146 evaluated compliance rates among sensitized patients (n =
288), finding 4% of patients with direct exposure to home animals complied with removal
recommendations (Table IX.A.3). EC has therefore been evaluated to decrease antigen
exposure, with mixed results. Björnsdottir et al.1147 evaluated outcomes of multimodality
EC among 40 patients with diagnosed cat (Fel d 1) sensitization, finding significant
improvements in nasal airflow and clinical symptoms. However, despite reductions in
environmental antigens, single-modality EC has not been associated with improved
symptoms. Wood et al.1148 evaluated HEPA filtration in a high-quality randomized
controlled study of 35 patients with Fel d 1 sensitization, finding unchanged nasal symptom
scores, sleep disturbance, rescue medication usage, and spirometry following a 3-month
trial. Several lower-quality studies have evaluated the duration of antigen reduction
following pet washing, finding that cat and dog washing must be completed at least twice
weekly to maintain significant reductions in environmental antigens.1149,1150 Furthermore,
pet removal may only result in decreased allergen levels after several months1151 and Can f
1 levels in homes with “hypoallergenic” animals are generally similar to homes with nonhypoallergenic species.1152
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An additional study has identified benefits of pet avoidance in the secondary prevention of
asthma among previously sensitized individuals.1153 Similarly, current asthma treatment
guidelines recommend pet removal from a sensitized individual’s home.1154
•

Aggregate Grade of Evidence: B (Level 1b: 1 study; Level 2b: 2 studies; Table
IX.A.3.)

•

Benefit: Decreased environmental antigen exposure with possible reduction in
nasal symptoms and secondary prevention of asthma.
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•

Harm: Emotional distress caused by removal of household pets. Financial and
time costs of potentially ineffective intervention.

•

Cost: Low to moderate.

•

Benefits-Harm Assessment: Equivocal.

•

Value Judgments: While several studies have demonstrated an association
between EC and reductions in environmental antigens, only a single,
multimodality RCT has demonstrated clinical improvement in nasal symptoms
among patients with Fel d 1 sensitivity. The secondary prevention and treatment
of asthma in sensitized individuals must also be considered.

•

Policy Level: Option.

•

Intervention: Pet avoidance and EC strategies, particularly multimodality EC
among patients with diagnosed Fel d 1 sensitivity, are an option for the treatment
of AR related to pets.

IX.A.4. Other (pollen, occupational)—For patients with pollen allergy, avoidance
measures aim to minimize allergen exposure during the respective pollen season.101
However, pollination is a global natural phenomenon which periodically occurs, making it
nearly impossible for patients to thoroughly avoid exposure. There are some practical
methods to minimize patients’ exposure via EC measures. However, there is a paucity of
clinical trials evaluating the clinical efficacy of therapeutic strategies. Most of the
recommended strategies are based on expert consensus and clinical experience.1155
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One potential EC strategy is limiting residential exposure during periods of high pollination
(ie, vacationing in geographical regions with a reduced intensity of local pollen
concentration).1156 Patients can get further information about the current pollen count in
their respective region through internet sources (ie, the European Aeroallergen Network
[EAN] database [https://ean.polleninfo.eu/Ean/]; Foundation German Pollen Information
Service [http://www.pollenstiftung.de/]; American Academy of Allergy Asthma and
Immunology [AAAAI] [http://www.aaaai.org/global/nab-pollen-counts]). This information
may be used, for example, in avoidance of extensive outdoor exercise during peak pollen
levels or timing of preventive medication.1157,1158 Although expert opinion endorses these
strategies, there is no evidence to support their clinical efficacy.
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In addition, patients may open their home windows when the pollen counts are low or keep
windows closed and use air conditioning during times of high pollination. Special dust and
pollen filters may be used in cars to reduce the pollen concentration within the car.
Furthermore, pollen-allergic patients may be educated on removal of clothing and washing
their hair before entering their bedrooms during pollen season as pollen grains stick to both
hair and clothing. Again, expert opinion endorses these strategies, but there is no evidence to
support their clinical efficacy.1159,1160
Another EC strategy utilizes physical barriers to minimize mucosal exposure to airborne
allergens. In a prospective trial, 70 patients with SAR caused by grass pollen were
randomized to receive wrap-around eyeglasses in addition to standard medical care (first
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study group) or just standard medical care (second study group) during 3 consecutive grass
pollen seasons.1161 Interestingly, the authors found a significant improvement in ocular and
nasal symptoms as well as RQLQ in the group provided with wraparound eyeglasses
compared to the controls. Another approach is an active nasal filter by means of a membrane
removing particles from the inhaled air.1162 In a prospective, single-center, randomized,
double-blind, placebo-controlled, crossover study performed in an ACC, 24 adult patients
with grass-pollen induced SAR were randomly assigned to either a group that received this
nasal filtering membrane or to a group that did not.1162 Under repeated exposure in the
ACC, patients with the membrane filter significantly improved in some of their nasal
symptoms. However, the primary endpoint measuring maximum TNSS in this trial was not
significant; thus, meaningful conclusions are difficult to draw from this study.1162 The small
sample size was a notable limitation. A real-world, single-center, double-blind, crossover
trial of 65 patients by the same researchers, however, did find significant reductions in daily
TNSS and maximum TNSS with nasal filters used in-season compared to placebo1163 (Table
IX.A.4).
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Avoidance of exposure to occupational inhalant allergens is feasible, in principle, in
occupational allergic patients.112 Several modalities of reducing workers’ exposure to
occupational allergens such as “engineering controls” and “administrative controls” have
been described in the literature.1164 The former includes substitution of a hazardous
chemical with a nonhazardous or less-hazardous alternative, isolation of the hazardous
chemical, or efficient ventilation to reduce workers’ exposure. The latter includes workers’
education and personal protective equipment. A prospective controlled trial of 20 patients
with confirmed diagnosis of occupational allergy demonstrated that cessation of the
exposure of the causal allergen in the workplace led to a significant improvement of
patients’ nasal symptom scores as well as disease-specific QOL.1165
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•

Aggregate Grade of Evidence: B (Level 1b: 3 studies; Level 2b: 1 study; Table
IX.A.4).

•

Benefit: Decreased allergen exposure with possible reduction in symptoms and
need for allergy medication, along with improved QOL.

•

Harm: Financial and time costs of potentially ineffective intervention.

•

Cost: Low, but dependent on the EC strategy (ie, for occupational allergy
ventilation measures and other “engineering controls” may be high).

•

Benefits-Harm Assessment: Equivocal.

•

Value Judgments: A limited number of studies show clinical effects of
investigated EC measures. General EC recommendations are mainly based on
expert opinions rather than evidence.

•

Policy Level: Option.

•

Intervention: Pollen and occupational allergen avoidance by EC strategies are an
option for the treatment of AR; however, clinical efficacy has not been
definitively demonstrated. More RCTs with larger samples are warranted to
prospectively evaluate clinical efficacy.
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Whether selected by patients themselves or prescribed by medical personnel, medications
are the primary modality for control of allergic symptoms. There are numerous options for
oral or systemic use, topical intranasal application, and alternative therapies that can be
considered. It is, therefore, imperative to understand the data supporting the efficacy and
appropriate use of these pharmacotherapy options.
IX.B.1.

Antihistamines
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IX.B.1.a. Oral H1 antihistamines.: Histamine is a major mediator associated with the
symptomatology of AR. Oral H1 antihistamines block the action of histamine by binding the
histamine H1 receptor, thereby inhibiting the proinflammatory effects of histamine.
Antihistamines are typically categorized by generation, such as first or second-generation
agents. The older first-generation agents (ie, diphenhydramine, chlorpheniramine,
brompheniramine) were lipophilic and readily crossed the blood-brain barrier. This caused
unwanted side effects such as sedation, drowsiness, fatigue, and impaired concentration, and
memory as well as anti-muscarinic effects. First-generation antihistamines are also inhibitors
of the CYP2D6 hepatic enzymes. They may, therefore, alter the metabolism of other
medicines dependent upon CYP2D6 metabolism, such as tricyclic antidepressants, some
antipsychotics, β-blockers, anti-arrhythmics, and tramadol. Because of these significant side
effects, in previously published guidelines and other papers, first-generation antihistamines
have not been recommended for the treatment of AR.218,1166,1167 The newer-generation
agents (ie, loratadine, desloratadine, fexofenadine, cetirizine, levocetirizine) were developed
to minimize the adverse effects of earlier drugs. They are highly selective for the H1
receptor, lipophobic, and have limited penetration across the blood-brain barrier.
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Newer-generation antihistamines, except for cetirizine, levocetirizine, bilastine, and
fexofenadine, are metabolized by the hepatic cytochrome P450 CYP3A4 system.
Practitioners should be cognizant that the concurrent use of other medicines (eg, macrolides,
antifungals, or calcium-channel blockers) that inhibit CYP3A4 can result in accumulation of
drug concentrations and increase the risk for side effects and toxicity. Furthermore, adverse
cardiac effects (torsades de pointes, arrhythmia, and prolongation of the QT interval) were
reported with astemizole and terfenadine, leading to their ultimate withdrawal from the
market.1168,1169 RCTs have established the long-term safety and efficacy of the newergeneration H1 antihistamines cetirizine, desloratadine, fexofenadine, levocetirizine, and
loratadine (Table IX.B.1.a-1).
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Because oral antihistamines have been in use since the early 1940s, there have been many
RCTs establishing oral antihistamines as an appropriate pharmacotherapy for AR.218 As
such, this section does not list every published study but summarizes the highest-grade
evidence that has been published. Guidelines on AR have been published, including those by
the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS)761 and the
ARIA group.1167 The AAO-HNS concluded, based upon RCTs and a preponderance of
benefit over harm, a “strong recommendation” for the use of newer-generation oral H1
antihistamines for patients with AR.218 Similar consensus came from ARIA where a “strong
recommendation” was given for oral H1 antihistamines for AR.1167 Furthermore, ARIA and
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EAACI have published a set of recommendations that outline the pharmacological criteria
that should be met by medications commonly used in the treatment of AR.1170 The main
thrust of the ARIA/EAACI criteria was to assess the efficacy, safety, and pharmacology of
newer-generation oral H1 antihistamines using level 1a studies. Using these criteria, a
favorable risk-benefit ratio was determined for using newer-generation oral H1
antihistamines over first-generation oral antihistamines.1170 The evidence was further
strengthened with several meta-analyses of the current data, where accurate and robust effect
estimations can be derived from a large population1171 (Table IX.B.1.a-1).

Author Manuscript

The choice of a specific oral H1 antihistamine is often based upon the dosing, onset, drug
interactions, and potential cost (Table IX.B.1.a-2). Systematic reviews evaluating multiple
oral H1 antihistamines note benefits of certain drugs that may be important in deciding
which drug to recommend or prescribe. Direct costs of newer-generation antihistamines are
similar given the availability of many of these drugs as over-the-counter medications. In
contrast, the cost of prescription-only formulations (levocetirizine and desloratadine) is
much higher. Indirect costs would be expected to be similar among the newer-generation
oral antihistamines given similar side-effect profiles.

Author Manuscript

•

Aggregate Grade of Evidence: A (Level 1a: 21 studies; Table IX.B.1.a-1). There
is a preponderance of high-grade investigations that have examined oral H1
antihistamines. Only level 1a studies are summarized in the table.

•

Benefit: Reduced nasal itching, sneezing, rhinorrhea, and nasal obstruction.

•

Harm: Mild drowsiness, fatigue, headache, nausea, and dry mouth.

•

Cost: Direct costs low (average $2 per daily dose). Indirect costs for newer
generation agents lower than first-generation agents.1172,1173

•

Benefits-Harm Assessment: Benefits outweigh harm for use of newer-generation
oral H1 antihistamines.

•

Value Judgments: Due to the central nervous system side effects of the firstgeneration oral H1 antihistamines, their use is not recommended for typical AR.

•

Policy Level: Strong recommendation for use of newer-generation oral
antihistamines to treat AR.

•

Intervention: Prescribing newer-generation oral H1 antihistamines for patients
with AR should be considered early in treatment.

Author Manuscript

IX.B.1.b. Oral H2 antihistamines.: The role of the H2 receptor in mediating histaminerelated nasal symptoms in AR is controversial. Few small studies have investigated the
impact of H2 receptor antagonism, with varied results (Table IX.B.1.b). Further, no data
exists comparing H2 receptor antagonism efficacy to common modern first-line therapy such
as nasal topical corticosteroids. Finally, the clinical significance of the changes associated
with H2 antihistamines has not been clearly defined. Despite these caveats, some studies
support the addition of an H2 antihistamine for patients with recalcitrant nasal airway
obstruction while on oral H1 antihistamines. There are drug-drug interactions that can occur
with H2 antihistamines through decreased gastric acidity and inhibition of P450.1192
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However, due to the low cost of these medications, clinical situations may arise that would
justify their use.

Author Manuscript

All but 1 of the RCTs investigating the efficacy of H2 antihistamines are within the context
of pretreatment of a subject prior to a nasal allergen challenge. Wood-Baker et al.1193
compared oral cetirizine to oral ranitidine. Objective measures of nasal airway resistance
showed greater improvement with ranitidine, yet cetirizine decreased objective measures of
nasal secretion more than ranitidine. Taylor-Clark et al.1194 found similar improvement in
nasal airway resistance between cetirizine and ranitidine, but a significant improvement with
the use of combination therapy. Combination therapy was also shown to improve nasal
airflow when cimetidine was added to cetirizine.1195 Two studies did not find improvement
in nasal airflow with the addition of an H2 antihistamine.1196,1197 The clinical significance
of these objective findings is unclear, and the studies that employed PROMs did not
demonstrate subjective improvement in nasal obstruction.

Author Manuscript

Four studies investigated the impact of H2 antagonism on symptoms; however, these studies
did not utilize standardized outcome measures as they pre-dated the development of such
tools. Subjects were asked to report some combination of congestion, blockage, itching,
drainage, sneezing, eye symptoms, and asthma with a categorical severity measure. Three of
the 4 studies examined symptoms after nasal allergen challenge, and none demonstrated
efficacy of H2 antihistamines, either alone or in conjunction with an H1 antihistamine in
diminishing allergic symptoms.1195-1198 One study of 23 subjects1198 did investigate the
impact of cimetidine in conjunction with chlorpheniramine in a real-world setting. Subjects
with known late-summer AR were randomized during this season to receive alternating 2week courses of either chlorpheniramine plus placebo, or chlorpheniramine plus cimetidine,
and symptom scores were recorded twice daily along with adjuvant medical therapies
(specifically, oral corticosteroids). Patients receiving both H1 and H2 antihistamines reported
decreased medication usage (28 corticosteroid days vs 44 corticosteroid days, p < 0.02) and
decreased symptoms scores during 1 of the 8 weeks when weed pollen counts were high. A
caveat of this study is its utilization of a first-generation antihistamine that is no longer
recommended as a first-line treatment of AR.

Author Manuscript

The data existing on the use of H2 antihistamines in AR are limited in scope and quality. The
objective findings of improved nasal airway resistance suggest that the H2 histamine
receptor does modulate nasal tissue response to histamine.1193-1195 However, the clinical
significance of this mechanism is not clear, particularly in the context of modern treatment
algorithms.1195-1198 The relatively manageable side effect profile and costs of H2
antihistamines, does offer patients with otherwise recalcitrant AR symptoms an additional
treatment option.
•

Aggregate Grade of Evidence: B (Level 1b: 6 studies; Table IX.B.1.b).

•

Benefit: Decreased objective nasal resistance, and improved symptom control in
1 study when used in combination with H1 antagonists.

•

Harm: Drug-drug interaction (P450 inhibition, inhibited gastric secretion and
absorption),
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•

Cost: Increased cost associated with H2 antagonist.

•

Benefits-Harm Assessment: Unclear benefit and possible harm.

•

Value judgments: No studies evaluating efficacy of H2 antihistamines in context
of topical nasal corticosteroids.

•

Policy Level: No recommendation. The data available does not adequately
address the question as to the benefit of H2 antihistamines in clinical AR as part
of modern treatment protocols.

•

Intervention: Addition of an oral H2 antagonist to an oral H1 antagonist may
improve symptom control in AR; however, the evidence to support this is not
strong.

Author Manuscript

IX.B.1.c. Intranasal antihistamines.: The use of intranasal antihistamine spray for AR
has been well studied. Two agents are currently available in North America for intranasal
use as a topical spray, azelastine hydrochloride and olopatadine hydrochloride. A systematic
review of the English-language literature was performed for clinical trials of azelastine or
olopatadine for the treatment of AR. A total of 44 papers were identified that reported results
of RCTs of intranasal antihistamine monotherapy against either placebo or active
control1046,1199-1241 (Table IX.B.1.c). Of these, 11 studies included comparison of different
doses of intranasal antihistamine1204,1205,1207,1211,1212,1216,1218,1219,1231,1235,1237 and 29
studies utilized inactive placebo.
1201,1202,1204,1205,1207-1209,1211-1214,1216,1218-1222,1224,1225,1227-1231,1233,1235,1237-1239

Overall, there were 38 studies of azelastine1046,1199-1201,1203,1205,1207-1213,1215,1217,1220-1241
and 10 studies of olopatadine1202,1204,1206,1208,1210,1211,1214,1216,1218,1219 as monotherapy.

Author Manuscript

Outcome measures were predominantly patient-reported symptom scores or QOL
assessments. The most common outcome measure was the TNSS (23 studies), which records
the severity of runny nose, sneezing, itching, and congestion. Other outcome measures
included the RQLQ (7 studies), the Total Ocular Symptom Score (TOSS, 5 studies), the
Caregiver Treatment Satisfaction Questionnaire (2 studies), the Pediatric Rhinoconjunctivitis
Quality of Life Questionnaire (1 study), the Short Form-36 (1 study), the Epworth
Sleepiness Scale (ESS, 1 study), the Rhinitis Severity Score (1 study), and a Subjective
Global Assessment (1 study). Multiple studies, particularly those published prior to 2002,
used a variety of nonvalidated symptom scoring systems ranging from 5 to 13 items each (19
studies). Objective measures included nasal lavage (3 studies), response to methacholine
challenge (2 studies), nasal flow rate (2 studies), and rhinomanometry (1 study).

Author Manuscript

Study duration ranged from 2 days to 8 weeks, with the most frequent duration being 14
days of treatment. The number of subjects in each study ranged from 20 to 1188. Intranasal
antihistamine was compared to placebo in 29 studies,
1201,1202,1204,1205,1207-1209,1211-1214,1216,1218-1222,1224,1225,1227-1231,1233,1235,1237-1239 with
primary outcomes showing superiority to placebo in all studies. Intranasal antihistamine was
trialed against an active treatment comparator of a different medication class in 24 studies.
1046,1199,1203,1206,1213-1215,1217,1220,1221,1224,1226,1227,1229,1231-1236,1238-1241 Although not
reported in all studies, the intranasal antihistamine spray consistently had a more rapid onset

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Wise et al.

Page 92

Author Manuscript

of action, occurring as early as 15 minutes after administration. Azelastine and olopatadine
were directly compared in 3 studies, with no significant difference in symptom relief
between agents.1208,1210,1211 In 2 additional studies, azelastine was compared with an
experimental formulation of intranasal levocabastine, with either comparable or superior
results for azelastine.1200,1223

Author Manuscript

Intranasal antihistamine was compared to INCS in 12 studies, with the primary outcome
favoring antihistamine in 2 studies,1213,1214 corticosteroid in 3 studies,1224,1227,1229 and
showing equivalency in 7 studies.1199,1203,1206,1233,1238,1239,1241 In 2 of the studies showing
equivalency, antihistamine was superior for ocular symptoms.1203,1239 The 3 studies
showing superiority of corticosteroids were all conducted prior to 2000 and used
heterogeneous nonvalidated symptom scores as primary outcomes. Intranasal antihistamine
was compared to oral antihistamine monotherapy in 8 studies, with the primary outcome
favoring intranasal antihistamine in 3 studies1215,1217,1232 and showing equivalency in 5
studies.1221,1234-1236,1240 One study included a treatment arm with oral chlorpheniramine as
a positive control without intent to compare efficacy with azelastine.1231 One study
comparing azelastine spray with oral loratadine plus intranasal beclomethasone found that
azelastine monotherapy was at least as effective as combination therapy.1226 Two studies
comparing intranasal azelastine plus oral antihistamine to intranasal azelastine monotherapy
showed no additional benefit for combination therapy.1220,1221
The minimum age of subjects in the included studies was generally 12 years or older.
Children aged 6 to 12 years old were included in 3 studies, which in aggregate showed
superiority of intranasal antihistamine to placebo in improving symptoms and QOL.
1202,1204,1228
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Serious adverse effects were not reported in any study. Intranasal antihistamine was
generally well tolerated, with the most commonly reported adverse effect of an unpleasant
taste. One study that compared the commercially available form of azelastine with a
reformulated vehicle found no difference in taste aversion.1205 One study directly comparing
olopatadine with azelastine reported better sensory attributes for olopatadine.1210 Other
reported adverse effects included somnolence, headache, epistaxis and nasal discomfort, all
occurring in less than 10% of cases in any study.

Author Manuscript

•

Aggregate Grade of Evidence: A (Level 1b: 43 studies; Level 2b: 1 study; Table
IX.B.1.c). Due to the large number of studies with high level of evidence, studies
of lower evidence levels are not considered here.

•

Benefit: Intranasal antihistamines have a rapid onset, are more effective for nasal
congestion than oral antihistamines, are more effective for ocular symptoms than
INCS, and show consistent reduction in symptoms and improvement in QOL in
RCTs compared to placebo.

•

Harm: Concerns for patient tolerance, especially due to taste. Intranasal
antihistamines are less effective for congestion than INCS.

•

Costs: Low-to-moderate financial burden; available as prescription only.
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•

Benefits-Harm Assessment: Preponderance of benefit over harm. Intranasal
antihistamine as monotherapy is consistently more effective than placebo. Most
studies show intranasal antihistamines superior to INCS for sneezing, itching,
rhinorrhea, and ocular symptoms. Adverse effects are minor and infrequent.

•

Value Judgments: Extensive level 1 evidence comparing intranasal antihistamine
monotherapy to active and placebo controls demonstrates overall effectiveness
and safety.

•

Policy Level: Recommendation.

•

Intervention: Intranasal antihistamines may be used as first-line or second-line
therapy in the treatment of AR.

IX.B.2.

Corticosteroids

Author Manuscript
Author Manuscript

IX.B.2.a. Oral corticosteroids.: The anti-inflammatory effect of oral corticosteroids in
AR is well known and has been demonstrated experimentally using the nasal challenge
model and clinically in the context of seasonal disease. Compared to placebo, premedication
with oral prednisone for 2 days prior to an allergen challenge showed a reduction in sneezes,
and levels of histamine and mediators of vascular permeability in nasal lavages during the
late phase response884 (Table IX.B.2.a). Further, active treatment resulted in a reduction in
the priming response to consecutive allergen challenge.884 Prednisone has also been shown
to reduce the influx of eosinophils and levels of the eosinophil mediators (major basic
protein and eosinophil derived neurotoxin) into nasal secretions during the late-phase
response compared to placebo.1242,1243 Non–placebo-controlled studies have demonstrated
efficacy of oral corticosteroids for SAR. Schwartz et al.1244 demonstrated that 15 days of
cortisone 25 mg 4 times daily during the ragweed season resulted in significant relief of
symptoms in 21 of 25 patients. Similarly, 100 mg of cortisone daily for 4-day courses during
the pollen season showed rhinitis symptom relief in 42 of 51 patients, with 20 patients
relapsing within 7 days after cessation of therapy.1245 Oral hydrocortisone 40 to 80 mg daily
has also been shown to reduce symptoms of ragweed allergies.1246 Brooks et al.1247
performed a placebo-controlled study comparing the efficacy of methylprednisolone 6, 12,
or 24 mg PO daily for 5 days to placebo in controlling nasal symptoms during the ragweed
season. Whereas the 6-mg and 12-mg doses led to a significant reduction in some of the
symptoms compared to placebo (congestion, postnasal drainage, and eye symptoms), the 24mg dose resulted in a significant reduction of all symptoms (congestion, runny nose,
sneezing, itching, postnasal drainage, and eye symptoms).

Author Manuscript

Because of the recognized systemic adverse events associated with oral corticosteroids,101
their use has been largely replaced by the intranasal preparations. In a double-blind, placebocontrolled trial, the effect of intranasal flunisolide and its oral dose bioequivalent (an oral
dose that would lead to similar systemic levels) were compared in ragweed-induced SAR.
1248 The intranasal preparation was shown to be efficacious in reducing rhinitis symptoms
while the oral dosing was not. This suggested that INCSs achieve their benefit primarily by
their local activity as opposed to systemic bioavailability. In a head-to-head comparison of
the efficacy of intranasal vs systemic steroids, Karaki et al.1249 performed an open-label,
parallel, randomized trial during the cedar pollen season in Japan. Patients received
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loratadine 10 mg daily alone, loratadine with intranasal mometasone furoate (200 μg once
daily), or loratadine with oral betamethasone 0.25 mg twice daily for 1 week. The groups
receiving some form of steroid in addition to loratadine had significantly lower symptoms of
sneezing, rhinorrhea, and nasal obstruction compared to loratadine alone, with no significant
difference between the intranasal and oral preparations. The oral steroid was more effective
than the INCS in controlling allergic eye symptoms.
The above data suggest that oral corticosteroids are effective for the treatment of AR.
However, given the significant systemic adverse effects related to using oral corticosteroids
for prolonged periods of time these agents are not recommended for the routine treatment of
AR.

Author Manuscript
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•

Aggregate Grade of Evidence: B (Level 1b: 5 studies; Level 2b: 1 study; Level 4:
3 studies; Table IX.B.2.a).

•

Benefit: Oral corticosteroids can attenuate symptoms of AR.

•

Harm: Oral corticosteroids have known undesirable adverse effects. These
include effects on the hypothalamic-pituitary axis, growth and musculoskeletal
system, gastrointestinal system, hypertension, glycemic control, mental/
emotional state, and others.

•

Cost: Low.

•

Benefits-Harm Assessment: The risks of using oral corticosteroids outweigh the
benefits when compared to similar symptom improvement with the use of INCS.

•

Value Judgments: In the presence of effective symptom control using INCS, the
risk of adverse effects from using oral corticosteroids for AR appears to
outweigh the potential benefits.

•

Policy Level: Recommendation against the routine use of oral corticosteroids for
AR.

•

Intervention: Although not recommended for routine use in AR, certain clinical
scenarios warrant the use of short courses of systemic corticosteroids after a
discussion of the risks and benefits with the patient. This may include patients
with significant nasal obstruction that would preclude penetration of intranasal
agents (INCS or antihistamines). In these cases, a short course of systemic oral
corticosteroids could improve congestion and facilitate access and efficacy of the
topical agents.

Author Manuscript

IX.B.2.b. Injectable corticosteroids.: Corticosteroids have been injected intramuscularly
or into the turbinates for management of AR. The evidence evaluating deep intramuscular
injections will be reviewed first. Overall, several early studies1250-1254 demonstrated clinical
effectiveness in improving allergic symptoms; however, the safety outcomes demonstrated
the risk of undesired systemic corticosteroid adverse effects. More recent evidence1255
confirms the increased risk of endogenous cortisol suppression along with other
corticosteroid-related adverse effects such as osteoporosis and hyperglycemia (Table
IX.B.2.b).

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Wise et al.

Page 95

Author Manuscript

Kronholm1250 demonstrated that a single injection of either betamethasone dipropionate/
betamethasone phosphate or methylprednisolone acetate given at the onset of the hay fever
season led to a significant reduction of both nasal and ocular symptoms during the 5 weeks
of the study, with the betamethasone combination being more effective. Ohlander et al.1251
compared 3 long-acting corticosteroid injections given at the beginning of the season, and
showed that all treatments led to significant reductions in nasal and ocular symptoms during
the season with no difference between groups. However, all preparations also suppressed
endogenous cortisol, in some cases for more than 14 days after injection, and 2 out of the 3
injections resulted in increases in blood sugar levels.

Author Manuscript

When compared to other agents, injected corticosteroids demonstrated similar effectiveness
outcomes. Specifically, there were similar clinical outcomes when comparing preseasonal
steroid injections to both daily oral prednisolone1252 and daily intranasal beclomethasone
dipropionate spray.1253 An adrenal corticotropic hormone (ACTH) test performed at 3
weeks showed significant suppression of adrenal function in the oral steroid treatment group
and no evidence of suppression in the corticosteroid injection or topical intranasal
corticosteroid groups.1252 This was probably related to the short duration of adrenal
suppression expected after a single injection of corticosteroids compared to continuous
administration.

Author Manuscript

When evaluating the timing of injectable corticosteroid therapy, Borum et al.1254 compared
the effects of a single depot injection of methylprednisolone given either at the beginning of
the allergy season or later when pollen counts peaked. Compared to placebo, intramuscular
methylprednisolone was efficacious against nasal congestion with less pronounced effects
against rhinorrhea and sneezing. The authors argue that depot injectable steroids may be
considered after other safer medical therapy fails and may provide an effective alternative
treatment even if provided late in the allergy season.
Injectable corticosteroid preparations may have significant side effects that include adrenal
suppression and growth retardation.1256 In a large retrospective study of Danish National
Registries, the relative risk and incidence of both osteoporosis and diabetes were higher in
allergic individuals receiving at least 1 depot corticosteroid injection during the allergy
season compared to those receiving immunotherapy.1255
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Several early reports detailed significant improvement in symptoms of AR in a large
proportion of patients who received intraturbinate injections of cortisone,1257 hydrocortisone
acetate,1258 or prednisolone.1259 Similar, noncontrolled, studies showed improvement in AR
symptoms after intraturbinate injections.1260,1261 A more recent randomized, placebocontrolled, single-blind trial by Yang et al.1262 compared the efficacy of intraturbinate
injections of either onabotulinum toxin A, triamcinolone, or isotonic saline in patients with
PAR. Both onabotulinum toxin A and triamcinolone therapy showed better control of nasal
symptoms than placebo with onabotulinum toxin A efficacy lasting longest.
Orbital complications have been reported with intraturbinate but not intramuscular
injections. Based on a large clinical experience, Mabry cites an estimated incidence of visual
loss after intraturbinate injections to be 0.006%.1263 Other complications have included
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transient visual loss and diplopia,1264 blurred vision and temporary blindness,1265 temporary
distorted vision, and decreased visual acuity and paresis of the medial rectus.1265 Martin et
al.1266 reported the rapid onset of ocular pain, blurred vision, and decreased visual acuity
after an intraturbinate injection of triamcinolone acetonide. Choroidal and retinal arterial
embolization were confirmed as the cause and they resolved completely within 24 hours.
The mechanism of embolization is likely related to retrograde flow from the anterior tip of
the inferior turbinate to the ophthalmic artery, followed by anterograde flow with the
particles lodging in the end arteries of the choroid and retinal vessels. Steroids with larger
particle size (eg, methylprednisolone) are thought to present higher risk than lower-sized
particles (eg, triamcinolone).

Author Manuscript
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•

Aggregate Grade of Evidence: B (Level 1b: 3 studies; Level 2b: 3 studies; Level
4: 7 studies; Table IX.B.2.b).

•

Benefit: Injectable corticosteroids improve symptoms of AR in clinical studies.

•

Harm: Injectable corticosteroids have known adverse effects on the
hypothalamic-pituitary axis, growth suppression, osteoporosis, hyperglycemia,
and other systemic adverse effects. Intraturbinate corticosteroids have a small,
but potentially serious, risk of ocular side effects including decline or loss of
vision.

•

Cost: Low.

•

Benefits-Harm Assessment: In routine management of AR, the risk of serious
adverse effects outweighs the demonstrated clinical benefit.

•

Value Judgments: Injectable corticosteroids are effective for the treatment of AR.
However, given the risk of significant systemic adverse effects, the risk of serious
ocular side effects, and the availability of effective alternatives (ie, topical INCS
therapy), injectable corticosteroids are not recommended for the routine
treatment of AR.

•

Policy Level: Recommendation against.

•

Intervention: None.

Author Manuscript

IX.B.2.c. Intranasal corticosteroids (INCSs).: INCSs are effective for the treatment of
AR. Their potent anti-inflammatory properties directly affect the pathophysiologic
mechanisms of nasal inflammation in AR. In both nasal allergen challenge models and
seasonal disease, treatment with INCS results in significant reduction in mediator and
cytokine release along with a significant inhibition in the recruitment of basophils,
eosinophils, neutrophils, and mononuclear cells to the nasal mucosa and secretions.
187,389,1267,1268 INCSs also reduce the antigen-induced hyperresponsiveness of the nasal
mucosa to subsequent challenge by antigen187 and histamine.1269,1270
Multiple placebo-controlled clinical trials in adults and children have demonstrated the
effectiveness of INCS in the reduction of nasal symptoms in AR, including sneezing,
itching, rhinorrhea, and congestion.1271,1272 With the reduction of nasal symptoms, INCS
significantly improve the QOL1272-1274 and sleep673,706,707,1275,1276 of these patients. No
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significant differences in efficacy between available agents have been demonstrated in
studied populations1273; therefore, sensory attributes may be an important factor in patient
preference and adherence to therapy.1277 These sensory attributes include aftertaste, nose
runout, throat rundown, and smell. Addressing some of these concerns are 2 intranasal nonaqueous preparations with hydrofluoroalkane (HFA) aerosols recently approved for the
treatment of AR in the United States. These include beclomethasone dipropionate and
ciclesonide, both approved and effective for SAR and PAR in adults and children 12 years
and older.688,1278-1281 Onset of action for INCS starts at time points ranging from 3 to 5
hours to 60 hours after first dosing.1282-1285 Although the recommended continuous daily
use of INCS is superior to other dosing strategies,1286,1287 studies have demonstrated the
efficacy of as-needed use of intranasal fluticasone propionate compared to placebo1288,1289
(Table IX.B.2.c-1).
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Along with improved nasal symptoms, INCSs have beneficial effects on allergic eye
symptoms including itching, tearing, redness, and puffiness.1290-1292 This is secondary to a
reduction in the naso-ocular reflex, which contributes to these eye symptoms.1293 Most
INCSs lead to improved ocular symptoms, but the evidence suggests that the effects are not
equal among INCS preparations.1294 Some studies have suggested that INCSs improve
asthma control measures in patients suffering from both AR and asthma1295,1296 (Table
IX.B.2.c-2).
In comparative studies, INCSs have shown superior efficacy to H1 antihistamines in
controlling nasal symptoms, including nasal congestion, with no significant difference in the
relief of ocular symptoms.1297-1299 INCSs are more effective than LTRAs1299,1300 (Table
IX.B.2.c-3).
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The most common side effects of INCSs are a result of local irritation and include dryness,
burning, stinging, blood-tinged secretions, and epistaxis. The incidence of epistaxis with
different preparations ranges from 4% to 8% over short treatment periods (2 to 12 weeks)
with no differences between placebo and active therapy.1301,1302 In studies carried over 1
year, epistaxis is as high as 20%.1303,1304 Septal perforations are rare complications of
INCS.51 A systematic review of published articles looking at biopsy studies in patients with
AR or CRS using INCS identified 34 studies. Of those, 21 studies included patients with
AR, mixed rhinitis, and NAR, and 13 involved patients with CRS with/without polyposis.
1305 None of the studies that included atrophy of the nasal mucosa as an outcome measure
reported any atrophy with INCS. A meta-analysis of a subgroup of the studies showed no
significant chance of developing atrophy while taking INCS, and no difference between
active and control groups in basement membrane characteristics. The review also found a
significant reduction in the OR for the development of squamous metaplasia in patients
using INCS, suggesting a favorable effect. Studies in adults and children evaluating effects
of INCS on the hypothalamic pituitary axis have assessed morning cortisol concentrations,
cosyntropin stimulation, 24-hour serum cortisol and 24-hour urinary free cortisol excretion.
They show no adverse effects.1304,1306-1317 Although there has been a report of an
association between the use of INCS and the development of posterior subcapsular cataracts,
1318 a systematic review of controlled trials did not demonstrate a clinically relevant impact
of INCS on either ocular pressure, glaucoma, lens opacity, or cataract formation.1319 The
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effect of INCS on growth in children has been investigated in controlled studies using both
knemometry in short-term studies (2 to 4 weeks) and stadiometry in long-term (12 months)
studies. A meta-analysis of 8 randomized controlled trials with appropriate controls showed
that, compared to children using placebo, mean growth was significantly lower among
children using INCS in trials using knemometry (n = 4) and that there was no significant
growth difference in studies using stadiometry (n = 4).1320 The data suggests that INCS
might have deleterious effects on short-term growth in children, but the heterogeneity in the
stadiometry studies makes the effects on long-term growth suppression unclear (Table
IX.B.2.c-4).
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INCSs are first-line therapy for the treatment of AR due to their superior efficacy in
controlling nasal congestion and other symptoms of this inflammatory condition. Subjects
with known SAR should start prophylactic treatment with INCS several days before the
pollen season with an evaluation of the patient’s response in 2 weeks. In addition to making
changes to the treatment regimen according to the patient’s response, a nasal exam evaluates
for signs of local irritation due to the drug or mechanical trauma from the applicator itself.
Aiming the spray away from the nasal septum may also reduce irritation in this area.
Children receiving INCS should be on the lowest effective dose to avoid negative growth
effects.

Author Manuscript
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•

Aggregate Grade of Evidence: A (Level 1a: 15 studies; Level 1b: 33 studies;
Level 2a: 3 studies; Level 2b: 1 study; Level 5: 1 study; Tables IX.B.2.c-1,
IX.B.2.c-2, IX.B.2.c-3, and IX.B.2.c-4).

•

Benefit: INCSs are effective in reducing nasal and ocular symptoms of AR. They
have superior efficacy compared to oral antihistamines and LTRAs.

•

Harm: INCS have known undesirable local adverse effects such as epistaxis with
some increased frequency compared to placebo in prolonged administration
studies. There are no apparent negative effects on the hypothalamic-pituitary
axis. There might be some negative effects on short-term growth in children, but
it is unclear whether these effects translate into long-term growth suppression.

•

Cost: Low.

•

Benefits-Harm Assessment: The benefits of using INCS outweigh the risks when
used to treat SAR and PAR.

•

Value Judgments: None.

•

Policy Level: Strong recommendation for the use of INCS to treat AR.

•

Intervention: The well-proven efficacy of INCSs, as well as their superiority over
other agents, make them first-line therapy in the treatment of AR.

IX.B.3.

Decongestants

IX.B.3.a. Oral decongestants.: Oral decongestants, such as pseudoephedrine, act on
adrenergic receptors and lead to vasoconstriction, which can relieve nasal congestion in
patients with AR. With extended-release oral decongestants nasal decongestion can last up
to 24 hours. Oral decongestants are available for use alone or in combination with oral
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antihistamines. (See section IX.B.10.a. Management – Pharmacotherapy – Combination
therapy – Oral antihistamine and oral decongestant for additional information on this topic.)

Author Manuscript

Availability of pseudoephedrine in the United States has been limited to behind-the-counter
at pharmacies since 2006 due to stricter control over the distribution and sale of substances
that can be used to manufacture methamphetamine. In a study by Mucha et al.,1321
pseudoephedrine resulted in significant improvement in all symptoms in adults with
ragweed-induced AR (Table IX.B.3.a). Phenylephrine has been marketed as an over-thecounter (OTC) medication as a substitute for pseudoephedrine for nasal decongestion.
However, an RCT by Horak et al.1322 found that while pseudoephedrine was significantly
more effective at reducing nasal congestion than both placebo and phenylephrine, there was
no significant difference between phenylephrine and placebo. In addition, Meltzer et al.1323
performed a randomized, open-label, dose-range trial in 539 patients with SAR and found
phenylephrine to be no more effective than placebo in reducing symptomatic nasal
congestion.

Author Manuscript

Known side effects of this class of medications include insomnia, nervousness, anxiety,
tremors, palpitations, and increased blood pressure (BP). Two systematic reviews by Salerno
et al.1324,1325 looked at the effect of oral decongestants on blood pressure. The first study
showed that phenylpropanolamine significantly increased systolic blood pressure (SBP) by
5.5 mmHg (95% CI, 3.1 to 8.0) and diastolic blood pressure (DBP) by 4.1 mmHg (95% CI,
2.2 to 6.0) with no effect on heart rate as compared to placebo.1324 The second study found
that pseudoephedrine also caused a small but significant increase in SBP by 0.99 mmHg
(95% CI, 0.08 to 1.9) and heart rate (HR) by 2.83 beats/minute (95% CI, 2.0 to 3.6) with no
effect on DBP.1325 Additionally, higher doses and immediate-release preparations of
pseudoephedrine were associated with greater BP elevations.1325 Further, in a study by
Kernan et al.,1326 phenylpropanolamine use in women was an independent risk factor for
hemorrhagic stroke. Phenylpropanolamine is no longer available on the market. Given these
cardiovascular side effects, oral decongestants should be used with caution in patients who
are already at risk for hypertension and its sequelae (eg, coronary artery disease, cerebral
vascular disease, hyperthyroidism, arrhythmias). Blood pressure should be closely
monitored for any changes when using oral decongestants in this population.

Author Manuscript

Oral decongestants are known to be effective in children older than 6 years of age. However,
care should be taken in the younger population (less than 2 years of age) as this population is
more prone to toxicity, and safe dosing recommendations have not yet been established for
this age group.1327 In infants and young children, oral decongestants may have central
nervous system (CNS) stimulatory effects with known cases of psychosis, ataxia, and
hallucinations with ingestion.1328,1329 Evaluation of risk and benefits should be considered
in patients less than 6 years old.
•

Aggregate Grade of Evidence: B (Level 1a: 2 studies; Level 1b: 3 studies; Level
3b: 2 studies; Level 4: 2 studies; Table IX.B.3.a).

•

Benefit: Reduction of nasal congestion with pseudoephedrine. No benefit with
phenylephrine.
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•

Harm: Side effects include insomnia, loss of appetite, irritability, palpitations,
and increased blood pressure. Risk of toxicity in young children.

•

Cost: Low.

•

Benefits-Harm Assessment: Balance of benefit and harm for pseudoephedrine.
Harm likely outweighs benefit for phenylephrine.

•

Value Judgments: Patient’s other comorbidities and age should be considered
before use.

•

Policy Level: Option for pseudoephedrine. Recommendation against for
phenylephrine.

•

Intervention: Pseudoephedrine as an oral decongestant can be effective in
reducing symptom of nasal congestion in patients with AR; used for short-term
symptom relief. Side effects, comorbidities, and age of patient should be
considered before use.

IX.B.3.b. Intranasal decongestants.: Topical decongestants, such as xylometazoline and
oxymetazoline, are alpha-adrenergic stimulators delivered directly to nasal mucosal tissue
that result in vasoconstriction and reduction of mucosal thickness. In an 18-day study,
Barnes et al.1330 found that nasal xylometazoline was a stronger decongestant than nasal
corticosteroids (Table IX.B.3.b). Topical decongestants relieve the symptom of nasal
congestion, however they have no effect on other symptoms of AR, such as sneezing,
rhinorrhea, or nasal itching.

Author Manuscript

Rhinitis medicamentosa (RM), a condition thought to result from prolonged usage of topical
decongestants, involves an increase in symptomatic nasal congestion, thereby precluding a
recommendation for chronic use of this medication. Studies to identify the duration of
topical decongestant use that leads to rhinitis medicamentosa have shown variable results.
Some studies show prolonged use up to 8 weeks does not produce any symptoms of rebound
nasal congestion,83,1331 while others note development of RM within 3 days of use.72
Known adverse effects of topical decongestants include nasal burning, stinging, dryness,
epistaxis, and mucosal ulceration. While topical decongestants are effective at reducing
nasal congestion, short-term use of the medication, 3 days or less, is recommended to avoid
the potential for rebound nasal congestion and effects on mucociliary activity. (See section
III.C.2. Definitions, classifications, and differential diagnosis – Allergic rhinitis differential
diagnosis – Rhinitis medicamentosa (RM) for additional information on this topic.)

Author Manuscript

•

Aggregate Grade of Evidence: B (Level 1b: 3 studies; Level 2b: 1 study; Table
IX.B.3.b).

•

Benefit: Reduction of nasal congestion with topical decongestants.

•

Harm: Side effects include nasal burning, stinging, dryness, and mucosal
ulceration. Potential for rebound congestion when used long term.

•

Cost: Low.
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•

Benefits-Harm Assessment: Harm likely outweighs benefit if used more than 3
days.

•

Value Judgments: Topical decongestants can be helpful for short-term relief of
nasal congestion.

•

Policy Level: Option.

•

Intervention: Topical decongestants can provide effective short-term nasal
decongestion in patients with AR, but recommend against chronic use due to risk
for RM.

Author Manuscript

IX.B.4. Leukotriene receptor antagonists (LTRAs)—LTRAs have been studied and
used in the treatment of AR. Montelukast is approved by the FDA for the treatment of SAR
in adults and children over 2 years of age, and for PAR in adults and children over 6 months
of age. Several systematic reviews and meta-analyses of RCTs have demonstrated symptom
reduction and improved QOL in patients treated with LTRA monotherapy compared to
placebo.1300,1332-1335 Nevertheless, in a clinical practice guideline on AR from the AAOHNS there was a recommendation against LTRA monotherapy, citing decreased
effectiveness compared to other first-line agents.761

Author Manuscript

Systematic review identified 28 studies, of which 19 were considered level 1 evidence,
examining the use of LTRA monotherapy in AR (Table IX.B.4). Multiple systematic
reviews1300,1332-1335 and RCTs1336-1344 demonstrated that LTRA monotherapy was superior
to placebo at improving patient symptoms and QOL. This effect was consistent in studies of
SAR,1340-1344 PAR,1339 and artificial allergen exposure.1336-1338 Furthermore, in a doubleblind RCT by Philip et al.1341 montelukast improved both AR and asthma disease-specific
QOL in patients with concurrent SAR and asthma.

Author Manuscript

Despite multiple studies demonstrating superior effect of LTRA monotherapy over placebo
in the treatment of AR, there is consistent evidence that LTRA is inferior to INCS.
1300,1333-1335,1345,1346 Multiple systematic reviews and meta-analyses have shown that INCS
result in greater symptom reduction and QOL improvement compared to LTRA.
1300,1333-1335 A double-blinded RCT by Pullerits et al.1346 showed decreased numbers of
activated tissue eosinophils in nasal mucosa biopsies in patients treated with intranasal
beclomethasone compared to zafirlukast and placebo. There is conflicting evidence on the
relative effect of LTRA compared to oral antihistamines, with 2 systematic reviews
demonstrating that oral antihistamines have superior symptom reduction and QOL
improvement1300,1333 and a third study indicating equivalent effect.1334 Moreover, a doubleblind RCT by Mucha et al.1321 indicated that montelukast and pseudoephedrine yielded
equivalent symptom reduction and QOL improvement. In that study, objective measurement
of nasal peak inspiratory flow was not different between the montelukast and
pseudoephedrine treatment groups.
In addition to less relative effectiveness compared to other agents, the AAO-HNS clinical
practice guideline on AR cited increased costs of LTRA in the recommendation against this
drug class as monotherapy in patients with AR without asthma.761 Goodman et al.1347
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generation oral antihistamines. Montelukast was determined to have increased cost for
relative effectiveness compared to levocetirizine, desloratadine, and branded and generic
fexofenadine. The annual drug and incurred medical costs for montelukast were estimated to
be $631.
LTRA monotherapy may be a useful alternative in rare patients with contraindications for
both INCS and oral antihistamines, but this limits recommendations or options for these
agents in general. In patients with concurrent AR and asthma, LTRA can contribute to
symptom management of both respiratory diseases. LTRA monotherapy is not recommended
as first-line treatment for patients with concurrent AR and asthma, although this may be a
consideration in patients with contraindications to INCS.

Author Manuscript
Author Manuscript

•

Aggregate Grade of Evidence: A (Level 1a: 6 studies; Level 1b: 17 studies; Level
2a: 2 studies; Level 2b: 3 studies; Level 4: 3 studies; Table IX.B.4).

•

Benefit: Consistent reduction in symptoms and improvement in QOL compared
to placebo, as demonstrated in RCTs and systematic review of RCTs.

•

Harm: Consistently inferior compared to INCS at symptom reduction and
improvement in QOL in RCTs and systematic reviews of RCTs. Equivalent-toinferior effect compared to oral antihistamines in symptom reduction and
improvement of QOL.

•

Cost: Annual incurred drug and medical costs estimated to be $631 for generic
montelukast.

•

Benefits-Harm Assessment: Preponderance of benefit over harm. LTRAs are
effective as monotherapy compared to placebo. However, there is a consistently
inferior or equivalent effect to other, less expensive agents used as monotherapy.

•

Value Judgments: LTRAs are equivalent to oral antihistamine alone and more
effective than placebo at controlling both asthma and AR symptoms in patients
with both conditions. Control of AR symptoms with LTRAs, however, is less
effective than INCS, and inferior or equivalent to oral antihistamines. Therefore,
evidence is lacking to recommend LTRAs as first-line or second-line
monotherapy in the management of AR alone or in combination with asthma.

•

Policy Level: Recommendation against as first-line therapy for AR.

•

Intervention: LTRAs should not be used as monotherapy in the treatment of AR
but can be considered as second-line therapy, such as when INCSs are
contraindicated.

Author Manuscript

IX.B.5. Cromolyn—Disodium cromoglycate (DSCG) [synonyms: cromolyn sodium,
sodium cromoglycate, disodium 4,4′-dioxo-5,5′-(2-hydroxytrimethylenedioxy)-di(4Hchromene-2-carboxylate)] was first used by ancient Egyptians for its spasmolytic properties.
It is derived from the plant Ammi visnaga. DSCG is a mast cell stabilizer that prevents
histamine release. It impedes the function of chloride channels important in regulating cell
volume and prevents extracellular calcium influx into the cytoplasm of the mast cell, thus
preventing the degranulation of sensitized cells.1349,1350 DSCG is best used prophylactically
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to prevent the onset of symptoms by interrupting the physiological response to nasal
allergens.
DSCG was discovered over 50 years ago, and since that time other cromoglycate type agents
(chromones) have been developed. The chromones have demonstrated the ability to inhibit
the early-phase and late-phase reactions of asthma.1351 Initial studies focused on histamine
and cytokine release from mast cells. More recent studies have shown anti-allergy activity
unrelated to mast cell activation, but rather through the inhibition of macrophages,
eosinophils, monocytes, and platelets.1352-1354

Author Manuscript

DSCG can be used in an inhaled form as a prophylactic agent in the treatment of mild to
moderate asthma, as a nasal spray to treat SAR, or as an ophthalmic solution to treat allergic
or vernal conjunctivitis. DSCG may also be taken orally to control allergic reactions to
certain foods. It can be used for patients 2 years and older but has a short half-life requiring
dosing of 3 to 6 times daily.1355 DSCG has an excellent safety profile, although the need for
frequent dosing may affect compliance. Minor adverse effects include nasal irritation or
burning, sneezing, epistaxis, and bad taste.1355

Author Manuscript

Most studies comparing DSCG directly to placebo have shown that it is effective in patients
with SAR (Table IX.B.5). Studies on the efficacy of DSCG in PAR have been controversial.
1356-1360 In a recent RCT, Lejeune et al.1356 examined the role of DSCG in monosensitized
PAR patients and found that DSCG resulted in significant reduction in symptom scores for
nasal obstruction, discharge, and sneezing compared to placebo. When compared to INCS,
DSCG has been shown to be less effective.1357,1361-1369 To date, there have been no direct
comparisons between DSCG and intranasal antihistamines. Ultimately, the role of DSCG as
a primary treatment for AR is limited given its lower efficacy when compared to INCS and
potential compliance challenges secondary to frequent dosing regimen.

Author Manuscript

•

Aggregate Grade of Evidence: A (Level 1b: 13 studies; Level 2b: 9 studies; Table
IX.B.5).

•

Benefit: DSCG is effective in reducing sneezing, rhinorrhea, and nasal
congestion.

•

Harm: Rare local side effects include nasopharyngeal irritation, sneezing,
rhinorrhea, and headache.

•

Cost: Low.

•

Benefits-Harm Assessment: Preponderance of benefit over harm. Benefit is
considered mild to moderate. Less effective than INCS.

•

Value Judgments: Useful for preventative short-term use in patients with known
exposure risks.

•

Policy Level: Option.

•

Intervention: DSCG may be considered for the treatment of AR, particularly in
patients known triggers who cannot tolerate INCS.
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IX.B.6. Intranasal anticholinergics—Ipratropium bromide (IPB) nasal spray acts by
controlling watery nasal secretory output from seromucous glands. IPB is used primarily to
reduce rhinorrhea and is effective in adults and children with perennial rhinitis and common
cold.1378,1379 It has a quick onset of action and short half-life administered up to 6 times per
day, with less than 10% absorption over a range of 84 μg/day to 336 μg/day.1380 Local side
effects include nasal dryness, irritation, epistaxis, and burning. Systemic side effects have
not been observed with therapeutic dosing, as plasma concentrations of greater than 1.8
ng/mL are needed to produce systemic anticholinergic effects.1380 However, care should be
taken to avoid over-dosage that could lead to high serum concentrations of ipratropium.

Author Manuscript

All studies have shown that the use of IPB significantly controls rhinorrhea in children and
adults with PAR (Table IX.B.6). The combined use with INCS have also been shown to be
more effective than either agent alone, suggesting a role of IPB for patients with persistent
rhinorrhea.1381

Author Manuscript

•

Aggregate Grade of Evidence: B (Level 1b: 9 studies; Level 2b: 5 studies; Table
IX.B.6).

•

Benefit: Reduction of rhinorrhea with topical anticholinergics.

•

Harm: Local side effects include nasopharyngeal irritation, burning, headache,
pharyngitis, epistaxis, nasal dryness, nasal congestion, and dry mouth. Care
should be taken to avoid over-dosage leading to systemic side effects.

•

Cost: Low to moderate.

•

Benefits-Harm Assessment: Preponderance of benefit over harm in PAR patients
with rhinorrhea.

•

Value Judgments: No significant benefits in controlling symptoms other than
rhinorrhea. Evidence for combined use with INCS is limited but encouraging for
patients with persistent rhinorrhea.

•

Policy Level: Option.

•

Intervention: IPB nasal spray may be considered as an adjunct medication to
INCS in PAR patients with uncontrolled rhinorrhea.

Author Manuscript

IX.B.7. Biologics (omalizumab)—Biologics have been studied in the treatment of AR,
specifically omalizumab, either alone or in combination with specific AIT. Omalizumab is a
humanized antibody that binds to human IgE. No biologic is currently approved by the FDA
for the treatment of AR. One systematic review and meta-analysis of RCTs has
demonstrated reduced symptoms, reduced rescue medication use, and improved QOL in
patients treated with omalizumab.1391 However, the cost of omalizumab is very high,
estimated to be over $18,000 year in the United States.
Systematic review identified 5 level 1 evidence studies examining the use of omalizumab in
AR (Table IX.B.7). Four RCTs1392-1395 demonstrated that omalizumab monotherapy was
superior to placebo at improving patient symptoms and QOL. The first RCT evaluating
different delivery routes and dose-ranges did not show efficacy against ragweed-induced
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AR, but reported no significant adverse events associated with omalizumab.1396 A second
study randomized birch pollen-induced SAR patients to receive either 300 mg of
omalizumab (originally named rhumAb-E25) or placebo given 2 or 3 times over the season,
depending on baseline IgE levels. RhemAB-E25 treatment significantly reduced nasal
symptom severity scores, the average number of tablets of rescue antihistamines per day, the
proportion of days with any SAR medication use, and all domains of QOL.1392 A third study
applied omalizumab, 50 mg, 150 mg, or 300 mg, vs placebo subcutaneously prior to
ragweed season and repeated every 3 to 4 weeks during the pollen season dependent on the
patient’s base-line serum IgE.1393 At the highest dose studied, 300 mg of omalizumab
significantly reduced nasal symptom severity scores and rhinitis-specific QOL scores. A
significant association was observed between IgE reduction and nasal symptoms and rescue
antihistamine use. The frequency of adverse events was not significantly different between
omalizumab and placebo groups.

Author Manuscript
Author Manuscript

Omalizumab was also studied in the treatment of PAR, significantly reducing the mean daily
nasal severity score and the rescue medication, and improving QOL when given
subcutaneously every 4 weeks for 16 weeks.1394 Omalizumab therapy was well tolerated.
Similarly, effectiveness and safety of subcutaneously injected omalizumab was shown in the
treatment of Japanese cedar pollen-induced SAR.1395 Omalizumab treatment markedly
reduced serum free IgE and the clinical response to nasal allergen challenge in an open
study, but did not affect IgE-secreting B cells and epsilon mRNA in nasal lavage fluid,
suggesting that treatment for 6 months does not significantly modulate synthesis of nasal
IgE.1397 The biologic also suppressed tryptase and ECP levels in nasal secretions in seasonal
allergy.1398 Omalizumab showed significantly greater improvements than suplatast tosilate,
a selective T-helper type 2 cytokine inhibitor, in the treatment of SAR induced by Japanese
cedar pollens.1399

Author Manuscript

In 4 trials, a combination of omalizumab with AIT was studied to determine whether
combined therapy could provide better efficacy and lower adverse events than AIT alone. In
children and adolescents with SAR to birch or grass pollen, combination therapy
significantly reduced symptom load over AIT alone independent of the allergen.1400 AntiIgE monotherapy alone significantly diminished rescue medication use and reduced the
number of symptomatic days. The combined treatment with AIT and anti-IgE showed
superior efficacy on symptom severity compared with anti-IgE alone.1401 Combination
therapy may, therefore, be useful for the treatment of AR, particularly for polysensitized
patients. Patients receiving omalizumab and rush ragweed AIT showed a significant
improvement in severity scores during season compared with AIT alone.1402 Although
omalizumab carries some risk of anaphylaxis itself, addition of omalizumab resulted in a
significant decrease in risk of anaphylaxis caused by AIT. Combination therapy also
significantly reduced the symptom load in HDM-allergic subjects better than AIT
monotherapy, and improved asthma control and QOL with respect to asthma and AR.1403
These effects were limited to the combined treatment period.1404
There are no other published studies evaluating other biologics (anti-IL5, anti-IL4, or IL-4R)
as monotherapy for AR. A combination therapy of anti-IL4 with suboptimal AIT provided
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no additional benefit over subcutaneous immunotherapy (SCIT) alone in suppressing the
allergen-induced skin late-phase response.1405
Although there is consistent evidence that omalizumab monotherapy is superior to placebo
in symptom reduction and QOL improvement in AR, the benefits are relatively small over
pharmacotherapy. Omalizumab is superior in combination with AIT vs AIT alone and
reduces the risk of anaphylaxis associated with AIT, but the costs of the treatment preclude a
widespread use. The combination therapy might be indicated in selected patients who are
polysensitized and highly sensitive.

Author Manuscript
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•

Aggregate Grade of Evidence: A (Level 1a: 1 study; Level 1b: 5 studies; Table
IX.B.7).

•

Benefit: Consistent reduction in symptoms and rescue medication as well as
improvement in QOL in RCTs and systematic review of RCTs compared to
placebo.

•

Harm: Injection site reactions, possibility of anaphylactic reaction.

•

Costs: High. Annual incurred drug costs estimated to be above $18,000 per year
in the United States.

•

Benefits-Harm Assessment: No therapy option as omalizumab is not registered
for treatment of AR alone. This review was limited to evaluation of AR only;
comorbid asthma was not evaluated.

•

Value Judgments: Omalizumab monotherapy is superior to placebo, but effects
are small over pharmacotherapy. May be evaluated in exceptional cases of highly
sensitive polysensitized individuals in combination with AIT.

•

Policy Level: No indication for the treatment of AR alone.

•

Intervention: Omalizumab should not be used as monotherapy in the treatment of
AR but may be considered in combination with AIT for highly sensitive
polyallergic rhinitis patients with increased risk of anaphylaxis. As omalizumab
is not currently approved by the FDA for AR treatment, in the US this treatment
approach would likely not be performed in routine clinical practice presently.

Author Manuscript

IX.B.8. Nasal saline—Nasal saline is frequently utilized in the treatment of AR.
However, the term “nasal saline” encompasses a wide variety of therapeutic regimens. These
can include hypertonic saline, isotonic/normal saline, seawater, buffered or nonbuffered
solutions, and volumes varying from 300 μL to 500 mL per administration. Irrigation
regimens are also used with varying frequency.
This review included only level 1 evidence published in the English language. The search
identified 5 RCTs in adults151,1406-1409 (Table IX.B.8-1), 6 RCTs in children1410-1415 (Table
IX.B.8-2), and 1 systematic review1416 encompassing all ages (included in both tables),
which evaluated the efficacy of nasal saline in the treatment of AR.
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In adults, all 5 studies found improvements in clinical outcomes with the use of various
types of nasal saline. These studies varied in their evaluation of SAR vs PAR, as well as the
type and volume of saline. Studies by Garavello et al.151 and Rogkakou et al.,1407 found that
the addition of hypertonic saline significantly improved nasal symptoms and QOL compared
to not using saline. Ural et al.1408 further compared the efficacy of hypertonic to isotonic
saline irrigations, finding improved mucociliary clearance time with the isotonic solution.
They postulated that in PAR, the rheologic properties of the mucus are enhanced most by
isotonic saline, thus improving mucociliary clearance. Chusakul et al.1409 also identified that
buffered isotonic saline with mild alkalinity had the greatest impact on reducing nasal
symptom scores and was preferred by the most patients. Finally, Cordray et al.1406 found
that Dead Sea saline spray had a significant improvement in the RQLQ compared to isotonic
saline. Cordray et al.1406 suggested that the magnesium in the Dead Sea saline may have
anti-inflammatory properties, resulting in improved AR outcomes.

Author Manuscript

In the pediatric population, all studies evaluating either PAR or SAR found an improvement
in nasal symptoms or QOL with the incorporation of nasal saline. Both studies by Garavello
et al.1410,1411 showed a significant improvement after the addition of hypertonic saline
irrigations TID when compared to no irrigations. Marchisio et al.1413 and Satdhabudha and
Poachanukoon1414 further identified that hypertonic saline irrigations resulted in a greater
improvement in nasal symptom scores in children vs isotonic saline. Finally, Li et al.1412 and
Chen et al.1415 found an additive effect in the utilization of nasal saline spray as an adjunct
to a nasal steroid spray when compared to either therapy independently.

Author Manuscript

The systematic review by Hermelingmeier et al.1416 included 10 studies of which 7 were
RCTs evaluating both adult and pediatric patients. Several of these studies are also included
above.151,1406-1408,1410-1412 This review found that almost all studies showed an
improvement in nasal symptoms from 3.1% to 70.5% with the addition of nasal saline.
Additionally, they identified a 24.2% to 100% reduction in medication usage, as well as an
improvement in QOL of 29.8% to 37.5%. This review also suggested that isotonic saline
was more effective than hypertonic saline. Perhaps surprisingly, they found that nasal saline
sprays resulted in greater symptom improvement than saline irrigations. Overall, they
concluded that nasal saline was as effective as other frequently utilized AR pharmacologic
treatments (ie, nasal antihistamines, oral antihistamines, etc.) in treatment of both SAR and
PAR.

Author Manuscript

Overall, there is substantial evidence to support the use of nasal saline as an adjunct
treatment for SAR and PAR. It appears that in adults, a buffered isotonic spray may provide
maximum benefit. However, in children, a hypertonic solution may be more effective. Some
studies have suggested less intranasal irritation when using isotonic solutions rather than
hypertonic. Hypotonic saline has not been studied as a treatment for AR. Adding mild
alkalinity (pH 7.2 to 7.4) to the solution may further improve tolerability.1409 Although nasal
saline has been shown to improve symptoms and QOL outcomes when used alone, it is often
implemented as an adjunct to other therapies including nasal steroid, antihistamine sprays,
or oral antihistamines. In both adults and children, nasal saline appears to have an additive
effect when used in combination with other standard AR treatments. Further, nasal saline is
of relatively low cost and has an excellent safety profile. While adverse effects are rare, they
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can include local irritation, ear pain, nosebleeds, headache, nasal burning, nasal drainage,
and bottle contamination.1417
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•

Aggregate Grade of Evidence: A (Level 1a: 1 study; Level 1b: 11 studies; Table
IX.B.8-1 and IX.B.8-2). Lower-level studies were not considered in this review.

•

Benefit: Reduced nasal symptom scores, improved QOL, improved mucociliary
clearance; well tolerated with excellent safety profile.

•

Harm: Intranasal irritation, headaches, ear pain.

•

Cost: Minimal.

•

Benefits-Harm Assessment: Preponderance of benefit over harm.

•

Value Judgments: Nasal saline should be used as an adjunct to other
pharmacologic treatments for AR. Isotonic solutions may be more beneficial in
adults, while hypertonic may be more effective in children.

•

Policy Level: Strong recommendation.

•

Intervention: Nasal saline is strongly recommended as part of the treatment
strategy for AR.

Author Manuscript

IX.B.9. Probiotics—The relationship between microbiome and development of atopy is
complex and incompletely understood. (See section IV.G. Pathophysiology and mechanisms
of allergic rhinitis - Microbiome for additional information on this topic.) Preliminary data
from observational studies suggest that microbial exposure, especially in infancy, shapes the
gut and airway microbiome and affects subsequent Th2 or Th1 immunologic bias. Given the
link between gut flora and atopy, manipulation of the microbiome via probiotic
administration could theoretically lead to clinical improvement of allergic disease. Probiotics
have been posited to elicit immunomodulatory effects on atopic disease via gut-associated
lymphoid tissue. Stimulation of dendritic cells induces Th1 responses via IL-12 and IFN-γ,
upregulation of Treg cells via IL-10 and TGF-β, and suppression of Th2 pathways through
downregulation of IL-4, sIgE, IgG1, and IgA.1418

Author Manuscript

The optimal timing of probiotic administration for the treatment of atopy is unknown. A
meta-analysis of 17 double-blind RCTs demonstrated that probiotics in pregnancy and early
infancy were associated with decreased incidence of eczema but not asthma or rhinosinusitis
in early childhood.1419 Many double-blind RCTs and randomized crossover studies have
investigated the effects of probiotics on AR in older children and adults (Table IX.B.9).
Meta-analyses of these studies have been published in 2015 by Zajac et al.1420 and 2016 by
Guvenc et al.1421 with positive results. Adverse events due to probiotics were rare and
minor, including diarrhea, abdominal pain, and flatulence.
Guvenc et al.1421 performed a systematic review and meta-analysis of 22 double-blind RCTs
comprising 2242 patients aged 2 to 65 years with SAR or PAR. Patients received daily
probiotic or placebo for 4 weeks to 12 months as an adjuvant to standard allergy therapies;
primary outcomes included Total Nasal/Ocular Symptom Scores and QOL. Secondary
outcomes included specific nasal symptom scores and immunologic parameters. Seventeen
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trials demonstrated clinical benefit of probiotics, with improvement in TNSS (standardized
mean difference [SMD] −1.23, p < 0.001), TOSS (SMD −1.84, p < 0.001), total QOL (SMD
−1.84, p < 0.001), nasal QOL (SMD −2.30, p = 0.006), and ocular QOL (SMD −3.11, p =
0.005). Subgroup analysis demonstrated improvement in clinical parameters for SAR and
PAR. Th1:Th2 ratio was improved (SMD −0.78, p = 0.045) in the probiotic group, with no
difference in tIgE, sIgE, or eosinophil count.

Author Manuscript

Zajac et al.1420 published a systematic review and meta-analysis of 21 double-blind RCTs
and 2 randomized crossover studies comprising 1919 adult and pediatric patients with SAR
or PAR treated with 3 weeks to 12 months of probiotic vs placebo. A total of 26 level 1b
studies analyzed by Guvenc et al.1421 and Zajac et al.1420 are included in Table IX.B.9.
Zajac et al.1420 limited outcomes measures to validated QOL or symptom scores and
immunologic variables; 17 studies demonstrated clinical benefit of probiotics in AR. Metaanalysis demonstrated improvement in RQLQ global score (SMD −2.23, p = 0.02) and
RQLQ nasal symptom score (SMD −1.21, p < 0.00001). No effect was found for RTSS,
tIgE, or sIgE.
The preponderance of data from meta-analyses and double-blind RCTs suggests a beneficial
effect for probiotics in the treatment of SAR and PAR in both adults and children, but
interpretation is limited by the heterogeneity of age and diagnosis, interventions, and
outcomes included in the studies. Probiotics varied in dose, were delivered via milk, yogurt,
powder, or capsules, and included a number of diverse strains: 19 studies employed
Lactobacillus species1422-1440; 6 studies Bifidobacterium1061,1433,1437,1441-1443; and 1 study
each Tetragenococcus halophilus,1444 Escherichia coli,1445 and Bacillus clausii.1446

Author Manuscript
Author Manuscript

•

Aggregate Grade of Evidence: A (Level 1a: 2 studies; Level 1b: 26 studies; Table
IX.B.9).

•

Benefit: Improved nasal/ocular symptoms or QOL in most studies. Possible
improvement in immunologic parameters (Th1:Th2 ratio).

•

Harm: Low.

•

Benefits-Harm Assessment: Balance of benefit and harm.

•

Value Judgments: Minimal harm associated with probiotics, but heterogeneity
across studies makes magnitude of benefit difficult to quantify. Variation in
organism and dosing across trials prevents specific recommendation for
treatment.

•

Policy Level: Option.

•

Intervention: Consider adjuvant use of probiotics for patients with symptomatic
SAR and PAR.

IX.B.10.

Combination therapy

IX.B.10.a Oral antihistamine and oral decongestant.: Oral antihistamines function as
reversible competitive antagonists of the histaminic H1 receptor and prevent the binding of
histamine to its receptors. Oral decongestants, such as pseudoephedrine and phenylephrine,
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are alpha-adrenergic stimulatory drugs which bind to precapillary and post-capillary blood
vessels resulting in vasoconstriction of nasal mucosa.1447 The unrelated biologic targets of
these medications’ mechanisms of action has been shown in RCTs to result in synergistic
improvement in AR symptoms.1448,1449

Author Manuscript

The combination of an oral antihistamine along with an oral decongestant has been shown to
be more effective than placebo in controlling sneezing, nasal itching, and reducing nasal
congestion in patients with AR1044,1050,1052,1167,1450-1456 (Table IX.B.10.a). Investigations
by Kaiser et al.1450 found that both once-daily or twice-daily loratadine-pseudoephedrine
were consistently superior to placebo in reducing total nasal and non-nasal symptom scores
with significantly higher risk of insomnia and dry mouth in both antihistamine-decongestant
arms compared to placebo. Additionally, Nathan et al.1451 reported in 2006 that cetirizinepseudoephedrine reduced AR total symptom severity scores, asthma symptom severity
scores, and improved asthma QOL scores significantly vs placebo. However, they found no
significant changes in pulmonary function testing in patients receiving cetirizinepseudoephedrine or placebo and they identified similar rates of discontinuation and adverse
events in both treatment arms.

Author Manuscript

Oral antihistamine and oral decongestant combinations have also been shown to be more
effective in controlling AR symptoms when compared to INCS or compared to treatment
with either oral antihistamines or oral decongestants alone.1050,1455,1457-1460 In 2005,
Zieglmayer et al.1449 found that the combination of cetirizine with prolonged release
pseudoephedrine was significantly superior to budesonide nasal spray for improving nasal
congestion after exposure to HDM, as measured by anterior rhinomanometry and nasal
imaging. The combination of second-generation oral antihistamines and pseudoephedrine
has been shown to significantly reduce symptom scores in patients with SAR more than
either drug alone.1050,1455,1457-1462 Additionally, the type of second-generation
antihistamine and medication dosing schedule does not seem to have a significant effect on
efficacy.1463,1464

Author Manuscript

Oral decongestants have the benefit of relieving the symptoms of nasal congestion through
their ability to vasoconstrict capillaries within the nasal mucosa; however, their mechanism
of action can also result in unfavorable systemic adverse effects such as hypertension and
urinary retention. Oral decongestants have also been linked to an increased incidence of
specific birth defects including pyloric stenosis and endocardial cushion defects when
utilized by pregnant women.1465 Furthermore, decongestants are not recommended for
children under 4 years of age secondary to the high risk of adverse drug events associated
with utilization in this age group.1466 Finally, oral decongestants have OTC sales restrictions
secondary to their potential utilization in the production of methamphetamines. Therefore,
caution must be applied in the utilization of these medications, particularly in children under
4 years and patients who are pregnant or have a preexisting cardiovascular condition,
hypertension, or benign prostatic hypertrophy. Oral antihistamines are well tolerated, with a
favorable risk-benefit ratio. However, caution should still be exercised as antihistamines
have cardiac side effects, alter the metabolism of other medicines, and have been linked to a
higher incidence of adverse events and drug-drug interactions in the elderly.216
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It is likely because of this significant risk of adverse events and propensity for interactions
with other medications that the ARIA 2010 guidelines recommended against the routine
treatment of AR with a combination oral decongestant and oral antihistamine.1167 The 2010
ARIA document suggested that oral decongestants only be added in patients who are not
controlled by antihistamines alone and are less averse to side effects or adverse reactions.
Additionally, they suggested that oral decongestants be limited to utilization primarily as a
rescue medication during periods of significant symptom exacerbations.
Overall, despite the available evidence verifying the efficacy of combination oral
antihistamines and oral decongestants in improving AR symptoms, caution should still be
exercised when prescribing this treatment, particularly in patients with cardiovascular or
urologic comorbidities.

Author Manuscript
Author Manuscript

•

Aggregate Grade of Evidence: A (Level 1b: 21 studies; Table IX.B.10.a).

•

Benefit: Improved control of nasal congestion with combination of oral
antihistamines and oral decongestants.

•

Harm: Oral decongestants can cause significant adverse effects, particularly in
patients with hypertension, cardiovascular disease, or benign prostatic
hypertrophy. Additionally, these medications should not be used in children
under 4 years of age or pregnant patients. This should be weighed against the
potential benefits prior to prescribing.

•

Cost: Low.

•

Benefits-Harm Assessment: Harm likely outweighs benefit when used on a
routine basis.

•

Value Judgments: Combination therapy of oral antihistamines and oral
decongestants can be helpful for relief of an acute exacerbation of AR, especially
nasal symptoms, when exposed to triggers. Caution should be exercised
regarding long-term use given the possibility of significant adverse effects.

•

Policy Level: Option, particularly for acute exacerbations of nasal congestion.

•

Intervention: Combination therapy with oral antihistamine and oral decongestant
can provide effective reduction of nasal congestion symptoms in patients with
AR; however, recommend against chronic use given the significant side effect
profile of oral decongestants.

Author Manuscript

IX.B.10.b Oral antihistamine and intranasal corticosteroid.: A combination of an oral
antihistamine and INCS is often used in clinical practice for the treatment of AR. As
previously mentioned, oral antihistamines function as a reversible competitive antagonist of
the histamine H1 receptor and thereby prevent the binding of histamine that is present in the
circulation. The newer, second-generation agents, such as fexofenadine and cetirizine, are
less sedating, have fewer adverse effects, and provide good control of sneezing, rhinorrhea,
and nasal itching, but with less effect on nasal congestion.1448 Additionally, INCSs, such as
fluticasone or beclomethasone, have repeatedly been validated as an effective treatment
option for AR while offering a good safety profile and low systemic absorption.1448
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Several RCTs have examined the efficacy of combination therapy utilizing both an oral
antihistamine and INCS and demonstrated no added benefit of combination therapy (Table
IX.B.10.b). In 2000, Wilson et al.1469 demonstrated that oral cetirizine and intranasal
mometasone were effective at improving nasal peak inspiratory flow rates as well as nasal
symptoms and total daily symptoms after 4 weeks of use. However, the combination was not
significantly better than cetirizine and placebo or cetirizine and montelukast. In a doubleblinded crossover study, Barnes et al.1470 compared the combination of fluticasone and
levocetirizine vs fluticasone and placebo and found, in most patients, that the benefits of an
additional oral antihistamine to an effective nasal steroid regimen were not significant.
Additionally, Ratner et al.1471 found that fluticasone monotherapy compared to fluticasone
plus loratadine had comparable efficacy in nearly all clinician and patient rated symptoms.
Finally, Di Lorenzo et al.1472 demonstrated similar results in patients with SAR, noting that
combination therapy did not appear to offer substantial improvement in daily nasal symptom
scores or in reduction of nasal lavage inflammatory markers.
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In contrast, a 2008 study by Pinar et al.1473 compared mometasone spray monotherapy to
mometasone plus desloratadine and found that the combination therapy group had
significantly better nasal symptom scores at the end of study week 2 and better QOL scores
throughout the study. A recent systematic review and meta-analysis by Feng et al.1474
summarized the efficacy of the combination therapy of an oral antihistamine and INCS as
compared to either therapy independently. They concluded that the combination
demonstrated significant improvement in symptom scores in AR when compared to an oral
antihistamine alone, but do not provide significant additional benefit when compared to
monotherapy with an effective INCS.1474 Limitations to this data include the fact that the
studies did not control for variations in the specific oral antihistamines or INCS utilized and
that the studies predominantly evaluated patients with SAR, excluding patients with PAR.
Additionally, the conclusions of this meta-analysis are supported by the updated 2010 ARIA
guidelines, which also do not recommend the addition of an oral antihistamine to an
effective INCS, in contrast to prior recommendations.1167 It should also be noted that
adverse effects of oral antihistamine and INCS combination therapies include drowsiness
and dry mouth (from oral antihistamines) as well as epistaxis and nasal irritation (from
INCS).

Author Manuscript

•

Aggregate Grade of Evidence: B (Level 1b: 5 studies; Table IX.B.10.b).

•

Benefit: Reduction of nasal congestion with combination of oral antihistamines
and INCS compared to oral antihistamines alone.

•

Harm: Side effects include sedative properties of antihistamines, although
significantly decreased with the newer second-generation agents. Side effects of
topical INCS include nasal dryness and epistaxis, burning in the nose, and with
prolonged usage, possible growth suppression in the pediatric population.

•

Cost: Low.

•

Benefits-Harm Assessment: Harm likely outweighs benefit of adding the oral
antihistamine unless treating symptoms other than nasal symptoms.

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Wise et al.

Page 113

Author Manuscript

•

Value Judgments: Combination therapy of oral antihistamine and INCS can be
helpful when managing the symptoms of nasal congestion.

•

Policy Level: Option.

•

Intervention: Combination therapy of INCS and oral antihistamine does not
improve symptoms of nasal congestion over INCS use alone, and does risk the
adverse effects of systemic antihistamine use.

Author Manuscript

IX.B.10.c. Oral antihistamine and LTRA.: Combination therapy with LTRA and oral
antihistamines in the treatment of AR has been studied in a single systematic review1300 and
multiple RCTs1467,1472,1475-1483 (Table IX.B.10.c). Combination therapy generally
improved symptoms and QOL compared to placebo in multiple RCTs.1472,1475,1479,1482,1483
The efficacy of combination therapy compared to monotherapy with either LTRA or oral
antihistamine is less clear. In the systematic review by Wilson et al.,1300 combination
therapy improved patient symptoms compared to either agent as monotherapy, but there
were no differences in standardized QOL measures. An RCT by Cingi et al.1477 indicated
that montelukast and fexofenadine combination therapy was superior at reducing symptoms
and nasal resistance measured by rhinomanometry, compared to either fexofenadine alone or
fexofenadine administered concomitantly with placebo. Several other RCTs, however, did
not demonstrate a difference in symptom reduction between combination therapy and oral
antihistamine monotherapy.1475,1479,1482

Author Manuscript

Several studies also examined the relative effectiveness of combination LTRA and oral
antihistamine therapy compared to INCS. Combination therapy was generally less effective
than INCS monotherapy,1472,1479,1481 although some studies did not detect a statistically
significant difference.1300,1484 The systematic review by Wilson et al.1300 did not discern a
difference in symptom reduction between LTRA and oral antihistamine combination therapy
and INCS. In contrast, 3 RCTs showed that INCS resulted in improved nasal symptoms
compared to treatment with the combination,1472,1479,1481 in addition to decreased nasal
mucosa eosinophil counts.1472,1481

Author Manuscript

There is conflicting evidence on whether combination therapy is more effective than oral
antihistamine alone, and there appears to be relatively consistent evidence that INCS
monotherapy is more effective at nasal symptom reduction than LTRA and oral
antihistamine combination therapy. Therefore, combination therapy may be an option in
patients whose symptoms are incompletely controlled with oral antihistamine monotherapy,
and in whom INCS are not tolerated or contraindicated. This may be particularly useful in a
subset of these patients with concurrent asthma. Montelukast may be effective at
simultaneously reducing AR symptoms and improving asthma control.1341
Drug interaction and safety are an important consideration when using combination
therapies. Reported adverse events for montelukast and loratadine in combination were
similar to montelukast and loratadine monotherapy and placebo.1485 The most common
reported adverse events were headache (4.5%), fatigue (1.2%), and pharyngolaryngeal pain
(1.2%). There were no changes of vital signs, electrocardiogram, or physical exam findings
during the monitoring period.1485 Combination LTRA and oral antihistamine therapy can be
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administered with minimal adverse events, and with similar frequency to either agent as
monotherapy.
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•

Aggregate Grade of Evidence: A (Level 1a: 1 study; Level 1b: 11 studies; Level
2b: 1 study; Table IX.B.10.c).

•

Benefit: Inconsistent evidence that combination LTRA and oral antihistamine
were superior in symptom reduction and QOL improvement than either agent as
monotherapy. Combination therapy is inferior in symptom reduction compared to
INCS alone.

•

Harm: No significant safety-related adverse events from combination therapy.

•

Costs: Generic montelukast was more expensive than either generic loratadine or
cetirizine on a per dose basis, according to weekly National Average Drug
Acquisition Cost (NADAC) data provided by the Centers for Medicare &
Medicaid Services (CMS).

•

Benefits-Harm Assessment: Balance of benefit and harm.

•

Value Judgments: Combination therapy of LTRA and oral antihistamines does
not result in consistently improved AR symptoms compared to either agent
alone. There are few reported safety-related adverse events from combination
therapy. The addition of an LTRA may have a role in management of comorbid
asthma.

•

Policy Level: Option.

•

Intervention: Combination therapy of LTRA and oral antihistamines is an option
for management of AR, particularly in patients with comorbid asthma or those
who do not tolerate INCS and symptoms are not well-controlled on oral
antihistamine monotherapy.

Author Manuscript

IX.B.10.d. Intranasal corticosteroid and intranasal antihistamine.: The use of
combination intranasal antihistamine and corticosteroid spray for AR has been well studied.
One topical formulation is currently available in North America for intranasal use as a
combination of azelastine hydrochloride and fluticasone propionate (AzeFlu; Mylan,
Canonsburg, PA). This agent is also designated in the literature as MP-AzeFlu or MP29-02,
and is marketed in the United States under the trade name Dymista. A systematic review of
the English-language literature was performed for clinical trials of combination INCS and
intranasal antihistamine for the treatment of AR. A total of 10 RCTs (9 double-blind, 1 nonblinded) evaluated combination therapy against either placebo or active control.1486-1495 An
additional 2 observational studies in the allowable search date range for this document
reported outcomes of AzeFlu as a single treatment arm1496,1497 (Table IX.B.10.d).
Outcome measures were predominantly patient-reported symptom scores or QOL
assessments. The most common outcome measure was the TNSS (9 studies), which records
the severity of runny nose, sneezing, itching, and congestion. Other outcome measures
included the TOSS (4 studies), a VAS (3 studies), the RQLQ (2 studies), the Pediatric RQLQ
(1 study), and a threshold/discrimination/identification (TDI) score (1 study).
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The minimum age of subjects in most included studies was 12 years or older. Study duration
was 14 days of active treatment in most studies, except 1 study with a 3-month duration1495
and 1 study with a 52-week duration.1488 The number of subjects in each study ranged from
47 to 3398. Combination therapy with AzeFlu was compared to placebo in 6 studies, with
primary outcomes showing superiority to placebo in all studies.1486,1487,1489-1492 AzeFlu
was compared to active treatment with fluticasone propionate monotherapy in 6 studies, all
of which showed superiority of the combination therapy.1488-1490,1492,1494,1495 Similarly,
intranasal AzeFlu was compared to active treatment with azelastine hydrochloride
monotherapy in 4 studies, all of which showed superiority of the combination therapy.
1489,1490,1492,1494 AzeFlu was directly compared to combination therapy with intranasal
olopatadine and fluticasone in 1 study, with no significant difference in symptom relief
between treatment groups.1493 One study found superiority of an experimental combination
of solubilized azelastine and budesonide compared to either a suspension-type formulation
of azelastine and budesonide or placebo.1491
Two studies evaluated children aged between 6 and 12 years old. Like findings in adults,
AzeFlu showed superiority to placebo in improving symptoms and QOL in children.1486,1495
Several studies reporting time to onset found that AzeFlu had a more rapid effect compared
to INCS alone.

Author Manuscript

Serious adverse effects were not reported in any study. Intranasal antihistamine and
corticosteroid combination therapy was generally well tolerated, with the most commonly
reported adverse effect being an unpleasant taste. Other reported adverse effects included
somnolence, headache, epistaxis, and nasal discomfort, all occurring in less than 5% of cases
in each study. One study that compared combination therapy of fluticasone propionate with
either azelastine or olopatadine reported more treatment-related events for the azelastine
group (16/68) than the olopatadine group (7/67).1493

Author Manuscript

•

Aggregate Grade of Evidence: A (Level 1b: 9 studies; Level 2b: 1 study; Level
2c: 2 studies; TableIX.B.10.d).

•

Benefit: Rapid onset, more effective for relief of multiple symptoms than either
INCS or intranasal antihistamine alone.

•

Harm: Patient intolerance, especially due to taste.

•

Costs: Moderate financial burden. Average wholesale price of $202 USD per 23g bottle (1-month supply when used as labeled).

•

Benefits-Harm Assessment: Preponderance of benefit over harm. Combination
therapy with intranasal antihistamine and INCS is consistently more effective
than placebo. Low risk of non-serious adverse effects.

•

Value Judgments: Despite level 1 evidence demonstrating that combination spray
therapy (INCS plus intranasal antihistamine) is more effective than monotherapy
and placebo, the increased financial cost and need for prescription limit the value
of combination therapy as a routine first-line treatment for AR.

•

Policy Level: Strong recommendation for the treatment of AR when
monotherapy fails to control symptoms.
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IX.B.11.

Intervention: Combination therapy with INCS and intranasal antihistamine may
be used as second-line therapy in the treatment of AR when initial monotherapy
with either INCS or antihistamine does not provide adequate control.
Nontraditional and alternative therapies

IX.B.11.a. Acupuncture.: In complimentary medicine, acupuncture has the distinction of
being 1 of the oldest forms of healing arts practiced, with its origins dating back to the 6th to
5th centuries BC.1498 Traditional Chinese medicine holds to the concept that the body’s vital
energy (Qi) flows through a network of meridians beneath the skin.1499 In a healthy state,
the flow of the Qi is uninterrupted whereas disease states mark a disruption of the Qi. The
aim of acupuncture is to stimulate acupuncture points (acupoints) with needles to recover
equilibrium. Acupoints are specific anatomic points located along meridians that are
believed to correspond to the flow of energy through the body.

Author Manuscript

There have been several blinded RCTs evaluating acupuncture as a treatment for AR.
Acupuncture has an excellent safety profile with only minor side effects reported.1500,1501
Some studies have shown acupuncture to influence allergic and inflammatory mediators
including IgE and IL-10 levels in AR patients significantly more than controls,1501,1502
suggesting a possible immunomodulatory effect. The clinical significance of these changes,
however, remains to be seen.

Author Manuscript

Two meta-analyses addressing acupuncture have been performed (Table IX.B.11.a). The
first, published in 2008 reviewed 7 RCTs and found a high degree of heterogeneity between
studies with most studies being of low quality.1500 No overall effects of acupuncture on AR
symptom scores or use of relief medications were identified.1500 A more recent metaanalysis of 13 studies had more favorable findings, demonstrating a significant reduction in
nasal symptoms, improvement in RQLQ scores, and decreased use of rescue medications in
the group receiving acupuncture.1501 This meta-analysis included 6 of the 7 studies in the
2008 review and 7 new studies. Again, a high level of heterogeneity between studies and
varied quality of the studies was noted. Most important to note is that neither meta-analysis
discussed the specific consideration of concomitant AR medication use during the trials,
which is common in most acupuncture trials. The uncontrolled use of AR medications could
have significantly impacted the outcomes in any of these studies and raises concerns when
interpreting the results.

Author Manuscript

•

Aggregate Grade of Evidence: B (Level 1a: 2 studies; Level 2b: 13 studies; Table
IX.B.11.a). Only level 1a studies are presented in the table.

•

Benefit: Unclear, as 1 meta-analysis showed no overall effects of acupuncture on
AR symptoms or need for rescue medications and a second meta-analysis
showed an effect of acupuncture on symptoms, QOL, and need for rescue
medications.

•

Harm: Needle sticks associated with minor adverse events including skin
irritation, pruritis, erythema, subcutaneous hemorrhage, infection, and headache.
Need for multiple treatments and possible ongoing treatment to maintain any
benefit gained.
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•

Cost: Cost of acupuncture treatment with multiple treatments required.

•

Benefits-Harm Assessment: Balance of benefit and harm.

•

Value Judgments: The authors determined that the evidence was inconclusive but
that acupuncture could be appropriate for some patients to consider as an adjunct
therapy.

•

Policy Level: Option.

•

Intervention: In patients who wish to avoid medications, acupuncture may be
suggested as possible therapeutic adjunct.

Author Manuscript

IX.B.11.b. Honey.: A long-held belief has been that honey is effective in treating
symptoms of AR; however, evidence in support of this is scarce. It is postulated that
environmental antigens contained within locally produced honey could, when ingested
regularly, lead to the development of tolerance in a manner similar to SLIT. It is important to
note that heavy, insect-borne pollens do not meet Thomen’s postulates, as they are not
airborne and hence should not be able to induce allergic sensitivity.818 Studies in animals
have demonstrated the ability of honey to suppress IgE antibody responses elicited against
different allergens and to inhibit IgE-mediated mast cell activation.1503-1505 As yet, these
same effects have not been tested for in humans; however, studies in humans have
demonstrated various anti-inflammatory properties of honey which point to a potential
benefit for its use in the treatment of AR.1506,1507

Author Manuscript

There have been 2 randomized, double-blind, placebo-controlled trials and 1 RCT evaluating
honey in the treatment of AR (Table IX.B.11.b). The studies differed in geographic location,
length of honey treatment, dose of honey, and timing regarding specific allergy seasons. One
double-blind trial and 1 RCT showed a significant decrease in total symptom scores in the
treatment group compared to control.1508,1509 The RCT additionally reported fewer number
of severe symptom days and decreased need for antihistamines in the honey group.1509
Contradicting these findings, a randomized, double-blind, placebo-controlled trial by Rajan
et al.1510 found no benefit of honey ingestion compared to controls for the relief of AR
symptoms. Of note, it has been reported that higher doses (50 to 80 g daily intake) of honey
are required to achieve health benefits from honey1511 and only the study by Asha’ari et al.
1508 dosed patients at that level.

Author Manuscript

•

Aggregate Grade of Evidence: B (Level 1b: 2 studies; Level 2b: 1 study; Table
IX.B.11.b).

•

Benefit: Unclear, as studies have shown differing results. Honey may be able to
modulate symptoms and decrease need for antihistamines.

•

Harm: Some patients stopped treatment because they could not tolerate the level
of sweetness. Some patients could have an allergic reaction to honey intake, and
in rare instances, anaphylaxis. Use of this therapy in prediabetics and diabetics
would likely need to be avoided out of concern for elevated blood glucose levels.

•

Cost: Cost of honey; low.
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•

Benefits-Harm Assessment: Balance of benefit and harm.

•

Value Judgments: Studies are inconclusive and heterogeneous.

•

Policy Level: No recommendation due to inconclusive evidence.

•

Intervention: None.

Author Manuscript

IX.B.11.c. Herbal therapies.: Like acupuncture and honey, herbal remedies have been
used for the treatment of various physical ailments, including AR, world-wide for thousands
of years. This area of complementary/alternative medicine is an attractive alternative to
mainstream medicine for patients who wish to avoid traditional pharmacotherapy or who
have not tolerated various anti-allergic medications in the past. There are a vast number of
studies looking at the effectiveness of numerous herbs and herbal supplements in the
treatment of AR; however, most are small and of poor quality. Those herbal remedies that
have been subjected to more rigorous study are summarized in Table IX.B.11.C
Given the lack of robust and repeated large double-blind randomized placebo-controlled
trials on any 1 herbal remedy, no evidence based recommendations can be made supporting
the routine use of any 1 herb or compound; this should be considered an area requiring
further research before any such recommendations can be made.

Author Manuscript
IX.C.

•

Aggregate Grade of Evidence: Uncertain.

•

Benefit: Unclear, but some herbs may be able to provide symptomatic relief.

•

Harm: Some herbs are associated with mild side effects. Also, the safety and
quality of standardization of herbal medications is unclear.

•

Cost: Cost of herbal supplements; variable.

•

Benefits-Harm Assessment: Unknown.

•

Value Judgments: The authors determined that there is a lack of sufficient
evidence to recommend the use of herbal supplements in AR.

•

Policy Level: No recommendation.

•

Intervention: None.

Surgical treatment

Author Manuscript

AR is a medical disease, but at times may become refractory to medical management.
Surgery for AR is primarily aimed at reducing nasal obstruction and/or rhinorrhea, with the
contributing structures being the nasal septum and turbinates.1551 Vidian neurectomy is
historically a surgical technique that seeks to overcome chronic and intractable rhinitis.
No Cochrane review of septoplasty or vidian neurectomy for allergic patients currently
exists. A Cochrane review of turbinate reduction in allergic patients refractory to medical
management was explored, but was unable to identify any qualifying studies (selection
criteria stringently required randomized controlled trials of inferior turbinate surgery vs
continued medical treatment for proven AR, or comparisons between 1 technique of inferior
turbinate surgery vs another technique, after maximal medical treatment).1552 Physicians
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must, therefore, rely upon less scientifically rigorous data when deciding upon surgery for
AR patients.

Author Manuscript

The role of septoplasty for the treatment of nasal obstruction in AR is poorly understood.
The nasal septum is not a major contributor to allergic disease because it does not experience
the extent of dynamic change the turbinate tissue does, and therefore, there is a paucity of
literature investigating septoplasty alone to improve nasal patency in AR. The nasal septal
swell body may serve to alter nasal airflow and humidification, but no literature exists to
implicate a role in AR.1553 Karatzanis et al.1554 found that subjective improvement in
patients undergoing septoplasty was higher in those without AR than those with it. For this
reason, a cautious approach to the management of nasal septal deviation in AR is warranted.
On the other hand, Kim et al.1555 found that AR patients undergoing septoplasty with
turbinoplasty felt more relief of nasal obstruction then those undergoing turbinoplasty alone
(Table IX.C).
In contrast to the septum, the inferior turbinates are a prime target of allergic effects,
characterized by vasodilation of capacitance vessels leading to engorgement, in turn causing
nasal obstruction and congestion. Although surgery will not eliminate the inflammatory
origins of AR, additional patency of the nasal cavity reduces the effects of edematous
mucosa. From a surgical standpoint, inferior turbinate reduction is the most beneficial
treatment for nasal obstruction in AR refractory to medical therapy.1552 The inferior
turbinate consists of 3 primary components: a mucosal covering, a submucosal layer
(containing the capacitance vessels), and a bony center. Surgery is typically aimed at the
submucosa or bone, or total/partial turbinectomy which involves removal of all 3
components.

Author Manuscript

The submucosal tissue can be reduced through direct removal (eg, submucous bony
resection or microdebrider submucosal resection) or energy applied to damage tissue with
subsequent remodeling (eg, cautery, radiofrequency, laser, Coblation™). These various
techniques have substantial support in the literature. Mori et al.1556 reported on long-term
outcomes on patients undergoing submucous bony resection over a 5-year follow-up period
and noted a significant improvement in symptoms and nasal allergen responses.
Additionally, QOL was enhanced in postoperative patients and maintained long term.
Microdebrider submucous reduction targets the cavernous tissue surrounding the bony
turbinate. Advantages include real-time suction with precise tissue removal. Compared to
submucosal bony resection, data suggests improved mucociliary time due to less tissue
trauma.1557

Author Manuscript

Laser turbinate reduction seeks to induce scarring in the submucosa, though the overlying
superficial mucosal layer is transgressed in the process. Caffier et al.1558 reported on the
effects of diode laser turbinoplasty in 40 patients with AR. Statistically significant
improvements occurred in rhinomanometry and nasal obstruction, rhinorrhea, sneezing, and
nasal pruritus. The improvement in nasal obstruction was sustained at 2 years.1558
In radiofrequency ablation (RFA) for nasal obstruction, a probe is inserted directly into the
inferior turbinate to deliver a low-frequency energy, causing ionic agitation of tissues.1559
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The thermal effect is limited to the submucosal layer, which preserves surface epithelium
and ciliary function.1560 Following RFA, coagulative necrosis occurs first, with scar
contracture and tissue retraction occurring later in the healing process. Over time, portions
of the fibrotic scar undergo resorption and the submucosal scar will adhere to the bony
periosteum, which reduces turbinate bulk and renders it less susceptible to edema and
engorgement.1560,1561 In the first long term study of its kind, Lin et al.1562 published a
report on 101 patients who were followed up to 5 years postoperatively after undergoing
RFA turbinoplasty for the treatment of AR. The 6-month and 5-year response rates were
77.3% and 60.5%, respectively, and statistically significant improvement was achieved in
nasal obstruction, rhinorrhea, sneezing, itchy nose, and itchy eyes.1562 Coblation™
technology relies on electrodissection by molecular activation. This technology can similarly
target the submucosal layers. Siméon et al.1563 investigated the efficacy of Coblation™ on 9
AR patients with a mean age of 12.7 years. Favorable decreases in nasal resistance, pruritus,
sneezing, hyposmia, and rhinorrhea were observed and sustained at 6-month follow-up.1563
RFA and Coblation™ procedures are well-tolerated with minimal adverse effects and can be
safely performed in the operating room or the outpatient office setting.
Bony outfracture seeks to shift the bony skeleton of the inferior turbinate laterally into the
inferior meatus, thereby creating more breathing space. Aksoy et al.1564 found statistically
significant reductions in the distance between the inferior turbinate and the lateral nasal wall
after outfracture in 40 patients. This effect was sustained at 6 months postoperatively, which
suggests that lateralization persists.1564 Radical turbinate excision might overcome
obstruction, but, at the cost of dryness and possibly empty nose syndrome.1565
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Vidian neurectomy is an older technique that seeks to damage the parasympathetic nerve
impulses to the nasal cavity. Tan et al.1566 found significant improvement in QOL measures
in a prospective group undergoing vidian neurectomy over septoplasty/partial turbinectomy
or medical management groups. This technique is considered more effective for non-allergic
patients and seeks to primarily address severe rhinitis.1567 Posterior nasal nerve section may
also be considered for recalcitrant rhinorrhea; this technique aims to avoid the dry eye
complications of vidian neurectomy.1568
Recent publications have identified isolated middle turbinate polypoid edema or frank
polyps to have a significant correlation with inhalant allergy, especially in more severe cases.
785,786 In cases where the polypoid changes in the middle turbinate are significant enough to
cause nasal obstruction, conservative recontouring of the middle turbinate(s) can reduce
nasal obstructive symptoms.
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To summarize, surgical treatment of the septum, inferior and/or middle turbinates, and
possibly vidian/posterior nasal neurectomy may be considered in both allergic and nonallergic patients. Outcomes of these various techniques are variable in patients with AR.
•

Aggregate Grade of Evidence: C (Level 1a: 1 study; Level 1b: 1 study; Level 2b:
1 study; Level 3b: 4 studies; Level 4: 5 studies; Table IX.C).

•

Benefit: Improved postoperative symptoms and nasal airway.
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•

Harm: Possible septal perforation, empty nose syndrome, nasal dryness, mucosal
damage, epistaxis.

•

Cost: Office-associated vs operating room-associated procedural costs.

•

Benefits-Harm Assessment: Preponderance of benefit over harm.

•

Value Judgments: Properly selected patients can experience an improved nasal
airway with judicious surgical intervention.

•

Policy Level: Option.

•

Intervention: Turbinate reduction with or without septoplasty may be considered
in AR patients that have failed medical management, and have anatomic features
which explain symptoms of nasal obstruction.

Allergen immunotherapy (AIT)
In addition to allergen avoidance and numerous pharmacotherapy options, AIT is frequently
considered in the management of AR. AIT involves scheduled administration of allergen
extracts at effective doses with the goal of instituting a sustained immunologic change. AIT
effectiveness is often measured through control of allergy symptoms and reduction in allergy
medication use. The following section reviews the specifics of allergen extract units and
standardization, allergen extract adjuvants and modifications, and subcutaneous and
sublingual immunotherapy (SCIT, SLIT), as well as less traditional types of immunotherapy.
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IX.D.1. Allergen extract units, potency, and standardization—Historically,
allergy testing began with pollen grains placed directly on the conjunctiva,1569,1570 but as
skin testing and SCIT became the diagnostic and immunotherapy treatment methods of
choice, injectable allergen extracts were required. Inhaled allergenic particles are composed
of a complex heterogeneous mixture of allergenic and non-allergenic proteins and
macromolecules. Allergen extracts are created by collecting raw material from a particular
species of plant, mold, or animal and then using a solution to extract proteins from the
source.1571
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There are multiple sources of variance in allergen extracts. There is biologic variability in
the raw material, and proteins can vary in antigenicity and composition; furthermore, the
relative amounts of allergenic proteins may vary.1572,1573 Impurities in the source materials,
such as mold growing on pollen granules or bacteria on cat pelts, may also be immunogenic
even if nonviable. Variation occurs in the collection and processing of the raw material.1573
There is variability in the extraction process with different manufacturers using different
techniques including filtration, extraction, sterilization, and preservation.1571,1572,1574,1575
Only a very small fraction of the proteins extracted are allergenic.1571 Given that the protein
composition of allergen extracts is not known, producing and labeling allergen extracts that
are safe and effective is challenging.
Units and potency.: Allergen extracts are labeled with an assortment of units that provide
an indirect indication of the allergen content of the extract. Most allergen extracts are labeled
in units that do not convey information about biological composition or potency. There are
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multiple types of units that can be grouped into nonstandardized, standardized, or
proprietary. The difference between standardized and nonstandardized extracts is discussed
later this section.
Potency of an allergen can have different meanings. Potency sometimes refers to the
allergenicity of a source material’s proteins or the biologic activity. For example, grass
pollens are generally more potent than tree pollens. The typical grass-allergic person would
have a larger clinical reaction to grass pollen than a tree-allergic person to the same amount
of tree pollen. However, a measure of potency of an allergen extract may also just refer to
the strength or concentration measured in units.

Author Manuscript

Nonstandardized allergen extracts.: Most allergen extracts available in the United States
are nonstandardized. Allergen extracts are regulated by the Center for Biologics Evaluation
and Research (CBER) under the FDA in the United States.1576 Allergen extracts are required
to list the biologic source, a potency unit, and an expiration date.

Author Manuscript

•

Weight/volume (wt/vol). Weight/volume refers to the ratio of grams of dry raw
material to milliliters of extract solvent. Commonly this is 1/20 wt/vol, which
means that for every 1 g of raw material (pollen for example) there is 20 mL of
extract solvent. This does not provide direct information about the amount of
allergenic proteins in the allergen extract nor its biologic activity. However, it
implies a reproducible methodology was employed.1571

•

Protein nitrogen units (PNUs). This is the second most common nonstandardized
unit currently used in the United States. PNU refers to an assay of the
precipitable protein nitrogen by phosphotungstic acid which correlates with the
total protein. While most of the protein is non-allergenic, the total protein is
another method to quantitate an allergen extract’s content.1571

In Europe, many manufacturers use proprietary units and internal quality controls which
must utilize a validated assay.1572 This European manufacturer-based quality control is
known as “In House Reference Preparation.”1573 However, the European Medical Agency
has been developing a standardized framework based on protein homology rather than
source species.1577 The EU is also developing additional allergen standards with the WHO
starting with Bet v 1 and Phl p 5a.1577

Author Manuscript

Standardized allergen extracts.: In the United States, standardized allergen extracts are
tested by the manufacturer to be within a reference range (70-140%) when compares to a
standard provided by the CBER. The government’s standard is referenced to the reactivity in
highly allergic individuals, creating a standard of biologic activity.
The CBER creates the standard extract through testing in known “highly allergic”
individuals. They use serial intradermal 3-fold titrations and measure potency by how many
dilutions are needed to produce a flare reaction of a certain size. The size is determined by
measuring the largest diameter and adding the length of a line 90 degrees to the largest
diameter line. The orthogonal sums are plotted for each dilution and a best fit line drawn.
The concentration that corresponds to where the orthogonal sum of the flare is 50 mm
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(ID50EAL) determines the units listed in either Allergy Units (AU) or Biologic Allergy
Units (BAU). AU is used for dust mites. A mean ID50EAL of 14 threefold dilutions is
defined as 100,000 BAU/mL and 12 threefold dilutions 10,000 BAU/mL.1577

Author Manuscript

The FDA allergen standards are compared to the produced allergen extracts by the
manufacturers. The process is different for extracts where the major allergen reactivity
correlates with overall allergen reactivity (cat and ragweed) than for extracts that do not have
a major allergen that correlates as strongly. A major allergen is defined as a specific protein
epitope that more than 50% of individuals allergic to that species react. If there is a major
allergen that correlates strongly with the population’s clinical reactivity, the manufacturer
can compare their extract to the standard extract by gel electrophoresis with the gel having
monoclonal IgG antibodies to the major allergen protein. If there is not a single allergen that
correlates well with the reactivity of the population, the manufactured extract and the
standard are compared through competition enzyme-linked immunosorbent assay (ELISA)
using pooled serum IgE from known allergic subjects. The manufacturer’s extract must fall
within a 70% to 140% range of the FDA’s reference.1576 The amount of major allergen is
sometimes listed in μg/mL, Fel d 1 units (cat), or Antigen E units (ragweed). Standardized
inhalant allergens within the United States include cat, Dermatophagoides pteronyssinus,
Dermatophagoides farinae, short ragweed, and multiple grass species.1577
Some allergen extracts in Europe use the Nordic method where 10,000 biologically
standardized units/mL is comparable to a skin reaction elicited by 10 mg/mL of histamine.
1577
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In conclusion, an international consensus has not been established for allergen units or
standardization of allergen extracts. While standardization and transparent potency assays
increase manufacturing costs, it is widely agreed that greater standardization and consistency
across manufacturers would be beneficial. Variations in allergen extracts between
manufacturers may discourage medical providers from changing between vendors reducing
the effect of price on competition. The multitude of allergen extract units and variability also
complicates the interpretation and application of published studies between the United
States, the EU, and other countries. The WHO has identified allergen standardization as a
problem and the EU funded a project known as CREATE, “Development of Certified
Reference Materials for Allergenic Products and Validation of Methods for the
Quantification.”1578 But as of 2017, multiple allergen units are still in use worldwide.
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IX.D.2. Modified allergen extracts—The goal of AIT is to suppress the underlying
inflammatory diathesis and induce a state of clinical tolerance to the relevant allergen. This
thereby attenuates, if not completely arrests, the inflammation that manifests as AR.
Traditional AIT with native, unmodified extracts is successful but has several limitations.
Immunotherapy can lead to adverse reactions which rarely can be life-threatening. Besides
the risks, allergen extracts have significant production costs with limitations of availability
and consistency between batches. Variations exist in pharmaceutical-produced native
extracts in the allergen amounts, potencies, and immunogenicity of individual allergen
molecules that cannot be controlled in the manufacturing process.1579
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New advances in AIT have focused on redirecting the untoward allergic diathesis through
upregulation of T-regulatory and B-regulatory cells, restoring the balance between Th2 and
Th1 cell subtypes, and establishing T-cell immune tolerance. The use of recombinantderived allergens, synthetic peptides, allergoids, and adjuvants has been sought to provide
safer, more consistent, readily available, and effective allergens compared to commercially
available native extracts1580-1582 (Table IX.D.2-1).
The laboratory production of allergens allows for modification of extracts and epitope
structures that aim to enhance immunogenicity while decreasing the risk of adverse
reactions. Clinical studies have reported outcomes for AIT using recombinant-produced
molecules, synthetically-produced peptides, and modifications of allergens via allergoids
with adjuvant molecules or through denaturing of proteins.

Author Manuscript

Recombinant allergens.: Recombinant-derived allergens are produced by cloning of native
allergen proteins with use of recombinant DNA technology. The allergy protein is reverse
transcribed to yield a complimentary DNA molecule which can then be transferred into
bacteria which produce copies of the incorporated DNA. This technique allows for
controlled production of a high-yield product with consistent structure. Immunotherapy
trials with recombinant allergens has been reported for birch pollen and Timothy grass
pollen (Table IX.D.2-2). Recombinant birch AIT demonstrated equivalent clinical outcomes
to native birch extract and improved symptoms over placebo.1583-1585 Recombinant Timothy
grass AIT showed improved outcomes compared to placebo with a good safety profile.
805,1586 Recently, a recombinant peptide carrier fusion grass vaccine has reported positive
outcomes with a B-cell epitope-based vaccine for immunotherapy of grass pollen allergy.798

Author Manuscript

•

Aggregate Grade of Evidence for birch: B (Level 1b: 3 studies; Level 2b: 1
study).

•

Aggregate Grade of Evidence for Timothy grass: B (Level 1b: 3 studies).

•

These studies of recombinant allergens for birch and Timothy grass demonstrate
safety and efficacy.

Author Manuscript

Peptide constructs. Synthetic peptides for immunotherapy are linear fragments of amino
acids that correspond to T-cell epitopes. These fragments lack the secondary and tertiary
structure that activate IgE receptors, but can induce immunologic tolerance by targeting
allergen-specific T-cells to induce tolerance. The premise with synthetic peptides is that the
lack of IgE activation will eliminate the risk of IgE-mediated adverse reaction while
preserving the immunogenicity that leads to desensitization. AIT trials with synthetic
peptides have been reported for cat, birch, and ragweed allergens (Table IX.D.2-2). Overall,
studies have shown mixed outcomes from synthetic peptides with some peptide molecules
resulting in an increase in late adverse reactions. The recently completed large-scale
multicenter field trial (https://clinicaltrials.gov/ct2/show/NCT01620762; Phase III Cat-PAD
Study) with cat peptide failed; however, as of this writing, the HDM peptide study is
ongoing.1587,1588 Newer peptide constructs under investigation include overlapping peptides
that reproduce the entire sequence of the naturally-occurring allergen in an attempt to cover
all T-cell epitopes and natural peptide fragments that cover a broad panel of epitopes.1589
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•

Aggregate Grade of Evidence for cat: B (Level 1b: 5 studies).

•

Aggregate Grade of Evidence for birch: Indeterminate, based on only 1 Level 1b
study.

•

Aggregate Grade of Evidence for ragweed: B (Level 1b: 1 study; Level 2b: 1
study).

Author Manuscript

Allergoids and polymerized allergens. Allergoids are chemically modified allergens which
were developed for improved immunotherapy protocols via accelerated dosing and
decreased side effects. Initial attempts at development of an allergoid by partial denaturing
of the allergenic moiety with formalin resulted in reduced allergenicity; however, concurrent
reduction in the immunogenicity of the allergoids, as defined by IgG antibody production,
was seen.1590 Studies using a glutaraldehyde-linked polymerization of allergens for grass
and ragweed allergens demonstrated efficacy and tolerability.1591,1592 However,
standardization criteria and production factors negatively impacted regulatory approval in
the United States. Clinical trials for allergoids employing ragweed, grass, and HDM
allergens have been reported. Promising early results are seen for these allergoids. In
addition, more recent work has focused on depigmented allergoid constructs, which are
currently in use in Europe1593,1594 (Table IX.D.2-2).
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•

Aggregate Grade of Evidence for ragweed: B (Level 1b: 1 study; Level 2b: 1
study).

•

Aggregate Grade of Evidence for grass: B (Level 1b: 7 studies).

•

Aggregate Grade of Evidence for HDM: Indeterminate, based on only 1 Level 2b
study.

•

Allergoid or polymerized allergen products have been approved in Europe but
none has received FDA approval.

Adjuvant constructs.: The addition of molecules (adjuvants) to the native allergen has been
attempted to improve desensitization protocols. Alum was the first adjuvant to gain
acceptance in AIT. Early studies with alum-precipitated extracts demonstrated an augmented
immunologic response. However, alum induced an initial IgE immune response which
hindered its therapeutic application.1595 Clinical trials with adjuvants have been reports for
ragweed, grass, and HDM allergens (Table IX.D.2-2).
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Creticos reported the proof-of-concept study for using bacterial DNA (CpG oligonucleotide
synthetically derived from Mycobacterium bovis) to upregulate an immunostimulatory
response to allergen through the corresponding ligand (TLR ligand) on a specific class of
regulatory dendritic cells.1596 The TLR-9 agonist was administered in a 2-year double-blind
placebo-controlled study of ragweed-allergic subjects immunized with a 6-injection regimen
administered prior to the initial ragweed season. A similar magnitude of effect vs placebo
was observed over both ragweed seasons indicating that the vaccine conferred meaningful
long-term efficacy (clinical and immune tolerance) over 2 ragweed seasons.1596 Subsequent
large-scale multicenter trials were not able to satisfy regulatory approval requirements and
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this specific product is not going forward in development.1597 However, the field of adjuvant
approaches to immunization is moving forward.
A TLR-4 adjuvant is also currently in clinical development. This construct is comprised of
monophosphoryl lipid A, derived from detoxified lipopolysaccharide of gram-negative
bacterium (Salmonella minnesota, a TLR-4 inducing adjuvant), and formulated with pollen
allergoids absorbed onto microcrystalline tyrosine. This compound reduces IgE-mediated
allergenicity but preserves immunogenicity. A large grass study showed significant
improvement in symptom and medication scores vs placebo with subgroup analysis showing
greater benefit in patients with more severe symptoms.1598 An abbreviated ragweed trial
showed clinical effect in the primary endpoint vs placebo.1066
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These studies of adjuvant-modified extracts demonstrate potential for improved
immunotherapy protocols; however, several challenges remain. Each of the modified extracts
requires robust clinical outcomes data to demonstrate short and long-term improvement in
both efficacy and safety over conventional allergenic extracts.
•

Aggregate Grade of Evidence for ragweed: B (Level 1b: 3 studies).

•

Aggregate Grade of Evidence for grass: B (Level 1b: 2 studies).

•

Aggregate Grade of Evidence for HDM: Indeterminate, based on only 1 Level 2b
study.
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In summary, a wide variety of immunotherapeutic agents are currently undergoing clinical
development with the goal of improving safety and achieving immune tolerance with longlasting therapeutic efficacy. This new generation of vaccines includes recombinant allergens,
peptide constructs, allergoids/polymerized allergens, and adjuvant constructs—each of
which must undergo rigorous clinical evaluation to demonstrate acceptable safety and
meaningful clinical outcomes that meet regulatory guidelines for approval. For some of the
studied preparations, there appears to be improvement over placebo and comparable
outcomes to native allergens. The TLR-9 agonist trial showed 2 years of efficacy postdiscontinuation of drug. However, some peptide molecules demonstrated increased late
reactions as well as mixed clinical outcomes depending on the preparation. Allergoids,
adjuvants, and peptides have also shown efficacy in multiyear clinical trials. There is
insufficient evidence to make recommendations based on the low number of studies for each
preparation and lack of long-term outcomes, as no study has examined outcomes for longer
than a 2-year period.
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IX.D.3. Subcutaneous immunotherapy (SCIT)—AIT is a treatment for IgEmediated sensitivity to environmental allergens.101,1613,1614 SCIT involves the injection of
increasing doses of an extract of the allergen in question, followed by repeated injections of
the top or maintenance dose for periods of 3 to 5 years, to reduce symptoms on exposure to
that allergen. SCIT has been practiced for over a century using aqueous extracts of the
naturally occurring allergens.1615 SCIT has been shown to be effective for AR, allergic
asthma, and sensitivity to hymenoptera venom, along with demonstrated benefit in selected
patients with AD. Although meta-analyses conclude that AIT is effective, this positive
judgment of efficacy (and safety) should be limited to products tested in the clinical trials. It
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is incorrect to make a general assumption that “AIT is effective,” since this may lead to the
clinical use of products that have not been properly studied.1614,1616 However, as currently
practiced, SCIT has the drawbacks not only of the prolonged period of treatment and
multiple visits to health care facilities but also the ever-present risk of systemic reactions.
There are now attempts to overcome these limitations by modifying the native allergens or
using recombinant technology to produce extracts that are less reactive with sIgE, allowing
higher dosing with greater safety and shorter courses of treatment.1615 (See section IX.D.2.
Management – Allergen immunotherapy (AIT) – Modified allergen extracts for additional
information on this topic.)
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Two U.S. healthcare agencies have recently commissioned systematic reviews of the medical
literature on the use of AIT in AR1617,1618 (Table IX.D.3-1). The National Institute for
Health Research commissioned an update of the 2007 Cochrane Review of AIT for SAR1617
and the Agency for Healthcare Research and Quality commissioned a systematic review of
the use of SCIT and SLIT for the treatment of AR and bronchial asthma.1618 The first of
these systematic reviews found highly significant differences in favor of SCIT over placebo
for improvement of symptoms and medication use for treatment of AR, as well as for
improvement in the rhinitis QOL, all with a p value of < 0.00001.1617 The second systematic
review found high-quality evidence for SCIT, compared to placebo, improving rhinitis and
rhinoconjunctivitis symptoms and QOL, with moderate quality of evidence for reduction in
medication use for treating AR.1618 A third systematic review using the EBRR methodology
found that SCIT for SAR and PAR has Aggregate Grade of Evidence A and recommended
SCIT for SAR or PAR patients not responsive to medical therapy, whose symptoms
significantly affect QOL.1619
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A search of the EMBASE, MEDLINE, and Cochrane Library databases for systematic
reviews and randomized controlled clinical trials yielded a recent otolaryngology clinical
practice guideline for AR761 and an International Consensus on Allergy
Immunotherapy1577,1620 as well as 5 double-blind, placebo-controlled trials of SCIT in AR
that were published since the previously discussed systematic reviews (Table IX.D.3-1). All
5 of these trials were conducted with aldehyde-modified natural pollen extracts (allergoids).
1593,1594,1605,1621,1622 These trials all support the efficacy of SCIT in treating AR.
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Patient selection.: There are 3 therapeutic options for patients with AR: avoidance,
pharmacotherapy, and immunotherapy. The evidence supporting avoidance is reviewed in
section IX.A. Management – Allergen avoidance. Pharmacotherapy is discussed in section
IX.B. Management – Pharmacotherapy. There are 2 primary reasons to consider AIT.101,1623
One is that addition of AIT to pharmacotherapy alone will likely result in a more
pronounced decrease of symptoms (even after a short course of AIT). The second relates to
the failure of pharmacotherapy to alter the underlying immunologic process. Patients may
choose AIT largely to obtain a lasting benefit, prevent the progression of AR to bronchial
asthma, or prevent new sensitizations.1624-1626
Contraindications for AIT.: The 2015 EAACI Position Paper noted contraindications for
instituting SCIT for AR.1627 Absolute contraindications were poorly controlled or
uncontrolled asthma, active autoimmune disorders, and malignant neoplasm. Relative
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contraindications were partially controlled asthma, autoimmune diseases in remission,
cardiovascular disease, and use of beta-adrenergic blocking agents. The Allergy
Immunotherapy: Practice Parameters 3rd Update, on the other hand, found no substantive
evidence that immunotherapy is harmful in patients with autoimmune diseases.1623 The
Practice Parameters also list pregnancy as a contraindication to initiating SCIT.1623 It may,
however, be continued if the patient is on maintenance dosing.
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Extracts.: In the United States, most pollen, dander, insect, and fungal extracts are available
either in a buffered saline with phenol or in 50% glycerin. The exception is those extracts
that have been standardized by the FDA which only come in 50% glycerin. There is 1 line of
alum-precipitated extracts, consisting solely of pollen extracts. In Europe, on the other hand,
alum-precipitated extracts are commonly employed and there is increasing use of allergoid
extracts consisting of natural allergens partially denatured by mixture with an aldehyde.
1593,1594,1605,1621,1622,1628 (See sections IX.D.1. Management – Immunotherapy – Allergen
extract units, potency, and standardization and IX.D.2. Management – Immunotherapy –
Modified allergen extracts for additional information on this topic.)
Dosing.: The beneficial results of SCIT have been repeatedly shown to be dependent on
administering a sufficient maintenance dose of each extract with each maintenance injection.
1609,1629-1631 Reduction of the effective maintenance dose by 90% to 95% causes partial or
complete loss of efficacy.1632 The results of many double-blind, placebo-controlled studies
have been utilized to formulate the recommendations for dosing in Table IX.D.3-2, adapted
from the Immunotherapy Practice Parameters 3rd Update.1623

Author Manuscript

Monosensitization vs polysensitization.: In most large studies of AR, 80% to 85% of the
subjects are sensitized to more than 1 unrelated allergen. Analysis of some of these studies
has shown that the polysensitized subjects respond as well to (sublingual) AIT as those with
sensitivity only to the administered allergen.1633 There is no immunological rationale why
this should be different in subcutaneous AIT, but this specific question is an important unmet
need which should be addressed in future trials.28,1634

Author Manuscript

Single-allergen vs multiple-allergen AIT.: It is the common practice among US allergists
to include in their treatment multiple allergen extracts to which the patient is sensitized. A
recent survey of 670 patients in 6 practices found a mean of 18 allergen extracts in their
treatment.29,1635 On the other hand, European guidelines recommend treating with the single
most troublesome allergen identified clinically,1636 or if more than 1 extract is to be given
they should be given at separate sites with at least 30 minutes in between administration.32
Scientific support for the U.S. allergists’ approach of using multiple allergen mixtures for
SCIT can be found in 4 double-blind, placebo controlled studies, 2 in patients with AR,
1629,1637 1 in children with asthma,1630 and 1 in patients with both rhinitis and asthma,1638
all of which demonstrated significant improvement in patients receiving mixtures of
multiple, unrelated allergen extracts. However, a recent review concluded that multiallergen
immunotherapy in polysensitized patients, whether delivered sublingually or
subcutaneously, requires more supporting evidence from well-designed, well-powered,
double-blind, placebo-controlled clinical trials to validate its efficacy in practice.1634
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Mixing.: If multiple-allergen mixtures are to be used for SCIT, there are several
considerations, in addition to ensuring that each extract in the mixture is at a concentration
that will provide an effective dose when delivered with the maintenance injection. These
considerations are (1) avoiding mixing extracts with strong proteolytic activity with extracts
whose allergens are susceptible to this activity; (2) paying attention to allergenic crossreactivity; and (3) using preservatives that are appropriate for the allergens.1632
All fungal and some insect body extracts (but not U.S. HDM extracts) have strong
proteolytic activity to which many pollen, mite, and animal dander allergens are susceptible.
1639 Fungal and cockroach extracts should not be mixed, but fungal extracts can be
combined.1640
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Plant pollens contain some allergens that are like the allergens of unrelated plants (panallergens) but generally the major allergens are unique. When the appropriate allergens are
available in the testing panel, the use of molecular diagnosis or CRD can be of great use in
differentiating cross-reactivity due to pan-allergens from that due to multiple related major
allergens. (See section VIII.F.6. Evaluation and diagnosis - In vitro testing - Component
resolved diagnosis (CRD) for additional information on this topic.) When the patient is
sensitized to the major allergens of botanically related plants there are 2 approaches that can
be employed.1641 One approach is to only include the locally most important member of a
related group (such as ragweed or northern pasture grasses); the other approach is to use a
mixtures of related allergen extracts, but treating it as if it were 1 allergen.1641

Author Manuscript

Diluents.: Diluents containing 50% glycerin are excellent at maintaining extract potency
and are used in the United States routinely for extracts with high protease activity.1639,1642
The drawback to using extracts with high glycerin content is that they cause pain when
injected.1633 A phenol-saline extract containing 0.3% human serum albumin is well tolerated
and, in the absence of high proteolytic activity, is an excellent diluent that may be used
routinely for making dilutions for initiation of SCIT in the United States.1643
Regimens.: For reasons of safety, SCIT is initiated at a dilution of the final dose and built up
usually with weekly injections of increasing amounts and concentrations over a period of
weeks or even months. Once maintenance doses are achieved, the interval between
injections can be increased but usually not beyond 4 weeks with aqueous extracts used in the
United States,1623 but up to 4 to 6 weeks for depot extracts as used in Europe.1614
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Venue for administering SCIT.: SCIT in allergy practices in the United States is associated
with a rate of severe systemic reactions of 0.1%.1644 For this reason the Immunotherapy
Practice Parameters 3rd Update state that injections should be given only in a medical
facility where prompt recognition and treatment of anaphylaxis is assured and patients
should remain under observation for at least 30 minutes following the injection.1623 This is
in line with the European perspective.32 There is a company in the United States that
promotes the practice of home administration of SCIT.1645 Their protocol calls for
administration of relatively low doses of SCIT several times per week resulting in a
cumulative dose that approaches that recommended in the Practice Parameters. However,
there is evidence to suggest that it is the size of the individual dose rather than the
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cumulative amount administered that determines efficacy,1646 and no blinded studies have
been offered to support the efficacy of this low-dose approach.
Accelerated SCIT administration.: To shorten the length of the buildup, cluster dosing is
sometimes employed. Two or 3 injections are given on each visit on nonconsecutive days,
with a 30-minute waiting between injections. If visits are twice weekly, maintenance dosing
can be achieved in 4 weeks1647 or even after a shorter period depending on the product
administered and schedule followed.1648 A retrospective analysis of rates of systemic
reactions in a large, multiple-physician practice1649 and a double-blind randomized trial1650
showed no increase in the rate of systemic reactions in patients, comparing cluster to
conventional regimens. Another (open) trial supports these findings.1651
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Rush regimens administer many injections per day on consecutive days, typically achieving
maintenance dosing in 1 to 3 days. Even with the use of premedication, there is an increased
rate of systemic reactions compared to conventional dosing.1652
Mechanism of action.: In general, the immunologic response to SCIT involves 2 sequential
steps. The first is a generation of regulatory T-cells secreting IL-10 and TGF-β, leading to a
switch from IgE to IgG4 antibody formation.1653,1654 With continued AIT the Treg response
declines and an immune deviation from Th2 to Th1 responses dominates.1577,1653 (See
section IV. Pathophysiology and mechanisms of allergic rhinitis for additional information
on this topic.)
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Modification of disease.: An advantage of SCIT over pharmacotherapy is that it alters the
underlying immunologic response towards that which is seen in non-allergic individuals.1654
The results of this alteration in the underlying immune response by SCIT can be seen
clinically in the reduction in new sensitizations, in the progression from AR to asthma, and
in the persisting benefit following an adequate course of therapy.
In children, adolescents, and young adults, who are sensitized only to the allergen being
administered, the development of new sensitizations is reduced not only during AIT but for
several years following completion of the course of AIT.1625,1626 A similar protective effect
has not been demonstrated in patients polysensitized at the initiation of AIT.
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SCIT has also been shown to prevent the progression from AR to asthma. A total of 205
children, sensitized to grass, birch or both, and showing no evidence of asthma during an
observational year, were treated with Timothy and/or birch SCIT for 3 years, or standard
pharmacotherapy alone, and observed for an additional 7 years after completion of SCIT in
an open trial.1624 The risk for developing asthma was significantly reduced at the end of
SCIT and persisted for the 7 years of follow-up. The database of the German National
Health Insurance was used to follow patients with AR without asthma who were or were not
placed on AIT in 2006.1655 During a 5-year follow-up, those patients who received AIT
(90% on SCIT) were significantly less likely to have developed asthma.
Duration of treatment and persistence of treatment effect.: Regarding persistence of
benefit, a double-blind, randomized study was conducted in patients with AR who had
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received 3 or 4 years of SCIT with Timothy grass extract.1656 Subjects were randomized to
continue maintenance SCIT or receive placebo for 3 years. There was no difference in
symptom/medication scores over the 3 grass pollen seasons between those receiving and not
receiving Timothy extract injections. In another trial, grass SCIT was discontinued in 108
grass-sensitive patients who had responded well to the treatment after 3 or 4 years of SCIT.
1657 The patients were followed through up to 4 grass pollen seasons looking for relapse.
Approximately 30% relapsed by the third grass pollen season, with few more subsequently
relapsing.
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In the 2 studies discussed in the preceding paragraph,1656,1657 3 or 4 years of SCIT with
grass extract induced remissions that persisted in most of the subjects for at least 3 years.
There are only a few studies that look at longer or shorter periods of treatment. A study that
compared 3 or 5 years of SCIT with HDM extract found significant improvement after 3
years but added clinical improvement in rhinitis after 5 years of SCIT.1658
Safety.: Information regarding the occurrence of fatal reactions to SCIT was obtained
retrospectively by the Immunotherapy Committee of the AAAAI by periodic surveys of its
members from 1985 to 20011659,1660 and by an online website since 2008.1644 The earlier
retrospective surveys suggested that a fatal reaction occurs with every 2 to 2.5 million
injection visits.1659,1660 The online survey elicited information on 2 fatal reactions in 28.9
million injection visits, which was thought to represent an improvement due to more careful
monitoring of patients with asthma.1644 The rate of systemic reactions has remained steady,
with 1.9% of patients experiencing a systemic reaction, most mild, but with 0.08%
experiencing a grade 3 and 0.02% a grade 4 reaction.1644 The occurrence and size of local
reactions do not predict the occurrence of a systemic reaction with the next injection.
1661,1662
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Cost effectiveness.: SCIT can be administered for 3 to 5 years with continuing relief of
symptoms for years after discontinuation. Pharmacotherapy, on the other hand, must be
continued indefinitely, since it has no disease-modifying activity. Because of this difference,
the initial higher cost of SCIT may be offset by the continuing benefit after it is stopped.
This factored into a decision-making analysis that suggested if a patient with SAR requiring
nasal steroids 6 months per year is seen before age 41 years, the cost will be less in the long
term if they are placed on SCIT.1662,1663 If the patient has perennial need for nasal steroids,
and they are less than 60 years of age, the most cost effective approach is SCIT. Another
cost-effectiveness analysis found that SCIT for SAR may be more effective and less
expensive than pharmacotherapy from the societal perspective when costs of productivity
loss are considered.1664 A retrospective study compared U.S. Medicaid-treated adults and
children who were newly diagnosed with AR and were or were not placed on AIT. Eighteenmonth follow-up revealed 30% and 42% healthcare cost savings, respectively, in the AIT
treated patients.1665
•

Aggregate Grade of Evidence for SCIT in the treatment of AR: A (Level 1a: 3
recent studies listed; Level 1b: 5 recent studies listed; Table IX.D.3-1). Of note,
due to the large body of literature supporting SCIT as a treatment for AR, only
recent systematic reviews and select double-blind, placebo-controlled RCTs are

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Wise et al.

Page 132

Author Manuscript

included in Table IX.D.3-1, as these achieve an Aggregate Grade of Evidence of
A.
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•

Benefit: Improvement in symptoms and decreased need for rescue medication.
Decreased likelihood of progression from AR to bronchial asthma. Persistent
benefit for years after completion of 3 to 5 years of SCIT.

•

Harm: Inconvenience of multiple visits to a medical facility to receive injections.
Potential for systemic reactions, including anaphylaxis.

•

Cost: Cost for preparation of allergen extract for treatment. Cost of visits to
medical facilities to receive injections.

•

Benefits-Harm Assessment: Benefit greater than harm for patients who cannot
obtain adequate relief with symptomatic treatment and whose symptoms extend
more than a few weeks each year.

•

Value Judgments: Patients who can obtain adequate relief of symptoms with
medication must decide if the short-term increased cost and inconvenience of
SCIT is compensated for by the long-term persisting clinical benefit and relief
from need to take medication. Pharmacoeconomic studies suggest that in the
long term, SCIT is cost effective over symptomatic therapy.

•

Policy Level: Strong recommendation for SCIT in patients unable to obtain
adequate relief with symptomatic therapy.

•

Intervention: SCIT should be recommended to the AR patient who cannot obtain
adequate relief from symptomatic medication for significant periods of time each
year and to those who would benefit from its secondary disease-modifying
effects (prevention of bronchial asthma and new sensitization), particularly
children and adolescents.
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IX.D.4. Sublingual immunotherapy (SLIT)—SLIT is an alternative application
variant of SCIT, which was first practiced over a century ago by Noon and others.1570,1666
The first double-blind placebo-controlled trial with SLIT was not conducted until 1986 by
Scadding and Brostoff1667 in London, UK. After that, only several small trials were
conducted until the beginning of the new millennium, when several “big trials” finally
demonstrated the clinical efficacy and safety of SLIT. Since then, many high-quality SLIT
trials have been reported. As a result, the actual evidence for SLIT appears to be at least as
solid as that for SCIT. The literature on SLIT for AR/rhinoconjunctivitis is vast and several
good meta-analyses and systematic reviews have been published over the past decade; the
decision was made to primarily analyze results from these reviews and to complement them
with findings from large randomized trials published during 2016 (Table IX.D.4-1).
Efficacy in adults.: Most systematic reviews and meta-analyses show a low to moderate
efficacy of SLIT over placebo (SMD = 0.30 to 0.50), and this approaches high efficacy with
longer treatment1668 (greater than 12 months’ treatment SMD = 0.70). It must be considered
that all patients, both those in the SLIT and the placebo arms, have open access to rescue

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Wise et al.

Page 133

Author Manuscript

medication, and that SLIT results in an efficacy on top of the symptom improvement
obtained with rescue medication.
Efficacy in children.: Over 5 years ago, Dutch colleagues analyzed systematic reviews of
SLIT in children and concluded that the methodological quality should be improved. They
especially questioned the heterogeneity of the included trials and the risk of bias.1669 Roder
et al.1670 also determined in 2008 that there was not enough evidence to support the
usefulness of SLIT in children. These flaws have been improved in recent studies. There is
strong1671 evidence that grass pollen SLIT tablets in children reduce symptoms of AR. The
evidence for aqueous SLIT is moderate.1672 The evidence for HDM SLIT is of moderate-tolow quality.
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Efficacy of SLIT over pharmacotherapy.: For PAR, SLIT with HDM tablets is more
effective than any single pharmacotherapy, including antihistamines, antileukotrienes and
INCS.1673 For SAR, grass and ragweed tablet SLIT is almost as effective as INCS and more
effective than the other pharmacotherapies.1673 These data had already been confirmed for
the SLIT grass pollen tablets by a previous meta-analysis; in this publication the separate
analysis of the 5-grass tablet showed its superiority over all pharmacotherapy treatments.1332
Efficacy of SLIT compared to SCIT.: Several investigators have tried to compare the
efficacy of SLIT against that of SCIT. Most meta-analyses are based on indirect
comparisons, as there are only a very few direct head-to-head randomized trials comparing
both treatments; therefore, the evidence that SCIT is more effective than SLIT is weak. Also
in children, SCIT seems more effective than SLIT, but again the quality of evidence is low.
1672

Author Manuscript
Author Manuscript

Safety.: Rare systemic and serious adverse events have been reported with SLIT, but in
general, meta-analyses found SLIT to be safer than SCIT. In the complete data-set of
systemic reviews there were 7 reports of the use of epinephrine in the SLIT group and 1 case
of eosinophilic esophagitis with a grass pollen SLIT tablet. There was no administration of
epinephrine in trials outside of the United States. A 2012 review by Calderon et al.1674
estimated the anaphylaxis rate of SLIT to be 1 per 100 million doses, or 1 per 526,000
treatment years. Grass pollen SLIT tablets are just as safe in AR patients with and without
mild asthma.1675 Starting SLIT in-season appeared to be safe. Although there were 2 serious
treatment-related adverse events with co-seasonal SLIT initiation, none required epinephrine
administration.1676 In the United States, the FDA requires patients be prescribed an
epinephrine autoinjector and the first dose be given in the physician’s office for those on
SLIT tablets. Continuing AIT during pregnancy did not augment the incidence of adverse
outcomes during delivery nor alter the risk of developing atopic disease in the offspring. No
conclusion can be drawn regarding the safety of starting SLIT in a pregnant woman, due to
lack of cases.1677
Preventative effects.: There are no systematic reviews specifically addressing the
preventative effects of SLIT that fall within the allowable search date range of this ICAR:AR
document. The preventative effect SLIT on asthma development was investigated in an open
RCT by Marogna et al.1678 involving 216 children treated with SLIT for 3 years. Mild
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persistent asthma was less common in patient treated with SLIT than patients receiving only
pharmacotherapy. In a double-blind RCT involving 812 children with grass pollen-induced
rhinoconjunctivitis, after 3 years of therapy with SQ-standardized grass pollen tablet,
children in the treatment group presented a reduced risk of developing asthma compared to
placebo group at 2-year follow-up (OR 0.71; p < 0.05).1679 Although these findings are
interesting, the overall strength of evidence for the prevention of asthma in SLIT studies is
low at present, though the evidence for asthma symptom and medication reduction is high.
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Developing new allergen sensitizations frequently occurs in the natural history of respiratory
allergy. Preventative effects of AIT on the onset of new sensitizations is often discussed.
However, currently available SLIT data for prevention of new allergen sensitivities is also
limited. The above referenced Marogna et al.1678 study did note that the rate of new
sensitizations was low, corresponding to 3.1% of SLIT-treated patients and to 34.8% of
controls, with an OR of 16.85 to develop new sensitizations in controls. Another study by
Marogna et al.1680 prospectively evaluated the long-term effect of SLIT given for 3, 4, or 5
years in 78 SLIT patients vs 12 controls. Over a 15-year follow-up, all the control subjects
developed new allergen sensitivities, while this occurred in less than 25% of the patients
receiving SLIT (21% in treated for 3 years, 12%, in treated for 4 years, and 11% in treated
for 5 years, respectively).
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Cost-effectiveness.: The meta-analysis comparing the efficacy and cost-savings of the 5grass SLIT tablet vs the Timothy grass SLIT tablet has several flaws, as some trials were
reported in several publications and thus these publications should be analyzed as one. More
importantly, the outcome variables and the precise definition of the pollen season vary
between the Timothy grass SLIT tablet and the 5-grass SLIT tablet trials, so direct
comparison of outcomes should not be done, as was reviewed in detail previously.1681,1682
The 5-grass SLIT tablet ($1003 Canadian dollar) was associated with cost savings against
year-round SCIT (+$2471), seasonal SCIT (+$948), and the Timothy grass SLIT tablet (+
$1168) during the first year of therapy and still during the second and third year of
treatment. The higher costs for SCIT were due to the elevated indirect costs from missing
working hours and transportation costs due to in-office SCIT administration. The higher
costs for the Timothy grass SLIT tablet were due to the year-round dosing vs the
preseasonal/co-seasonal 6-month total dosing of 5-grass SLIT tablet.
A UK meta-analysis of costs showed that SCIT and SLIT may be cost-effective compared
with standard pharmacotherapy for 6 years (when considering a threshold of pound
20,000-30,000 per quality-adjusted life-year [QALY]). The investigators were not able to
establish a clear difference between SCIT and SLIT in cost-effectiveness.1617
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Additional data from double-blind placebo-controlled trials.: Some of the most
important recent trials with data that add to the already presented systematic reviews are
listed here:
•

High-dose tree pollen aqueous SLIT was effective in reducing symptommedication scores in children in a high-quality double-blind placebo-controlled
trial.1683
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•

Double-blind, placebo-controlled trials with ragweed SLIT reduced the
combined symptom-medication score when administered as drops1684,1685 and
as tablets, particularly at the high dose.1686,1687

•

In a small, double-blind, placebo-controlled trial of moderate-high quality,
Alternaria SLIT for AR (and asthma) was shown to be effective in significantly
reducing the AR combined symptom-medication score.1688

•

As for the SLIT HDM tablets, a dose-effect for a reduction in AR symptomsmedication scores has been shown in 3 double-blind, placebo-controlled trials.
1064,1689 One trial demonstrated a significant difference and a symptom score
reduction of 29% only in those patients with more moderate-severe disease.799

•

Moderate evidence for efficacy of dual grass pollen-HDM SLIT after 12 months
of treatment and 1 year after discontinuation.1690

•

Multi-allergen SLIT has been tested in a single-center, double-blind, placebocontrolled trial with Timothy grass monotherapy, Timothy grass plus 9 other
pollen allergens, or placebo. Only the Timothy grass monotherapy group showed
statistically significant improvement in the nasal challenge test, titrated SPT,
sIgE (reduction), and IgG4 (increase). Due to a very low pollen season, there
were no differences in symptom-medication scores between any of the groups.
1691 Additional study on multi-allergen SLIT is needed.

Aggregate grade of evidence and recommendations.: In Table IX.D.4-2 the grade of
evidence is shown and how this leads to recommendations in the decision-making
concerning SLIT.
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•

Aggregate Grade of Evidence: A (Level 1a: 10 studies; Level 1b: 3 studies; Level
2a: 11 studies; Level 3a: 1 study; Table IX.D.4-1).

•

Benefit: SLIT improved patient symptom scores, even as add-on treatment on top
of rescue medication. SLIT reduced medication use. The effect of SLIT lasts for
at least 2 years after a 3-year course of high-dose therapy. Benefit is generally
higher than with single-drug pharmacotherapy; however, it is possibly somewhat
less than with SCIT. Although a very recent high-quality head-to-head trial did
not show a statistically significant difference in efficacy between SCIT and SLIT,
this evidence is not presented here, as the publication date is outside the review
period for this manuscript.797

•

Harm: Minimal harm with very frequent, but mild, local adverse events. Very
rare systemic adverse events. SLIT seems to be safer than SCIT.

•

Cost: Intermediate, SLIT becomes cost-effective compared to pharmacotherapy
after several years of administration. Data on cost of SLIT compared to SCIT is
variable.

•

Benefits-Harm Assessment: Benefit of treatment over placebo is small, but
tangible. SLIT benefit is demonstrated beyond the improvement seen with rescue
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medications. Lasting effect at least 2 years off treatment. Minimal harm with
SLIT, greater risk for SCIT.
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•

Value Judgments: SLIT improved patient symptoms with low risk for adverse
events.

•

Policy Level:

•

∘ Use of SLIT: grass pollen tablet, ragweed tablet, HDM tablet, tree pollen
aqueous solution - Strong recommendation.

•

∘ Alternaria SLIT - Recommendation.

•

∘ Epithelia SLIT - Option.

•

∘ Dual SLIT in biallergic patients - Recommendation.

•

Intervention: We recommend high-dose tablet or aqueous SLIT be administered
in patients (adults and children) with SAR and/or PAR who wish to reduce their
symptoms and their medication use. SLIT can be continued safely in the
pregnant patient.
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IX.D.5. Transcutaneous/epicutaneous immunotherapy—Transcutaneous or
epicutaneous immunotherapy is a noninvasive form of AIT that consists of the application of
allergens to the skin. The epidermis is rich in APCs while being less vascularized potentially
reducing the risk for systemic reaction.1707,1708 To improve delivery of antigens through the
stratum corneum to the immune cells of the epidermis and dermis, different techniques have
been used: scarification or scratching of the skin, tape stripping, microneedle arrays, and
sweat accumulation through the application of a patch.1709 Epicutaneous immunotherapy
has recently been investigated in a mouse model using nanoparticles containing an allergen
encoding DNA.1710 Records of allergen administration via the skin date back to 1926, where
29 patients with hay fever received intradermal pollen extract administrations; all benefited
after only 3 doses without significant side effects.1711 The first RCT was in 2009. To date, 4
clinical trials using this procedure have been published (Table IX.D.5)
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In a single-center, placebo-controlled, double-blind trial, 37 adults with positive SPT and
nasal challenge to grass pollen were randomized to treatment with allergen (n = 21) or
placebo patches (n = 16).1712 Treatment was started 1 month before the 2006 pollen season.
The skin was tape-stripped 6 times; patches were applied weekly for 12 weeks, and removed
48 hours later. Patients were assessed before, at the beginning of, and after the 2006 pollen
season, and followed up before (n = 26) and after (n = 30) the pollen season of 2007. The
primary outcome was nasal provocation test with grass extract; secondary outcomes
included a rhinitis questionnaire, medication use, and adverse events. In grass
immunotherapy-treated patients, nasal challenge test scores significantly decreased in the
first (p < 0.001) and second year (p = 0.003). In placebo-treated patients, scores decreased
after year 1 (p = 0.03), but the effect diminished in year 2 (p = 0.53). However, the
improvement of nasal provocation test scores was not significantly better in the treatment vs
placebo groups. Patients in the treatment arm had improvement in subjective symptom
scores, both after the pollen seasons of 2006 (p = 0.02) and 2007 (p = 0.005). Eczema at the
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application site was significantly higher in the treatment arm, and there were no serious
adverse events.
A second single-center, double-blind RCT treated 15 children with grass transcutaneous
immunotherapy and 15 children with placebo.1713 The adhesive patch was placed weekly
from February to April 2008, and removed after 24 hours. There were no significant
differences in prick tests between groups before and after treatment. Both groups had an
increase in symptoms, but the treatment group had lower rhinorrhea, nasal obstruction,
dyspnea, and ocular tearing. The treatment group had a significant reduction in antihistamine
use (p = 0.019). There were no systemic or local reactions.
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A third single-center, double-blind, placebo-controlled trial, published by the same authors
enrolled 132 adults with grass pollen allergic rhinoconjunctivitis.1714 Patients received
placebo, low-dose, medium-dose, and high-dose grass extract treatment (n = 33 in each
arm). Weekly for 6 weeks, starting 1 month prior to the initiation of the 2008 pollen season,
patches were applied with subsequent removal after 8 hours. SPT and conjunctival
provocation tests were done at baseline, and after the pollen seasons of 2008 and 2009.
Ninety-three of 132 patients were included in the efficacy analysis. The primary endpoint
was subjective rhinoconjunctivitis symptoms using a VAS. Five months after application of
the first patch, all treatment and placebo groups improved. One year later, only the high-dose
treatment group had improved compared to control (p = 0.017); symptoms were reduced by
more than 30% (2008 pollen season) and 24% (2009 pollen season) compared with placebo.
There were no differences in rescue medication use, SPTs, or CPTs. Local reactions were
more frequent with higher doses and improved with subsequent applications. Systemic
reactions leading to discontinuation of treatment occurred in 11 patients (8.3%) within 45
minutes of patch application; reactions were milder (grade 1 to 2) and did not require
treatment with epinephrine.
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A fourth single-center, double-blind, placebo-controlled trial, published by the same authors
enrolled 98 adults with grass allergic rhinoconjunctivitis; 48 received grass patches and 50
received placebo.1715 Treatment consisted of 6 weekly patches kept on for 8 hours. After
treatment in the year 2009, median rhinitis symptoms improved by 48% in the treatment
group vs 10% in the placebo group (p = 0.003); a year later, this was 40% compared to 18%
for placebo (p = 0.43). There was no change in combined symptom and medication scores.
CPT scores improved after the first year in the treatment group but not the placebo group. In
the first year, allergen-specific IgG4 increased in the treatment group, while allergen-specific
IgE decreased in the placebo group; there was no difference in both measures compared to
baseline in the second year. Eight systemic reactions led to study exclusion. The authors
concluded that this treatment strategy may have a potential role in treating IgE-mediated
allergies, but further research was needed to find an optimal regimen that balances efficacy
and safety.
•

Aggregate Grade of Evidence: B (Level 1b: 4 studies; Table IX.D.5).

•

Benefit: Transcutaneous immunotherapy resulted in limited and variable
improvement in symptoms, medication use, and allergen provocation tests in
patients with AR or conjunctivitis.
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•

Harm: Transcutaneous immunotherapy resulted in systemic and local reactions.
Systemic reactions occurred in up to 14.6% of patients receiving grass
transcutaneous immunotherapy.

•

Cost: Unknown.

•

Benefits-Harm Assessment: There is limited and inconsistent data on benefit of
the treatment, while there is a concerning rate of adverse effects. Three out of 4
studies on this topic were published by the same investigators from 2009 to
2015.

•

Value Judgments: Transcutaneous immunotherapy could offer a potential
alternative to SCIT and SLIT, but further research is needed.

•

Policy Level: Recommend against.

•

Intervention: While transcutaneous immunotherapy may potentially have a future
clinical application in the treatment of AR, at this juncture there are limited
studies that show variable and limited effectiveness, and a significant rate of
adverse reactions. Given the above and the availability of alternative treatments,
transcutaneous immunotherapy is not recommended presently.

IX.D.6. Intralymphatic immunotherapy (ILIT)—Intralymphatic immunotherapy
(ILIT) is a novel method for AIT, where allergen is injected directly into lymph nodes.1716
The major advantages of this route of allergen application are the markedly reduced duration
of immunotherapy treatment (both time spent and number of visits) and the much lower
amount of allergen required to achieve results. This lower dose of allergen also confers a
lower risk of adverse allergic side effects.
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Clinical trials have illustrated that a reduction in AR symptoms can be achieved with just 3
doses of injected allergen, with a dosage interval of 1 month1716-1720 (Table IX.D.6). This
contrasts with subcutaneous application, where up to 70 doses may be needed over a 5-year
period. ILIT involves the injection of allergen directly into inguinal lymph nodes under
ultrasound guidance.
Five of the clinical trials published to date have compared ILIT with placebo. In 2008, Senti
et al.1716 compared ILIT to SCIT and not to placebo. All trials have used aluminum
hydroxide-adsorbed antigen as the vaccine. Most trials1716,1718-1721 used commercially
available grass pollen or birch pollen allergen extract as the antigen. One trial1717 used
recombinant major cat dander allergen fused to a translocation sequence and to part of the
human invariant chain generating a modular antigen transporter, or “MAT,” vaccine.
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The general protocol for administration was 3 injections with 1000 standardized quality
units (SQ-U) of aluminum hydroxide-adsorbed allergen at 4-week intervals. Variations to
this included a shorter dose interval in 1 trial1721 and no translation of allergen quantities
into SQ-U in the trial using recombinant major cat dander allergen.1717
Of the 6 trials published thus far, 5 have demonstrated clinical efficacy and safety.1716-1720
In total, 127 patients have received active treatment and 45 patients have received placebo.

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Wise et al.

Page 139

Author Manuscript

Witten et al.1721 demonstrated immunological changes with ILIT, but no improvement in
symptoms. Of note, the dose interval in this trial was shorter than in the trials that
demonstrated clinical efficacy, with allergen administered at 2-week intervals instead of 4week intervals.
The greatest variation between the trials to date is in the selection of clinical endpoints and
the measurement of clinical outcomes, as illustrated in Table IX.D.6. All trials have used
subjective measures to define clinical endpoints, most commonly in the form of symptom
questionnaires.

Author Manuscript

Given the reduction in treatment duration, allergen dose, financial burden relative to SCIT,
and the low risk of adverse effects, ILIT is a promising new therapy for AR. Before ILIT is
integrated into clinical practice, a well-designed pharmacoeconomic evaluation of ILIT vs
SCIT and larger RCTs are needed, as well as further studies investigating the impact of
treatment protocol on outcomes.

Author Manuscript

•

Aggregate Grade of Evidence: B (Level 1b: 5 studies; Level 2b: 1 study; Level 4:
1 study; Table IX.D.6).

•

Benefit: Reduced treatment period, reduced number of injections, reduced dose
of allergen injected, decreased risk of adverse events.

•

Harm: Risk of anaphylaxis.

•

Cost: ILIT might be associated with reduced costs relative to SCIT (reduced
time, reduced financial burden for patients and healthcare provider). Application
requires training.

•

Benefits-Harm Assessment: Balance of benefit over harm for ILIT relative to
SCIT.

•

Value Judgments: ILIT appears to be efficacious in the treatment of AR.
Preliminary data indicates that, relative to SCIT, the burden of treatment on the
patient and on the healthcare system is lower.

•

Policy Level: Option, pending additional studies.

•

Intervention: While the research is promising, further studies are needed before
ILIT can be translated into routine clinical practice.

Author Manuscript

IX.D.7. Alternative forms of immunotherapy—Oral, nasal, and inhaled
(intrabronchial) AIT represent alternate options for the treatment of AR, with primarily
historical significance.1623 While alternative forms of AIT have been evaluated in an effort
to avoid the local discomfort and resource utilization associated with SCIT, the adoption of
SLIT has largely replaced these methods.1623
Non-injectable, alternative immunotherapies involve the topical absorption of allergen
extracts via oral/gastrointestinal, nasal, or inhalational exposures. SLIT, intralymphatic, and
epicutaneous routes are reviewed separately in this document. Double-blind, placebocontrolled studies have evaluated oral/gastrointestinal immunotherapy for the treatment of

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Wise et al.

Page 140

Author Manuscript

birch,1723 cat,1724 and ragweed1725 sensitivity, without a significant decline in nasal
symptoms, improvements in provocation testing, or reductions in medication utilization.
Additionally, oral/gastrointestinal allergen administration requires extract concentrations
approaching 200 times greater than SCIT, and is associated with adverse gastrointestinal
side effects.1623,1724 However, the efficacy of oral/gastrointestinal immunotherapy has been
demonstrated for the treatment of food hypersensitivity, where this approach remains
investigational.1726

Author Manuscript

Oral mucosal immunotherapy (OMIT) is an alternative form of AIT that is distinctly
different from SLIT and oral/gastrointestinal strategies. OMIT utilizes a glycerin based
toothpaste vehicle to introduce antigen to high-density antigen processing oral Langerhans
cells in the oral vestibular and buccal mucosa.1727 Theoretical benefits include induction of
immune tolerance with lower antigen concentrations, decreased local side effects and higher
adherence vs SLIT.1728 A recently completed pilot study of OMIT vs SLIT identified
clinically meaningful improvements in disease-specific QOL measures with a significant
rise in specific IgG4 over the first 6 months of treatment.1729 No adverse events were
reported, and there were no significant differences between outcome measures for both
treatment arms.1729 Additional study is needed to define the role of OMIT in the treatment
of AR.

Author Manuscript

Local nasal immunotherapy has been established as an effective approach for the treatment
of pollen and HDM sensitivity.1730 However, high rates of local adverse reactions limit
patient compliance, with 1 prior study finding that 43.9% of treated children abandoned this
treatment option within the first year of therapy.1731 High-quality studies of inhaled/
intrabronchial immunotherapy for the treatment of AR have not yet been completed, with
current studies limited to the treatment of allergic asthma.1732 In light of these findings,
including poor compliance and limited efficacy, oral/gastrointestinal, nasal, and inhaled
immunotherapies have limited utility in the current treatment of AR, while OMIT represents
an emerging alternative to SCIT and SLIT.
IX.D.8. Combination omalizumab and SCIT—In consideration of combination
therapy with concurrent biological omalizumab and AIT, each intervention targets different
mechanisms in the allergic cascade. AIT desensitizes the body’s response to a specific
antigen, with alteration of the Th1/Th2 balance and induction of T-cell anergy.1623
Omalizumab indiscriminately targets the humoral effector of allergic inflammation, with use
of a humanized monoclonal antibody to block unbound IgE.1623 While both modalities have
independently demonstrated efficacy as treatment options, improved strategies are needed,
especially in patients with multiple sensitizations.1733

Author Manuscript

Two benefits of combination therapy have been described: decreased incidence of AITassociated systemic allergic reactions and improved control of AR symptoms.
1400-1402,1734-1736 Anaphylaxis is a persistent concern with AIT, with incidence of reported
systemic reactions as high as 65% following rush protocols.1737,1738 Omalizumab
pretreatment has therefore been evaluated as a strategy to improve AIT tolerance, with
positive findings. Two multicenter, randomized, placebo-controlled studies have evaluated
the incidence of AIT-induced systemic allergic reactions following pretreatment with
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omalizumab1402,1736 (Table IX.D.8VIII.E.4.a-1VIII.E.4.a-2). Massanari et al.1736 evaluated
248 patients with moderate persistent asthma receiving omalizumab pretreatment or placebo
prior to cluster AIT, an accelerated AIT buildup schedule. A significantly lower incidence of
systemic and respiratory-related reactions was reported among the omalizumab group, with
an improved likelihood of reaching maintenance therapy compared to the group without
preventive treatment with this biological. Casale et al.1402 evaluated 123 adult patients with
ragweed-induced AR receiving omalizumab prior to 1-day rush AIT, finding a 5-fold
decreased risk of systemic allergic reactions with omalizumab pretreatment (OR, 0.17).
Further outcomes included significant improvement in daily symptom scores among patients
receiving combination therapy (continued omalizumab + AIT) vs AIT alone. Additional
study of AIT for the treatment of food1739 or insect venom1740,1741 hypersensitivity has also
demonstrated improved safety with omalizumab pretreatment.

Author Manuscript
Author Manuscript

The efficacy of combination therapy for the treatment of AR has been further evaluated by
several iterative analyses of a single RCT.1400,1401,1735 Kuehr et al.1400 evaluated 221
adolescents (6 to 17 years) with moderate to severe AR and sensitization to birch and grass
pollen. Using a randomized, controlled design, the effectiveness of combination therapy was
evaluated during sequential birch and grass pollen seasons, with comparison of AIT +/−
concurrent omalizumab. Significant findings included superiority of combination therapies
vs AIT alone, with 48% reduction in symptom load (sum of mean daily symptom severity
score plus mean daily rescue medication use) during an entire pollen season and 80%
reduction in median rescue medication score. Two additional studies report unique findings
generated by this trial.1401,1735 Rolinck-Werninghaus et al.1401 completed a subgroup
analysis of study patients receiving specific AIT +/− concurrent omalizumab during the
matched grass season. Results included decreased symptoms scores and rescue medication
usage for patients receiving combination vs either therapy alone. Kopp et al.1735 evaluated a
subgroup of 92 children, with findings of decreased leukotriene (LTC4, LTD4, and LTE4)
release among patients receiving combination therapies following in vitro antigen
stimulation of collected blood cells. An unrelated study by Klunker et al.1734 provides
further evidence for the efficacy of combination therapy, with in vitro demonstration of
inhibition of allergen-specific IgE binding for 42 weeks after discontinuation of combination
therapy (vs 30 weeks with omalizumab alone).
While a prior study has estimated the cost of omalizumab (1,253 EUR/patient/month) and
AIT therapies (425 EUR/patient/year), evaluation of economic and productivity outcomes
has not been completed for patients undergoing combination therapy.1401 Finally,
omalizumab has been associated with anaphylactic reactions in 0.09% to 0.2% of patients,
with current recommendations to monitor patients for 30 minutes following administration.

Author Manuscript

1742,1743

•

Aggregate Grade of Evidence: B (Level 1b: 4 studies, plus 2 additional iterative
analyses of a parent study; Table IX.D.8).

•

Benefit: Improved safety of accelerated cluster and rush AIT protocols, with
decreased symptom and rescue medication scores among a carefully selected
population.
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X.

•

Harm: Financial cost and risk of anaphylactic reactions.

•

Cost: Moderate to high.

•

Benefits-Harm Assessment: Preponderance of benefit over harm.

•

Value Judgments: Combination therapy increases the safety of AIT, with
decreased systemic reactions following cluster and rush protocols. Associated
treatment costs and likelihood of systemic reactions must be considered, with
greater consideration for omalizumab pretreatment prior to higher-risk AIT
protocols. While 2 high-quality RCTs have demonstrated improved symptom
control with combination therapy over AIT or omalizumab alone, not all patients
will require this approach. Rather, an individualized approach to patient
management must be considered, with evaluation of alternative causes for
persistent symptoms, such as unidentified allergen sensitivity. The current
evidence does not support the utilization of combination therapy for all patients
failing to benefit from AIT alone.

•

Policy Level: Option, based on current evidence. However, it is important to note
that omalizumab is not currently approved by the FDA for the treatment of AR.

•

Intervention: Omalizumab may be offered as a premedication prior to induction
of cluster or rush AIT protocols. Combination therapy is an option for a carefully
selected patient with persistent symptomatic AR following AIT. An
individualized approach to patient management must be considered. In addition,
as omalizumab is not currently approved by the FDA for AR treatment, in the
United States this treatment approach would likely not be performed in routine
clinical practice presently.

Associated conditions
Several medical conditions have been associated with AR, with varying prevalence
dependent upon the specific comorbidity. In contrast, certain conditions are often associated
with allergy or AR by conjecture, yet the available literature fails to identify a close
association. This section examines various medical conditions that have a potential
association with AR, specifically examining the evidence that supports or refutes the
association

X.A.

Asthma

Author Manuscript

X.A.1. Asthma definition—Asthma is a heterogeneous and complex disease, perhaps
better characterized as a syndrome with overlapping phenotypes. The definition of asthma
has evolved over the past several decades, combining clinical symptoms, examination
findings, and functional parameters. When analyzing current international or national asthma
guidelines,1744-1747 all include respiratory symptoms such as cough, shortness of breath,
wheezing or chest tightness, and the presence of a variable expiratory airflow limitation that
needs to be documented from bronchodilator reversibility testing or bronchial
hyperreactivity tests (eg, methacholine test or other tests such as inhaled histamine,
mannitol, exercise, or eucapnic hyperventilation). All guidelines also include the statement
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that symptoms and airflow limitation characteristically vary over time and in intensity and
may resolve spontaneously or in response to medication. Discussion of chronic airway
inflammation is included in all guideline documents. This has been characterized by several
important cellular elements including mast cells, eosinophils, T-cells, macrophages, and
neutrophils, but none of the guidelines require demonstration of inflammation by invasive or
noninvasive methods. The Global Initiative of Asthma guidelines1744 specify that asthma is
usually associated with bronchial hyperresponsiveness but highlight that demonstration of
airway hyperresponsiveness and inflammation are not necessary or sufficient to make the
diagnosis. Asthma is also classified by severity (ie, mild, moderate, severe) and by
persistence (ie, intermittent vs persistent); however, the specific definitions of these
categories vary dependent upon the specific guideline. Since asthma is defined as a
heterogeneous disease, or rather as a syndrome, there appear to exist significant and variable
etiologies that may manifest in similar phenotypes. Consequently, in the last decade, the
definition of asthma has sought to include recognizable clusters of clinical and/or
pathophysiological characteristics to more accurately characterize endotypes that exist.

Author Manuscript

1748,1749

X.A.2. Asthma association with allergic and non-allergic rhinitis—Most
patients with asthma (both allergic and non-allergic) also have rhinitis, whereas 10% to 40%
of patients with AR have comorbid asthma.101,1167 Asthma and allergy may have similar
underlying pathogenesis and immunologic mechanisms. IgE-mediated inflammation can
involve both the upper and lower airways, suggesting an integration of the involved areas of
the airway. This pattern of similarities gave rise to the concept of the unified airway model,
which considers the entire respiratory system to represent a functional unit that consists of
the nose, paranasal sinuses, larynx, trachea, and distal lung.1750

Author Manuscript

Some, but not all, studies suggest that asthma is more common in patients with moderate-tosevere persistent rhinitis than in those with mild rhinitis.25,1751-1753 Other large studies
found a link between the severity and/or control of both diseases in children and adults.
1754-1758 Adults and children with asthma and documented concomitant AR experience
more asthma-related hospitalizations and doctors’ visits and also incur higher asthma drug
costs than adults with asthma alone1759-1764 (Table X.A.2). Concerning changes in
prevalence of rhinitis and asthma, some studies have demonstrated a parallel increasing
prevalence of asthma and rhinitis,1765,1766 whereas others have not.1767-1775 It appears that
in regions of highest prevalence, the proportion of subjects suffering from asthma or rhinitis
may be reaching a plateau.

Author Manuscript

Rhinitis and asthma are closely associated and thus AR should be evaluated in asthmatic
patients, and likewise, the possibility of a diagnosis of asthma should be evaluated in
patients with AR.
•
X.A.3.

Aggregate Grade of Evidence: C (Level 3b: 7 studies; Table X.A.2).

Allergic rhinitis as a risk factor for asthma
AR and NAR are risk factors for developing asthma. This has been demonstrated in several
large epidemiological studies (Table X.A.3). The Children’s Respiratory Study597 showed
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that physician-diagnosed AR during infancy is independently associated with a doubling of
the risk of developing asthma at age 11 years. In children and adults, AR is a risk factor for
asthma according to a 23-year follow-up of college students.1776 These studies were
confirmed by other studies.458,1764,1777-1786 Some of these studies showed that rhinitis is a
significant risk factor for adult-onset asthma in both atopic and nonatopic subjects.
1779,1780,1783 Therefore, rhinitis is a risk factor independent of allergy for developing asthma
in both adults1779,1780,1783 and children.597 In adulthood, the development of asthma in
patients with rhinitis is often independent of allergy, whereas in childhood, it is frequently
associated with allergy,597,1785 as almost all asthma in children is allergic.

Author Manuscript

Asthma and AR also share common risk factors. Sensitization to allergens is probably the
most important. Most inhaled allergens are associated with nasal1787 and bronchial
symptoms, but in epidemiologic studies, differences have been observed (eg, in pollen
allergy). Some genetic polymorphisms are different in the case of AR and asthma. Other risk
factors for asthma such as gender, obesity, viral infections in infancy, exposure to tobacco
smoke (passive smoking or active smoking), diet, or stress are not found as common risk
factors for AR. Outdoor or indoor air pollution is still a matter of debate as risk factor for
AR or NAR.101 In summary, AR and NAR are risk factors for developing asthma.
•

X.A.4.

Aggregate Grade of Evidence: C (Level 2a: 2 studies; Level 3b: 11 studies; Table
X.A.3).

Treatment of allergic rhinitis and its effect on asthma

Author Manuscript

The 2015 AR clinical practice guideline from the AAO-HNS has highlighted the overlap of
AR and asthma, specifically recommending that clinicians should assess for and document
associated medical comorbid conditions including asthma.761 The guidelines also review
and consider the impact of comorbid asthma on treatment decisions for AR, though the
action statements may not apply to AR with comorbid asthma. However, there is a body of
evidence to suggest that AR therapies, including INCS,1296,1788-1790 oral antihistamines,
1791,1792 LTRAs,7,1793,1794 and AIT1672,1788,1795,1796 may benefit both conditions. Some of
the most promising results in altering the course of allergic inflammation common to AR
and asthma have been seen with AIT.1678,1797,1798 Given this increased understanding of the
relationship between AR and asthma as similar inflammatory processes affecting the upper
and lower airways, respectively, the importance of understanding the overlap of AR
treatment with the treatment of asthma is increasingly evident. The studies reviewed in this
section are limited to prospective randomized trials to minimize inherent biases and
weaknesses of retrospective studies.1794

Author Manuscript

Allergen avoidance.
Allergen avoidance is often advocated for allergy treatment, specifically for AR and allergic
asthma.7 Despite the intuitive acceptance of this and reasonable biological plausibility, the
evidence for benefit of avoidance and environmental control measures in AR with associated
asthma is limited. A Cochrane review examining randomized trials of subjects with asthma
who underwent chemical or physical methods to reduce HDM allergen found no benefit with
these methods.1799 Single allergen avoidance or elimination plans such as removing or
washing pets, mattress coverings, removing carpeting, and use of HEPA filters have shown
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limited evidence-based clinical benefit for reducing asthma and/or AR symptoms.
101,1799,1800 However, there is theoretical benefit of reducing allergen exposure, a paucity of
data on multimodality approaches to reduce allergen load, and minimal negatives to
attempting these various techniques; therefore, allergen avoidance could be considered as
part of a multifactorial approach in the management of asthma associated with comorbid
AR.1801,1802 (See section IX.A. Management – Allergen avoidance for additional
information on this topic.)

Author Manuscript
Author Manuscript

Pharmacotherapy: oral H1 antihistamines.—We identified 6 RCTs which specifically
evaluated oral H1 antihistamines for the treatment of asthma in the context of coexistent AR
(Table X.A.4-1). There are many oral H1 antihistamine medications, but cetirizine and
loratadine are the 2 most highly studied second-generation antihistamines used
concomitantly in AR and asthma. There is biologic plausibility for a role of antihistamines
in the treatment of allergic asthma, as elevated histamine levels after allergen challenge are
associated with bronchoconstriction responses in acute asthma episodes. Cetirizine also has
bronchodilatory effects which are significant both as monotherapy as well as in combination
with albuterol.1803 Despite improvement in asthma symptoms, objective measures using
pulmonary function testing and peak expiratory flow have failed to demonstrate significant
improvements.1804-1806 Alternatively, there is growing evidence that antihistamines may
have a preventive effect on the development of asthma in atopic patients, as shown in the
Early Treatment of the Atopic Child trial.1807 Briefly, atopic infants were treated with 18
months of cetirizine and followed for the development of asthma. While analysis of the
entire group found no significant difference between cetirizine-treated and placebo-treated
patients, subgroup analysis revealed approximately 50% reduced risk of developing asthma
among certizine-treated patients with grass pollen and HDM sensitivities. The authors
hypothesize that variation in key genes related to histamine regulation may explain these
differences.1807,1808 (See section IX.B.1.a. Management – Pharmacotherapy –
Antihistamines – Oral H1 antihistamines for additional information on this topic.)

Author Manuscript

Pharmacotherapy: oral corticosteroids.—Oral corticosteroids are an effective
component of the asthma treatment algorithm, particularly for cases which are inadequately
controlled with bronchodilators and inhaled corticosteroids.1809 They are also effective for
symptoms of rhinitis.1247 However, oral corticosteroids have significant side effects,
especially with increasing duration of use.7 Because of the side effect profile associated with
these medications, they are not recommended for the routine treatment of AR, and
utilization is only recommended for select cases after thorough discussion of the associated
risks and benefits. (See section IX.B.2.a. Management - Pharmacotherapy - Corticosteroids Oral corticosteroids for additional information on this topic.)
Pharmacotherapy: intranasal corticosteroids.—In the 1980s, topical INCSs were
reported to improve asthma symptoms in patients with coexistent AR and asthma.1364,1810
Since then, it has been shown that very little intranasally administered corticosteroid reaches
the lung (approximately 2%), suggesting this effect on the lower airway may be related to its
intranasal effects.1788,1811 We have identified 2 meta-analyses and 12 RCTs that address this
potential “unified airway” effect of INCS on asthma (Table X.A.4-2). A 2003 Cochrane
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review evaluated the efficacy of INCS on asthma outcomes in patients with coexistent
rhinitis, finding no significant improvement in asthma outcomes with the use of INCS.1295
Heterogeneity in study designs may have limited the findings of this meta-analysis and
explain the discrepancy of the results compared to high-quality RCTs. Alternatively, a 2013
systematic review and meta-analysis of the efficacy of INCS for asthmatics with
concomitant AR demonstrated improvements in asthma outcomes with the use of INCS
compared to placebo, but a lack of further improvement with INCS as an addition to inhaled
corticosteroids.1296 Interestingly, patients with concomitant AR and asthma who received
training on the proper use of INCS and education on the relationship of AR and asthma
demonstrated significant reductions in asthma symptoms and albuterol use compared to
patients receiving INCS without additional education.1812 This demonstrates the importance
of patient instruction for both therapy evaluation and future trial design. (See section
IX.B.2.a. Management – Pharmacotherapy – Corticosteroids – Intranasal corticosteroids
(INCSs) for additional information on this topic.)

Author Manuscript

Pharmacotherapy: leukotriene receptor antagonists.—LTRAs (montelukast and
zafirlukast) have demonstrated benefit for the treatment of both asthma and AR, consistent
with efficacy in addressing inflammation in the “unified airway”1813 (Table X.A.4-3). In
2008, the ARIA group reviewed the evidence for effectiveness of montelukast in treating
patients with asthma and AR, finding improvement of both nasal and bronchial symptoms as
well as reduction of β-agonist use.101 In fact, the LTRAs are the only class of medications
specifically described in the 2008 AR management guide for primary care physicians, and in
the full ARIA report, as effective for both asthma and AR.101,1814 The 2010 ARIA update
further supports the recommendation of LTRAs for both AR and asthma, but specifies that
LTRAs are not recommended over other first-line therapies for the respective conditions (ie,
it is better to treat asthma and AR with both a nasal and inhaled steroid, than try to treat both
with an LTRA). A more recent review in 2015 also identified some utility of LTRAs for
patients with concomitant AR and asthma.1802 Despite this evidence, the limited additional
benefit and added cost leads to a strong recommendation (based on moderate quality
evidence) for inhaled glucocorticoids over LTRAs for single-modality treatment of asthma
in patients with comorbid AR.1167 Based on the summarized RCTs, an evidence-based
recommendation is made for LTRAs not to be used as monotherapy for AR, but LTRAs may
be considered as part of the treatment of comorbid asthma and AR (See section IX.B.4.
Management – Pharmacotherapy – Leukotriene receptor antagonists (LTRAs) for additional
information on this topic) (Table X.A.4-3).
Pharmacotherapy recommendations for the treatment of AR with coexisting asthma.

Author Manuscript

•

Aggregate Grade of Evidence: A (Level 1a: 2 studies; Level 1b: 23 studies).
Antihistamines (Level 1b: 6 studies; Table X.A.4-1). INCS (Level 1a: 2 studies;
Level 1b: 12 studies; Table X.A.4-2). LTRAs (Level 1b: 5 studies; Table
X.A.4-3).

•

Benefit: Pharmacotherapy improves subjective and objective severity of asthma
in patients with coexistent AR. Patient education and training on medication use
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improves compliance and benefits for INCS, and likely all patient-administered
pharmacotherapy.

Author Manuscript

•

Harm: Pharmacotherapy other than systemic steroids—minimal harm with rare
mild adverse events such as drowsiness. No serious adverse events reported in
the studies reviewed. Systemic corticosteroids have significant side effects.

•

Cost: Generally low cost for pharmacotherapy.

•

Benefits-Harm Assessment: There is a benefit over placebo for asthma treatment,
though no significant benefit is seen over standard asthma pharmacotherapy.
Risks of routine use of systemic corticosteroids generally outweighs the benefits,
though short courses for acute indications (eg, asthma exacerbation) have a
favorable likelihood of benefit relative to harm.

•

Value Judgments: Pharmacotherapy for AR may also benefit asthma symptoms
and objective parameters of pulmonary function in patients with coexisting
asthma and AR, however, the benefit for asthma should be considered a positive
side effect rather than an indication for use as there appears to be limited benefit
compared to standard asthma therapy.

•

Policy Level: Use of pharmacotherapy other than systemic steroids:
Recommended use for optimal control of AR, with potential additional benefit
for coexistent asthma, though not recommended for primary intent of asthma
treatment. Use of systemic corticosteroid: Not recommended for routine use in
AR with comorbid asthma due to unfavorable risk-benefit profile, though certain
situations may indicate a short course (eg, acute asthma exacerbation).

Author Manuscript
Author Manuscript

Biologics: omalizumab.—Omalizumab is an anti-IgE mAb that binds free IgE,
preventing interactions with high-affinity IgE receptors and resulting in receptor downregulation on inflammatory cells.1815 Omalizumab has demonstrated effectiveness
separately for asthma as well as AR.1393,1815-1818 Despite a number of studies evaluating
omalizumab in AR or asthma,1815,1819 there is only 1 double-blind RCT which specifically
evaluates the efficacy of omalizumab in patients with concomitant moderate-to-severe
asthma and persistent AR.1820 Additionally, another study evaluates omalizumab as an
adjunct to SCIT,1403 with both studies showing a reduction in symptoms as well as an
improvement in QOL measures (Table X.A.4-4). The 2010 ARIA update makes a
conditional recommendation of using a mAb against IgE, such as omalizumab for treatment
of asthma in patients with both AR and asthma, where there is a clear IgE-dependent allergic
component and failure of other maximal therapy.1167 Additional biologics, including antiIL5, anti-IL4, and IL-4 receptor mAbs, are currently in varying stages of development/
emergence with positive findings for the treatment of asthma and other atopic diseases.
Additional evaluation is needed to further evaluate their role for the treatment of coexistent
AR and asthma. (See section IX.B.7. Management – Pharmacotherapy – Biologics for
additional information on this topic.)
Biologics recommendations for the treatment of AR with coexisting asthma.
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•

Aggregate Grade of Evidence: B (Level 1b: 2 studies; Table X.A.4-4). Grade A
evidence with multiple 1b RCTs and 1a reviews exist for asthma and AR
individually, but only 1 double-blind RCT specifically evaluating omalizumab vs
placebo in patients with concurrent conditions.

•

Benefit: Decreased asthma exacerbations, decreased symptom scores, and
improvement in disease-specific QOL in patients with coexisting asthma and
AR.

•

Harm: There is evidence for acceptable safety for use up to 52 weeks.1821
Potential longer-term harm unknown. Minor events such as mild injection site
reactions are reported. Possibility of anaphylaxis.

•

Cost: Substantially higher cost than conventional therapy for asthma and AR.

•

Benefits-Harm Assessment: Benefits appear to outweigh potential harm for the
treatment of more severe/persistent coexistent AR and asthma.

•

Value Judgments: Added benefit of omalizumab as therapy for patients with AR
and asthma that is uncontrolled despite maximal conventional interventions.
However, given the significant increased cost associated with omalizumab, the
value of this therapy is likely greatest for patients with severe asthma and
symptoms that persist despite usual therapies.

•

Policy Level: Omalizumab is recommended for those patients with clear IgEmediated allergic asthma with coexistent AR who fail conventional therapy. The
significant additional cost of this therapy should be considered in evaluating its
value.

Author Manuscript
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Allergen immunotherapy.—Both SCIT and SLIT have been shown to improve the
control of comorbid AR conditions, such as asthma1618,1788,1822 (Table X.A.4-5). AIT also
appears to prevent the development of asthma.1678,1797,1798 The efficacy of SLIT for AR has
been confirmed by several systematic reviews.1694,1695,1823 Both SCIT and SLIT have been
shown to be efficacious for AR, though there is ongoing debate as to whether 1 form is
superior.1697,1703 AIT is also thought to help halt the progression of allergic disease,
including prevention of new allergic sensitivities and the development of asthma.
1624,1626,1678,1797,1798,1824-1826 AIT also appears to have long-lasting effects even after
discontinuing treatment, unlike pharmacotherapy. Such promising results have led to a 2010
ARIA update statement recommending both SCIT and SLIT for the treatment of asthma in
patients with AR and asthma.1167 Recent systematic reviews demonstrate that SCIT and
SLIT reduce both asthma and rhinitis symptoms, as well as medication use.1694,1822 These
evidence-based reviews also demonstrate strong evidence for the utility of SCIT and SLIT in
the treatment of asthma alone in studies that did not specifically address the condition of
combined asthma and AR.1694,1822 Evidence for AIT (SCIT and SLIT) for asthma in context
of comorbid asthma and AR, is reviewed in Table X.A.4-5. (See section IX.D. Management
– Allergen immunotherapy (AIT) for additional information on this topic.)
Allergen immunotherapy recommendations for the treatment of AR with coexisting asthma.
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•

Aggregate Grade of Evidence: A (Level 1a: 2 studies; Level 1b: 4 studies; Level
2b: 1 study; Table X.A.4-5).

•

Benefit: AIT (both SCIT and SLIT) has demonstrated benefit in concomitant AR
and asthma, with decreased symptoms, rescue medication use, and bronchial
hyperresponsiveness, as well as reduced development of asthma in patients with
AR only.

•

Harm: Local site reactions are common and there is potential for anaphylactic
events with any form of AIT.

•

Cost: Increased cost compared to standard therapy for AR and asthma, though
the potential to treat the underlying disease process and prevent progression of
disease could reduce long-term costs.

•

Benefits-Harm Assessment: Significant evidence to support the use of AIT for
patients with AR and asthma, as well as the potential utility of AIT for
preventing progression of allergic disease from AR to the development of
allergic asthma. Harms are generally limited to minor local reactions, though
there is a potential risk of anaphylaxis. Benefits appear to outweigh potential
harm, given that anaphylaxis is rare.

•

Value Judgments: There appears to be unique value in AIT, as this therapy treats
the underlying pathology of AR and asthma, with potential to halt the
progression of allergic disease. The unique benefits of this therapy are of value,
despite some uncertainty of their true magnitude.

•

Policy Level: AIT (SCIT and SLIT) is recommended for treatment of AR with
asthma in patients following an appropriate trial of medical therapy, and may
also be considered for the benefit of preventing progression of AR to asthma in
patients with AR only, and for whom AIT is otherwise indicated.

Rhinosinusitis

Author Manuscript

AR may be associated with rhinosinusitis in several clinical settings. In general, AR is
regarded as a disease-modifying factor for rhinosinusitis.1 Rhinosinusitis may be broadly
divided into ARS, RARS, CRSwNP, or CRSsNP. The association between each of these
forms of rhinosinusitis with AR will be discussed individually below. Of note, many of these
studies used SPT or in vitro testing for confirmation of allergic disease. While positive
testing does indicate evidence of sensitization, this does not necessarily correlate with
allergic nasal disease.1843 Given the paucity of literature exclusively discussing AR and
rhinosinusitis (vs allergy and rhinosinusitis), this literature will be included.
AR is thought to be a potential risk factor for the development of rhinosinusitis in general.
Exposure to allergens in allergic patients has been associated with increased eosinophilia in
the maxillary sinus.1844,1845 In addition, the majority of ragweed allergic patients (60%)
display abnormal opacification of CT scans of the paranasal sinuses in peak allergic seasons.
1846 These CT findings persist despite symptom resolution outside the allergic season.1846
These studies do not always delineate whether ARS, RARS, or CRS is the form of
rhinosinusitis associated with AR.
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Allergic rhinitis and acute rhinosinusitis—In addition to these more general studies,
evidence exists to support the concept of an increased risk of ARS with AR. There is a
significantly higher incidence of ARS in both children and adult patients with a history of
AR.1847,1848 Children with AR are also more likely to experience orbital complications of
ARS compared to those without AR, especially in pollinating seasons.1849 A mouse model
has also shown that ongoing nasal allergy is associated with worsened episodes of ARS.
1850,1851 Available data supports an association between AR and ARS. However, AR is
thought to be a disease-modifying or risk-modifying factor rather than a causative one.
There are no studies examining the effects of treating AR on the risk of developing an
episode of ARS. For example, it is unclear whether treating AR decreases the incidence of
ARS. Future study may help clarify the interaction between AR and ARS (Table X.B-1).
•

Author Manuscript

Aggregate Grade of Evidence: C (Level 2a: 2 studies; Level 2b: 1 study; Level
3a: 1 study; Level 3b: 1 study; Table X.B-1).

Author Manuscript

Allergic rhinitis and recurrent acute rhinosinusitis—The potential link between AR
and RARS is an extension of the link between AR and ARS. The increase in sinonasal
inflammation associated with AR is proposed to increase mucosal edema, sinus ostium
obstruction, and the retention of sinus secretions.1 This environment may support secondary
bacterial overgrowth and subsequent ARS or RARS.1 Two studies have specifically
examined the association between RARS and AR, with a focus on potentially altered innate
immunity. The results of these 2 studies are conflicting. One study suggests there is a
decrease in the antimicrobial properties of sinonasal secretions in patients with RARS and
AR compared to AR only patients as well as control patients.1852 The second study
identified an upregulation in toll-like receptor 9 expression, suggesting increased resistance
to bacterial infection rather than susceptibility.1853 Further study is required to define the
association between AR and RARS (Table X.B-2).
•

Aggregate Grade of Evidence: D (Level 2b: 2 studies; conflicting evidence;
Table X.B-2).

Author Manuscript

Allergic rhinitis and chronic rhinosinusitis without nasal polyposis—CRS is a
condition of the sinonasal cavity characterized by persistent inflammation. The cause of the
inflammation varies from patient to patient. As AR is a cause of sinonasal inflammation,
many have suspected there may be an association with the pathogenesis of CRS. However,
there are no controlled studies examining the role of AR in the development of CRSsNP.
Additionally, there are no studies showing that the treatment or control of allergic disease
alters the progression of CRSsNP, or vice versa.1 Given the varied pathophysiology of
CRSsNP, it is challenging to determine the association between allergy and CRSsNP. Wilson
et al.1854 performed a systematic review of allergy and CRS, excluding studies that did not
differentiate between CRSsNP and CRSwNP. Their review found 4 studies that supported an
association between allergy and CRSsNP and 5 that did not.1854 Because the relationship
remains unclear, allergy testing is listed as an option in CRSsNP patients based on the
theoretical benefit of identifying and treating comorbid allergic disease1,1854 (Table X.B-3).
•

Aggregate Grade of Evidence: D (Level 1b: 1 study; Level 3a: 1 study; Level 3b:
8 studies; conflicting evidence; Table X.B-3). Adapted from Wilson et al.1854
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Allergic rhinitis and chronic rhinosinusitis with nasal polyposis—The
pathogenesis of CRSwNP is strongly associated with Th2-mediated inflammation.1
Additionally, nasal polyps in CRSwNP have high levels of tissue eosinophilia, as well as
mast cells and basophils.1 AR follows a similar inflammatory pathway and this suggests
there may be a pathophysiologic similarity between CRSwNP and AR. Wilson et al.1854
examined the association between allergic disease and CRSwNP. Again, the evidence was
conflicting. Ten studies supported an association while 7 did not. One study had equivocal
findings.1854 Since this review, Li et al.1855 examined the association between atopy and
CRSwNP and concluded that there was no correlation between atopic status and disease
severity. They did note that atopy-positive patients were younger than atopy-negative
patients.1855 Despite some overlapping pathophysiologic features between allergic disease
and CRSwNP, conflicting evidence exists and there is no clear association between AR and
CRSwNP. Allergy testing is once again an option in CRSwNP patients based on the
theoretical benefit of identifying and treating comorbid allergic disease1,1854 (Table X.B-4).

Author Manuscript

•

Aggregate Grade of Evidence: D (Level 2b: 1 study; Level 3a: 1 study; Level 3b:
15 studies; Level 4: 4 studies; conflicting evidence; Table X.B-4). Adapted from
Wilson et al.1854

Author Manuscript

In summary, AR has a moderate level of evidence supporting an association with ARS
(Level C). Regarding RARS, CRSsNP and CRSwNP, the preponderance of evidence does
not support an association, though the evidence is highly conflicting. The available literature
is also limited as it often assumes patients who test positive on allergy testing have nasal
allergic disease and may not differentiate between systemic allergy and nasal allergy. Further
study is needed to determine the association between AR and rhinosinusitis, as well as the
impact treating 1 process has on the progression of the other. However, the diagnosis and
treatment of comorbid allergic disease is an option in rhinosinusitis patients balancing the
cost and low evidence with the low risk of allergic rhinosinusitis treatment and the
theoretical benefits of reducing allergic sinonasal inflammation.1
X.C.

Conjunctivitis

Author Manuscript

Although the burden of illness (impaired QOL) associated with allergic conjunctivitis (AC)
is well established, this condition is often under recognized and consequently undertreated
except when it is most severe.1882 Its frequent association with AR contributes to the
substantial burden associated with AR. Although this association is well recognized
clinically, its extent remains poorly defined due to methodologic differences and deficiencies
of the studies which have examined this association in the literature. Further compounding
this problem is the phenotypic diversity of both AR and AC, and the observation that very
few studies have adequately characterized the phenotypes of their study populations.
Additionally, many epidemiologic studies are limited by being based solely on questionnaire
results rather than on objective clinical evidence of allergic sensitization.
The largest data source regarding the AR-AC association derives from the ISAAC study, a
worldwide study established in 1991 with the aim of investigating the epidemiology and
etiology of asthma, rhinitis, and atopic dermatitis in each country, using standard
methodology including questionnaire and SPT. ISAAC has reported the prevalence of AC
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symptoms in 257,800 children aged 6 to 7 years in 91 centers in 38 countries and 463,801
children aged 13 to 14 years in 155 centers in 56 countries. Although the ISAAC survey was
not validated for the diagnosis of AC, ISAAC studies support the frequent association of AR
with itchy-watery eyes, reporting that ocular symptoms affect approximately 33% to 50% of
children with AR1883 (Table X.C).
The best evidence of disease-association derives from studies of AR patients assessed for the
prevalence of AC as a comorbidity.1884-1890 The evidence suggests that AR is associated
with 35% to 74% prevalence of AC and that among patients with AC, the prevalence of AR
may be as high as 97%.

Author Manuscript

To summarize, there is a substantial body of evidence which supports AC as a frequently
occurring comorbidity of AR, particularly in children. Not only is this disease-association
common, but ocular allergy symptoms also contribute significantly to the QOL impairment
associated with AR. It is not surprising, therefore, that ocular symptoms of allergic
rhinoconjunctivitis are among the most common symptoms which cause patients to seek
allergy treatment.1891 It is advisable, when assessing patients with AR, to also assess for
ocular symptoms and to consider treatment specific to providing relief of AC.
•

X.D.

Aggregate Grade of Evidence: C (Level 2b: 2 studies; Level 3a: 2 studies; Level
3b: 3 studies; Table X.C).

Atopic dermatitis (AD)

Author Manuscript

AD is a chronic and/or relapsing skin disorder characterized by pruritus, scratching, and
eczematous lesions.1892 Its burden of illness, impact on QOL, and complications are
substantial.1893 AD commonly presents as the first manifestation of atopy in infants and
children who later develop AR and/or asthma, a pattern that has been referred to as “the
atopic march.”1894
Although the association between AR and AD has long been clinically recognized, the
extent of this association remains poorly defined due to methodologic differences and
limitations of the studies that have examined this association537,556,636,1895-1912 (Table
X.D). Further compounding this problem is the phenotypic diversity of both AR and AD,
and the observation that very few studies have adequately characterized the phenotypes of
their study populations. Additionally, many epidemiologic studies are limited by being based
purely on questionnaire results rather than objective evidence of allergic sensitization, such
as SPT or in vitro testing.

Author Manuscript

The largest data source regarding AR-AD association comes from the ISAAC study,
investigating the epidemiology and etiology of asthma, rhinitis, and AD using standard
methodology including questionnaires, SPT, and flexural dermatitis examination.1895
ISAAC reported the prevalence of AD symptoms in 256,410 children aged 6 to 7 years in 90
centers from 37 countries, and 458,623 children aged 13 to 14 years in 153 centers from 56
countries. These studies indicate that AD is a major public health problem worldwide,
affecting approximately 5% to 20% of children aged 6 to 7 and 13 to 14 years.1896 While
longitudinal studies demonstrate improvement or resolution of AD with age,1897 increasing
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severity of AD has been shown to correlate with an increased risk of developing AR, with
prevalence of AR among people with AD ranging from 15% to 61%.1898-1900
The best evidence of disease association derives from studies which compare the incidence
and/or prevalence of AR in populations with and without AD. In this regard, the limited
evidence available suggests that AD is associated with a 2-fold increase in AR among
people with AD compared with the normal population.1901 In this study, among those
children with present or past AD, 60.8% reported AR compared to 31% in subjects without
AD.
•

X.E.

Aggregate Grade of Evidence: C (Level 2b: 4 studies;, Level 3b: 15 studies;
Level 4: 1 study; Table X.D).

Food allergy and pollen-food allergy syndrome (PFAS)

Author Manuscript
Author Manuscript

Approximately 5% to 8% of patients with pollen allergy will develop food allergy and
pollen-food allergy syndrome (PFAS).1916 Patients with pollen allergies may have allergyrelated manifestations after consuming specific fruits, vegetables, nuts, or spices. The
prevalence of pollen-food allergies varies with the type of pollen. As many as 70% of
patients with birch allergy will manifest a food-related sensitivity.1917 PFAS is an IgEmediated reactivity, which occurs in the oral mucosa, leading to itching, stinging pain,
angioedema, and rarely systemic symptoms. The term, “oral allergy syndrome” (OAS), has
also been frequently used and refers to a pollen-food allergy that occurs only at the level of
the oral mucosa. OAS is, therefore, a specific manifestation of the broader PFAS. The
symptoms of OAS manifest because of IgE specific for the offending pollen cross-reacting
with highly homologous proteins found in a variety of fruits, vegetables, and nuts. The most
common example of this cross-reactivity in western populations is birch pollen and apples.
Table X.E-1 lists common pollen allergens with plant-derived foods that may demonstrate
cross-reactivity. These pollen-food relationships have been observed clinically and are also
demonstrated at a molecular level through identification of the homologous amino acids,
cross-reactive carbohydrate determinants, and lipid transfer proteins. The birch-apple
syndrome is due to the high homology of the major birch allergen Bet v 1 and the apple
allergen Mal d 1.1918

Author Manuscript

The diagnosis of PFAS is typically established by a detailed history and physical exam. The
history should be guided by an understanding of the patient’s underlying pollen allergy and
foods that share highly homologous proteins. The clinician should elicit a detailed history of
the allergic response including any systemic symptoms and history of anaphylaxis. The
estimated rate of systemic reaction from a pollen-food allergy is 10% and the estimated rate
of anaphylaxis is 1.7% to 10%.1742,1919,1920 Systemic symptoms are the manifestation of an
allergic response by organ systems that have not come into direct contact with the ingested
food and include: urticaria, nasal congestion, sneezing, flushing, wheezing, cough, diarrhea,
and hypotension. The gold standard for establishing a diagnosis of PFAS is a double-blind
food challenge. However, this is difficult to perform because of the bias inherent to the
appearance, texture, and taste of foods.1921 Oral food challenge, SPT, and food-specific IgE
levels have also been used to establish the diagnosis. The diagnostic approach should be
guided by the patient’s history and severity of allergic response.
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The standard recommendation for the treatment of PFAS has been elimination of the
offending food. Patients should be counseled on the risk for systemic and anaphylactic
reactions. Patients with a history of systemic or anaphylactic reactions should be provided
with an epinephrine autoinjector. The proteins responsible for PFAS are often labile and may
be denatured by heat. The denatured proteins are typically not cross-reactive with the pollen
IgE. Therefore, pollen-associated foods may become edible when heated. In 1 study, food
challenges were performed with cooked apple, carrot, or celery in patients with atopic
dermatitis and birch pollen allergy who had OAS and dermatologic symptoms upon
ingestion of the raw foods. Cooked versions of the offending foods did not cause oral allergy
symptoms.1922 However, some patients did manifest a late eczematous skin reaction, which
was likely T-cell–mediated (Table X.E-2).

Author Manuscript

There is also 1 RCT in a group of 30 patients evaluating the use of an antihistamine to
reduce PFAS symptoms, which demonstrated a clinically significant reduction in allergy
symptoms compared to placebo when ingesting offending foods.1923 The antihistamine used
in this study, astemizole, has been removed from the market due to QT interval prolongation
on electrocardiogram.

Author Manuscript

There have been several studies evaluating the effect of targeted immunotherapy for pollen
allergy at reducing PFAS symptoms. The results are mixed. Several small cohort studies and
RCTs have shown an increased tolerance to the offending food when patients are treated
with pollen specific immunotherapy.1916,1924-1926 However, 1 RCT failed to demonstrate
any improved tolerance to apple in birch allergic patients treated with birch specific
immunotherapy compared to placebo.1921 One study evaluating the persistence of tolerance
for apple after birch immunotherapy demonstrated that some patients had an increased apple
tolerance for up to 30 months after immunotherapy. However, there was no statistically
significant difference between the immunotherapy and control groups.1927 Immunotherapy
is not currently recommended for the sole purpose of treating PFAS. Patients receiving
immunotherapy for the treatment of pollen allergies should be counseled on the potential but
unsubstantiated benefit for improved food tolerance.
•

X.F.

Aggregate Grade of Evidence: B (Level 2b: 8 studies; Level 4: 1 study; Table
X.E-2).

Adenoid hypertrophy

Author Manuscript

In children, adenoid hypertrophy (AH) and AR may exhibit similar symptoms including
nasal obstruction and rhinorrhea. The potential relationship between AR and AH is explored
in this section. Adenoid enlargement most commonly begins during infancy; it continues
through the first 5 to 6 years of life and involutes with puberty.1930,1931 Symptomatic AH
affects an unknown percentage of children and may contribute to a range of symptoms
including nasal obstruction, nasal drainage, sleep disturbance, increased episodes of
rhinosinusitis, increased lower respiratory tract infections, worsened asthma, and Eustachian
tube dysfunction.1930,1932
Case series evaluating the relationship between AH and allergic sensitization fall into 2 main
categories: (1) cohorts of children with allergic conditions assessed for AH; or (2) children
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identified with AH assessed for allergy sensitization. These may not represent the same
populations.

Author Manuscript

Three studies assessing allergic children found a higher rate of AH than controls (when
present). In 2015, 1322 children (mean age 5.9 ± 3.3 years) treated for “allergic conditions”
were compared to 100 age-matched children with no allergic disease for AH. They found
AH was more prevalent in the allergic group (12.4%) than controls (3%) (p < 0.0001). AH
was statistically associated with AR and cigarette smoke exposure (p = 0.004).1933 Similarly,
Dogru et al.1934 found that among 566 children with AR the prevalence of AH was 21.2%
(no control group). Additionally, they reported that children with both AH and AR had a
higher frequency of persistent rhinitis (p < 0.05), moderate/severe rhinitis (p = 0.005), and
nasal congestion (p = 0.001) than those with AR alone. The AR-only group had a higher
prevalence of asthma (p = 0.037) and “itchy nose” (0.017). In another study, adenoid size in
seasonally allergic children was assessed by Modrynski and Zawisza,1935 concluding that
seasonal adenoid enlargement was observed in birch pollen–allergic children more than
controls not allergic during the tree-pollen season. The increased adenoid size resolved after
pollen season in the study group, and the seasonal increase in adenoid size was not observed
in birch-allergic children treated co-seasonally with topical nasal steroid and antihistamines.
The study was small (n = 67 among 4 groups) and did not state whether it was blinded
(Table X.F).

Author Manuscript

Exposure and sensitization to mold and AH has been specifically examined. Atan Sahin et
al.1936 compared 242 children living in a less humid environment to 142 children living on
the more humid Turkish Mediterranean coast. Mite-sensitive children in the coastal group
had an increase in AH (p = 0.01). Those living in the more humid coastal location
demonstrated increased mold and pollen sensitization but no significant correlation with
adenoid hypertrophy was found. In contrast, Huang and Giannoni1937 compared 315
children with AH and AR to age-matched controls with AR-alone. There was a higher
prevalence of positive skin tests to molds in the AH group (p = 0.013 to <0.0001). Dogru et
al.1934 also reported an increased sensitization to Alternaria in children with both AH and
AR compared to AR alone (p = 0.032), although a statistical correction for multiple
variables was not described.

Author Manuscript

In studies where children were recruited by nasal obstruction, the degree of AH sometimes
showed either no relationship or an inverse relationship with the prevalence of allergy
sensitization. Cassano et al.1931 reported that the prevalence of specific inhalant IgE
sensitization decreased as the AH increased: AH first degree (37% sensitized), AH second
degree (35% sensitized), and AH third degree (19% sensitized). Karaca et al.1938 did SPT on
82 children who presented with upper airway obstruction to an otolaryngology clinic and
compared allergy sensitization to radiographic adenoid size and clinically assessed tonsil
size. They concluded that there was not a statistically significant association with adenoid
size (p = 0.195) and a negative correlation with tonsil size (p = 0.045). The methods are
vague on how the correlation was performed with tables showing percentages of “negative”
SPT and the text incongruently stating “all of the cases were positive for at least 1 of the 14
allergens.”1938 Ameli et al.1939 assessed 205 children (mean age 6.7 years) with nasal
endoscopy and SPT and found an association between negative SPT and adenoid volume (p
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< 0.0001). In an exception to the previously noted studies, Sadeghi-Shabestari et al.1940
compared 117 children aged 1 to 14 years with adenotonsillar hypertrophy to 100 controls of
similar age for allergen SPT, total IgE, and smoking parents. They reported 70.3% of the
adenotonsillar hypertrophy group had a positive SPT compared to 10% of the control group
(p = 0.04); however, they included SPTs for foods (highest positive allergen subgroup) and
latex.
In a study that is difficult to categorize by recruitment, 155 children (mean age 8.7 years)
referred from Pediatric Allergy to Otolaryngology were assessed by rigid nasal endoscopy
and SPT. Children on allergy medication were excluded. They observed a negative
correlation between AH and allergen positivity (r = −0.208, p = 0.009).1941

Author Manuscript

Immunologic evidence of allergy in adenoid tissue is limited in the literature. Ni et al.1942
found a higher Th17/Treg ratio in adenoid tissue from children with AR than controls.
Masieri et al.1943 reported Th1 gene expression in non-allergic adenoid tissue, Th1 and Th2
gene expression in adenoid tissue in those with AR treated with antihistamines, and a down
regulation in Th1 and Th2 gene expression in adenoid tissue from children treated with
SLIT. Both studies were small.
Treatment studies are also limited. One retrospective, uncontrolled study (n = 47) reported
improvement in rhinitis symptoms in similar percentages for both AR (86%) and NAR
(76%) after adenoidectomy.1944 The effect of INCS on reducing nasal obstruction in the
setting of AH, independent of allergy, has been demonstrated in systematic reviews,1932,1945
but whether this is due to decrease in adenoid size is less clear and blinded studies are
uncommon. 1946

Author Manuscript

In conclusion, there is a trend among allergic children who are assessed for AH to have
increased prevalence AH compared to non-allergic controls. However, when children are
selected for upper airway obstruction and then assessed for inhalant allergy sensitivity, a
consistently increased prevalence of allergic sensitivity is not found. One potential
explanation for this discrepancy is that symptomatic AH peaks in younger children than
pediatric AR, with the allergic cohorts having a higher average age. This is supported in the
literature by Pagella et al.1947 who retrospectively reviewed records of children referred to
Otolaryngology for nasal symptoms (n = 795). They found an association between allergy
and AH in children aged 8 to 14 years (p = 0.0043), but not for children aged 1 to 7 years (p
= 0.34).
•

Author Manuscript

X.G.

Aggregate Grade of Evidence: C (Level 4: 11 studies; Table X.F).

Otologic conditions Eustachian tube dysfunction
Ear symptoms are commonly experienced by patients with AR. Ear fullness and pressure,
otalgia, popping or other sounds during swallowing, and transient hearing loss can all be
manifestations of Eustachian tube dysfunction. The Eustachian tube opens into the
nasopharynx and is in direct continuity with the upper respiratory tract. Inflammation of the
nasal mucosa may involve the torus tubarius or Eustachian tube mucosa, resulting in
obstruction that leads to negative pressure as middle ear gases are resorbed. Frequent
sniffing or swallowing during nasal obstruction may transmit negative pressure to the middle
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ear space. The frequently observed clinical association of Eustachian tube symptoms and
AR is corroborated by high-level evidence that demonstrates that in AR patients, nasal
challenge with histamine or relevant aeroallergens results in transient Eustachian tube
obstruction.1948-1950 These studies used the 9-step inflation-deflation swallow test of
Eustachian tube function developed by Bluestone and Cantekin.1951 The development of
negative middle ear pressure after allergen challenge corresponds with increases in nasal
airway resistance.1952 AR appears to increase the incidence of Eustachian tube dysfunction
relative to control populations,1953 and natural pollen exposure has been associated with
negative middle ear pressures1954 and defects in Eustachian tube opening.1955 This body of
evidence supports a direct causal role for AR in some cases of Eustachian tube dysfunction
(Table X.G-1).
•

Author Manuscript

Aggregate Grade of Evidence: C (Level 1b: 3 studies; Level 2b: 1 study; Level
3b: 1 study; Level 4: 2 studies; Table X.G-1).

Author Manuscript

Otitis media—The role of allergy as a causative factor in otitis media has not been clearly
demonstrated. Historically, allergy was considered an important etiologic factor in otitis
media. However, as clinical definitions have become more stringent and evidence
expectations have evolved, it has become apparent that a clear etiopathogenic connection
between AR and otitis media is yet to be demonstrated. Investigations into the connection
between these 2 conditions have examined the evidence for type 1 IgE-mediated
inflammation in the middle ear space, epidemiologic associations between the 2 conditions,
and the effect of allergy treatment on otitis outcomes. The middle ear mucosa may behave in
a manner similar to nasal mucosa and be a site of local IgE-mediated inflammatory
reactions.1956-1958 However, direct intranasal allergen challenge in allergic subjects does not
appear to cause otitis media.1948-1950 Studies of the epidemiologic association of AR or
atopy and otitis media with effusion (OME) are widely discordant. Some studies have found
no significant difference in allergic sensitization or clinical allergy in OME patients
compared to control groups,1959,1960 while others have shown a dramatically increased
prevalence of IgE sensitization or clinical allergy in OME patients,1961-1964 or that AR is an
independent risk factor for the development of OME.1965 Finally, some studies suggest a
nearly universal association of OME and allergic disease.1966-1970 These inconsistencies in
the literature are likely related to highly selected patient populations in specialty practices,
variability in allergy test methods, and the problems incumbent in identifying appropriate
control groups. Thus, the relationship of allergy and OME remains unclear (Table X.G-2).

Author Manuscript

In general, randomized placebo-controlled trials have shown that INCS do not improve
OME outcomes.1971-1973 Also, a Cochrane systematic review found no benefit of
antihistamines and/or decongestants in the treatment of OME. Thus, traditional medical
treatments for AR do not appear to be an effective option for OME and recent otitis media
CPGs recommend against the use of these agents.1974 Additional investigation is needed to
discern the effect of allergy on the incidence or natural history of OME and to determine if
AIT has beneficial effects.
•

Aggregate Grade of Evidence: C (Level 2b: 2 studies; Level 3b: 3 studies; Level
4: 11 studies; Table X.G-2).
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Inner ear disease—Meniere’s disease is characterized by recurring episodes of tinnitus,
hearing loss, aural fullness, and vertigo. The basic pathophysiologic defect in Meniere’s
disease appears to be a dysregulation of endolymph in the inner ear (endolymphatic
hydrops).1975 An immunologically-mediated disturbance in fluid handling by the
endolymphatic sac has been postulated as 1 cause for the disease.1976 The notion that
“allergy” of the inner ear is a cause of Meniere’s disease predates our modern understanding
of type 1 IgE-mediated hypersensitivity, and is still evoked as a possible causative or
contributing factor for the disease in some individuals. Indeed, AR has been postulated as a
cause of inner ear dysfunction,1977 and a connection between allergy and inner ear disorders
such as Meniere’s disease is plausible based on compiled circumstantial evidence. Derebery
and colleagues have published studies suggesting that inhalant and food allergies are more
common in Meniere’s patients,1978 and that allergy treatment including AIT results in
improved Meniere’s disease symptoms.1979,1980 However, these studies generally provide
low grade evidence, and aside from 1 small study that also found a higher prevalence of IgEmediated hypersensitivity in Meniere’s patients,1981 these findings have not been duplicated
by others. Case-control studies examining total serum IgE levels have provided conflicting
results.1981,1982 A few small studies have shown changes in objective parameters such as the
electrocochleographic summating potential/action potential (SP/AP) ratio in response to
aeroallergen or food challenge in Meniere’s patients.1983,1984 Overall, the evidence
supporting a connection between type 1 IgE-mediated hypersensitivity and Meniere’s
disease is of low grade, with substantial defects in study design (Table X.G-3).
•

Aggregate Grade of Evidence: C (Level 3b: 4 studies; Level 4: 4 studies; Table
X.G-3).
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X.H. Cough—Cough is a sudden reflex used to clear the breathing passage of any foreign
particles or irritants. There is evidence that vagal afferent nerves regulate an involuntary
cough; yet, there is also cortical control of this overall visceral reflex.1985 Cough is often
considered a comorbidity of AR. The rhinobronchial reflex is 1 of the mechanisms that may
explain the ability of stimuli on the nasal mucosa, such as an allergen, to result in direct
bronchospasm.1986 The role of descending secretions (postnasal drip) from the upper to
lower airways is a second theory. While many practitioners link postnasal drainage to cough,
there is very little evidence to support this. When functioning normally, the vocal folds
protect the lower airways from upper airway secretions and foreign bodies. Third, a direct
mechanism due to diffuse inflammation and activation of eosinophils may be responsible for
the common upper and lower airway manifestations. The American College of Chest
Physicians evidence-based clinical practice guidelines on cough suggest the term upper
airway cough syndrome, rather than postnasal drip syndrome, when discussing a cough
originating from the upper airway due to the varying possible causes.1985
AR and asthma may coexist and may indeed produce a continuum of the same airway
disease.1167 Associations with cough in AR patients can relate to their underlying asthma or
a seasonal asthma during peak pollen season. The Asia Pacific Burden of Respiratory
Diseases study, a 1000-person cross-sectional observational study, revealed that cough was
the primary reason for a visit to the physician for patients with asthma and or COPD.
However, AR patients were more likely to present with classic watery, sneezing, runny nose.
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The study however did find that 33.5% of patients were diagnosed with combinations of
respiratory disease; the most frequent was asthma and AR1987,1988 (Table X.H).
While patients with AR that have concomitant chest symptoms such as cough often do have
asthma, seasonal asthma, and/or a nonspecific bronchial hyperreactivity, many studies show
generalized inflammation of the upper airways extending to the lower airways. There is a
complex interplay between cells and inflammatory cytokines and hence one should consider
the upper and lower airways as a single unique functional unit.1986 The key pathogenic
mechanism is the inflammation of the upper airways with extension to the lower airways and
the induction of a systemic dysregulation via a complex interaction between cells and
inflammatory cytokines.1986
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Many patients with AR and cough do not have the diagnostic airflow obstruction or the
reversibility of forced expiratory volume in 1 second (FEV1) following bronchodilator
administration to make a diagnosis of asthma.1167 Krzych-Falta et al.1989 performed a nasal
challenge in 30 patients with AR. Extranasal symptoms were noted, including a cough and
breathlessness, especially in those with PAR. In 2000, Chakir et al.1990 performed
histochemical tests on bronchial biopsies of patients with AR but without current or history
of asthma. They demonstrated increased numbers of lymphocytes, eosinophil recruitment
and IL-5 expression in the bronchial mucosa after exposure with natural pollen.1990 This
2000 study followed a prior investigation of deposition of type I and III collagens and
fibronectin by bronchial myofibroblasts in AR patients.1991 This is suggestive of an active
structural remodeling of the lower airways in AR patients that is similar to asthma patients
but less severe. In addition, Buday et al.1992 demonstrated that guinea pigs sensitized to
HDM had a significantly enhanced cough response compared to those that were not
sensitized; however, airway resistances did not change. This study is relevant to humans,
since the neurophysiology of the vagus nerve in the guinea pig is thought to be closest to
humans. These studies demonstrate that AR, unrelated to asthma, can indeed result in
bronchial inflammation, possible lower airway remodeling and ultimately a symptom of
cough.
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A large-scale cross-sectional, multinational observational study set out to determine the
symptom of cough as it relates to respiratory diseases in the Asia-Pacific region. With over
5250 patients enrolled, the study found that 47% of patients with AR frequently reported
cough as a symptom; however, only 11% of these patients had cough as the main reason for
seeking medical care.1993 The numbers were 61% and 33%, respectively, for patients with
asthma and cough. In a prospective study with 2713 AR patients, He et al.1994 found the
occurrence of comorbidities, including cough, to gradually increase from mild intermittent,
to mild persistent, to moderate-severe intermittent, and moderate-severe persistent AR.
There is low level evidence that associates AR with cough or, more commonly, cough as a
comorbidity of AR.1990-1992 The severity of AR may affect its manifestation toward upper
airway cough syndrome.1994 AR is often a comorbidity with asthma which also has an
increased correlation with cough. The exact pathways and mechanisms by which the unified
airway functions continue to unfold.
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X.I.

Aggregate Grade of Evidence: C (Level 2b: 2 studies; Level 3b: 2 studies; Level
4: 4 studies; Level 5: 1 study; Table X.H).

Laryngeal disease
AR has been implicated as a cause of laryngeal disease. However, further understanding of
its precise role has been limited. While previous research has provided anecdotal evidence of
a relationship between the 2, establishing a causal relationship between AR and laryngeal
dysfunction had proven difficult due to a lack of safe and effective models for studying the
larynx.1995 Findings of laryngeal inflammation have largely been attributed to
laryngopharyngeal reflux (LPR), but various etiologies may contribute to laryngeal
dysfunction.
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Vocal dysfunction can have a significant psychosocial impact on patients, including those
with AR. Several studies have reported higher Voice Handicap Index (VHI) scores in
patients with AR compared to control subjects.1996-1999 Dysphonia is particularly disturbing
for professional voice users. Singers with self-perceived voice issues were 15% more likely
to have AR than singers without vocal complaints.2000 The likelihood of AR increased as the
number of vocal symptoms increased.2000 When comparing patients with AR and NAR to
control patients, Turley et al.2001 found that dysphonia was more prevalent in patients with
asthma. A prior study had similar overall findings in patients with AR while controlling for
asthma.2002 Studies have reported the adverse effects of AR on voice-related QOL, and
Turley et al.2001 validated this by showing that patients who reported poor rhinitis-related
QOL on questionnaires also had poor voice-related QOL and more severe chronic laryngeal
symptoms.1996,1998 The greater the degree of allergen load, the greater severity of vocal
symptoms.1999 Overall, patients with vocal dysfunction have a higher than anticipated
incidence of AR and vice versa1999,2001,2002 (Table X.I).
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Allergic laryngitis can be difficult to distinguish from other laryngeal inflammatory
disorders, including LPR, due to the limitations of current diagnostic methods, which overall
have poor specificity and interrater reliability. In a study of patients presenting with voice
complaints, Randhawa et al.2003 noted that two-thirds of patients were diagnosed with
allergies whereas only one-third were diagnosed with LPR. However, allergy testing may be
positive in up to 46% of the general population.2004 Laryngeal findings in AR and LPR can
be indistinguishable and include laryngeal edema, excessive mucus, vocal fold erythema,
and arytenoid erythema.1995,2005 A study by Eren et al.2005 supported this diagnostic
challenge in demonstrating no significant difference in the appearance of the larynx between
allergy-positive and LPR-positive subjects; however, thick endolaryngeal mucus has been
shown to be a predictor of allergy. Belafsky et al.2006 and Mouadeb et al.2007 examined the
effects of Dermatophagoides on the laryngeal mucosa of guinea pigs and found an increase
in eosinophilia compared to those exposed to saline, which provides some support for
etiologies other than reflux contributing to laryngeal disease. In contrast, Krouse et al.1998
were unable to demonstrate a difference in acoustic and speech aerodynamic testing or
videostroboscopic evaluation between allergic patients compared to control subjects.
Despite anecdotal evidence implicating the role of allergic laryngitis in laryngeal
dysfunction, there have been limited studies demonstrating a direct causal relationship
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between the 2. Three studies with similar design evaluated the symptoms and laryngeal
appearance and function in patients with proven allergies exposed to direct laryngeal
stimulationship by the nebulized allergen D. pteronyssinus.2008-2010 Initially, Reidy et al.
2009 were unable to find any significant difference between antigen-challenged and placebochallenged subjects on any of the evaluated measures, including VHI, Sinus Symptoms
Questionnaire, laryngoscopic findings, and acoustic and speech aerodynamic testing. In a
subsequent study, Dworkin et al.2010 increased the concentration of allergen in the antigenic
suspension and noted an increase in endolaryngeal mucus in addition to coughing and throat
clearing. The study was terminated prematurely due to adverse pulmonary reactions
attributed to the higher antigen concentration, and it is possible that the lower airway
reactivity contributed to the visualized endolaryngeal mucus.2010 Roth et al.2008 then
performed a study using similar methods but isolated the larynx by utilizing a nose clip to
ensure oral inhalation and by eliminating patients with reactive airways based on
methacholine challenge testing. They demonstrate an apparent causal relationship between
allergen stimulation and impaired vocal function.2008
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There is mounting evidence suggesting a relationship between AR and laryngeal
dysfunction. There have not been consistently reported laryngeal findings specific to allergic
laryngitis, though thick endolaryngeal mucous should raise suspicion for allergy as a cause.
Although its exact role in the pathophysiology of laryngitis has yet to be fully elucidated,
AR should be considered in the differential diagnosis of patients with vocal complaints as it
may have implications on treatment of laryngeal disease.
•
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X.J.

Aggregate Grade of Evidence: C (Level 2b: 8 studies; Level 3a: 1 study; Level
3b: 4 studies; Level 4: 5 studies; Table X.I).

Eosinophilic esophagitis (EoE)
Eosinophilic esophagitis is an allergic inflammatory condition of the esophagus with
infiltration of eosinophils. Symptoms include dysphagia, heartburn, and vomiting. Several
studies have examined the prevalence of clinician-diagnosed AR and aeroallergen
sensitization in patients with eosinophilic esophagitis (EoE) (Table X.J). Among both
pediatric and adult patients with EoE, it has consistently been found that 50% to 75% have
AR.2013-2020 Although many of these studies were case series, the consistency of the
findings strongly suggests that most patients with EoE have comorbid AR.
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The evidence for an association between environmental allergies and EoE pathogenesis is
less clear. A few case series, among both children and adults, have observed seasonal peaks
of EoE diagnosis in the spring and summer.2021-2023 One of these studies found that EoE
diagnosis was correlated with grass pollen counts.2021 Another showed that esophageal
eosinophilia on biopsies was least intense in the winter.2023 There is 1 reported case of a
pediatric EoE patient whose symptoms flared seasonally, in whom biopsies revealed
moderate to severe esophageal eosinophilia during pollen seasons with no or mild
inflammation in winter months, with no change in diet.2024 Another case report described
resolution of esophageal eosinophilia in a pediatric patient with EoE and dust mite
sensitization after a course of high-dose dust mite immunotherapy.2025 Therefore, there is
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very limited observational data suggesting a potential association between aeroallergens and
EoE pathogenesis, but more study is needed.
•

X.K.

Aggregate Grade of Evidence: C (Level 3a: 1 study; Level 4: 12 studies; Table
X.J).

Sleep disturbance and obstructive sleep apnea (OSA)
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Nasal congestion is reported by as many as 90% of AR patients.2026 Nocturnal nasal
congestion can significantly affect sleep quality. Nasal obstruction due to AR has been well
established as a cause of sleep disruption.707,714,2026 One population-based survey study of
children with AR identified sleep disturbance due to AR as a significant factor affecting
health-related QOL.2027 Diminished sleep quality resulting from AR has been shown to
negatively impact work performance and productivity.2028 Another population-based study
found that patients with AR were more likely to report suffering from insomnia, snoring and
sleep apnea than control groups.727 The severity of AR symptoms was also shown to affect
the duration of sleep, frequency of daytime somnolence, and sleep latency. The influence of
AR on sleep is multifactorial. Upper airway resistance, biochemical and hormonal effects,
and pharmacologic interventions all play a role in altering sleep. A large population-based
survey of AR patients demonstrated a strong correlation between AR disease severity and
sleep disturbance.679 The study showed that increasing severity of AR symptoms caused
worse sleep quality.
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When establishing a diagnosis of AR, the impact of allergy symptoms on sleep should be
assessed by detailed history. There are several different instruments, which have been used
to assess the impact of AR on sleep. These include: the ESS, Stanford Sleepiness Score,
Jenkins Questionnaire, Pittsburgh Sleep Quality Index, University of Pennsylvania
Functional Outcomes of Sleep, Sleep scale from the Medical Outcome Study, Sleep
Disorders Questionnaire, The Pediatric Sleep Questionnaire, and The Pediatric Daytime
Sleepiness Scale. These metrics may be useful in establishing baseline symptoms and
monitoring a response to treatment.
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There have been several studies that have investigated the relationship between AR and
sleep-disordered breathing (SDB) (Table X.K). SDB refers to a spectrum of conditions
including primary snoring, upper airway resistance syndrome, and obstructive sleep apnea.
In a population-based analysis, Young et al.714 found that moderate-to-severe SDB were 1.8
times more frequent in participants with nasal congestion due to allergy. In a small case
series of patients with SAR who underwent repeat PSG, patients with symptomatic AR had
an average 1.7 occurrences of obstructive apnea per hour of sleep that decreased to 0.7 per
hour when patients were symptom free.718 A 2011 case-control study assessing differences
in polysomnography between persistent AR sufferers and healthy controls found no
statistically significant difference in apnea-hypopnea index (AHI) between the 2 groups.720
There were modest differences in sleep efficiency, arousal index, and snoring time.
A standard approach to the treatment of AR should help to decrease or alleviate the
symptoms that adversely impact sleep. Medications that act to treat nasal congestion are
typically effective at improving sleep quality. INCS have been shown to improve nasal
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congestion, daytime somnolence, and sleep quality.2029 INCS are also thought to improve
sleep quality by reducing proinflammatory cytokines, which have been shown to negatively
impact sleep.2030 There have been 5 RCTs assessing the efficacy of INCSs on nasal
congestion and sleep.673,706,707,1275,1276 The results of all 5 studies demonstrated an
improvement in sleep quality and sleep-related QOL metrics. A meta-analysis by Weiner et
al.1297 found that INCSs were more effective than oral antihistamines at treating nasal
blockage, although there was no significant differences between treatments on nasal
resistance.
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The pharmacologic interventions used in the treatment of AR may also have consequences
on sleep. The first-generation H1 antagonists are known to cause sedation due to the
capability of crossing the blood-brain barrier and acting as a depressant on the central
nervous system leading to drowsiness.2031 While this may be a desirable side effect at
bedtime, it is an undesirable consequence for daytime symptom management. The secondgeneration H1 antagonists have less propensity for crossing the blood-brain barrier and are
therefore less sedating. Fexofenadine and loratadine are reported as the least sedating oral
antihistamine treatment options.2032,2033 Patients should be counseled regarding the
potential for sedation when taking oral H1 antihistamines. There has been 1 RCT study
looking at pseudoephedrine (taken in the morning) and the impact on sleep quality, daytime
somnolence, and fatigue. The study found no significant negative or positive impact on all
measures compared to placebo.2030 There was a statistically significant beneficial effect on
nasal congestion.
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The impact of AR on sleep should be assessed by history, sleep and QOL questionnaires,
and careful physical examination. A standard treatment algorithm for symptomatic
management of AR should be effective at improving the symptoms which adversely affect
sleep. INCSs are the most effective pharmacologic therapy for alleviating nasal congestion.
Patients treated with oral antihistamines should be mindful of the potential for sedation.
•

XI.

Aggregate Grade of Evidence: B (Level 1b: 5 studies; Level 2b: 1 study; Level
2c: 5 studies; Level 3b: 7 studies; Level 4: 2 studies; Table X.K).

Knowledge gaps and research opportunities
The existing literature related to AR is quite deep in certain areas but notably lacking in
others (Table XI). We continue to see more and more citations related to AR every year, yet
the process undertaken to produce this ICAR:AR document has identified some important
knowledge gaps. The sections below highlight the need for future research related to specific
aspects of AR.
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XI.A.

Epidemiology and risk factors
Studies have previously been undertaken to determine the prevalence of AR in various parts
of the world. While the data from these studies is often quoted, it is limited by its
methodology relating primarily to surveys (sometimes complemented by allergen sensitivity
testing). Our world is better connected by technology today than it had been previously. We
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should leverage these capabilities to better understand the epidemiology of AR. Research
opportunities include:
•

Improved understanding of the incidence and prevalence of AR and its
phenotypes (ie, SAR, PAR, IAR, PER) worldwide.

•

Improved understanding of AR variation by geographic region, patient age, and
sex.

•

Evaluation of climate change and its effect on the pattern and degree of allergen
exposure.

Author Manuscript

Our understanding of the risk factors for the development of AR should also be improved.
While certain areas (ie, early childhood exposure to pets as a risk factor vs protective factor)
have seen numerous articles published, the data is highly conflicting. In other areas, such as
early exposure to pollens and mites, the data is more limited. Genetic studies provide some
notable evidence for potential AR risk but functional data needs to be expanded. Research
opportunities include:
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XI.B.

•

Understanding the role of candidate gene alterations in the pathophysiology of
AR via functional characterization.

•

Investigation of epigenetic mechanisms to provide a functional explanation
between gene-environment interactions and AR disease development.

•

Improved understanding of environmental exposures as a risk/protective factor
for AR disease development, especially in diverse geographic locations.

•

Further study of the role of pollutants and tobacco smoke in the development of
AR and in the severity of allergic rhinitis symptoms.

•

Greater elucidation of the environmental risk factors and protective factors for
AR, particularly exposure to pets, HDM, and breastfeeding.

•

Longitudinal study evaluating risk factor reduction and its effect on the incidence
of AR.

Evaluation and diagnosis
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Evaluation of the patient with suspected AR classically relies on a thorough history, often
reinforced by findings on physical examination. The diagnosis is further supported with skin
or in vitro testing methods. These techniques have been rather dependable, provided
objective testing is correlated to the patient’s clinical symptoms and not used in isolation to
determine a treatment plan, as there are distinct differences between sensitization and
clinical allergy. As newer testing methods gain their footing, we have the opportunity to
bring them to widespread clinical practice with solid supporting evidence. Research
opportunities include:
•

Improved characterization of newer testing techniques (ie, nasal sIgE, BAT) in
larger populations to provide standardization for incorporation into mainstream
clinical practice.

•

Need for comparative studies for IDT and single-dilution intradermal testing.
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Page 165

•

Further study of the role of single intradermal testing after a negative prick test.

•

Development of standardized testing and interpretation of testing for LAR, as
well as further defining the clinical utility of testing.

•

Further elucidation of clinical uses for CRD in patient management.

•

Need for international consensus on allergen units in antigen standardization.

Management
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There are several options for management of the AR patient. Allergen avoidance and EC
strategies are often discussed, yet high-level evidence is frequently lacking, especially as it
relates to AR symptom control. Many pharmacotherapy options have very high LOEs, which
is helpful as we strive to choose the best drug options to control patient symptoms. SCIT and
SLIT also have very high LOEs in general, yet specific issues related to AIT management
could be bolstered with additional evidence. Research opportunities include:
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XI.D.

•

Improved understanding of the impact of EC strategies on AR symptom control
and rescue medication use, especially for cockroach, pet, and pollen allergens.

•

Improved understanding of the polyallergic AR patient and appropriate AIT
regimens in this population.

•

Improved understanding and characterization of ILIT for possible routine clinical
application.

•

Further study of comparative efficacy/effectiveness of SLIT vs SCIT.

•

Further study of AIT with multiple allergens.

•

Improved understanding of cost effective management for optimal AR control
and the use of multimodality therapy, including combinations of
pharmacotherapy and AIT.

•

Further study of the comparative effectiveness of various AR treatments.

Associated conditions
The evidence supporting an association between AR and numerous other conditions is weak
or conflicting. There is clearly a need to better define the relationship between AR and
several of the comorbidities identified in this document (especially rhinosinusitis, otitis
media with effusion, cough, laryngeal disease, and eosinophilic esophagitis), and to further
delineate the role that AR treatment has for potential improvement of associated conditions.
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XII.

Conclusion
In summary, the authors of ICAR:AR have worked to collate the best external evidence for
various aspects of AR, providing evidence grades and recommendations where appropriate.
From this evidence, knowledge gaps and research opportunities have been identified. It is
our sincere hope that the ICAR:AR document will be a reference for understanding the
current AR evidence and a springboard for future investigation.
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FIGURE II.A-1.

Topic development. AAP = American Academy of Pediatrics; EBRR = evidence-based
review with recommendation; PE = principal editor; 10 = primary; PRISMA = Preferred
Reporting Items for Systematic Reviews and Meta-Analyses.
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FIGURE II.A-2.

Topic EBRR iterative review. 10 = primary; 20 = secondary; 30 = tertiary; EBRR = evidencebased review with recommendation; PE = principal editor.
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FIGURE II.A-3.

ICAR: Allergic Rhinitis statement iterative review. ICAR:AR = International Consensus
Statement on Allergy and Rhinology: Allergic Rhinitis; PE = principal editor.
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FIGURE III.C.3.

Classification of work-related rhinitis.84 Adapted from Moscato et al. Allergy.
2008;63:969-980.
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Aggregate grade of evidence6
Grade

Research quality

A

Well-designed RCTs

B

RCTs with minor limitations; Overwhelming consistent evidence from observational studies

C

Observational studies (case control and cohort design)

D

Expert opinion; Case reports; Reasoning from first principles

RCT = randomized controlled trial.
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Author Manuscript
Author Manuscript
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Author Manuscript
Option

RCT = randomized controlled trial.

Recommendation

D. Expert opinion; case reports; reasoning from first principles

Strong recommendation

Preponderance of benefit
over harm

C. Observational studies (case-control and cohort design)

B. RCTs with minor limitations; overwhelmingly consistent evidence from observational studies

A. Well-designed RCTs

Evidence quality

No recommendation

Option

Balance of benefit and harm

Author Manuscript

American Academy of Pediatrics-defined strategy for recommendation development6

Recommendation against

Strong recommendation against

Preponderance of harm over
benefit
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Differential diagnosis of allergic rhinitis*
a

Types of rhinitis

• Drug-induced rhinitis
• Rhinitis medicamentosa
• Occupational rhinitis
• Chemical rhinitis
• Smoke-induced rhinitis
• Infectious rhinitis
• Rhinitis of pregnancy and hormonally-induced rhinitis
• Food- and alcohol-induced rhinitis
• NARES

Author Manuscript

• Vasomotor rhinitis (nonallergic rhinopathy)
• Age-related rhinitis (ie, elderly)
• Empty nose syndrome
• Atrophic rhinitis
• Autoimmune, granulomatous, and vasculitic rhinitis
• Rhinosinusitis

*

For each of these conditions, the similarities and differences to allergic rhinitis are discussed within each content section.

a

This table is specific to various etiologies of rhinitis. Structural sinonasal conditions (ie, deviated septum), tumors, and cerebrospinal fluid leak are
not listed here. NARES = nonallergic rhinitis with eosinophilia syndrome.

Author Manuscript
Author Manuscript
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Author Manuscript

Idiopathic

Neurogenic and
neuromuscular

Local inflammatory

Type of drug-induced
rhinitis

Angiotensin converting
enzyme inhibitor

Phosphodiesterase inhibitors

α- and β-Adrenergic receptor
modulators

General drug category

β-1, β-2: pindolol;
β-1, β-2, α-1: carvedilol, labetalol

•
•

Sildenafil, tadalafil, vardenafil
Pentoxifylline

Phosphodiesterase-5 specific
Nonselective phosphodiesterase

Chlorpromazine, thioridazine, amitriptyline, alprazolam, reserpine, risperidone, mianserin
Cyclosporine
Estrogen, oral contraceptives
Amiloride, chlorothiazide, hydralazine, hydrochlorothiazide
Gabapentin, gingko biloba

Psychotropics
Immunomodulators
Hormones
Antihypertensives
Other

Ramipril, captopril, lisinopril, benazepril, quinapril, enalapril

Cilostazol

Guanethidine

β-1: metoprolol, atenolol, bisoprolol;

•

Clonidine, methyldopa, guanfacine, piribedil

α-1: doxazosin, silodosin, prazosin, tamsulosin, alfuzosin, indoramin;
α-1, α-2: phentolamine

•

Ketorolac (if administered via nasolacrimal duct)

•

•

Aspirin;

•

Examples
NSAIDs (ibuprofen, indomethacin, diclofenac, sulindac, ketoprofen, naproxen,
flurbiprofen, fenoprofen, piroxicam, meclofenamate, etodolac);

Phosphodiesterase-3 specific

Presynaptic depletion of norepinephrine
stores

Beta-antagonists

Presynaptic α-2 agonists

α Antagonists

Specific drug category
•

Author Manuscript

Medications causative or contributory to drug-induced rhinitis40,44,48

Author Manuscript
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Intranasal decongestants associated with rhinitis medicamentosa26,61
Sympathomimetic amines

Phenylephrine, pseudoephedrine, ephedrine, amphetamine, Benzedrine, caffeine, mescaline

Imidazoline derivatives

Oxymetazoline, xylometazoline, naphazoline, clonidine
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Examples of high-risk occupations for occupational rhinitis and causal agents
Occupation

Agent

High molecular weight agents
Bakers, food industry

Cereal flours87

Laboratory workers

Laboratory animals (rat, mouse)88

Health care workers

Latex89

Farmers

Animal-derived allergens, plant allergens, molds90

Seafood workers

Shellfish, bony fish91

Pharmaceutical & detergent industries

Biological enzymes92

Low molecular weight agents

Author Manuscript

Hairdressers

Persulphates93

Carpentry, furniture making

Wood dust94,95

Pharmaceutics, health care workers

Drugs96

Chemical factories

Mixture of irritants96

Cleaners

Mixture of irritants97,98
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Author Manuscript
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Nested casecontrol with
replication

Meta-analysis
of 4 cohorts

Meta-analysis
of 4 cohorts/
datasets

Andiappan et al.
515 (2011)

Ramasamy et al.
(2011)

Ferreira et al.486
(2010)

488

Private
company data
(23andMe)

Meta-analysis
of 7 cohorts

Study design

Hinds et al.487
(2013)

512

Bunyavanich et al.
(2014)

Author
(year)

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
16,513 hay
fever cases;
17,256
controls

3933 AR
cases; 8965
controls

1132 AR
cases; 997
controls

46,646 total

2712 AR
cases; 2921
controls

Sample size

EA, L, AA

EA

Chinese

>97% EA

EA, L, AA

Ethnicity

4E–12

7E–10

rs2155219

9.7E–07

rs1044573
rs4833095

7.4E–07

3.8E–08

rs17513503

rs2155219

1.3E–04

rs505101

9.9E–15

rs10189629
7.3E–05

6.0E–17

rs2101521

rs811930

3.7E–19

2.0E–08 (all
groups)

rs7780001
rs1438673

1.4E–08 (L)

4.5E–09 (L)

p

rs6583203

rs17133587

Top SNPs
for AR

Asthma, eczema, atopy487

Co-morbidity: asthmaatopy489; asthmaeczema491; asthma-hay
fever486

LRRC32 or
C11orf30

No

ENTPD6
TLR1

No

Co-morbidity: asthmaatopy489; asthmaeczema491; asthma-hay
fever486
Eczema,487, 490 asthma,
atopy487

LRRC32 or
C11orf30,
SLCA25A46

TMEM232

Atopy515

BCAP (PIK3AP1)

See above

Pathogen recognition and
activation of innate immunity

Catabolism of extracellular
nucleotides

Transmembrane protein

LRRC32: T-cell regulation,
TGF-β activity. C11orf30:
regulation of viral immunity and
interferon pathways

Protein tyrosine kinase

Protein synthesis within the
mitochondrion

Proinflammatory effects, Thelper cell function

Asthma487, 514; eczema487;
atopy487

IL1RL2; IL1RL1

No

Pathogen recognition and
activation of innate immunity

Asthma, eczema, atopy487

TLR1–TLR6;
TLR10

MRPL4

Cellular processes and T-cell
activation

Transcription factor

Asthma487, 513; eczema488;
atopy487

No

FERD3L

Scaffolding protein involved in
cell metabolism

NAD(P)H-dependent
oxidoreduction

Protein function

WDR36

No

No

Reported association
with other allergic
diseases

DLG1

AKR1E2

Nearby
gene(s)

Author Manuscript

Key findings from GWASs on allergic rhinitis or hay fever

Author Manuscript
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Ethnicity

rs10197862

2E–09

p

IL1RL1

Asthma487, 514; eczema487;
atopy487

Eczema,487, 490 asthma,
atopy487

Reported association
with other allergic
diseases

Proinflammatory effects, Thelper cell function

Protein function

LOE

AA = African American; AR = allergic rhinitis; EA = European ancestry; GWAS = genome-wide association study; L = Latino; LOE = level of evidence; NADPH = nicotinamide adenine dinucleotide
phosphate.

Sample size

Author Manuscript
Study design

Nearby
gene(s)

Author Manuscript

Top SNPs
for AR

Author Manuscript
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(year)
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2006
2000

2002

Corver et al.516

Kulig et al.468

Kim et al.521
3b

2b

2b

2b

2b

2b

LOE

Cross-sectional

Prospective birth
cohort

Prospective birth
cohort

Whole-population
birth cohort

Prospective birth
cohort

Prospective birth
cohort

Study design

16,624 children (7–18 years
old)

587 children (7 years old)
from MAAS study

416 children (4 years old)
from PIAMA study

815 children (5 years old)
from MAAS study

513 children (5 years old)
from PAULA study

399 children (7–13 years
old) from COPSAC study

Study groups

History of spider mite exposure

Mite (Der p 1 + Der f 1) exposure at 0–18 months
(measured as allergen levels obtained from carpet
dust samples)

Der p 1 and Der f 1 exposure on the children’s
mattresses

Der p exposure at 0–5 years old (measured as
allergen levels recovered from child’s bed, child’s
bedroom floor, parental bed, and lounge floor)

Risk factor for rhinitis (OR 1.3; 95% CI, 1.2–1.5).

No association with SAR (OR not reported).

No association with rhinitis in 4th year (OR 0.9;
95% CI, 0.6–1.3).

Protective factor for current rhinoconjunctivitis (OR
0.8; 95% CI, 0.7–0.98). This finding failed to reach
significance in multivariate analysis.

No association with current AR (OR not reported).

No association with AR at 7 years (OR 0.9; 95%
CI, 0.7–1.1).

Der f 1 in dust sample at 1 year
Mite allergen exposure at 3 months (measured as
allergen levels in the living room floor and in the
mother’s or child’s mattress)

No association with AR at 7 years (OR 0.9; 95%
CI, 0.7–1.1).

Conclusion

Der p 1 in dust sample at 1 year

Type of exposure

*

AR = allergic rhinitis; CI = confidence interval; COPSAC = Copenhagen Prospective Study on Asthma in Childhood; Der p = Dermatophagoides pteronyssinus; Der f = Dermatophagoides farinae; LOE =
level of evidence; MAAS = Manchester Asthma and Allergy Study; OR = odds ratio; PAULA = Perinatal Asthma and Environment Long-term Allergy; PIAMA = Prevention and Incidence of Asthma and
Mite Allergy; SAR = seasonal allergic rhinitis.

ORs are unadjusted and reported with 95% CIs.

*

2007

Marinho et al.520

2016

Year

2014

al.518

Illi et al.517

Schoos et

Study

Evidence for the effects of mite allergen exposure (in utero and early childhood exposure) on the development of allergic rhinitis
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3b

2b

LOE

Cross-sectional

Prospective birth
cohort

Study design

583 children with atopic heredity (4–5
years old)

620 children (6–7 years old) from MACS
RCT (with at least 1 first-degree family
member with a history of eczema, asthma,
hay fever, severe food allergy)

Study groups

No association with allergic rhinoconjunctivitis
(OR 1.3; 95% CI, 0.8–2.2)

High-dose exposure to birch pollen at
1 year

Risk factor for hay fever (OR 1.1; 95% CI, 1.01–
1.3)

No association with allergic rhinoconjunctivitis
(OR 1.0; 95% CI, 0.6–1.8)

CI = confidence interval; LOE = level of evidence; MACS = Melbourne Atopy Cohort Study; OR = odds ratio; RCT = randomized controlled trial.

ORs are adjusted and reported with 95% CIs in parentheses.

b

b

Conclusion

High-dose exposure to birch pollen at
0–3 months

a

Pollen exposure during infancy (at 3–
6 months)

Type of exposure

Defined as birth “inside” or “outside” the pollen season and by measuring daily 24-hour average pollen concentrations for grass and others (which include trees, weeds, and herbs).

a

2002

2013

Erbas et al.481

Kihlström et al.519

Year

Study

Evidence for the effects of pollen allergen exposure (in utero and early childhood exposure) on the development of allergic rhinitis

Author Manuscript
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Year

LOE

Study design

Study groups

Type of exposure

2011

2008

2001

Lampi et al.532

Perzanowski et al.529

Nafstad et al.524
2b

2b

2b

2b

2b

Birth cohort

Birth cohort

Prospective birth
cohort

Prospective birth
cohort

Prospective birth
cohort

2531 children (4 years old)

257 children (5 years old)
from African American or
Dominican mothers

5509 adults (31 years old)

4465 children (4.5 years
old); 246 children with
current AR

620 children (12 years old)
with a family history of
allergic diseases

2016

2014

2012

2012

Schoos et al.518

Illi et al.517
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Kellberger et al.550

Lodrup-Carlsen et al.552
2b

2b

2b

2b

Prospective birth
cohort

Prospective
population-based
cohort

Prospective birth
cohort

Prospective birth
cohort

22,840 children (6–10 years
old)

2,810 adolescents (15–18
years old)

513 children (5 years old)
from PAULA study

399 children (7–13 years
old) from COPSAC study

a

Borderline protective factor for AR (OR 0.5; 95% CI,
0.2–1.4).
Borderline protective factor for AR to grass/pollen (OR
0.8; 95% CI, 0.4–1.6).

Exposure to cats at birth
Exposure to dogs at birth

Protective factor for AR at 5 years old (OR 0.4; 95% CI,
0.2–0.9).

Borderline protective factor for AR (OR cat 0.8; 95%
CI, 0.7–0.96); (OR dog 0.9; 95% CI, 0.8–1.01).

Exposure to cats or dogs at age less
than 7 years old
Cat ownership (up to age of health
outcomes)

Borderline protective factor for AR ever (OR 0.9; 95%
CI, 0.7–1.03).

Protective factor for AR (unadjusted OR 0.5; 95% CI,
0.4–0.8, not significant in multivariate analysis).

Borderline protective factor for hay fever (OR 0.7; 95%
CI, 0.5–1.02). Stronger protective effects if children of
non-sensitized fathers (OR cats alone 0.3; 95% CI, 0.2–
0.8); (OR cats or dogs 0.4; 95% CI, 0.2–0.8).

Conclusion

*

Exposure to farm animals (cows,
pigs, sheep, poultry, minks)

Exposure to cats at 1 year

Exposure to cats or dogs at birth

Pet (cat, dog, bird, rodent) ownership
at 0–2 years old

Pet (cat, dog, hamster, guinea pig,
rabbit) ownership at 0–1 years old

No association with AR (OR cat only 1.02; 95% CI,
0.8–1.3); (OR dog only 0.8; 95% CI, 0.6–1.1); (OR cat

No association with incidence/persistence of physiciandiagnosed AR.

No association with current AR (OR not reported as
value, only in figure).

No association with AR (OR prenatal, AR at 13 years
old 0.9; 95% CI, 0.2–4.3); (OR perinatal, AR at 7 years
old 0.9; 95% CI, 0.1–7.4).

Prenatal (at 3rd trimester of
pregnancy) and perinatal (at 1 year)
dog exposure
Cat allergen exposure at 3 months
(measured as allergen levels in the
living room floor and in the mother’s
or child’s mattress)

No association with AR at 7 years old (OR prenatal 0.4;
95% CI, 0.06–3.6); (OR perinatal 0.9; 95% CI, 0.2–3.9).

Prenatal (at 3rd trimester of
pregnancy) and perinatal (at 1 year)
cat exposure

Early exposure to animal dander is not associated with AR (Level 2b studies listed. Level 3b studies referenced.528, 530, 536, 538, 539, 543-546, 548, 551, 553, 554)

Early exposure to animal dander as a risk factor for AR (All studies Level 3b.523, 530, 536-542)

2011

2012

Alm et al.531

Lodge et al.534

Early exposure to animal danders as a protective factor for AR (Level 2b studies listed. Level 3b studies referenced.522, 523, 525-528, 533, 535, 1530)

Study

Evidence for the effects of pet dander exposure (in utero and early childhood exposure) on the development of allergic rhinitis

Author Manuscript
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2007

2001

2000

Marinho et al.520

Nafstad et al.524

Kulig et al.468
2b

2b

2b

2b

2b

2b

Prospective birth
cohort

Birth cohort

Whole-population
birth cohort

Prospective birth
cohort

Prospective birth
cohort, RCT

Prospective birth
cohort

587 children (7 years old)
from MAAS study

2531 children (4 years old)

815 children (5 years old)
from MAAS study

2166 children (4–6 years
old) (hay fever: 66/1599)
from LISA study

1223 children (5 years old)
born to allergic families,
who participated in a RCT

5509 adults (31 years old)

Study groups

a

No association with SAR (OR not reported).

No association with SAR (OR not reported).

Pets in household (at 18 months)

No association with AR to grass/pollen (OR 0.8; 95%
CI, 0.4–1.6).

Dog keeping at birth
Cat (Fel d 1) exposure at 0–18
months (measured as allergen levels
obtained from carpet dust samples)

No association with AR (OR 0.5; 95% CI, 0.2–1.4).

No association with current rhinoconjunctivitis
(unadjusted OR cat 1.02; 95% CI, 0.9–1.1); (unadjusted
OR dog 1.03; 95% CI, 0.9–1.2).

No association with doctor-diagnosed hay fever (OR
parents’ mattress 0.9; 95% CI, 0.5–1.5); (OR children’s
mattress 0.7; 95% CI, 0.4–1.1).

No association with AR (OR 0.98; 95% CI, 0.5–1.8).

No association with AR (OR 0.9; 95% CI, 0.7–1.2).

and dog 0.8; 95% CI, 0.4–1.4); (OR bird only 1.3; 95%
CI, 0.9–1.8); (OR rodent only 0.8; 95% CI, 0.5–1.5).

Conclusion

Cat keeping at birth

Cat and dog exposure at 0–5 years old
(measured as allergen levels
recovered from child’s bed, child’s
bedroom floor, parental bed and
lounge floor)

Cat allergen exposure at 3 months
(measured as Fel d 1 levels from
children’s or parents’ mattress)

Dog/cat at home at 0–2 years old or
0–5 years old

Maternal work with farm animals
(cows, pigs, sheep, poultry, minks)
during pregnancy

Type of exposure

AR = allergic rhinitis; CI = confidence interval; COPSAC = Copenhagen Prospective Study on Asthma in Childhood; Fel d = major cat allergen; LISA = Lifestyle-Immune-System-Allergy; LOE = level of
evidence; MAAS; Manchester Asthma and Allergy Study; OR = odds ratio; PAULA = Perinatal Asthma and Environment Long-term Allergy; RCT = randomized controlled trial; SAR = seasonal allergic
rhinitis.

a
All ORs are adjusted unless differently specified and are reported with 95% CIs in parentheses.

Level 2b studies are listed in the table. Level 3b studies are referenced.

*

2007

2011

Sandini et al.549

Chen et al.547

2011

Author Manuscript

Lampi et al.532

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript
Year

LOE

Study design
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2016

2016

2014
2012
2010
2007
2006
2005

Deng et al.557

Lin et al.558

Lam et al.553

Kim et al.551

Lombardi et al.538

Ibargoyen-Roteta et
al.527

Kuyucu et al.556

Bornehag et al.560
3b

3b

3b

3b

3b

3b

3b

3b

2b

2b

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Birth cohort

Birth cohort

Biagini et al.465
2006

2b

Cross-sectional

Early exposure to fungal allergens is not associated with AR

2005

2016

Stark et al.555

Thacher et al.559

Early exposure to fungal allergens as a risk factor for AR

Study

585 infants (1 year) born to
families with at least 1 parent
with positive SPT

10,851 children (1–6 years old)

2774 children (9–11 years old)

3360 schoolchildren (5–8 years
old)

20,016 children (median age 7
years old) from SIDRIA-2 Study

4554 schoolchildren (mean age
9.50 years old, SD 1.73)

508 preschool children (4–6 years
old)

4246 children (3–8 years old)
from 18 day cares

2598 children (3–6 years old)
attending kindergarten

405 children of asthmatic/allergic
parents from metropolitan
Boston, Massachusetts (younger
than 5 years old)

3798 adolescents (16 years old)
from BAMSE study; 785 with AR

Study groups

a

Risk factor for doctor-diagnosed AR at 0–5 years
(HR 2.7; 95% CI, 1.3–5.7)

Exposure to high levels of dust-borne yeasts
at 0–3 months

No association with AR (OR 1.2; 95% CI, 0.6–2.5)

No association with AR (OR 3.2; 95% CI, 0.7–
14.8)

Low mold exposure (mold in one room (<0.2
m2 or a combined area of visible mold and

Risk factor for rhinitis (OR 2.7; 95% CI, 1.4–5.4)

Risk factor for AR (OR 1.7; 95% CI, 1.3–2.3)

Risk factor for allergic rhinoconjunctivitis (OR 2.5;
95% CI, 1.5-4.0)

Risk factor for current rhinoconjunctivitis
(unadjusted OR 1.4; 95% CI, 1.2–1.6)

Risk factor for current AR (OR 1.8; 95% CI, 1.4–
2.4)

Risk factor for rhinoconjunctivitis (OR 2.1; 95% CI,
1.2–3.8)

Risk factor for new onset of rhinitis symptoms (OR
1.3; 95% CI, 1.01–1.6). Exposure was a significant
risk factor for the remission of rhinitis (OR 0.6;
95% CI, 0.3–0.9)

High mold exposure (mold in 1 room (≥0.2
m2 or a combined area of visible mold and
water damage on the same surface ≥0.2 m2)
during early infancy (average 7.5 months)

Visible mold or damp spots in the child’s or
parent’s bedroom at 1–6 years

Dampness/mold at 1 year

Having mold on walls at 0–1 year

Mold exposure at 0–1 year

Mold exposure in house during infancy

Exposure to moisture/mold <1 year

Visible indoor mold (weekly/sometimes vs
never) at 0–2 years

Risk factors for rhinitis-like current symptoms:
prenatal (OR 1.5; 95% CI, 1.2–1.9); postnatal (OR
2.1; 95% CI, 1.6–2.8)

Risk factor for doctor-diagnosed AR at 0–5 years
(HR 3.0; 95% CI, 1.3–6.9)

Exposure to high levels of dust-borne
Aureobasidium at 0–3 months

Prenatal (whole pregnancy) or postnatal (from
birth to current) exposure to indoor mold/
dampness

Risk factor for doctor-diagnosed AR at 0–5 years
(HR 3.3; 95% CI, 1.5–7.1)

Risk factor for AR (OR 1.3; 95% CI, 1.04–1.6)

Conclusion

Exposure to high levels of dust-borne
Aspergillus at 0–3 months

Visible mold at 2 months

Type of exposure

Evidence for the effects of fungal allergens exposure (in utero and early childhood exposure) on the development of allergic rhinitis

Author Manuscript
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2014

Yang et al.542
3b

3b

Cross-sectional

Cross-sectional

7389 schoolchildren (mean age
13.9 years, SD 0.9)

2598 children (3–6 years old)
attending kindergarten

Study groups

Mold exposure during infancy

Prenatal (during the whole pregnancy) or
postnatal (from birth to the current) exposure
to indoor mold or dampness

water damage on the same surface <0.2 m2)
during early infancy (average 7.5 months)

Type of exposure

a

No association with AR (OR 0.99; 95% CI, 0.8–
1.3)

No association with AR: prenatal (OR 0.7; 95% CI,
0.4–1.1), postnasal (OR 1.0; 95% CI, 0.6–1.7)

Conclusion

AR = allergic rhinitis; BAMSE = Barn/Child Allergy Milieu Stockholm Epidemiology; CI = confidence interval; HR = hazard ratio; LOE = level of evidence; OR = odds ratio; SD = standard deviation;
SIDRIA-2 = Studi Italiani sui Disturbi Respiratori del l’Infanzia el Ambiente; SPT = skin prick test.

ORs are adjusted unless otherwise specified.

a

2016

Author Manuscript

Deng et al.557

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript
2b

2a

1b

1b

1b

LOE

Populationbased,
prospective
birth cohort
study

Meta-analysis

RCT

RCT

RCT

Study design

Standard feeding practices.

2

Strictly cow’s milk-free and egg-free diet from
week 28 to delivery;
Normal diet including cow’s milk and egg.

2

Daily ingestion of egg and cow’s milk.

2
1

Very low ingestion of egg and cow’s milk;

1

Women with respiratory allergy to animal danders and/or
pollens in the last 3 months of pregnancy randomized to:

Infants whose mothers avoided cow’s milk,
egg, and peanut in the last trimester of
pregnancy and lactation and who themselves
avoided cow’s milk until age 1 year (casein
hydrolysate supplementation before age 1),
egg until age 2 years, and peanut and fish until
age 3 years;

1

Study groups

AR = allergic rhinitis; IgE = immunoglobulin E; LOE = level of evidence; RCT = randomized controlled trial.

Zutavern et al.572
2008

2016

Alduraywish et al.

564

1987

Falth-Magnusson
et al.571

1995

Year

1989

al.573

Lilja et al.570

Zeiger et

Study

Asthma, AR, eczema or
sensitization against food or
inhalant allergens

Asthma, AR, eczema or
sensitization against food
allergens

Skin prick, serum IgE, atopic
manifestations (not AR)

Incidence of atopic diseases at
18 months of age

Food allergy, atopic dermatitis,
AR, asthma, any atopic disease,
lung function, food or
aeroallergen sensitization, serum
IgE level, presence of nasal
eosinophils or basophilic cells at
age 7 years.

Clinical endpoint

Conclusion

No evidence supporting a delayed
introduction of solids beyond 4–6
months.

Food sensitization in the first 2 years of
life can identify children at high risk of
subsequent allergic disease, including
AR.

Maternal elimination diet during late
pregnancy does not protect the baby
against atopy. Maternal elimination diet
during late pregnancy is associated with
low weight gain and preterm birth.

No significant difference in the
distribution of atopic disease in relation
to the maternal diet during late
pregnancy.

No significant difference between
treatment groups, though children with
food allergy by 4 years had a higher 7year prevalence of AR and asthma.

Evidence for the effects of food allergen exposure (in utero and early childhood exposure) on the development of allergic rhinitis

Author Manuscript
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Author Manuscript

Author Manuscript
2015

Codispoti et al.

2015

2011

2016

2016

2016

2016

Gehring et al.580

Kim et al.579

Chiang et al.587

Chung et al.588

Deng et al.557

Kim et al.476

578

Year

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
4

4

3b

3b

2b

2b

2b

LOE

Cross-sectional

Cross-sectional

Case-control
study

Case-control
study

Prospective
cohort

Pooled
prospective
cohort

Prospective
cohort

Study design

Metropolitan city

2

Low exposure

2

Low exposure

2

Low exposure

2

High exposure;
Low exposure

1
2

Exposure to 5 air pollutants (PM10, NO2, SO2, CO,
O3):

High exposure;

1

Exposure to 3 air pollutants (PM10, NO2, SO2):

High exposure;

1

Exposure to 5 air pollutants (PM10, NOx, SO2, CO,
O3):

High exposure;

1

Exposure to SO2 over 11 years:

Industrial area;

1

Concentrations of 5 air pollutants (NO2, O3, SO2, CO,
PM10):

High exposure to NO2, PM2.5, PM10;
Low exposure to air pollutants

1

<66th percentile

2

2

≥66th percentile;

1

DEP exposure at 1 year:

Study groups

Diagnosis of AR by the age of 6–
7 years

Diagnosis of AR in kindergarten
children

Diagnosis of AR in preschool
children

Diagnosis of AR in children

Development of AR in children
over 2 years

Incidence and prevalence of
rhinoconjunctivitis from age 4 to
14–16 years

Development of AR by age 4
years

Clinical endpoint

Author Manuscript

Evidence for the effects of pollution exposure on the development of allergic rhinitis

Higher exposure to CO was associated with an
increased lifetime prevalence of physiciandiagnosed AR.

Prenatal exposure to high NO2 correlated with
AR; postnatal exposure to high PM10 correlated
with AR.

Prediagnosis levels of CO and NOx were
significantly related to AR diagnosis.

High exposure to SO2 correlates with an
increased diagnosis of AR.

Incidence of AR is not associated with air
pollutants; however, there was a positive
association between higher O3 levels and AR in
industrial areas.

No association between air pollution exposure
and rhinoconjunctivitis incidence or prevalence
at various ages.

High DEP exposure did not correlate with the
development of AR.

Conclusion

Author Manuscript
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2016

2016

Liu et al.586

2016

2015

2015

2010

Wang et al.585

Jung et al.582

Shirinde et al.583

Anderson et al.

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
4

4

4

4

4

4

4

Cross-sectional
study

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Study design

Low exposure

Low exposure

2

Less frequent

2

Exposure to PM10:
High exposure;
Low exposure

2
3

Trucks passing less frequently

2
1

Trucks passing near residence almost
all day;

Living more than 75 m from main road

2
1

Living less than 75 m from main road;

Low exposure

2
1

High exposure;

1

Exposure to 6 air pollutants (PM10, PM2.5, NO2, SO2,
CO, O3):

Almost all day;

1

Frequent passage of trucks near home:

High exposure;

1

Exposure to 3 air pollutants (PM10, NO2, SO2):

High exposure;

1
2

Exposure to 5 air pollutants (PM10, NOx, SO2, BC,
O3):

Study groups

Diagnosis of rhinoconjunctivitis
at ages 6–7 and 13–14 years

Diagnosis of AR in 13-year-old to
14-year-old children

Lifetime AR, past-year AR
symptoms, diagnosed AR, and
treated AR in children

Diagnosis of AR in children

Diagnosis of AR in children ages
6–7 and 13–14 years

Diagnosis of AR in children

AR treatment over the past 12
months in children

Clinical endpoint

Only significantly increased association
between PM10 levels and rhinoconjunctivitis
and atopy in 13-year-olds to 14-year-olds in
countries with more than 1 testing center.

Diagnosis of AR is significantly associated with
the frequency of trucks passing by the
residence.

Positive correlation between distance from main
road and AR symptoms, diagnosis, and
treatment.

High levels of PM2.5 correlate with an increased
risk of AR.

Frequent passage of trucks was correlated with
the occurrence of AR in both age groups.

High exposures to NO2 during gestation, the
first year of life, second year, and throughout
life correlated with the development of AR.

High exposure to BC, SO2, and NO2 were
significantly associated with increased
treatment of AR.

Conclusion

particulate matter <10 μm; PM2.5 = particulate matter <2.5 μm; SO2 = sulfur dioxide.

AR = allergic rhinitis; BC = black carbon; CO = carbon monoxide; DEP = diesel exhaust particles; LOE = level of evidence; NO2 = nitrogen dioxide; NOx = nitrogen oxides; O3 = ozone; PM10 =

581

2016

Singh et al.584

Kim et

LOE

Author Manuscript
Year

Author Manuscript

al.589

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript

al.593
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2014

Hur et al.594
3a

2b

2b

2b

2b

2b

2a

LOE

SR of predominantly
case-control studies

Prospective cohort
study

Prospective cohort
study

Prospective cohort
study

Prospective cohort
study

Prospective cohort
study

SR of cohort, crosssectional, and casecontrol studies

Study design

Passive

Passive

Active

Active

Passive

Passive

Both

No exposure

2

Exposure to passive smoking;
No exposure to passive
smoking

1
2

No smoking in the first year
2

Current smokers

3

Maternal smoking;

Ex-smokers(>1 month);

2

1

Lifetime nonsmokers;

No current smoking

1

2

Current smoking;

1 Allergic parent;
Non-allergic parents

2
3
1

2 Allergic parents;

1

Maternal smoking vs no smoke exposure
with:

Environmental tobacco smoke
exposure;

No active or passive smoking

3
1

Passive smoking;

Active smoking;

2

1

Study groups

Diagnosis of AR

Physician diagnosed AR at
age 6 years

Chronic rhinitis, SAR, or
perceived nasal
hyperresponsiveness

Self-reported SAR or PAR

Diagnosis of AR over the first
10 years of life

Diagnosis of AR by age 3
years

Diagnosis of AR

Clinical endpoint

AR = allergic rhinitis; LOE = level of evidence; PAR = perennial allergic rhinitis; SAR = seasonal allergic rhinitis; SR = systematic review.

1994

Wright et al.597

600

AnnesiMaesano et al.

1997

2008

Bendtsen et al.

598

2009

2010

2014

Year

Keil et al.596

599

Codispoti et al.

Saulyte et

Study

Active vs
passive
smoke
exposure

Evidence for the effect of active and passive tobacco smoke exposure on the development of allergic rhinitis

Most studies did not show a
relationship between passive smoke
exposure and AR.

No significant association between
maternal smoking and physician
diagnosed AR.

No association between smoking and
seasonal AR. Significant association
between chronic rhinitis and current
smoking.

Smoking more than 15 cigarettes/day
was associated with a decreased risk of
SAR.

There was no association between
maternal smoking and the
development of AR regardless of the
allergic status of the parents.

Environmental tobacco exposure has
no effect on the development of AR by
age 3 years.

No association between active
smoking and maternal pre-natal
passive smoking and AR. Significant
association between all other passive
smoking and AR.

Conclusion

Author Manuscript
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Author Manuscript

Author Manuscript
2015

Grabenhenrich et al.

2005

2000

1998

2016

Almqvist et al.611

Bergmann et al.610

Lewis & Britton608

Ahn et al.478

613

Year

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
4

2b

2b

2b

2b

LOE

Cross-sectional
survey

Prospective
cohort

Prospective
cohort

Prospective
cohort

Prospective
cohort

Study design

Low/intermediate white collar;
One high level white collar; 4.
Two high level white collar

2
3

Middle;
Low

2
3

SES:

Less than average income

Advantaged;
Most advantaged

4
5

2

Average;

3

Greater than average income;

Disadvantaged;

2

1

Most disadvantaged;

1

Level of “social advantage”:

High;

1

Parental SES:

Blue-collar workers;

1

Parental SES:

Poor

Average;

2
3

Rich;

1

Parental SES:

Study groups

2

1

Allergy test–based AR

Symptom-based AR;

Diagnosis of hay fever at ages 5, 10, and
16 years

Diagnosis of AR parents and in children
3–6 years old

Diagnosis of AR at 4 years old

Diagnosis of AR by age 20 years

Clinical endpoint

Author Manuscript

Evidence for the association between allergic rhinitis and socioeconomic factors

Significant association between higher
SES and symptom-based AR; but no
association between SES and allergy
test–based AR.

Social advantage was significantly
related to the diagnosis of AR with the
“most advantaged” having the highest
prevalence of AR.

Parental high SES correlated to high AR
rates in parents; however, SES had no
correlation with AR in children 3–6
years old.

Parents of higher SES had children with
a lower risk of AR, asthma, and food
allergens.

No association between SES and
diagnosis of AR.

Conclusion

Author Manuscript

TABLE VI.F.
Wise et al.
Page 307

Author Manuscript
2016

2016

Penaranda et al.616

2014
2005

Hammer-Helmich et
al.612

Braback et al.609
4

4

4

4

4

Cross-sectional
study

Cross-sectional
survey

Cross-sectional
survey

Cross-sectional
survey

Cross-sectional
survey

Study design

Study groups

High;
Low

High

3

2

Middle;

1

Low;

2

High

3

1

Middle;

2

High vs low SES

Parental SES

SES:

SES:

Low;

1

Family affluence scale:

AR = allergic rhinitis; LOE = level of evidence; SES = socioeconomic status.

2016

Wronka et al.617

Lee et

LOE

Author Manuscript
Year

Diagnosis of AR upon enrollment in
military service

Diagnosis of AR in children 11–15 and
3–6 years old

Diagnosis of AR in university students
(ages 19–25 years)

Diagnosis of AR in children and adults

Diagnosis of AR in adolescents

Clinical endpoint

Author Manuscript

al.615

In the 1950s, low SES and AR were
inversely related, but this association
significantly decreased by 1970.

No association between household
income and diagnosis of AR.

Higher proportion of AR in students
from high SES compared to low.

Middle and high SES was associated
with increased AR symptoms in
children but not in adults.

High Family Affluence Scale was
associated with higher prevalence of
AR.

Conclusion

Author Manuscript

Study
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Author Manuscript

Author Manuscript

623

2002

2015

Year

3a

3a

LOE

SR

SR

Study
design
Study groups

Prospective studies evaluating the effects of
exclusive breastfeeding for the first 3 months
on AR development

Association between breastfeeding and AR

AR = allergic rhinitis; LOE = level of evidence; SR = systematic review.

These systematic reviews include all published studies to date.

*

al.624

Mimouni Bloch et al.

Lodge et

Study

*

Development of AR

Development of AR

Clinical endpoint

Conclusion

Protective effect close to statistical significance in the general
population but not in children with a family history of atopic disease.

Nonsignificant protective effect overall. Protective benefit for children
under 5 years old, but not over 5 years old.

Author Manuscript

Evidence for the effects of breastfeeding on the development of allergic rhinitis

Author Manuscript
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Author Manuscript

Author Manuscript
2010

2008

Chen et al.640

Takkouche et al.

Christensen et al.

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2012

2b

2b

2a

2a

2a

2a

2a

2a

LOE

Prospective birth
cohort

Population based
cross-sectional
study follow-up

Meta-analysis

SR of birth and
non-birth cohort
studies and crosssectional studies

SR

Pooled analysis of
individual data first
year of recruitment

SR

SR

Study design

13 reported dog ownership or Can f
1 in dust;
26 cross-sectional studies reported
cat or dog exposure

2
3

MACS cohort: 620 infants with family history of
allergic disease

RHINE cohort (2010–2012): 13,376 subjects born
in Northern Europe 1945–1973

32 studies (1985–2006); 5 studies (n = 6818)
reported rhinitis

17 birth cohorts reported cat
exposure or Fel d 1 in dust;

1

62 articles (2000–2009); subjects 6–69 years old:

26 articles: exposure to dogs 20 weeks from
gestation to 1 year.

(1989–1997): 11 European birth cohorts; 11,489
participants aged 6–10 years

(2001–2008): 9 longitudinal studies; 6498 subjects
aged 0–11 years

19 studies (2011–2012): 9 longitudinal, 8 crosssectional, 2 case-control

Study groups

Association of hay fever after 7 years
of age with exposure to cats and dogs
at birth

Association of AR in adulthood with
exposure to pets at birth, during
childhood and to livestock farm in
childhood

Association of AR with exposure to
furred pets

Association of AR with exposure to
cats or dogs in cross-sectional studies

Association of allergic symptoms with
exposure to dogs

Association of sensitization to
aeroallergens with ownership of cats
only, dogs only, cats and dogs only,
birds only or rodents only during 0–2
years of age

Association of physician diagnosed
hay fever with exposure to pets, or
cats and dogs during perinatal period
in urban environment

Association of AR with exposure to
cats

Conclusion

In high-risk cohort, pet exposure at birth
is protective against hay fever at age 7
years in children with nonsensitized
fathers

Exposure to pets in childhood decreases
the risk of AR in adulthood
independently of urban or rural
upbringing.

Inconsistent association. Possible
protective effect of furred pets on
rhinitis.

Inconsistent association. Dog exposure
may be protective. Design of the study
influences the association.

Inconsistent association. Dog exposure
at birth may be protective against
allergic symptoms.

Dog and rodent exposure protective
against sensitization to aeroallergens. No
association with AR.

Dogs may reduce sensitization or
allergic disease in families with low risk
of allergy. No association with cats.

Inconsistent association. If exposure
during the first year, less AR or
sensitization, or no effect. Possible
protective effect until adulthood.

AR = allergic rhinitis; LOE = level of evidence; MACS = Melbourne Atopy Cohort Study; RHINE = Respiratory Health in Northern Europe; SR = systematic review.

Lodge et al.534

643

2016

2012

Smallwood &
Ownby641

639

2012

Lodrup-Carlsen et
al.552

2012

Year

2012

al.562

Lodge et al.642

Dharmage et

Study

Clinical endpoint

Author Manuscript

Evidence for the effect of early childhood pet exposure of the development of allergic rhinitis

Author Manuscript
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Author Manuscript

Author Manuscript
2016

2016

2016

2015

2015

2015

2011
2011

Fujimura et al.645

House et al.648

Hua et al.664

Arrieta et al.663

Strachan et al.646

Valkonen et al.661

Bisgaard et al.449

Ege et al.659

2015

Year

2002

al.647

Karmaus &
Botezan645

Campbell et

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2b

2b

2b

2b

2b

2b

2b

2b

2a

2a

LOE

Two crosssectional studies

Longitudinal study

Cross-sectional
stratified
population study

Cross-sectional
study

Longitudinal
nested case-control
study

Cross-sectional
study

Nested casecontrol study

Longitudinal birth
cohort study

Meta-analysis

SR

Study design

PARSIFAL study: 489 rural and
suburban children; GABRIELA
study: 444 rural children

253 high-asthma-risk children
followed from birth to age 7 years

GABRIELA study: 224 children, 6–
12 years

Children 6–7 years of age in 31
countries (n = 210,200); 13–14
years of age in 52 countries (n =
337,226)

319 children followed from birth
until 5 years of age

1879 adult subjects

Farmers and spouses: Cases: asthma
(n = 1198); Controls: no asthma (n
= 2031).

298 children followed until age 4
years

53 studies (1986–2000). Hay fever:
17 studies (n = 253,304);
Sensitization: 16 studies (n =
46,758)

29 studies (1999–2014): 26 crosssectional, 3 longitudinal. Metaanalysis: 8 studies

Study groups

Association of sensitization with microbes
in mattress (PARSIFAL) and in airborne
dust (GABRIELA)

Association of sensitization and AR with
high fecal microbial biodiversity

Association of sensitization with mattress
bacterial diversity

Association of hay fever with three or
more siblings vs no siblings

Association of sensitization and wheezing
at 1 year with fecal microbiota at age 3
months and 1 year

Association of seasonal allergy with fecal
microbial biodiversity

Association of sensitization, rhinitis,
eczema, and asthma with living on a farm
when born and with being exposed to
farm environment when mother was
performing farm activities during
pregnancy

Association of sensitization and asthma at
age 2 years with fecal microbiota in
neonates targeted at age 1 month (n =
130) or 6 months (n = 168)

Association of sensitization and AR with
3 or more siblings vs no siblings

Association of farm exposure with
sensitization in childhood or adulthood

Clinical endpoint

Author Manuscript

Evidence for the hygiene hypothesis in the development of allergic rhinitis

Farm-children had less asthma and atopy. Indoor
microbial exposure much higher and diverse in
farm homes. Microbial diversity related to asthma
but not to atopy.

Reduced bacterial diversity associated with
higher risk of sensitization and AR in childhood.

Exposure to more diverse bacterial flora
associated with less sensitization.

Protective effect of older and total number of
siblings on self-reported AR. Effect was
significantly stronger in affluent countries.

Reduced colonization of Faecalibacterium,
Lachnospira, Veillonella, and Rothia during the
first 3 months of life may increase the risk of
atopic asthma.

Reduced fecal biodiversity and altered
composition associated with more allergy. No
association with asthma and eczema.

Early-life farm exposure associated with less
atopy. No association with asthma.

Reduced colonization of Bifidobacteria,
Lactobacillus, Faecalibacterium, Akkermansia,
and Malassezia during the neonatal period may
influence the risk of multisensitization predictive
for asthma.

Higher number of siblings was associated with
less atopy. Effect was not explained by hygiene
factors.

Protective effect of farm exposure in infancy on
allergic disease in childhood and adulthood in
majority of studies. Exposure during adulthood
had no consistent relationship with sensitization.

Conclusion

Author Manuscript

TABLE VI.G.3.
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Author Manuscript
2015

Cuello-Garcia et al.

2014

Abrahamsson et al.

3b

3a

3a

2b

2b

Longitudinal casecontrol study

Review

Systematic review
and meta-analysis

Cross-sectional
study

Nested casecontrol study

Study design

47 infants (n = 20 IgE-associated
eczema; n = 27 healthy controls)
followed until 7 years of age

(2000–2007): 6 rural studies; 10
urban studies

29 randomized controlled trials in
infants

563 children aged 7–16 years in
Finnish and Russian Karelia

678 children at the age of 6 years
from German (n = 346) and Dutch
(n = 332) birth cohorts

Study groups

Association of sensitization, asthma and
AR with fecal diversity in infancy

Association of sensitization with exposure
to endotoxin

Association of AR with probiotic
supplementation to pregnant mothers,
breast-feeding women, or infants

Association of sensitization with
microbial content in drinking water
samples from school kitchens

Association of rhinitis and asthma with
mattress dust biological components of
mold and endotoxin

Clinical endpoint

Low microbial diversity associated with asthma
later in childhood. No association with
sensitization or rhinitis.

Exposure to endotoxin protective in over 50% of
studies. Endotoxin may be marker of other
protective factors.

No effect on allergies.

Microbial count much higher and sensitization
much lower in Russia. High count of microbes
associated with less atopy.

Inconsistent results. Microbial exposures at home
had different effects on allergy in German and
Dutch birth cohorts.

Conclusion

AR = allergic rhinitis; GABRIELA = GABRIEL Advanced Survey; IgE = immunoglobulin E; LOE = level of evidence; PARSIFAL = Prevention of Allergy-Risk Factors for Sensitization Related to
Farming and Anthroposophic Lifestyle; SR = systematic review.

442

2010

Simpson &
Martinez656

658

2007

2011

von Hertzen et al.660

Tischer et

LOE

Author Manuscript
Year

Author Manuscript

al.657

Author Manuscript

Study
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Author Manuscript

Author Manuscript
2012

2010

2009

2009

2008

2006

Yamada et al.673

Hoiby et al.678

Holmberg et al.676

Witt et al.692

Brinkhaus et al.680

Canonica et al.677

2013

Year

2013

al.674

Tatar et al.672

Bousquet et

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1b

1b

1b

1b

1b

1b

1b

LOE

RCT, double-blind

RCT

RCT

RCT, double-blind,
crossover

RCT

RCT, double-blind,
crossover

RCT

RCT

Study design

Placebo (n = 356)

2

Mometasone + levocetirizine (n = 21);
Mometasone + montelukast (n = 21)

2
3

Placebo (n = 26)

2

Control (n = 494)

2

Not randomized but received
acupuncture (n = 4256)
3

1

Levocetirizine (n = 278);

Conventional medical care (n = 494);
2

AR (n = 551):

Randomized to acupuncture (n = 487);

1

AR (n = 5237):

Acupuncture (n = 487);

1

AR (n = 981):

Desloratadine (n = 293);
Placebo (n = 291)

1
2

AR (n = 584):

SCIT (n = 27);

1

AR (n = 53):

PAR (n = 57): mometasone

Mometasone(n = 14);

1

AR (n = 56):

Desloratadine (n = 360);

1

AR (n = 716):

Study groups

RQLQ, SF-36

RQLQ, SF-36

SF-36

RQLQ, symptom
score

Symptom and
medication scores

TSS, QOL score,
sleep quality, nasal
nitric oxide

Mini-RQLQ

Symptoms scores,
sleep questionnaire,
RQLQ, WPAIAS

Clinical endpoint

Author Manuscript

Effect of allergic rhinitis on general and disease-specific quality of life

QOL significantly affected by AR. Levocetirizine
improves QOL compared to placebo.

QOL significantly affected by AR. Acupuncture
group improves more than conventional medical
care.

Acupuncture improves QOL more than control at
3 months.

Desloratadine improves RQLQ and symptom
score significantly compared to placebo.

SCIT reduces symptom and medication scores
compared to placebo.

Nasal mometasone improves nasal symptoms,
QOL, and sleep quality and decreases nitric oxide.

QOL significantly affected by AR. Combination
of mometasone with levocetirizine or montelukast
improves QOL more than mometasone alone.

Desloratadine improves symptoms, QOL, and
functional impairment.

Conclusion

Author Manuscript
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2006

2004

2003

2000
1991

2016
2014

2016

2016
2013

Bachert et al.675

Radcliffe et al.693

Gerth Van Wijk et al.694

Juniper et al.671

Linneberg et al.667

Hahn-Pedersen et al.668

Filanowicz et al.695

Jaruvongvanich et al.684

Bousquet et al.681

Author Manuscript

Colas et al.679

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2b

2b

2b

2a

2a

1b

1b

1b

1b

1b

Observational
cross-sectional

Observational
cohort

Observational
cohort

SR

SR

RCT, double-blind

RCT

RCT, double-blind

RCT, double-blind

RCT, double-blind

Study design
2

Study groups

Control (n = 19)

2

Placebo (n = 273)

2

Placebo (n = 93)

2

AR (n = 990)

AR (n = 260)

Allergic asthma (n = 101);
AR (n = 99)

1
2

SCIT (n = 200):

AR

AR

AR questionnaire development (n = 85); validation
(n = 60)

AR and nasal capsaicin (n = 26)

Enzyme potentiated desensitization (n
= 90);

1

SAR (n = 183):

Levocetirizine (n = 278);

1

PAR (n = 551):

SCIT (n = 41);

Placebo (n = 273)

1

AR (n = 60):

Author Manuscript
LOE

VAS, RQLQ, TSS

SF-12, TSS

RQLQ

QOL

QOL

RQLQ

VAS, RQL

RQLQ, problemfree days

SF-36, RQLQ

RQLQ, symptoms
score, medication
score

Clinical endpoint

Author Manuscript

Year

20% mild intermittent, 17% mild persistent, 15%
moderate-severe intermittent, 48% moderatesevere persistent. Severity and duration of AR
impact on QOL. Ocular symptoms impact RQLQ
more than nasal obstruction. Sneezing/rhinorrhea
do not impact RQLQ.

Extranasal symptoms in AR correlate with
physical and mental health QOL domains.

QOL is significantly affected by AR. SCIT
significantly improved QOL in asthma and AR.

AR patients have significantly worse general and
disease-specific QOL with physical, practical, and
activity domains most affected. SCIT improves
QOL and symptoms.

Patients with AR suffer from decreased QOL in
terms of both physical and mental health.

In addition to local symptoms, patients experience
impaired QOL through systemic, sleep, emotional
symptoms, and practical/activity limitations.
Beclomethasone use correlated to RQLQ.

Capsaicin does not sufficiently control rhinitis
symptoms.

Enzyme potentiated desensitization does not
improve QOL compared to placebo.

Levocetirizine improves QOL and decreases
disease-related costs.

QOL significantly affected by AR. SCIT improves
RQLQ, symptom and medication scores.

Conclusion

Author Manuscript

Study
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Author Manuscript
2012

2010
2009

2008
2008

2007

2006

2005

2001
2000

2013

Ciprandi et al.699

Stull et al.682

Cadario et al.683

Petersen et al.700

Ciprandi et al.701

Di Rienzo et al.702

Laforest et al.703

Majani et al.691

Leynaert et al.689

Cingi et al.704

2012

2013

Meltzer et al.698

697

de la Hoz Caballer et al.

Demoly et

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2c

2b

2b

2b

2b

2b

2b

2b

2b

2b

2b

2b

2b

LOE

Outcomes research

Observational
cross-sectional

Observational
cohort

Observational
cohort

RCT, double-blind

Observational
cohort

Observational
cross-sectional

RCT

Observational
cross-sectional

Observational
cohort

Observational
cross-sectional

Observational
cross-sectional

Observational
cohort

Study design

Study groups

Asthma (n = 52)

AR but not asthma (n = 240);
Neither AR or asthma (n = 349)

2
3

PAR treated with desloratadine and montelukast (n =
40)

AR and asthma (n = 76);
1

SAR (n = 33)

SAR (n = 83);

2

Placebo (n = 15)

2
1

SLIT (n = 19);

1

AR (n = 34):

AR (n = 123)

AR (n = 248); AR and asthma (n = 121)

AR treated with SLIT (n = 40)

AR (n = 404)

AR undergoing SLIT (n = 167)

Nasal allergy (n = 522); no nasal allergy (n = 400)

Primary care patients (n = 616)

AR (n = 990)

Author Manuscript
Year

Acoustic
rhinometry, RQLQ

SF-36

SF-36, SAT-P

Mini-RQLQ, SF-12

RQLQ

RQLQ

RQLQ; 15D

Nonvalidated QOL
scale

Symptom scale,
nocturnal RQLQ,
WPAI, MOS-12
Sleep, PANAS-X

RQLQ

Nonvalidated phone
interview questions

SF-36, generic
HRQOL, WPAI

VAS, RQLQ, TSS

Clinical endpoint

Author Manuscript

al.696

Desloratadine + montelukast improves nasal
obstruction and QOL.

Both asthma and AR impact QOL. AR impacts
emotional and mental health, social activities, and
activities of daily living. Comorbid asthma caused
more physical limitations than AR alone.

QOL is significantly affected by AR during peak
season.

QOL is significantly affected by SAR and asthma.
Female gender, rural residence, and lower
education levels associated with worse QOL in
SAR.

QOL is significantly affected by AR. SLIT
improved QOL compared to placebo.

QOL is significantly affected by AR. >2
sensitivities, eosinophil count, and nasal flow
related to QOL. Eye symptoms correlate most
strongly to QOL.

AR patients have worsened QOL during allergen
exposure. 15D generates more comprehensive
view of impact on QOL than RQLQ.

QOL is significantly affected by AR. SLIT
improves QOL and symptoms.

Nasal congestion is more strongly correlated to
outcomes, but ocular symptoms can have
significant impact of QOL.

QOL is significantly affected by AR. SLIT
effective at improving QOL and symptoms.

AR patients rate overall health lower, have worse
sleep function, and decreased productivity than
those with non-AR.

AR impacts productivity to a greater magnitude
than hypertension and DM type II, but not
depression.

20% mild intermittent, 17% mild persistent, 15%
moderate-severe intermittent, 48% moderatesevere persistent. VAS can detect QOL variations
with high sensitivity.

Conclusion

Author Manuscript

Study
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Author Manuscript
2013

Katelaris et al.687
3b

3b

3b

Observational
cross-sectional

Observational
cross-sectional

Observational
cohort

Study design

AR (n = 303)

Middle school students, cross-sectional stratified
random sampling (n = 814)

PAR treated with beclomethasone (n = 527)

Study groups

Questionnaire

Questionnaire

RCAT, treatment
satisfaction, WPAI,
PSQI, mini-RQLQ

Clinical endpoint

AR impacts work/school performance, general
QOL, and sleep quality.

AR in 17.2%. AR impacts QOL, sleep, emotions,
and memory.

Beclomethasone improves QOL, school-related
activities, satisfaction, productivity, and sleep
quality.

Conclusion

15D = Generic 15 Dimension Instrument for measuring health related quality of life; AR = allergic rhinitis; DM = diabetes mellitus; HRQOL = Health-Related Quality of Life; LOE = level of evidence;
MOS-12 Sleep = Medical Outcomes Study 12-Item Sleep Scale; PANAS-X = Positive and Negative Affect Schedule-Expanded Form; PAR = perennial allergic rhinitis; PSQI = Pittsburgh Sleep Quality
Index; QOL = quality of life; RCAT = Rhinitis Control Assessment Test; RCT = randomized controlled trial; RQL = rhinitis quality of life; RQLQ = rhino-conjunctivitis quality of life questionnaire; SAR =
seasonal allergic rhinitis; SAT-P = satisfaction profile; SCIT = subcutaneous immunotherapy; SF-12 = short form 12; SF-36 = short form 36; SLIT = sublingual immunotherapy; SR; systematic review; TSS
= total symptom score; VAS = visual analogue scale; WPAI = Work Productivity and Activity questionnaire; WPAIAS = Work Productivity and Activity Allergy Specific questionnaire.

2015

2016

Song et al.685

Bukstein et

LOE

Author Manuscript
Year

Author Manuscript

al.688

Author Manuscript

Study
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Author Manuscript
2007

2005

2003
1998
2014

2013

2013

2007

2004
2000
1996
2012

Gurevich et al.705

Hughes et al.706

Craig et al.707

Parikh et al.715

Acar et al.716

Lavigne et al.717

Udaka et al.723

Mintz et al.724

Camhi et al.713

Janson et al.725

Colas et al.726

2009

Year

Mansfield & Posey708

Shanqun et

al.709

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2c

2b

2b

2b

2b

2b

2b

2b

1b

1b

1b

1b

1b

LOE

Population-based

Observational
cross-sectional

Case-control

Individual cohort

Observational
cross-sectional

Observational
cross-sectional

Observational
cohort

Observational
cohort

RCT, crossover

RCT, crossover

RCT, crossover

RCT

RCT

Study design

Study groups

Placebo (n = 16)

OSA without rhinitis (n = 21)

2

AR (n = 2275)

n = 2661 random population of the ECRHS

n = 437 from TESOAD with sleep problems/
snoring

AR (n = 651)

Daytime workers (n = 3442)

OSA and AR (n = 34);

1

OSA and AR (n = 80)

OSA and rhinitis (n = 43)

AR (n = 20), flunisolide vs placebo

PAR (n = 22), nasal budesonide vs placebo

PAR (n = 26), nasal budesonide

Fluticasone (n = 16);

2

Placebo (n = 45)

2
1

Montelukast + budesonide (n = 44);

1

AR and OSA (n = 89):

Author Manuscript

Study

TSS, RQLQ, PSQI

SPT, methacholine
challenge, questionnaire

Questionnaire

Nocturnal RQLQ, PSQI

Questionnaire, ESS,
SF-36

PSG, nasal biopsies

ESS, PSG

ESS, symptoms scores,
CPAP compliance

Symptom and sleep
diary

ESS, FOSQ, RQLQ,
symptom diary

ESS, sleep diary,
questionnaire

TOVA, ESS, TSS

ESS, RQLQ, TSS,
CSAQLI, symptoms
diary

Clinical endpoint

Author Manuscript

Effect of allergic rhinitis on sleep in adults

AR disease severity has strong relationship with
sleep disturbance.

AR independently associated with difficulty
initiating sleep and daytime sleepiness (OR 2.0).

AR is a risk factor for snoring.

Treatment with triamcinolone improves nocturnal
rhinitis QOL and sleep quality.

Severity of nasal obstruction (nonvalidated
questionnaire) correlates with worse ESS and
lower QOL.

In AR, nasal corticosteroids reduce nasal
inflammation and improve PSG parameters.

Nasal corticosteroids improve sleep quality and
AR symptoms. Addition of antihistamine did not
have effect.

Control of rhinitis (with varying regimens of
steroid sprays, antihistamines, leukotrienes
inhibitors, anticholinergics, etc.) important for
OSA control. No difference: AR vs NAR.

Nasal corticosteroids improve symptoms and
subjective sleep compared to controls.

Budesonide improves daytime fatigue and sleep
quality in PAR.

Budesonide reduces nasal congestion, daytime
somnolence/fatigue, and improves sleep quality in
PAR.

Fluticasone improves daytime sleepiness,
cognitive performance, and nasal symptoms.

Montelukast + budesonide improves AR and OSA
QOL, sleep quality, and daytime somnolence.

Conclusion

Author Manuscript
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Author Manuscript
2006

1997
2017

Young et al.714

Bozkurt et al.721

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2012

2011

2009

2004

2004

2002

1981

1982

Park et al.729

Meng et al.720

Rimmer et al.711

Canova et al.730

Stuck et al.731

Krouse et al.719

Lavie et al.712

McNicholas et al.718
4

3b

3b

3b

3b

3b

3b

3b

3b

3b

2c

2c

Case series

Observational
cohort

Exploratory cohort

Observational
cohort

Case-control

Observational
cohort

Case-control

Observational
cross-sectional

Observational
cross-sectional

Case-control

Population-based

Population-based

Study design

Controls (n = 95)

2

Controls (n = 7)

AR (n = 7)

AR (n = 14);

2

Controls (n = 4)

1

AR (n = 4);

2

Controls (n = 25)

2
1

SAR (n = 25);

COPD controls (n = 44)

2
1

OSA (n = 72);

Control (n = 10)

1

PAR (n = 10);

2

Controls (n = 30)

1

PAR (n = 98);

2

OSA without rhinitis (n = 75)

2
1

OSA and AR (n = 37);

1

Sleep clinic patients (n = 157)

PAR and OSA symptoms (n = 150);

1

Survey subjects (n = 4297); objective testing
subjects (n = 911)

AR (n = 591)

Study groups

Nasal resistance, PSG

PSG

PSG, serum and nasal
cytokines

ESS, SF-36, PSG

Symptom score,
spirometry, SPT

Actigraphy

PSG

ESS, stress score,
fatigue score, coping
score, RQLQ

History, laboratory
testing

SPT, PSG

Questionnaire, PSG

SDQ, ESS, symptom
score

Clinical endpoint

AR patients have worse OSA symptoms when
symptoms are present and have high nasal
resistance.

AR patients had 10-fold increase in microarousals
compared to controls.

Differing cytokine levels associated with
variations in PSG.

SAR leads to increased daytime sleepiness
compared to controls.

OSA more likely to be sensitized to perennial
allergens (11% in OSA vs 2.3% COPD).

AR has increased sleep fragmentation and reduced
sleep quality.

PSG parameters showed modest changes in PAR
patients.

AR in OSA increases stress and fatigue, worsens
sleepiness and QOL.

62% OSA; 53% AR in OSA. No difference in
AR/atopy between OSA and non-OSA cohorts.

PAR did not affect PSG findings compared to
controls.

AR and nasal obstruction associated with snoring,
daytime sleepiness, and SDB.

All dimensions of sleep impaired by AR, disease
severity correlated with degree of sleep
impairment.

Conclusion

AR = allergic rhinitis; COPD = chronic obstructive pulmonary disease; CPAP = continuous positive airway pressure; CSAQLI = Calgary Sleep Apnea Quality of Life Index; ESS = Epworth Sleepiness
Scale; FOSQ = Functional Outcomes of Sleep Questionnaire; LOE = level of evidence; NAR = non-allergic rhinitis; OR = odds ratio; OSA = obstructive sleep apnea; PAR = perennial allergic rhinitis; PSG
= polysomnogram; PSQI = Pittsburgh Sleep Quality Index; QOL = quality of life; RCT = randomized controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SAR = seasonal allergic

2017

Gadi et al.728

Leger et

LOE

Author Manuscript
Year

Author Manuscript

al.727

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

rhinitis; SDB = sleep disordered breathing; ECRHS = European Community Respiratory Health Survey; SDQ = Sleep Disorders Questionnaire; SF-36 = Short Form 36; SPT = skin-prick test; TESOAD =
Tucson Epidemiology Study of Obstructive Airway Disease; TOVA = Test of Variables Attention; TSS = total symptom score.
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2015

2015

2013
2010
2010
2009
2008

Chimenz et al.736

Poachanukoon et al.737

Kwon et al.738

Li et al.739

Vichyanond et al.740

Sogut et al.741

Liukonnen et al.742

2005
2005

Ng et al.744

Sogut et al.745

2006

2016

Di Francesco et al.735

Kalra et

2013

Lin et al.734

al.743

2009

2015

2015

Year

Barone et al.733

Koinis-Mitchell et al.732

Kim et

al.722

3b

3b

3b

3b

3b

3b

3b

3b

3b

3b

3b

3a

2b

2b

2b

LOE

Cross-sectional

Cross-sectional

Cross-sectional

Population-based

Cross-sectional

Case-control

Cross-sectional

Population-based

Case-control

Case-control

Cross-sectional

Systematic review

Case-control

Individual cohort

Individual cohort

Study design

Study groups

Controls (n = 139)

2

Control (n = 104)

2

Turkish children (n = 1,198)

School children (n = 3,047)

Children in CCAAPS (n = 681)

Children in Helsinki (n = 2,100)

Turkish children (n = 1,030)

Children with rhinitis (n = 302)

Children (n = 6,349)

Children with AR (n = 85,002)

AR (n = 65);

AR and adenoid grade III-IV (n = 27)

2
1

AR and adenoid grade I-II (n = 32);

1

SDB undergoing T&A (n = 135)

N/A

Children from sleep disorders clinic
(n = 149);

1

Non-white Latino and African American urban
children (n = 195)

SDB undergoing T&A (n = 70)

Author Manuscript

Study

Questionnaire

Questionnaire

Questionnaire

Questionnaire

Questionnaire

History

Questionnaire

National survey data

Questionnaire

History

PSG

Association between
AR and SDB

PSG

Clinical evaluation
and follow-up

OSA-18, SPT,
questionnaire

Clinical endpoint

Author Manuscript

Effect of allergic rhinitis on sleep in children

AR associated with habitual snoring (OR 4.23; 95%
CI, 2.14–8.35).

AR associated with witnessed apnea.

29% of patients with HS have positive SPT,
significant association.

AR more common in snorers.

AR associated with habitual snoring (OR 3.7; 95%
CI, 1-13).

Upper airway obstruction associated with NAR.

Habitual snoring associated with AR (OR 2.9; 95%
CI, 2.0–4.2).

Association between late sleep time and short sleep
duration with AR.

Higher incidence of sleep disturbance in AR.

AR may influence development of nocturnal
enuresis.

AR affected REM sleep in children with SDB
without OSA. AR is not an aggravating factor in
AHI severity.

Most studies show association between AR and SDB
in children, but all studies were low level of
evidence.

AR associated with OSA, OR 2.24.

Poor AR and asthma control related to high
frequency of sleep problems and poor sleep hygiene.

AR may be risk factor for deterioration of OSA QOL
after T&A.

Conclusion

Author Manuscript
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Author Manuscript
2001
2010
2005

Anuntaseree et al.747

Bhattacharjee et al.748

Goldbart et al.749

1997

al.752

Mansfield et

McColley et

4

4

4

4

4

3b

3b

Case series

Case series

Case series

Case series

Prognostic cohort

Cross-sectional

Cross-sectional

Study design

Children with HS (n = 39)

Children with AR (n = 14)

Children with AR undergoing SPT (n = 202)

SDB (n = 24)

Children undergoing AT for OSA (n = 578)

Randomly selected children (n = 1,142)

School children (n = 11,114)

Study groups

PSG

PSG, RQLQ

History

PSG, lateral neck Xray

PSG

PSG, questionnaire

Questionnaire

Clinical endpoint

Positive skin test associated with OSA.

Treating AR decreases AHI.

17% of AR patients reported HS.

Montelukast treatment for 16 weeks decreased
adenoid size and respiratory sleep disturbances.

AR identified in 39% of children with OSA
undergoing AT.

Prevalence habitual snoring 8.5%, OSAS 0.69%; OR
5.27 in children with AR.

Snoring in 34%, AR associated with snoring (OR
2.9; 95% CI, 2.06–4.08).

Conclusion

AHI = apnea-hypopnea index; AR = allergic rhinitis; AT = adenotonsillectomy; CCAAPS = Cincinnati Allergy and Air Pollution Study; CI =confidence interval; HS =habitual snoring; LOE = level of
evidence; NAR = non-allergic rhinitis; OR = odds ratio; OSA = obstructive sleep apnea; OSA-18 = 18-item quality-of-life survey for obstructive sleep apnea; OSAS = obstructive sleep apnea syndrome;
PSG = polysomnogram; QOL = quality of life; REM = rapid eye movement; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SDB = sleep disordered breathing; SPT = skin prick test; T&A =
tonsillectomy and adenoidectomy.

2004

al.751

Kidon et al.750
2004

2004

Chng et

LOE

Author Manuscript
Year

Author Manuscript

al.746

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript
2011

Costa et al.780

2000

2015
2008

2007
2001

Ng et al.779

Seidman et al.761

Wallace et al.26

Small et al.777

Bousquet et al.7
5

5

5

5

4

4

4

3b

LOE

Guideline

Guideline

Guideline

Guideline

Case-control

Survey

Cohort study

Crosssectional

Study design

Physicians of
group 1

2

Adults with AR

Adults and
children >12 years
with AR;

1

Adults with AR

Adults with AR

Study groups

Recommendations on the diagnosis
and treatment of AR in asthmatic
patients

Recommendations on diagnosis and
treatment of rhinitis

Recommendations on the diagnosis
and treatment of rhinitis

Recommendations on diagnosis and
treatment of AR

History, physical examination, SPT,
sIgE

Self-completed patient questionnaire,
physician patient record form

Physician interview and structured
questionnaire

History, physical examination, SPT

Clinical endpoint

AR = allergic rhinitis; LOE = level of evidence; sIgE = antigen-specific immunoglobulin E; SPT = skin prick test.

2007

Shatz778

Raza et

2011

Year

al.781

Study

Evidence for the role of history taking and physical examination in the diagnosis of allergic rhinitis

Symptom type and timing (obtained through history) is essential
to correct diagnosis. Lung exam is recommended in asthmatic
patients with symptoms of AR.

History of allergic symptoms is essential in the diagnosis of AR.
Physical exam aids in supporting the diagnosis of AR.

Thorough allergic history remains the best diagnostic tool
available. All organ systems potentially affected by AR should be
examined. Typical allergic exam findings are supportive but not
specific.

Clinical diagnosis of AR made with a history and physical
examination consistent with AR.

Rhinorrhea, sneezing, sniffing, impaired sense of smell, blocked
nose, edematous nasal mucosa, and itchy nose ranked highest in
diagnostic utility. Physical examination performed to eliminate
other potential causes of symptoms.

Persistent AR patients reported more symptoms than intermittent
AR patients.

Many patients diagnosed on history alone without confirmatory
testing.

Physical examination alone yields unreliable and inconsistent
results in diagnosing AR.

Conclusion

Author Manuscript
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Author Manuscript

Author Manuscript

al.786

2011
1999

Ameli et al.782

Jareoncharsri et al.784
4

4

4

3b

3b

LOE

Case series

Case series

Case series

Cross-sectional

Cross-sectional

Study design

Adults and children with PAR

Children with suspected AR

Adults with rhinitis

Adults with isolated MT polypoid
edema

Adults with rhinitis and nasal
obstruction

Study groups

Clinical endpoint

Nasal endoscopy, nasal
symptoms

Nasal endoscopy, AR
diagnosis

Nasal endoscopy, AR
diagnosis

Nasal endoscopy, allergy
testing

Nasal endoscopy, allergy
testing

AR = allergic rhinitis; LOE = level of evidence; MT = middle turbinate; PAR = perennial allergic rhinitis.

2013

2014

2016

Year

Eren et al.783

White et al.785

Hamizan et

Study

Author Manuscript

Evidence for the role of nasal endoscopy in the diagnosis of allergic rhinitis

No significant correlation between individual symptoms and
endoscopic findings.

Inferior or middle turbinate septal contact was predictive for AR,
whereas pale turbinates were not.

Nasal endoscopic findings do not provide reliable diagnosis of
AR.

Isolated MT polypoid edema is associated with positive allergy
testing.

MT edema is a useful nasal endoscopic feature to predict presence
of inhalant allergy.

Conclusion

Author Manuscript
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AR, AC, asthma
AR, AC, asthma
AR
Rhinoconjunctivitis
Rhinoconjunctivitis
Rhinitis
AR, NAR
AR
AR, NAR, asthma
Rhinitis, AC, asthma
Rhinitis, AC
AR, asthma
AR
Rhinoconjunctivitis
Rhinoconjunctivitis
Rhinoconjunctivitis
Total nasal and non-nasal
symptoms

DMS: Daily Medication Score

DCS: Daily Combined Score

TCRS: Total Combined Rhinitis Score

Mini-RQLQ: Mini-Rhinoconjunctivitis Quality
of Life Questionnaire

RQLQ: Rhinoconjunctivitis Quality of Life
Questionnaire

VAS: Visual Analogue Scale

RCAT: Rhinitis Control Assessment Test

ARCT: Allergic Rhinitis Control Test

CARAT10: Control of Allergic Rhinitis and
Asthma Test

ACS: Allergy Control Score

RC-ACS: Rhinoconjunctivitis Allergy Control
Score

RAP: Respiratory Allergy Prediction

SFAR: Symptom Score For Allergic Rhinitis

RMS: Rescue Medication Score

RTSS: Rhinoconjunctivitis Total Symptom
Score

CS: Combined Score

Global Assessment: Global Assessment of
Severity of Allergy

1

6+ meds

6

Meds

8

9+ meds

7+ meds

10+ meds

10

5

6

1 or more

28

14

Varies

Varies

Varies

4

Number of
questions

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Symptom
questions

No

Yes

No

Yes

No

Yes

Yes

Yes

Yes

Yes

No

No

No

No

Yes

Yes

Yes

No

Higher score equates to better control of disease. A score of 0 denotes zero control of symptoms.

b

Maximum score may vary depending on specific number of symptom related questions and specific medication score included.

a

AR

Disease targeted

TNSS: Total Nasal Symptom Score

Survey

Medication
questions

The sum of the combined symptoms medication scores

a

Used to compare groups in clinical trials

b

1–7

0–3

0–18

0–3

0–16

0–9

0–42

0–60

0–30

Single question about rhinitis severity

Combined scores of RTSS/6 + RMS/2

Evaluates symptoms only

Evaluates medication use only

Weighted score used to detect prevalence of AR

Used to determine the need for referral and additional
testing

Similar to ACS but without asthma related questions

Combined tool used for clinical trials and daily clinical
practice

Self-assessment of ongoing AR symptoms control

b
5–25

6–30

Self-assessment of rhinitis symptom control

Tool may be used to evaluate multiple symptomatologies

Reflective assessment of previous week’s symptoms often
used in clinical trials

b

0–10 cm

0–168

0–84

0–24

Shortened version of RQLQ often used in clinical trials

Combined symptom and medication score for clinical trials

a

0–48

0–36

Varies depending on medication scoring

Simple daily symptom score to evaluate AR severity and
control used in clinical trials

Comments and indications

a

0–12

Scoring
range

Author Manuscript

Validated surveys used to diagnose AR or evaluate disease severity and treatment

Author Manuscript
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Author Manuscript
AC = allergic conjunctivitis; AR = allergic rhinitis; meds = medications; NAR = nonallergic rhinitis.
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Author Manuscript

Author Manuscript

Author Manuscript
2016
2015
2015
2016

Zieglmayer et al.798

Klimek et al.805

Mosbech et al.799

al.802

2012

Hafner et al.806
2b

2b

2b

2b

1b

1b

1b

1b

1a

1a

LOE

Cohort

Cohort

Cohort

Cohort

RCT

RCT

RCT

DBRPCT

Systematic review

Systematic review

Study
design

ARC

ARC

AR, AC,
asthma

AR

AR

ARC

AR

AR

AR

ARC

Study
groups

Evaluation of RC-ACS test in 81 subjects

Minimal clinically important difference of
RTSS

Evaluation of RAP test

Evaluation of AR by VAS, RTSS and RQLQ

Efficacy of HDM SLIT for AR

Effectiveness of recombinant birch SCIT

Efficacy of B-cell vaccine

Efficacy of HDM SLIT tablet

Comparison of scoring systems

Meta-analysis of grass SLIT efficacy

Clinical endpoint

RC-ACS is a valid test for evaluating ARC without asthma.

RTSS vs RQLQ showed minimal clinically important difference of
1.

RAP test is valid for screening allergic disease

Comparison of various outcome measures validates their utility.

RQLQ used effectively in this evaluation.

Combined score and VAS revealed no difference between
recombinant and standard birch SCIT.

TNSS score used to determine efficacy in large study.

TCRS confirmed efficacy of SLIT.

TNSS and combined medication scores should be used in clinical
trials.

Combined symptom and medication score showed efficacy of grass
SLIT.

Conclusion

AC = allergic conjunctivitis; AR = allergic rhinitis; ARC = allergic rhinoconjunctivitis; DBRPCT = double-blind randomized placebo controlled trial; HDM = house dust mite; LOE = level of evidence;
RAP = Respiratory Allergy Prediction; RC-ACS = Rhinoconjunctivitis Allergy Control Score; RCT = randomized controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; RTSS =
Rhinoconjunctivitis Total Symptom Score; SCIT = subcutaneous immunotherapy; SLIT = sublingual immunotherapy; TCRS = Total Combined Rhinitis Score; TNSS = Total Nasal Symptom Score; VAS =
visual analog scale.

2014

Devillier et al.813

Galimberti et

Devillier et
2015

2016

Demoly et al.803

al.814

2014

Calderon et al.801

Di Bona et

2015

Year

al.815

Study

Evidence for the role of validated survey instruments in the evaluation, diagnosis, and follow-up of allergic rhinitis
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Author Manuscript

Author Manuscript

Author Manuscript
2004

2004

2004

2000

1999

1998

Krouse et al.831

Krouse et al.832

Zarei et al.834

Pumhirun et al.835

Wood et al.793

Tschopp et al.822

2016

Year

2004

al.830

Gungor et al.833

Nevis et

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
3b

3b

3b

3b

3b

3b

3b

1a

LOE

Prospective
case-control

Prospective
case-control

Prospective
case-control

Prospective
case-control

Prospective
case-control

Prospective
case-control

Prospective
case-control

Systematic
review and
meta-analysis

Study design

A randomly selected sample of 8329
Swiss adults

Patients with cat allergy determined
by history and a cat-exposure model

Perennial rhinitis patients

Nasal provocation test
negative

2

Timothy grass negative

3
Nasal provocation test
positive;

Timothy grass
intradermal #2 dilution
positive;

2

1

Timothy grass SPT
positive;

Alternaria negative

3
1

Alternaria SPT positive;
Alternaria intradermal
#2 dilution positive;

1

Nasal provocation test
negative

2

2

Nasal provocation test
positive;

1

Not applicable

Study groups

Evidence for the role of skin-prick testing in the diagnosis of allergic rhinitis

Compared the sensitivity,
specificity, PPV, and NPV of
SPT, IgE levels, and
fluoroenzyme immunoassay
in diagnosing AR

Compared the predictive
values of SPT, intradermal
testing, and RASTs in the
diagnosis of cat allergy

Compared sensitivity and
specificity of intradermal
testing to SPT and specific
IgE assay for D.
pteronyssinus and D. farinae

Wheal size that best identifies
clinical allergy to cat based on
nasal provocation testing

Acoustic rhinometry of
minimal cross-sectional area
of nasal cavity

Acoustic rhinometry of
minimal cross-sectional area
of nasal cavity

Sensitivity and specificity of
SPT vs SET for diagnosing
AR

Accuracy of SPT

Clinical endpoint

Sensitivity of fluoroenzyme immunoassay was significantly
higher than SPT and IgE. However, SPT was more specific and
had a better PPV. SPT was the most efficient test to diagnose
AR.

SPT and RAST values exhibited excellent efficiency in diagnosis
of cat allergy. Intradermal testing added little to the diagnostic
evaluation. Sensitivity and specificity of SPT were 79% and
91%, respectively.

SPT for D. pteronyssinus and D. farinae were 90.4% and 86.4%
sensitive and 99.5% and 93.1%, specific, respectively. This
compared to sensitivity of 96.3% and 88.9% and specificity of
96.2% and 88.9% of specific IgE assay, respectively.

On SPT with cat antigen, a wheal size of ≥3 mm had a sensitivity
of 100% and specificity of 74.1%. This improved with increasing
size of wheal.

Analysis of nasal provocation test results among groups showed
a sensitivity of 87% and specificity of 86% with multi-test
application of Timothy grass antigen.

Analysis of nasal provocation test results among groups showed
a sensitivity of 42% and specificity of 44% for SPT using
Alternaria antigen.

SPT more sensitive (85.3% vs 79.4%) and specific (78.6% vs
67.9%) than SET as a screening procedure for multiple antigens.
SPT had a greater PPV (82.9% vs 75%) and NPV (81.5% vs
73%) than SET. None of these differences were statistically
significant.

Pooled estimate for SPT sensitivity and specificity was 85% and
77%, respectively. SPT is accurate in discriminating subjects
with or without AR.

Conclusion

Author Manuscript
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Author Manuscript
2013

Heinzerling et al.

5

5

5

Practice
parameter

Review

Guideline

Study design

Not applicable

Not applicable

Not applicable

Study groups

Not applicable

Not applicable

Not applicable

Clinical endpoint

Sensitivity of SPT ranges from 85% to 87% while specificity is
79% to 86%. Many studies have verified the sensitivity and
specificity of SPT.

SPT is a reliable method to diagnose AR with specificity of 70%
to 95% and sensitivity of 80% to 90% for inhalant allergies.
Further standardization of SPT is needed.

Clinicians should perform and interpret or refer for specific IgE
(skin or blood) allergy testing for patients with a clinical
diagnosis of AR who do not respond to empiric treatment or the
diagnosis is uncertain.

Conclusion

AR = allergic rhinitis; IgE = immunoglobulin E; LOE = level of evidence; NPV = negative predictive value; PPV = positive predictive value; RAST = radioallergosorbent test; SET = skin endpoint titration;
SPT = skin prick test/testing.

Bernstein et al.818

836

2008

2015

Seidman et

LOE

Author Manuscript
Year

Author Manuscript

al.761

Author Manuscript

Study
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Author Manuscript

Author Manuscript
2015

Larrabee et al.
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2004

2004

1999
1996

1993

Krouse et al.832

Krouse et al.831

Wood et al.793

Nelson et al.856

Escudero et al.

860

2004

Gungor et al.833

859

Nevis et

2016

Year

al.830

Study

2b

2b

2b

2b

2b

2b

2b

1a

LOE

Cohort

Cohort

Cohort

Cohort

Cohort

Cohort

Cohort

Systematic
review

Study design

Negative SPT, negative ID
test

3

Negative SPT, negative ID
test

3

SAR, positive SPT;
SAR, positive SPT, positive
ID test;
No rhinitis

2
3
4

Rhinitis patients (n = 66), 31 with
Alternaria allergy

SAR, negative SPT, positive
ID test;

1

(n = 70):

Patients with a history of symptoms with cat
exposure (n = 120)

Positive SPT;
Negative SPT, positive ID
test;

1
2

AR (n = 44):

Positive SPT;
Negative SPT, positive ID
test;

1
2

SAR (n = 37):

Patients with SAR and ragweed sensitivity
(n = 62)

AR patients who underwent ID testing
based on high suspicion after negative SPT
(n = 87)

AR patients who underwent skin testing (n
= 430)

Study groups

SPT, ID, challenge tests and in
vitro sIgE. Clinical history and
nasal/bronchial challenge
considered gold standard.

Nasal challenge with Timothy
grass

Cat exposure challenge, symptom
scores, FEV1

Nasal allergen provocation score
for Alternaria, visual analog
scale, rhinomanometry

Nasal provocation with Timothy
grass, rhinomanometry

Nasal provocation testing,
rhinomanometry

Result of ID test

Sensitivity and specificity of skin
testing methods

Clinical endpoint

Author Manuscript

Evidence for the role of intradermal skin testing in the diagnosis of allergic rhinitis

For rhinitis patients, SPT, ID, and conjunctival challenge
were more sensitive than serum sIgE. All testing methods
had similar specificity.

Positive ID along with negative SPT did not indicate the
presence of clinically significant sensitivity.

ID scores added little value beyond SPT and RAST
values.

ID testing after SPT increased the sensitivity from 42% to
58%.

ID testing after SPT increased the sensitivity from 87% to
93%.

Sensitivity and specificity of ID testing was comparable to
SPT.

21% were ID positive, more likely for indoor allergens.

ID testing had higher sensitivity and specificity when used
as a stand-alone test than when used to confirm SPT.

Conclusion

Author Manuscript
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2007

2006

2005

2005

Peltier &
Ryan844

Peltier &
Ryan850

Purohit et al.852

Schwindt et al.
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4

3b

3b

3b

3b

2b

2b

2b

2b

Retrospective
cohort

Cohort

Cohort

Cohort

Cohort

Cohort

Cohort

Cohort

Cohort

Allergy clinic patients (n = 34)

Patients with allergy (n = 97)

Patients with birch pollen allergy (n = 18)

Volunteers tested simultaneously for mold
allergens with SPT and IDT (n = 86)

Volunteers underwent simultaneous SPT
and IDT for 5 common allergens (n = 134)

Patients referred for allergy diagnostic
testing (n = 54)

Patients with perennial rhinitis (n = 34),
negative SPT for 60 allergens but with at
least 1 positive ID test

Suspected allergy patients (n = 497)

Allergy patients (n = 41)

Study groups

Patients tested for aeroallergen
sensitivity with both IDT and
SPT.

Using clinical history as gold
standard, prick, ID, and challenge
test results compared

Correlations among IDT
endpoint, serum sIgE, and
provocation thresholds for
basophil histamine release.

SPT wheal size compared to IDT
endpoints

SPT wheal size compared to IDT
endpoint

Positive clinical histories
compared to RAST results and
IDT results

RAST, nasal provocation and
leukocyte histamine release
compared to ID positivity, SPT
negativity

Simultaneous ID, pRAST, and
clinical history compared.
Standardized grass pollen, tree
pollen, cat, dust mite tested.

Simultaneous SPT, ID testing
with varying concentrations of
Phleum and D. pteronyssinus, as
well as pRAST on all subjects.

Clinical endpoint

A significantly greater number of patient tested positive
with IDT compared to SPT. SPT wheal size and IDT
endpoint correlated for several allergens. IDT may be
more sensitive than SPT.

If SPT with multi-test II device was negative, 17% of
subjects had a positive ID test that corresponded with
clinical history. None of these positive ID tests
corresponded with a positive nasal challenge. When multitest II results are negative, positive ID tests are unlikely to
identify clinically relevant aeroallergen sensitivity.

IDT endpoint correlated directly with basophil histamine
release in response to allergen exposure. IDT endpoint did
not correlate with rBet v 1 serum sIgE level.

In subjects with clinical symptoms of allergy there was a
direct statistically significant correlation between SPT
wheal size and IDT endpoint. ID tests identified 10%
more positive results compared to SPT alone.

IDT endpoint directly correlates with SPT wheal size for
all antigens tested, especially for Bermuda, dust mite, and
ragweed.

High degrees of skin reactivity (positive ID tests at high
allergen concentrations) correspond with a higher rate of
positive clinical history and positive RAST results.

Patients with only ID positive skin tests (SPT negative)
did not have a positive RAST nor a positive leukocyte
histamine release. In contrast, SPT positivity was
associated with positive RAST test and leukocyte
histamine release assay. When SPT are negative for
perennial rhinitis patients, positive ID tests are not likely
to indicate the presence of IgE-mediated allergy.

Ideal cutoff for positive ID test is wheal diameter 0.7
times the size of histamine control. ID has 83% predictive
value vs RAST and 77% predictive value vs clinical
history.

Coefficient of variation of ID test histamine wheal size is
6% within patients and 12% between patients. Optimum
concentration of tested allergens was 10–100 BU/mL, a
7.5 mm ID wheal is ideal cutoff value for positive result
(0.83× the size of average histamine wheal).

Conclusion

AR = allergic rhinitis; BU = biological units; FEV1 = forced expiratory volume in 1 second; ID = intradermal; IDT = intradermal dilutional titration; LOE = level of evidence; pRAST = Phadebas
radioallergosorbent test; RAST = radioallergosorbent test; SAR = seasonal allergic rhinitis; sIgE = antigen-specific immunoglobulin E; SPT = skin-prick test.

Simons et al.851
2004

1975

Perera et al.853

858

1978

1993

Reddy et al.857

855

Niemeijer et al.

846

1993

Author Manuscript

Niemeijer et al.

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript

al.862

2006

Peltier & Ryan850
4

4

4

4

3b

LOE

Case series

Case series

Case series

Systematic review

Systematic review
with costeffectiveness analysis

Study design

Adults with AR (n
= 86)

Adults with AR (n
= 9)

Adults with AR (n
= 134)

Study groups

MQT for 6 mold antigens

2

SNOT-20, AOS, RSDI

3
Intradermal tests for 6 mold antigens;

IgE and IgG4 levels for 3 antigens;

1

MQT;

2

2

SPT and subsequent IDT following MQT
protocol for 5 antigens

1

1

Intradermal tests for 5 antigens;

Review of skin testing techniques

Comparison of sIgE, intradermal tests, and MQT from a
payer perspective

Clinical endpoint

MQT-based testing is a safe method for
determining starting AIT doses for fungal
allergens.

MQT-based AIT demonstrates immune system
changes and QOL improvement.

MQT is a safe alternative to classic IDT for
determining AIT starting doses.

MQT is a valid form of skin testing.

MQT most cost-effective when population
prevalence of AR is 20% or higher.

Conclusion

AIT = allergen immunotherapy; AOS = Allergy Outcome Survey; AR = allergic rhinitis; IDT = intradermal dilutional testing; IgG4 = immunoglobulin G4; LOE = level of evidence; MQT = modified
quantitative testing; QOL = quality of life; RSDI = Rhinosinusitis Disability Index; sIgE = antigen-specific immunoglobulin E; SNOT-20 = 20-item Sino-Nasal Outcome Test; SPT = skin-prick testing;

2006

2007

2014

2008

Year

Krouse & Krouse861

Peltier &

Ryan844

Fornadley847

Lewis et

Study

Evidence for the role of blended skin testing techniques in the diagnosis of allergic rhinitis
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TABLE VIII.E.3.
Wise et al.
Page 331

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Author Manuscript

Author Manuscript
2003

2003

2003
2003

1997

1989

1989

1987

1974

Hill & Krouse876

More et al.889

Noga et al.890

Pearlman et al.869

Simons &
Simons865

Miller &
Nelson870

Pipkorn et al.891

Andersson &
Pipkorn883

Slott &
Zweiman879

2007

Year

2004

al.871

Spergel et al.888

Kupczyk et

Study
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1b

1b

1b

1b

1b

1b

1b

1b

1b

1b

1b

LOE

DBPCT,
crossover

DBPCT

RDBPCT

RDBT

RDBPCT,
crossover

RPCT

RDBPCT

RDBPCT

RDBPCT

RDBT, within
subject
comparison

DBPCT,
crossover

Study design

Atopic patients (n = 15)

AR patients (n = 17)

AR patients (n = 10)

Healthy subjects (n = 23)

Adult males (n = 20)

SAR patients (n = 78)

Moderate-severe asthmatics (n = 35)
treated with placebo or omalizumab

Healthy volunteers (n = 15). Single
blinded dose of placebo, fexofenadine, 23
other herbal preparations. Minimum 72hour washout period between doses

Atopic subjects (n = 23)

Atopic dermatitis and AR or asthma (n =
12 adults). Vehicle or pimecrolimus on
each arm

Atopic subjects (n = 21). SPT with
histamine, codeine, allergen, negative
control after 5 days of ranitidine,
loratadine, or placebo

Study groups

Intradermal wheal size differences for
histamine, allergen, and compound 48/80

Effect of topical clobetasol (BID application
for 1 week) on histamine and allergen SPT
response

Allergen SPT wheal and flare before and
after 2 to 4 weeks of twice daily clobetasol
cream applied to forearm skin test sites

Histamine-induced and compound 48/80induced skin prick wheal and flare after
placebo or ranitidine 150 mg ×7 doses

SPT wheal and flare response after single
day dosing of PO fexofenadine and
loratadine

Inhibition of histamine-induced wheal after
single dose or 2 weeks of azelastine nasal
spray

SPTs for allergen before and 16 weeks after
treatment

Histamine 1 mg/mL wheal at baseline and 4
hours after single dose of herbal preparation

Intradermal whealing response after
loratadine, montelukast, or placebo
treatment

Allergen SPT wheal and flare, before and
after topical 1% pimecrolimus cream

Wheal, flare measured in mm. Pruritis
measured with 10-point scale

Clinical endpoints

Author Manuscript

Evidence for the effect of medication on allergy skin test reactivity

No effect of 7 days of methylprednisolone on
intradermal wheal size.

Topical clobetasol significantly suppresses
allergen-induced wheal and flare response.

Clobetasol treated skin had significantly
reduced wheal and flare response to allergen.
Histamine-induced wheal was reduced at 4
weeks by topical steroid.

Ranitidine reduced the histamine-induced
wheal and flare by 22%. No significant
reduction in compound 48/80-induced wheal
and flare.

Fexofenadine and loratadine both inhibited
SPT wheal and flare response for 24 hours.

2 weeks of azelastine inhibited wheal and flare
in some patients. Histamine skin test responses
returned to baseline at 48 hours after cessation.

Omalizumab caused significant reduction in
SPT wheal size compared to placebo.

Fexofenadine significantly reduced SPT wheal
size compared to placebo. None of the 23
herbal preparations tested showed a
statistically significant effect on wheal size
compared to placebo.

Loratadine, but not montelukast, reduced the
intradermal wheal diameter after allergen
injection.

1% pimecrolimus cream does not significantly
impact allergy skin test results.

Relative to placebo, ranitidine reduced
histamine wheal (41%) and flare (16%); and
allergen wheal (23%) and flare (22%).
Loratadine reduced histamine wheal (51%) and
flare (33%); and allergen wheal (40%) and
flare (44%), respectively. Ranitidine and
loratadine both reduced pruritis score by
almost 30%.

Conclusion

Author Manuscript
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2005

Narasimha et al.

1988

1988

1985

Rao et al.873

Long et al.863

1996

Almind et al.867

878

Des Roches et al.

877

Cuhadaroglu et al.

2001

2008

Gradman &
Wolthers885

882

2008

2011

Isik et al.874

Corren et al.875

1973

Author Manuscript

Cook et al.868
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2b

2b

2b

2b

2b

2b

2b

2b

2b

1b

Cohort

Cohort

Cohort

Cohort

Cohort

Cohort

Randomized
crossover
cohort

Cohort

Cohort

Double blind
randomized
controlled
study

Study design

Asthma and/or AR (n = 66)

2

18 subjects; 10 had positive SPT to grass
or ragweed allergens

Healthy subjects (n = 33)

Healthy individuals (n = 23)

Steroid-dependent asthma
patients (n = 33);

Controls (n = 8)

2
1

Asthma/AR patients (n =
9);

1

26 subjects

Atopic eczema patients (n = 12 children)

PAR patients (n = 40)

Patients on SSRIs for depression (n = 24)

AR patients (n = 18 adults)

Study groups

Author Manuscript
LOE

Effect of 6 different antihistamines on SPT
wheal and flare reaction to histamine or
morphine or relevant aeroallergen. Effect of
hydroxyzine and chlorpheniramine on skin
test responses to other antihistamine classes.

Histamine prick tests for 1 week after single
dose of desipramine or doxepin.

Effect on histamine SPT wheal size after 2day treatment with dexchlorpheniramine,
cyproheptadine, astemizole, loratadine,
terfenadine. Duration of SPT wheal
suppression after cessation.

Codeine and dust mite induced SPT
response with or without exposure to longterm systemic steroids.

SPT to histamine and allergens before and
after zafirlukast 20 mg BID for at least 5
days.

Effect of topical clobetasol application on
histamine-induced wheal response.

SPT for 10 allergens before and after active
treatment with topical mometasone or
topical tacrolimus. Skin test sites were
presumably treated daily for a total of 2
weeks.

Dust mite allergen skin test reactivity
(titrated prick tests) before during and after
omalizumab therapy.

Histamine-induced and allergen-induced
prick test wheal responses before and after
starting SSRI treatment.

Intradermal wheal size suppression after 3
day course of chlorpheniramine,
tripelennamine, promethazine, hydroxyzine,
and diphenhydramine

after 7 days of methylprednisolone 24 mg
per day

Clinical endpoints

Author Manuscript

Year

Antihistamines varied in their ability to
suppress SPT wheal response. Administration
of hydroxyzine for 3 weeks leads to reduced
skin test suppression for the antihistamines
tested, suggesting induction to tolerance to
antihistamine effects.

Desipramine inhibits wheal response for 2
days; doxepin inhibits wheal response for 4
days.

All antihistamines suppressed SPT wheal
response to histamine. Duration of suppression
exceeded 72 hours for all agents tested.

Systemic steroid therapy does not alter SPT
reactivity to codeine or allergen.

Zafirlukast did not suppress histamine-induced
or allergen-induced wheal and flare response.

Topical clobetasol inhibited skin prick
whealing response to histamine at the site of
topical steroid application in a dose-dependent
and duration-dependent manner.

Topical mometasone and tacrolimus
significantly reduced SPT wheal diameter.
Topical mometasone also reduced histamine
induced wheal, while tacrolimus did not.

Omalizumab (anti-IgE) therapy significantly
reduces allergy skin test reactivity.

SSRIs fluoxetine, sertraline, and escitalopram
did not significantly affect skin prick whealing
responses.

All antihistamines suppressed wheal size to
varying degrees. Hydroxyzine suppressed
responses for 4 days after cessation vs 2 days
for diphenhydramine.

Conclusion

Author Manuscript

Study
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Author Manuscript
2010

2009
1990

Shah et al.886

Duenas-Laita et
al.887

Olson et al.880
4

4

4

3b

2b

2b

Retrospective
cohort

Cohort

Retrospective
cohort

Case-control

Cohort

Cohort

Study design

Controls (n = 125)

2

Atopic patients with
chronic systemic steroid
treatment (n = 25);
Atopic patients without
systemic steroid use (n =
25)

1

2

Drug abusers taking alprazolam 2 mg TID
(n = 42)

Histamine SPT responses in patients with
variable exposure to a variety of
medications

Cases with negative
histamine control tests
despite avoidance of
antihistamine medications
(n = 52);

1

Healthy subjects (n = 10)

Atopic subjects (n = 10)

Study groups

Intradermal skin test reactivity to codeine
and histamine

Histamine (10 mg/mL) SPT

SPT wheal area and SPT positivity as
function of medication exposure and time
since last dose

OR that multiple clinical variables including
medication use predict negative histamine
control test

Titrated intradermal histamine wheal before
and after treatment with hydroxyzine,
cimetidine, or both.

Inhibition of allergen-induced and
histamine-induced wheals by local
intradermal antihistamine and cromoglycate
injection.

Clinical endpoints

Chronic systemic steroid use reduces codeineinduced wheal response but not histamineinduced wheal response.

All subjects taking alprazolam had negative
histamine SPT.

H1 antagonists impaired whealing responses
within 3 days of discontinuation; tricyclic
antidepressants, benzodiazepines, mirtazapine,
quetiapine had wheal suppression; other SSRIs
and SNRIs as well as H2 antagonists were not
independently associated with wheal
suppression.

ICU stay, systemic steroid use, H2 blockers,
and older age associated with negative
histamine control test.

Hydroxyzine inhibited cutaneous wheal
response to histamine. Cimetidine did not.
However, the 2 together produced significantly
reduced whealing compared to either alone.

Antihistamines ketotifen, clemastine, and
chlorpheniramine significantly inhibit skin
whealing responses. Sodium cromoglycate had
no effect.

Conclusion

AR = allergic rhinitis; BID = twice a day; DBPCT = double-blind placebo controlled trial; ICU = intensive care unit; IgE = immunoglobulin E; LOE = level of evidence; OR = odds ratio; PAR = perennial
allergic rhinitis; PO = per os (by mouth); RDBPCT = randomized double-blind placebo controlled trial; RDBT = randomized double blind trial; RPCT = randomized placebo controlled trial; SAR =
seasonal allergic rhinitis; SNRI = selective norepinephrine reuptake inhibitor; SPT = skin-prick test; SSRI = selective serotonin reuptake inhibitor; TID = 3 times a day.

2015

1980

1983

Geng et al.881

Harvey &
Schocket872

Phillips et

LOE

Author Manuscript
Year

Author Manuscript

al.864

Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
Aggregate Grade of Evidence: A (Level 1b: 2 studies, Level 2b: 3 studies)
• Should be discontinued 2-7 days prior to testing.
Aggregate Grade of Evidence: B (Level 1b: 2 studies)
• Ranitidine suppresses skin whealing response, may result in false negatives.
Aggregate Grade of Evidence: Unable to determine from one Level 1b study.
• Should be discontinued 2 days prior to testing.
Aggregate Grade of Evidence: A (Level 1b: 2 studies)
• Results in negative allergy skin test results.
Aggregate Grade of Evidence: A (Level 1b: 2 studies, Level 2b: 1 study)
• May be continued during testing.
Aggregate Grade of Evidence: Unable to determine from one Level 2b study.
• Agents with antihistaminic properties suppress allergy skin test responses.
Aggregate Grade of Evidence: A (Level 1b: 2 studies, Level 2b: one study)
• Skin tests should not be placed at sites of chronic topical steroid treatment.
Aggregate Grade of Evidence: C (No effect – Level 1b: 1 study, Level 2b: 1 study; Suppression – Level 3b: 1 study, Level 4: 1 study)
• Systemic corticosteroid treatment does not significantly impair skin test responses.
Aggregate Grade of Evidence: B (Level 2b: 1 study, Level 4: 1 study)
• Does not suppress allergy skin test response.
Aggregate Grade of Evidence: C (Level 4: 1 study, Level 5: 1 case report)
• May suppress skin test responses.
Aggregate Grade of Evidence: D (Level 1b: 1 study, Level 2b: 1 study – results conflicting)
• Conflicting results regarding skin test suppression.

H1 antihistamines

H2 antihistamines

Topical antihistamines (nasal, ocular)

Anti-IgE (omalizumab)

Leukotriene receptor antagonists

Tricyclic antidepressants

Topical (cutaneous) corticosteroids

Systemic corticosteroids

Selective serotonin reuptake inhibitors (SSRIs)

Benzodiazepines

Topical calcineurin inhibitors (ie. tacrolimus, picrolimus)

Aggregate grades of evidence: medications that affect allergy skin testing

Author Manuscript
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2011

2007

2016

2014

2014

2013

Jung et al.895

Marinho et al.893

Li et al.901

Chung et al.899

Jacobs et al.900

Hatcher et al.897

896

2012

2016

Park et al.902

Demirjian et al.

Year

Study
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3b

3b

3b

3b

2b

2b

2b

2b

LOE

Retrospective
case series,
followed by a
prospective study

Cross-sectional

Retrospective
case series

Retrospective
case series

Wholepopulation birth
cohort

Prospective
cohort

Prospective
cohort

Prospective
cohort

Study design

30 patients (≥6 years) with a
negative allergy screen and
serum tIgE >116 kU/L;
26 control patients with
negative allergy screen and
stIgE < 2.95 kU/L; Chronic
sinusitis in 76.9% of study
group and 19.2% of control
group; p < 0.0001.

1

2

547 children (6–14 years) from randomly
selected households; 265 with skin test
positive AR.

Patients from otolaryngology clinic. Total
patients (n = 1073 children and adults, 753
with rhinitis), mean age 36.9 years.

Patients from otolaryngology clinic. Total
patients (n = 610 adults, 349 with AR),
median age 27.0 years.

478 children from MAAS

Patients with AR symptoms (n = 442),
median age 33 years.

Patients referred to allergy clinic. Total
patients (n = 358,184 with rhinitis), mean
age 57 years.

313 school children, 2-year follow-up study

Study groups

Serum tIgE (kU/mL),
continuous variable

Log serum tIgE (kU/L)

Serum tIgE level >150
IU/mL

Serum tIgE (IU/mL),
continuous variable

Serum tIgE (kU/L),
continuous variable

Serum tIgE >98.7 IU/mL

Elevated serum tIgE in the presence of a negative inhalantspecific IgE screen may suggest the presence of unidentified
inhalant allergen sensitization or chronic respiratory
inflammatory disease other than AR. Mean serum tIgE of the
study group was 363.3 kU/L vs control group 2.2 kU/L, p <
0.0001.

Serum tIgE level are significantly associated with increased
odds of skin test positive AR in children with asthma (OR 2.3;
95% CI, 1.5–3.5) but not with those without asthma (OR 1.6;
95% CI, 0.9–2.8). AR can be diagnosed if serum tIgE ≥100
kU/L both in asthmatics (AUC: 0.77 [range, 0.72–0.82], PPV:
85.1%, NPV: 68%) and in non-asthmatics (AUC: 0.84 [range,
0.79–0.89], PPV: 77.8%, NPV: 90.9%).

Serum tIgE levels (cutoff value: 150 IU/mL) has good PPV
(89.6%), and NPV (10%) in the in vitro diagnosis of AR
(AUC: 0.88).

Serum tIgE were higher in AR (166.0 [range, 58.4–422.5]
IU/mL) than in NAR pts (68.8 [range, 24.5–141.0]) IU/mL. p
< 0.001

Borderline association with current rhinitis (UnAdjORb 1.2;
95% CI, 1.02–1.3), not significant at multivariate analysis.
Association with current rhinoconjunctivitis (UnAdjORb 1.3;
95% CI, 1.1–1.5), not significant at multivariate analysis.

tIgE cutoff: 98.7 IU/mL is a strong predictor of AR. (OR
6.93; 95% CI, 4.19–9.62; p < 0.001); AUC: 0.79 [range, 0.74–
0.83]; PPV: 71.3%; NPV: 73.7%.

tIgE levels >140 IU/mL is suggestive of an atopic etiology for
patients with rhinitis.

Associated with newly developed allergic sensitization
(sensitivity: 69.9%; specificity: 100.0%).

Initial examination:
allergic symptoms but
negative SPT, serum tIgE
>17.4 IU/mL
Serum tIgE (IU/mL),
continuous variable

Associated with the risk for allergic sensitization (sensitivity:
46.3%; specificity: 85.3%; OR: 4.8).

a
Conclusion

Initial examination: no
allergic sensitization,
serum tIgE >17.7 IU/mL

Endpoint

Author Manuscript

Evidence supporting the use of total IgE in allergic rhinitis or allergy diagnosis

Author Manuscript

TABLE VIII.F.1-1.
Wise et al.
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2007

Ando & Shima892
3b

3b

3b

3b

Cross-sectional

Retrospective
case series

Cross-sectional

Retrospective
case series

Serum tIgE (kU/L),
continuous variable

Female

School children (n = 98 with AR), 9–10
years old

Serum tIgE higher in AR (230.4; 95% CI, 157.6–337.0) than
in NAR (96.5; 95% CI, 76.9–121.1), p < 0.001

Serum tIgE higher in AR (261) than in NAR (126), p < 0.01.

Association with current HF (OR 1.7; 95% CI, 1.2–2.3).

Association with current HF (OR 2.1; 95% CI, 1.6–2.8).

Association with current HF (OR 1.9; 95% CI, 1.4–2.6).

AR = allergic rhinitis; AUC = area under the curve; CI = confidence interval; HF = hay fever; IgE = Immunoglobulin E; LOE = level of evidence; MAAS = Manchester Asthma and Allergy Study; NAR =
non-allergic rhinitis; NHANES = The National Health and Nutrition Examination Survey; NPV = negative predictive value; OR = odds ratio; PPV = positive predictive value; RC = rhinoconjunctivitis; SPT
= skin prick test; tIgE = total immunoglobulin E; UnAdjOR = unadjusted odds ratio.

Serum tIgE levels
(IU/mL) expressed as
geometric means,
continuous variable

Serum tIgE (IU/mL),
continuous variable

Serum tIgE (kU/L),
continuous variable

Male

Consecutive and unselected pts from a
tertiary care clinic (n = 323,205 with AR);
mean age 31.7 years

Serum tIgE (kU/L),
continuous variable

Association with current HF (OR 2.2; 95% CI, 1.1–4.4).

Serum tIgE (kU/L),
continuous variable
Adults (>18 years)

Association with current HF (OR 2.1; 95% CI, 1.4–3.1).

Serum tIgE >40.8 kU/L
(median)

Association with current HF (OR 1.9; 95% CI, 1.4–2.4).

tIgE <20 U/mL in 23.7%, tIgE 20-100 U/mL in 38.3%, tIgE
>100 U/mL 33.8%. tIgE is a factor in confirming the
diagnosis, but routine use is not recommended due to high
cost and testing time.

Children (6–17 years)

The OR indicates an increase in the risk of current rhinitis/chronic RC per log unit increase of IgE levels.

b

a

Conclusion

Serum tIgE (kU/L),
continuous variable

Serum tIgE (U/mL),
continuous variable

Endpoint

7398 subjects (>6 years) from NHANES
2005–2006.

Patients from otolaryngology clinic with at
least 2 complaints of nasal itching, nasal
obstruction, rhinorrhea, and sneezing, and/or
presumed AR (n = 295), mean age 33.9
years.

Study groups

All reported ORs are adjusted unless differently specified and are reported with 95% CIs in parentheses.

a

2009

2011

Salo et al.454

Kalpaklioglu et
al.894

2013

Author Manuscript

Karli et al.898

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript

2009

Satwani et al.903
3b

3b

2b

2b

LOE

Cross-sectional

Retrospective case
series

Population-based
cohort

Prospective cohort

Study design

258 patients (6 months-12 years) from a
Pediatric Medicine Unit (n = 172 with AR)

352 patients with serum tIgE >1000 IU/mL
attributable to atopic eczema, allergic
bronchopulmonary aspergillosis, helminthic
infection, and rare primary
immunodeficiencies. (n = 84 with AR)

1321 children (5-18 years) from PATCH study

313 schoolchildren, 2-year follow-up study

Study groups

Sensitivity: 57.0%, specificity: 71.3%, PPV: 45.5%,
NPV: 79.8%
Sensitivity: 68.1%, specificity: 62.5%, PPV: 43.2%,
NPV: 82.4%

Serum tIgE >164.3 kU/L
Serum tIgE >100 kU/L

Elevated serum tIgE

serum tIgE (IU/mL)

Sensitivity: 74.7%, specificity: 56.6%, PPV: 41.9%,
NPV: 84.2%

Serum tIgE >77.7 kU/L

No association of tIgE and AR (UnAdjOR 1.3; 95%
CI, 0.8-2.2).

The elevated IgE level in AR is of limited diagnostic
utility.

Insufficient diagnostic accuracy of serum tIgE levels to
detect allergic diseases regardless of cutoff value used.
Serum tIgE is linked more to atopy than directly to
symptoms.

AUC of serum tIgE for diagnosing rhinitis: 0.70.

No association with newly developed allergic nasal
symptoms.

Conclusion

Serum tIgE (kU/L)

Initial examination: no allergic
sensitization, serum tIgE
<17.7 IU/mL

Endpoint

AR = allergic rhinitis; UnAdjOR = unadjusted odds ratio; AUC = area under the curve; CI = confidence interval; IgE = immunoglobulin E; LOE = level of evidence; NPV = negative predictive value;
PATCH = Prediction of Allergies in Taiwanese Children; PPV = positive predictive value; tIgE = total immunoglobulin E.

2016

Tay et al.905

2016

Year

2013

al.902

Tu et al.904

Park et

Study

Evidence indicating a limited role for the use of total IgE in allergic rhinitis or allergy diagnosis

Author Manuscript
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2000

Pumhirun et al.

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1998

1986

1986

1978

1967
2015

2008

Tschopp et al.822

Ferguson &
Murray926

Ownby &
Bailey925

Reddy et al.857

Wide et al.911

Seidman et al.761

Bernstein et al.

818

1999

Wood et al.793

835

Chinoy et

2005

Year

al.927

Study

5

5

3b

3b

3b

3b

3b

3b

3b

3b

LOE

Reviewpractice
parameter

Guideline

Prospective
cohort

Prospective
cohort

Prospective
cohort

Prospective
cohort

Prospective
cohort

Prospective
cohort

Prospective
cohort

Prospective
cohort

Study design

19 patients with
history PR and
positive SPT;
Healthy controls

2

3

Not applicable

Not applicable

31 allergic patients

34 patients with
history of PR but
negative SPT;

1

Children age 4–19 years

168 children with clinical suspicion
of allergy to cats and/or dogs

Randomly selected sample of 8329
Swiss adults

Patients with cat allergy determined
by history and a cat-exposure model

Perennial rhinitis patients

Patients with AR and/or bronchial
asthma (n = 118)

Study groups

Clinical endpoint

Not applicable

Not applicable

AcR of minimal CSA of nasal
cavity

To determine the clinical relevance
of positive intracutaneous test when
epicutaneous test is negative

Diagnostic levels by MAST and
RAST were compared to skin test
reactions for ragweed, grass, house
dust, and mite

Compared the predictive values of
skin tests and RASTs in children
with history of allergy to cats and/or
dogs

Compared the sensitivity,
specificity, PPV and NPV of SPT,
tIgE, and fluoroenzyme
immunoassay in diagnosing AR

Compared the predictive values of
SPT, IDT and RASTs in the
diagnosis of cat allergy

Compared sensitivity and specificity
of SPT to sIgE assay for D.
pteronyssinus and D. farinae

Compare skin test reactivity with
serum sIgE antibodies

Evidence for the use of serum sIgE testing in the diagnosis of allergic rhinitis

Sensitivity of sIgE ranges from 50% to 90% with an average
of 70% to 75%. sIgE may be used along with history and

Clinicians should perform and interpret or refer for sIgE (skin
or blood) allergy testing for patients with a clinical diagnosis
of AR who do not respond to empiric treatment or the
diagnosis is uncertain.

Good correlation between provocation tests and in vitro tests
for allergy.

Good agreement between SPT, RAST, and NPT. Poor
agreement between positive IDT at 1:1000 concentration and
SPT, RAST, and NP tests.

MAST had a sensitivity of 59%, specificity of 97%, efficiency
of 72%, compared with 67%, 97%, and 78%, respectively, for
RAST. Neither MAST or RAST as sensitive as skin test.

RAST sensitivity and specificity was 71%-74% and
88%-90%, respectively. SPT sensitivity and specificity
68%-76% and 83%-86%, respectively.

Sensitivity of fluoroenzyme immunoassay was significantly
higher than SPT and IgE. SPT was more specific and had a
better PPV. SPT was the most efficient test to diagnose AR.

SPT and RAST values exhibited excellent efficiency in
diagnosis of cat allergy. IDT added little to the diagnostic
evaluation. Overall sensitivity and specificity of RAST was
69% and 100%, respectively.

sIgE for D. pteronyssinus and D. farinae had sensitivity of
96.3% and 88.9% and specificity of 96.2% and 88.9%,
respectively. This compared to sensitivity of 90.4% and 86.4%
and specificity of 99.5% and 93.1% for SPT, respectively.

For 4 indoor allergens, skin test was more sensitive than
RAST. Skin test and RAST scores showed weak to moderate
correlation.

Conclusion

Author Manuscript
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Author Manuscript
Study groups

Clinical endpoint

Conclusion
physical for diagnosis of allergy and may be preferable in
certain conditions.

AcR = acoustic rhinometry; AR = allergic rhinitis; CSA = cross-sectional area; IDT = intradermal testing; LOE = level of evidence; MAST = multiple allergosorbent test; NP = nasal provocation; NPV =
negative predictive value; PPV = positive predictive value; RAST = radioallergosorbent test; SPT = skin-prick testing.

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript
2013
2008

al.932

1999
1998
1996
1990
2010
2014
2016
2015
2015
2005
2002
1995
2016
2011

al.937

Nelson et al.856

Adinoff et al.948

Jung et al.792

Gendo & Larson930

Haxel et al.947

Tantilipikorn et al.949

Tversky et al.928

Choi et al.943

McCann & Ownby942

Pastorello et al.946

Westwood et al.794

Mucci et al.791
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3a

3a

2b

2b

2b

2b

2b

2b

2a

1c

1b

1b

1b

1b

1b

1b

1b

1a

LOE

SR

SR

Exploratory case-control

Individual cohort

Retrospective cohort

Individual cohort

Individual cohort

Retrospective cohort

Systematic review

All or none case series

Validating cohort

Validating cohort

Validating cohort

Validating cohort

Prospective controlled trial

Validating cohort

Validating cohort

Systematic review

Study design

AR

AR

AR

AR

HDM allergy

All subjects

AR

AR

AR

HDM allergies

AR

AR to grass

All subjects

Cat allergy

AR

Mouse allergy

AR and asthma

AR

Review of AR

Microarray results

ImmunoCAP vs SPT

SPT measurements

RAST vs SPT

Wheal and flare of various devices

Intradermal test vs serum sIgE

Nasal challenge vs SPT vs RAST

Utility of allergy testing

ImmunoCAP versus SPT

SPT results

Intradermal test vs challenge

Wheal and flare of various devices.

RAST vs SPT vs intradermal test

Evaluation of 8 devices for skin testing

RAST vs SPT vs intradermal test

Concordance of SPT and serology

SPT accuracy

Clinical endpoint

Review of AR diagnosis and treatment.

Utility and cost of microarray testing needs further validation.

Specific IgE accuracy depend on cutoff values.

SPT results are not reproducible across centers.

IgE cutoff level determine sensitivity and specificity.

Results of SPT depend on device, technique, and control reagents
chosen.

Intradermal testing has higher sensitivity and lower specificity
than sIgE for HDM.

Nasal challenge should be performed to confirm eligibility for
HDM AIT.

History and pretest probability determine allergy testing utility.

Sensitivity and specificity depend on patient demographics.

SPT is accurate for various aeroallergens.

Positive intradermal test may not be relevant if SPT negative.

Results of SPT depend on device, technique, and control reagents
chosen.

Sensitivity and specificity differ across tests.

Consensus guidelines on skin testing.

Sensitivity and specificity differ across tests.

SPT and serology are discordant.

Various factors determine SPT accuracy.

Conclusion

AIT = allergen immunotherapy; AR = allergic rhinitis; HDM = house dust mite; IgE = immunoglobulin E; LOE = level of evidence; RAST = radioallergosorbent test; sIgE = allergen-specific IgE; SPT =
skin-prick test.

Nelson et

Wood et

al.793

Carr et

al.939

Sharma et
2005

2016

al.931

de Vos et

Nevis et

Year

al.830

Study groups

Author Manuscript

Study

Author Manuscript

Evidence for various allergy testing techniques

Author Manuscript

TABLE VIII.F.3-1.
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Author Manuscript
48%

Cat
74-92.2%

69-75.5%

Grass

Mouse

61.6-76.3%

100%

Mouse
HDM

60%

Cat

91%

100%

76.5%

47.6-72.8%

65%

39.5-46.2%

75%

85%

94%

90-92.7%

61-85.7%

47.6-95.2%

Specificity
survey,946 nasal challenge943, 947

Gold standard

Nasal challenge932

Cat room793

Survey946

Bronchoprovocation,943 survey,946 nasal challenge943, 947, 949

Nasal challenge932

Cat room793

Nasal challenge856

Nasal challenge949

Nasal challenge932

Survey,948 cat room793

Survey856, 946

HDM = house dust mite; N/A = not available; sIgE = allergen-specific IgE.

sIgE (ImmunoCAP)

78.6%

Grass

67%

Mouse
N/A

90%

Cat

HDM

61.6-76%

Grass

Skin intradermal test

66.3-90.5%

HDM

Skin-prick test

Sensitivity

Allergen
Bronchoprovocation,943

Author Manuscript

Test

Author Manuscript

Comparative studies of allergy testing techniques

Author Manuscript
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Author Manuscript
2016

2015

2014

2011

2010

2010

2009

Bozek et al.304

Sakaida et al.960

Fuiano et al.955

López et al.306

Powe et al.950

Rondon et al.307

2016

Year

Lee et al.959

Kim et

al.958

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2b

2b

2b

2b

2b

2b

2b

2b

LOE

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Study design

Study groups

NPT negative (n = 21)

2

AR, children (n = 15);
NAR, adults (n = 9);
AR, adults (n = 15)

2
3
4

Perennial NAR, children (n = 36)

2

Control (n = 50)

2

NARES (n = 90);
Control (n = 90)

2
3

1

LAR (n = 30);

Collection technique: nasal lavage.

AR (n = 90);

1

Collection technique: cotton ball, immunohistochemistry.

LAR (n = 40);

1

Collection technique: nasal lavage.

Perennial AR, children (n = 20);

1

Collection technique: cellulose membrane.

Collection technique: suction of nasal secretions (n = 46
participants, 33 sensitized to allergen)

Collection technique: nasal lavage.Elderly patients, (n =
219)

NAR, children (n = 12);

1

Collection technique: nasal lavage.

NPT positive (n = 39);

1

Collection technique: cotton ball.

Author Manuscript

Study

Nasal sIgE, sIgE,
tryptase, eosinophil
cationic protein

Nasal Ig free light
chains

Nasal tIgE, sIgE,
tryptase, eosinophil
cationic protein,
symptoms

NPT, nasal sIgE

Nasal sIgE

NPT, nasal sIgE

Nasal sIgE

NPT, nasal sIgE

Clinical endpoint

Author Manuscript

Evidence for nasal sIgE testing

30% with nasal sIgE. LAR have local production
of sIgE, mast cell/eosinophil activation.

Free light chains increased in AR and NAR nasal
mucosa, suggesting role in hypersensitivity.

LAR: Nasal sIgE to D. pteronyssinus detected in
25% immediately and at 24 hours, increase mast
cells/eosinophils. Controls: Negative NPT, nasal
sIgE, and other markers.

Nasal sIgE to Alternaria detected in 69% of
positive NPT.

93% had nasal sIgE, higher levels in sensitized
subjects, correlation between nasal and serum
sIgE.

LAR and AR common in elderly patients. 21%
with LAR, 40.2% with AR, and 38.8% with
NAR.

AR with higher nasal sIgE to HDM than NAR,
no difference between adults and children.
Correlation between nasal and serum IgE only in
children.

Nasal sIgE detected in all patients, no difference
between NPT groups. No comparison pre- and
post-NPT was performed.

Conclusion

Author Manuscript

TABLE VIII.F.4.
Wise et al.
Page 343

2007

2003

2000

1997

2005

1997

Rondon et al.301

Powe et al.284

KleinJan et al.377

KleinJan et al.951

Takhar et al.312

Durham et al.310

2008

Author Manuscript

Rondon et al.300
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3b

3b

2b

2b

2b

2b

2b

Cross-sectional,
nonconsecutive

Cross-sectional,
nonconsecutive

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Study design

Study groups
Control (n = 30)

AR to pollen (n = 35);
AR to HDM (n = 30);
Control (n = 50)

2
3
4

AR to HDM (n = 30);
Control (n = 30)

2
3

AR (n = 11);
Control (n = 12)

2
3

Control (n = 12)

3

Control (n = 10)

3

Control (n = 4)
2

1

AR (n = 21)

Collection technique: mucosal biopsy.

AR (n = 12);

1

Collection technique: mucosal biopsy.

SAR (n = 11);
PAR (n = 10);

1
2

Collection technique: mucosal biopsy.

SAR (n = 12);
PAR (n = 16);

1
2

Collection technique: mucosal biopsy.

NAR (n = 10);

1

Collection technique: mucosal biopsy.

NAR (n = 50);

1

Collection technique: nasal lavage.

Seasonal NAR (n = 32);

1

Collection technique: nasal lavage.

2

Author Manuscript
LOE

NPT, nasal IgE
heavy chain

Nasal mRNA and
gene transcripts

Nasal sIgE to grass
and HDM

Nasal B and plasma
cells with IgE

Nasal sIgE

NPT, nasal sIgE

NPT, nasal sIgE

Clinical endpoint

Author Manuscript

Year

Local IgE synthesis and cytokine regulation
occur is the nasal mucosa of AR patients.

Allergen stimulates local class switching to IgE
in the nasal mucosa.

sIgE to grass and HDM found in SAR and PAR
subjects, respectively.

sIgE produced in nasal tissue of AR patients but
not healthy controls.

Nasal sIgE to grass detected in 30% NAR. No
nasal sIgE to HDM was detected.

Nasal sIgE to HDM detected in 22% of NAR
patients with positive NPT.

Nasal sIgE to grass pollen detected in 35% NAR
patients with positive NPT, and with similar sIgE
profile as AR.

Conclusion

Author Manuscript

Study
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2016
2015
2013

2012
2003

1994

1979

Zicari et al.292

Becker et al.962

Reisacher963

Reisacher964

Coker et al.309

Sensi et al.965

Platts-Mills311
4

4

4

4

4

4

4

4

3b

Descriptive

Descriptive

Descriptive

Descriptive

Descriptive

Descriptive

Descriptive

Descriptive

Cross-sectional,
nonconsecutive

Study groups
control (n = 10)

AR (n = 6);
Control (n = 5)

2
3

Collection technique: nasal lavage. AR (n = 50)

Collection technique: nasal lavage. Children with asthma
and rhinitis (n = 18)

Collection technique: mucosal biopsy. AR (n = 6)

Collection technique: mucosal brush. AR (n = 18)

Collection technique: mucosal brush. NAR (n = 20)

Collection technique: cotton ball. NARES (n = 19)

Collection technique: nasal lavage. NAR, children (n =
20)

Collection technique: mucosal biopsy. AR (n = 11)

NAR (n = 14);

1

Collection technique: filter paper.

2

Nasal IgG, IgA, and
IgE

Nasal and serum
sIgE measured after
allergen avoidance

Nasal IgE heavy
chain

Nasal sIgE, SPT

Nasal sIgE

Nasal sIgE

NPT, nasal sIgE

Nasal and serum
sIgE

SPT, NPT, serum
and nasal sIgE to
HDM

Clinical endpoint

Antibody response in AR patients is local in the
nasal mucosa.

Nasal sIgE may be more sensitive than serum
sIgE.

Somatic hypermutation, clonal expansion, and
class switching occurs within the nasal mucosa of
AR patients.

Nasal sIgE in 75% of subjects, association
between brush testing and SPT.

Nasal sIgE detected in 100% of patients. Varied
from 0% Alternaria to 90% cockroach. No
association to QOL.

No detectable nasal sIgE in any of the patients.

66% had positive NPT. Nasal sIgE present in 8%
to 42%.

Detection of sIgE in inferior turbinate mucosa
and serum.

Nasal sIgE in AR and NAR patients with positive
NPT; but not in controls.

Conclusion

AR = allergic rhinitis; HDM = house dust mite; Ig = immunoglobulin; IgA = immunoglobulin A; IgG = immunoglobulin G; LAR = local allergic rhinitis; LOE = level of evidence; NAR = non-allergic
rhinitis; NARES = non-allergic rhinitis with eosinophilia syndrome; NPT = nasal [allergen] provocation test; PAR = perennial allergic rhinitis; SAR = seasonal allergic rhinitis; sIgE = allergen-specific
immunoglobulin E; SPT = skin-prick test; tIgE = total immunoglobulin E.

2016

Ota et al.961

1975

Author Manuscript

Huggins &
Brostoff303

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript

Author Manuscript

2014

Schmid et al.

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

2015

Campo et al.

308

2015

2016

Ando et al.979

974

Lesniak et al.

976

Zidarn et al.

2012

2015

Zidarn et al.

977

2011

Van Overtvelt
et al.978

971

Year

Study

3b

3b

3b

2b

2b

1b

1b

LOE

Casecontrol

Casecontrol

Casecontrol

Cohort

Cohort

RCT

Open
RCT

Study
design

Open control

2

Placebo

2

Nonsensitized healthy controls (n = 10)

4

LAR patients (n = 12);
Controls (n = 12);

2
3

AR patients (n = 12);

Controls (n = 11)

2
1

SAR patients (n = 18);

Birch-negative, HDM-positive (n = 15)

2
1

Birch-positive, HDM-negative (n =
15);

1

Allergy patients (n = 30) diagnosed by clinical
symptoms, SPT, or serum IgE.

Positive NPT (n = 13);
Negative NPT (n = 13);

2
3

Positive skin test and sIgE to Timothy
grass pollen (n = 26);

No treatment (n = 20)

2

1

SCIT (n = 30);

1

Moderate-severe SAR to grass pollen;

SLIT tablet;

1

SAR to grass pollen (n = 89);

SCIT;

1

SAR to grass pollen (n = 24);

Study groups

NPT, serum sIgE, BAT.

CD203c expression on
basophils when stimulated
with Japanese cedar pollen.

BAT, basophil reactivity.

CD-sens, CD63
responsiveness. Tested
before and after pollen
season.

BAT using CD63 as marker
for basophil response.
Evaluated after 1st pollen
season, after 2nd pollen
season, and 1–2 years after
finishing 3–5 years of
SCIT.

BAT using CD203c at 2 and
4 months of treatment.

Clinical measures of
allergy, basophil sensitivity,
basophil reactivity.

Clinical endpoint

Author Manuscript

Evidence for the use of basophil activation testing in allergic rhinitis

NPT positive in all AR and 10/12 LAR. Serum sIgE positive in
AR, negative in LAR. BAT positive in AR and in 8/12 LAR.
NPT remains the gold standard, but if unable to be done, BAT
should be considered.

CD203c expression has diurnal variation and should be
considered when using CD203c as a marker. This was also
shown in basophils derived from marrow of mice-models.

Sensitivity for basophil reactivity 83%–100%; specificity
78%–89%; PPV 75%–87%; and NPV 89%–100%. BAT may
replace NPT when NPT is contraindicated. Small numbers of
patients used needs to be validated in larger study.

CD-sens 10-fold higher in symptomatic patients. Significant
difference between CD63 responsiveness in those with positive
NPT vs negative NPT. CD-sens a good predictor of allergic
rhinitis symptoms in those sensitized to Timothy grass pollen.

BAT significantly decreased with SCIT; remains decreased 1–2
years after 3–5 years of SCIT treatment. BAT is an objective
measure of response to AIT and is a stable marker of allergen
response over a long period.

BAT using CD203c did not correlate with patient response.

Basophil sensitivity changes correspond to clinical changes in
allergy symptoms in patients on SCIT. Basophil reactivity did
not change.

Conclusion

Author Manuscript
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2007

Ocmant et al.
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Nopp et al.970

2013

2015

Lesniak et al.

973

2001

Sanz et al.967

968

2009

2011

Nopp et al.969

972

Ozdemir et al.

318

2013

Author Manuscript

Gomez et al.

4

4

3b

3b

3b

3b

3b

Case
series

Case
series

Casecontrol

Casecontrol

Casecontrol

Casecontrol

Casecontrol

Study
design

Controls (n = 14);

4

SAR to grass pollen (n = 31);

Patients sensitized to birch (n = 19);

2

Cat-allergic patients (n = 20);

AR or asthma patients sensitized to
grass (n = 51);
Atopic, non-allergic patients (n = 24);
Healthy controls (n = 38)

2
3
4

SAR to grass pollen (n = 26)

12 patients with AR sensitized to birch or mites

AR or asthma patients sensitized to
HDM (n = 53);

Controls (n = 19)

1

2

1

Treated with conventional or ultra-rush AIT.

Patients sensitized to Timothy grass (n
= 14);

Healthy non-atopic controls (n = 9)

1

2

1

Tested to D. pteronyssinus

AR patients (n = 14);
NAR patients (n = 10);

2

LAR patients (n = 16);

3

1

Tested to olive tree pollen

Study groups

Author Manuscript
LOE

CD-sens, nPIF.

Blood sample tested 1, 4,
and 24 hours after sampling
compared to SPT, sIgE, and
NPT.

Skin tests, BAT, histamine
release tests, leukotriene
production.

Tested both CD63 and
CD203c expression using
prescribed protocol.

CD-sens.

Discrimination of pollen
allergic individuals from
controls using CD203c
expression as marker of
allergy; cutoff values of
14%. Performed during offseason.

BAT, nasal sIgE, NPT.

Clinical endpoint

Author Manuscript

Year

Positive nPIF and positive CD-sens in 92%. Positive nasal
symptom scores and positive CD-sens scores in 85%. Subjects
tested twice: CD-sens 100% reproducible vs 78% for nasal
symptom scores and 94% for nPIF. CD-sens results
reproducible and correlate well with other allergen testing
methods. Has potential for diagnosis and follow-up after
treatment.

No differences in ROC characteristics between tests. BAT can
be a useful approach to determine the clinically relevant
allergen in sensitized patients.

Significant correlation between skin tests and BAT (r = 0.72, p
< 0.001). Positive and significant correlation between BAT and
histamine release tests (r = 0.80, p < 0.001); allergen-specific
LTC4, LTD4, LTE4 production (r = 0.7, p < 0.001); and the
occurrence of serum sIgE (r = 0.71, p < 0.001). BAT is a
highly reliable technique in the diagnosis of allergy to inhalant
allergens. BAT sensitivity = 93.3%, specificity = 98.4%, when
using a cutoff point of 15% activated basophils as positive
result.

100% sensitivity for both CD63 and CD203c in cat-allergic
patients. CD203 is as reliable as CD63 for diagnosis of
patients with IgE-mediated allergy to cat.

CD-sens decreases during early phases of treatment. No
change in basophil reactivity. CD-sens good objective measure
to use to assess response to AIT.

BAT CD203c can be used to test for grass allergens if
conventional measures not available.

AR: BAT sensitivity 85%, specificity 93%. LAR: BAT
sensitivity 50%, specificity 93%. BAT diagnosed at least 50%
of cases of LAR to D. pteronyssinus and was more sensitive
than detection of nasal sIgE and less time-consuming than
NPTs.

Conclusion

Author Manuscript

Study

Wise et al.
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Author Manuscript

2006

4

Case
series

SAR to Timothy grass (n = 27) by
clinical history, positive SPT, and sIgE;
Patients receiving anti-IgE for 4 years
(n = 7)

1
2

Study groups
CD-sens, SPT, NPT, IgE
antibody concentration.

Clinical endpoint

CD-sens correlates significantly with SPT, NPT, and IgE
antibody concentration. CD-max (reactivity) did not correlate
with any sensitization measures. CD-max varies substantially
between patients and does not correlate to treatment or other
allergy testing measures. Using CD-sens as a quantitative
measure of response to therapy or to complement other testing
methods is more reliable.

Conclusion

AIT = allergen immunotherapy; AR = allergic rhinitis; BAT = basophil activation test; CD-sens = EC50 for allergen concentration inverted and multiplied by 100; HDM = house dust mite; IgE =
immunoglobulin E; LAR = local allergic rhinitis; LOE = level of evidence; LTC4, LTD4, LTE4 = leukotriene C4, D4, E4; nPIF = nasal peak inspiratory flow; NPT = nasal provocation test; NPV = negative
predictive value; PPV = positive predictive value; RCT = randomized controlled trial; ROC = receiver operating characteristic; SAR = seasonal allergic rhinitis; SCIT = subcutaneous immunotherapy; sIgE
= specific immunoglobulin E; SLIT = sublingual immunotherapy.

Nopp et

al.975

Study
design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript
Par j 2 (lipid transfer protein)
Sal k 1 (pectinesterase)
Che a 1 (trypsin inhibitor)
Phl p 1 (expansin);
Phl p 4 (berberine bridge enzymes);
Phl p 5 (ribonuclease);
Phl p 6 (Pooideae grass only)
Cyn d 1 (expansin)
Aln g 1 (ribonuclease)
Bet v 1 (PR-10)

Ole e 1 (trypsin inhibitors);
Ole e 7 (lipid transfer protein);
Ole e 9 (glucanase)
Cry j 1 (pectate lyases)
Cup a 1 (pectate lyases)
Pla a 1 (invertase inhibitor);
Pla a 2 (polygalacturonases)

Russian thistle or saltwort

Goosefoot

Timothy

Bermuda grass

Alder

Birch

Olive

Japanese cedar

Cypress

Plane tree

Art v 1 (defensin);
Art v 3 (lipid transfer protein)

Mugwort

Parietaria, wall pellitory

Amb a 1 (pectate lyase)

Ragweed

Specific components

Pla a 3 (lipid transfer protein)

Bet v 1 (PR10);
Bet v 2 (profilin);
Bet v 4 (polcalcin)

Aln g 1 (PR 10)

Cyn d 1 and Phl p 1

Phl p 4 (berberine);
Phl p 7 (polcalcin);
Phl p 11 (trypsin inhibitor);
Phl p 12 (profilin)

Par j 2 (lipid transfer protein)

Art v 3 (lipid transfer protein)

Cross-reactivity components

Author Manuscript

Pollen

Author Manuscript

Pollen allergens

Author Manuscript
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Author Manuscript

Author Manuscript
2016

Krzych-Fałta et al.

2015

2013

Jang & Kim1084

Agarwal et al.1083
2b

2b

2b

2b

LOE

Open
controlled

Open
controlled

Open
controlled

Open
controlled

Study design

Controls (n = 39)

2

Allergic to molds (n = 11);
Controls (n = 11)

2

Negative SPT (n = 110)

3
1

Strongly positive SPT (n = 99);
Weakly positive SPT (n = 53);

1
2

HDM allergy:

HDM allergy patients (n = 49);

Controls (n = 30)

Allergic (n = 30);

1

2

1

Study groups

Results of NPT by optical rhinometry

Sensitivity and specificity of NPT by
acoustic rhinometry, TNSS

Sensitivity and specificity of a rapid
NPT by clinical symptoms and
rhinomanometry, safety also evaluated

Sensitivity and specificity of NPT by
optical rhinometry, TNSS

HDM = house dust mite; LOE = level of evidence; NPT = nasal provocation test; SPT = skin-prick test; TNSS = Total Nasal Symptom Score.

2015

de Blay et al.1085

1086

Year

Study

Clinical endpoint

Author Manuscript

Recent studies evaluating the sensitivity and specificity of nasal provocation testing

No significant difference between allergic and
control subjects.

TNSS ≥6.5 had 90.6% sensitivity and 77.4%
specificity, acoustic rhinometry had 73.4%
sensitivity and 58.1% specificity for diagnosis of
AR.

Rapid NPT had a sensitivity of 83.7% and a
specificity of 100%. No adverse reactions.

TNSS had a 93.3% sensitivity and a 77.4%
specificity, optical rhinometry had a 100%
sensitivity and specificity for diagnosis of AR.

Conclusion

Author Manuscript
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Author Manuscript

Author Manuscript

al.1093

2014

Gelardi1099
4

3b

3b

3b

LOE

Cohort

Casecontrol

Cohort

Casecontrol

Study
design

NAR (n = 404)

Moderate-severe (n = 32)

2
Patients with overlapping AR and NAR (n = 671)

Mild (n = 30);

1

AR patients (n = 62):

2

AR (n = 1107);

Polyallergic (n = 48)

2
1

Monoallergic (n = 35);

1

AR patients (n = 83):

Study groups

Sneezing in response to nasal
endoscopy according to type
of rhinitis found on cytology

Association of cell counts
with ARIA stage of disease

NC eosinophil count

Comparison of NC cell
counts

Clinical endpoint

In patients with NARES, NARMA, and NARESMA there
was a significantly higher rate of sneezing (p < 0.01).

In moderate-severe AR there was a significantly higher
number of eosinophils (p = 0.01), mast cells (p = 0.001),
neutrophils (p = 0.046), and lymphocytes (p = 0.001).

High eosinophil count had an odds ratio of 1.14 (95% CI,
1.10-1.18) to identify AR.

Higher number of eosinophils (p = 0.005) and mast cells
(p = 0.001) in polyallergy.

Conclusion

AR = allergic rhinitis; ARIA = Allergic Rhinitis and its Impact on Asthma; CI = confidence interval; LOE = level of evidence; NAR = non-allergic rhinitis; NARES = non-allergic rhinitis with eosinophilia
syndrome; NARESMA = non-allergic rhinitis with eosinophils and mast cells; NARMA = non-allergic rhinitis with mast cells; NC = nasal cytology.

2011

2011

2015

Year

Gelardi et al.1094

1092

Di Lorenzo et al.

Gelardi et

Study

Author Manuscript

Studies assessing the diagnostic performance of nasal cytology
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2005

2002

Rak et al.1107

Plewako et al.
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1110

Wilson et al.

1109

Pullerits et al.

2001

2001

2008

Asai et al.1106

1108

2010

Yang et al.1105

2010

2010

al.1103

Year

Uller et al.1104

Sivam et

Study

1b

1b

1b

1b

1b

1b

1b

1b

LOE

RPCT

RPCT

SBRPCT

DBRPCT
(double
dummy)

RPCT

DBRPCT

DBRPCT

DBRPCT

Study
design

Placebo (n = 7)

2

Placebo (n = 11)

2

Placebo (n = 38)

2

Placebo (n = 7)

2

Budesonide

2

Placebo (n = 11)

2

Placebo (n = 5)

2

1

AIT (n = 20);

SAR to grass pollen (n = 37):

Beclomethasone (n = 16);

1

SAR to grass pollen (n = 21):

Omalizumab (n = 19);

1

SAR to grass (n = 30):

AIT;

1

SAR to birch (n = 41):

AIT (n = 12);

1

SAR to ragweed (n = 19):

Chinese herbal Xin-yi-san (n = 62);

1

PAR to dust mite or animal epithelia (n = 100):

Budesonide (n = 10);

1

SAR to grass or birch (n = 21)

Mometasone (n = 10);

1

SAR (n = 17):

Study groups

Relationship between symptomatic
improvement after AIT and eosinophil
numbers and IL-5 expression in the nasal
mucosa during the pollen season.

Comparison of IL-16 expression during
the pollen season in actively vs placebotreated patients.

Comparison of anti-CD4, CD8, antieosinophil peroxidase, anti-human
neutrophil lipocalin, and antibodies
against IgE and FcεRI.

Measurement of the number of CD1a+,
IgE+, and FcεRI+ cells during birch
pollen season.

To determine the in vivo effect of shortcourse AIT on CD4+CD25+ regulatory
T-cells in the nasal mucosa of ragweedsensitive subjects.

To determine the effectiveness of Xin-yisan in the treatment of AR and
investigation of its molecular mechanism
of anti-allergic activity.

Mucosal eosinophilia, apoptotic
eosinophils, and expression of CCL5 and
CCL11 (eotaxin).

Measurement of olfactory function and
histological analysis of the olfactory
region.

Clinical endpoint

Author Manuscript

Studies investigating allergic rhinitis pathophysiology by nasal histology from biopsies

Improvement in symptoms after grass pollen AIT
may result from inhibition of IL-5-dependent
tissue eosinophilia during the pollen season.

Local upregulation of IL-16 expression
contributes to the inflammation observed in
seasonal AR.

The number of eosinophil peroxidase-positive
staining cells significantly increased in the
placebo-treated patients but not in the actively
treated patients.

Treatment with budesonide, but not AIT,
decreased the number of CD1a+, IgE+, and
FcεRI+ cells.

AIT increases CD4+ CD25+ regulatory T-cell
infiltration in the nasal mucosa following allergen
challenge after seasonal ragweed-pollen.

Xin-yi-san exerts diverse immunomodulatory
effects, including suppression of serum IgE levels
and increased production of IL-10, sICAM-1, and
IL-8 compared to placebo group.

Inhibition of CCL5-dependent recruitment of
cells to diseased tissue, reduced cell proliferation,
and general cell apoptosis, but not increased
eosinophil apoptosis, are involved in early phase
steroid-induced resolution of AR.

Mometasone use associated with reduced
olfactory eosinophilic inflammation and
improved AR symptoms.

Conclusion

Author Manuscript
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2001

2008

3b

3b

3b

Casecontrol

Casecontrol

Casecontrol

Study groups

Control (n = 30);
Untreated (n = 30)

2
3

Control (n = 9)

2

Fluticasone (n = 23);
Control (n = 23)

1
2

SAR to grass pollen (n = 46):

AIT (n = 13);

1

SAR to grass pollen (n = 22):

Mometasone (n = 30);

Placebo (n = 17)

1

AR (n = 90):

2

Effect of allergen exposure on nasal
antigen-presenting cell and epithelial
CD1a+ Langerhans cells, CD68+
macrophages, and CD20+ B-cells.

Effect of AIT on the numbers of
Foxp3(+) CD4(+) and Foxp3(+)
CD25(+) T-cells in and out of season and
expression of IL-10 in nasal mucosa.

Compare by histochemical staining with
anti-CD31 and VEGF-C the
vascularization of the nasal mucosa of
non-allergic, non-treated allergic, and
allergic patients treated with
mometasone.

Clinical endpoint

Recruitment of CD1a+ Langerhans cells to the
nasal mucosa during seasonal allergen exposure
may contribute to local T-cell responses.

The presence of local Foxp3(+)CD25(+) cells in
the nasal mucosa, their increase after AIT, and
their association with suppression of seasonal
allergic inflammation support a role for T-reg
cells in the induction of allergen-specific
tolerance.

Significantly lower values of CD31 and VEGF-C
expression were observed in non-allergic
compared with non-treated allergic and patients
treated with mometasone.

Conclusion

AIT = allergen immunotherapy; AR = allergic rhinitis; DBRPCT = double-blind randomized placebo-controlled trial; ICAM = intercellular adhesion molecule; IgE = immunoglobulin E; IL = interleukin;
LOE = level of evidence; PAR = perennial allergic rhinitis; RPCT = randomized placebo-controlled trial; SAR = seasonal allergic rhinitis; SBRPCT = single-blind randomized placebo-controlled trial; T-reg
= T-regulatory cell; VEGF = vascular endothelial growth factor.

Till et al.1113

1112

Radulovic et al.

1111

2013

Author Manuscript

Kujundzić et al.

Study
design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study

Wise et al.
Page 353

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Author Manuscript

Author Manuscript

Author Manuscript

Nurmatov et al.

2006

1999

1995

Moon & Choi1122

Geller-Bernstein
et al.1119

2010

Brehler &
Kneist1128

1127

Stillerman et al.

1114

2012

2003

1124

Terreehorst et al.

2010

Year

2004

al.1126

Ghazala et al.1120

Sheikh et

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2b

2b

2b

2b

2a

1b

1b

1a

LOE

Double-blind
RCT

Open RCT

RDBPCT,
parallel-group

RDBPCT,
crossover

SR of RCTs

Double-blind
RCT

Randomized
crossover study

SR

Study design

Acaricides and HDM impermeable bedding
in isolation and combination (n = 1)

4

Children with atopy, bedroom sprayed with
acaricide;
Children with atopy without acaricide
2

Adults and children with atopy and verbal
advice on allergen avoidance

2

1

Adults and children with atopy and
multimodality environmental control;

Children with atopy without HDMimpermeable bedding

2

1

Children with atopy and HDM-impermeable
bedding;

Same adults with atopy, without PAF

1

2

Adults with atopy and PAF;

HEPA filtration (n = 2);

3

1

Acaricides (n = 2);

2

Use of HDM impermeable bedding (n = 4);

Children with atopy without HDM
impermeable bedding

2

1

Children with atopy and HDM impermeable
bedding;

Adults with atopy without use of
impermeable encasings

2

1

Adults with atopy and use of impermeable
encasings;

1

RCTs examining the effectiveness of environmental
measures for HDM

Study groups

Daily rhinitis and asthma
symptom scores, medication
use, twice-weekly PEF

Change in HDM load, daily
rhinitis symptom scores

Allergy symptom scores, use of
anti-allergic medication

Reported nasal symptoms, QOL
scores using the nocturnal
RQLQ

HDM load, symptom scores,
medication scores, diseasespecific QOL

Rhinitis-specific visual analogue
scale, daily symptom score,
nasal allergen provocation, Der
p 1 and Der f 1 concentration

Allergen content (Der p 1, Der f
1, mite group 2), subjective
clinical complaints

Symptoms

Clinical endpoint

Conclusion

Acaricide is associated with decreased
mean symptom scores.

Multimodality environmental control is
associated with reductions in mean dust
mite concentration and nasal symptom
scores.

HDM-impermeable bedding is
associated with significant reduction in
symptom scores without change in antiallergic drug utilization.

PAF is associated with improved nasal
symptom and QOL scores.

Environmental controls significantly
reduced HDM load. Acaricides most
effective single method. Combination
therapies more effective than single
interventions and may offer symptom
relief.

Impermeable encasings significantly
reduce allergen concentration, without
difference in symptoms or nasal
provocation testing.

Impermeable encasings significantly
reduce allergen concentration, without
difference in subjective symptom
scores.

Acaricides are the most effective as a
single measure or in combination with
other measures to decrease HDM and
improve symptoms.

Evidence of the effectiveness of house dust mite avoidance and environmental controls in the management of allergic rhinitis

Author Manuscript
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1991

Antonicelli et al.

2b

2b

2b

Double-blind
crossover RCT

Randomized
crossover study

Double-blind
matched pair
controlled trial

Study design

Adults with atopy and HEPA filtration;
Adults with atopy and placebo filtration

2

Adults and children with atopy without
HEPA filtration

2

1

Adults and children with atopy and HEPA
filtration;

Adults and children with atopy and intensive
home cleaning alone

2

1

Adults and children with atopy and intensive
home cleaning plus acaricide;

1

Study groups

Particulate counts in bedroom
air, symptom and medication
scores, patients’ subjective
response to treatment

HDM concentration, rhinitis and
asthma symptom score

Daily symptoms and medication
scores, physician assessment,
tIgE, sIgE, serum and nasal
eosinophils, guanine exposure

Clinical endpoint

HEPA filtration is associated with
improved particulate counts and
symptom/medication scores.

HEPA filtration had no significant
effect on rhinitis symptom scores.

Acaricide associated with improvement
in all outcome measures except for
mite-specific IgE.

Conclusion

HDM = house dust mite; HEPA = high-efficiency particulate air; IgE = immunoglobulin E; LOE = level of evidence; PAF = personal air filtration; PEF = peak expiratory flow; QOL = quality of life; RCT =
randomized controlled trial; RDBPCT = randomized double-blind-placebo-controlled trial; RQLQ; Rhinoconjunctivitis Quality of Life Questionnaire; sIgE = antigen specific immunoglobulin E; SR =
systematic review; tIgE = total immunoglobulin E.

Reisman et al.1123

1125

1990

1992

Kniest et

LOE

Author Manuscript
Year

Author Manuscript

al.1121

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript
2016

Le Cann et al.
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2004

Morgan et al.

1142

2004

Arbes et al.1135

1134

McConnell et al.

2005

2005

Eggleston et al.

1141

2007

Sever et al.1133

1132

Year

Study

1b

1b

1b

1b

1b

1a

LOE

RCT with blocked
randomization

RCT with
crossover of control
group

RCT

RCT

3-arm RCT; follow
up for 12 months

SR of RCTs

Study design

Education-based intervention
(environmental remediation for
multiple allergens); professional pest
control provided for CR-sensitized
children
Control
2

Control: no intervention for months
0–6; insecticide bait placement at
months 6 and 9

2

1

Intervention: education; insecticide
bait placement; professional
cleaning;

Comparison group

2
1

Education-based intervention
(sealing cracks and crevices;
cleaning with bleach solutions;
insecticide bait traps);

1

Control

2

Control

3
Home-based education, CR and
rodent extermination, mattress and
pillow encasings, HEPA filters;

Pest control by randomly assigned
commercial company;

2

1

Insecticide baits and CR monitoring;

1

Combination of both. Interventions
included multiple-allergen control
measures.

Physical methods;

2
3

Education-based methods;

1

Home group interventions in 3 categories:

Study groups

Asthma symptoms, use of
healthcare services

No direct clinical endpoints,
Bla g 1 and Bla g 2 CR
allergen level

No direct clinical endpoints;
CR count and CR allergen
level

Primary outcome: Bla g 1
CR allergen level. Secondary
outcome: asthma symptoms

No direct clinical endpoints.
CR trap counts and CR
allergen levels (Bla g 1 and
Bla g 2)

Allergic and respiratory
symptoms (eg, cough,
daytime symptoms, wheeze,
night time symptoms); lung
function; medication use;
urgent care use for
respiratory symptoms

Clinical endpoint

Conclusion

Intervention group: Reduced levels of CR allergen
in bedroom were strongly correlated with
decreased asthma-related morbidity.

CR allergen levels reduced in 6 months with
professional cleaning and insecticide bait traps; but
lower CR allergen levels maintained at month 12
with bait traps alone.

Achieved 60% reduction in CR count in
intervention group. Greatest reduction in allergen
level in homes with heavier CR infestation but
levels still higher than median level associated with
severe symptoms.

CR allergen reduced by 51% at 6 months. in
treatment group but not sustained at 1 year; only
modest effect on morbidity.

Significant reduction in CR counts in both
treatment groups vs control. Insecticide bait traps
more effective in reducing CR infestation than
sprays. Elimination of CR populations leads to
reduction in CR allergen and exposure.

Overall studies supported effectiveness of home
interventions in decreasing respiratory symptoms
and urgent care use.

Evidence of the effectiveness of cockroach avoidance and environmental controls on the management of allergic rhinitis

Author Manuscript
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3b

2b

1b

1b

1b

Prospective casecontrol

Single-blind, nonrandom, stratified,
placebo-controlled
study

RCT: Phase II of a
multi-city study

RCT

RCT

Identical-appearing placebo bait
traps

Professional cleaning followed by pest control
treatments

2

Bait traps with insecticide;

Control

2
1

Education-based intervention for
parents: asthma triggers,
environmental controls; pest control;
house cleaning;

1

Control without cleaning,
extermination

2

No cleaning or bait traps

3
Professional cleaning with sodium
hypochlorite and insecticide bait
traps;

Professional cleaning and bait traps
with no insecticide;

2

1

Professional cleaning and insecticide
bait traps;

1

Study groups

No direct clinical endpoints,
CR counts and Bla g 1 CR
allergen level

No direct clinical endpoints,
CR counts and CR allergen
levels Bla g 1 and Bla g 2

No direct clinical endpoints,
Bla g 1 CR allergen level

No direct clinical endpoints,
CR count and Bla g 1 CR
allergen level

No direct clinical endpoints,
CR count and Bla g 2 CR
allergen level

Clinical endpoint

CR = cockroach; HEPA = high-efficiency particulate air; LOE = level of evidence; RCT = randomized controlled trial; SR = systematic review.

1139

Eggleston et al.

1999

1999

Williams et al.

1140

1999

2001

Gergen et al.1138

Wood et al.1137

1136

2003

Author Manuscript

McConnell et al.

Study design

Author Manuscript
LOE

Author Manuscript

Year

CR numbers eliminated in most inner-city homes
with professionally applied insecticides. CR
allergen levels decreased by 78% to 93% over 8
months; mean allergen concentrations still above
threshold of asthma morbidity.

Treated homes had a significant decrease in
number of CR compared to placebo, which
continued for 6 months. Minimal reduction in Bla
g 1 and Bla g 2 CR allergen. No significant
difference: active vs placebo.

CR allergen levels decreased within 6 months but
returned or exceeded baseline levels by 12 months.
Compliance with cleaning protocol was poor.

Professional extermination reduced CR numbers
and median allergen levels by 80% to 90%.
Cleaning solution did not add any improvements.
Unclear if this level of reduction is sufficient to
have clinical benefits.

Decreased CR count and allergen concentration in
insecticide bait treatment was low. Homes with
high initial CR counts had larger reductions in Bla
g 2 CR allergen concentration. Professional
cleaning may help in homes with higher CR.

Conclusion

Author Manuscript

Study
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Author Manuscript

Author Manuscript
a

2b

2b

1b

LOE

RCT

Cohort
Study

RCT

Study
design

Placebo

2

EC;
Unchanged environment

1
2

Cat-allergic patients:

Patients with diagnosed allergy

HEPA filter;

1

Cat-sensitive adults:

Study groups

Environmental (settled dust) Fel d 1
levels, nasal inspiratory flow, nasal
symptoms

Sensitization to household animals,
compliance with avoidance
recommendations and EC

Cat allergen levels (airborne and settled
dust), symptom scores, medication scores,
spirometry

Clinical endpoint

EC = environmental control; HEPA = high-efficiency particulate air; LOE = level of evidence; RCT = randomized controlled trial.

Follow-up <80% prevents 1b.

a

2003

Björnsdottir et al.1147

1998

2015

al.1148

Year

Sanchez et al.1146

Wood et

Study

Author Manuscript

Evidence of the effectiveness of pet avoidance and environmental controls

Multimodality EC is associated with decreased allergen
concentration and significant improvements in nasal
inspiratory flow and patient symptoms.

Avoidance recommendations may be impractical with
high rates of sensitization, indirect exposure, and low
rates of compliance.

HEPA filters are associated with reduced airborne but
not settled dust, cat allergen levels without effect on
disease activity.

Conclusion

Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript

2013

2014

2b

1b

1b

1b

LOE

Cohort, prospective,
open trial

Randomized doubleblind, placebocontrolled crossover

Randomized doubleblind, placebocontrolled crossover

RCT

Study design

Standard medical care alone

2

Placebo filter

2

Occupational allergy (n = 20)

Nasal membrane filter;
Placebo filter

1
2

Adults with SAR to grass pollen (n = 24):

Nasal membrane filter;

1

Adults with SAR to grass pollen (n = 65):

Wrap-around eyeglasses plus
standard medical care;

1

SAR to grass pollen (n = 70):

Study groups

Nasal symptoms, diseasespecific QOL, nasal patency,
nasal inflammation, olfactory
function

Following ACC exposure: nasal
symptom scores, conjunctival
symptom scores, throat irritation,
intranasal volume, oral FeNO

In-season exposure: TNSS,
individual symptoms

Nasal and conjunctival symptom
scores, rescue medication use,
RQLQ

Clinical endpoint

EC in occupational allergy patients results in
improved QOL, rhinitis-associated symptoms,
and general well-being.

Primary endpoint, TNSS, was not significant.
Some secondary endpoints were positive. In
the absence of natural allergen exposure, the
conclusions of this trial are limited.

Daily sum TNSS and maximal TNSS were
significant. Individual symptoms (sneezing,
watery eyes, rhinorrhea) were also
significantly decreased compared to placebo.

Significant improvement of ocular/nasal
symptoms and RQLQ in wrap-around eyeglass
group.

Conclusion

ACC = allergen challenge chamber; FeNO = fraction of exhaled nitric oxide; LOE = level of evidence; QOL = quality of life; RCT = randomized controlled trial; RQLQ = Rhinoconjunctivitis Quality of
Life Questionnaire; SAR = seasonal allergic rhinitis.

1165

Castano et al.

1162

Kenney et al.

1163

Kenney et al.

2015

2016

Comert et al.

1161

Year

Study

Evidence of the effectiveness of pollen and occupational allergen avoidance and environmental controls
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2013
2013

2011
2011

2011
2010

2009

2009

Compalati &
Canonica1171

Mösges et al.1177

Compalati et al.1178

Ferrer1179

Mösges et al.1180

Brozek et al.1167

Bachert1182

Katiyar & Prakash1181

2015

Ridolo et al.1174

2015

2015

Mullol et al.1175

Scadding1176

Year

Study
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1a

1a

1a

1a

1a

1a

1a

1a

1a

1a

1a

LOE

SR

SR

SR with consensus
statement

SR and metaanalysis

SR

SR and metaanalysis

SR and metaanalysis

SR

Review of
consensus
statements: ARIA,
EAACI, Royal
College of
Paediatrics, and
Child Health

SR

SR

Study design

Rupatadine; ebastine;
cetirizine; loratadine;
desloratadine

Desloratadine;
fexofenadine;
levocetirizine;
cetirizine; loratadine;
terfenadine

Oral antihistamines

Levocetirizine;
loratadine

Levocetirizine;
desloratadine;
fexofenadine

Fexofenadine

Desloratadine;
ebastine;
fexofenadine;
levocetirizine

Rupatadine

Oral antihistamines

Bilastine; cetirizine;
desloratadine

Rupatadine

Study groups

ARIA criteria evaluated for:
intermittent/persistent, SAR/PAR.
TSS, DTSSm, DSSm, QT changes

TSS, PNIF, TSSC (with nasal
obstruction), nasal congestion, and
obstruction

Evidence was graded and
recommendation given

TSS, DNS, DES, in patients with
persistent and SAR/PAR

TSS, PNIF, decongestion test, QOL,
pruritus, ESS, wheal and flare, AE

TSS, individual symptoms (sneezing,
rhinorrhea, itching congestion), AE

TSS and TNSS

Allergy symptoms, AE

–

Subjective and objective measures,
TNSS, RQLQ

Allergy symptoms, ARIA criteria,
AE

Clinical endpoint

Evidence for the role of oral H1 antihistamines in the management of allergic rhinitis

Rupatadine is a non-sedating, efficacious, and safe oral H1
antihistamine for intermittent/persistent, SAR/PAR.

Oral antihistamines have good efficacy for improving both
subjective and objective measures, effective in relieving nasal
congestion associated with AR compared to placebo.

Strong recommendation to use second-generation oral
antihistamines that do not cause sedation and do not interact
with CYP450 enzyme.

Improvement in TSS, Total 5 Symptoms Score, daytime nasal
symptoms, and QOL.

Oral newer-generation antihistamines are well tolerated in
adults and children. Efficacy and improvement in QOL and
nasal obstruction. Benefits outweigh harm. Very low risk of
sedation. No QT prolongation found.

Fexofenadine has good efficacy with improvement in outcome
measures. No significant AE compared to placebo.

Second-generation levocetirizine significantly improved
symptom scores especially in severe AR cases.

Favorable risk-benefit ratio for rupatadine in treating AR.

Second-generation, non-sedating, antihistamines are
recommended for mild to moderate AR and in combination for
severe AR. Sedating antihistamines should not be used.

Bilastine at therapeutic dose has similar efficacy to other
second-generation oral antihistamines. Demonstrated
improvement in TNSS and RQLQ with good safety profile.

Rupatadine is recommended for use in adults and children for
intermittent/persistent AR and SAR/PAR.

Conclusion
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2005
2004
2004

2003

1989

Passalacqua &
Canonica1188

Bousquet et al.1170

Greisner1189

Limon & Kockler1190

Bojkowski et al.1191
1a

1a

1a

1a

1a

1a

1a

1a

1a

1a

SR

SR

SR

SR with consensus
statement

SR

SR of RDBCT

SR

SR and metaanalysis

SR and metaanalysis

SR

Acrivastine (40
studies reviewed)

Desloratadine

Cetirizine;
desloratadine;
fexofenadine;
loratadine

Desloratadine

Levocetirizine;
desloratadine

H1 antihistamine vs
placebo

Desloratadine

Levocetirizine

Desloratadine

Desloratadine

Study groups

Rhinoconjunctivitis symptoms, nasal
congestion, adverse events,
drowsiness, CNS depression for
SAR/PAR

TSS, TNSS, TNNSS, nasal
congestion, nasal airflow, TASS for
SAR/PAR

Onset of action

ARIA/EAACI criteria efficacy,
safety, pharmacology

Nasal symptoms, wheal-flare
response, QOL, TSS

Nasal obstruction

Morning symptoms, TSS, TNSS,
TNNSS

Nasal obstruction

TSS, TNSS, nasal airflow

TSS, TNSS, TNNSS, PNIF, for
intermittent/persistent SAR/PAR

Clinical endpoint

Newer-generation oral H1 antihistamine acrivastine has
excellent efficacy for patients with SAR/PAR. Improved nasal
congestion. Small increase in drowsiness over terfenadine. No
CNS depression found.

Desloratadine is a safe and efficacious for patients with SAR/
PAR. Improved TSS, TNSS, and TNNSS, TASS, nasal
congestion. Nasal congestion was excluded in the PAR group.

Inconsistent results. Onset of action is dependent on how it is
defined and measured.

Desloratadine is recommended for treating patients with AR.

Improved QOL and TSS for SAR/PAR. Levocetirizine has a
faster onset.

Oral H1 antihistamines improve nasal obstruction by 22% over
placebo.

Desloratadine improves TSS and improved QOL in patients
with SAR/PAR. 24-hour action makes it effective in controlling
morning symptoms.

Improved nasal obstruction under artificial and natural allergen
exposure.

Reduction in TSS, TNSS, and improved nasal airflow.

Desloratadine is well tolerated and efficacious for intermittent
and persistent AR with reductions in congestion, TSS, TNSS,
and TNNSS, with improved QOL.

Conclusion

RDBCT = randomized double-blind controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SAR = seasonal allergic rhinitis; SR = systematic review; TASS = Total Asthma Symptom
Score; TNNSS = Total Non-Nasal Symptom Score; TNSS = Total Nasal Symptom Score; TSS = Total Symptom Score; PNIF = peak nasal inspiratory flow; TSSC = Total Symptom Severity Complex.

H1; LOE = level of evidence; PAR = perennial allergic rhinitis; QOL = quality of life; QT = measure of time between the onset of ventricular depolarization and completion of ventricular repolarization;

AE = adverse effects; AR = allergic rhinitis; ARIA = Allergic Rhinitis and its Impact of Asthma; CNS = central nervous system; DES = Daytime Eye Symptoms; DNS = Daytime Nasal Symptoms; DSSm
= mean Daily Symptom Score; DTSSm = mean Total Daily Symptom Score; EAACI = European Academy of Allergy and Clinical Immunology; ESS = Epworth Sleepiness Scale; H1 = histamine receptor

2005

Hore et al.1187

2006

Patou et al.1185
2006

2007

Canonica et al.1184

Schenkel1186

2007

Author Manuscript

Bachert & van
Cauwenberge1183

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript
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Author Manuscript

Author Manuscript
1–3
0.7

2

Fexofenadine

Levocetirizine

Loratadine

>24

>24

>24

24

>24

<24

Duration
(hours)

Unlikely

Unlikely

Unlikely

Unlikely

Unlikely

Unlikely

Drug
interactions

BID = twice per day; N/A = not applicable; QD = once per day.

2

2–2.6

0.7

Onset (hours)

Bilastine

Desloratadine

Cetirizine

Antihistamine
medication

7.8

7

11–15

14.5

27

6.5–10

Elimination
(hours)

10 mg QD or5mg BID

5 mg QD

60 mg BID or 180 mg QD

20 mg QD

5 mg QD

5–10 mg QD

Adults

2–5 years; 5 mg QD;
≥6 years; 10 mg QD

2–5 years: 1.25 mg QD;
6–11 years: 2.5 mg QD;
≥12 years: 2.5–5 mg QD

2–11 years: 30 mg BID

6–11 years: 10 mg QD

2–5 years: 1.25 mg QD;
6–11 years: 2.5 mg QD

2–5 years; 2.5 mg or 5 mg QD;
6–12 years: 5–10 mg QD

Dosage
Children

Author Manuscript

List of commonly used second-generation antihistamines

Author Manuscript
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2005

Taylor-Clark et al.

1996

1996

Wang et al.1195

Wood-Baker et al.
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1982

Brooks et al.1197
1b

1b

1b

1b

1b

1b

LOE

RCT

RCT

RCT

RCT

RCT

RCT

Study
design

PO cetirizine + ranitidine;
Placebo

3
4

Placebo

4

PO cetirizine + cimetidine

2

PO ranitidine

2

PO cimetidine;
Placebo

1
2

Allergy challenge with premedication:

PO chlorpheniramine;
PO chlorpheniramine + cimetidine

1
2

During allergy season medicated with:

PO cetirizine;

1

Allergy challenge with premedication:

PO cetirizine;

1

Allergy challenge with premedication:

PO cimetidine;
PO terfenadine + cimetidine;

2
3

PO terfenadine;

1

Allergy challenge with premedication:

PO ranitidine;

PO cetirizine;

2

1

Histamine challenge with premedication:

Study groups

Subjective symptoms (congestion,
itch, drainage, sneeze), nasal
resistance, nasal secretion weight

Symptoms (rhinorrhea, sneezing,
nasal congestion, nasal pruritus,
eye discomfort), medication usage
beyond study therapy

Nasal lavage fluid protein
concentration, nasal airway
resistance

Symptoms (itching, sneezing,
rhinorrhea, congestion), sneeze
count, nasal airway resistance

Laser Doppler flowmeter, allergic
symptoms

Nasal airway resistance

H2 = histamine receptor H2; LOE = level of evidence; PO = per os (medication taken orally); RCT = randomized controlled trial.

1983

Carpenter et al.1198

1193

1996

Juliusson &
Bende1196

1194

Year

Study

Clinical endpoint

Author Manuscript

Evidence for the role of oral H2 antihistamines in the management of allergic rhinitis

No difference in subjective scores. Increased secretion
and sneeze count, no difference in nasal resistance.

Reduced symptoms and medication scores in
cimetidine plus chlorpheniramine group.

Ranitidine improved nasal resistance more than
cetirizine. Cetirizine decreased total protein and
albumin more than ranitidine.

Combination of cetirizine + cimetidine showed
improved nasal airway resistance and nasal airflow
over cetirizine alone.

No difference in symptoms or flowmetry with
cimetidine. No additive effect of cimetidine with
terfenadine.

Cetirizine alone and ranitidine alone improve nasal
resistance. Cetirizine plus ranitidine improves nasal
resistance more than either alone.

Conclusion
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2011

2011

2009

2009

2009

2009

Howland et al.1201

Meltzer et al.1202

Berger et al.1204

Bernstein et al.1205

Kaliner et al.1206

Shah et al.1207

2012

2011

al.1199

Year

Han et al.1200

Carr et

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1b

1b

1b

1b

1b

1b

1b

LOE

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT
(post hoc
analysis)

Study
design

Placebo 2 sprays

5

Azelastine 0.82 mg BID;
Azelastine 0.56 mg BID;
Placebo

1
2
3

Fluticasone 0.2 mg spray daily

Reformulated azelastine 0.56 mg BID;

4

2

Azelastine 0.56 mg BID;

3

Olopatadine 2.66 mg BID;

Reformulated azelastine 0.28 mg BID;

1

Azelastine 0.28 mg BID;

Placebo

3

2

Olopatadine 2.66 mg BID;

1

Olopatadine 1.33 mg BID;

2

Placebo

1

Olopatadine 1.33 mg BID;

2

Placebo

2
1

Azelastine 0.82 mg BID;

Levocabastine hydrochloride 0.05% spray (dose
not given)

2

1

Azelastine 0.1% (dose not given);

Fluticasone propionate 0.1 mg spray BID

2
1

Azelastine 0.28 mg BID;

1

Study groups

TNSS

rTNSS, rTOSS

TNSS

TNSS, TOSS, PRQLQ,
CGTSQ, SGA

rTNSS, rTOSS,
PRQLQ, CGTSQ-AR

rTNSS, rTOSS, RQLQ

rTNSS

rTNSS, rTOSS, RQLQ

Clinical endpoint

Evidence for the role of topical intranasal antihistamines as monotherapy in the management of allergic rhinitis

Both azelastine doses superior to placebo;
greater improvement with higher dose.

Both treatments improve symptoms; faster
onset for olopatadine.

Both azelastine spray formulations superior
to placebo; dose-response effect between
dosages; no difference in bitter taste
between formulations.

Olopatadine superior to placebo in reducing
symptoms in children, improving QOL, and
satisfying caregivers.

Olopatadine superior to placebo in reducing
symptoms in children, improving QOL, and
satisfying caregivers.

Azelastine superior to placebo for nasal and
eye symptoms and QOL.

Comparable symptom improvement.

Fluticasone superior to azelastine for
improving rhinorrhea; comparable symptom
and QOL improvement.

Conclusion

Author Manuscript
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2008

2008

2007

2007

2007

2006

2006

Pipkorn et al.1211

Lumry et al.1212

Patel et al.1213

Patel et al.1214

Berger et al.1215

Hampel et al.1216

2009

2009

Meltzer et al.1210

van Bavel et al.1209

Shah et

al.1208

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1b

1b

1b

1b

1b

1b

1b

1b

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

Study
design

Olopatadine 2.66 mg BID;
Olopatadine 1.77 mg BID;
Placebo

2
3

Cetirizine 10-mg tablet daily

1

Azelastine 0.56 mg BID;

Placebo

3

2

Mometasone furoate 0.2 mg spray QD;

1

Olopatadine 2.66 mg daily;

Placebo

3

2

Mometasone furoate 0.2 mg spray QD;

2

1

Azelastine 0.56 mg daily;

1

Azelastine 0.28 mg BID;
Placebo

2

Placebo

4

3

Azelastine 0.1% (dose not given);

3

Azelastine 0.28 mg daily;

Olopatadine 0.2% (dose not given);

2

1

Olopatadine 0.1%, (dose not given);

Azelastine 0.56 mg BID

2
1

Olopatadine 2.66 mg BID;

1

Azelastine 0.82 mg daily;
Placebo

Placebo

3
1

Azelastine 0.56 mg BID;

2

Olopatadine 2.66 mg BID;

2

Study groups
1

Author Manuscript
LOE

Clinical endpoint

Total Symptom Score,
RQLQ

TNSS, RQLQ

TNSS, patient
satisfaction

TNSS

TNSS

4-item symptom score,
nasal lavage

Sensory perception

TNSS

TNSS

Author Manuscript

Year

Olopatadine (both doses) superior to
placebo in majority of domains for QOL
improvement.

Azelastine superior for sneezing and nasal
congestion; azelastine superior for QOL.

Olopatadine superior to placebo and
mometasone in reducing symptoms; faster
onset for olopatadine.

Azelastine superior to mometasone and
placebo.

Azelastine both doses superior to placebo.

Both olopatadine doses superior to placebo
for reducing symptoms; higher
concentration inhibits mast cell
degranulation.

Olopatadine favored for taste, aftertaste, and
likelihood of use.

Azelastine superior to placebo.

Both treatments superior to placebo; no
difference between treatments; less bitter
taste with olopatadine.

Conclusion

Author Manuscript
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2006

2005

Corren et al.1217

2005

2005

2004

2003

2002

2001

2000

Meltzer et al.1218

Ratner et al.1219

LaForce et al.1220

Berger & White1221

Saengpanich et al.1222

Falser et al.1223

Berlin et al.1224

Horak et

al.1046

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1b

1b

1b

1b

1b

1b

1b

1b

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

Study
design

Azelastine 0.56 mg BID;
Flunisolide 0.116 mg spray BID;
2

Levocabastine 0.2 mg spray BID

2
1

Azelastine 0.56 mg BID;

1

Placebo

Placebo spray + placebo tablet

4

2

Desloratadine 5-mg tablet + placebo spray;

3

Azelastine 0.28 mg BID;

Azelastine 0.56 mg BID + loratadine 10-mg
tablet;

2

1

Azelastine 0.56 mg BID;

Placebo spray + placebo tablet

3
1

Azelastine 0.56 mg BID + fexofenadine 60-mg
tablet BID;

2

Placebo

3
Azelastine 0.56 mg BID;

Olopatadine 1.77 mg BID;

1

Olopatadine 2.66 mg BID;

Placebo

3

2

Olopatadine 1.77 mg BID;

1

Olopatadine 2.66 mg BID;

2

Cetirizine 10-mg tablet daily

1

Azelastine 0.56 mg BID;

2

Placebo spray

3
1

Azelastine 0.4 mg daily;
Desloratadine 5-mg tablet daily;

1

Study groups

2

Author Manuscript
LOE

Clinical endpoint

9-item symptom score

10-item symptom score,
global assessment

TNSS, nasal lavage,
methacholine challenge

TNSS

TNSS

TNSS

TNSS, RQLQ

TNSS, RQLQ

TNSS

Author Manuscript

Year

Flunisolide superior to azelastine; both
treatments superior to placebo.

Azelastine superior to levocabastine.

Azelastine superior to placebo for
symptoms; no effect on nasal eosinophils or
cytokines; azelastine inhibits methacholine
response.

All treatments superior to placebo;
azelastine at least as effective as
desloratadine; no additional benefit of
adding oral loratadine to azelastine
monotherapy.

Azelastine superior to placebo; no additional
benefit of adding oral fexofenadine to
azelastine monotherapy.

Olopatadine (both doses) superior to
placebo.

Olopatadine (both doses) superior to
placebo for symptoms and QOL
improvement.

Azelastine superior cetirizine for symptoms
and QOL.

Azelastine superior to desloratadine and
placebo.

Conclusion

Author Manuscript

Study
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1998

1997

1997

1997

1996

1995

1995

Herman et al.1228

Newson-Smith et al.1229

Weiler & Meltzer1230

LaForce et al.1231

Charpin et al.1232

Pelucchi et al.1233

1999

Berger et al.1226

Stern et al.1227

2000

Author Manuscript

Golden et al.1225
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1b

1b

1b

1b

1b

1b

1b

1b

1b

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

Study
design

Azelastine 0.28 mg BID;
Beclomethasone dipropionate 0.1 mg spray
BID;
2

Cetirizine 10-mg tablet daily

1

Azelastine 0.28 mg BID;

2

Placebo

4
1

Azelastine 0.56 mg BID;
Chlorpheniramine 12-mg tablet BID;

2
3

Azelastine 0.56 mg daily;

1

Placebo spray + azelastine 0.5-mg tablet BID

2

Placebo

3

Azelastine 0.56 mg spray BID + azelastine 0.5mg tablet BID;

Beclomethasone 0.2 mg spray BID;

2

1

Azelastine 0.56 mg BID;

1

Placebo

2

Placebo

3
Azelastine 0.28 mg BID;

Budesonide 0.256 mg spray daily;

2

1

Azelastine 0.28 mg BID;

Loratadine 10-mg tablet daily + beclomethasone
dipropionate 0.168 mg spray BID

1

2

Azelastine 0.56 mg BID;

Placebo

1

Azelastine 0.56 mg BID;

Study groups

2

Placebo

1

3

Author Manuscript
LOE

Clinical endpoint

8-item symptom score,
nasal lavage,
methacholine challenge

8-item symptom score

8-item symptom score

13-item symptom score

6-item symptom score

TNSS

3-item symptom score

5-item symptom score,
global evaluation

RSS, ESS

Author Manuscript

Year

Azelastine superior to placebo and
comparable to beclomethasone for symptom
improvement; neither treatment prevented
bronchial responsiveness; no effect of
azelastine on eosinophils.

Azelastine superior for nasal stuffiness and
rhinorrhea; no difference in other symptoms.

Azelastine superior to placebo at both doses;
no comparison with chlorpheniramine.

Azelastine spray showed limited benefit
over placebo in patients already treated with
systemic azelastine.

Beclomethasone superior to azelastine for
long-term symptom improvement; both
treatments superior to placebo; azelastine
more rapid onset.

Azelastine superior to placebo for children.

Budesonide superior to azelastine; both
treatments superior to placebo.

Azelastine at least as effective as
combination therapy with loratadine plus
beclomethasone spray.

Azelastine superior to placebo for
improving rhinorrhea and sleep quality.

Conclusion

Author Manuscript

Study
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1994

1994

1993

1993

1993

1993

2010

Ratner et al.1237

Davies et al.1238

Dorow et al.1239

Gambardella1240

Gastpar et al.1241

Kalpaklioglu & Kavut1203

1994

Meltzer et al.1235

Passali & Piragine1236

1994

Author Manuscript

Gastpar et al.1234
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2b

1b

1b

1b

1b

1b

1b

1b

1b

Singleblind RCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

Study
design

Azelastine 0.56 mg BID;
Triamcinolone acetonide 0.22 mg spray daily
2

Budesonide 0.10 mg spray BID

2
1

Azelastine 0.28 mg BID;

Loratadine 10-mg tablet daily

2
1

Azelastine 0.28 mg BID;

1

Budesonide 0.10 mg spray BID;
Placebo

2
3

Placebo

3
Azelastine 0.28 mg BID;

Beclomethasone dipropionate 0.1 mg spray
BID;

2

1

Azelastine 0.28 mg BID;

Placebo

3
1

Azelastine 0.28 mg daily;
Azelastine 0.28 mg BID;

1

Cetirizine 10-mg tablet daily

2

2

Azelastine 0.28 mg BID;

Placebo

4
1

Azelastine 0.28 mg BID;
Chlorpheniramine 12-mg tablet BID;

2

Azelastine 0.28 mg daily;

3

1

Azelastine 0.28 mg daily;
Terfenadine 60-mg tablet daily

Study groups

1

Placebo

2

3

Author Manuscript
LOE

Clinical endpoint

TNSS, nPIFR, ESS,
SF-36, mini-RQLQ

10-item symptom score,
nasal flow rate

12-item symptom score,
global assessment

13-item symptom score

TNSS, rhinomanometry

8-item symptom score

13-item symptom score

11-item symptom score

13-item symptom score

Author Manuscript

Year

Comparable improvement in nasal
symptoms, nPIFR, ESS and QOL; azelastine
superior for ocular symptoms.

Azelastine at least as effective as budesonide
for symptoms; flow rate improved in both
treatment groups.

Azelastine at least as effective as loratadine.

Azelastine comparable to budesonide for
nasal symptoms and superior for ocular
symptoms; both treatments superior to
placebo.

Azelastine superior to beclomethasone and
placebo for symptoms; no change in airway
resistance with either treatment.

Azelastine twice-daily superior to placebo.

Azelastine at least as effective as cetirizine.

Azelastine comparable to chlorpheniramine
and superior to placebo at both doses.

Comparable symptom improvement.

Conclusion

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

AR = allergic rhinitis; BID = twice a day; CGTSQ = Caregiver Treatment Satisfaction Questionnaire; CGTSQ-AR = Caregiver Treatment Satisfaction Questionnaire for Allergic Rhinitis; DBRCT = doubleblind randomized controlled trial; ESS = Epworth Sleepiness Scale; LOE = level of evidence; nPIFR = nasal peak inspiratory flow rate; PRQLQ = Pediatric Rhinoconjunctivitis Quality of Life
Questionnaire; QD = once daily; QOL = quality of life; RCT = randomized controlled trial; RCT = randomized controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; RSS = Rhinitis
Severity Score; rTNSS = reflective Total Nasal Symptom Score; rTOSS = reflective Total Ocular Symptom Score; SF-36, 36-Item Short Form; SGA = Subjective Global Assessment; TNSS = Total Nasal
Symptom Score; TOSS = Total Ocular Symptom score.
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1987

1985

2013

1954
1953
1952

Pipkorn et al.884

Kwaselow et al.1248

Karaki et al.1249

Schwartz1246

Schiller &
Lowell1245

Schwartz et al.1244
4

4

4

2b

1b

1b

1b

1b

1b

LOE

Observational case series

Observational case series

Observational case series

Open label, parallel,
randomized trial

Multicenter, randomized,
double-blind, placebocontrolled study

Placebo controlled,
crossover, nasal
challenge study

Placebo controlled,
crossover, nasal
challenge study

Placebo controlled,
crossover, nasal
challenge study

Placebo-controlled,
parallel group study

Study design

Intranasal flunisolide 50 μg per nostril BID × 4
weeks

2

SAR during season (n = 25): cortisone 100 mg daily × 15
days

SAR during season (n = 51): cortisone 100 mg daily × 4 days

SAR during season (n = 10): Hydrocortisone 40-80 mg daily

2. Loratadine with PO betamethasone 0.25 mg BID

2. Loratadine with intranasal MF (200 μg QD);

1. Loratadine 10 mg daily;

SAR during season (n = 72):

Oral flunisolide 500 μg BID × 4 weeks;

1

SAR during season (n = 99):

SAR out of season (n = 13): prednisone 60 mg PO daily for 2
days

SAR out of season (n = 10): prednisone 60 mg PO daily for 2
days

SAR out of season (n = 13): prednisone 60 mg PO daily for 2
days

SAR during season (n = 31): MP 6, 12, 24 mg QD × 5 days

Study groups

Symptom relief

Symptom relief

Symptom relief

Symptom scores

Symptom scores

Sneezes, levels of
histamine, TAMEesterase, kinins, PGD2,
LTC4/D4, and albumin
in nasal lavages

Number of neutrophils,
eosinophils, and
mononuclear cells in
nasal lavages

Number of eosinophils
and levels of MBP and
EDN in nasal lavages

Symptom scores

Clinical endpoint

21/25 patients reported symptom
relief.

42/51 patients reported symptom
relief.

7/10 patients reported symptom
relief.

The groups on steroids had lower
symptoms compared to loratadine
alone, with no significant
difference between them.

Intranasal preparation only one to
show efficacy in reducing rhinitis
symptoms.

Prednisone inhibited the late-phase
response to nasal allergen
challenge.

Prednisone reduced the influx of
eosinophils into nasal secretions
after allergen challenge.

Prednisone reduced the number of
eosinophils and the levels of its
mediators after allergen challenge.

All doses more effective than
placebo in reducing symptoms
with the highest dose most
effective.

Conclusion

BID = twice daily; EDN = eosinophil-derived neurotoxin; LOE = level of evidence; LTC4/D4 = leukotriene C4/D4; MBP = major basic protein; MF = mometasone furoate; MP = methylprednisolone;
PGD2 = prostaglandin D2; PO = per os (medication taken orally); QD = once daily; SAR = seasonal allergic rhinitis; TAME = N-a-p-tosyl-L-arginine methyl ester.

1988

Bascom et al.1242

1993

Year

1989

al.1247

Bascom et al.1243

Brooks et

Study

Evidence for the role of oral corticosteroids in the management of allergic rhinitis

Author Manuscript
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1980

Ohlander et al.

Kronholm1250
1979

1987

Laursen et al.1252

1251

1987

Borum et al.1254

2008

Year

1988

al.1262

Laursen et al.1253

Yang et

Study

2b

2b

2b

1b

1b

1b

LOE

Prospective,
parallel,
randomized, open
label

Prospective,
randomized,
parallel group

Randomized,
double-blind
comparative

Double-blind,
placebo controlled,
parallel study
during 2
consecutive pollen
seasons

Double blind,
double dummy,
placebo controlled,
study

Randomized,
placebo-controlled
single-blind trial

Study design

Triamcinolone (20 mg, 1 mL in each turbinate);
Isotonic saline (1 mL in each turbinate)

2
3

IM injection of 2 mL betamethasone
dipropionate/betamethasone disodium
phosphate at start of season

2

Placebo

2

Single IM injection of 2 mL betamethasone
dipropionate/betamethasone disodium
phosphate at start of season

2

Methylprednisolone acetate (40 mg)

3

1

2 mL betamethasone dipropionate/
betamethasone phosphate (5 and 2 mg/mL);

SAR during season. IM injection at season onset (n = 42):

Betamethasone dipropionate (5 mg);
Betamethasone disodium phosphate (3 mg)/
acetate (3 mg);

1
2

SAR during season (n = 60). Received 1 of 3 long-acting IM
injections:

Oral prednisolone 7.5 mg PO daily × 3 weeks;

1

SAR during season (n = 37):

IM injection of 80 mg methylprednisolone
given either at the beginning of the season or at
peak pollen count;

1

SAR during 2 consecutive allergy seasons (n = 24):

Intranasal beclomethasone dipropionate (400
μg daily) for 4 weeks;

1

SAR during season (n = 30):

Onabotulinum toxin A (25 units in each
turbinate);

1

Patients with PAR received intraturbinate injections (n = 39):

Study groups

Clinical endpoint

Weekly nasal and ocular
symptoms for 5 weeks

Scores of rhinorrhea, congestion,
and ocular symptoms at 1, 2, and
4 weeks after injection. Cortisol
and glucose blood levels in 38
subjects.

Nasal peak flow and symptom
scores. ACTH test performed at
3 weeks.

Number of sneezes and nose
blowing during the day.
Symptom scores of sneezing,
rhinorrhea, nasal blockage, eye
itching recorded at the end of the
day.

Rhinoconjunctivitis symptom
scores

Symptoms of rhinorrhea, nasal
obstruction, sneezing and itching
at 1, 4, 8, 12, 16, and 20 weeks
after injections

Author Manuscript

Evidence for the role of corticosteroid injections in the management of allergic rhinitis

Both preparations led to a significant
reduction of nose and eye
symptoms; betamethasone
combination was more effective.

All treatments led to significant
reductions in nose and eye
symptoms during season; no
difference between groups. All
preparations suppressed endogenous
cortisol; 2 out of 3 injections caused
increases in blood sugar levels.

IM and oral steroid resulted in a
significant reduction of nasal/ocular
symptoms during season. Significant
suppression of adrenal function with
oral steroid treatment only.

IM injection was efficacious against
nasal congestion with less
pronounced effects against
rhinorrhea and sneezing in active vs
placebo treatment irrespective of
timing of administration.

IM injection significantly more
effective than placebo or intranasal
preparation.

onabotulinum toxin A controlled
nasal symptoms for the longest time
after injection. Steroid injection was
better than placebo but the duration
of action was shorter than
onabotulinum toxin A.

Conclusion

Author Manuscript
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4

Retrospective study
of Danish National
Registries between
1995 and 2011

Study groups
2 mL methylprednisolone acetate (40 mg/mL)

Patients receiving IM steroid injections in April–July or
immunotherapy against grass or birch pollen (n = 47,382)

2
Incidence and relative risk of
osteoporosis, diabetes, tendon
rupture, and respiratory tract
infection

Clinical endpoint

Relative risk and incidence of
osteoporosis and diabetes were
higher in individuals receiving at
least 1 depot corticosteroid injection
vs those receiving immunotherapy.

Conclusion

ACTH = adrenal corticotropic hormone; IM = intramuscular; LOE = level of evidence; PAR = perennial allergic rhinitis; PO = per os (medication taken orally); SAR = seasonal allergic rhinitis.
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2007

2003

2003

Kaiser et al.1284

Craig et al.1275

Dykewicz et al.

Hughes et al.1706
2003

2010

Meltzer et al.1276

1289

2012

Yamada et al.673

1271

2011

2013

Rachelefsky &
Farrar1274

Rodrigo &
Neffen1272

Year

Study

1b

1b

1b

1b

1b

1b

1a

1a

1a

LOE

Double-blind,
placebocontrolled,
crossover study

RDBPCT

Double-blind,
placebo-controlled
study

Double-blind,
parallel-group,
randomized,
placebo-controlled
study

Double-blind,
parallel group,
placebo-controlled
study

Randomized,
placebocontrolled, doubleblind, crossover
study

Meta-analysis of
RDBPCTs

SR with metaanalysis

SR

Study design

PAR (n = 22).
Budesonide 128 μg/day or placebo for 8 weeks.

Adults and adolescents ≥12 year (n = 241), SAR to
fall allergen.
FPNS 200 μg PRN vs placebo for 4 weeks.

PAR (n = 32).
Fluticasone NS vs placebo.

Adults and adolescents with SAR (n = 299).
FFNS 110 μg vs placebo.

Adults with PAR, moderate rhinitis and disturbed
sleep (n = 30).
MFNS 200 μg vs placebo, 4-week trial.

PAR (n = 57).
MFNS vs placebo for 14 days.

16 trials (n = 2998).
MFNS vs placebo.

16 trials (n = 5348).
SAR:7 studies; PAR: 9 studies.
Adults and adolescents ≥12 years: 13 studies;
children: 3 studies.
FFNS vs placebo.

SAR (n = 2290) and PAR (n = 800).
Sixteen controlled clinical trials ≥2 weeks in
duration.
Children aged 2–18 years.

Study groups

ESS, Functional Outcomes of
Sleep Questionnaire, RQLQ.
Daily diary of nasal symptoms,
sleep problems, and daytime
fatigue.

Mean change from baseline in
TNSS.

Questionnaires, QOL
instruments, daily diary, ESS,
and polysomnography.

Nasal and ocular symptoms on
4-point scale. rTNSS, iTNSS,
rTOSS, iTOSS

Primary endpoint: AHI.
Secondary measures: TNSS,
nighttime symptom score,
daytime nPIF, nighttime flow
limitation index, RQLQ, ESS,
WPAI-AS

Nasal symptom scores, QOL,
and sleep quality, ESS.

TNSS, individual nasal
symptoms, and TNNSS.

Primary outcomes: rTOSS,
iTOSS, rTNSS, and iTNSS.
Secondary outcomes: QOL, and
adverse effects.

Measures that assessed
impairment and/or risk of
comorbid conditions.

Clinical endpoint

Evidence for the clinical efficacy of intranasal corticosteroids in the management of allergic rhinitis

Budesonide significantly improved daytime
fatigue, somnolence, and quality of sleep vs
placebo.

Patients treated with FPNS PRN had a
significantly greater reduction from baseline in
TNSS. Individual symptoms were also
significantly improved by active therapy.

Fluticasone improved subjective sleep vs
placebo. There was no difference in the AHI in
treated subjects.

FFNS significantly improved daily rTNSS,
morning pre-dose iTNSS, daily rTOSS, and
patient-rated overall response to therapy. Onset
of therapeutic effect occurred at 8 hours after
initial administration.

AHI was not statistically significantly different
between groups. MFNS significantly improved
morning and evening TNSS, nasal obstruction/
blockage/congestion, daily nPIF, ESS, QOL
score, and 2 of 5 WPAI–AS domains.

MFNS significantly improved nasal symptoms,
QOL, and sleep quality. Significant reduction of
the ESS observed in the MFNS group with high
sleep disturbance.

MFNS was associated with a significant
reduction in TNSS and TNNSS. Significant
effect was seen for nasal stuffiness/congestion,
rhinorrhea, sneezing, and nasal itching.

FFNS significantly improved rTOSS, iTOSS,
rTNSS, and iTNSS scores compared with
placebo in patients with SAR and PAR. There
were greater improvements in QOL with a
favorable safety profile.

Intranasal steroids improved risk outcomes
associated with asthma and OSA.

Conclusion

Author Manuscript
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2000

1998

1998

1990

2007

1993

Craig et al.707

Day &
Carrillo1285

Juniper et al.1286

Herman1273

Juniper et al.1287

2000

Jen et al.1288

Day et al.1282

1283

2002

Author Manuscript

Fokkens et al.
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2b

2a

1b

1b

1b

1b

1b

1b

Randomized, nonblinded, parallel
group comparison

Review of
randomized,
controlled,
comparison trials

Randomized,
double-blind,
parallel-group

RDBPCT,
multicenter,
parallel-group

Double-blind,
placebo-controlled
study

RDBPCT, parallelgroup.

RDBPCT, parallelgroup

RDBPCT, parallelgroup, multicenter

Study design

Study groups

100 μg of the spray, taken PRN, up
to 400 μg daily

2

Adults, SAR, ragweed sensitivity (n = 60).
Beclomethasone dipropionate NS regular use (400
μg daily) vs PRN use.

SAR and PAR.
14 studies reviewed.
BANS, MFNS, FPNS, or TANS.

200 μg aqueous beclomethasone
dipropionate NS, twice daily, 1 week
before until 1 week after the
ragweed-pollen season (regular);

1

Adults, SAR, ragweed sensitivity (n = 60).

Adults, PAR (n = 273).
BANS and FNSP nasal sprays.
Baseline: 8–14 days.
6 weeks: Active treatment.

PAR (n = 20).
Topical INCS vs placebo

Adults, SAR, ragweed sensitivity (n = 52).
FPNS PRN vs placebo for 4 weeks.

SAR, ragweed-sensitivity (n = 217), symptoms for
at least 1 year.
Challenge via chamber.
BANS 64 μg vs BANS 256 μg vs placebo.

PAR (n = 202, age 6–16 years).
BANS 128 μg daily vs placebo.

Author Manuscript
LOE

Daily symptoms and medication
use, QOL, and patient
satisfaction with symptom
control.

Different endpoints for different
studies

Sneezing, stuffy nose, and
rhinorrhea, measured by a daily
diary. QOL questionnaires and
rescue medication use
(terfenadine).

Mean combined nasal symptoms
scores (nasal blockage, runny
nose, and sneezing).

Daily symptom diary of nasal
symptoms, sleep, and daytime
sleepiness.

Nasal symptom score, QOL,
eosinophil count, and
eosinophilic cationic protein in
nasal lavage.

Combined nasal score,
individual nasal symptoms,
overall evaluation of treatment
efficacy, nPIF.

Daily nPIF, nasal symptom
scores, and overall evaluation of
treatment efficacy. Subset (n =
76) QOL by validated
questionnaires.

Clinical endpoint

Author Manuscript

Year

27% of PRN patients reported unsatisfactory
control, worse QOL, and increased medication
use. Patients who achieved satisfactory control
in the PRN group had similar symptom and
QOL scores to the regular group.

All 4 INCSs administered once daily were
effective and well tolerated in the treatment of
AR in adult patients, with similar efficacy and
adverse event profiles. Based on sensory
attributes, patients preferred BANS and TANS
vs MFNS and FPNS.

Nasal symptoms, QOL, and use of rescue
medications were significantly better controlled
in the regular-treated group as compared to the
PRN group.

BANS significantly decreased nasal symptoms
vs FPNS. Both treatments significantly
decreased nasal symptoms vs placebo. Time to
achieve statistically significant improvement:
BANS 36 hours, FPNS 60 hours. Adverse
events were mild and transient.

Nasal congestion and subjective sleep improved
significantly in the INCS-treated subjects but
not in the placebo group.

Nasal symptom score lower with FPNS vs
placebo. QOL significantly improved with
FPNS. Eosinophil count significantly lower in
with FPNS.

7–12 hours: BANS better than placebo in
reducing combined nasal and blocked nose
symptoms. nPIF: onset of action (3 hours) was
shortest for BANS 256 μg. Treatment efficacy
was higher for those receiving BANS compared
with placebo starting at 5 hours. All treatments
well tolerated, no specific adverse events
occurred.

BANS significantly more effective than placebo
for nPIF, combined and individual nasal
symptom scores, and the overall evaluation of
treatment efficacy. Onset of action within the
first 12-hour time interval for combined nasal
symptoms and within 48 hours for nPIF.

Conclusion

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

AHI = apnea-hypopnea index; BANS = budesonide aqueous nasal spray; ESS = Epworth Sleepiness Scale; FFNS = fluticasone furoate nasal spray; FPNS = fluticasone propionate nasal spray; INCS =
intranasal corticosteroid; iTNSS = instantaneous Total Nasal Symptom Score; iTOSS = instantaneous Total Ocular Symptom Score; LOE = level of evidence; MFNS = mometasone furoate nasal spray;
nPIF = nasal peak inspiratory flow; NS = nasal spray; OSA = obstructive sleep apnea; PAR = perennial allergic rhinitis; PRN = as needed; QOL = quality of life; RDBPCT = randomized double-blind
placebo-controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; rTNSS = reflective Total Nasal Symptom Score; rTOSS = reflective Total Ocular Symptom Score; SAR = seasonal
allergic rhinitis; SR = systematic review; TANS = triamcinolone aqueous nasal spray; TNSS = Total Nasal Symptom Score; TOSS = Total Nasal Symptom Score; WPAI-AS = Work Productivity and
Activities Impairment-Allergy Specific questionnaire.
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2003

2015

2009

Ratner et al.1292

Baroody et al.1293
1b

1b

1a

1a

1a

1a

LOE

Double-blind, placebocontrolled, crossover
trial

Randomized, doubleblind, parallel,
multicenter study

Meta-analysis of RCTs

Retrospective analysis
of multicenter,
RDBPCTs

Meta-analysis of
placebo-controlled
RCTs

SR and meta-analysis

Study design

SAR out of season (n = 20).
FFNS 110 μg daily vs placebo × 1
week.
Nasal allergen challenge.

SAR (n = 614).
FPNS 200 μg daily vs placebo × 14
days.

Asthma and AR.
14 studies (n = 477).
INCS vs placebo/routine asthma
treatment.

7 studies.
Efficacy of FPNS 200 μg daily for
nasal and ocular symptoms in patients
with SAR.

10 studies (n = 3132).
SAR: 6 studies;
PAR: 4 studies;
MFNS 200 μg daily.

Asthma and AR.
18 studies (n = 2162).
Efficacy of INCS on asthma
outcomes.

Study groups

Nasal and ocular symptoms after
allergen challenge.

Mean change from baseline in patientrated rTOSS.

Asthma outcomes: symptom scores,
FEV1, PEF, and methacholine airway
responsiveness.

Mean change from baseline in the
clinician-rated TOSS (itching, tearing,
redness, and puffiness) at 7 and 14 days
of therapy.

Severity of reflective ocular symptoms
(itching/burning, redness, and tearing/
watering) on a 4-point scale over 12
hours.

Asthma outcomes: pulmonary function,
bronchial reactivity, asthma symptom
scores, asthma-specific QOL, and
rescue medication use.

Pretreatment with FFNS significantly reduced
eye symptoms after nasal allergen challenge.

FPNS was significantly more efficacious in
reducing the ocular symptoms of AR vs placebo.

No statistically significant benefit of INCS in
asthma.

FPNS group had significantly greater mean
changes from baseline in the TOSS and in all 4
individual symptom scores vs placebo at days 7
and 14.

Overall treatment effect was significant for all 3
individual ocular symptoms in SAR and PAR
studies.

Use of INCS resulted in significant
improvements in FEV1, bronchial challenge,
asthma symptom scores, and rescue medication
use vs placebo. INCS improved morning and
evening PEF. Addition of INCS spray to orally
inhaled corticosteroids did not result in
additional improvement.

Conclusion

AR = allergic rhinitis; FEV1 = forced expiratory volume in 1 second; FFNS = fluticasone furoate nasal spray; FPNS = fluticasone propionate nasal spray; INCS = intranasal corticosteroid; LOE = level of
evidence; MFNS = mometasone furoate nasal spray; PAR = perennial allergic rhinitis; PEF = peak expiratory flow; QOL = quality of life; RCT = randomized controlled trial; RDBPCT = randomized
double-blind placebo-controlled trial; rTOSS = reflective Total Ocular Symptom Score; SAR = seasonal allergic rhinitis; SR = systematic review; TOSS = Total Ocular Symptom Score.

2003

Taramarcaz &
Gibson1295

1290

DeWester et al.

2013

Year

2011

al.1296

Bielory et al.1291

Lohia et

Study

Clinical endpoint
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Effect of intranasal corticosteroids on comorbidities: ocular symptoms and asthma
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2010

Benninger et al.

2002

1998

Yanez &
Rodrigo1298

Weiner et al.1297
1a

1a

1a

1a

LOE

Meta-analysis of RCTs

SR of RCTs

SR and meta-analysis of
RCTs of the effectiveness
of LTRAs

SR of RCTs of at least 2week duration, and
studying U.S.-approved
INCS indication/dose

Study design

AR: 16 studies (n = 2267).
INCS vs oral antihistamines.

AR: 9 studies (n = 648).
INCS vs topical antihistamines.

SAR: 11 studies.
8 evaluating LTRAs (alone or plus other
treatments) vs placebo or other
treatments (n = 3924);
3 evaluating LTRAs plus antihistamine
(n = 80).

SAR: 38 studies (n = 11,980 adults, 946
children);
PAR: 12 studies (n = 3800 adults, 366
children).

Study groups

Nasal blockage, nasal
discharge, sneezing, nasal
itch, postnasal drip, nasal
discomfort, total nasal
symptoms, nasal resistance,
and eye symptoms and global
ratings.

Total nasal symptoms,
sneezing, rhinorrhea, itching,
and nasal blockage.

Composite daily rhinitis
symptom scores and rhinitisspecific quality of life.

Median percentage changes
from baseline for TNSS.

Clinical endpoint

INCS produced greater relief of nasal blockage, nasal
discharge, sneezing, nasal itch, postnasal drip, and
total nasal symptoms vs oral antihistamines. No
difference between the 2 treatments for nasal
discomfort, nasal resistance, or eye symptoms.

INCS produced greater relief of nasal symptoms vs
topical antihistamines. No difference between the 2
treatments for ocular symptoms.

LTRAs are modestly better than placebo, as effective
as antihistamines, but less effective than INCS in
improving symptoms and QOL in patients with SAR.

INCS produce the greatest improvements in nasal
symptoms in SAR. INCS effective for PAR, but data
quality variable; oral antihistamines may be equally
effective for some patients.

Conclusion

AR = allergic rhinitis; INCS = intranasal corticosteroid; LOE = level of evidence; LTRA = leukotriene receptor antagonist; PAR = perennial allergic rhinitis; QOL = quality of life; RCT = randomized
controlled trial; SAR = seasonal allergic rhinitis; SR = systematic review; TNSS = Total Nasal Symptom Score.
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Wilson et al.1300
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Comparison of intranasal corticosteroids to other agents for the treatment of allergic rhinitis
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2009

2009

2009

Meltzer et al.1302

Ratner et al.1304

Tripathy et al.
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Patel et al.1314

1301

Maspero et al.

1315

Weinstein et al.

2008

2008

2009

2015

Hampel et al.1317

1316

2015

Verkerk et al.1305

2015

Year

2015

al.1319

Mener et al.1320

Ahmadi et

Study

1b

1b

1b

1b

1b

1b

1b

1a

1a

1a

LOE

RDBPCT,
parallel-group

Double-blind,
placebocontrolled study

RDBPCT,
multicenter,
parallel-group

Double-blind,
randomized
parallel-group
study

Multicenter,
randomized,
controlled trial

Subanalysis of 3
RDBPCTs,
focusing on the
6-11 age group

RDBPCT

SR

SR with metaanalysis

SR

Study design

PAR, 12–65 years (n = 112).
FF 110 μg daily for 6 weeks vs
prednisone 10 mg daily for last 7 days
of study vs placebo.

PAR, children 2–11 years (n = 558).
FF 110 μg vs FF 55 μg vs placebo daily
for 12 weeks.

PAR, children 2–5 years (n = 474).
TAA 110 μg vs placebo daily for 4
weeks.

PAR, children 2–11 years (n = 112).
FF 110 μg vs placebo daily for 6 weeks.

PAR, children 6–11 years (n = 255).
MFNS 100 μg vs BDP 168 μg daily for
12 months.

SAR: 2-week U.S. study.
PAR: 12-week global study.
HPA axis safety: 6-week U.S. study.
FF 55 μg vs FF 110 μg vs placebo daily
(n = 948).

PAR, children 6–11 years.
BDP 800 μg daily (n = 67) vs placebo (n
= 32) for 6 weeks.

34 studies (11 RCTs, 5 cohorts, 20 case
series) included.
INCS use with or without control group.

8 RCTs (n = 755) investigating INCS
for AR in children 3-12 years.

19 studies of INCS reporting original
ocular endpoints (10 RCTs, 1 casecontrol, 8 case series) included.

Study groups

Change in 24-hour serum cortisol and
24-hour urinary free cortisol, total 24hour urinary free cortisol, 6-beta
hydroxycortisol excretion, and plasma
concentration of FF.

Nasal symptom scores for efficacy.
Nasal and ophthalmic examinations, and
HPA assessments for safety.

Adverse events, morning serum cortisol
levels, and growth as measured using
office stadiometry.

24-hour serum and urinary cortisol. FF
plasma measurements.

Symptom control and safety.

Different endpoints, which included:
adverse event monitoring, nasal
examinations, ophthalmic examinations,
24-hour urinary cortisol excretions, and
serum cortisol concentrations.

Change in 24-hour serum cortisol from
baseline.

Histopathology of nasal mucosa.
Mucosal atrophy reported in 17 studies.

Interval change in growth. Knemometry
(n = 342 participants, duration 2–4
weeks). Stadiometry (n = 413
participants, duration 12 months).

IOP, lens opacity, glaucoma or cataract
incidence.

Clinical endpoint

Author Manuscript

Studies evaluating adverse effects of intranasal corticosteroids

Ratio from baseline in serum cortisol weighted
mean: FF noninferior to placebo, prednisone
significantly reduced the ratio. 24-hour urinary
cortisol excretion was similar in the FF and placebo
groups. Plasma levels of FF were undetectable after
6 weeks of treatment.

Epistaxis 6% in all groups. There were no
significant ophthalmic or HPA related side effects
in the treated subjects. The lower dose of FF
reduced nasal symptoms.

Adverse event rates comparable between groups.
No significant change from baseline in serum
cortisol levels after cosyntropin infusion.
Distribution by stature-for-age percentile remained
stable.

FF was non-inferior to placebo with respect to 24hour serum cortisol. Urinary cortisol excretion over
24 hour at baseline and end of treatment similar
between treatment groups.

There was appropriate symptom control in both
groups. Adverse events were mild. Incidence of
epistaxis was 12.7% with MFNS and 9.4% for BDP.

Epistaxis 4% in both active and placebo groups. No
differences between groups for IOP, and no
posterior subcapsular cataracts. No difference in
HPA measures between groups.

Serum cortisol values remained stable in both
groups. Concentration-time profiles similar for the
placebo and BDP groups at baseline and week 6.

The concept of nasal mucosal atrophy is poorly
defined. No histological evidence for deleterious
effects from INCS use on human nasal mucosa.

Knemometry studies: Mean growth lower among
children using INCS. Stadiometry studies: No
significant growth difference in INCS vs placebo.
Limitations: Difficulty in predicting longer-term or
catch-up growth.

None of the 10 RCTs reporting IOP demonstrated
changes vs control. None of the 6 RCTs reporting
cataract or lens opacity demonstrated changes vs
control.

Conclusion

Author Manuscript
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2003

2007

2007

1b

1b

1b

1b

RDBPCT

RDBPCT,
parallel-group

Two separate
phase 3, doubleblind, parallelgroup, placebocontrolled trials

RDBPCT

AR, children 2-3 years (n = 65).
FP 200 μg vs placebo daily for 6 weeks.

PAR (n = 806).
FF 110 μg vs placebo daily for 12
months.

PAR, children 2–5 years.
Safety, tolerability, and efficacy of
intranasal ciclesonide 200 μg once daily.
First study: 6 weeks.
Second study: 12 weeks.

PAR patients ≥12 years (n = 663).
Ciclesonide 200 μg vs placebo daily for
up to 52 weeks.

Study groups

12-hour urinary free cortisol
concentration at baseline and after 6
weeks of treatment.

Adverse events, 24-hour urinary cortisol
excretion, nasal and ophthalmic
examinations, electrocardiograms and
clinical laboratory tests.

Cortisol levels were measured at the
beginning and end of each study. The
systemic exposure of ciclesonide and its
active metabolite measured at treatment
end in the 6-week study.

Adverse events, exam findings, 24-hour
urinary free cortisol, morning plasma
cortisol, IOP, lens opacification.

Clinical endpoint

FP group equivalent to placebo group in mean
change from baseline of 12-hour urinary free
cortisol at treatment end.

Incidence of adverse events similar to placebo,
except epistaxis (active 20%, placebo 8%). No
clinically meaningful differences in ophthalmic
parameters or urine cortisol excretion.

Changes in plasma or urine cortisol levels showed
no difference in active vs placebo group. Serum
concentrations were below the lower limit of
quantification, suggesting that systemic exposure to
ciclesonide was low.

No clinically relevant differences observed between
the ciclesonide and placebo groups.

Conclusion

AR = allergic rhinitis; BDP; beclomethasone dipropionate; FF = fluticasone furoate; FP = fluticasone propionate; HPA; hypothalamic pituitary axis; INCS = intranasal corticosteroid; IOP = intraocular
pressure; LOE = level of evidence; MFNS = mometasone furoate nasal spray; PAR = perennial allergic rhinitis; RCT = randomized controlled trial; RDBPCT = randomized double-blind placebo-controlled
trial; SAR = seasonal allergic rhinitis; SR = systematic review; TAA = triamcinolone acetonide.

Galant et al.1311

1303

Rosenblut et al.

Kim et al.1312
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2009

2006

2008

2000

1999

1998

Horak et al.1322

Mucha et al.1321

Vernacchio et al.1327

Kernan et al.1326

Roberge et al.1328

Sauder et al.1329
4

4

3b

3b

1b

1b

1b

1a

1a

LOE

Case report

Case report

Case-control

Nonconsecutive
cohort

RCT

RCT

RCT

SR

SR

Study design

History of subarachnoid or
intracerebral hemorrhage;
Control

1
2

Pseudoephedrine;
Montelukast

1

Placebo

3

2

Phenylephrine;

2

Placebo (n = 103)

5
Pseudoephedrine;

Phenylephrine 40 mg (n = 112);

4

1

Phenylephrine 20 mg (n = 108);
Phenylephrine 30 mg (n = 107);

2
3

Phenylephrine 10 mg (n = 109);

Placebo

2
1

Pseudoephedrine;

Placebo

2
1

Phenylpropanolamine;

1

Study groups

Association between the use of
phenylpropanolamine and the
risk of a hemorrhagic stroke.

Pseudoephedrine use in
pediatric population

Nasal symptoms, nPIF, QOL

Subjective evaluation of nasal
congestion

Daily reflective nasal
congestion score

SBP, DBP, HR

SBP, DBP, HR

3-year-old with visual hallucinations caused by
inappropriately high doses of pseudoephedrine.

2-year-old developed psychosis and ataxia after
being overmedicated with pseudoephedrine/
dextromethorphan cough preparation.

Phenylpropanolamine is an independent risk
factor for hemorrhagic stroke in women.

Children less than 2 years of age are at the highest
risk for toxicity with pseudoephedrine. Safe
dosing recommendations are lacking for this age
group.

Significant improvement from baseline in all
symptoms of AR, nPIF, and QOL with both
pseudoephedrine and montelukast.

Pseudoephedrine resulted in improvement in nasal
congestion. Phenylephrine did not improve nasal
congestion.

Phenylephrine is not better than placebo at
relieving nasal congestion.

Pseudoephedrine caused increase in SBP and HR.

Phenylpropanolamine caused increase in SBP.

Conclusion

AR = allergic rhinitis; DBP = diastolic blood pressure; HR = heart rate; LOE = level of evidence; nPIF = nasal peak inspiratory flow; QOL = quality of life; RCT = randomized controlled trial; SBP =
systolic blood pressure; SR = systematic review.

2015

Meltzer et al.1323

2005

Year

2005

al.1324

Salerno et al.1325

Salerno et

Study

Clinical endpoint

Author Manuscript

Evidence for the role of oral decongestants in the management of allergic rhinitis

Author Manuscript

TABLE IX.B.3.a.
Wise et al.
Page 380

Author Manuscript

Author Manuscript

Author Manuscript
1997

Yoo et al.83
2b

1b

1b

1b

LOE

Individual
cohort study

RCT

RCT

RCT

Study design

Nasal mometasone furoate

2

Placebo

2

Intermittent oxymetazoline;
Placebo

2
3
(n = 10): Daily oxymetazoline

Daily oxymetazoline;

1

(n = 50):

Oxymetazoline TID;

1

(n = 30):

Nasal xylometazoline;

1

(n = 36):

Study groups

Clinical endpoint

Subjective history, physical exam,
anterior rhinomanometry

Nasal airway resistance, subjective
scaling of nasal patency, clinical
examination

Subjective nasal blockage, nPIF, airway
resistance, airway volume

nPIF, nasal forced inspiratory volume in
1 second, nasal blockage score

LOE = level of evidence; nPIF = nasal peak inspiratory flow; RCT = randomized controlled trial; TID = 3 times daily.

1997

Morris et al.72

2005

Year

2003

al.1330

Watanabe et al.1331

Barnes et

Study

Evidence for the role of topical intranasal decongestants in the management of allergic rhinitis

All subjects remained responsive to oxymetazoline
4 weeks and 8 weeks after the study began.

Evidence of rebound nasal congestion was found
following 3 days of both daily and intermittent
oxymetazoline treatment.

No significant nasal blockage or impaired
decongestant response to oxymetazoline following
4-week treatment.

Xylometazoline was a stronger nasal decongestant
than mometasone furoate.

Conclusion

Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
2006

2006

2004

2003

2012

Grainger & DrakeLee1333

Rodrigo & Yanez1334

Wilson et al.1300

Gonyeau &
Partisan1335

Endo et al.1336

2014

Year

2008

al.1332

Goodman et al.1347

Devillier et

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1a

1a

1a

1a

1a

1a

LOE

RCT

SR of RCTs, with
homogeneity

SR of RCTs, with
homogeneity

SR of RCTs, with
homogeneity

SR of RCTs, with
homogeneity

SR of RCTs, with
homogeneity

SR of RCTs, with
homogeneity

Study design

Placebo
2

Placebo
3

Pranlukast;

INCS;

1

Montelukast;

Placebo

4

2

INCS;

3

1

Oral antihistamine;

2

Placebo

4
Montelukast;

INCS;

3

1

Oral antihistamine;

2

Placebo

4
LTRA;

INCS;

3

1

Oral antihistamine;

Fexofenadine

4
Montelukast;

Desloratadine;

3

2

Levocetirizine;

1

Montelukast;

Placebo

3

2

SLIT;

2

1

LTRA;

1

Study groups

Symptoms

Symptoms

Symptoms, QOL

Symptoms, QOL

Symptoms, QOL

Symptoms, cost

Symptoms

Clinical endpoint

Pranlukast prevented and reduced symptoms compared to
placebo after artificial introduction of allergen.

Montelukast was more effective than placebo in reducing
symptoms, but was inferior to INCS.

Montelukast improved QOL compared to placebo, and was
inferior to antihistamines and INCS.

LTRA improved symptoms and QOL compared to placebo,
was equally effective to oral antihistamine, and inferior to
INCS.

Montelukast improved symptoms and QOL compared to
placebo, and was inferior to oral antihistamines and INCS.

Montelukast with higher incremental cost-effectiveness
ratio than levocetirizine and desloratadine.

SLIT superior clinical effect to LTRA. LTRA with clinical
effect compared to placebo.

Conclusion

Evidence for the use of leukotriene receptor antagonists as monotherapy in the treatment of allergic rhinitis (Level 1a and 1b studies only)

Author Manuscript

TABLE IX.B.4.
Wise et al.
Page 382

Author Manuscript
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2005

2004

2004

2003

2003

Patel et al.1339

Chervinsky et al.1340

Philip et al.1341

Ratner et al.1345

van Adelsburg et al.

van Adelsburg et al.

1343

2003

2006

Mucha et al.1321

1342

2006

2008

2012

Jiang1348

Day et al.1338

Wakabayashi et

1b

1b

1b

1b

1b

1b

1b

1b

1b

1b

LOE

RCT

RCT

RCT

RCT

RCT

RCT

RCT

RCT

RCT

RCT

Study design

Loratadine;
Placebo

2
3

Montelukast;

Placebo

3
1

Loratadine;

2

Montelukast;

Fluticasone

2
1

Montelukast;

Placebo

1

Montelukast;

2

Placebo

1

Montelukast;

2

Placebo

2
1

Montelukast;

Pseudoephedrine

1

Montelukast;

Loratadine + pseudoephedrine

3

2

Loratadine;

1

Zafirlukast;

2

Levocetirizine;
Placebo

2
3
1

Montelukast;

Placebo

1

Pranlukast;

2

Study groups
1

Author Manuscript
Year

Symptoms, QOL

Symptoms, QOL

Symptoms, QOL

Symptoms, rhinitis
QOL, asthma QOL

Symptoms, pollen
count

Symptoms, QOL

Symptoms, QOL,
nasal peak inspiratory
flow

Symptoms, acoustic
rhinometry,
rhinomanometry

Symptoms

Symptoms

Clinical endpoint

Author Manuscript

al.1337

Montelukast was more effective than placebo in reducing
symptoms and improving QOL. Montelukast not directly
compared to loratadine.

Montelukast was more effective than placebo in reducing
symptoms and improving QOL. Montelukast not directly
compared to loratadine.

Fluticasone was more effective than montelukast in
reducing symptoms and improving QOL.

Montelukast improved symptoms, rhinitis QOL, and
asthma QOL compared to placebo in patients with
concurrent seasonal allergic rhinitis and asthma.

Montelukast was more effective than placebo in reducing
symptoms. The effect size was related to the amount of
pollen exposure.

Montelukast was more effective than placebo in reducing
symptoms and improving QOL in patients with perennial
allergic rhinitis

Montelukast and pseudoephedrine had equivalent
improvement of symptoms (except nasal congestion for
which pseudoephedrine was more effective), QOL, and
nasal peak inspiratory flow.

All treatment groups had a significant reduction of
pretreatment symptoms. Zafirlukast was superior at
reduction of nasal congestion. There were no differences in
acoustic rhinometry and rhinomanometry between the 3
treatment groups.

Both montelukast and levocetirizine improved symptoms
following artificial allergen exposures. Levocetirizine was
more effective than montelukast.

Pranlukast reduced symptoms compared to placebo in
children with artificial allergen exposure.

Conclusion

Author Manuscript

Study

Wise et al.
Page 383

Author Manuscript
1999

2002

1b

1b

RCT

RCT

Study design

Placebo

Beclomethasone;

3

Zafirlukast;

Placebo

3

2

Loratadine;

2

1

Montelukast;

1

Study groups

Symptoms, tissue
eosinophilia

Symptoms, QOL,
peripheral eosinophil
count

Clinical endpoint

Zafirlukast was not different from placebo in symptom or
tissue eosinophilia reduction. Both were inferior to
intranasal beclomethasone.

Montelukast was more effective than placebo in reducing
symptoms and peripheral eosinophil count, and improving
QOL. Montelukast not directly compared to loratadine.

Conclusion

INCS = intranasal corticosteroids; LOE = level of evidence; LTRA = leukotriene receptor antagonist; QOL = quality of life; RCT = randomized controlled trial; SLIT = sublingual immunotherapy; SR =
systematic review.

Pullerits et al.1346

Philip et

LOE

Author Manuscript
Year

Author Manuscript

al.1344

Author Manuscript

Study
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Author Manuscript

Author Manuscript
1990

1982

1981

1977

1977

1977

Schuller et al.1371

Chandra et al.1372

Brown et al.1367

Craig et al.1373

Handelman et al.1374

McDowell & Spitz1358

2015

Year

2002

al.1356

Meltzer1370

Lejeune et

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1b

1b

1b

1b

1b

1b

1b

LOE

DBRCT, crossover

DBRCT

DBRCT

RCT

DBRCT, crossover

DBRCT

DBRCT

DBRCT

Study design

Placebo (n = 7)

2

Placebo (n = 570)

2

DSCG 4%, 1 spray QID (n = 7);
Placebo (n = 77)

2
3

DSCG 2.6 mg 6 times per day (n = 29);
Flunisolide 25 μg BID (n = 38)

1
2

Placebo

2

Placebo (n = 45)
2

1

DSCG 2.5 mg 6 times per day;

PAR, 17–71 years old (n = 13):

DSCG 62.4 mg 6 times per day (n = 45);
1

SAR, 6–51 years old:

DSCG 5.2 mg 6 times per day (n = 22);
Placebo (n = 17)

1
2

SAR (n = 39):

SAR:

DSCG 4%, 1 spray q3-4 hours;

1

SAR, 9–41 years old (n = 47):

Nedocromil 1% (n = 80);

1

SAR, 12–65 years old:

DSCG 4%, 1 spray q4–6 hours (n = 580);

1

SAR, over 12 years old:

DSCG QID (n = 14);

1

PAR, adults:

Study groups

Clinical endpoint

Nasal symptoms,
cytology

Symptom score,
medication use

Nasal symptoms,
medication use

Nasal symptoms

Nasal symptoms,
medication use

Nasal symptoms

Nasal symptoms

Symptom scores, nasal
cytology, allergic
mediators

Author Manuscript

Evidence for the use of disodium cromoglycate in the treatment of allergic rhinitis

No significant difference in majority of
patients.

DSCG performed better than placebo.

No difference between DSCG and placebo.

Flunisolide performed better than DSCG.

DSCG performed better than placebo.

Nedocromil was equivalent to DSCG. Both
performed better than placebo.

DSCG performed better than placebo.

DSCG performed better than placebo.

Conclusion

Author Manuscript

TABLE IX.B.5.
Wise et al.
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1977

1977

1977

1976

1976

2005

1994

1993

Posey & Nelson1376

Warland & Kapstad1359

Cohan et al.1360

Knight et al.1377

Lange et al.1361

Fisher1362

Bousquet et al.1363

Author Manuscript

Nizami & Baboo1375

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2b

2b

2b

1b

1b

1b

1b

1b

DBRCT, no
placebo

RCT, blinded, no
placebo

RCT, no placebo

DBRCT

DBRCT, crossover

DBRCT, crossover

DBRCT

DBRCT, crossover

Study design
2

Study groups
Placebo

Placebo

2

Placebo (n = 17)

2

Placebo

2

DSCG 10 mg QID (n = 35);
Placebo (n = 41)

1
2

Placebo

2

Levocabastine 200 μg BID (n = 40);
DSCG 5.6 mg QID (n = 42)

2
3

SAR:
FP 200 μg QD (n = 110);
DSCG 5.2 mg QID (n = 108)
2

Budesonide BID, 400 μg/day (n = 30)
2

1

DSCG 31.2 mg, 6 times per day (n = 26);

1

SAR, 6–15 years old:

MF 200 μg QD (n = 41);

1

SAR, 18–65 years old:

SAR:

DSCG 4%, 6 times per day;

1

PAR, 16–37 years old:

DSCG 10 mg QID;

1

PAR, 15–57 years old (n = 17):

DSCG 4%, 6 times per day (n = 17);

1

SAR, 12–54 years old:

DSCG 10 mg QID;

1

SAR, 7–59 years old (n = 92):

Author Manuscript
LOE

Clinical endpoint

Nasal/ocular symptoms,
medication use

Nasal symptoms

Symptom scores, nPIF

Nasal symptoms

Symptom score,
medication use

Nasal symptoms

Symptom score,
medication use

Nasal symptoms

Author Manuscript

Year

FP better in all except nasal discharge. No
difference in medication use.

Budesonide performed better than DSCG.

MF performed best.

DSCG performed better than placebo.

DSCG performed better than placebo.

No difference between DSCG and placebo.

No difference, except for in-season use of
medications in DSCG group.

DSCG performed better than placebo.

Conclusion

Author Manuscript

Study

Wise et al.
Page 386

Author Manuscript
1980

1976

1975

Tandon & Strahan1357

Wilson & Walker1368

Frankland & Walker1369
2b

2b

2b

2b

2b

2b

DBRCT, no
placebo

RCT, no placebo

DBRCT, crossover,
no placebo

RCT, no placebo

DBRCT, no
placebo

RCT, blinded

Study design

Flunisolide 2 sprays BID, 200 μg/day;
DSCG 1 spray QID, 41.6 mg/day;
Placebo

2
3
4

DSCG 5.2 mg, 5 times per day (n = 21)

2

DSCG 2.6 mg, 6 times per day (n = 39)

2

DSCG 10 mg QID

2

DSCG 80 μg, 6 times per day (n = 14);
BV 100 μg BID (n = 18)

1
2

SAR, adults:

DSCG 10 mg QID (n = 10);
BV 100 μg BID (n = 10)

1
2

SAR, adults:

BDP 50 μg QID;

1

PAR, 13–45 years old (n = 14):

BDP 2 sprays BID, 400 μg/day (n = 47);

1

SAR, 11–71 years old:

Budesonide 200 μg BID (n = 22);

1

SAR, 15–55 years old:

BDP 2 sprays BID, 336 μg/day;

1

Study groups

Nasal symptoms, nPIF

Nasal symptoms

Nasal symptoms

Symptom score,
medication use

Nasal symptoms

Symptom score,
medication use

Clinical endpoint

BV performed better than DSCG for
symptoms. The 2 medications performed
the same for nPIF.

BV performed better than DSCG.

BDP performed better than DSCG.

BDP performed better than DSCG. No
difference in rescue medications.

Budesonide was better than DSCG.

All medications were better than placebo.
DSCG was the least effective.

Conclusion

BDP = beclomethasone dipropionate; BID = 2 times daily; BV = betamethasone valerate; DBRCT = double-blind randomized controlled trial; DSCG = disodium cromoglycate; FP = fluticasone propionate;
LOE = level of evidence; MF = mometasone furoate; nPIF = nasal peak inspiratory flow; PAR = perennial allergic rhinitis; QD = once daily; QID = 4 times daily; RCT = randomized controlled trial; SAR =
seasonal allergic rhinitis.

1984

1985

1987

Morrow-Brown et al.1366

Bjerrum & Illum1365

Welsh et

LOE

Author Manuscript
Year

Author Manuscript

al.1364

Author Manuscript

Study

Wise et al.
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Author Manuscript

Author Manuscript

Author Manuscript
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1997

1993

1992

1986

Meltzer et al.1383

Gorski et al.1384

Meltzer et al.1385

Sanwikarja et al.

1386

1998

Kaiser et al.1379

1999

1998

al.1381

Year

Finn et al.1382

Dockhorn et

Study

1b

1b

1b

1b

1b

1b

1b

LOE

DBRCT,
crossover

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT,
crossover

DBRCT

Study design

IPB 0.03%, 2 sprays (42 μg) TID (n = 222);
BDP 82 μg BID (n = 222);
Placebo (n = 55)

2
3
4

Placebo + terfenadine

2

IPB 0.06% (84 μg) TID;
Placebo

2
3

Placebo (n = 102)

2

Placebo (n = 53)

2

1

IPB 80 μg QID;

SAR or PAR (n = 14), non-allergic perennial rhinitis (n = 10), 18-49
years old:

IPB 21 μg (n = 48) or 42 μg (n = 54), 1 spray TID;

1

PAR, 18–70 years old:

IPB 80 μg QID;
Placebo

1
2

PAR, 23–33 years old (n = 18):

IPB 0.03% 2 sprays (42 μg) BID (n = 102);

1

PAR and perennial NAR, 6–18 years old:

IPB 0.03% (42 μg) TID;

1

PAR, adults:

IPB 0.03% (42 μg) TID + terfenadine 60 mg PO BID;

1

PAR, 18–75 years old (n = 205):

IPB 0.03%, 2 sprays (42 μg) TID + BDP 82 μg BID (n =
109);

1

PAR, 8–75 years old:

Study groups

Evidence for the use of ipratropium bromide in the treatment of allergic rhinitis

Nasal symptoms

Nasal symptoms,
nasal cytology

Sneezing,
albumin and total
protein in nasal
lavage

Nasal symptoms,
medication use,
QOL

Nasal symptoms

Nasal symptoms

Rhinorrhea

Clinical
endpoint

IPB has suppressive effects on sneezing
and hypersecretion, but no influence on
nasal airway resistance.

IPB is effective in controlling rhinorrhea.
No differences in other outcomes.

IPB resulted in a decrease in albumin, total
protein, eosinophil count, and an increase
in nasal reactivity to histamine with an
increase in the number of sneezes.

In perennial NAR, IPB reduced symptoms.
In PAR, a modest effect was seen.

High-dose and low-dose IPB resulted in
significant reduction of nasal
hypersecretion vs placebo.

Control of rhinorrhea and sneezing better
in IPB + terbinafine. No differences in
nasal congestion.

Combined use of IPB with BDP is more
effective than either agent alone for
controlling rhinorrhea.

Conclusion

Author Manuscript

TABLE IX.B.6.
Wise et al.
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2005
1999

1995

Kim et al.1378

Milgrom et al.1389

Kaiser et al.1390
2b

2b

2b

1b

1b

Prospective

RCT, blinded,
no placebo

Prospective

RCT,
crossover

RCT,
crossover

Placebo

Placebo

2

Placebo

2

BDP (n = 71)

2
PAR, 18–75 years old (n = 219): First 6 months: 0.06% IPB TID (84 μg);
6 months to 1 year: lowest dose IPB controlling rhinorrhea

IPB 0.03% nasal spray (42 μg), 2 sprays BID (n = 75);

1

PAR, non-allergic perennial rhinitis, 6–18 years old:

Common cold, SAR or PAR; 2–5 years old (n = 230);
Allergy group: IPB 0.06%, 1 spray (42 μg) TID for 14 days (n = 187)

IPB 1 puff 20 μg QID;

1

PAR, 18–82 years old (n = 20):

IPB 80 μg QID;

1

PAR, 23–84 years old (n = 20):

2

Study groups

Nasal symptoms,
medication use,
QOL

Nasal symptoms,
QOL

Nasal symptoms

Nasal symptoms

Nasal symptoms

Clinical
endpoint

IPB was effective in controlling rhinorrhea,
congestion, postnasal drip, and sneezing.
Reduction in the use of medications and
improvement in QOL.

Equally effective in controlling rhinorrhea
and improving QOL. BDP more effective
in controlling sneezing.

IPB is effective in controlling rhinorrhea.

IPB had a significant effect on rhinorrhea.
No effect on other symptoms.

IPB is effective in controlling rhinorrhea.

Conclusion

BDP = beclomethasone dipropionate; DBRCT = double-blind randomized controlled trial; IPB = ipratropium bromide; LOE = level of evidence; NAR = non-allergic rhinitis; PAR = perennial allergic
rhinitis; QID = 4 times daily; QOL = quality of life; RCT = randomized controlled trial; SAR = seasonal allergic rhinitis; TID = 3 times daily; BID = 2 times daily.

1979

Borum et al.1388

1983

Author Manuscript

Schultz Larsen et
al.1387

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript
2001

2000

1997

Casale et al.1393

Adelroth et al.1392

Casale et al.1396
1b

1b

1b

1b

1b

1a

LOE

RCT

RCT

RCT

RCT

RCT

SR of RCTs, with
homogeneity

Study design

Omalizumab;
Placebo

2

Placebo

1

Omalizumab;

2

Placebo

1

Omalizumab;

2

Placebo

2
1

Omalizumab;

Placebo

2
1

Omalizumab;

Placebo

2
1

Omalizumab;

1

Study groups

Symptom score, rescue medication,
QOL

Symptom score, rescue medication,
QOL

Symptom score, rescue medication,
QOL

Symptom score, rescue medication,
QOL

Symptom score, rescue medication

Symptom score, rescue medication,
QOL

Clinical endpoint

Conclusion

First dose-finding study, safety confirmed.

Omalizumab was significantly superior to placebo in
improving symptoms and QOL. Well tolerated.

Dose-finding trial, 300-mg dose effective in improving
symptoms and QOL compared to placebo.

Efficacy and tolerability in PAR.

Efficacy and tolerability in cedar pollen AR.

Omalizumab was superior to placebo. Omalizumab was
generally well tolerated.

AR = allergic rhinitis; LOE = level of evidence; PAR = perennial allergic rhinitis; QOL = quality of life; RCT = randomized controlled trial; SR = systematic review.

2003

Chervinsky et al.1394

2014

Year

2006

al.1391

Okubo et al.1395

Tsabouri et

Study

Evidence for the use of omalizumab as monotherapy in the treatment of allergic rhinitis (Level 1a and 1b studies with clinical endpoints only)

Author Manuscript
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Author Manuscript

Author Manuscript
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2008

2005

2005

Ural et al.1408

Cordray et al.1406

Rogkakou et al.1407
1b

1b

1b

1b

1b

1a

LOE

RCT, no
blinding

SBRCT

RCT, no
blinding

RCT, no
blinding

DBRCT,
crossover

SR and metaanalysis

Study design

Non-buffered isotonic saline;
Buffered with mild alkalinity (pH 7.2–7.4);
Buffered with alkalinity (pH 8.2–8.4)

1
2
3

PAR:

SAR:

PAR:

Hypertonic saline spray QID + cetirizine;
Cetirizine only

2

Placebo nasal saline spray

3

1

Dead Sea saline spray;
Triamcinolone spray;

1

Isotonic saline irrigations BID

2

2

Hypertonic saline irrigations BID;

No irrigations

2

1

Hypertonic saline irrigations TID;

1

SAR, pregnant women:

AR:

SAR and PAR, adults and children

Study groups

Nasal symptoms, QOL
(Rhinasthma
questionnaire)

RQLQ

Mucociliary clearance
time

Nasal symptom score,
oral antihistamine use

Nasal symptom score

Nasal symptom score,
medicine use, QOL

Clinical endpoint

The addition of hypertonic saline resulted in a
significant improvement in symptoms and
QOL.

Dead Sea saline group had significant
improvements but not as significant as
triamcinolone group; no change in placebo
group.

Isotonic saline improved mucociliary
clearance time.

Hypertonic saline irrigations during pollen
season improves nasal symptoms and
decreases oral antihistamine use.

Nasal symptoms were improved from
baseline only by buffered saline with mild
alkalinity.

Nasal symptoms and medicine use decreased
with the use of nasal saline. Adults benefit
more than children.

Conclusion

AR = allergic rhinitis; BID = 2 times daily; DBRCT = double-blind randomized controlled trial; LOE = level of evidence; PAR = perennial allergic rhinitis; QID = 4 times daily; QOL = quality of life; RCT
= randomized controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SAR = seasonal allergic rhinitis; SBRCT = single-blind randomized controlled trial; SR = systematic review; TID
= 3 times daily.

2010

Garavello et al.151

2012

Year

2013

al.1416

Chusakul et al.1409

Hermelingmeier et

Study

Author Manuscript

Evidence for the use of nasal saline in the treatment of allergic in adults

Author Manuscript

TABLE IX.B.8-1.
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Author Manuscript

Author Manuscript
2012

2012

2009

2005

2003

Marchisio et al.1413

Satdhabudha et al.1114

Li et al.1412

Garavello et al.1411

Garavello et al.1410

2012

Year

2014

al.1416

Chen et al.1415

Hermelingmeier et

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1b

1b

1b

1b

1b

1a

LOE

RCT, no
blinding

RCT, no
blinding

RCT, no
blinding

DBRCT

SBRCT

RCT, no
blinding

SR and metaanalysis

Study design

SAR:

SAR:

PAR:

AR:

SAR:

PAR:

Hypertonic saline irrigations TID;
No irrigations
2

No irrigations

1

Hypertonic saline irrigations TID;

Both

3

2

Isotonic nasal saline irrigations
BID;

2

1

Steroid nasal spray daily;

Normal saline irrigations BID

2

1

Buffered hypertonic saline
irrigations BID;

1

Normal saline irrigations BID;
No irrigations

2
3

Both

3

Hypertonic saline irrigations BID;

Seawater spray BID;

2

1

Steroid nasal spray daily;

1

SAR and PAR, adults and children

Study groups

Nasal symptom score, oral
antihistamine use

Nasal symptom score, oral
antihistamine use

Nasal symptoms

TNSS, QOL (Rcq-36),
oral antihistamine use

Nasal symptom score,
turbinate and adenoid
hypertrophy, oral
antihistamine use

Nasal symptom score,
nasal signs

Nasal symptom score,
medicine use, QOL

Clinical endpoint

Author Manuscript

Evidence for the use of nasal saline in the treatment of allergic rhinitis in children

Hypertonic saline irrigations during pollen season
improves nasal symptoms and decreases oral
antihistamine use.

Hypertonic saline irrigations during pollen season
had significant improvement in nasal symptoms and
reduction in oral antihistamine use after 5 weeks.

All groups improved. Steroid spray plus saline
irrigations had more significant improvement than
other arms.

Greater improvement in symptoms with buffered
hypertonic saline. No significant difference in QOL
or antihistamine use at 4 weeks.

Hypertonic saline was significantly more effective
in improving symptom score, decreasing adenoid
and turbinate hypertrophy, and decreasing duration
of antihistamine use.

All groups improved. Steroid spray plus seawater
had more significant improvements than other arms.

Nasal symptoms and medicine use decreased with
the use of nasal saline. Adults benefit more than
children.

Conclusion

Author Manuscript

TABLE IX.B.8-2.
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Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

AR = allergic rhinitis; BID = 2 times daily; DBRCT = double-blind randomized controlled trial; LOE = level of evidence; PAR = perennial allergic rhinitis; QOL = quality of life; Rcq-36 =
rhinoconjunctivitis QOL questionnaire; RCT = randomized controlled trial; SAR = seasonal allergic rhinitis; SBRCT = single-blind randomized controlled trial; SR = systematic review; TID = 3 times
daily; TNSS = Total Nasal Symptom Score.
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Author Manuscript

Author Manuscript
2014
2014

2013
2013

2013
2012
2011

2010
2010

2009

2009

Costa et al.1425

Lin et al.1434

Dolle et al.1445

Lin et al.1426

Singh et al.1441

Lue et al.1422

Jan et al.1438

Chen et al.1432

Nagata et al.1431

Gotoh et al.1439

Kawase et al.1427

2016

Year

2015

al.1421

Zajac et al.1420

Guvenc et

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1b

1b

1b

1b

1b

1b

1b

1b

1b

1b

1a

1a

LOE

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

Randomized
crossover

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

SR and metaanalysis

SR and metaanalysis

Study design

Author Manuscript

SAR to JCP, adults (n = 40).
Lactobacillus GG and L. gasseri TMC0356 × 10 weeks

SAR, adults (n = 107).
Lactobacillus gasseri × 8 weeks

Lactobacillus plantarum #14 × 6 weeks

SAR to JCP, adults (n = 55).

SAR and PAR, children (n = 105).
Lactobacillus gasseri A5 × 8 weeks

PAR to HDM, children (n = 240).
Lactobacillus gasseri × 12 weeks

Lactobacillus johnsonii EM1

PAR, children (n = 63).

SAR to grass pollen, adults (n = 20).
Bifidobacterium lactis NCC2818 × 8 weeks

PAR to HDM, children (n = 199).
Lactobacillus salivarius × 12 weeks

SAR to grass pollen, adults (n = 34).
Escherichia coli Nissle 1917 × 6 months

Lactobacillus paracasei HF.A00232 × 8 weeks

PAR to HDM, children (n = 60).

SAR to grass pollen, adults (n = 425).
Lactobacillus paracasei-33 × 5 weeks

SAR and PAR, adults and children.
Daily probiotic vs placebo.
21 DBRCTs and 2 crossover studies, (n = 1919)

SAR and PAR, adults and children.
Daily probiotic vs placebo.
22 DBRCTs (n = 2242)

Study groups

Evidence for the use of probiotics in the treatment of allergic rhinitis

Mean symptom score, mean
symptom-medication score,
tIgE, sIgE

Symptom-medication score,
RQLQ, tIgE, sIgE, blood
eosinophil count, Th1:Th2
ratio

Symptom-medication score,
tIgE, sIgE

Subjective symptoms, tIgE

SCORing Allergic Rhinitis
Index: specific symptom
score, symptom-medication
score, tIgE, blood eosinophil
count

RTSS, PRQLQ

TNSS

Specific symptom score,
symptom-medication score,
tIgE

Symptom-medication score

RTSS, PRQLQ

RQLQ, RTSS

Validated QOL or symptom
scores, immunologic
parameters

Symptom scores, QOL,
immunologic parameters

Clinical endpoint

Probiotic improved nasal blockage
and medication score.

Probiotic improved symptommedication score.

Probiotic improved symptommedication score and ocular
itching.

Probiotic decreased nasal
symptoms.

No benefit.

Probiotic improved RTSS.

Probiotic improved TNSS.

Probiotic improved nasal, eye,
medication scores.

No benefit.

Probiotic improved PRQLQ,
sneezing, ocular itching/swelling
at 12 weeks.

Probiotic improved RQLQ.

17 studies demonstrated clinical
benefit of probiotics. Improvement
in RQLQ global and nasal
symptom scores.

17 studies demonstrated clinical
benefit of probiotics. Improvement
in TNSS, TOSS, total QOL, nasal
QOL, and ocular QOL.

Conclusion

Author Manuscript
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Author Manuscript
2009
2009

2009

Ouwehand et al.1433

Yonekura et al.1435

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2007

2007
2007
2006
2006
2005
2005
2005
2004
2002
2002

Giovannini et al.1428

Tamura et al.1429

Xiao et al.1061

Xiao et al.1442

Xiao et al.1443

Ciprandi et al.1446

Ishida et al.1436

Peng & Hsu1424

Wang et al.1423

Aldinucci et al.1437

Helin et al.1430
1b

1b

1b

1b

1b

1b

1b

1b

1b

1b

1b

1b

1b

1b

1b

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

Randomized
crossover

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

Study design

SAR to birch, adults and children (n = 36).
Lactobacillus rhamnosus × 5.5 months

SAR and PAR, adults (n = 20).
Lactobacillus acidophilus and Bifidobacterium × 4 months

PAR to HDM, children (n = 90).
Lactobacillus paracasei-33 × 30 days

PAR to HDM, children (n = 90).
Lactobacillus paracasei × 30 days

Lactobacillus acidophilus L-92 × 8 weeks

PAR to HDM, adults (n = 49).

SAR, children (n = 20).
Bacillus clausii × 3 weeks

Bifidobacterium longum BB536 × 13 weeks

SAR to JCP, adults (n = 44).

SAR to JCP, adults (n = 40).
Bifidobacterium longum BB536 × 14 weeks

Bifidobacterium longum BB536 × 4 weeks

SAR to JCP, adults (n = 24).

SAR to JCP, adults (n = 120).
Lactobacillus casei Shirota × 8 weeks

SAR and PAR, children (n = 187).
Lactobacillus casei × 12 months

SAR to grass pollen, adults (n = 20).
Lactobacillus casei × 5 months

Lactobacillus paracasei KW3110 × 3 weeks

SAR to JCP, adults (n = 116).

Lactobacillus acidophilus NCFM and Bifidobacterium lactis B1-04
× 4 months

SAR to birch, children (n = 47).

Tetragenococcus halophilus Th221 × 8 weeks

PAR to HDM, adults (n = 45).

Study groups

RTSS; nose, eye, lung
symptoms

Subjective symptoms

Modified PRQLQ

Modified PRQLQ

Symptom-medication score,
tIgE, sIgE

RTSS, medication use

Subjective symptoms

Subjective symptoms

Subjective symptoms

Symptom-medication score

Time free of asthma/rhinitis,
number of episodes of
rhinitis, tIgE

tIgE, sIgE, sIgG, cytokines

RQLQ, sIgE

Subjective symptoms

Disease severity, TNSS,
tIgE, sIgE

Clinical endpoint

No benefit.

Probiotic decreased nasal
symptoms.

Probiotic improved PRQLQ
(frequency, level of bother).

Probiotic improved PRQLQ
(frequency, level of bother).

Probiotic improved nasal
symptom-medication scores.

Probiotic reduced medication use.

Probiotic improved rhinorrhea,
congestion, composite scores.

Probiotic decreased ocular
symptoms.

Probiotic reduced throat and
ocular symptoms.

No benefit.

Probiotic decreased annual rhinitis
episodes.

Probiotic decreased Th2 cytokines
(IL-5, IL-6), sIgE, IFN-γ, and
increased sIgG.

Probiotic improved QOL when
pollen scattering low.

No benefit.

Probiotic improved TNSS at high
dose.

Conclusion

DBRCT = double-blind randomized controlled trial; HDM = house dust mite; IFN = interferon; IL = interleukin; JCP = Japanese cedar pollen; LOE = level of evidence; PAR = perennial allergic rhinitis;
PRQLQ = Pediatric Rhinoconjunctivitis Quality of Life Questionnaire; QOL = quality of life; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; RTSS = Rhinitis Total Symptom Score; SAR =
seasonal allergic rhinitis; sIgE = antigen-specific immunoglobulin E; sIgG = antigen-specific immunoglobulin G; SR = systematic review; tIgE = total immunoglobulin E; TNSS = Total Nasal Symptom
Score; TOSS = Total Ocular Symptom Score.

2008

Ivory et al.1440

Nishimura et

LOE

Author Manuscript
Year

Author Manuscript

al.1444

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript
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2006

2006

2005

Chiang et al.1463

Nathan et al.1451

Chervinsky et al.

1461

2007

Chen et al.1464

2009

2009

al.1050

Year

Grubbe et al.1462

Badorrek et

Study

1b

1b

1b

1b

1b

1b

LOE

RCT

RCT

RCT

RCT

RCT

RCT

Study
design

Cetirizine;
Pseudoephedrine;
Placebo

2
3
4

Desloratadine;
Pseudoephedrine

2
3

Loratadine-pseudoephedrine twice daily

2

Loratadine- pseudoephedrine

2

Desloratadine-pseudoephedrine;
Desloratadine;
Pseudoephedrine

1
2
3

(n = 650):

Cetirizine-pseudoephedrine;
Placebo

1
2

(n = 274):

Cetirizine-pseudoephedrine;

1

(n = 51):

Loratadine-pseudoephedrine daily;

1

(n = 48):

Desloratadine-pseudoephedrine;

1

(n = 598):

Cetirizine-pseudoephedrine;

1

(n = 49):

Study groups

TSS without nasal congestion,
TSS with nasal congestion

Symptoms (total and asthma),
PFTs, asthma QOL

Nasal total symptom scores

TSS

TSS (without nasal congestion),
nasal congestion score

Symptoms, nasal flow, nasal
secretions

Clinical endpoint

Evidence for oral antihistamine and oral decongestant combination therapy for the treatment of allergic rhinitis

Nasal congestion symptoms scores were significantly
reduced with desloratadine-pseudoephedrine
compared to monotherapy.

Combination therapy significantly reduced symptoms
of SAR, asthma symptom scores, and asthma QOL
scores.

Both groups had a significant improvement in
symptoms with no statistically significant difference
between groups.

Both groups showed significant improvement without
significant difference between groups.

Combination therapy was significantly more effective
then monotherapy in reducing symptoms, including
nasal congestion.

Cetirizine-pseudoephedrine was more effective than
the other arms in improving nasal obstruction, nasal
flow, and nasal secretions after controlled pollen
exposures.

Conclusion

Author Manuscript

TABLE IX.B.10.a.
Wise et al.
Page 396

Author Manuscript
2005

2005

Zieglmayer et al.

2004

2002

2001

2000

1999

Moinuddin et al.1467

Berkowitz et al.1044

Stubner et al.1468

McFadden et al.1452

Sussman et al.1457

1449

Pleskow et

al.1460

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1b

1b

1b

1b

1b

1b

RCT

RCT

RCT

RCT

RCT

RCT

RCT

Study
design

Desloratadine;
Pseudoephedrine

2
3

Budesonide nasal spray

2

Loratadine + montelukast

2

Placebo

2

Placebo

2

Fexofenadine-pseudoephedrine;
Fexofenadine;
Pseudoephedrine

1
2
3

(n = 651):

Loratadine-pseudoephedrine;

1

(n = 20):

Cetirizine-pseudoephedrine;
Xylometazoline nasal spray

1
2

(n = 36):

Fexofenadine-pseudoephedrine;

1

(n = 298):

Fexofenadine-pseudoephedrine;

1

(n = 72):

Cetirizine + prolonged release
pseudoephedrine;

1

(n = 36):

Desloratadine-pseudoephedrine;

1

(n = 1047):

Study groups

Author Manuscript
LOE

Total symptoms, nasal
congestion

Acoustic rhinometry,
endoscopic inferior turbinate
photography, QOL

Nasal congestion by
photographs and digital airflow,
nasal secretions, nasal and
ocular symptoms

Single exposure major symptom
complex, total symptom
complex, individual symptoms

RQLQ, nasal symptoms, nPIF

Rhinomanometry, nasal cavity
images, nasal congestion

TSS, morning instantaneous
TSS, nasal congestion score

Clinical endpoint

Author Manuscript

Year

Combination therapy significantly more effective in
improving total symptom score and nasal congestion,
produced greater improvement in daily activities and
work productivity.

Significant improvement in nasal edema and
secretions and nasal/ocular symptoms of
rhinoconjunctivitis in the treatment group compared to
placebo.

Nasal congestion by photographs was similar between
groups. Cetirizine-pseudoephedrine was significantly
better in improving all subjective symptoms.

Fexofenadine-pseudoephedrine was more effective in
reducing all symptoms following a single exposure to
allergen; onset of action: 45 minutes.

Fexofenadine-pseudoephedrine and loratadinemontelukast were equally effective in improving
RQLQ, total symptoms, and nPIF, except for the sleep
domain (loratadine-montelukast better).

Oral cetirizine + pseudoephedrine was superior to
budesonide in reducing nasal congestion when
exposed to HDM.

Combination therapy was more effective than either
drug alone in reducing TSS and nasal congestion.

Conclusion

Author Manuscript

Study
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Author Manuscript
1998

1998

Kaiser et al.1450

1998

1997

1997

1996

1995

Serra et al.1453

Corren et al.1454

Grosclaude et al.1459

Bertrand et al.1458

Bronsky et al.1455

Horak et

al.1052

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1b

1b

1b

1b

1b

1b

RCT

RCT

RCT

RCT

RCT

RCT

RCT

Study
design

Placebo

2

Loratadine-pseudoephedrine twice
daily;
Placebo

2
3

Placebo

2

Placebo

2

Pseudoephedrine

3

Cetirizine;
Pseudoephedrine

2
3

Loratadine-pseudoephedrine;
Loratadine;
Pseudoephedrine;
Placebo

1
2
3
4

(n = 874):

Cetirizine-pseudoephedrine;

1

(n = 210):

Cetirizine-pseudoephedrine;
Cetirizine;

1
2

(n = 687):

Loratadine-pseudoephedrine;

1

(n = 193):

Loratadine-pseudoephedrine;

1

(n = 40):

Loratadine-pseudoephedrine once daily;

1

(n = 469):

Cetirizine-pseudoephedrine;

1

(n = 24):

Study groups

Author Manuscript
LOE

Composite symptom scores:
total, nasal and non-nasal

Daily symptom scores

5 daily symptoms: congestion,
sneezing, rhinorrhea, nasal and
ocular pruritus

Nasal and chest symptoms,
albuterol use, peak expiratory
flow

Nasal symptoms or signs, mean
TSS

Total nasal and non-nasal
symptom scores

Nasal obstruction, nasal
patency/airflow

Clinical endpoint

Author Manuscript

Year

Combination drug was significantly superior to either
drug alone or placebo in reducing symptom scores.

Cetirizine-pseudoephedrine resulted in significantly
reduced symptoms and more symptom-free days than
either drug alone.

Combination was significantly more effecting in
controlling all symptoms and providing more
comfortable days than either medication alone.

Combination drug significantly reduced symptom
scores and improved peak flow rates and FEV1
compared to placebo.

Combination drug was significantly better than
placebo in improving signs and TSS; both placebo and
combination drug improved nasal symptoms.

Loratadine-pseudoephedrine (either dose) was
superior to placebo in reducing symptom scores.

Cetirizine-pseudoephedrine was significantly better
than placebo in improving nasal obstruction and
airflow.

Conclusion

Author Manuscript

Study

Wise et al.
Page 398

Author Manuscript
1989

1b

RCT
Loratadine-pseudoephedrine;
Placebo

1
2

(n = 264):

Study groups
4 nasal and 4 non-nasal
symptoms

Clinical endpoint
Treatment group had significantly lower nasal and
non-nasal symptom scores than the placebo group.

Conclusion

FEV1 = forced expiratory volume in 1 second; HDM = house dust mite; LOE = level of evidence; nPIF = nasal peak inspiratory flow; PFT = pulmonary functiontest; QOL = quality of life; RCT =
randomized controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SAR = seasonal allergic rhinitis; TSS = Total Symptom score.

Grossman et

al.1456

Study
design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript
2004

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1998

Ratner1471
1b

1b

1b

1b

1b

LOE

DBRCT,
double
dummy

SBRCT

DBRCT,
double
dummy

DBRCT,
crossover

RCT

Study design

Placebo

4

Fluticasone + oral placebo

2

Cetirizine + montelukast;
Placebo

3
4

Cetirizine and montelukast

3

Fluticasone INCS + loratadine;
Loratadine;
Fluticasone INCS

1
2
3

SAR, (n = 600):

Mometasone INCS + cetirizine;
Cetirizine;

1
2

SAR, (n = 38):

Fluticasone INCS + cetirizine;
Fluticasone INCS;

1
2

SAR, (n = 100):

Fluticasone + oral cetirizine;

1

(n = 27):

Mometasone furoate INCS + montelukast;

Mometasone furoate INCS + desloratadine;

2
3

Mometasone furoate INCS;

1

(n = 95):

Study groups

Symptoms

nPIF, symptom diary card

DNSS, nasal lavage
eosinophil count and ECP
level

TNSS, mini-RQLQ, nPIF,
nasal nitric oxide

TNSS, rhinoconjunctivitis
Scores, nPIF

Clinical endpoint

Combination therapy, although significantly
better than an oral antihistamine alone, offered
no significant advantage over INCS alone.

Combination of oral cetirizine and
mometasone INCS was not significantly better
than cetirizine alone for SAR.

Combination therapy was equivocal to
monotherapy INCS in reducing nasal
symptoms in SAR.

Nasal symptom scores are equivalent with
combination therapy compared to INCS.

Combination therapy resulted in better nasal
symptom scores at week 2 and better QOL
scores than INCS monotherapy.

Conclusion

DBRCT = double-blind randomized controlled trial; DNSS = Daily Nasal Symptom Score; ECP = eosinophil cationic protein; INCS = intranasal corticosteroid; LOE = level of evidence; mini-RQLQ =
mini-Rhinoconjunctivitis Quality of Life Questionnaire; nPIF = nasal peak inspiratory flow; QOL = quality of life; RCT = randomized controlled trial; SAR = seasonal allergic rhinitis; SBRCT = singleblind randomized controlled trial; TNSS = Total Nasal Symptom Score.

2000

Wilson et al.1469

1472

Di Lorenzo et al.

2008

Year

2006

al.1473

Barnes et al.1470

Pinar et

Study

Evidence for the use of combination oral antihistamine and intranasal corticosteroids in the treatment of allergic rhinitis

Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
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2009

2009

2008

Li et al.1478

Lu et al.1479

Watanasomsiri et al.

DiLorenzo et al.1472
2004

2010

Cingi et al.1477

1480

2012

Yamamoto et al.1476

2004

Year

2013

al.1300

Ciebiada et al.1475

Wilson et

Study

1b

1b

1b

1b

1b

1b

1b

1a

LOE

RCT

RCT

RCT

RCT

RCT

RCT

RCT

SR of RCTs,
with
homogeneity

Study design

Montelukast;
Loratadine ;
Placebo

3
4
5

Montelukast + cetirizine;
Fluticasone INCS;
2

Loratadine + placebo
1

2

Montelukast + loratadine;

Beclomethasone INCS;

2

1

Montelukast + loratadine;

1

Fexofenadine

2

Fexofenadine

3
Fexofenadine + montelukast;

Fexofenadine + placebo;

2

1

Fexofenadine + montelukast;

1

Montelukast + placebo

Placebo

4

2

Montelukast + oral antihistamine;

3

Montelukast + loratadine;

Oral antihistamine;

2

1

Montelukast;

1

INCS

Oral antihistamine;

3
4

LTRA + oral antihistamine;
LTRA;

1
2

Study groups

Symptoms, peripheral
eosinophilia, nasal
eosinophil counts

Symptoms, turbinate
hypertrophy

Symptoms, QOL

Symptoms, acoustic
rhinometry, cytokine
levels

Symptoms,
rhinomanometry

Symptoms

Symptoms, ICAM-1
levels, eosinophilia

Symptoms, QOL

Clinical endpoint

Conclusion

Montelukast + cetirizine improved symptoms and
decreased nasal eosinophil counts compared to placebo.

No difference in symptoms with combination therapy vs
antihistamine alone. Turbinate swelling significantly
reduced with combination therapy.

Combination therapy improved symptoms more than
placebo or montelukast alone. There was no difference
compared to loratadine alone. Combination therapy was
inferior to beclomethasone INCS.

Combination therapy improved symptoms, increased
nasal volume by rhinometry. No difference in cytokine
levels.

Combination therapy improved symptoms and decreased
nasal resistance compared to fexofenadine alone or with
placebo.

Combination therapy improved symptom scores,
specifically sneezing and rhinorrhea.

Active treatments were superior to placebo at reducing
symptoms, ICAM-1 levels and eosinophilia. Active
treatments were not statistically different from each
other.

Combination therapy improved symptoms vs either
treatment alone. No differences in QOL measures. No
difference in symptoms for combination therapy
compared to INCS.

Evidence for the use of combination leukotriene receptor antagonist and oral antihistamine in the treatment of allergic rhinitis

Author Manuscript
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2002

2000

Nayak et al.1482

Meltzer et al.1483
1b

1b

1b

1b

RCT

RCT

RCT

RCT

Montelukast;
Loratadine;
Placebo

3
4

Placebo

4

2

Loratadine;

3

Montelukast + loratadine;

Montelukast;

1

Montelukast + loratadine;

2

Fluticasone INCS

2
1

Montelukast + loratadine;

Fexofenadine + pseudoephedrine

2
1

Montelukast + loratadine;

1

Fluticasone INCS + montelukast;
Placebo

4
5

Study groups
Fluticasone INCS + cetirizine;

3

Symptoms, QOL

Symptoms, QOL,
peripheral eosinophilia

Symptoms, nasal
eosinophil count, nasal
ECP level

Symptoms, QOL, nPIF

Clinical endpoint

Conclusion

Combination therapy improved symptoms and QOL
compared to placebo. Combination therapy not directly
compared to monotherapy.

Combination therapy decreased symptoms and improved
QOL compared to placebo. Effect did not reach statistical
significance compared to monotherapy. Combination
therapy decreased peripheral eosinophilia compared to
placebo and loratadine only.

No difference in total symptom score, but nasal
symptoms reduced in the fluticasone group. Decreased
eosinophil cell count and ECP level in the fluticasone
group.

No significant difference between treatment groups for
symptoms, QOL, and nPIF. Montelukast + loratadine
reduced sleep domain symptoms.

Generally inferior to fluticasone INCS alone or in
combination.

ECP = eosinophil cationic protein; ICAM = intercellular adhesion molecule; INCS = intranasal corticosteroid; LOE = level of evidence; LTRA = leukotriene receptor antagonist; nPIF = nasal peak
inspiratory flow; QOL = quality of life; RCT = randomized controlled trial; SR = systematic review.

2003

Saengpanich et al.1481

2004

Author Manuscript

Moinuddin et al.1467

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript

Author Manuscript

Author Manuscript
2013

2012

2012

2011

2010

2010

Price et al.1488

Carr et al.1489

Meltzer et al.1490

Salapatek et al.1491

Hampel et al.1492

LaForce et al.1493

2016

Year

2013

al.1486

Meltzer et al.1487

Berger et

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1b

1b

1b

1b

1b

1b

1b

LOE

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

DBRCT

Study design

Olopatadine + fluticasone propionate

Placebo
4

2

Fluticasone propionate;

3

AzeFlu;

Azelastine;

2

1

AzeFlu;

1

Azelastine + budesonide suspension;
Placebo

2
3

Placebo

4

Solubilized azelastine + budesonide
(CDX-313);

Fluticasone propionate;

3

1

Azelastine;

Placebo

4
AzeFlu;

Fluticasone propionate;

3

2

Azelastine;

1

AzeFlu;

2

Fluticasone propionate

2
1

AzeFlu;

Placebo

2
1

AzeFlu;

Placebo

2
1

AzeFlu;

1

Study groups

TNSS

TNSS

TNSS

rTNSS, rTOSS,
RQLQ

rTNSS, rTOSS,
RQLQ

rTNSS, symptomfree days

rTNSS, rTOSS

rTNSS, rTOSS,
PRQLQ

Clinical endpoint

Conclusion

No difference between treatments.

AzeFlu superior to either spray alone; all treatments
superior to placebo.

Both treatments superior to placebo; CDX-313 superior to
suspension-type spray for symptoms and speed of onset.

AzeFlu superior to either spray alone for symptom and
QOL improvement.

AzeFlu superior to either spray alone for symptom and
QOL improvement; faster onset.

AzeFlu superior to fluticasone for symptom reduction;
faster onset.

AzeFlu superior to placebo for all symptoms.

AzeFlu superior to placebo for symptoms and QOL
improvement in children; symptoms improved when
children self-rate.

Evidence for the use of combination intranasal corticosteroids and intranasal antihistamine in the treatment of allergic rhinitis

Author Manuscript
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Author Manuscript
2008

2016

Berger et al.1495

2015

Klimek et al.1497
2c

2c

2b

1b

Prospective
observational

Prospective
observational

RCT, non-blinded

DBRCT

Study design

Fluticasone propionate

AzeFlu

AzeFlu

AzeFlu;

Fluticasone propionate

3

2

Azelastine;

2

1

AzeFlu;

1

Study groups

VAS

VAS

Total symptom
score

TNSS

Clinical endpoint

Rapid symptom relief across all age groups.

76% of subjects had symptom control after 14 days;
significant improvement from baseline.

AzeFlu superior to fluticasone for children; faster onset.

Combination superior to either agent alone.

Conclusion

AzeFlu = combination spray of azelastine hydrochloride and fluticasone propionate; DBRCT = double-blind randomized controlled trial; LOE = level of evidence; PRQLQ = Pediatric Rhinoconjunctivitis
Quality of Life Questionnaire; QOL = quality of life; RCT = randomized controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; rTNSS = reflective Total Nasal Symptom Score;
rTOSS = reflective Total Ocular Symptom Score; TNSS = Total Nasal Symptom Score; VAS = visual analog

2016

Klimek et al.1496

Ratner et

LOE

Author Manuscript
Year

Author Manuscript

al.1494

Author Manuscript

Study
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Author Manuscript

Author Manuscript

al.1501

2008

2015

Year

1a

1a

LOE

SR and metaanalysis

SR and metaanalysis

Study design

Acupuncture;
Sham acupuncture

1
2

Acupuncture;
Sham acupuncture

1
2

Study groups

AR symptom scores, rescue
medication use

Nasal symptom scores, RQLQ
scores, rescue medication use

Clinical endpoint

AR = allergic rhinitis; LOE = level of evidence; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SR = systematic review.

Roberts et al.1500

Feng et

Study

Author Manuscript

Evidence for the use of acupuncture in the treatment of allergic rhinitis

No overall effect on AR symptom scores or need for rescue
medications.

Significant reduction in nasal symptoms, improvement in
RQLQ scores and use of rescue medications with
acupuncture.

Conclusion

Author Manuscript
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Author Manuscript

Author Manuscript
2b

1b

1b

LOE

RCT

RDBPCT

RDBPCT

Study design

Birch pollen honey;
Regular honey;
No honey

3

Placebo

3
1

Nationally collected, pasteurized,
filtered honey;

2

2

Locally collected, unpasteurized,
unfiltered honey;

Placebo

2
1

Honey;

1

Study groups

Daily AR symptoms, number of
asymptomatic days, rescue
medication use

Daily AR symptoms, rescue
medication use

AR symptom scores

Clinical endpoint

AR = allergic rhinitis; LOE = level of evidence; RCT; randomized controlled trial; RDBPCT = randomized double-blind placebo-controlled trial.

2011

Saarinen et al.1509

2013

Year

2002

al.1508

Rajan et al.1510

Asha’ari et

Study

Author Manuscript

Evidence for the use of honey in the treatment of allergic rhinitis

Birch pollen honey significantly lowered total
symptom scores and decreased use of rescue
medications. Honey groups had significantly more
asymptomatic days.

No significant difference in AR symptoms or need
for rescue medication.

Improvement in overall and individual AR
symptoms with honey.

Conclusion

Author Manuscript
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Author Manuscript

Author Manuscript
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RDBPCT showed 4 tablets of RCM-101 TID for 8 weeks significantly improved
symptom scores and RQLQ.1540
RDBPCT showed 2000 mg/day spirulina significantly improved sneezing, rhinorrhea,
congestion, and nasal itching.1543

Inhibits leukotriene and histamine synthesis and
mast cell degranulation1521

Thought to desensitize and deplete sensory Cfibers1522, 1523
Inhibits production of prostaglandin D21525

Contains catechin monomers that may inhibit
allergen-induced histamine release1526
Inhibited histamine release from rat
macrophages.1528 Thymoquinone may inhibit
Th2 cytokines and eosinophil infiltration in
airways.1529
Polyphenolic phytochemicals such as rosmarinic
acid inhibit inflammatory processes and the
allergic reaction.1533-1536
Inhibits histamine release and prostaglandin E2
production1538, 1539
Reduces IL-4 levels,1541 inhibits histamine release
from mast cells1542
Inhibits cyclooxygenase activity and histamine
release by mast cells1544

Butterbur (Petasites
hybridus)

Capsaicin

Cinnamon bark,
Spanish needle, acerola
(ClearGuard)

Grape seed extract

Nigella sativa (Black
seed)

Perilla frutescens

RCM-101

Spirulina

Ten-Cha (Rubus
suavissimus)

TJ-19

Inhibits histamine signaling and IL-4 and IL-5
expression in a rat model1546

RDBPCT showed 450 mg CG TID comparable to loratadine 10 mg in symptom
reduction. CG prevented increase in prostaglandin D2 release following nasal allergen
challenge.1525

Unknown

Biminne

a

No evidence of a therapeutic effect of intranasal capsaicin in AR.1524, 1694

Inhibits type I and type IV hypersensitivity
reactions1517, 1518

Benifuuki green tea

RDBPCT showed 3 g TJ-19 TID significantly improved sneezing, stuffy nose, and runny
nose.1547

RDBPCT showed no significant improvement in symptom scores, RQLQ, or need for
antihistamine with 400 mg daily of Ten-Cha extract.1545

RDBPCT showed 50 mg or 200 mg P. frutescens enriched for rosmarinic acid did not
significantly improve symptom scores.1537

2 RDBPCTs showed N. sativa capsules and 1 RDBPCT showed N. sativa nasal drops
improve AR symptoms.1530-1532 1 RDBPCT did not find significant differences
between treatment and placebo.1530

RDBPCT showed no benefit of 100 mg grape seed extract BID on nasal symptoms, need
for rescue medications, or QOL.1527

1516

Not reported

None reported

Not reported

Mild gastrointestinal side
effects

None reported

Gastrointestinal
complaints with oral
intake. Nasal dryness with
topical drops.

None reported

None reported

Mucosal irritation,
burning

Hepatic toxicity,
headache, gastric upset

Not reported

RDBPCT found 12 weeks of biminne significantly reduced sneezing.1520
3 RDBPCTs showed Butterbur effective in alleviating symptoms, attenuating nPIF
recovery, and reducing maximum % nPIF decrease from baseline after adenosine
monophosphate challenge. Butterbur similar to antihistamine for improving QOL and
symptom relief.1516 1 RDBPCT demonstrated no benefit for nPIF, symptoms, or QOL.

None reported

Dry mouth, gastric
discomfort

Pharyngitis, rhinosinusitis

Side effects

RDBPCT showed 700 mL Benifuuki green tea daily significantly reduced AR
symptoms, improved QOL, and suppressed peripheral eosinophils.1519

2 RDBPCTs showed some relief of symptoms with Aller-7. However, there were some
contradictory findings.1516

Possibly through antioxidant and antiinflammatory pathways1513-1515

Aller-7

RDBPCT comparing 80 mg daily × 6 weeks showed significant improvement in
rhinorrhea, changes in TSS, and QOL.1512

Evidence

Unknown

Mechanism of action

Astragalus
membranaceus

Herb

Author Manuscript

Evidence for the use of herbal therapies in the treatment of allergic rhinitis

Author Manuscript

TABLE IX.B.11.c.
Wise et al.
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Author Manuscript
Possibly through anti-inflammatory

In vitro: antagonist/negative agonist activity
against Histamine-1 receptor, inhibits mast cell
tryptase, prevents mast cell degranulation, inhibits
prostaglandin formation1549

Tinofend (Tinospora
cordifolia)

Urtica dioica (stinging
nettle)

Leukocytosis

Not reported

1 RDBPCT showed symptom improvement over placebo at 1 hour.1550 1 systematic
review showed no significant intergroup differences.1516

Side effects

RDBPCT showed 300 mg Tinofend × 8 weeks significantly improved multiple AR
symptoms and a significant decrease in eosinophil, neutrophil, and goblet cell counts on
nasal smear.1548

Evidence

AR = allergic rhinitis; BID = 2 times daily; CG = ClearGuard; IL = interleukin; nPIF = nasal peak inspiratory flow; QOL = quality of life; RDBPCT = randomized double blind placebo controlled trial;
RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; TID = 3 times daily; TSS = Total Symptom Score.

Not available in the United States as it contains ephedra.

a

Author Manuscript
effects1548

Author Manuscript

Mechanism of action

Author Manuscript

Herb
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Author Manuscript

Author Manuscript
2010
2008

al.1557

Year

Coatesworth2

1999

2012

2011

2009
2002
2011
2010

Passali et al.1236

Tan et al.1566

Kim et al.1555

Karatzanis et al.1554

Mori et al.1556

Caffier et al.1558

Aksoy et al.1564

Chen et

Jose &

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
4

4

3b

3b

3b

3b

2b

1b

1a

LOE

Case series

Case series

Observational
cohort

Case-control

Case-control

Observational
cohort

RCT

RCT

SR of RCTs

Study design

Bony resection

Microdebrider submucous resection;

Cryotherapy;
Laser ablation;
Submucosal resection without lateral
displacement;
Submucosal resection with lateral
displacement;
Turbinectomy

2
3
4
5
6

Turbinectomy and/or septoplasty;
Medical treatment

2
3

2

AR patients undergoing IT outfracture

AR patients undergoing mucosal laser reduction, 95%
to IT

AR patients undergoing IT submucous turbinectomy

Septoplasty in patients with or without AR

Septoplasty with IT turbinoplasty;
IT turbinoplasty alone

1

AR patients undergoing:

Vidian neurectomy;

1

AR patients undergoing:

Electrocautery;

1

AR patients undergoing IT:

2

1

AR patients undergoing IT:

Turbinate reduction in refractory AR

Study groups

CT sinus preoperatively, and 1
and 6 months postoperatively

Rhinomanometry and VAS

Standard symptom score,
rhinometry, nasal challenge

NOSE scores, anterior
rhinomanometry

Mean rescue medication score,
Rhinasthma Questionnaire

QOL outcomes

Rhinomanometry, acoustic
rhinometry, mucociliary
transport time, secretory IgA
levels, symptom scores

VAS, anterior
rhinomanometry, saccharin
transit time

No studies qualified as RCT

Clinical endpoint

Author Manuscript

Evidence for surgery in the treatment of allergic rhinitis

Statistically significant reductions were
noted in the angle and distances in all
sections.

Objective and subjective improvement up
to 2 years.

Significant improvement seen at 1 and 3
years.

Non-AR subjects showed more
improvement than AR subjects.

Significant improvement in both groups but
less obstruction in septoplasty group.

All subjects improved, but improvement in
vidian neurectomy group exceeded group
undergoing turbinectomy and/or
septoplasty.

Submucosal resection with lateral
displacement of the IT results in the
greatest increase in nasal airflow and nasal
respiratory function with the lowest risk of
long-term complications.

Significant improvement in all parameters
for both treatment groups at 1, 2, and 3
years.

No conclusions could be made.

Conclusion

Author Manuscript

TABLE IX.C.
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Author Manuscript
2010

2010
1998

Siméon et al.1563

Li et al.1561
4

4

4

Case series

Case series

Case series

Study design

AR patients undergoing IT radiofrequency
turbinoplasty

Children with AR undergoing IT coblation
turbinoplasty

AR patients undergoing IT radiofrequency
turbinoplasty

Study groups

Questionnaires and VAS

Rhinomanometry, VAS,
PRQLQ

Symptoms per VAS

Clinical endpoint

21 of 22 showed improved symptoms at 8
weeks.

All improved per PRQLQ.

Statistically significant reductions were
noted in obstruction, rhinorrhea, sneezing,
and itching.

Conclusion

AR = allergic rhinitis = CT = computed tomography; IgA = immunoglobulin A; IT = inferior turbinate; LOE = level of evidence; NOSE = Nasal Obstruction Symptom Evaluation score; PRQLQ = Pediatric
Rhinoconjunctivitis Quality of Life Questionnaire; QOL = quality of life; RCT = randomized controlled trial; SR = systematic review; VAS = visual analog scale.

Lin et

LOE

Author Manuscript
Year

Author Manuscript

al.1562

Author Manuscript

Study
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TABLE IX.D.2-1.

Author Manuscript

Modified allergen immunotherapy constructs

*

Injectable immunotherapy approaches
Recombinant allergens (SQ)
Peptide constructs (ID)
Chemical modifications (SQ)
Alum salts (SQ)
Allergoids/polymerized allergens
Adjuvant constructs (SQ; IM)
DNA vaccines
TLR-9 (CpG oligonucleotides) (SQ)
Linked to allergen; co-combined

Author Manuscript

Nanoparticle-based VLPs
TLR-4 (MPL) (SQ)

*Modified and used with permission; from: Creticos PS. Allergen immunotherapy: vaccine modification. Immunol Allergy Clin North Am.
2016;36:103-124.
CpG = cytosine phosphorylated to guanine; ID = intradermal; IM = intramuscular; MPL = monophosphoryl lipid A; SQ = subcutaneous; TLR =
toll-like receptor; VLP = viral-like particles.

Author Manuscript
Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
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2013

2012

2008

2005

2015

Meyer et al.1063

Klimek et al.1585

Pauli et al.1583

Jutel et al.1586

Klimek et al.805

Peptide constructs

2015

2016

Year

Nony et al.1584

Zieglmayer et al.798

Recombinant allergens

Study

2b

1b

1b

1b

1b

1b

1b

LOE

Open RCT

RDBPCT

RDBPCT

RDBPCT

RDBPCT

RDBPCT

RDBPCT

Study
design

Recombinant birch extract (rBet v 1-FV);
Native birch extract

2

Placebo

2
1

Recombinant Timothy grass antigens (Phl p 1, Phl p
2, Phl p 5a, Phl p 5b, Phl p 6);

Placebo

4
1

Licensed birch pollen extract;
Natural purified birch pollen allergen;

2
3

Recombinant birch pollen allergen;

Placebo

2
1

Study groups: 20 μg, 40 μg, 80 μg, 120 μg protein;

1

Recombinant Timothy grass antigens (Phl p 1, Phl p 2, Phl p 5a,
Phl p 5b, Phl p 6):

Placebo

Placebo

4

2

50 μg cGMP-grade rBet v 1 SLIT;

3

rBet v 1-FV in multiple doses;

25 μg cGMP-grade rBet v 1 SLIT;

1

12.5 μg cGMP-grade rBet v 1 SLIT;

2

Control

2
1

Recombinant peptide vaccine with grass epitopes at
3 doses;

1

Study groups

Symptom scores, IgG levels

Symptoms, medication use,
RQLQ, immunologic markers,
conjunctival provocation test

Symptoms, immunologic
markers

Primary: systemic allergic
reactions; Secondary:
Improvement in symptoms,
conjunctival provocation test

Symptom scores, change in
IgG1 and IgG4

Symptom scores, medication
scores

Total nasal symptoms scores,
ocular symptoms, skin tests

Clinical endpoint

Evidence for the use of recombinant, peptide, allergoid/polymerized, and adjuvant allergen immunotherapy

Both were safe and equally
efficacious over 2 seasons.

Recombinant allergens safe and
effective over 2 grass seasons.

Recombinant allergens were safe
and effective for 2 seasons.

Recombinant allergens safe and
effective even at high protein levels.

All dosing regimens were more
effective than placebo.

SLIT with rBet v 1 resulted in a
significant decrease of symptom
score and medication score vs
placebo.

Improvement in primary endpoint
for 2 higher doses but not the lower
dose.

Conclusion

Author Manuscript
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Author Manuscript
2016

2015

2013

2008

2002

1999

1996

1991

Couroux et al.1599

Patel et al.1065

Purohit et al.1600

Oldfield et al.1601

Maguire et al.1602

Norman et al.1603

Litwin et al.1604

Spertini et

al.1589

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2b

1b

1b

1b

1b

1b

1b

1b

Placebocontrolled
trial

RDBPCT

RCT

RCT

DBPCT

DBPCT

RDBPCT

RDBPCT

Study
design

Pre-seasonal ragweed;
Pre-seasonal ragweed peptide fragments;
Histamine placebo control

2
3

750 μg Allervax CAT peptide;
Placebo

3
4
1

7.5 μg Allervax CAT peptide;
75 μg Allervax CAT peptide;

1

750 μg/dose SC Allervax Cat peptide;
Placebo

2
3

2

75 μg/dose SC Allervax Cat peptide;

Placebo

1

Fel d 1 peptide 90 μg;

Placebo

3

2

Pre-seasonal Bet v 1 fragments;

2

1

Pre-seasonal Bet v 1 primer;

Fel d 1-derived peptide 4 × 6 nmol 4 weeks apart;
8 × placebo

2
3
1

Fel d 1-derived peptide 8 × 3 nmol 2 weeks apart;

Control

3
1

Cat-PAD 8 doses 3 nmol;
Cat-PAD 4 doses 6 nmol;

Placebo

3
1

Bet v 1-derived contiguous overlapping peptides 100
μg;

2

2

Bet v 1-derived contiguous overlapping peptides 50
μg;

Study groups
1

Author Manuscript
LOE

Clinical endpoint

Symptom-medication scores

Nose, lung, and symptom
scores during live cat exposure

Improvement in pulmonary
function, adverse events

Development of late respiratory
reaction

Primary: symptom medication
scores; Secondary: skin and
nasal sensitivities,
immunoglobulins, adverse
reactions

Total rhinoconjunctivitis score
at 20 weeks and 52 weeks

Rhinoconjunctivitis symptom
scores 2 years after start of
treatment, symptom scores after
challenge

Combined rhinoconjunctivitis
symptom and medication
scores, QOL

Author Manuscript

Year

Subjects receiving the peptide
fragment preparation had improved
scores vs other groups.

Dose response was observed at
highest dose, resulting in the most
significant decrease in lung and
nasal symptoms upon cat exposure.

Improvement in pulmonary
function. Increased incidence of late
adverse reaction.

Increase in late respiratory reaction
with treatment. Tolerance may
develop with continued treatment.

No significant difference in
symptom and medication scores
between the groups.

Durable treatment effect at 1 year
with best regimen 4 × 6 nmol at 4
weeks apart.

Significant reduction in symptoms
was observed in the 6 nmol dose
group but not the other groups.

Improved symptom, medication,
and QOL scores in both treatment
groups vs placebo.

Conclusion

Author Manuscript

Study
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Author Manuscript
2014

2013

2012

2005

1990

1989

1983

1982

2016

Klimek et al.1605

Pfaar et al.1594

Pfaar et al.1593

Corrigan et al.1606

Bousquet et al.1607

Bousquet et al.1608

Grammer et al.1592

Grammer et al.1591

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Pfaar et al.1609
2b

1b

1b

1b

1b

1b

ib

1b

1b

Allergoids/polymerized allergens

RCT

DBPCT

RDBPCT

RDBPCT

RDBPCT

DBPCT

DBRCT

DBPCT

DBPCT

Study
design

Placebo

3

Mite allergoid SCIT 20,000 AUeq/mL;
2

No treatment

3

Mite allergoid SCIT 6667 AUeq/mL;

Placebo

2

1

Pre-seasonal polymerized ragweed;

Placebo

1

Pre-seasonal polymerized whole grass;

2

Placebo

4
1

High molecular weight grass pollen allergoid;
Standardized grass pollen extract;

2
3

Unfractionated grass pollen allergoid;

High-dose grass pollen allergoid;

1

Low-dose grass pollen allergoid;

2

Placebo

3
1

Pre-seasonal grass pollen allergoid (low dose);
Pre-seasonal grass pollen allergoid (high dose);

1

Placebo

2

2

Pre-seasonal depigmented polymerized grass pollen
SCIT;

Placebo

2
1

Mixed depigmented polymerized birch and grass
pollen extract;

Cluster immunotherapy with grass/rye polymerized
antigen

Study groups

1

1

Author Manuscript
LOE

Clinical endpoint

Clinical response to a titrated
nasal provocation test

IgE and blocking antibodies,
daily symptom scores

Blocking antibodies, daily
symptom scores

Clinical symptoms: rhinitis,
conjunctivitis, asthma

Symptom and medication
scores during pollen season

Combined symptom and
medication score

Combined symptom and
medication score

Combined symptom and
medication score

Combined symptom and
medication score, rescue
medication use, total
rhinoconjunctivitis symptom
score

Author Manuscript

Year

All doses above 20,000 AUeq/mL
showed improved efficacy
compared to placebo.

Significant elevations in blocking
antibodies and decrease in
symptoms scores in treatment
group.

Significant elevations in blocking
antibodies and decrease in
symptoms scores in treatment
group.

High molecular weight and pollen
extract were most effective,
followed by unfractionated
allergoid. All better than placebo.

Significant reduction in symptom
and medication scores for both
treatment groups compared to
placebo.

Pre-seasonal grass pollen allergoid
resulted in significantly improved
symptom and medication score
compared to placebo.

Significantly improved combined
scores in peak season at year 2
compared to placebo.

Significant reduction in median
combined scores at year 2 compared
to placebo.

Improvement in symptoms and
medication usage compared to
placebo.

Conclusion

Author Manuscript

Study
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2006

2004

2001

Creticos et al.1596

Tulic et al.1610

Drachenberg et al.
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2b

1b

1b

1b

1b

1b

2b

Open trial

RDBPCT

RCT

RDBPCT

RCT

RDBPCT

Open trial

Placebo

2

10 weekly injections of dust mite with A-type CpG
oligodeoxynucleotides with virus-like particles

Pre-seasonal tyrosine-adsorbed glutaraldehydemodified grass pollen extract containing 3deacylated monophosphoryl lipid;

Placebo

1

Amb a 1-oligodeoxyribonucleotide conjugate;

2

Placebo

2
1

Ragweed Amb a 1-phosphorothioate
oligodeoxyribonucleotide conjugate (TLR-9
agonist);

Placebo

2
1

Pre-seasonal grass modified allergen tyrosine
adsorbate monophosphoryl lipid A;

Placebo

2
1

Four weekly injections of short ragweed pollen
allergoid adsorbed to L-tyrosine monophosphoryl
lipid A;

1

Allergoid ragweed (formaldehyde-treated);
Allergen ragweed

1

Placebo

5

2

Mite allergoid SCIT 100,000 AUeq/mL;

4

Study groups
Mite allergoid SCIT 50,000 AUeq/mL;

3

Symptoms, conjunctival
provocation, skin-prick tests,
IgG and IgE levels

Symptom scores, medication
scores, skin reactivity, IgG and
IgE antibodies

Primary: symptom and
medication scores; Secondary:
tissue markers of inflammation.

Symptoms, immune changes,
adverse reactions

Symptom and medication
scores

Rhinoconjunctivitis symptoms
after exposure in a chamber

Daily symptom and medication
scores

Clinical endpoint

Significant reduction in symptoms,
improved conjunctival tolerance,
increase in IgG, and decreased skin
reactivity.

Significant improvement in nasal,
ocular, and combined symptom and
medication scores in treatment
group.

No difference in primary endpoint
after 1 season, chest symptoms were
better in the treatment group after
the second season.

Efficacious, benefits lasted for 2
more seasons.

Significant improvement in subjects
with severe symptoms and longstanding symptoms with treatment.

Significant improvement in
symptom scores in the treatment
group.

Significant improvement of
allergoid over allergen.

Conclusion

DBPCT = double blond placebo controlled trial; Ig = immunoglobulin; LOE = level of evidence; QOL = quality of life; RCT = randomized controlled trial; RDBPCT = randomized double blind placebo
controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SCIT = subcutaneous immunotherapy; SLIT = sublingual immunotherapy; TLR = toll-like receptor.

Senti et al.1612
2009

2011

Dubuske et al.1598

1611

2014

Patel et al.1066

Adjuvant constructs

1981

Author Manuscript

Norman et al.1590

Study
design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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2016
2014
2013

2012
2012

Bozek et al.1622

Klimek et al.1605

Pfaar et al.1594

Pfaar et al.1593

Rajakulasingam1621
1b

1b

1b

1b

1b

1a

1a

1a

LOE

RDBPCT

RDBPCT

RDBPCT

RDBPCT

RDBPCT

Systematic
review

Systematic
review

Systematic
review

Study design

SAR (n = 37), ages 22-54 years.
Maintenance dose 25.2 μg group 5

SAR (n = 179), age 11-69 years.
Maintenance dose 31.5 μg Phl p 5

SAR (n = 269), age 12-70 years.
Maintenance dose Betv 1 6.75 μg and Phl
p 5 15.75 μg

SAR (n = 102), age 18-75 years;
Maintenance dose 24 μg Gp 1 plus Gp 5

SAR (n = 55), age 65-75 years;
Maintenance dose 26.3 μg Phl p 5

SAR and PAR, adults and children, level
1b evidence, single-extract AIT

SAR, adults and children.

Rhinoconjunctivitis and/or asthma, adults
and children

Study groups

Symptom
improvement from
baseline year

Symptom-medication
score

Symptom-medication
score

Symptoms,
medication use

Combined symptommedication score

Symptoms,
medication use, QOL

Clinical effectiveness,
cost effectiveness.
Symptoms,
medication use, QOL.

Efficacy,
effectiveness, safety.
Symptoms,
medication use, QOL.

Clinical endpoint

Conclusion

QOL (n = 955): SMD −0.53, p < 0.00001, a 0.74-unit
reduction in RQLQ compared with placebo.

3

Improvement from baseline year of ≥2/10 in symptoms: active 65%,
placebo 35% (p = 0.024).

Symptom-medication score reduced: 1st year 16% (p < 0.01), 2nd year
37% (p < 0.01).

Symptom-medication score reduced for grass and birch pollen seasons:
1st year 21% (NS), 2nd year 19.4% (p = 0.0385).

Reduction in symptoms: 34% (p = 0.004). Reduction in medication use:
40% (p = 0.004).

Third-year combined symptom-medication score reduced 41% from
baseline (p = 0.004) and 37% vs placebo.

SCIT for SAR and PAR has Aggregate Grade of Evidence A. SCIT is
recommended for SAR or PAR patients not responsive to medical
therapy, whose symptoms significantly affect QOL.

Medication use (n = 621 active, 483 placebo): SMD
−0.55, p < 0.00001 favoring SCIT.

2

QOL (n = 532): Strength of evidence high for SCIT.

3

Symptoms (n = 659 active, 525 placebo): SMD −0.65, p
< 0.00001 favoring SCIT.

Medication use (n = 564): Strength of evidence moderate
for SCIT.

2

1

Symptoms (n = 1734): Strength of evidence high for
SCIT.

1

LOE = level of evidence; NS = not significant; PAR = perennial allergic rhinitis; QOL = quality of life; RDBPCT = randomized double-blind placebo-controlled trial; RQLQ = Rhinoconjunctivitis Quality
of Life Questionnaire; SAR = seasonal allergic rhinitis; SCIT = subcutaneous immunotherapy; SMD = standardized mean difference.

2013

Purkey et al.1619

2013

Year

2013

al.1618

Meadows et al.1617

Lin et

Study
Rhinitis or rhinoconjunctivitis:

Author Manuscript

Recent systematic reviews and selected RDBPCTs for the use of SCIT in allergic rhinitis

Author Manuscript
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100,000 BAU/mL
10,000 BAU/mL
1:10 wt/vol, 1:20 wt/vol 100,000 AU/mL
1:100 wt/vol
1:10wt/vol to 1:20 wt/vol
1:10 to 1:40 wt/vol or 10,000 to 40,000 PNU/mL
1:10 to 1:40 wt/vol or 10,000 to 40,000 PNU/mL

Grass, standardized

Bermuda

Short ragweed

Acetone precipitated (AP) dog

Nonstandardized dog extracts

Nonstandardized pollen extracts

Nonstandardized fungal, cockroach extracts

80–400 μg/mL Can f 1
0.5–10 μg/mL Can f 1

15 μg Can f 1
15 μg Can f 1

Highest tolerated dose

Not available

Not available

1:10 wt/vol;
300 μg/mL Amb a 1

6–12 μg Amb a 1 or 1000–4000 AU

0.5 of 1:100 or 1:200 wt/vol

10,000 BAU/mL;
141–422 Cyn d 1 μg/mL

100,000 BAU/mL;
425–1100 Phl p 5

10,000 BAU/mL;
20–50 μg/mL Fel d 1

10,000 AU/mL;
20–160 μg/mL Der p 1, Der f 1;
2–180 μg/mL Der p 2, Der f 2

Range of estimated major allergen
content in U.S. licensed extracts

300–1500 BAU

1000–4000 BAU

1000–4000 BAU

500–2000 AU

Probable effective dose range

AU = allergy units; BAU = bioequivalent allergy units; PNU = protein nitrogen unit; SCIT = subcutaneous immunotherapy; wt/vol = weight by volume.

*Adapted from Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127:S1-S55.1623

5000, 10,000 BAU/mL

3000, 5000, 10,000, 30,000 AU/mL

Labeled potency or concentration

Cat hair

House dust mites: D. farinae and D. pteronyssinus

Allergenic extract

Author Manuscript
*

Author Manuscript

Recommended dosing for SCIT

Author Manuscript

TABLE IX.D.3-2.
Wise et al.
Page 417

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Author Manuscript

Author Manuscript
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2015

2014
2014

2013
2013

2011
2011
2016

2015

2016

2015

Devillier et al.1332

Makatsori et al.1693

Lin et al.1694

Meadows et al.1617

Di Bona et al.1696

Radulovic et al.1695

Durham et al.1673

Maloney et al.1675

Creticos et al.1676

Oykhman et al.1677

2015

Di Bona et al.815

Leatherman et al.1692

Year

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
3a

2a

1b

1b

1a

1a

1a

1a

1a

1a

1a

1a

LOE

Systematic review of
cohort studies

Systematic review

Pooled analysis from
RCTs

Pooled analysis from
RCTs

Meta-analysis of
RDBPCTs

Meta-analysis of
RDBPCTs

Meta-analysis of
RDBPCTs, cost
analysis

Systematic review of
RCTs

Systematic review of
RCTs

Meta-analysis of
RCTs

Systematic review of
RCTs for SLIT doses

Meta-analysis of
RCTs

Study design

Pregnant women with vs without SLIT
or SCIT and their offspring. 422
pregnancies continuing AIT and 31
starting AIT.

Patients treated with SLIT, started inseason, vs out-of-season vs placebo

Grass SLIT tablet vs placebo. Grass
SLIT in AR patients with (24%) and
without (76%) mild asthma.

SAR: grass or ragweed SLIT tablet vs
pharmacotherapy.
PAR: HDM SLIT tablet vs
pharmacotherapy.

SLIT vs placebo for AR

Grass pollen SLIT vs placebo for SAR
(and asthma)

SCIT and SLIT vs placebo for SAR

Aqueous SLIT vs placebo for SAR (and
asthma)

SLIT vs placebo

Pollen SLIT vs pharmacotherapy vs
placebo for SAR

SLIT for AR vs placebo

SLIT grass pollen tablets vs placebo for
SAR

Study groups

Pregnancy outcome,
allergy in offspring

Serious treatment-related
AE, systemic AE
discontinuations

Treatment related AE
frequency

Total Nasal Symptom
Score

Symptom and medication
scores

Symptom and medication
scores

Several efficacy variables,
costs

Symptom and medication
scores

Drop-out rates in SLIT
and placebo groups

b

Relative clinical impact

Doses of the effective vs
doses of non-effective
SLIT

Symptom and medication
score

Clinical endpoint

Conclusion

a

No difference in prematurity, proteinuria, hypertension,
congenital malformations, perinatal death. No fetal
complications of 10/453 systemic reactions to SCIT. No
altered risk of developing atopic disease in offspring.

11 SLIT trials (n = 2668 subjects total). No epinephrine
administration. 0% to 4% systemic AE with in-season vs
0% out-season initiation. 2 serious treatment-related AE
with co-season SLIT initiation.

Severe asthma-related adverse events due to treatment in
6/120 SLIT and 2/60 placebo. No difference between the
2 groups. Both adults and children were included.

SAR: SLIT numerically greater than montelukast and
antihistamine; almost equal to mometasone furoate INCS.
PAR: SLIT effect numerically greater than all
pharmacotherapy.

SLIT vs placebo: Reduction in symptoms (SMD −0.49)
and medication use (SMD −0.32). No epinephrine use.

SLIT vs placebo: Reduction in symptoms (SMD −0.32)
and medication use (SMD −0.33). No epinephrine use.

Symptom reduction with SCIT and SLIT is greater than
placebo.

Moderate evidence aqueous SLIT reduces symptoms and
medication use in AR/ARC.

No tendency for a skewed dropout ratio between SLIT
and placebo groups. Confirms trial results are unbiased
and SLIT appears to be safe.

Clinical impact: 5-grass pollen tablet > INCS > Timothy
grass pollen tablet > montelukast > antihistamines

Wide dose ranges between studies. For certain antigens,
effective and non-effective dose ranges often overlap. For
other allergens: insufficient data.

Small improvement in symptom and medication scores vs
placebo: (SMD −0.28; 95% CI, −0.37 to −0.19; p <
0.001) and (SMD −0.24; 95% CI, −0.31 to −0.17; p <
0.001).
Adverse events: 7/2259 SLIT patients were given
epinephrine.

Evidence for the use of SLIT in the treatment of allergic rhinitis—systematic reviews and meta-analyses from the last decade

Author Manuscript
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2008

Roder et al.1670

2012
2015

2015

2014

2013

2013

Di Bona et al.1698

Nelson et al.1699

Aasbjerg et al.1700

Dranitsaris and
Ellis1701

Calderon et al.1702

Dretzke et al.1703

2013

2008

Kim et al.1672

Hoeks et al.1704

SLIT vs SCIT: children only

2013

Chelladurai et al.1697

SLIT vs SCIT

2013

Larenas-Linnemann
et al.1671

2a

2a

2a

2a

2a

2a

1b

1a

1a

2a

2a

Systematic review of
RCTs

Systematic review of
RCTs and indirect
comparison

Systematic review of
RCT and indirect
comparison

Systematic review of
RCTs

Systematic review of
RCTs and indirect
comparison

Systematic review of
RCTs, product
information, registry

Network metaanalysis of RCTs

Meta-analysis based
comparison

Systematic review of
RCT

Systematic review of
RCTs

Systematic review of
RCTs

SLIT vs placebo in children with
asthma/ARC

Children with SAR (asthma): Aqueous
SLIT vs SCIT vs placebo for SAR (and
asthma)

SCIT and aqueous SLIT vs placebo,
SCIT vs SLIT in AR

Patients allergic to HDM, with AR and
asthma, treated with HDM SCIT vs
SLIT vs placebo

Timothy grass tablet, 5-grass tablet,
grass pollen SCIT vs placebo in SAR

AR patients receiving Phleum pratense
SCIT, SLIT drops, or SLIT tablets vs
placebo. (including 314 children.)

Grass pollen SLIT tablets vs placebo.
Grass pollen SLIT drops vs placebo.
Grass pollen SCIT vs placebo.

Grass pollen SCIT; placebo vs grass
pollen SLIT; placebo in SAR

SCIT vs SLIT (and vs placebo) in AR

Children 0–18 years with AR: any form
of AIT vs placebo

Children with AR and/or asthma treated
with SLIT vs placebo/open controls

Study groups

Clinical endpoint

Symptom and medication
scores

Symptom and medication
scores

Symptom and medication
scores

Symptom score, IT
schedule, dosing

Efficacy, safety, cost for
Canadian setting

Safety data

Symptom and medication
scores

SMD of symptom and
medication scores

Symptom and medication
scores

Symptom and medication
scores

Symptom and medication
scores

a

Not enough evidence because of poor quality of the
studies.

In children, moderate evidence that SLIT improves AR
symptoms and medication use, low evidence that SCIT is
superior to SLIT for both outcomes.

Trend favoring SCIT over SLIT for AR symptom and
medication score reduction. No conclusive results.

Improved symptom score vs placebo was observed more
frequently for SCIT. Data is weak as the basic treatment
parameters vary widely.

Symptoms: all IT treatments better than placebo. Costs
for 5-grass tablet greater than costs for Timothy grass
tablet and SCIT.

Many products without structured collection of safety
data. General safety assessment: SLIT safer than SCIT.

Symptom and medication scores with SCIT, SLIT tablets
and drops all reduced vs. placebo, except for symptom
score with SLIT drops.

SCIT more effective than SLIT (drops) and SLIT (tablet)
for symptom and medication score reduction.

Low grade evidence favors SCIT over SLIT for AR
symptom and medication reduction. Moderate evidence
for nasal and eye symptom reduction.

Insufficient evidence that AIT in any form has a positive
effect on AR in children.

Strong evidence that grass pollen SLIT in children
reduces symptoms of AR. Moderate-low evidence for
HDM SLIT.

Conclusion

AE = adverse event; AIT = allergen immunotherapy; AR = allergic rhinitis; ARC = allergic rhinoconjunctivitis; CI = confidence interval; HDM = house dust mite; INCS = intranasal corticosteroid; LOE =
level of evidence; PAR = perennial allergic rhinitis; RCT = randomized controlled trial; RDBPCT = randomized double-blind placebo-controlled trial; SAR = seasonal allergic rhinitis; SCIT = subcutaneous
immunotherapy; SLIT = sublingual immunotherapy; SMD = standardized mean difference.

Clinical impact score = season-long nasal or total symptom scores: 100 × (scorePlacebo – scoreActive)/scorePlacebo.

b

Only outcomes with statistically significance are mentioned here.

a

Author Manuscript

SLIT or SCIT: children only

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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SLIT is cost-effective after several years of
treatment

SLIT is cost-effective in the 1st year

Tablet SLIT is more effective than
pharmacotherapy. Exception in SAR: INCS are as
efficacious as tablet SLIT.

It is safe to start SLIT during the season

It is safe to continue SLIT during pregnancy

The total cost of SLIT is less than SCIT

SLIT is safer than SCIT

SCIT is more effective than SLIT

SLIT is safe for the treatment of AR in children

SLIT is safe for the treatment of AR in adults

SLIT is effective for AR symptom reduction in
children

SLIT is effective for AR symptom reduction in
adults

Issue
Yes

Direction of
impact
Low impact

Magnitude of impact

Yes

Low impact

Yes

——

a

Safety profile is very good

Recommendation

Strong recommendation

Recommendation,
considering: harm and
cost

Yes

——

Safety profile is very good

Yes

Weak evidence

Recommendation

Yes

Yes

Moderate evidence

Weak evidence

Yes

Slightly added risk.

No added risk.

Moderate: antihistamine, montelukast.
Weak: INCS

Moderate evidence

Moderate evidence

LOE: Meadows 1a; Dranitsaris 2a

B

LOE: Meadows 1a; Dranitsaris 2a

B

Yes

No

Weak-moderate

Moderate evidence

LOE: Devillier 1a (pollen tablet SLIT); Durham 1b (grass pollen or ragweed tablet SLIT).

A

LOE: Creticos 2a

B

LOE: Oykman 3a

B

LOE: Meadows 1a (UK setting); Dranitsaris 2a (Canadian setting)

A

LOE: Aasbjerg 2a

B

Recommendation

Option (considering its long-term benefit)

Recommendation

Option

Recommendation

Recommendation

Recommendation

LOE: Chelladurai 1a; Dretzke 2a; Calderon 2a; Kim 2a. Grass pollen tablets/drops vs SCIT: Di Bona 2012 1a; SCIT = grass pollen tablets only,
drops slightly less effective Nelson 1b.

A

The systematic reviews (Kim, Larenas-Linnemann, Roder: all 2a) included safety evaluation. Makatsori 1a: same dropout rates SLIT vs placebo.

B

Many of the systematic reviews (1a and 2a) included safety evaluation. Makatsori 1a: same dropout rates SLIT vs placebo.

A

LOE: Kim 2a; Larenas-Linnemann 2a. Not enough evidence: Roder 2a.

B

LOE: Lin 1a; Radulovic 1a; Di Bona (2 studies) 1a; Nelson 1b; Calderon 2a.

A

Aggregate
grade of
evidence

Author Manuscript

Aggregate grades of evidence for specific SLIT issues

Author Manuscript
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SLIT with fungi is effective for AR

SLIT with epithelia is effective for AR

SLIT with HDM is effective for AR

SLIT with ragweed-pollen is effective for SAR

SLIT with tree-pollen is effective for SAR

SLIT with grass-pollen is effective for SAR

20121705
2b, Didier

Yes

Yes

20151706
2b

Yes

Yes

Moderate effect

Moderate effect

Low impact

Moderate evidence

b

b
Strong recommendation

b

Strong recommendation

Strong recommendation

Recommendation

Recommendation,
considering: harm and
cost

Yes

Low impact

No data

No data

Yes

Weak evidence

No separate data in the systematic reviews/meta-analyses. Cortellini 20101688 1b

B

No separate data in the systematic reviews/meta-analyses; no recent trials

—

LOE: Nolte 2015, Bergmann 2014, Mosbech 2015 all 1b; Calderon 2a

A

Option

Option

Strong recommendation

b

LOE: Durham 2016, Nolte 2013, Creticos 2013, 1b (tablet ragweed); Creticos 2014 (drop ragweed); Skoner 2010 (drop ragweed) 1b

A

LEO: Valovirta 20061683 1b

A

LOE: Di Bona (2 studies) 1a; Nelson 1b; Durham 1b.

A

LOE: Durham

B

Magnitude of impact

a

AR = allergic rhinitis; INCS = intranasal corticosteroids; LOE = level of evidence; SAR = seasonal allergic rhinitis; SCIT = subcutaneous immunotherapy; SLIT = sublingual immunotherapy.

Considering the added long-term posttreatment effect and the possible preventive effects on the development of asthma and new sensitizations.

b

For those variables with meta-analysis: according to Cohen’s classification: low impact SMD 0.2-0.5, moderate 0.5-0.8, high above 0.8. For those with only systematic review: strength of evidence.

a

Author Manuscript

SLIT has a long-term effect beyond 3-years’
application

Author Manuscript

Issue

Author Manuscript
Direction of
impact

Author Manuscript

Aggregate
grade of
evidence
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Author Manuscript

Author Manuscript

Author Manuscript
1b

1b

1b

1b

LOE

RDBPCT

RDBPCT

RDBPCT

RDBPCT

Study
design

Placebo patches (n = 50)

2

Grass patches (n = 21);
Placebo patches (n = 17)

1
2

Adults:

Grass patches (n = 15);
Placebo patches (n = 15)

1
2

Children:

2. High-dose grass patches (n = 33)

3. Medium-dose grass patches (n = 33);

2. Low-dose grass patches (n = 33);

1. Placebo patches (n = 33);

Adults:

Grass patches (n = 48);

1

Adults:

Study groups

Nasal provocation test,
subjective symptom score

SPT endpoint, subjective
symptoms, antihistamine
use

Subjective symptoms,
medication use, SPT,
conjunctival provocation
test

Subjective symptoms,
conjunctival provocation
test

Clinical endpoint

LOE = level of evidence; RDBPCT = randomized double-blind placebo-controlled trial; SPT = skin-prick test.

Senti et al.1712
2009

2009

1713

Agostinis et al.

2015

2012

al.1715

Year

Senti et al.1714

Senti et

Study

Conclusion

No significant difference in nasal provocation test. Subjective
symptoms score improved. More local reactions (eczema) in
treatment group.

No difference in SPT endpoint. Treatment group had less
rhinoconjunctivitis symptoms and antihistamine use.

Symptoms improved only in the highest dose group. There was no
difference in medication use, SPT, or conjunctival provocation test.
Local reactions were common. Systemic reactions occurred in 8.3%
of patients.

Symptom score improved in the treatment arm in year 1, but was not
significantly different from control in year 2. Conjunctival
provocation improved in the treatment group. Systemic reactions
occurred in 7 treatment (14.6%) and 1 control patients.

Evidence for the use of transcutaneous/epicutaneous immunotherapy in the treatment of allergic rhinitis

Author Manuscript
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Author Manuscript

Author Manuscript

Patterson et al.

2012

2008

Senti et al.1716

2013

2013

Senti et al.1717

1721

Witten et al.

1718

Hylander et al.

1720

2016

2016

Hylander et al.

1719

Year

Study
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2b

1b

1b

1b

1b

1b

LOE

RCT, open

RCT,
blinded

RCT,
blinded

Pilot study
and RCT,
blinded

RCT,
blinded

RCT,
blinded

Study
design

Placebo

2

Placebo

2

Placebo

2

Three injections of 1000 SQ-U followed by 3 placebo
injections;
Six placebo injections

2
3

Three 0.1-mL injections with 1000 SQ-U of
aluminum hydroxide-adsorbed grass pollen extract
injected into lymph node at day 0 and after 4 and 8
weeks;
54 subcutaneous injections over 3 years (cumulative
dose of 4,031,540 SQ-U)

1

2

Grass pollen-induced AR (n = 165):

MAT-Fel d 1;
Placebo (saline in alum)

1
2

Cat-dander-induced AR (n = 20):

6 injections of 1000 SQ-U of depot grass pollen
extract, minimal interval of 14 days;

1

Grass pollen-induced AR (n = 45):

Three intralymphatic inguinal injections of 1000 SQU birch pollen or grass pollen;

1

Birch-pollen/grass-pollen-induced AR (pilot n = 6; RCT n = 15):

Aluminum hydroxide-adsorbed grass pollen extract;

1

Adolescents, grass-pollen-induced AR (n = 15):

Aluminum hydroxide adsorbed, depot birch-pollen or
grass-pollen vaccine;

1

Birch-pollen-induced or grass-pollen-induced AR (n = 36):

Study groups

Clinical endpoint

Seasonal allergic symptoms by VAS,
adverse events, safety of injections,
rescue medication use, SPT, grassspecific IgE levels

Immunological parameters, systemic
adverse effects, nasal provocation
test, SPT, validated rhinitis QOL
questionnaire

Combined symptom and medication
score, global seasonal assessment,
RQLQ

Seasonal allergic symptoms by VAS,
SPT, validated rhinitis QOL
questionnaire

Patient diary score of allergy and
asthma symptoms and medication
use, local and systemic symptoms
score after injections

Seasonal allergic symptoms by VAS,
safety of injections, nasal symptom
score following nasal provocation
test, IgE and IgG4 levels,
inflammatory cells, rescue
medication use

Author Manuscript

Evidence for the use of intralymphatic immunotherapy in the treatment of allergic rhinitis

ILIT enhanced safety and efficacy
of immunotherapy and reduced
treatment time from 3 years to 8
weeks.

ILIT with MAT-Fel d 1
(Recombinant major cat dander
allergen fused to a modular antigen
transporter) was safe and induced
allergen tolerance after 3 injections.

ILIT produced immunological
changes but no improvement in
symptoms.

ILIT is effective and safe.

ILIT is effective and safe, with
notably low adverse reactions.

ILIT is effective and safe; results in
a marked reduction of seasonal
allergic symptoms.

Conclusion

Author Manuscript
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4

Pilot study,
open, no
control
group
1

Three injections of 1000 SQ-U of allergen, dose
interval 23-36 days

Grass-pollen-allergy-induced AR (n = 7):

Study groups
Combined symptom and medication
score, RQLQ, number of IgE+ and
IgE− plasmablasts specific for grass

Clinical endpoint

ILIT may induce allergen-specific
plasmablasts. Confirms an effect on
provocation of mast cells in skin
and nasal mucosa during the
ensuing winter.

Conclusion

AR = allergic rhinitis; Ig = immunoglobulin; ILIT = intralymphatic immunotherapy; LOE = level of evidence; MAT = modular antigen transporter; QOL = quality of life; RCT = randomized controlled trial;
RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SPT = skin-prick test; SQ-U = standardized quality units; VAS = visual analogue scale.

1722

2016

Author Manuscript

Schmid et al.

Study
design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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2002

2002

b

2004

b

Kuehr et al.1400,

Kopp et al.1735,

et al.1401,

b

Rolinck-Werninghaus

2006

2007

2010

Year

Omalizumab Rhinitis Study Group.

b

1b

1b

1b

1b

1b

1b

LOE

Immune Tolerance Network Group.

a

a

Casale et al.1402,

a

al.1736

Klunker et al.1734,

Massanari et

Study

RCT

RCT

RCT

RCT

RCT

RCT

Study
design

Placebo + cluster AIT

2

AIT-ragweed alone;
Omalizumab alone;
Placebo

2
3
4

AIT-birch + placebo;
AIT-grass + omalizumab;
AIT-grass + placebo

2
3
4

AIT-birch + omalizumab;

1

Children and adolescents with SAR and:

Daily symptom severity,
rescue medication use

In vitro leukotriene release
following antigen
stimulation

Subgroup analysis of Kuehr et al.1400 study

Placebo for both interventions

4

Daily symptom severity,
rescue medication use

Placebo [omalizumab] + RIT;

3

Daily symptom severity,
incidence of adverse events

Ragweed hypersensitivity
via IgE-FAB assay, allergenspecific IgG4

Incidence of systemic
allergic reactions

Clinical endpoint

Subgroup analysis of Kuehr et al.1400 study

Omalizumab pretreatment + RIT;
Omalizumab pretreatment + placebo [IT];

1
2

Adults with ragweed induced AR:

AIT-ragweed + omalizumab;

1

Adults with ragweed induced AR:

Omalizumab pretreatment + cluster AIT;

1

Adults with poorly controlled moderate persistent allergic
asthma:

Study groups

Evidence for the combination of omalizumab and subcutaneous immunotherapy in the treatment of allergic rhinitis

Combination therapy is clinically superior to
either component monotherapy, with reduced
symptom severity and rescue medication scores.

Combination therapy is associated with reduced
leukotriene release following antigen
stimulation.

Combination therapy is associated with reduced
symptom severity and rescue medication scores.

Pretreatment with omalizumab resulted in a 5fold decrease in risk of RIT associated
anaphylaxis. Combination therapy is associated
with significant reduction in symptom severity
versus AIT alone.

Combination therapy enhanced the inhibition of
sIgE binding for 42 weeks after discontinuation.

Omalizumab pretreatment is associated with a
lower incidence of systemic allergic reactions
and higher likelihood of reaching maintenance
AIT dose.

Conclusion

Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

AIT = allergen immunotherapy; AR = allergic rhinitis; Ig = immunoglobulin; IgE-FAB = IgE-facilitated allergen binding; IT = immunotherapy; LOE = level of evidence; RCT = randomized controlled trial;
RIT = rush immunotherapy; SAR = seasonal allergic rhinitis; sIgE = antigen-specific IgE.
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al.1754

2005
2004
2002
2001

Bousquet et al.25

Leynaert et al.1753

Linneberg et al.1752

Bresciani et al.1757
3b

3b

3b

3b

3b

3b

3b

LOE

Case series

Cohort

Cohort

Case-control

Case series

Case series

Case series

Study design

Study groups

Patients with severe steroid-dependent asthma (n =
35)

Follow-up on 2 occasions 8 years apart (n = 734)

International cross-sectional study of
representative samples of young adults (n = 3000)

Patients consulting ENT and allergy specialists for
AR (n = 591) vs controls (n = 502)

Patients with severe asthma (n = 557)

Patients with AR (n = 3225)

Asthmatic patients (n = 26,680)

AR = allergic rhinitis; ENT = ear, nose and throat; LOE = level of evidence.

2008

2009

2011

Year

Ponte et al.1755

Valero et al.1756

Ohta et

Study

Sinonasal disease

Rhinitis and asthma in
patients sensitized to pollen

Rhinitis and asthma
diagnosis

Presence of asthma

Asthma severity

Rhinitis comorbidities

Rhinitis and asthma
diagnosis

Clinical endpoint

Author Manuscript

Evidence for the association between asthma, allergic rhinitis and non-allergic rhinitis

Frequency of rhinosinusitis in patients with mild-tomoderate or severe steroid-dependent asthma is similar.

AR and allergic asthma are manifestations of the same
disease.

Association between asthma and rhinitis was not fully
explained by atopy.

Asthma prevalence increases with duration and severity
of rhinitis.

Moderate/severe rhinitis is a strong predictor for greater
severity of asthma.

Asthma was influenced by skin sensitization and
severity of AR.

Rhinitis is common in asthma and impairs asthma
control.

Conclusion
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Author Manuscript
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2010
2008
2007
2007

2006
2006

2002
2000
2000

Rochat et al.1785

Shaaban et al.1783

Burgess et al.1786

Shaaban et al.1784

Bodtger et al.1777

Porsbjerg et al.1781

Toren et at1780

Plaschke et al.1778

Settipane et al.1776
3b

3b

3b

3b

3b

3b

3b

3b

3b

3b

3b

2a

2a

LOE

Cohort

Cohort

Case-control

Cohort

Cohort

Cohort

Cohort

Cohort

Cohort

Cross-sectional
study

Cross-sectional
study

Cohort

Nested casecontrol study

Study design

Follow-up of students

Random sample

General population

Random population
sample

Population-based

General population

General population

Population-based
study

Birth cohort

General population

Children with AR

Birth cohort

Longitudinal cohort

Study groups

Asthma development

Risk factors and onset or remission of
AR and asthma

Adult-onset physician-diagnosed
asthma

Prevalence of asthma

Rhinitis onset

Changes in bronchial
hyperresponsiveness in nonasthmatic
subjects

Incident of asthma in preadolescence,
adolescence, or adult life

Frequency of asthma

Wheezing onset

Self-reported current asthma

Associated diseases

Respiratory symptoms at age 6 years

Asthma onset

Clinical endpoint

Conclusion

Allergic asthma depends on: elevated IgE, eosinophilia, airway
hyperresponsiveness, exposure to allergens, and the predominance of the
Th2 pathway of immunologic reactions.

AR, sensitization to pets, and smoking were risk factors for onset of
asthma.

Noninfectious rhinitis and current smoking, especially among
nonatopics, are associated with increased risk for adult-onset asthma.

Presence of bronchial hyperresponsiveness and concomitant atopic
manifestations in childhood increase the risk of developing asthma in
adulthood.

Asymptomatic sensitization, but not NAR, was a significant risk factor
for later development of AR.

AR was associated with increased onset of bronchial
hyperresponsiveness.

Childhood AR increased the likelihood of new-onset asthma.

Rhinitis, even in the absence of atopy, is a powerful predictor of adultonset asthma.

AR is a predictor for subsequent wheezing onset.

Asthma was associated with chronic rhinosinusitis.

Asthma was present in 49.5% of patients with AR.

Asthma in the child (OR, 4.06; 95% CI, 2.06-7.99).

Rhinitis is a significant risk factor for adult-onset asthma in both atopic
and nonatopic subjects.

AR = allergic rhinitis; CI = confidence interval; IgE = immunoglobulin E; LOE = level of evidence; NAR = non-allergic rhinitis; OR = odds ratio.

2012

Jarvis et al.458

Ibáñez et

2013

1994

al.1764

Wright et al.597

Guerra et

2006

Year

al.1779

Study

Author Manuscript

Evidence for allergic rhinitis as a risk factor for asthma
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2002

2001

1996

1995

Aubier et al.1804

Aaronson1830

Grant et al.1831

2003

Berger et al.1829

1828

2006

Year

1b

1b

1b

1b

1b

1b

LOE

DBRCT

DBRCT

DBRCT,
crossover

DBRCT

DBRCT

DBRCT

Study
design

Placebo

2

Montelukast 10 mg;
Placebo

2
3

Placebo.

2

Placebo

2

Placebo

2

Cetirizine 10 mg daily;
Placebo

1
2

AR and asthma (n = 186):

Cetirizine 20 mg daily;

1

AR and perennial asthma (n = 28):

Cetirizine;

1

SAR and asthma (n = 12):

Desloratadine 5 mg;

1

AR and asthma (n = 326):

Desloratadine 5 mg;

1

SAR and asthma (n = 924):

Levocetirizine 5 mg;

1

Persistent AR and asthma (n = 50):

Study groups

Rhinitis and asthma symptoms,
pulmonary function by spirometry

Daily rhinitis and asthma symptoms,
medication use, PEFR, PC20, PFTs,
asthma management

BHR (measured as methacholine PD20).
NBI (measured using peak expiratory
flow meter and calculated as [oral peak
flow – nasal peak flow] divided by oral
peak flow).

TSS, asthma symptom scores, β-agonist
medication use

TASS, FEV1, β-agonist medication use

Daily rhinitis and asthma symptoms, QOL
by Rhinasthma questionnaire and SF-36

Clinical endpoint

Improvement in asthma symptoms with cetirizine. No
differences in objective measures.

management.

a

Cetirizine reduced asthma and rhinitis symptoms. No
difference in albuterol use. No difference in PFTs,
PC20, and patient PEFRs. No difference in asthma

BHR: increase with cetirizine; NBI: reduced with
cetirizine compared to placebo at 6 hours.

Desloratadine reduced rhinitis symptoms, asthma
TSS, and β-agonist medication use.

Desloratadine vs placebo: reduction in mean TASS,
improvement in FEV1, reduction in average βagonist medication use. Desloratadine vs
montelukast: No differences.

Rhinitis and asthma symptoms reduced with
levocetirizine. Rhinasthma QOL score reduced with
levocetirizine. No differences in SF-36.

Conclusion

pulmonary function test; QOL = quality of life; SAR = seasonal allergic rhinitis; SF-36 = The Short Form Health Survey; TASS = Total Asthma Symptom Severity Score; TSS = Total Symptom Score.

AR = allergic rhinitis; BHR = bronchial hyperresponsiveness; DBRCT = double blind randomized controlled trial; FEV1 = forced expiratory volume in 1 second; LOE = level of evidence; NBI = Nasal
Blocking Index; PC20 and PD20 = provocation “concentration” or “dose” of methacholine causing a 20% decrease in FEV1 (also described as PD20FEV1); PEFR = peak expiratory flow rate; PFT =

Note small sample size and no power-analysis or sample size calculation which limits interpretation of negative findings.

a

al.1827

Baena-Cagnani et al.

Pasquali et

Study

Evidence for oral H1 antihistamines for the treatment of asthma in the context of coexistent allergic rhinitis
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2010

Baiardini et al.

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Nair et al.1834
2010

2012

Kersten et al.1789

1833

2016

Jindal et al.1832

2013

2003

al.1296

Year

Taramarcaz &
Gibson1295

Lohia et

Study

1b

1b

1b

1b

1a

1a

LOE

DBRCT,
doubledummy, 3way
crossover

DBRCT

DBRCT

RCT, singleblind

Metaanalysis

SR and
metaanalysis

Study
design

INCS spray plus oral inhaled CS vs oral inhaled
CS alone;
Nasal inhaled CS vs placebo

2
3

INCS plus conventional vs conventional alone

3

Montelukast 10 mg at night

2

Placebo

Placebo

2

Inhaled FP 100 μg, inhaled placebo, placebo
nasal spray;
Inhaled FP 100 μg, inhaled placebo, FP INCS;
Inhaled FP 500 μg, inhaled placebo, placebo
nasal spray

1
2
3

Persistent AR and asthma (n = 25):

MF INCS 200 μg per day;

1

Moderate/severe persistent AR with intermittent asthma (n =
47):

Fluticasone furoate INCS;

1
2

AR and mild-to-moderate exercise exacerbated asthma (n =
32):

FP INCS 200 μg twice daily;

1

AR and asthma (n = 120):

INCS vs placebo;
INCS vs conventional asthma treatment;

1
2

14 RCTs with 3 interventions:

INCS spray vs placebo;

1

18 RCTs (n = 2162):

Study groups

Methacholine PC20, FeNO,
nPIF, FEV1, asthma and
rhinitis QOL

RAI, LA, and UA , rescue
asthma medication use

a

QOL by GS; symptom
scores; Rhinasthma scores of

Change in exercise induced
decrease in FEV1, change in
AUC of the FEV1 curve,
ACQ score, PAQLQ score,
FeNO

Symptom scores of rhinitis
and asthma, PEF

Asthma symptoms and βagonist use, asthma
exacerbation events, QOL,
FEV1, PEF, PC20, and PD20,
inflammatory markers

Asthma symptoms, rescue
medication use, FEV1, PEF,
PC20, QOL

Clinical endpoint

Evidence for intranasal corticosteroids for the treatment of asthma in the context of coexistent allergic rhinitis

Improvement of PC20 in all groups. No PC20
improvement with INCS and inhaled steroid
vs inhaled FP alone. No change in Asthma
QOL. FeNO and nPIF reduced only with
INCS.

GS score reduction with MF INCS. LA score
decreased with MF INCS. No difference
MFNS vs placebo for rescue medications.

Exercise induced decrease in FEV1 reduced
with FP. No difference in FEV1, ACQ,
PAQLQ, FeNO.

Reduction in asthma symptom severity score
and increase in PEF with FP INCS vs
montelukast.

Nonsignificant symptom improvement INCS
vs placebo. No difference in FEV1, PEF,
PC20, and PD20.

INCS improved FEV1, PC20, asthma
symptom scores, and rescue medication use.
No asthma outcome changes with INCS plus
oral inhaled CS vs oral inhaled CS alone.
Nasal inhaled CS improved PEF.

Conclusion
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2005

2005

Nathan et al.1838

Stelmach et al.

2000

1993

Thio et al.1840

Watson et al.1811

1839

2005

2008

2008

Dahl et al.1837

1836

Pedroletti et al.

Agondi et

al.1835

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
1b

1b

1b

1b

1b

1b

1b

DBRCT,
crossover

DBRCT

DBRCT

RCT, plus
open-label

DBRCT,
double
dummy

DBRCT

DBRCT

Study
design
Study groups

Placebo nasal spray

2

Placebo

2

FP INCS + inhaled placebo;
Intranasal placebo + inhaled FP;
Intranasal and inhaled placebo

2
3
4

Montelukast 10 mg;
Placebo.

2
3

Bdp INCS 400 μg and inhaled 1000 μg daily

3

Placebo nasal spray;
Bdp INCS 400 μg

2
3

1

Bdp INCS 100 μg twice daily, then placebo;

AR and controlled asthma (n = 21):

FP INCS 200 μg daily;

1

Two grass pollen seasons of treatment (season 1, n = 21;
season 2, n = 67):

Bdp INCS 400 μg + inhaled placebo;
Placebo nasal spray and inhaled Bdp 1000 μg;

1
2

PAR and mild-to-moderate persistent asthma (n = 59):

All received inhaled FP-salmeterol.

FP INCS 200 μg;

1

SAR and persistent asthma (n = 863):

FP INCS 200 μg daily + inhaled FP 250 μg BID;

1

Pollen-induced AR and asthma (n = 262):

MF INCS;

1

Perennial rhinitis and allergic asthma (n = 40):

Bdp INCS 400 μg per day;

1

AR and asthma (n = 33):

Author Manuscript
LOE

Asthma and rhinitis
symptoms, PC20, Bdp
depositionb

Asthma scores, rescue use of
salbutamol, methacholine
PD20, FEV1

Asthma and AR symptom
scores, PEF, FEV1 and BHR
(PC20), proxy indicators of
asthma-related morbidity
(work absence, emergency
department visits, etc.)

Daily PEF, daily asthma and
AR symptoms, rescue
albuterol use

Asthma and AR symptoms,
PFTs, methacholine BHR,
PEF

FeNO, ECP in nasal lavage,
PEF, FEV1

Rhinitis and asthma symptom
scores, rescue medication use,
BHR (histamine provocation)

Clinical endpoint

Author Manuscript

Year

No difference of all asthma symptoms with
Bdp. PC20 improved with Bdp. Evening
asthma symptoms reduced with Bdp.

No difference in asthma scores or rescue
salbutamol for all groups. PD20 not
significantly different. FEV1 increased with
FP and BDP in season 2.

Reductions of AR and asthma symptoms in
all groups. No change PEF or BHR.
Increased FEV1 for inhaled Bdp. Asthma
morbidity reduced for all.

FP INCS improved nasal symptoms. No
asthma outcome improvement with FP INCS
addition to inhaled FP-salmeterol.

Increased PEF for FP INCS + inhaled FP vs
other groups. PEF increase for inhaled FP vs
no inhaled FP. FEV1 higher with inhaled FP.
Increased BHR with FP INCS; no increase
with inhaled FP.

No difference of FeNO for MF INCS vs
placebo. Nasal ECP reduced. No difference
in PEF or FEV1.

Changes with Bdp INCS vs placebo: asthma
symptoms reduced, decrease in rescue
medication use, BHR reduced.

Conclusion

Author Manuscript

Study

Wise et al.
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1b

DBRCT
Placebo nasal spray (vehicle of Bdp
formulation);
Bdp INCS

1
2

Nasal and chest symptoms,
NBI, BHR (PC20)

Clinical endpoint

PC20 decreased over pollen season with
placebo, not Bdp. Morning NBI decreased
with placebo, improved with Bdp. No
difference in symptoms.

Conclusion

expiratory flow; PFT = pulmonary function test; nPIF = peak nasal inspiratory flow; QOL = quality of life; RAI = respiratory allergy impact; RCT = randomized controlled trial; SAR = seasonal allergic
rhinitis; SR = systematic review; UA = upper airway.

ACQ = Asthma Control Questionnaire; AR = allergic rhinitis; AUC = area under the curve; Bdp = beclomethasone dipropionate; BHR = bronchial hyper-responsiveness; CS = corticosteroid; DBRCT =
double-blind randomized controlled trial; ECP = eosinophil cationic protein; FeNO = fraction of exhaled nitric oxide; FEV1 = forced expiratory volume in 1 second; FP = fluticasone propionate; GS =
global summary; INCS = intranasal corticosteroid; LA = lower airway; LOE = level of evidence; MF = mometasone furoate; NBI = Nasal Blocking Index; PAQLQ = Pediatric Asthma Quality of Life
Questionnaire; PAR = perennial allergic rhinitis; PC20 and PD20 = provocation “concentration” or “dose” of methacholine causing a 20% decrease in FEV1 (also described as PD20FEV1); PEF = peak

Radiolabeled Bdp <2% deposition in lungs, 20%-50% in nasal cavity, and 48%-78% swallowed in 1993 Watson et al.1811 study.

b

Study groups
Placebo nasal spray, then Bdp INCS 100 μg
twice daily

Mild SAR and asthma (n = 18):

2

Rhinasthma GS includes scores from the 3 categories of RAI, LA, and UA.

a

1992

Author Manuscript

Corren et al.1788

Study
design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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2003

BaenaCagnani et al.

1828

2004

Philip et al.1341

1b

1b

1b

1b

1b

LOE

DBRCT

DBRCT

RCT, plus openlabel

DBRCT;
analysis of
COMPACT trial
data

RCT

Study design

FP-salmeterol inhaled 100/50 μg twice daily + FP
INCS 200 μg daily;
FP-salmeterol inhaled 100/50 μg twice daily +
montelukast 10 mg daily;
Montelukast 10 mg daily

2
3
4

Double dose budesonide

2

Montelukast 10 mg;
Placebo.

2
3

Placebo

2

Desloratadine 5 mg;
Montelukast 10 mg;
Placebo

1
2
3

SAR and asthma (n = 924):

Montelukast 10 mg daily;

1

SAR and asthma (n = 831):

All received inhaled FP-salmeterol.

FP INCS 200 μg;

1

SAR and persistent asthma (n = 863):

Montelukast + budesonide;

1

Asthma symptoms despite inhaled corticosteroid. Subgroup with
coexistent AR. (n = 889).

FP-salmeterol inhaled 100/50 μg twice daily;

1

SAR and asthma (n = 1385):

Study groups

TASS, FEV1, β-agonist
medication use

Rhinitis symptoms,
RQLQ, global evaluations
of asthma, β-agonist
medication use

Daily PEF, daily asthma
and AR symptoms, rescue
albuterol use

Improvement in morning
PEF compared to baseline

PEF, rescue albuterol use,
asthma and rhinitis
symptoms

Clinical endpoint

Montelukast vs placebo: reduction in mean
TASS, improvement in FEV1, reduction in
average β-agonist medication use.
Desloratadine vs montelukast: no
differences.

Global evaluation of asthma by patients and
physicians improved with montelukast.
Reduction in β-agonist medication use
montelukast.

FP INCS improved nasal symptoms. No
asthma outcome improvement with FP
INCS addition to inhaled FP-salmeterol.

budesonide.

a

Least-squares mean difference of morning
PEF greater increase from baseline in
montelukast + budesonide vs double dose

No additional improvements in asthma with
montelukast plus FP-salmeterol. FPsalmeterol associated with improvement in
all outcome measures vs montelukast.

Conclusion

AR = allergic rhinitis; COMPACT = Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy; DBRCT = double-blind randomized controlled trial; FEV1 = forced expiratory
volume in 1 second; FP = fluticasone propionate; INCS = intranasal corticosteroid; LOE = level of evidence; PEF = peak expiratory flow; RCT = randomized controlled trial; RQLQ = Rhinoconjunctivitis
Quality of Life Questionnaire; SAR = seasonal allergic rhinitis; TASS = Total Asthma Symptom Severity Score.

Least squared mean difference in Price et al. study calculated as [(montelukast + budesonide) – double dose budesonide].

a

2005

1838

Nathan et al.

2010

Year

2006

al.1841

Price et al.1842

Katial et

Study

Evidence for leukotriene receptor antagonists for the treatment of asthma in the context of coexistent allergic rhinitis
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Author Manuscript

Author Manuscript

Author Manuscript

Vignola et al.

1b

1b

LOE

DBRCT

DBRCT

Study
design

SCIT + placebo

2

Omalizumab;
Placebo

1
2

Moderate-to-severe persistent AR and allergic
asthma (n = 405):

SCIT + omalizumab;

1

AR and seasonal asthma. All patients received
SCIT. (n = 140):

Study groups

Asthma exacerbations, disease-specific QOL
by AQLQ and RQLQ, rescue medication use,
symptom scores, patient and investigator
GETE, inhaled corticosteroid use, FEV1, FVC,
and morning PEF

AR and asthma symptoms, rescue medication
use, PEF, patient and provider GETE, asthma
symptoms by ACQ, disease-specific QOL by
AQLQ and RQLQ, PFTs

Clinical endpoint

Omalizumab: reduced asthma exacerbations;
increased AQLQ and RQLQ; reduced asthma
symptoms; increased FEV1, FVC, and PEF.
No difference in β-agonist use.

Omalizumab addition to SCIT: reduced
symptom severity, improved QOL by ACQ
and AQLQ. No difference in rescue
medication use. No difference in FEV1 or
mean PEF.

Conclusion

ACQ = Asthma Control Questionnaire; AQLQ = Asthma Quality of Life Questionnaire; AR = allergic rhinitis; DBRCT = double-blind randomized controlled trial; FEV1 = forced expiratory volume in 1
second; FVC = forced vital capacity; GETE = Global Evaluation of Treatment Effectiveness; LOE = level of evidence; PEF = peak expiratory flow; PFT = pulmonary function test; QOL = quality of life;
RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SCIT = subcutaneous immunotherapy.

1820

2004

2009

Kopp et al.

1403

Year

Study

Evidence for omalizumab for the treatment of asthma in the context of coexistent allergic rhinitis
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2008

Marogna et al.

2002

Möller et al.

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

2000

2007

Grembiale et
al.1795

Inal et al.1825

1797

2004

Novembre et
al.1798

1678

2013

2014

Erekosima et
al.1822

Lin et al.1694

Year

Study

2b

1b

1b

1b

1b

1a

1a

LOE

Open,
nonrandomized,
prospective,
parallel group

DBRCT

RCT

RCT

RCT

SR

SR

Study design

SLIT vs pharmacotherapy

2

c

Pharmacotherapy plus SLIT

Pharmacotherapy;

Standard symptomatic treatment,
no SLIT

2

Control (no injections)

2

Placebo

2

1

SCIT;

HDM AR and/or mild-to-moderate asthma (n =
147):

SCIT;

1

HDM AR and BHR to methacholine (n = 44):

SCIT;

1

Rhinoconjunctivitis with or without asthma (n =
191):

SLIT, maintenance 3 years;

1

Rhinoconjunctivitis, no asthma (n = 97):

2

1

Rhinitis with/without intermittent asthma (n =
216):

SLIT vs placebo;

1
Combined medication use
plus symptoms

2

Asthma and rhinitis medication use,
positive HDM skin test, development of
asthma

BHR by PD20, serum IgE levels, rescue
medication use, additional visits for
symptoms, development of asthma

Development of asthma (if none at trial
start), BHR by PC20, VAS of symptoms

Symptoms, rescue medication use,
development of asthma

Development of persistent asthma (not at
baseline), symptom and medication
scores, daily medication use, new
sensitization

Asthma and rhinitis/
conjunctivitis symptoms;

1

Most adverse reactions mild.

Safety of SCIT

3
Systematic review of 63 RCTs (SCIT and SLIT):

SCIT;

scores reduced with SLIT.

Medication plus symptom

SLIT;

b

Symptoms reduced with

a

b

Medication use reduced with

Decreased asthma medication use with
SCIT. Improved atopy scores with SCIT.
Asthma incidence nearly half with SCIT.

BHR increased with SCIT. No HDM IgE
difference. Increased medication use and
visits with placebo. No difference in asthma
incidence.

Asthma incidence greater in controls. BHR
improved with SCIT after 1 year pollen
season.

Rescue medication use reduced with SLIT.
Relative risk of asthma after 3 years greater
in control group vs SLIT.

Persistent asthma incidence lower with
SLIT vs control. Methacholine-positive
patients after 3 years reduced with SLIT.
Lower symptom and medication scores with
SLIT.

2

1

3

2

SCIT vs pharmacotherapy

2

SCIT;

a

Asthma and rhinitis/
conjunctivitis medication
use;

2

Symptoms reduced with

SCIT vs placebo;

1

1

Asthma and rhinitis/
conjunctivitis symptoms;

Conclusion

1

Clinical endpoint

Systematic review of 61 RCTs (26 specifically
asthma and rhinitis):

Study groups

Evidence for allergen immunotherapy for the treatment of asthma in the context of coexistent allergic rhinitis

Author Manuscript

TABLE X.A.4-5.
Wise et al.
Page 435

Author Manuscript
2

Study groups
Medication only

Clinical endpoint

Conclusion

SLIT = sublingual immunotherapy; SR = systematic review; VAS = visual analogue scale.

PD20 = provocation “concentration” or “dose” of methacholine causing a 20% decrease in FEV1 (also described as PD20FEV1); RCT = randomized controlled trial; SCIT = subcutaneous immunotherapy;

AR = allergic rhinitis; BHR = bronchial hyper-responsiveness; DBRCT = double-blind randomized controlled trial; HDM = house dust mite; IgE = immunoglobulin E; LOE = level of evidence; PC20 and

c
SLIT administered as sublingual drops of standardized allergen for a buildup phase and then continued for maintenance phase.

The strength of evidence is moderate for both comparisons.

Strength of evidence moderate to high, for asthma-focused studies and rhinitis-focused studies, respectively.

b

a

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript

Author Manuscript

al.1856

2014
1989

Frerichs et al.1857

Savolainen1847
3b

3a

2b

2a

2a

LOE

Case-control

SR

Retrospective review

Questionnaire

Cross-sectional

Study design

Acute maxillary sinusitis with and without
allergy (n = 224)

Allergic and non-allergic patients

Children with orbital complications of ARS (n
= 102)

Children in Taiwan (n = 8723)

Atopic and nonatopic adults age 21-63 years (n
= 1008)

Study groups

ARS

Prolonged course (>4 weeks)
of RS

Prevalence of AR

Rhinosinusitis

Upper and lower respiratory
tract infections

Conclusion

Prevalence of AR 25% and 16.5% in non-AR
patients.

No significant increase in prolonged RS in AR
patients.

Orbital complications are more common in allergy
season.

Children reporting allergy are more likely to have
RS.

Individuals with atopic disease had higher risk of
developing URTI, including RS.

AR = allergic rhinitis; ARS = acute rhinosinusitis; LOE = level of evidence; RS = rhinosinusitis; SR = systematic review; URTI = upper respiratory tract infection.

2001

2001

2013

Year

Holzmann et al.1849

Chen et al.1848

Rantala et

Study

Clinical endpoint

Author Manuscript

Evidence for an association between allergic rhinitis and acute rhinosinusitis

Author Manuscript

TABLE X.B-1.
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Author Manuscript

Author Manuscript

al.1853

2004

2010

Year

2b

2b

LOE

Cross-sectional

Prospective cohort

Study design

Allergic-only patients

2

Allergic patients with RS;
Allergic-only patients;
Non-allergic controls

1
2
3

(n = 47):

Allergic patients with RS;

1

(n = 21):

Study groups

Nasal secretion levels of EDN and
lysozyme levels

Expression of TLR9 in sinonasal
epithelium

EDN = eosinophil-derived neurotoxin; LOE = level of evidence; RS = rhinosinusitis; TLR9 = toll like receptor 9.

Kalfa et al.1852

Melvin et

Study

Clinical endpoint

Author Manuscript

Evidence for an association between allergic rhinitis and recurrent acute rhinosinusitis

Allergic patients with RS have elevated levels of
EDN and decreased lysozyme levels.

Increased expression of TLR9 in allergic patients
with RS.

Conclusion

Author Manuscript

TABLE X.B-2.
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Author Manuscript

Author Manuscript
2009
2008

2008
2006
2004
2004
1999

Pearlman et al.1859

Gelincik et al.1860

Kirtsreesakul &
Ruttanaphol1861

Robinson et al.1862

Alho et al.1863

Van Zele et al.1864

Berrettini et al.1865
3b

3b

3b

3b

3b

3b

3b

3b

3a

1b

LOE

Prospective casecontrol

Prospective casecontrol

Prospective case
series

Prospective case
series

Retrospective case
series

Prospective case
series

Prospective case
series

Prospective casecontrol

SR

RCT

Study design

CRSsNP with or without allergy
(n = 77)

CRSsNP with or without allergy
(n = 31)

CRSsNP with or without allergy
(n = 48)

CRSsNP with or without allergy
(n = 193)

CRSsNP with or without allergy
(n = 198)

CRSsNP with or without allergy
(n = 66)

CRSsNP with or without allergy
(n = 115)

CRSsNP with or without allergy
(n = 63)

CRSsNP with or without allergy

CRSsNP with or without
ragweed allergy (n = 18)

Study groups

CT scan findings, nasal endoscopy,
nasal swabs, rhinomanometry

Rates of S. aureus colonization

CT findings during viral URTI,
incidence of S. aureus sensitization

Lund-Mackay CT scores and
symptoms scores

Sinus X-rays, nasal endoscopy

Prevalence of CRSsNP in allergic and
non-allergic rhinitis patients

CT scores

Rates of atopy in rhinitis vs CRSsNP

Association between CRSsNP and
allergy

Reactivity in ragweed season
determined by symptoms and sinus
inflammation

Increased CT evidence of sinusitis in allergy
(68%) vs non-allergic (33%) patients.

No difference in colonization rates.

Allergic patients had higher CT scores and
higher incidences of S. aureus sensitization.

Allergy was not associated with CT findings
or symptoms scores.

Allergic patients had a higher incidence of
abnormal sinus X-rays.

CRSsNP was equally prevalent in allergic
(43%) and non-allergic (50%) rhinitis
patients.

No difference in CT scores.

No significant difference in rates of atopy
(72% in rhinitis, 79% in CRSsNP).

Conflicting evidence with no clear
association.

Allergic patients have increased reactivity
and sinonasal inflammation in ragweed
season.

Conclusion

CRSsNP = chronic rhinosinusitis without nasal polyposis; CT = computed tomography; LOE = level of evidence; RCT = randomized controlled trial; SR = systematic review; URTI = upper respiratory
infection.

2011

Tan et al.1858

2008

Year

2014

al.1844

Wilson et al.1854

Baroody et

Study

Clinical endpoint

Author Manuscript

Evidence for allergic rhinitis and chronic rhinosinusitis without nasal polyposis

Author Manuscript
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Author Manuscript

Author Manuscript

Keen1866

2016
2016
2012
2011
2011
2009
2006
2004
2002

2001
2001
2000
2000
1999
1994

Li et al.1855

Gorgulu et al.1868

Lill et al.1869

Tan et al.1858

Munoz del Castillo et al.1870

Collins et al.1871

Van Zele et al.1864

Kirtsreesakul1872

Asero & Bottazzi1874

Voegels et al.1873

Asero & Bottazzi1875

Pang et al.1876

Pumhirun et al.1877

Keith et al.1878

2014

2008

Year

Al-Qudah1867

Wilson et al.1854

Houser &

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
3b

3b

3b

3b

3b

3b

3b

3b

3b

3b

3b

3b

3b

3b

3b

3a

2b

LOE

Prospective case-control

Prospective case-control

Prospective case-control

Prospective case-control

Prospective case-control

Prospective case-control

Prospective cohort

Prospective case-control

Prospective case-control

Prospective case-control

Prospective case-control

Prospective case-control

Prospective case-control

Prospective cohort

Prospective cohort
study

Systematic review

Retrospective case
series

Study design

CRSwNP with or without allergy (n =
64)

CRSwNP compared to controls (n =
40)

CRSwNP compared to controls (n =
80)

CRSwNP compared to allergic
controls (n = 20)

CRSwNP with or without allergy (n =
39)

CRSwNP compared to non-polyp
controls (n = 68)

CRSwNP with or without allergy (n =
68)

CRSwNP compared to CRSsNP and
controls (n = 55)

CRSwNP compared to controls (n =
40)

CRSwNP compared to controls (n =
190)

CRSwNP with or without allergy (n =
62)

CRSwNP compared to controls (n =
50)

CRSwNP compared to controls (n =
60)

CRSwNP with or without allergy (n =
210)

CRSwNP compared to CRSsNP (n =
155)

CRSwNP with or without allergy

CRSwNP with or without allergy (n =
373)

Study groups

Symptom scores, serum levels of
inflammatory markers

Incidence of house dust and
cockroach allergy

Rates of food sensitivity

Rates of Candida sensitivity

Rates of asthma in allergic or nonallergic patients

Rates of Candida and house dust
sensitivity

Response to budesonide nasal
sprays (sneezing, oral and nasal
peak flow, overall response to
therapy)

Rates of S. aureus colonization

Rates of food sensitivity

Rates of allergy compared to
control

Rates and number of antigen
sensitivity

Rates of food sensitivity

Rate of allergen sensitivity

Nasal endoscopy, CT scores, serum
inflammatory markers

Rates of food sensitivity

Association between CRSwNP and
allergy

Nasal polyposis

Clinical endpoint

Author Manuscript

Evidence for allergic rhinitis and chronic rhinosinusitis with nasal polyposis

No difference except in patients with
ragweed allergy. Ragweed-positive

Higher rates of allergy in CRSwNP
compared to controls.

Higher rates of food sensitivity in
CRSwNP.

Higher rates of sensitivity in CRSwNP.

Higher rates of asthma in allergic patients.

Higher rates of sensitivity in CRSwNP.

Improved response in non-allergic
patients.

Higher rates of colonization in CRSwNP.

Higher rates of food sensitivity in
CRSwNP.

Higher rates of allergy in CRSwNP
compared to controls.

No difference in rates of sensitivity.

Higher rate of milk sensitivity in
CRSwNP.

No difference between allergic and nonallergic patients.

No difference in allergic and non-allergic
patients.

No difference between allergic and nonallergic patients.

Conflicting evidence with no clear
association.

AR is associated with the development of
nasal polyposis.

Conclusion

Author Manuscript

TABLE X.B-4.
Wise et al.
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2007

Erbek et al.1880
4

4

4

4

Prospective case series

Retrospective case
series

Prospective case series

Prospective case series

CRSwNP with or without allergy (n =
180)

CRSwNP with or without allergy (n =
83)

CRSwNP with or without allergy (n =
63)

CRSwNP with or without allergy (n =
40)

Study groups

Endoscopy, CT scores

Polyp size, symptom scores,
recurrence

Postoperative course, recurrence

Prevalence of CRSwNP in allergic
or non-allergic patients

Clinical endpoint

Conclusion

No difference between allergic and nonallergic patients.

No difference between allergic and nonallergic patients.

No difference between allergic and nonallergic patients.

No difference between allergic and nonallergic patients.

patients had increase symptom scores and
serum inflammatory markers.

AR = allergic rhinitis; CRSsNP = chronic rhinosinusitis without nasal polyposis; CRSwNP = chronic rhinosinusitis with nasal polyposis; CT computed tomography; LOE = level of evidence.

2006

2008

Bonfils & Malinvaud1879

Bonfils et al.1881

2009

Author Manuscript

Pearlman et al.1859

Study design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript

Author Manuscript
2012

2010

2006

2001

Almaliotis et al.1888

Gradman & Wolthers1886

Kosrirukvongs et al.1887
3b

3b

3b

3a

3a

2b

2b

LOE

Case series

Retrospective
survey

Retrospective
case series

Cross-sectional

Case series

Cohort

Cross-sectional
survey

Study design

n = 445 patients (mean age 24.5 ± 16.3 years) with
a history of itching, foreign body sensation,
lacrimation and red eyes. No control group.

n = 458 children (5–15 years) selected from a
secondary pediatric outpatient clinic with diagnosis
of AC, asthma, AR, or eczema

n = 448 subjects selected by clinic referral and
diagnosis of AC by ophthalmologist

n = 4991 patients selected by referral for allergy
evaluation

Adult nonrandom patients referred to a Clinical
Immunology outpatient clinic 2001-2007 (n =
1851). AR defined according to ARIA.

1020 children total, 338 with AR. “The Allergic
Rhinitis Cohort Study for Kids (ARCO-kids)”

General population: 14,356 students, health
screening 2010-2014. “Korean International Study
of Asthma and Allergies in Childhood” AR defined
as symptoms + SPT positivity.

Study groups

Skin test. Evaluation of clinical
features and risk factors of
various AC types.

Prevalence of AC in children
with rhinitis, asthma and
eczema.

SPT, questionnaire. Evaluation
of comorbidities of ocular
allergy.

Characteristics of patients with
AR.

SPT, questionnaire, sIgE.
Evaluation of risk factors for
AR.

SPT, questionnaire, endoscopic
examination. Evaluation of risk
factors for AR.

SPT positivity, AR prevalence,
prevalence of comorbidities

73.8% of patients with perennial AC had
associated AR. Most common allergen
sensitization was HDM.

Prevalence of AC in children with
rhinitis: 42%. Prevalence of AR in
children with AC: 97%.

70% of patients with AC also had AR.
Symptoms of ocular allergy are very
common in patients with AR and
asthma.

AR prevalence was 55%. 65% had
associated AC.

AR prevalence was 38.4%. AC identified
as risk factor for AR (OR, 6.16; 95% CI,
4.71-8.06).

History of AC identified as risk factor for
AR (OR, 14.25; 95% CI, 4.99-40.74).

Most common comorbid allergic
diseases associated with AR: pollen
allergy (37.0%), AC (34.5%).

Conclusion

AC = allergic conjunctivitis; AR = allergic rhinitis; ARIA = Allergic Rhinitis and its Impact on Asthma; CI = confidence interval; LOE = level of evidence; OR = odds ratio; sIgE = allergen-specific IgE;
HDM = house dust mite; SPT = skin-prick test;

2009

Navarro et al.1890

1885

Alexandropoulos et al.

2016

Year

2015

al.1884

Han et al.1889

Kim et

Study

Clinical endpoint

Author Manuscript

Evidence for an association between allergic rhinitis and allergic conjunctivitis

Author Manuscript
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Author Manuscript

Author Manuscript
2016

2013

2010

Schneider et al.1900

Bozek & Jarzab1903

Batlles-Garrido et al.

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.

Peroni et al.1906

1905

Batlles-Garrido et al.

2008

2010

2005

Kusel et al.1909

537

2007

Lowe et al.1907

2015

Year

2015

al.1901

Sybilski et al.1902

Mortz et

Study

3b

3b

3b

3b

3b

2b

2b

2b

2b

LOE

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Cohort

Prospective
birth cohort

Prospective
birth cohort

Cross-sectional

Prospective
cohort

Study design

n = 1402 preschool children aged 3-5
years; response rate 92%. Part of
ISAAC study.

n = 1143 participants; 10 and 11year-old school children; 49.8%
response rate. Part of ISAAC II study.

n = 1143 participants; 10-year-old
and 11-year-old school children;
49.8% response rate. Part of ISAAC
II study.

n = 7124 Polish participants; mean
age 66-67 years; 70% participation

n = 1091 infants age 3-18 months
with AD followed for 3 years.

(n = 263); 75.3% of the 263 followed
for the full 5 years

n = 620 infants with family history of
atopic disease; 71.5% had sufficient
data for analysis.

Questionnaire (n = 22,703 Polish
subjects); Medical evaluation (n =
4783 patients)

The Odense Adolescence Cohort
Study (TOACS).
Cross-sectional study (n = 1501 8th
graders); 15-year retention cohort (n
= 899)

Study groups

SPT.
Assessment of prevalence of AD,
comorbidities and risk factors.

Homologated questionnaire, SPT,
physical examination.
Assessment of prevalence,
severity, and factors linked to
atopic eczema.

Homologated questionnaire, SPT.
Assessment of prevalence,
severity, and factors linked to
rhinitis.

Questionnaire, examination, SPT,
tIgE, sIgE.
Epidemiology of allergic disease
in an elderly Polish population.

Development of comorbidities in
patients with AD.

SPT at 6 months, 2 years, 5 years.
Evaluation of risk factors for
eczema in relation to atopic
status.

SPT, interview.
Risk of AR development amongst
infants with atopic AD vs those
with nonatopic AD.

Questionnaire (response rate
64.4%), SPT with 15
aeroallergens.
Diagnosis of AD and
comorbidities.

Questionnaire, interview, clinical
exam, serum IgE, patch test, SPT.
Persistence of AD, comorbidities

Clinical endpoint

Author Manuscript

Evidence for the association between allergic rhinitis and atopic dermatitis

Rhinitis symptoms present in 32.2% AD children. Allergic
sensitization to egg, cat, grass pollen and mites, presence
of symptoms of rhinitis, and family history of atopy were
risk factors for AD.

Prevalence of atopic eczema: 11.4%. Risk factors was
severe rhinitis (OR, 7.7; 95% CI, 1.79–33).

Prevalence of “rhinitis” during the previous year: 8.9%.
Concomitant with atopic eczema: 3.5%. Significant
association between “rhinitis” and atopic eczema (OR,
1.98; 95% CI, 1.36–2.88).

1.6% had AD/eczema (95% CI, 1.1–2.0).
12.6% had SAR (95% CI, 10.8–14.6).
17.1% had PAR (95% CI, 15.9–19.7).

18.5% of patients developed AR. Mean age at onset was
2.4 ± 1.3 years for AR.
Comorbidities developed more often in infants with greater
baseline AD severity.

Persistent eczema significantly associated with AR (OR,
2.8; 95% CI, 1.5–5.3).
AR significantly associated with AD (OR, 3.5; 95% CI,
1.7–7.1).
AR not associated with nonatopic dermatitis.

Children with atopic eczema had a substantially greater
risk of AR (OR, 2.91; 95% CI, 1.48–5.71). In children
with eczema within the first 2 years of life, SPT can
provide information on the risk of AR.

AD identified in 3.91% of subjects. Comorbidities of AD
included AR in 26.17%. Association of AD with rhinitis
subtypes: 9.5% with perennial vs 9.3% with seasonal and
9.6% with polyvalent vs 9.0% monovalent sensitization.

Lifetime prevalence of AD was 34.1%. 60.8% prevalence
of AR in those with AD vs 31% in those without AD.
Subjects with AD were twice as likely to develop AR.

Conclusion

Author Manuscript
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2002

2001

2000

2000

1998

1994

2005

Rhodes et al.1898

Min et al.1912

Gustafsson et al.1899

Ozdemir et al.1913

Garcia-Gonzalez et
al.1914

Leung & Ho1915

Kidon et al.1910
4

3b

3b

3b

3b

3b

3b

3b

3b

3b

3b

Prospective case
series

Cross-sectional

Cross-sectional

Cross-sectional

Longitudinal
cohort

Cross-sectional

Longitudinal
cohort

Cross-sectional

Cross-sectional

Cross-sectional

Cross-sectional

Study design

n = 175 newly diagnosed AR patients;
predominantly Chinese; mean age 7.9
years.

n = 2208 secondary school students;
response rate over 87%.

n = 365 students from Malaga, Spain

n = 1603 college students in
Eskisehir, Turkey; 94.5% response
rate.

n = 94 children with AD followed for
8 years

n = 71,120 randomly selected
subjects from Korean otolaryngology
clinics

n = 100 infants from atopic families
followed for 22 years; 63% retained
at last follow-up.

n = 1402 preschool children age 3-5
years; response rate: 92%. ISAAC
questionnaire.

n = 12,876 participants; 95% of those
eligible took part in the survey.

n = 2774 Turkish school children
aged 9-11 years; response rate:
89.2%. ISAAC II questionnaire.

n = 1217 children in 3rd, 4th, and 5th
grade in Izmir, Turkey; response rate
57.6%. ISAAC II methodology.

Study groups

Questionnaire, SPT.
Relative risk of sensitization and
associated risk factors.

Questionnaire, SPT (subset).
Evaluation of prevalence of
asthma and allergic disease.

Interview, SPT, tIgE, sIgE.
Evaluation of prevalence of
atopic disease.

Questionnaire, physical
examination and SPT (subset).
Determine prevalence of asthma,
AR, AD.

tIgE, sIgE, SPT.
Evaluation of development of AR
and asthma.

Questionnaire, examination, SPT,
serum allergy test.

Examination, SPT, tIgE,
bronchial hyper-responsiveness to
inhaled histamine.
Development of AR and asthma

Questionnaire, SPT.
Comparison of disease
associations between rhinitic and
non-rhinitic children.

Questionnaire, SPT (subset).
Prevalence of AD symptoms,
association with rhinitis
symptoms.

Questionnaire, SPT (subset),
flexural dermatitis.

Questionnaire, physical
examination, SPT.
Prevalence and etiologic factors
of asthma, rhinitis, and eczema.

Clinical endpoint

Prevalence of AD: 48%. SPT positive for HDM in 85%.
Children with AR and concomitant AD show preferential
sensitization to Dermatophagoides mites.

Hay fever prevalence: Hong Kong 15.7%; Kota Kinabalu
11.2%; San Bu 2.1%. Eczema prevalence: Hong Kong
20.1%; Kota Kinabalu 7.6%; San Bu 7.2%.

19.9% suffered from rhinoconjunctivitis, and 0.8% AD.

Eczema rate: 5.4% among females, 6.3% among males.
Rhinitis symptoms: 11.1% among females, 8.9% among
males.

AD improved in 84 of 92 children; 45% developed AR.
Severity of AD was a risk factor for subsequent
development of AR. Consistent with atopic march.

Prevalence of PAR in tertiary referral hospitals in Korea is
3.93%. Associated atopic dermatitis in 20.9% subjects
with PAR.

Prevalence of AD peaked at 20% of children by 1 year of
age, declined to 5% at end of the study. AR prevalence
slowly increased over time from 3% to 15%.

Prevalence of rhinitis in the last 12 months: 16.8%.
Rhinitic children had significantly more AD (22.9% vs
13.9%, p < 0.001).

Lifetime cumulative prevalence of AD symptoms: 1.2%.
AD symptoms strongly associated with rhinitis symptoms
(OR, 61.94; 95% CI, 42.66–89.95).

Prevalence of ever rhinitis: 36.3%, current rhinitis: 30.6%,
ever hay fever: 8.3%. SPT positivity: 20.4% among
children with current rhinitis. Flexural dermatitis
significantly associated with current rhinitis.

Prevalence of physician-diagnosed AR: 17%. Prevalence
of physician-diagnosed eczema: 4.9%. Atopic sensitization
prevalence: 8.8%; HDM sensitization most frequent.

Conclusion

AD = atopic dermatitis; AR = allergic rhinitis; HDM = house dust mite; IgE = immunoglobulin E; ISAAC = International Study of Asthma and Allergies in Childhood; LOE = level of evidence; OR = odds
ratio; CI = confidence interval; PAR = perennial allergic rhinitis; SAR = seasonal allergic rhinitis; sIgE = antigen-specific immunoglobulin E; SPT = skin-prick test; tIgE; total immunoglobulin E.

2003

2004

2006

2006

Peroni et al.636

1911

Yemaneberhan et al.

Kuyucu et al.556

Karaman et

LOE

Author Manuscript
Year

Author Manuscript

al.1908

Author Manuscript

Study

Wise et al.
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Author Manuscript

Pollen-food allergy cross-reactivity1928
Pollen

Food

Birch

Apple, pear, sweet cherry, peach, plum, apricot, almond, celery, carrot, potato, kiwifruit, hazelnut, mango

Japanese cedar

Tomato

Mugwort

Celery, carrot, mango, spice

Grass

Melon, watermelon, tomato, potato, kiwifruit, orange, peanut

Ragweed

Melon, watermelon, cantaloupe, zucchini, cucumber, banana

Plane

Hazelnut, apple, lettuce, corn, peanut, chickpea

Author Manuscript
Author Manuscript
Author Manuscript
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Author Manuscript

Author Manuscript
2004

2004

2003

1998

1994

Bolhaar et al.1925

Skamstrup
Hansen et al.1921

Asero1927

Asero1924

Bircher et al.1929

2015

2006

al.1916

Year

Bohle et al.1922

Inuo et

Study

Int Forum Allergy Rhinol. Author manuscript; available in PMC 2020 June 10.
2b

2b

2b

2b

2b

2b

2b

LOE

Casecontrol

Casecontrol

Casecontrol

RCT

RCT

Casecontrol

Cohort

Study
design

Pharmacologic intervention

2

No intervention

2

Patients with pollen allergy (n = 274);
Patients with cat allergy (no pollen allergy, n
= 36);
Patients with no allergies (n = 55)

1
2
3

Serum samples from:

AIT;

1

Patients with PFAS (birch-apple, n = 75) assigned to:

Birch pollen allergic patients without apple
allergy (n = 57)

2

Placebo

3
Birch pollen allergic patients with apple
tolerance after completing injection AIT (n =
30);

SCIT;

2

1

SLIT;

1

Patients with birch reactivity (n = 74) randomized to:

AIT;

1

Patients with PFAS (birch-apple, n = 25) randomized to:

Patients with birch pollen allergy and OAS

Children with AR to JCP and tomato sensitization (n = 23,
age 6–17

Study groups

Presence of IgE for 6 pollenassociated foods

Oral apple challenge and SPT
at 12, 24, and 36 months of
AIT

Prevalence of apple allergy at
30 months by symptoms or
SPT

Oral challenge with apple
before and after treatment

Double-blind placebocontrolled food challenge and
SPT

Oral challenge and basophil
activation assays

Basophil activation by tomato
and JCP extract, IgE and IgG4
levels against tomato and JCP
antigens

Clinical endpoint

Author Manuscript

Evidence for the role of pollen allergy in pollen-food allergy syndrome

There is a high prevalence of food specific IgE in
pollen allergic patients, but not in non–pollenallergic patients.

AIT with birch pollen extracts effectively reduces
clinical apple sensitivity and skin reactivity in most
cases after 1 year of treatment.

Most patients have propensity for apple resensitization. No significant difference between in
prevalence of PFAS between test group and controls
at 30 months. In some patients, pollen AIT can
exert a long-lasting effect on PFAS.

AIT was not accompanied by a significant decrease
in the severity of reactivity to apple compared with
placebo.

Birch pollen AIT decreases allergy to foods
containing homologous allergens (apple).

T-cell cross-reactivity occurs independently of IgE
cross-reactivity. The view that cooked pollenrelated foods can be consumed without allergologic
consequences should be reconsidered.

Tomato-specific basophil activation decreases after
JCP-based SCIT, suggesting efficacy in treating
PFAS symptoms in patients with JCP AR.

Conclusion

Author Manuscript

TABLE X.E-2.
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2011

Mauro et al.1926
4

2b

Cohort

RCT

Placebo

2

SLIT;
SCIT

1
2

Patients with birch allergy (n = 30) randomized to:

Antihistamine;

1

Patients with PFAS (birch-hazelnut, n = 30) randomized to:

Study groups

Oral challenge with apple
before and after treatment

Symptom score (0–5 rating)
with hazelnut provocation
before and after 2 weeks of
treatment

Clinical endpoint

Different doses of birch extract may be necessary to
induce apple tolerance amongst patient with birchapple PFAS.

Treatment with antihistamine (astemizole)
significantly reduced (but did not eliminate) the
severity of local symptoms after ingestion of
hazelnuts compared to placebo.

Conclusion

AIT = allergen immunotherapy; AR = allergic rhinitis; Ig = immunoglobulin; JCP = Japanese cedar pollen; LOE = level of evidence; OAS = oral allergy syndrome; PFAS = pollen-food allergy syndrome;
RCT = randomized controlled trial; SCIT = subcutaneous immunotherapy; SLIT = sublingual immunotherapy; SPT = skin-prick test.

1991

Author Manuscript

Bindslev-Jensen
et al.1923

Study
design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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Author Manuscript

Author Manuscript
2015
2015

2015

2013
2012

2011

2007

2003

Eren et al.1941

Evicimk et al.1933

Pagella et al.1947

Ameli et al.1939

Karaca et al.1938

Sadeghi-Shabestari
et al.1940

Modrzynski &
Zawisza1935

Cassano et al.1931

2017

Year

2016

al.1934

Atan Sahin et al.1936

Dogru et

Study
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4

4

4

4

4

4

4

4

4

4

LOE

Cohort (recruitment
not specified)

Prospective
unblinded,
controlled

Cohort

Case series

Consecutive cohort

Retrospective case
series

Retrospective, crosssectional,
nonrandomized

Consecutive cohort

Case-control

Retrospective, crosssectional,
nonrandomized

Study design

AR plus AH

2

NoAR

2

Tree-sensitive “treated” (n = 10)

4

Children with nasal obstruction (n = 98, age 3–
14 years)

Mugwort-sensitive (n = 14);
Nonatopic (n = 15);

2
3

Tree-sensitive (n = 28);

No adenotonsillar hypertrophy (n
= 100)

2

1

Adenotonsillar hypertrophy (n =
117);

1

Children with upper airway obstruction (n = 82)

205 children with persistent upper airway
obstruction

Otolaryngology clinic for nasal symptoms (1-7
years, n = 582; 8-14 years, n = 213)

AR;

1

155 children referred to Otolaryngology from
Pediatric Allergy

Children from humid vs less humid locations

AR;

1

Study groups

Nasal endoscopy. “Allergic
rhinitis was diagnosed by
prick test and RAST in 22
patients” (20.9%)

Acoustic rhinometry,
endoscopic adenoid exam

SPT for food, inhalant, and
latex

Radiographic AH, clinical
tonsillar hypertrophy,
allergy sensitivity

Nasal endoscopy and SPT

Allergy testing (n = 169),
endoscopic adenoid size,
clinical symptoms

AH, cigarette exposure,
gender, age, family history
of allergy, asthma, SPT

Nasal endoscopy and SPT

AH, SPT, IgE, vitamin D

Symptoms, allergen
sensitivities, allergy
comorbidities

Clinical endpoint

Author Manuscript

Evidence for the association between allergic rhinitis and adenoid hypertrophy

% with “allergy” decreased with increasing
adenoid size. Statistical significance not calculated.

Increased adenoid size in birch allergic children
during pollen season, decreased after pollen
season, and prevented by allergy pharmacotherapy.

Adenotonsillar hypertrophy and positive SPT
70.3%. No adenotonsillar hypertrophy and positive
SPT 10%. (p = 0.04).

Negative correlation: SPT and tonsil hypertrophy.
No correlation: SPT and AH.

Adenoid volume and % with no associated allergy
(p < 0.001).

In the whole population: AH and AR not
associated age 1-7 years (p = 0.34), AH and AR
associated with age in 8-year-old to 14-year-old
group (p = 0.0043).

AH was more prevalent in the AR group. Cigarette
smoke exposure was associated with AH.

There was a negative correlation between AH and
SPT positivity (r = −0.208, p = 0.009).

High humidity group had higher prevalence of AH,
higher IgE levels, and an association between AH
and SPT for dust mite.

The AR plus AH group had more severe symptoms
than the group with AR alone.

Conclusion

Author Manuscript

TABLE X.F.
Wise et al.
Page 448

4

Case-control

AR;
AR plus AH

1
2

Study groups

Clinical endpoint
SPT, otitis media, sinusitis,
lower respiratory tract
infection, secondhand
smoke, sleep-disordered
breathing

AH = adenoid hypertrophy; AR; allergic rhinitis; IgE = immunoglobulin E; LOE = level of evidence; SPT = skin-prick test.

2001

Author Manuscript

Huang &
Giannoni1937

Study design

Author Manuscript
LOE

Author Manuscript

Year
Higher prevalence of mold SPT positivity and
lower respiratory tract infection (in some age
groups) in AR plus AH group.

Conclusion

Author Manuscript
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Author Manuscript

Author Manuscript
1989
2005

1992

1984

Osur et al.1955

Lazo-Saenz et al.1953

Knight et al.1954

O’Connor et al.1952
4

4

3b

2b

1b

1b

1b

LOE

Cohort

Cohort

Case-control

Cohort

Double-blind
crossover, nasal
provocation (pollen
insufflation)

Cohort with
intervention (HDM
nasal provocation)

Double-blind
crossover with
provocation
(histamine)

Study design

Control (n = 5)

2

Control (n = 50)

2

Children with AR (n = 37)

SAR patients

AR (n = 80);

1

Children with AR, ragweed sensitive (n =
15)

8 adult AR subjects with ragweed or
Timothy grass allergy

HDM sensitive AR subjects with normal ET
function

AR (n = 5);

1

Study groups

Middle ear pressure and nasal
airway resistance after pollen
challenge

Middle ear pressure on
tympanometry, ETD symptoms
during pollen season

Tympanometry

9-step ET function test

Inflation-deflation swallow test of
ET function

Inflation-deflation swallow test of
ET function

Inflation-deflation swallow test of
ET function

Clinical endpoint

Conclusion

69% of children had negative middle ear
pressure after challenge.

Symptoms or tympanogram evidence of ETD
in 24% of subjects. Increased to 48% in
pollen season.

AR pts had negative pressure. 15% of AR
children had type B or C tympanograms.

60% of children developed ET obstruction
during ragweed season.

Allergen intranasal challenge induces
transient ET obstruction.

55% of ears developed ET obstruction after
provocation.

All AR subjects had ET obstruction after
challenge.

AR = allergic rhinitis; ET = Eustachian tube; ETD = Eustachian tube dysfunction; HDM = house dust mite; LOE = level of evidence; SAR = seasonal allergic rhinitis.

1983

Friedman et al.1948

1987

Year

1986

al.1950

Skoner et al.1949

Skoner et

Study

Author Manuscript

Evidence for the role of allergic rhinitis in Eustachian tube dysfunction

Author Manuscript
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Author Manuscript

Author Manuscript
1994

1983

2012

Corey et al.1964

Borge1963

Kreiner-Moller et al.
2008

2001
1996

1990
1988
1985
1983

Hurst1966

Alles et al.1969

Hurst1967

Hurst1968

Tomonaga et al.1962

Bernstein et al.1956

Bernstein et al.1957

1965

2006

Chantzi et al.1961

2007

1998

al.1960

Year

Caffarelli et al.1959

Yeo et

Study
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4

4

4

4

4

4

4

4

3b

3b

3b

2b

2b

LOE

Cohort

Cohort

Cohort

Cohort

Cohort

Cohort

Cohort

Case series

Case-control

Case-control

Case-control

Cohort with
control
group

Cohort with
control
group

Study
design

2

2

77 children with recurrent OME and history of
myringotomy tubes

100 patients with OME: 35 allergic, 65 non-allergic

259 children with OME; 605 nasal allergy; 104 controls

20 OME patients, all allergic: 17 treated with AIT, 3
untreated controls

OME (n = 73);
Controls (n = 16)

1

3-year-old to 8-year-old children with OME

OME patients treated with AIT (n = 89);
OME patients not treated with AIT (n = 21)

1

6-year-old children (n = 262)

Serous OM (n = 89);
Controls (n = 67)

1
2

OME (n = 89 children);
Controls (n = 59 children)

1

Controls (n = 80 children)

2

2

OME (n = 88 children);

Controls (n = 200)

2
1

AR and OME (n = 172, 4-14 years);

1

OME (n = 123 children);
Controls (n = 141 children)

1
2

Study groups

Allergy evaluation, serum,
nasal, MEE total IgE

Total and specific IgE in MEE
and serum

Allergy testing; tympanometry

AIT or food elimination diet

Allergy tests, effusion, ECP

Assessment of AR, asthma,
eczema

Resolution of effusion or
drainage at 2-year to 8-year
follow-up

Assessment for OME and
allergy

Allergy history and testing

RAST

Allergy history and tests

SPT and tympanogram for all
subjects

History, SPT

Clinical endpoint

Author Manuscript

Evidence for the role of allergic rhinitis in otitis media

Higher levels of IgE in MEE of allergic
children.

23% of allergic OME patients had evidence
of local IgE.

50% of OME cases had nasal allergy vs
17% control.

All patients treated with AIT or food
elimination resolved.

Allergies in 97% of COME.

57% with positive SPT, almost all with
rhinitis.

100% of OME had positive allergy tests;
85% of AIT treated patients cured.

39% of cohort had OME. OR of 3.36 for
AR and OME.

41% of serous OM patients had perennial
rhinitis vs 11% of controls.

Positive RAST: 61% in OME group vs 41%
in controls

IgE sensitization is independent risk factor
for OME.

Equal rates of sensitization between OME
group and controls.

AR was present in 28% of OME group vs
24% of control.

Conclusion

Author Manuscript

TABLE X.G-2.
Wise et al.
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Author Manuscript
1981
1981

McMahan et al.1970
4

4
Case series

Cohort
119 COME patients

41 patients with OME: 20 allergic, 21 non-allergic

Study groups

RAST test

Total and specific IgE in MEE
and serum

Clinical endpoint

93% of COME positive to inhalant
allergens.

15% of allergic OME cases had evidence of
local IgE.

Conclusion

AIT = allergen immunotherapy; AR = allergic rhinitis; COME = chronic otitis media with effusion; IgE = immunoglobulin E; LOE = level of evidence; MEE = middle ear effusion; OM = otitis media;
OME = otitis media with effusion; OR = odds ratio; RAST = radioallergosorbent test; SPT = skin-prick test.

Bernstein et

al.1958

Study
design

Author Manuscript
LOE

Author Manuscript

Year

Author Manuscript

Study
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1990

2000

1999
1992

1992

Hsu et al.1982

Derebery1979

Gibbs et al.1983

Derebery &
Valenzuela1980

Viscomi & Bojrab1984
4

4

4

4

3b

3b

3b

3b

LOE

Cohort

Cohort

Case series

Cohort

Casecontrol

Casecontrol

Casecontrol

Casecontrol

Study
design

Controls (n = 24)

2

5 patients with Meniere’s disease and AR

93 Meniere’s disease patients with suspected
allergy

7 patients with Meniere’s and inhalant allergy

Meniere’s disease treated with AIT
and diet (n = 113);

1

Meniere’s disease (n = 42);
Controls (n = 18)

1

Controls (n = 172)

2

2

Meniere’s disease (n = 734);

Controls (n = 46)

2
1

Meniere’s disease (n = 46);

Controls (n = 20)

2
1

AR (n = 30);

1

Study groups

Allergen challenge with
intracutaneous provocative food test.
>15% change in SP/AP ratio on
ECoG, provocation of Meniere’s
symptoms

Intradermal test, in vitro allergy tests,
serum IgE, provocative food testing,
AIT response

Change in ECoG after allergen
challenge

Self-reported symptoms via post
treatment survey

Serum total IgE

Allergy symptoms, history
questionnaire

Peripheral blood lymphocyte
populations, cytokines, allergenspecific and total IgE levels

Audiometry, OAE, ABR

Clinical endpoint

6/27 intracutaneous food challenges had
induction of aural symptoms and >15%
change in SP/AP ratio.

82% had normal serum IgE; AIT improved
vertigo in 62%

57% of subjects had >15% change in
SP/AP ratio after challenge.

Allergy treatment reduced tinnitus and
vertigo.

No difference in serum total IgE between
groups.

Meniere’s disease patients have more AR
and food allergy.

Meniere’s patients are more likely to have
positive allergy test. 41% Meniere’s
patients had elevated total IgE.

AR subjects had evidence of inner ear
dysfunction.

Conclusion

ABR = auditory-brainstem response; AIT = allergen immunotherapy; AR = allergic rhinitis; ECoG = electrocochleography; IgE = immunoglobulin E; LOE = level of evidence; OAE = oto-acoustic
emissions.

2000

Derebery &
Berliner1978

2011

2004

al.1977

Year

Keles et al.1981

Singh et

Study

Author Manuscript

Evidence for the role of allergic rhinitis in inner ear disease

Author Manuscript
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Author Manuscript

Author Manuscript

2011

Passali et al.

1996

Chakir et al.

2016

Ghoshal et al.
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5

4

4

4

4

3b

3b

2b

2b

LOE

Bench research

Case series

Case series

Case series

Case series

Case-control

Case-control

Individual cohort

Cohort,
prospective
nonrandomized

Study design

Allergic asthmatics (n = 6);
Controls (n = 5)

2
3

30 guinea pigs divided into the HDMsensitized group, OVA-sensitized group, and
control group

Adults with SAR, nonasthmatic (n = 12)

Patients aged ≥18 years with asthma, AR,
COPD, or rhinosinusitis (n = 1001)

Patients aged ≥18 years with asthma, AR,
COPD, or rhinosinusitis (n = 1,000)

Patients ages ≥18 years with asthma, AR,
COPD, or rhinosinusitis (n = 5250)

Nonasthmatic subjects with
SAR (n = 8);

Control (n = 30)

2
1

AR (n = 30);

1

159 patients from 9 otolaryngology and
pulmonary centers

AR patients (n = 2713)

Study groups

Symptoms of AR induced by
intranasal application of 15 μL 0.5%
HDM and cough challenges with
citric acid. Airway resistance
measurements.

Immunohistochemistry and cytokine
expression of bronchial biopsy
specimens.

Survey regarding symptoms,
healthcare resource utilization, work
productivity, activity impairment.

Survey regarding symptoms,
healthcare resource utilization, work
productivity, activity impairment.
Cost analysis.

Patient and physician surveys

Immunohistochemical analysis of the
distribution of collagens, laminin,
and fibronectin in bronchial biopsy
specimens

Safety evaluation of nasal allergen
challenge

Standardization of diagnostic
approach for rhinobronchial
syndrome

sIgE, questionnaire

Clinical endpoint

Both HDM and OVA-sensitized groups showed a
significantly enhanced nasal reactivity and cough
response compared with controls. The airway
resistance data did not show significant differences.

Natural pollen exposure is associated with an
increase in lymphocyte numbers, eosinophil
recruitment, and IL-5 expression in the bronchial
mucosa of nonasthmatic subjects with SAR.

AR was the most frequent primary diagnosis
(31.2%). Cough was the primary reason for the
medical visit for patients with asthma and COPD.
Nasal symptoms were the primary reasons for AR
and rhinosinusitis.

Asthma was the most frequent primary diagnosis
followed by AR, COPD, and rhinosinusitis. 33.5%
patients were diagnosed with combinations of the 4
respiratory diseases.

Report of cough symptom: COPD (73%), followed
by asthma (61%), rhinosinusitis (59%), AR (47%).
Cough as the main reason for seeking medical care:
COPD (43%), asthma (33%), rhinosinusitis (13%),
and AR (11%).

Content of type I and III collagens was increased in
rhinitic subjects compared with controls, suggesting
active structural remodeling in the lower airways of
AR patients.

In early phase of allergic reaction, extranasal
symptoms were observed (cough, breathlessness),
especially in PAR patients.

Increased frequency of rhinobronchial syndrome
with allergic disease (37.9% vs 20.9%). Cough was
a frequent symptom (96%).

D. pteronyssinus was the most common offending
allergen. The occurrence cough increased with
increasing AR severity.

Conclusion

AR = allergic rhinitis; COPD = chronic obstructive pulmonary disease; HDM = house dust mite; IL = interleukin; LOE = level of evidence; OVA = ovalbumin; PAR = perennial allergic rhinitis; SAR =
seasonal allergic rhinitis; sIgE = allergen-specific immunoglobulin E.

1992

Buday et al.

2016

2000

Chakir et al.

1990

2016

Lin et al.1987

1988

2016

Cho et al.1993

1991

2015

Krzych-Falta
et al.1989

1986

He et

2016

Year

al.1994

Study

Author Manuscript

Evidence for the association between allergic rhinitis and cough

Author Manuscript

TABLE X.H.
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Author Manuscript

Author Manuscript
2008

2006

2003

2010
2015

2014

2011

2006

2016

Krouse et al.1998

Millqvist et al.1996

Reidy et al.2009

Roth & Ferguson1995

Brook et al.2011

Koc et al.1997

Turley et al.2001

Hamdan et al.2000

Brook et al.2004

2013

Year

2009

al.2008

Dworkin et al.2010

Roth et

Study
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4

3b

3b

3b

3b

3a

2b

2b

2b

2b

2b

LOE

Retrospective case
series

Retrospective
case-control

Case-control

Case-control

Retrospective
case-control

Systematic review

RCT

Case-control

Prospective cohort

RCT

RCT

Study design

Singers with vocal symptoms

Patients undergoing in vitro allergy testing

Singers without vocal symptoms;
2

Patients without rhinitis

2
1

Patients with rhinitis symptoms, (+)
and (−) allergy tests;

Control

2
1

AR patients;

Nonatopic patients

2
1

Atopic patients;

1

Relationship of allergy and laryngeal disease

D. pteronyssinus challenge;
Placebo challenge

1
2

Birch pollen allergy;
Control

1

No HDM allergy

2

2

HDM allergy, (+) skin test;

Placebo challenge

2
1

D. pteronyssinus challenge;

1

Adults testing positive for HDM allergy:

Patients responding to an advertisement

Study groups

Symptom prevalence

Symptom prevalence

Prevalence of dysphonia

Laryngeal findings in AR

Endoscopic findings in
AR

Not applicable

Effect of allergen on
larynx

Prevalence of vocal
dysfunction

Effect of allergen on
larynx

Effect of allergen on
larynx

Effect of allergen on
larynx

Clinical endpoint

Author Manuscript

Evidence for an association between allergic rhinitis and laryngeal disease

Yield of in vitro allergy testing for laryngeal
symptoms comparable to other common allergy
testing indications.

Incidence of AR in singers is high. Occult
allergies may affect professional voice.

Patients with AR or NAR had higher prevalence of
dysphonia versus controls. Patients with worse
rhinitis symptoms had worse voice-related QOL
and more severe chronic laryngeal symptoms.

AR patients had higher incidence of dysphonia
and mean VHI.

Findings within the nasopharynx, rather than the
larynx, are predictive of positive atopic status.

Further investigations into mechanisms mediating
laryngeal response to allergy are necessary.

No significant differences between antigen and
placebo exposed subjects on any measure.

Statistically significant differences in VHI
between allergic patients and controls.

Significant changes in VHI in patients with HDM
allergy. Findings present among subjects without
symptomatic LPR/GERD.

Laryngeal abnormalities occurred secondary to
lower respiratory stimulation.

Relationship between allergen exposure and
impaired vocal function independent of asthma or
nasal exposure.

Conclusion

Author Manuscript

TABLE X.I.
Wise et al.
Page 455

Author Manuscript
2014

2010
2010

2007

1997

Randhawa et al.2003

Randhawa et al.1999

Simberg et al.2002

Jackson-Menaldi et al.

2009

Mouadeb et al.2007
5

5

4

4

4

4

4

Bench research

Bench research

Prospective cohort

Cross sectional

Cross sectional

Case series

Case series

Study design

Nonallergic controls

2

HDM + filtered air;
Saline + combustion particulates;
HDM + combustion particulates

2
3
4
Guinea pigs exposed to intranasal HDM for 9
weeks

Saline (allergen control) + filtered
air (pollution control);

1

Guinea pigs exposed to:

Subjects referred to voice center with a voice
problem

Allergy patients in AIT program;

1

Patients presenting to rhinology clinic, no prior
voice-related symptoms

Patients with primary voice disorder or globus
sensation

Patients referred from allergy clinic with SPT
testing

Study groups

Histopathologic findings

Mean eosinophilic profile
in the glottic, subglottic,
and tracheal epithelium
and submucosa

Association between AR,
LPR, laryngeal findings

Symptom prevalence

Allergy and vocal
dysfunction association

Prevalence of AR and
LPR

Laryngeal findings in AR
and LPR

Clinical endpoint

Twice as much eosinophilia in supraglottis in
animals exposed to HDM vs saline.

Iron soot and HDM resulted in eosinophilia in
glottic, subglottic, and tracheal epithelium and
submucosa.

Could not determine causative relationship
between allergy and vocal symptoms.

Individuals with allergies had more severe vocal
symptoms than non-allergic controls. Patients who
had undergone AIT >2 years had fewer symptoms.

The degree of allergen load correlates with the
severity of vocal symptoms, as per an increase in
score on the VHI.

Three times as many patients had allergies
compared with LPR, no statistical significance.

Thick endolaryngeal mucus was a predictor of
allergy. No association between allergic
sensitization and presence of LPR. No significant
difference in laryngeal appearance between
allergy-positive and LPR-positive individuals.

Conclusion

AIT = allergen immunotherapy; AR = allergic rhinitis; GERD = gastroesophageal reflux; HDM = house dust mite; LOE = level of evidence; LPR = laryngopharyngeal reflux; NAR = non-allergic rhinitis;
QOL = quality of life; RCT = randomized controlled trial; SPT = skin-prick test; VHI = Voice Handicap Index.

2015

Belafsky et al.2006

2012

Eren et

LOE

Author Manuscript
Year

Author Manuscript

al.2005

Author Manuscript
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Author Manuscript

Author Manuscript
Year

LOE

Study design

2008
2007
2007
2007
2006
2002

Roy-Ghanta et al.2014

Assa’ad et al.2016

Plaza-Martin et al.2017

Sugnanam et al.2018

Remedios et al.2019

Guajardo et al.2020
4

4

4

4

4

4

4

3a

Case series

Case series

Case series

Case series

Case series

Case series

Case series

Systematic review
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2010

2009
2007

2003

Moawad et al.2021

Almansa et al.2022

Wang et al.2023

Fogg et al.2024
4

4

4

4

4

Case report

Case series

Case series

Case series

Case report

Study groups

Pediatric patient with EoE

Pediatric patients with EoE (n = 234)

Adult patients with EoE (n = 41)

Adult patients with EoE (n = 127)

A pediatric patient with EoE and dust mite
allergy treated with dust mite immunotherapy

Adult and pediatric patients with EoE in
worldwide registry (n = 39)

Adult patients with EoE in Australia (n = 26)

Pediatric patients with EoE in Australia (n =
45)

Pediatric patients with EoE in Spain (n = 14)

Pediatric patients with EoE (n = 89)

Adult patients with EoE (n = 23)

Pediatric patients with EoE (n = 562)

Adult and pediatric patients with EoE

AR = allergic rhinitis; EoE = eosinophilic esophagitis; LOE = level of evidence.

2013

Ramirez & Jacobs2025

Evidence for role of aeroallergens in EoE pathogenesis

2009

2007

Spergel et al.2013

Furuta et al.2015

Evidence of AR prevalence in patients with EoE

Study

Seasonal biopsy findings

Season of EoE diagnosis and
biopsy findings by season

Season of EoE diagnosis

Season of EoE diagnosis and
correlation with pollen counts

Eosinophils on esophageal
biopsies

Demographic and clinical
characteristics

Demographic and clinical
characteristics

Demographic and clinical
characteristics

Demographic and clinical
characteristics

Demographic and clinical
characteristics

Demographic and clinical
characteristics

Demographic and clinical
characteristics

Demographic and clinical
characteristics

Clinical endpoint

Author Manuscript

Evidence for the association between allergic rhinitis and eosinophilic esophagitis

Increased esophageal eosinophilia during pollen
seasons.

Significantly fewer patients diagnosed with EoE
in winter vs spring, summer, and fall; least
intense esophageal eosinophilia in winter.

68% diagnosed in spring and summer vs 32% in
fall and winter.

Highest percentage (33%) diagnosed in spring
and lowest (16%) in winter; significant
correlation with grass pollen counts.

Resolution of esophageal eosinophilia was
observed after course of dust mite
immunotherapy.

64% had AR.

77% were atopic and 54% had AR.

93% had AR.

93% had AR and sensitization to aeroallergens.

79% were sensitized to environmental allergens.

78% had AR; 86% were sensitized to
aeroallergens.

68% were atopic and 43% had AR.

50% to 80% had AR and sensitization to
aeroallergens.

Conclusion

Author Manuscript
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Author Manuscript

Author Manuscript
2010

Meltzer et al.1276
2003
2003
1998
2011

2012
2009
2006
2006

1997
2012
2011

2009
2009
2009

Craig et al.1275

Hughes et al.706

Craig et al.707

Sherkat et al.2030

Colas et al.726

Meltzer et al.2027

Bousquet et al.2028

Leger et al.727

Young et al.714

Ishman et al.2034

Meng et al.720

Benninger & Benninger2036

Meltzer et al.2037

Yuksel et al.2035

Yamada et

2012

Year

al.673

Study
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3b

3b

3b

3b

3b

2c

2c

2c

2c

2c

2b

1b

1b

1b

1b

1b

LOE

Case-control

Case-control

Case-control

Case-control

Case-control

Population-based

Population-based

Population-based

Population-based

Population-based

RCT

RCT

RCT

RCT

RCT

RCT

Study design

SAR, children (n = 14)

AR, adults (n = 7024)

AR, adults (n = 701)

PAR, adults (n = 98)

AR, children (n = 21)

Adults (n = 4927)

AR, adults (n = 591)

AR, adults (n = 3052)

AR, children (n = 1004)

AR, adults (n = 2275)

AR, adults (n = 14)

PAR, adults (n = 20)

PAR, adults (n = 22)

AR, adults (n = 32)

PAR, adults (n = 30)

PAR, adults (n = 57)

Study groups

Author Manuscript

Evidence for an association between allergic rhinitis and sleep disturbance

PSQI and actigraphy

MOS-Sleep and mini-RQLQ

RSDI and sleep question by RSDI

PSG

PSQ, PDSS, Obstructive Sleep
Apnea-18

PSG, direct sleep questions

ESS, Sleep Disorders
Questionnaire, Score for Allergic
Rhinitis

Jenkins Questionnaire, RQLQ,
WPAI-AS

Direct sleep questions by
telephone interviews

PSQI RQLQ, direct sleep
questions based on Epworth scale

ESS, PSQI, FOSQ, RQLQ,
NRQLQ, Pennsylvania Quality of
Life, direct sleep questions in
daily diary

Direct sleep questions in daily
diary

ESS, SSS, FOSQ, RQLQ

PSG, ESS, RQLQ, direct sleep
questions in daily diary

PSG, ESS, RQLQ-S, and WPAIAS

ESS and RQLQ

Clinical endpoint

Sleep dysfunction scores, sleep latency and fragmentation
index are significantly higher in the AR group.

AR adversely affects QOL and sleep parameters.

AR has a significant negative impact on sexual function, sleep,
and fatigue.

Differences in most PSG parameters including sleep
efficiency, arousal index, and snoring time, statistically
significant (though clinically modest).

AR children have higher SDB and sleepiness scores.

Moderate-to-severe SDB was 1.8 times more frequent in
participants with NC due to allergy.

All dimensions of sleep were impaired by AR, and more
impaired in severe AR than in mild AR.

The severity of the AR has more effect on QOL and sleep,
than the duration (intermittent/persistent).

AR disrupts the pattern and quality of sleep.

Moderate-severe AR and NC are associated with worse sleep
quality.

Sleep quality is not significantly affected by pseudoephedrine.

Improvement in congestion and sleep with treatment with
INCS flunisolide.

INCS budesonide improved daytime fatigue, somnolence and
quality of sleep.

Improvement in NC and sleep with treatment with topical
nasal fluticasone.

INCS mometasone improves nasal symptoms and sleepiness.

INCS mometasone significantly improves nasal symptoms,
QOL, sleep quality, and upper airway condition.

Conclusion

Author Manuscript
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2009
1982

al.682

McNicholas et al.718
4

4

3b

3b

Case- series

Case series

Controlled trial

Case-control

Study design

SAR, adults (n = 7)

AR, adults (n = 404)

SAR, adults (n = 50)

AR, adults and children (n
= 2355)

Study groups

PSG

MOS-Sleep, NRQLQ, WPAI-AS,
PANAS-X

ESS, SF-36, PSG

Direct sleep questions

Clinical endpoint

In patients with SAR, obstructive sleep apneas are more
frequent during a period of symptomatic nasal obstruction.

Those with more severe NC or ocular symptoms report poorer
scores on sleep domains.

SAR increases daytime sleepiness, and worsens QOL.

>80% with NC affected in some way at night, primarily
causing them to wake up or made it difficult to fall asleep.

Conclusion

AR = allergic rhinitis; ESS = Epworth Sleepiness Scale; FOSQ = Functional Outcomes of Sleep; INCS = intranasal corticosteroid; LOE = level of evidence; mini-RQLQ = mini-Rhinoconjunctivitis Quality
of Life Questionnaire; MOS-Sleep = Sleep Scale from the Medical Outcomes Study; NC = nasal congestion; NRQLQ = Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire; PANAS-X = Positive
and Negative Affect Schedule-Expanded Form; PAR = perennial allergic rhinitis; PDSS = Pediatric Daytime Sleepiness Scale; PSG = polysomnogram; PSQ = Pediatric Sleep Questionnaire; PSQI =
Pittsburgh Sleep Quality Index; QOL = quality of life; RCT = randomized controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; RQLQ-S = Standardized Rhinoconjunctivitis Quality
of Life Questionnaire; RSDI = Rhinosinusitis Disability Index; SAR = seasonal allergic rhinitis; SDB = sleep disordered breathing; SF-36 = Medical Outcomes Study 36-item Short Form health survey; SSS
= Stanford Sleepiness Score; WPAI-AS = Work Productivity and Activity Impairment Questionnaire-Allergy-Specific.

Stull et

2004

Stuck et al.731

Author Manuscript
2005

LOE

Author Manuscript
Year

Author Manuscript

Shedden2026

Author Manuscript

Study
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Author Manuscript

Author Manuscript
2
39
13
5
14
9

10

In utero or early exposure
(pollen)

In utero or early exposure (animal
dander)

In utero or early exposure (fungal
allergens)

Restricted diet (during pregnancy
and early childhood)

Pollution

Tobacco smoke

Socioeconomic status
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6
15

Pet exposure

Microbial diversity (“hygiene
hypothesis”)

Clinical examination (history and
physical)

4

46

Effect on sleep

Evaluation and diagnosis

33

QOL

Disease burden

2 (SRs)

Breastfeeding

Potential protective effect on the development of AR

6

5 (GWAS)

Number of
listed studies

In utero or early exposure (mites)

Genetics

Risk factors for AR

Topic

D

B

B

B

C

C

C

A

C

A

C

C

C

C

C

Aggregate grade
of evidence

—

—

—

—

—

—

—

—

—

Recommendation

Recommendation

Recommendation

Option

—

Recommendation
level

—

Author Manuscript

Aggregate grades of evidence and recommendation levels

Despite the lack of studies to address clinical examination in the diagnosis of AR, history taking
is essential and physical examination is recommended. Multiple prior guideline documents
support this recommendation.

AR has significant negative effects on sleep. Treatment of AR is recommended to decrease sleep
disturbance.

AR has significant effects on general and disease-specific. QOL Treatment of AR is
recommended to improve QOL.

Microbial diversity of the skin, airways, and gut is important for the prevention of sensitization
and allergic disease in populations.

No evidence that pet avoidance in childhood prevents AR later in life. Early pet exposure,
especially dog exposure in non-allergic families early in childhood, may be protective.

Option for breastfeeding for the specific purpose of AR prevention. In general, breastfeeding has
been strongly recommended due to its multiple beneficial effects.

Most studies show an association between high SES and AR, but this is not a consistent finding
across all studies.

Most studies found no association between active or passive tobacco smoke exposure and AR.
Specific patient populations and temporal variations (ie, length of exposure) should be further
evaluated.

Data inconclusive.

Maternal diet restriction while the child is in utero does not influence the development of AR.
Food allergy during childhood is a risk factor for AR.

Data inconclusive.

Data inconclusive.

Data inconclusive.

Data inconclusive.

Some genes have been associated with development of AR and other atopic diseases.

Interpretation

Author Manuscript

TABLE XI.
Wise et al.
Page 460

Author Manuscript

Author Manuscript

Skin-prick testing

7

19
24
12
4
4
11

Serum total IgE (tIgE)

Serum antigen-specific IgE (sIgE)

Correlation between skin and in
vitro testing

Nasal sIgE

Basophil activation test

Nasal provocation testing

Nasal cytology

Nasal histology
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11
3
3

Cockroach

Pets

Pollen and occupational allergens

21
6

Oral H1 antihistamines

Oral H2 antihistamines

Management-pharmacotherapy

12

House dust mite

Management-avoidance measures and environmental controls

5
15

Blended skin testing techniques

17

8

Use of validated survey
instruments

Skin intradermal testing

0
10

Radiologic imaging

5

Nasal endoscopy

B

A

B

B

B

B

B

C

C

B

C

B

B

C

D

B

B

A

N/A

D

Aggregate grade
of evidence

—

—

—

No recommendation

Strong recommendation

Option

Option

Option

Option

Option

Option

—

Recommendation

Option

Option

Option

Recommendation

Strong recommendation

Recommend against

Option

Recommendation
level
Interpretation

Available data does not adequately address the question of benefit in the treatment of AR.

Newer-generation oral H1 antihistamines are strongly recommended for the treatment of AR.

Pollen and occupational allergen avoidance by EC strategies are an option for the treatment of
AR.

Pet avoidances and EC strategies are an option for AR related to pets.

Combination of physical measures (bait traps, house cleaning) and education is an option for
AR management related to cockroach exposure.

Concomitant use of acaricides and EC measures is an option for the treatment of AR.

Nasal histology is used for research on the pathophysiology of AR but is not routinely used in
clinical practice for the diagnosis of AR.

Nasal cytology is an investigational tool, rather than diagnostic.

NPT has been employed for diagnosis of occupational rhinitis and LAR.

BAT may be used for diagnosis when first-line tests are discordant, and for monitoring response
to AIT.

Nasal sIgE is an option in patients with suspected or known LAR to aid in diagnosis or guide
therapy.

Studies differ regarding the concordance of various allergy testing methods.

Serum sIgE testing is recommended for evaluation of allergen sensitivities in appropriately
selected patients. The practitioner may decide whether skin or in vitro sIgE testing is best in an
individual patient.

Serum tIgE is an option to assess atopic status.

MQT is a skin testing technique that may be used to determine a safe starting dose for AIT.

Intradermal testing may be used to determine specific airborne allergen sensitization for
individuals suspected of having AR.

SPT is recommended for evaluation of allergen sensitivities in appropriately selected patients.
The practitioner may decide whether skin or in vitro sIgE testing is best in an individual patient.

Validated survey instruments can be used to screen for AR, follow treatment outcomes, and as
an outcome measure for clinical trials.

Radiologic imaging is not recommended for the diagnosis of AR.

Evidence does not support the routine use of nasal endoscopy for diagnosing AR. However, it
may be helpful in ruling out other causes of symptoms.

Author Manuscript

Number of
listed studies

Author Manuscript

Topic
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Author Manuscript

Author Manuscript
9

4
31
22
14
6
12
28
21
5
13
12
15
3
—
12

Oral decongestants

Topical decongestants

Leukotriene receptor antagonists

Cromolyn (DSCG)

Intranasal anticholinergic (IPB)

Omalizumab

Nasal saline

Probiotics

Combination: oral antihistamine
and oral decongestant

Combination: oral antihistamine
and INCS

Combination: oral antihistamine
and LTRA

Combination: INCS and
intranasal antihistamine

Acupuncture

Honey

Herbal therapies

Surgical treatment

13

Injectable corticosteroids

53

9

Oral corticosteroids

Intranasal corticosteroids

44

Intranasal antihistamines
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C

—

B

B

A

A

B

A

A

A

A

B

A

A

B

B

A

B

B

A

Aggregate grade
of evidence

Option

No recommendation

No recommendation

Option

Strong recommendation

Option

Option

Option

Option

Strong recommendation

No indication

Option

Option

Recommend against

Turbinate reduction may be considered in AR patients with nasal obstruction who have failed
medical management.

Multiple different herbs studied, with few studies for each specific therapy. Results are
inconclusive.

Studies are inconclusive and heterogeneous.

In patients who wish to avoid medications, acupuncture many be suggested as a possible
therapeutic adjunct.

Strong recommendation for combination therapy when monotherapy fails to control AR
symptoms.

Combination is an option for AR management, particularly in patients with comorbid asthma
who do not tolerate INCS and are not well-controlled on oral antihistamine monotherapy.

Combination equivocal over either drug alone.

Option, particularly for acute exacerbations with a primary symptom of nasal congestion.

Probiotics may be considered in the treatment of AR.

Nasal saline is strongly recommended as part of the treatment strategy for AR.

Omalizumab is not approved by the FDA for the treatment of AR alone.

IPB nasal spray may be considered as an adjunct to INCS in PAR patients with uncontrolled
rhinorrhea.

DSCG may be considered in the treatment of AR, particularly for patients with known triggers
who cannot tolerate INCS.

LTRAs should not be used as monotherapy in the treatment of AR.

Option for topical IND use in the short-term for nasal decongestion. Chronic use carries a risk of
RM.

Recommend against phenylephrine, as it has not been shown to be superior to placebo.

Recommend against
Option

Option for pseudoephedrine for short-term treatment of AR symptoms.

INCS should be used as first-line therapy in the treatment of AR.

Due to the risks of injectable steroid use, along with the availability of other pharmacotherapy
options, systemic or intraturbinate injection of corticosteroids is not recommended for the
routine treatment of AR.

Due to the risks of oral steroid use, along with the availability of other pharmacotherapy options,
this therapy is not recommended for routine AR management.

Intranasal antihistamines many be used as first-line or second-line therapy for the treatment of
AR.

Interpretation

Option

Strong recommendation

Recommend against

Recommend against

Recommendation

Recommendation
level

Author Manuscript

Number of
listed studies

Author Manuscript

Topic
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Author Manuscript

Author Manuscript
4

Trans/epicutaneous
immunotherapy

11
7
16
8
9
18
13
20

Adenoid hypertrophy

Otologic conditions–Eustachian
tube dysfunction

Otologic conditions–otitis media

Otologic conditions–Meniere’s
disease

Cough

Laryngeal disease

Eosinophilic esophagitis

Sleep disturbance and OSA

21

Chronic rhinosinusitis with nasal
polyps

12

10

Chronic rhinosinusitis without
nasal polyps

Food allergy and PFAS

2

Recurrent acute rhinosinusitis

7

5

Acute rhinosinusitis

20

—

Asthma–benefit of AR treatment

Atopic dermatitis

13

Asthma–rhinitis as a risk factor

Conjunctivitis

7

Asthma-association with rhinitis

Associated conditions

7

25

Sublingual immunotherapy

Intralymphatic immunotherapy

8

Subcutaneous immunotherapy

Management–allergen immunotherapy
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B

C

C

C

C

C

C

C

B

C

C

D

D

D

C

—

C

C

B

B

A

A

Aggregate grade
of evidence

Option

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Recommend against

Strong recommendation

a

Strong recommendation

Recommendation
level
Interpretation

Sleep disturbance is associated with AR.

Limited observational data suggests a potential association between aeroallergens and EoE
pathogenesis.

There is some evidence for an association between AR and laryngeal disease.

Low level evidence for an association between AR and cough.

Evidence for an association is of low grade, with substantial defects in study design.

Relationship between AR and OTE is unclear.

There is a causal role for AR in some cases of ETD.

Data inconclusive.

There is evidence for a link between pollen allergy and PFAS.

There is evidence for an association between AR and AD.

AC is a frequently occurring comorbidity of AR.

Conflicting evidence for/against an association.

Conflicting evidence for/against an association.

Data inconclusive.

AR is thought to be a disease-modifying factor for ARS.

See section X.A.4 for specific recommendations.

AR and NAR are risk factors for developing asthma.

Asthma is associated with AR and NAR.

Pending additional studies, ILIT may be a viable option for AR treatment in the clinical
population.

Limited studies show variable effectiveness, along with adverse reactions. Trans/epicutaneous
immunotherapy is not recommended for AR treatment.

Strong recommendation for SLIT in patients unable to obtain adequate relief from
pharmacotherapy.

Strong recommendation for SCIT in patients unable to obtain adequate relief from
pharmacotherapy and those who would benefit from secondary disease-modifying effects.

Author Manuscript

Number of
listed studies

Author Manuscript

Topic
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Author Manuscript

Author Manuscript

Author Manuscript

AC = allergic conjunctivitis; AD = atopic dermatitis; AIT = allergen immunotherapy; AR = allergic rhinitis; ARS = acute rhinosinusitis; BAT = basophil activation test; DSCG = disodium cromoglycate; EC
= environmental controls; EoE = eosinophilic esophagitis; ETD = Eustachian tube dysfunction; FDA = Food and Drug Administration; GWAS = genome-wide association study; ILIT = intralymphatic
immunotherapy; INCS = intranasal corticosteroids; IND = intranasal decongestants; IPB = ipratropium bromide; LAR = local allergic rhinitis; LTRA = leukotriene receptor antagonist; MQT = Modified
Quantitative Testing; NAR = non-allergic rhinitis; NPT = nasal provocation testing; OSA = obstructive sleep apnea; OTE = otitis media with effusion; PAR = perennial allergic rhinitis; PFAS = pollen-food
allergy syndrome; QOL = quality of life; RM = rhinitis medicamentosa; SCIT = subcutaneous immunotherapy; SES = socioeconomic status; sIgE = antigen-specific immunoglobulin E; SLIT = sublingual
immunotherapy; SPT = skin-prick test; SR = systematic review; tIgE = total immunoglobulin E.

Specific recommendations for various SLIT preparations and treatment effects are given in section IX.D.4.
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